 ADVANCING NEUROLOGY. ADVANCING YOU.
2018 SCIENCE PROGRAM
EARLY REGISTRATION DEADLINE: MARCH 29, 2018
}Registration } }Annual } Meeting Schedule }Abstracts } AAN.com/view/AM18
1
MAKE THE MEETIN Your Single-registration Rate = Optimum Value and Flexibility
ADVANCING NEUROLOGY. ADVANCING YOU. 2
2018 AAN Annual Meeting
NG ALL YOUR OWN Register Early to Save Register once—no pre-registration required for most individual courses* Choose from 200+ expert-led courses and customize your schedule any way you want Explore courses, sessions, experiential learning areas—and even networking and social events—at your convenience Early Registration
(Before March 29, 2018)
Student Senior/Honorary Member Junior Member + Non-Neurologist Member † Member ‡ Nonmember
$0 $0 $245 $420 $720 $1,220
Late Registration
(After March 29, 2018)
$0 $0 $335 $570 $980 $1,660
Early Gold** Registration (Before March 29, 2018)
$199 $399 $444 $619 $1,119 $1,819
Late Gold** Registration (After March 29, 2018)
$199 $399 $534 $769 $1,379 $2,259
+
Junior Member: Junior, Intern Non-Neurologist Member: Advanced Practice Provider, Business Administrator, Researcher ‡ Member: Neurologist, Physician Affiliate †
*Some courses require pre-registration, may have a separate registration fee, and are subject to closure due to reaching maximum capacity. **Includes access to Annual Meeting On Demand
Early Registration Deadline March 29
AAN.com/view/AM18
AAN.com/view/AM18
1
CONTENTS “Best of” Scientific Platform Sessions . . . . . 91
INTRODUCTION Registration . . . . . . . . . . . . . . . . 6
ANNUAL MEETING OVERVIEWS Meeting-at-a-Glance Tear Out . . . . . . . . . 9 How to get the most from this Guide . . . . . 13 Annual Meeting Schedule Overview . . . . . 18 Saturday, April 21 . . . . . . . . . . 18 Sunday, April 22 . . . . . . . . . . . 20 Monday, April 23 . . . . . . . . . . . 22 Tuesday, April 24 . . . . . . . . . . . 24 Wednesday, April 25 . . . . . . . . . 27 Thursday, April 26 . . . . . . . . . . 29 Friday, April 27 . . . . . . . . . . . 31
Scientific Platform Sessions . . . . . . . . . 95 Sunday, April 22 . . . . . . . . . . 96 Monday, April 23 . . . . . . . . . . 100 Tuesday, April 24 . . . . . . . . . . 104 Wednesday, April 25 . . . . . . . . 108 Thursday, April 26 . . . . . . . . . 112 Friday, April 27 . . . . . . . . . . . 116 Poster Sessions . . . . . . . . . . . . . . 120 Poster Session I . . . . . . . . . . 122 Poster Session II . . . . . . . . . . 132 Poster Session III . . . . . . . . . . 142 Poster Session IV . . . . . . . . . . 152 Poster Session V . . . . . . . . . . 162 Poster Session VI . . . . . . . . . . 172
2018 Programs Listed By Topic . . . . . . .
34
70th Annual Meeting Exhibitors . . . . . . . 183
2018 Program Tracks . . . . . . . . . . . .
53
2018 Award Recipients . . . . . . . . . . . 184 2018 Research Program Recipients . . . . .
ANNUAL MEETING SESSIONS Plenary Sessions . . . . . . . . . . . . . Hot Topics Plenary Session . . . . . . 60 Presidential Plenary Session . . . . . . 61 Contemporary Clinical Issues Plenary Session . . . . . . . . . . . 62 Clinical Trials Plenary Session . . . . . . 63 Frontiers in Neuroscience Plenary Session 64 Controversies in Neurology Plenary Session 65 Neurology Year in Review: Emerging Therapies Plenary Session . . 66
59
HIGHLIGHTS AND FEATURES Experience Unique Opportunities for Students, Residents, and Fellows . . . . . . 190 Connect at Social Events . . . . . . . . . . 192 2018 Annual Meeting On Demand . . . . . . 194
ANNUAL MEETING INFORMATION General Information . . . . . . . . . . . . 196
Experiential Learning Areas . . . . . . . . . 67 HeadTalks . . . . . . . . . . . . . 68 Live Well: Taking Care of Your Patients Starts with Taking Care of You! . . . . . 70 Maximize Your Value / Advocacy to Action . 72 Navigating Your Career . . . . . . . . 74 Research Corner: Moving Neurology Forward . . . . . . . . . . . . . . 76 The Member Experience . . . . . . . 78 Neuroscience in the Clinic Sessions . . . . . Sunday, April 22 . . . . . . . . . . 80 Monday, April 23 . . . . . . . . . . . 82 Tuesday, April 24 . . . . . . . . . . . 82 Wednesday, April 25 . . . . . . . . . 83 Thursday, April 26 . . . . . . . . . . 84 Friday, April 27 . . . . . . . . . . . 85
79
Invited Science Sessions . . . . . . . . . .
87
Hotel and Reservations . . . . . . . . . .
2018 AAN Annual Meeting
201
Travel Information . . . . . . . . . . . . . 206 Meeting Information and Contacts . . . . .
March 2, 2018
Annual Meeting Hotel Reservation Deadline
March 29, 2018
Annual Meeting Early Registration Deadline
Location
Los Angeles Convention Center
Headquarter Hotel
JW Marriott Los Angeles L.A. LIVE
AAN.com/view/AM18
Current as of February 15, 2018. Program Subject to change
2
188
207
SPECIAL PRESENTATION Bennet Omalu, MBBS, MPH, MBA
Don’t Break the Rules, Change the Game: How Bennet Omalu SingleHandedly Changed American Football, Professional Sports, and How the World Perceives Traumatic Brain Injuries Tuesday, April 24, 1:00 p.m.–2:15 p.m. As chronicled in the 2015 film “Concussion,” Bennet Omalu’s story is one of triumph in the face of seemingly insurmountable odds. Born in eastern Nigeria during a civil war, Omalu and his family lived as refugees, yet he entered medical school at age 15 and became a physician by age 21. Steven DeKosky, MD, FAAN, FANA, FACP, is the Deputy Director of the McKnight Brain Institute in Gainesville, FL. In 2002, he was introduced to Dr. Omalu at the University of Pittsburgh. After looking at the case of the late Pittsburgh Steeler Mike Webster, they together confirmed the first case of dementia pugilistica/chronic encephalopathy in an American football player. Four more cases followed. As the first doctors to identify chronic brain damage as a major factor in the deaths of some professional athletes, DeKosky and Omalu withstood dismissals, backlash, and pressure from peers and the National Football League. Omalu’s new memoir, Truth Doesn’t Have a Side, will be available for purchase both before and after his presentation. Following Omalu’s presentation, he will be joined by DeKosky for a panel discussion.
April 21–27 • Los Angeles
Natalia S. Rost, MD, MPH, FAHA, FAAN Chair, Science Committee
To me, science is the most dynamic element of the Annual Meeting. It’s exciting. Cutting-edge. All-encompassing. Moreover, our vision for science at the Annual Meeting is to deliver it in an effective and engaging way, as to maximize our reach to the community of neurologists and neuroscientists we serve. And the 2018 Annual meeting promises to be the most exciting showcase of the best and the brightest in neurologic science yet! I am always excited about the meeting’s plenary sessions, which offer an unprecedented breadth and depth of science. We are thrilled to welcome NIH Director Dr. Francis Collins as this year’s Presidential lecturer, as he underlines the advances in neuroscience in the era of the BRAIN initiative, the importance of support for public research funding, the excitement of what’s yet to come in neurologic discoveries, and the promise of cures for our patients. The other plenary sessions cover every subspecialty on a daily basis and present a comprehensive array of the latest and groundbreaking developments in the field. I am also particularly proud of the Neuroscience in the Clinic (NIC) sessions, which first premiered in 2017 and received glowing reviews! The NICs were developed to encourage a dialogue between clinicians and scientists, the bi-directional flow of expertise and innovation, which brings meaning and purpose to the clinical applications of scientific discoveries—and, ultimately, benefits our patients. This type of exchange is only possible at the AAN Annual Meeting, where the clinical neurology and neuroscience worlds come together, and we hope you will join us for this unique experience! Finally, I am excited about the return of our Research Corner, one of the seven Experiential Learning Areas. (ELA) You have not fully experienced the Annual Meeting if you have not attended one of these most dynamic, motivating, and innovative “open” formats that the Annual Meeting has to offer! Our Research Corner ELA has been a particular hit with neurology trainees and junior faculty, who gained advice from our colleagues in the NINDS Career Development program, learned the tricks of grant writing, contemplated the complexity of the FDA regulations, and cheered on their colleagues presenting prize-winning abstracts. I will be stopping by Research Corner daily—and I encourage my colleagues to join us there as well!
SEE WHAT’S NEW! ■
Presidential Lecture by Francis S. Collins, MD, PhD, Director of National Institutes of Health:
■
This course will highlight dramatic changes in the management of acute ischemic stroke (AIS) that will impact the workforce, residency, staffing, and other aspects of the neurology profession and practice. These changes are based on the 2017 DAWN study, 2018 DEFUSE-3 study, and American Heart Association and the American Stroke Association’s new guidelines for early management of AIS, which the AAN recently affirmed, with recommendations to treat eligible patients for up to 24 with thrombectomy. Be sure to attend the Clinical Trials Plenary Session on Tuesday, April 25 to learn about the science behind the DEFUSE-3 study.
“California Dreaming: BRAIN and Precision Medicine in 2018”
■
Joint American Heart Association/American Stroke Association Session
A two-hour program will examine disparities in stroke care including bridging racial and ethnic disparities in the management of stroke and breakthroughs in engaging minority and rural communities in stroke studies.
■
BRAIN Initiative Session
This program will feature the latest findings from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, a large-scale effort aimed at revolutionizing our understanding of the human brain. Launched in 2013 by President Obama as a “moonshot to explore the frontiers of the mind,” this program seeks development of the technologies and insights to facilitate preventions, treatments, and cures of brain disorders.
Hot Topics in Stroke Education and Practice
■
Controversies in Neurology Plenary Session—Based on Member Suggestions!
For the first time, AAN members weighed in what they would like to see presented at this year’s session. Two memberchosen topics have been selected for presentation this year. Come hear about: Would You Let Your Child Play Contact Sports? and Should the Neurologist Be Primarily Responsible For Taking Care of Patients With Functional Disorders?
■
Expanded Use of Pulse Audience Response System
This popular, interactive response system will be making its way to the Hot Topics, Clinical Trials, and Controversies in Neurology Plenary Sessions, allowing audience members to submit questions directly to the moderators. In the Controversies in Neurology Plenary, audience members will be able to weigh in on which side of the debate they support.
■
■
New E-poster Set-up
Twelve semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for 12 different E-posters each day!
Special Presentation by Bennet Omalu, MBBS, MPH, MBA; and Steven DeKosky, MD, FAAN, FACP
As chronicled in the 2015 film “Concussion,” find out how Omalu and DeKosky changed American football, professional sports, and how the world perceives traumatic brain injury when together they confirmed the first case of dementia pugilistica/chronic encephalopathy in an American football player.
Anniversary Party
Secure Your Ticket(s) Before March 29! Join us on Sunday, April 22, from 7:00 p.m.to 11:00 p.m.at Universal Studios to celebrate 70 years of the AAN! A limited quantity of free tickets are available to the first 4,000 registered Annual Meeting attendees who reserve them in advance. Once free reserved tickets have been claimed you can still purchase a ticket for $115 each until March 29. Tickets include transportation to/ from the event, delicious food and beverages, and access to Universal Studios, including rides.
Reserve your ticket—and purchase additional tickets—before March 29 at AAN.com/view/AM18.
Tickets must be picked up at the Los Angeles Convention Center by 2:00 p.m. on Sunday, April 22; pre-reserved gratis tickets that are not picked up will be released for rush line.
REGISTRATION Plan Your Meeting Experience The 70th AAN Annual Meeting registration site makes planning your week as easy as 1-2-3:
1
Register and book your hotel quickly and easily online—enjoy the convenience and value of the single registration rate.
2
Use the handy Meeting-at-a-Glance starting on page 9 » of this book to plan your week, incorporating your favorite education programs, scientific sessions, and other Annual Meeting social and informational events.
3
Show up and experience the excellence of the world’s largest and most vibrant gathering of neurologists!
WAYS TO REGISTER
REGISTRATION OPTIONS
Online
Annual Meeting Registration
AAN.com/view/register
The single meeting registration fee is mandatory for all registrants and is determined by AAN member type at the time of the meeting, not at registration.
Telephone US/Canada: (800) 676-4226 International: (415) 979-2283
Registration Deadline: March 29, 2018 Registrations received after March 29, 2018, will be processed at a higher rate.
Hotel Reservation Deadline: March 2, 2018 For questions go to aanam.cmrushelp.com To obtain a registration form to pay by check, please contact CMR. Registration forms will only be accepted for check payments.
To qualify for the member registration rate, your 2018 membership dues must be paid by April 21, 2018. Failure to do so will result in a balance due.
Gold Registration Upgrade your meeting registration to include access to Annual Meeting On Demand.
WAYS TO SAVE }} Renew your AAN membership or join the AAN for maximum registration savings. Visit AAN.com/view/membership. }} Register by the March 29, 2018, early registration deadline to avoid increased rates after this date.
Look for this seal to ensure you are booking through the AAN’s official housing vendor, CMR, and avoid fraudulent sites by only booking on sites where you see this seal.
6
2018 AAN Annual Meeting
ADDITIONAL INFORMATION
Kosher meals may be provided at any lunch and must be arranged on or before March 29, 2018, through the registration website or by contacting AAN Registration/CMR at aanam.cmrushelp.com, (800) 676-4226, or (415) 979-2283. There is a $50 surcharge per kosher meal. On-site requests cannot be accommodated. There are no refunds for kosher meals.
Cancelled or Closed Programs Programs may be closed due to reaching maximum capacity or cancelled due to insufficient enrollment. In the event of cancellation, registration for the cancelled course will be fully refunded for courses that have a separate registration fee. The AAN is not responsible for airfare, hotel, or other costs incurred by participants in the event of program or registration closure or cancellation.
Group Registration Deadline: March 29, 2018 Group registrations are those in which 10 or more individuals’ fees are paid for with one check or credit card. Special registration instructions are available online at AAN.com/view/register or by contacting CMR’s Group Registration at (800) 676-4226 (US/Canada) or (415) 979-2283 (International) or aanam.cmrushelp.com. See page 201 » for housing information.
Cancellations/Refunds of Registration Until March 29, 2018—Refund less $100 administrative fee March 30–April 14, 2018—Refund less $200 administrative fee After April 14, 2018—No refund •• All cancellations must be submitted in writing to aanam.cmrushelp.com or faxed to (415) 293-4071. •• No-shows will not receive a refund. •• Name substitutions are not permitted. •• No refunds will be processed for amounts of $20 or less.
What Is Not Included with Annual Meeting Registration? While the single registration rate provides an exceptional value, some courses require pre-registration, may have a separate registration fee, and are subject to closure due to reaching maximum capacity. For information on pricing please visit AAN.com/view/register.
Special Accommodations Deadline: March 29, 2018 The Los Angeles Convention Center and the AAN strive to accommodate all visitors. Information booths, designated parking, and assisted listening devices are available. If you require special accommodation to attend the Annual Meeting, submit your request while registering online or contact Jill Zelinsky no later than March 29, 2018, at JZelinsky@aan.com or (612) 928-6049.
REGISTRATION RATES Note: All prices in US dollars
Early Registration (Before March 29, 2018)
Late Registration (After March 29, 2018)
Early Gold Registration4 (Before March 29, 2018)
Late Gold Registration4 (After March 29, 2018)
Student
$0
$0
$199
$199
Senior/Honorary Member
$0
$0
$399
$399
Junior Member
$245
$335
$444
$534
Non-neurologist Member
$420
$570
$619
$769
Neurologist Member
$720
$980
$1,119
$1,379
Nonmember
$1,220
$1,660
$1,819
$2,259
1 2
3
1 Junior, Intern 2 Researcher, Advanced Practice Provider, Business Administrator 3 Neurologist, Physician Affiliate 4 Includes Access to Annual Meeting on Demand
AAN.com/view/AM18
7
BEGIN PLANNING YOUR 2018 ANNUAL MEETING EXPERIENCE NOW. Download the new AAN Conferences Mobile App now to put all the information you need for the 2018 Annual Meeting conveniently on your phone or tablet: • Access program details, speakers, and materials • Customize your program schedule • View the hotel map • Explore the Los Angeles City Guide • Find and connect with other conference attendees • Submit your evaluations and claim CME Available for iPhone ®, iPad ®, or Android ®
NEW AAN Conferences App
Sponsored by:
AAN.com/view/MobileApp
ADVANCING NEUROLOGY. ADVANCING YOU.
MEETING-AT-A-GLANCE
Sat April 21
2018 PLENARY SPEAKERS
X For more detailed information regarding the Experiential Learning Areas and their schedules, see page 67 ». C = Educational Sessions
Sun April 22
Mon April 23
N = Neuroscience in the Clinic session S = Scientific Platform Session
Tue April 24
Wed April 25
Thur April 26
Fri April 27
Saturday, April 21 4:15 p.m.–5:30 p.m.
Hot Topics Plenary Session Moderator:
6:00 a.m.
7:00 a.m.
8:00 a.m.
Eric Klawiter, MD
C1–4
7:00 a.m.– 9:00 a.m.
C5
7:00 a.m.– 12:30 p.m.
C25–34
C6-7
C60–68
7:00 a.m.–9:00 a.m.
7:00 a.m.– 4:00 p.m.
S1
C133–143
6:30 a.m.–8:30 a.m.
7:00 a.m.–9:00 a.m.
S11
8:00 a.m.– 9:00 a.m.
Run/Walk for Brain Research
C96–104
7:00 a.m.–9:00 a.m.
Member, Science Committee
7:00 a.m.–9:00 a.m.
S20
8:00 a.m.– 9:00 a.m.
C172-181
8:00 a.m.– 9:00 a.m.
C216–223
7:00 a.m.–9:00 a.m.
S27
University of California San Francisco, San Francisco, CA
7:00 a.m.–9:00 a.m.
S38
8:00 a.m.– 9:00 a.m.
Michael R. Wilson, MD Amynah Pradhan, PhD
University of Illinois at Chicago, Chicago, IL
S47
8:00 a.m.– 9:00 a.m.
Jens Kuhle, MD
8:00 a.m.– 9:00 a.m.
Universitätsspital Basel, Oberwil, Switzerland
C8–14
10:00 a.m.
Contemporary Clinical Issues Plenary Session
9:15 a.m.–12:00 p.m.
9:30 a.m.– 11:30 a.m.
Clinical Trials Plenary Session
9:15 a.m.–11:30 a.m.
Frontiers in Neuroscience Plenary Session
9:15 a.m.–11:30 a.m.
Controversies in Neurology Plenary Session
9:15 a.m.–11:30 a.m.
Neurology Year in Review: Emerging Therapies Plenary Session
9:15 a.m.–11:30 a.m.
Sunday, April 22 9:15 a.m.–12:00 p.m.
Presidential Plenary Session
9:15 a.m.–11:30 a.m.
Moderator:
6:00 p.m.
Neurobowl®
8:00 p.m.
3:30 p.m.–5:30 p.m.
Faculty and Trainee Reception
6:00 p.m.–8:00 p.m. 7:00 p.m.
Member, Science Committee
Aleksandar Videnovic, MD, MSc, FAAN
Holly E. Hinson, MD, MCR
Amy R. Brooks-Kayal, MD, FAAN
Natalia S. Rost, MD, MPH, FAAN, FAHA Chair, Science Committee
Maria Glymour, ScD, MS
Sarah J. Tabrizi
David L. Perez, MD
Gregory W. Albers, MD
Andrea Leigh Haller, MD
David D. Adams
Jack W. Tsao, MD, DPhil, FAAN
Emily C. De Los Reyes, MD
Christopher Giza, MD
Member, Science Committee
Member, Science Committee
University of California, San Francisco, San Francisco, CA
Stanford University, Stanford, CA APHP, Le Kremlin-Bicetre, France
6:00 p.m.–9:00 p.m.
Industry Therapeutic Updates
7:00 p.m.– 10:00 p.m..
70th Anniversary Celebration 7:00 p.m.–11:00 p.m.
Industry Therapeutic Updates
7:00 p.m.– 10:00 p.m..
Emerging Science
5:45 p.m.– 7:15 p.m.
C160–171, 244 S33 3:30 p.m.– 4:15 p.m. N4 S34–36 Invited Science S37 3:30 p.m.–5:30 p.m.
5:30 p.m.
4:30 p.m.– 5:30 p.m.
Commitment to Cures
7:00 p.m.– 10:00 p.m..
C197–209 N6 S43–46 Invited Science 3:30 p.m.– 5:30 p.m.
2:30 p.m.
1:00 p.m.– 3:00 p.m.
5:00 p.m.
N7 S52–54 C235–243 3:30 p.m.– 5:30 p.m.
Closing Party Happy Hour
5:30 p.m.–7:00 p.m.
6:00 p.m.–10:00 p.m.
Industry Therapeutic Updates
1:00 p.m.– 3:00 p.m.
S48–51 C234 C224–233 1:00 p.m.–
C210–215 Industry Therapeutic Updates
7:00 p.m.– 10:00 p.m..
6:30 p.m.–9:30 p.m.
Poster Session VI 11:30 a.m.–5:30 p.m.
3:30 p.m.– 5:30 p.m.
5:00 p.m.
Invited C196 C182–195 S39 1:00 p.m.– Science 1:00 p.m.– N5 S40–42 2:15 p.m. 1:00 p.m.– 5:30 p.m.
Poster Session V 11:30 a.m.–7:00 p.m.
S24–26 C120–132
1:00 p.m.– 3:00 p.m.
Exhibit Hall 11:30 a.m.–3:00 p.m.
1:00 p.m.– 3:00 p.m.
1:00 p.m.– 5:30 p.m.
C144–156 S28 C157–158 C159 1:00 p.m.–2:00 p.m. 1:00 p.m.– S29–32 1:00 p.m.–
Francis S. Collins, MD, PhD
Robert J. Fox, MD, FAAN
Tallie Z. Baram, MD, PhD
Ramon R. Diaz-Arrastia, MD, PhD, FAAN
University of CA-Irvine, Irvine, CA
Experiential Learning Areas 7:00 a.m.–5:30 p.m.
3:30 p.m.– 5:30 p.m.
N2 S17–19 C84–95
1:00 p.m.– 2:15 p.m.
C119
Experiential Learning Areas 7:00 a.m.–5:30 p.m.
4:15 p.m.–5:30 p.m.
S7
3:30 p.m.– 4:30 p.m.
5:30 p.m.
Special Event
Experiential Learning Areas 7:00 a.m.–6:15 p.m.
Hot Topics Plenary Session
5:00 p.m.
Member, Science Committee
Nationwide Childrens Hospital, Columbus, OH
Director of National Institutes of Health, Bethesda, MD
Poster Session IV 11:30 a.m.–7:00 p.m.
4:00 p.m.
N1 S8–10 C50–59
1:00 p.m.– 3:00 p.m.
1:00 p.m.
N3 S21–23 C105–118 Invited Science
Experiential Learning Areas 7:00 a.m.–5:30 p.m.
3:00 p.m.–4:00 p.m.
5:30 p.m.
1:00 p.m.– 4:00 p.m.
C82–83
Poster Session III 11:30 a.m.–7:00 p.m.
AAN Business Meeting
5:00 p.m.
1:00 p.m.– 2:15 p.m.
C81
Exhibit Hall 11:30 a.m.–4:00 p.m.
1:30 p.m.– 3:30 p.m.
1:00 p.m.– 3:00 p.m.
S12
Experiential Learning Areas 7:00 a.m.–6:15 p.m.
C19–24
S13–16 C69–80
Poster Session II 11:30 a.m.–7:00 p.m.
1:00 p.m.– 4:00 p.m.
S2–6 C45–46 C47–49 C35–44 1:00 p.m.– 1:00 p.m.
Exhibit Hall 11:30 a.m.–6:00 p.m.
C18
Experiential Learning Areas 7:00 a.m.–5:30 p.m.
12:00 p.m.– 4:00 p.m.
Poster Session I 11:30 a.m.–5:30 p.m.
3:00 p.m.
C15–17
Exhibit Hall 11:30 a.m.–4:00 p.m.
2:00 p.m.
Moderators:
Deborah Hall, MD, PhD, FAAN
Controversies in Neurology Plenary Session
Massachusetts General Hospital, Boston, MA Fort Wayne Neurological Center, Fort Wayne, IN Memphis, TN
UCLA, Dept of Neurosurgery, Los Angeles, CA
Montefiore Medical Center, Bronx, NY
Experiential Learning Areas 7:30 a.m.–5:30 p.m.
1:00 p.m.
Moderators:
Natalia S. Rost, MD, MPH, FAAN, FAHA Michael J. Thorpy, MD Chair, Science Committee
11:00 a.m.
12:00 p.m.
Thursday, April 26 9:15 a.m.–11:30 a.m.
Clinical Trials Plenary Session
University of College London, London, United Kingdom
9:00 a.m.
Presidential Plenary Session
Tuesday, April 24 9:15 a.m.–11:30 a.m.
Cleveland Clinic, Cleveland, OH
Penn Presbyterian Medical Center, Philadelphia, PA
Richard S. Finkel, MD
Nemours Children’s Hospital, Orlando, FL
Lisa M. DeAngelis, MD, FAAN
Memorial Sloan-Kettering Cancer Center, New York, NY
Monday, April 23 9:15 a.m.–11:30 a.m.
Contemporary Clinical Issues Plenary Session Moderator:
Randolph S. Marshall, MD, FAAN Vice Chair, Science Committee
Michelle P. Lin, MD
Johns Hopkins University School of Medicine, Baltimore, MD
Valerie Biousse, MD Atlanta, GA
Ronald Postuma, MD
Montreal General Hospital, Montreal, QC, Canada
Aleksandar Videnovic, MD, MSc, FAAN
MGH Neurological Clinical Research Institute, Boston, MA
Wednesday, April 25 9:15 a.m.–11:30 a.m.
Frontiers in Neuroscience Plenary Session Moderator:
Paul M. George, MD, PhD, MSE Member, Science Committee
Emery Brown, MD, PhD
Massachusetts Institute of Technology, Cambridge, MA
Jeff Lichtman, MD, PhD Harvard University, Cambridge, MA
Amita Sehgal, PhD
University of Pennsylvania, Haverford, PA
Jack M. Parent, MD
University of Michigan, Ann Arbor, MI
Friday, April 27 9:15 a.m.–11:30 a.m.
Neurology Year in Review: Emerging Therapies Plenary Session Moderator:
Antonio M. P. Omuro, MD Member, Science Committee
Ericka P. Simpson, MD, FAAN Methodist Hospital, Houston, TX
Antonio M. P. Omuro, MD
University of Miami Miller School of Medicine, Miami, FL
Matthew S. Robbins, MD, FAAN Montefiore Headache Center, Bronx, NY
Kelly G. Knupp, MD
Children’s Hospital Colorado, Aurora, CO
Liana Apostolova, MD, FAAN
Indiana University School of Medicine, Indianapolis, IN
Steven R. Messé, MD, FAAN, FAHA Hospital of the University of Pennsylvania, Philadelphia, PA
Alan Evans, PhD
McGill University, Montreal, QC, Canada
Emmanuelle Waubant, MD, FAAN UCSF MS Center, San Francisco, CA
Kristoffer Edgar Leon
University of California San Francisco, San Francisco, CA
Shibani Mukerji, MD
Massachusetts General Hospital, Boston, MA
Maisha T. Robinson, MD, MS
9:00 p.m.
Mayo Clinic, Jacksonville, FL
Jeffrey Allan Cohen, MD Cleveland Clinic, Cleveland, OH
10:00 p.m.
Deborah I. Friedman, MD, MPH, FAAN University of Texas Southwestern Medical Center, Dallas, TX
Current as of February 15, 2018. Program Subject to change
ADVANCING NEUROLOGY. ADVANCING YOU.
AAN.com/vie
MEETING OVERVIEW Saturday, April 21 7:00 a.m.–9:00 a.m. C1 Mild Cognitive Impairment: Implications for Clinicians C2 Functional Neurologic Disorders I: Movement, Seizures, and Multiple Sclerosis C3 Emergency Room Neuro-ophthalmology C4 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment 7:00 a.m.–12:30 p.m. C5 Clerkship and Program Directors Conference: Demonstrating Your Impact as a Medical Educator 7:00 a.m.–4:00 p.m. C6 Neurology MOC Prep Course $ (registration required) C7 L Women in Leadership $ (registration required) 7:30 a.m.–8:15 a.m. X Are You My Mentor? How to Select a Good Mentor for Your Research Career 8:25 a.m.–9:10 a.m. X Work Life Balance in Research 9:15 a.m.–9:45 a.m. X How to Network at the Annual Meeting: Strategies for Trainees 9:15 a.m.–10:00 a.m. X Patient Centered Teaching 9:20 a.m.–9:50 a.m. X How to Successfully Publish Quality Improvement Projects 9:30 a.m.–10:00 a.m. X What Is the Axon Registry? 9:30 a.m.–11:30 a.m. C8 Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room C9 Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies C10 More than Medicine: How to Access Home Care, Support Caregivers, and Discuss Complex Situations in Advanced Neurologic Disease C11 Treatment of Pediatric Multiple Sclerosis in the Current Era C12 Functional Neurologic Disorders II: Life Experiences and Management of Functional Disorders C13 Neuroimaging Biomarkers Across the Dementia Spectrum C14 Parkinson’s Disease Update 10:00 a.m.–10:45 a.m. X Sleep: Why You Should Spend Your Career Helping People Do It Right 10:00 a.m.–10:50 a.m. X Investigator Panel: How I Launched My Career with NIH Funding, Private Funding, AAN Research Program Funding and/or Government Funding 10:15 a.m.–10:45 a.m. X Cognitive Biases and Diagnostic Errors at Bedside 11:15 a.m.–12:00 p.m. X Choosing a Career in Clinical Practice 11:30 a.m.–12:00 p.m. X Office Hours: Research Careers in Industry 12:00 p.m.–12:30 p.m. X Navigating the Annual Meeting App and Convention Center Tour X Office Hours: Writing a Great AAN Research Program Proposal 12:00 p.m.–12:45 p.m. X Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? 12:00 p.m.–4:00 p.m. Young Investigator Symposium C15 Resident Basic Science I: Neuropharmacology C16 L Leadership Challenges in Practice C17 Neurophysiologic Intraoperative Monitoring Skills Workshop $ (registration required) 12:15 p.m.–1:00 p.m. X What I Learned About Research—An Early Career Perspective 12:45 p.m.–1:45 p.m. X Ask Us Anything: Expert Panel on Headache and Facial Pain 1:00 p.m.–1:30 p.m. X Statistics—Sample Size
1:00 p.m.–4:00 p.m. C18 L Educators’ Leadership Program $ (registration required) 1:15 p.m.–2:00 p.m. X Interviewing Skills: Medical Students and Residents 1:30 p.m.–3:30 p.m. C19 Pediatric Neuro-ophthalmology Update C20 The Neurology of Social Behavior C21 Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia C22 Stroke in Young Adults and Women C23 Critical Care Consultations for Neurohospitalists C24 Diagnosis and Treatment of Functional Movement Disorders 1:40 p.m.–2:10 p.m. X Clinical Trials Methodology Course—Information Session with William Meurer, MD, MS, CTMC Principal Investigator 2:00 p.m.–2:30 p.m. X Paths for Success in the Quality Payment Program 2:00 p.m.–2:45 p.m. X Cafe Talk: Narratives in Neurology: Creative Expression to Promote Resilience and Prevent Burnout 2:00 p.m.–3:00 p.m. X Rural Neurology 2:15 p.m.–3:00 p.m. X Teleneurology: Is This for Me? Pre-hospital and Nontraditional Uses of Teleneurology 2:30 p.m.–3:00 p.m. X Ask the Expert: Paths for QPP Success 3:00 p.m.–3:30 p.m. X Clinical Decision Support for Ordering of Diagnostic Imaging 3:00 p.m.–3:45 p.m. X Acupuncture Demonstration: 4 Gates 3:00 p.m.–4:00 p.m. AAN Business Meeting 3:15 p.m.–4:00 p.m. X Social Media for Clinicians 3:15 p.m.–4:15 p.m. X Women in Neurology: Crafting Your Leadership Career: Lessons from Leaders 3:30 p.m.–4:00 p.m. X Growing Research in Medical Marijuana 4:00 p.m.–4:30 p.m. X TBI in Domestic Violence Victims: Care for Those Who Need It Most 4:00 p.m.–4:45 p.m. X Cafe Talk: Communication in Palliative Care 4:15 p.m.–5:30 p.m. Hot Topics Plenary Session 6:00 p.m.–8:00 p.m. Neurobowl 7:00 p.m.–10:00 p.m. Industry Therapeutic Updates
Sunday, April 22 7:00 a.m.–7:45 a.m. X Yoga (All-Levels Vinyasa) 7:00 a.m.–9:00 a.m. C25 Hot Topics and Controversies in Parkinson’s Disease C26 Neuro-ophthalmology I: Visual Loss, Optic Neuropathies, and Papilledema C27 Neurological Intensive Care I: The Essentials C28 Autism Spectrum Disorders What We Know and Where We Are Going C29 Faculty Development: Enhancing Your Role in Student and Resident Training C30 Controversies in Stroke Treatment and Prevention C31 Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies C32 Treatments for Drug-resistant Epilepsy: Surgery, Devices, and Other Updates C33 Clinicopathological Correlation Session in Dementia C34 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making 7:45 a.m.–8:15 a.m. X Research in Residency: How to Choose the Right Project
8:00 a.m.–9:00 a.m. S1 “Best of” Session: Cerebrovascular Disease and Interventional Neurology 8:00 a.m.–9:00 a.m. X Meditation for the Practicing Neurologist X How Can the Axon Registry Improve My Practice? 8:00 a.m.–9:10 a.m. X Challenges in Clinicogenetic Correlations: One Gene, Many Phenotypes; One Phenotype, Many Genes 8:15 a.m.–9:00 a.m. X K is for Career Development: Tips From Successful Applications for NIH Career Development Awards 8:30 a.m.–9:00 a.m. X Interviewing Skills: Negotiation 9:15 a.m.–9:45 a.m. X Giving and Receiving Feedback for Medical Students and Residents 9:15 a.m.–12:00 p.m. Presidential Plenary Session 10:00 a.m.–10:30 a.m. X Autoimmune Neurology X Office Hours: The Researcher Pipeline: The Benefits of Participating in Academic Medicine, Research, and Clinical Trials as a Medical Student or Resident 10:45 a.m.–11:15 a.m. X So You Want to Be a Residency Program Director? 11:30 a.m.–4:00 p.m. Exhibit Hall 11:30 a.m.–1:00 p.m. Exhibit Hall Opening Luncheon 11:30 a.m.–5:30 p.m. P1 Poster Session I 12:00 p.m.–12:50 p.m. Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session 12:00 p.m.–12:30 p.m. X Office Hours: Finding/Working with Epidemiologists on Your Grant 12:00 p.m.–12:45 p.m. X How to Promote Healthy Cognitive Aging: What Should We Tell Our Patients and Ourselves? 12:00 p.m.–1:00 p.m. X Neurology Pictionary X Pursuing a Career in Clinical Informatics 12:15 p.m.–1:00 p.m. X Sleep: A Frequently Forgotten Part of Your Patient’s Day 12:30 p.m.–1:00 p.m. X Office Hours: Surviving as a Clinician Researcher 12:30 p.m.–5:30 p.m. Medical Student Symposium: Careers in Neurology 1:00 p.m.–1:30 p.m. X Being a Great Chief Resident 1:00 p.m.–1:45 p.m. X Solving Burnout 1:00 p.m.–2:00 p.m. X California Neurological Society X Meet and Greet with the California Neurological Society 1:00 p.m.–3:00 p.m. S2 Clinical Trials and Therapeutic Approaches in Neurodegenerative Diseases S3 Movement Disorders: Parkinson’s Disease: Genetics, Biomarkers, and Diagnosis S4 Neuroepidemiology: Neurodegeneration, Epilepsy, Cerebrovascular Disease Risks S5 General Neurology: Advances in Neurotherapeutics S6 MS Neuroimaging C35 Borderlands of Neurology and Internal Medicine: Chalk Talk C36 Clinical Neurology for Advanced Practice Providers I C37 Nonmotor Manifestations of Parkinson’s Disease I C38 Neurological Intensive Care II: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction C39 Therapy in Neurology I: Headache and Stroke C40 Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS C41 Peripheral Neuropathy II: Diabetic and Inherited Neuropathies
C42 Acute and Chronic Clinical Epilepsy Update Explained
in 6 Cases C43 Developing the Treatments of Tomorrow I: Taking Molecules from Lab to Man C44 Neuro-ophthalmology II: Optic Neuritis, Visual Fields, and Anisocoria 1:00 p.m.–5:00 p.m. C45 L Being a Resilient Leader: How Do You Lead the Change? C46 L The Most Important Tool in Your Black Bag: Gallup StrengthsFinders™ Assessment $ (registration required) 1:00 p.m.–5:30 p.m. C47 Resident Basic Science II: Neuropathology C48 Genomic Neurology Skills Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies C49 Neuromuscular Ultrasound Skills Workshop $ (registration required) 1:15 p.m.–2:00 p.m. X Measuring Success: Quality Improvement 101 1:20 p.m.–1:50 p.m. X So You Have a Research Idea—How Do You Turn it into a Project? 1:30 p.m.–2:30 p.m. X Hall of Presidents: Using Past Experience to Solve the Future’s Problems 1:45 p.m.–2:15 p.m. X Career Stories: Challenges for the Physician Scientist 2:00 p.m.–2:30 p.m. X Breaking Down Silos: Interprofessional Team Education to Enhance Clinical Outcomes in Neurology 2:15 p.m.–3:00 p.m. X Education Administrator Building Blocks: Navigating the Role of the Administrator and Taking Your Role to the Next Level 2:30 p.m.–3:00 p.m. X Ask the Expert: Teaching through Simulation 3:00 p.m.–3:30 p.m. X Tip of the Iceberg: Ultra-High Cost Neurology Drugs 3:00 p.m.–3:45 p.m. X How Your Social Life Might Be Helping (or Harming) Your Brain 3:00 p.m.–4:00 p.m. X Blind Spots: The Impact of Conscious and Unconscious Biases 3:15 p.m.–3:45 p.m. X How to Get into Leadership in Professional Societies 3:15 p.m.–4:00 p.m. X Social Media for the Millennial Neurologist 3:30 p.m.–4:00 p.m. X How to Increase Investments in Neuroscience Research 3:30 p.m.–4:30 p.m. S7 Pain and Palliative Care 3:30 p.m.–5:30 p.m. N1 Neuroscience in the Clinic: Autism Myth Busters S8 Progressive MS Therapies and Age-Dependent Factors in MS Therapy S9 Epilepsy/Clinical Neurophysiology (EEG) I S10 Intracerebral and Subarachnoid Hemorrhage C50 Low and High Pressure Headache: Clinical Presentation and Approach to Evaluation and Management C51 Clinical Neurology for Advanced Practice Providers II C52 Nonmotor Manifestations of Parkinson’s Disease II C53 Neurological Intensive Care III: Vascular Diseases C54 Therapy in Neurology II: Epilepsy and Movement Disorders C55 Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience C56 Peripheral Neuropathy III: Genetic Testing and Next Generation Sequencing C57 Developing the Treatments of Tomorrow II: Clinical Trials in Neurology C58 Neuro-ophthalmology III: Diplopia, Ocular Motility Disorders, and Nystagmus C59 Actualización Sobre el Tratamiento de la Esclerosis Múltiple 4:00 p.m.–4:30 p.m. X Transitioning from Private Practice to Academics X Why Are Drug Prices So High? And What Can We Do About It?
4:00 p.m.–4:45 p.m. X Cafe Talk: Is that an Emotional or Cognitive Question? Navigating Difficult Conversations with Communication Skills 4:15 p.m.–5:00 p.m. X How Educating Can Improve Productivity During Clinical Activities 4:30 p.m.–5:00 p.m. X How to Start a Career in Clinical Trials X What Does BrainPAC Do for Me? 4:30 p.m.–5:30 p.m. X What Is That Twitch? 4:45 p.m.–5:15 p.m. X Everything You Wanted to Know About the R&F Section of Neurology 5:00 p.m.–5:30 p.m. X Statistics and Study Design: Pearls and Pitfalls 7:00 p.m.–11:00 p.m. 70th Anniversary Celebration
Monday, April 23 7:00 a.m.–7:45 a.m. X Yoga (All-Levels Vinyasa) 7:00 a.m.–9:00 a.m. C60 Balance and Gait Disorders C61 Starting a Practice From the Ground Up: A Guide for Early Career Neurologists C62 Neuro-ophthalmology: Overview and Update C63 Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis C64 Child Neurology I: Pediatric Stroke, MS/Autoimmune C65 Clinical Pearls: Learning from Complex Cases Simple Lessons that Apply to Everyday Problems C66 Update on Medical Management of Stroke C67 Video EEG: Name That Spell C68 Cognitive Impairment Due to Alzheimer’s Disease: Using Old Skills and New Tools for Diagnosis and Treatment 7:30 a.m.–8:00 a.m. X Defining and Managing Your Message as an Early Career Researcher 7:45 a.m.–8:15 a.m. X Using the R&F Section of Neurology for Your Residents and Residency 8:00 a.m.–8:45 a.m. X Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? 8:00 a.m.–9:00 a.m. S11 “Best of” Session: Epilepsy/Clinical Neurophysiology (EEG) 8:10 a.m.–9:00 a.m. X Your CV Is Talking About You Behind Your Back, and Your LORs Are Too! 8:15 a.m.–9:00 a.m. X Choosing An Academic Career in Neurology: Perspectives for Early Career Investigators and Foreign Medical Graduates 8:30 a.m.–9:00 a.m. X Tools to Transition from Trainee to Attending 9:15 a.m.–9:45 a.m. X Being a Great Chief Resident 9:15 a.m.–11:30 a.m. Contemporary Clinical Issues Plenary Session 10:00 a.m.–10:30 a.m. X How to be “Useful” on Rotations: Tips for Medical Students 10:45 a.m.–11:15 a.m. X Choosing a Neurohospitalist Career 11:30 a.m.–12:00 p.m. X Child Neurology—Staying on Track 11:30 a.m.–6:00 p.m. Exhibit Hall 4:30 p.m.–6:00 p.m. Exhibit Hall Networking Reception 11:30 a.m.–7:00 p.m. P2 Poster Session II 11:45 a.m.–12:35 p.m. Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session
11:45 a.m.–12:30 p.m. X Finding Your Niche in Neurology: Perspectives from an Epileptologist and Educator 12:00 p.m.–12:30 p.m. X Office Hours: Working with an Epidemiologist 12:00 p.m.–1:00 p.m. X Is There a Neurologist on This Flight? X Practice Models for Advanced Practice Providers X Using EHR for Better Communication with Patients and Colleagues 12:25 p.m.–1:45 p.m. X Perception Is Reality: Are Neurologists Helping Patients Live Well with Dementia? 12:45 p.m.–1:30 p.m. X Transitioning From a Clinical Research Career to an Educational and Clinical Focused Career 1:00 p.m.–1:30 p.m. X Subspecialty Sessions: IOM and cEEG X Office Hours: Creating Bridge Funding—How to Use Non-NIH Funding 1:00 p.m.–2:15 p.m. S12 Autonomic Disorders 1:00 p.m.–3:00 p.m. S13 Neuromyelitis Optica Spectrum Disorder and other Autoimmune Disorders S14 Education and Patient Outcomes Research S15 Cerebrovascular Disease Epidemiology and Outcomes S16 Neuro-Ophthalmology/Neuro-Otology C69 L Continuing Your Leadership Journey: Uncharted Waters (registration required) C70 Evaluating Tremor in the Office C71 Therapy in Neurology III: Neurological Infectious Diseases and Neuro-ophthalmologic Disorders C72 Sports Neurology: Enhancing Athletic Performance C73 Child Neurology II: Epilepsy and Neuromuscular C74 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I C75 Safe and Appropriate Opioid Prescribing in Neurology C76 Clinical Approach to Muscle Disease I: Role of Antibodies, Muscle Imaging and Genetic Testing C77 Epilepsy Surgery Update C78 Therapeutic Temperature Modulation in the ICU C79 Comprehensive Migraine Education Program I: Diagnosis, Risk Factors, and Neurobiology C80 Present and Future Biomarkers in Dementia: A Case-based Approach 1:00 p.m.–4:00 p.m. C81 Mitigating the Impact of Unconscious Bias Workshop 1:00 p.m.–5:30 p.m. C82 Resident Basic Science III: Neuroanatomy: All the Lesions C83 Neuro-ophthalmology and Neurovestibular Exam Lab Skills Workshop $ (registration required) 1:30 p.m.–2:00 p.m. X Office Hours: Statistics—Sample Size 1:30 p.m.–2:30 p.m. X Eminence-based Medicine vs Evidence-based Medicine 1:45 p.m.–2:30 p.m. X Creating a Career in Global Health with Design Thinking 2:00 p.m.–2:30 p.m. X Can Aviation Accidents Teach Neurologists Patient Safety and Error Management? 2:00 p.m.–2:45 p.m. X Physical Exercise and Cognitive Training in Neurology: Application in Aging and Neurodegenerative Disease 2:30 p.m.–3:00 p.m. X Office Hours: Defining and Managing Your Message as an Early Career Scientist 2:45 p.m.–3:30 p.m. X Mejora Tu Desempeño Como Educador Médico 3:00 p.m.–3:30 p.m. X Safety and Quality Awards 3:00 p.m.–3:45 p.m. X Introduction to Acupuncture I: Conceptual Framework and Mechanism of Action 3:00 p.m.–4:00 p.m. X Lifting the Curtain: Ask the AAN Publication Editors Anything!
3:30 p.m.–4:00 p.m. X What Does the AAN’s Latest Guideline Mean for My Practice? 3:30 p.m.–5:30 p.m. N2 Neuroscience in the Clinic: Antisense Oligonucleotide (ASO) Therapy S17 Sleep S18 Movement Disorders: Ataxia and Tremor S19 Epilepsy/Clinical Neurophysiology (EEG) II C84 Evidence Based Neurology Foresights for Busy Clinicians C85 Therapy in Neurology IV: Autoimmune PNS Synaptic Disorders and Neuro-Oncology C86 Child Neurology III: Headache, TBI/Post-concussion C87 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II C88 Core Concepts in Pain Management: Refractory Neuropathic Pain Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids C89 Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology C90 Comprehensive Migraine Education Program II: Behavioral and Psychological Approaches, and Preventive and Acute Treatment Advances C91 Chronic Traumatic Encephalopathy: Update C92 What Keeps You Up at Night? Addressing Mistakes and Injuries, In-n-Out-Patient Transition, and Building a Team to Support You C93 Advances in Neurogenetics C94 Hot Topics in Stroke Education and Practice C95 Actualización Sobre las Infecciones del Sistema Nervioso Central y la Medicina Tropical 3:45 p.m.–4:30 p.m. X Teaching Communication Skills: From Good to Great 4:00 p.m.–4:30 p.m. X Streamlining Clinic Scheduling and Access 4:00 p.m.–4:45 p.m. X Striking the Balance—A Neurologist’s Personal Wellness Journey 4:15 p.m.–5:00 p.m. X Foundations for Success in the AAN 4:15 p.m.–5:30 p.m. X Career Development for Medical Educators 4:30 p.m.–5:00 p.m. X Knowing Your Value: How to Negotiate to Get What You’re Worth 4:45 p.m.–5:30 p.m. X Career Development for Medical Educators 5:15 p.m.–6:15 p.m. X Practicing Neurology in the 1960s and 1970s 6:00 p.m.–9:00 p.m. Faculty and Trainee Reception 7:00 p.m.–10:00 p.m. Industry Therapeutic Updates
Tuesday, April 24 6:30 a.m.–8:30 a.m. 2018 AAN Run/Walk for Brain Research 7:00 a.m.–7:45 a.m. X Yoga (All-Levels Vinyasa) 7:00 a.m.–9:00 a.m. C96 Status Epilepticus C97 Vascular Cognitive Impairment and Dementia: Current Status and Future C98 Multiple Sclerosis Overview I: Clinical Pearls C99 Good Neurology in Challenging Conditions: Lessons from Military Neurology C100 Basic Principles of Brain Tumors: For Practice and for Certification C101 Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist C102 Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson’s Disease C103 Now You See It, Now You Know It: Pathognomonic Neuro-ophthalmology Examination Findings C104 Sports Concussion Skills Workshop: Event Coverage Foundational Skills and Sport Specific Pearls $ (registration required)
8:00 a.m.–8:30 a.m. X Welcome to NINDS Day/Overview of NIH Funding with NINDS Director and NINDS Deputy Director 8:00 a.m.–8:45 a.m. X Self-Management in Neurologic Disease 8:00 a.m.–9:00 a.m. S20 “Best of” Session: Headache 8:15 a.m.–9:00 a.m. X Career Development for Clinician Educators 8:30 a.m.–9:00 a.m. X Career Stories: Nuts and Bolts of Academic Leadership—Strategies I Have Learned in My Career 8:40 a.m.–9:10 a.m. X K Awards and Training Programs 9:15 a.m.–11:30 a.m. Clinical Trials Plenary Session 10:00 a.m.–10:30 a.m. X Choosing a Career in Neurocritical Care 10:45 a.m.–11:15 a.m. X Staying on an Academic Clinical Track 11:30 a.m.–12:00 p.m. X Reviewer to Editorial Board to Editor 11:30 a.m.–4:00 p.m. Exhibit Hall 11:30 a.m.–7:00 p.m. P3 Poster Session III 11:45 a.m.–12:35 p.m. Aging and Dementia Poster Discussion Session 11:45 a.m.–12:30 p.m. X Foreign Medical Graduates Adjustment Skills 12:00 p.m.–12:30 p.m. X Introduction to the 2018-2020 TRANSCENDS Scholars X Office Hours: How to Get a K-Award 12:00 p.m.–12:45 p.m. X Treatment of Neuropathy Symptoms Without Medication 12:00 p.m.–1:00 p.m. X Neurology Game Show: Localize the Lesion X Communicating via EHR 12:15 p.m.–12:45 p.m. X Neurohospitalists 2.0, How to Craft a Satisfying and Sustainable Career 12:30 p.m.–1:00 p.m. X Office Hours: Bridge Funding 12:40 p.m.–1:10 p.m. X NIH Funding and Professional Development Opportunities for Diverse Researchers 12:45 p.m.–1:30 p.m. X Choosing Teleneurology as a Career 1:00 p.m.–1:30 p.m. X Subspecialty Sessions: IOM and cEEG X Office Hours: VA Research Funding: Career Development Awards 1:00 p.m.–1:45 p.m. X Complementary Therapies in Parkinson’s Disease 1:00 p.m.–2:00 p.m. X Understanding Axon Registry and Using it to Improve Your Value 1:00 p.m.–2:15 p.m. Bennet Omalu, MBBS, MPH, MBA with Steven DeKosky, MD, FAAN, FANA, FACP 1:00 p.m.–3:00 p.m. Invited Science: Movement Disorders N3 Neuroscience in the Clinic: Challenges in Genetic Diagnosis in Neurology S21 Revascularization in Acute Ischemic Stroke S22 Advances in Muscular Dystrophy and Congenital Myopathy S23 Biologic and Clinical Discoveries in Neuro-oncology C105 L Mentoring…Growing the Next Generation of Neurologist $ (registration required) C106 Critical Care EEG Monitoring C107 What Do I Do Now?: Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders C108 Introduction to Primary Headache Disorders I: Migraine and Other Primary Headaches Including Tension-Type, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine
C109 Multiple Sclerosis Overview II: Clinical Advances C110 Neurologic Complications in Adults with Down Syndrome C111 Enhancing Your Career and Practice Through Neuropalliative Care
C112 Continuum ® Test Your Knowledge: A Multiplechoice Question Review I
C113 Sleep for the Practicing Neurologist I: Is it Narcolepsy
or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence C114 Concussion: Pathogenesis, Fluid and Imaging Biomarkers, Diagnosis, and Treatment of Post-Concussion Headache C115 Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia C116 Cerebrovascular Disease I: Prevention C117 Introduction to Clinical Research and Methods C118 L Leadership in the Era of Burnout: A Practical Approach to Becoming a True Physician Leader 1:00 p.m.–5:30 p.m. C119 EMG Skills Workshop: Basic $ (registration required) 1:20 p.m.–1:50 p.m. X NIH Grant Review Process 1:30 p.m.–2:00 p.m. X Office Hours: Clinical Research Recommendations for Residents and Fellows 1:30 p.m.–2:30 p.m. X Neurological Exam Tips and Tricks 1:45 p.m.–2:15 p.m. X Academic Career Panel: Find out How to Get Your Career Started 1:45 p.m.–2:30 p.m. X The Encompassing Value of the Patient-Physician Relationship 2:00 p.m.–2:30 p.m. X NINDS Clinical Trials (New NIH Definition) and Networks, NeuroNEXT, StrokeNET, SIREN X Caring for Telemedicine Patients 2:00 p.m.–2:45 p.m. X Dancing with Parkinson’s 2:30 p.m.–3:00 p.m. X How to Start a Career in Neurology Education X Office Hours: Finding Collaborators 2:30 p.m.–3:30 p.m. X What Is the AAN Doing for Small and Solo Practitioners? 2:40 p.m.–3:10 p.m. X Pain Research Funding Opportunities, Clinical and Basic 2:45 p.m.–3:30 p.m. X Training in Neurology While on a Visa: Challenges and Possible Solutions for Foreign Medical Graduates 3:00 p.m.–3:45 p.m. X StrengthsFinders Social Hour 3:00 p.m.–4:00 p.m. X Biological and Chemical Neuroterrorism and Neurowarfare 3:15 p.m.–3:45 p.m. X Staying on Track: A Career as a Clinical Researcher 3:20 p.m.–3:50 p.m. X Pain Research Funding Opportunities, Clinical and Basic 3:30 p.m.–5:30 p.m. S24 MS Outcome Measures and Biomarkers S25 Advances in Amyotrophic Lateral Sclerosis S26 Movement Disorders: Parkinson’s Disease Clinical Trials C120 Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome C121 Introduction to Primary Headache Disorders II: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches C122 Multiple Sclerosis Overview III: The Pathogenesis of Multiple Sclerosis and Mechanism of Action of Treatments for MS C123 Child Neurology: A Case-based Approach C124 The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and Endof-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders C125 Continuum ® Test Your Knowledge: A Multiplechoice Question Review II
C126 Sleep for the Practicing Neurologist II: Night Fighting:
Sleep Related Hypermotor Epilepsy, Sleepwalking, and Dream Enactment C127 Concussion Management: Chronic Sequelae and Symptom Targeted Treatment in the Acute, Subacute and Chronic Phase After Concussion C128 Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics C129 Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke C130 Disorders of Motor Programming: The Apraxias and Action-Intentional Disorders Chalk Talk C131 Introduction to Integrative Neurology C132 Actualization Científica Durante el Congreso Anual I 3:45 p.m.–4:30 p.m. X International Members: What Can the AAN Do for You? 4:00 p.m.–4:30 p.m. X Your Grant Proposal Was Rejected: Now What? Turning a Feedback Into a Successful Project 4:00 p.m.–4:45 p.m. X The Sleep Mythbuster!: Illuminating the Facts and Fiction Towards Achieving the Sleep Healthy Neurologist 4:30 p.m.–5:30 p.m. X Controversies in Neurology: Is the Zombie Apocalypse Upon Us? Local Outbreaks, Bioterrorism or Bioengineering Run Amok… 4:45 p.m.–5:30 p.m. X Teaching During a Busy Clinic 5:00 p.m.–5:30 p.m. X Guided Meditation 5:45 p.m.–7:15 p.m. Emerging Science Session 7:00 p.m.–10:00 p.m. Industry Therapeutic Updates
Wednesday, April 25 7:00 a.m.–7:45 a.m. X Yoga (All-Levels Vinyasa) 7:00 a.m.–9:00 a.m. C133 Higher Cortical Visual Disorders: Case-based Review C134 Tuberculosis of the Central Nervous System C135 Neurocognitive Assessment for Neurologists C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I C137 What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders C138 Clinical EEG I: Normal EEG, Normal Variants, and How to Avoid The Common Pitfall of Over-reading C139 Neurologic Case Studies in Pregnancy C140 Paroxysmal Movement Disorders C141 Integrating Sleep Medicine Concepts into Your Child Neurology Practice C142 Mastering EMG Waveform Recognition Skills in Just Two Hours! C143 Evaluation and Treatment of Common Spine Disorders 8:00 a.m.–8:45 a.m. X Acupuncture Demonstration: Auriculotherapy 8:00 a.m.–9:00 a.m. S27 “Best of” Session: Movement Disorders 8:00 a.m.–9:00 a.m. X Step Away from the Desktop! Recapturing the Joy in Practice 8:00 a.m.–9:10 a.m. X How to Write and Publish Research Papers, Reviews, and Other Scientific Communications 8:15 a.m.–9:00 a.m. X How to Give Effective Feedback 8:30 a.m.–9:00 a.m. X Office Hours: Selecting an AAN Research Program Mentor 9:15 a.m.–11:30 a.m. Frontiers in Neuroscience Plenary Session 11:30 a.m.–3:00 p.m. Exhibit Hall 11:30 a.m.–7:00 p.m. P4 Poster Session IV 11:45 a.m.–12:35 p.m. Cerebrovascular Disease and Interventional Neurology Poster Discussion Session
Current as of February 15, 2018. Program Subject to change
12:00 p.m.–12:30 p.m. X Office Hours: Recruiting Difficult and Underrepresented Populations in Research X Recruiting Minorities 12:00 p.m.–12:45 p.m. X Neurology and Wellness—Physician, Heal Thyself 12:00 p.m.–1:00 p.m. X Neuro-Jeopardy: Telencephalon Twisters 12:30 p.m.–1:00 p.m. X Office Hours: Navigating Uncommon Pathways in Academic Neurology: A Journey from Bedside to Bench 12:40 p.m.–1:10 p.m. X Neuroscience of Bias 12:45 p.m.–1:30 p.m. X Clinical Research in the Area of Practice, Quality and Patient Safety 1:00 p.m.–1:30 p.m. X So You Want to Work for a Hospital? 1:00 p.m.–1:50 p.m. X Community Education in Minority Population 1:00 p.m.–2:00 p.m. S28 Practice, Policy, and Ethics 1:00 p.m.–3:00 p.m. S29 Child Neurology and Developmental Neurology I S30 Movement Disorders: Dystonia, Chorea, and other Disorders S31 Therapeutics, Phenotypes, and Biomarkers in Neuromuscular Disorders S32 Headache: Therapeutics C144 Neurology Update I: Epilepsy, Behavioral Neurology, and Neurologic Infections C145 Severe TBI: From ICU to Rehabilitation C146 Non-Alzheimer’s Dementia I: Frontotemporal Dementias C147 Multiple Sclerosis Therapy: Disease-modifying Treatment II C148 LGBTQI Health in Neurology C149 What Do I Do Now?: Neurologic Consultations in Cancer Patients I C150 Where is the Lesion? A History of Neurological Investigations Part I C151 Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke C152 Nystagmus and Saccadic Intrusions Made Simple C153 Circadian Rhythm Disorders: Implications for Neurology C154 The Global Burden of Neurologic Diseases C155 Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System C156 Clinical EEG II: Focal, Diffuse, and Epileptiform Abnormalities in Adults 1:00 p.m.–5:00 p.m. C157 L Advanced Leadership Training: Preparing for Your Career’s Insurmountable Opportunities C158 L Leadership Strengths in Neurology: The Data, Tools and Practical Application of Strengths for Leadership, Team Building, and Personal Development $ (registration required) 1:00 p.m.–5:30 p.m. C159 Clinical Uses of Botulinum Toxin for Dystonia Skills Workshop $ (registration required) 1:30 p.m.–2:30 p.m. X Parkinson Disease: Raising Your Game 2:00 p.m.–2:30 p.m. X Office Hours: Mentor-Mentee Relationships X Women in Neuroscience 2:00 p.m.–2:45 p.m. X Resiliency for the Neurologist 2:40 p.m.–3:10 p.m. X Patient-Reported Measures in Neurology 2:45 p.m.–3:30 p.m. X Pursing a Career in Health Care Administration 3:00 p.m.–3:30 p.m. X Office Hours: Research Careers in Industry 3:00 p.m.–3:45 p.m. X Introduction to Acupuncture II: Evidence-based Applications for Acupuncture in the Treatment of Neurologic Conditions 3:00 p.m.–4:00 p.m. X Health Care Disparities Among Underserved Populations
3:30 p.m.–4:15 p.m. S33 Global Health 3:30 p.m.–5:30 p.m. Invited Science: Sleep N4 Neuroscience in the Clinic: Opioid Use and Abuse: The Overlapping Neurobiology of Pain and Addiction, and the Path Toward Better Treatments S34 Behavioral and Cognitive Neurology S35 Child Neurology and Developmental Neurology II S36 MS Therapeutics and Clinical Research C160 Neurology Update II: Movement Disorders, Spine Disorders, and Sleep Disorders C161 Non-Alzheimer’s Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias C162 Multiple Sclerosis Therapy: Symptom Management C163 How to Run a Practice: Business Strategies for Neurology Private Practices, Academic Centers, and the Future C164 What Do I Do Now?: Neurologic Consultations in Cancer Patients II C165 Where is the Lesion? A History of Neurological Investigation Part II C166 Cerebrovascular Disease IV: Telestroke C167 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia C168 CNS Toxicities C169 Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System C170 Clinical EEG III: Neonatal and Pediatric C171 Actualización Sobre Opciones Terapéuticas para la Epilepsìa Farmacorresistente C244 Joint AAN and AHA/ASA Session 3:45 p.m.–4:30 p.m. X Navigating Fellowship in Neurology 4:00 p.m.–4:45 p.m. X Diets and Supplements in MS: What’s the Evidence Thus Far? 4:15 p.m.–5:00 p.m. X The Neurology of VooDoo 4:30 p.m.–5:30 p.m. S37 Neurorehabilitation 4:45 p.m.–5:30 p.m. X Top Ten Clinical, Educational and Leadership Pearls 5:00 p.m.–5:30 p.m. X Guided Meditation 5:15 p.m.–6:15 p.m. X Neurology Illustrated: The Neurology of Art 6:00 p.m.–10:00 p.m. Commitment to Cures 7:00 p.m.–10:00 p.m. Industry Therapeutic Updates
Thursday, April 26
7:00 a.m.–7:45 a.m. X Yoga (All-Levels Vinyasa) 7:00 a.m.–9:00 a.m. C172 Clinical Epilepsy I: Basics C173 Using Sleep Medicine to Help Solve Difficult Neurologic Cases C174 Rehabilitation in Neurology C175 Clinical Pearls in Autoimmune Neurology: Real World Cases C176 The Dystonia: Diagnosis, Treatment and Update on Etiologies C177 So You’ve Diagnosed Your Patient with a Neuroinfectious Disease, Now What? Practical Pearls in the Treatment and Management of Neuroinfectious Diseases C178 Neuro-oncology in 2018: Navigating Current Trends C179 Clinical EMG I: Principles and Practice of NCS and Needle EMG C180 Principles of Genomic Medicine: Clinical Exome Sequencing in Neurologic Disease C181 Preventive Neurology: How Neurologists Can Improve Outcomes That Matter to Patients 8:00 a.m.–8:30 a.m. X How to Bridge to Careers in Industry 8:00 a.m.–8:45 a.m. X Sleep and Performance in Elite Athletes 8:00 a.m.–9:00 a.m. S38 “Best of” Session: Clinical Trial Updates in Neuromuscular Disorders
8:00 a.m.–9:00 a.m. X Enhancing Epilepsy Care in Your Practice: In-Person Digital Learning and Emotional for Self-Management, Education, and Community Supports from the National Epilepsy Education and Awareness Collaborative 8:40 a.m.–9:10 a.m. X The Pathway to Become a Clinical Trialist 9:15 a.m.–11:30 a.m. Controversies in Neurology Plenary Session 11:30 a.m.–7:00 p.m. P5 Poster Session V 11:45 a.m.–12:35 p.m. MS and CNS Inflammatory Disease Poster Discussion Session 11:45 a.m.–12:30 p.m. X Teaching History and Exam with Teleneurology 12:00 p.m.–12:45 p.m. X The Purpose Checkup: Find Meaning, Live Longer, Better 12:00 p.m.–1:00 p.m. X Who Wants to be a Millionaire 12:45 p.m.–1:30 p.m. X Effective Neurology Residency Program 1:00 p.m.–1:30 p.m. X Office Hours: Early Career Research Funding and Career Development X What Do I Need to Know About Coding in My Practice? 1:00 p.m.–1:45 p.m. X Medical Marijuana: What do Neurologists Need to Know? 1:00 p.m.–2:15 p.m. S39 History of Neurology 1:00 p.m.–2:30 p.m. Invited Science: The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative 1:00 p.m.–3:00 p.m. N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis S40 Acute Stroke Care S41 Neurologic Infections S42 Neurocritical Care C182 Clinical Epilepsy II: Considerations Across the Age Span Pediatrics, Pregnancy, and Elderly C183 Hot Topics in Sleep Neurology C184 Behavioral Neurology I: Network Anatomy of Behavior and Language C185 Neurology Update III: Neuromuscular, Headache, and Stroke C186 Myelopathies I: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes C187 Cerebellar and Afferent Ataxias: Diagnosis and Management C188 Neuroimaging for the General Neurologist I: Spine and Peripheral Nerve C189 Business Strategies for Payer Negotiations and/or How to Go off the Grid C190 Neuro-oncologic Predicaments in the Hospital Setting C191 Neuro-otology I: The Common Peripheral Vestibular Disorders C192 Clinical EMG II: Neuromuscular Junction Testing and Quantitative EMG C193 Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Antibody-Mediated Rapidly Progressive Dementia C194 Actualización Sobre el Manejo del Ictus Cerebrovascular C195 Practical Training in Injection Techniques in the Treatment of Headache Disorders Skills Workshop $ (registration required) 1:00 p.m.–5:30 p.m. C196 Brain Death Skills Workshop: How to Perform a Brain Death Evaluation, Avoid Pitfalls and Convey the News to the Family $ (registration required) 1:30 p.m.–2:30 p.m. X The Value of the Neurologic Exam: Caring for Your Patient for $500 or Less 1:45 p.m.–2:30 p.m. X Interviewing Skills 2:00 p.m.–2:45 p.m. X Cafe Talk: Communication in Neurology Practice 2:00 p.m.–3:00 p.m. X Using Your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency
10 2018 AAN Annual Meeting
2:45 p.m.–3:30 p.m. X O Funding, Where Art Thou? How to Develop a FullTime Academic Career in Global Neurology 3:00 p.m.–3:45 p.m. X Magnifying Your Life Through Poetry 3:00 p.m.–4:00 p.m. X Consejos Prácticos para un Buen Examen Neurológico 3:30 p.m.–5:30 p.m. Invited Science Session: Neuro Trauma N6 Neuroscience in the Clinic: Neurologic Complications of Cancer Immunotherapy: A New Frontier in Neuro-Inflammation S43 Migraine S44 MS Risk Factors, Susceptibility, Diagnosis, and Cognitive Impairment S45 Movement Disorders: Parkinsonian Disorders, Basic Science, and Imaging S46 Advances in Spinal Muscular Atrophy C197 Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG) C198 Behavioral Neurology II: Memory and Attention C199 Neurology Update IV: Multiple Sclerosis, Neuroophthalmology, and Autoimmune Encephalopathies C200 Myelopathies II: Approaches to Rehabilitation and Psychosocial Challenges C201 Differential Diagnosis of Neurologic Infections C202 Neuroimaging for the General Neurologist II: Spine and Peripheral Nerve C203 Endovascular Treatment of Acute Stroke and Cerebrovascular Disease C204 Making Sure You Get Paid Under the New Health Care Laws C205 Neuro-otology II: Diagnosis and Treatment of Nuanced Causes of Dizziness C206 Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches C207 Mitochondrial Disorders in Neurology C208 Assessment of Rapidly Progressive Dementias II: Neurodegenerative Diseases and Infections Presenting as Rapidly Progressive Dementia C209 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop $ (registration required) 4:30 p.m.–5:00 p.m. X Grantwriting 101: Getting Started 4:30 p.m.–5:30 p.m. X Neurology History: Weaving Past with Present 6:30 p.m.–9:30 p.m. C210 Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease C211 Case Studies in the ICU C212 Case Studies: Test Your Knowledge: A Case-based Approach to Neuroimaging C213 Case Studies: Unusual Movement Disorders C214 Case Studies: Challenging Headache Cases C215 Case Studies in Behavioral Neurology: Focus on Frontotemporal Degeneration
Friday, April 27
7:00 a.m.–7:45 a.m. X Yoga (All-Levels Vinyasa) 7:00 a.m.–9:00 a.m. C216 Neuroendocrine Update: Nuts and Bolts of What You Need to Know C217 Current Management of Incidental and Asymptomatic Cerebrovascular Lesions C218 Infections of the Nervous System I: Diagnostic Testing of Neurological Infections C219 The Early-Onset Dementias C220 Drugs and Toxin-induced Neurologic Emergencies C221 REM Sleep Behavior Disorder C222 Therapy of Movement Disorders: A Case-based Approach C223 The Burden of Epilepsy: Managing Comorbidities and Quality of Life 8:00 a.m.–9:00 a.m. S47 “Best of” Session: MS and CNS Inflammatory Diseases 8:00 a.m.–9:10 a.m. X Role of Placebo in Neuromuscular Clinical Trials and in Management of NM Disorders 9:15 a.m.–11:30 a.m. Neurology Year in Review: Emerging Therapies Plenary Session
X = Experiential Learning
11:30 a.m.–5:30 p.m. P6 Poster Session VI 11:45 a.m.–12:35 p.m. Movement Disorders Poster Discussion Session 2:00 p.m.–12:30 p.m. X How to Bridge to Careers in Industry X Incorporating a Semi-Concierge Model into Your Own Neurology Practice 12:00 p.m.–12:45 p.m. X Outsmart Stress 12:00 p.m.–1:00 p.m. X The Neurology of Creativity and the Keyboard 12:30 p.m.–1:00 p.m. X Office Hours: Making the Transition from Research Fellow to Clinical Research Faculty 12:40 p.m.–1:10 p.m. X How to Put Together an Effective Research Presentation 1:00 p.m.–3:00 p.m. S48 Novel Biomarkers in Aging and Dementia S49 Neuro Trauma and Sports Neurology S50 Updates in General Neurology S51 Pediatric MS C224 Neuromyelitis Optica Spectrum Disorders C225 Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia C226 Infections of the Nervous System II: Neuro-ID Emergencies C227 Behavioral Neurology: A Case-based Approach (Cancelled) C228 Neuroimaging for the General Neurologist I: Brain C229 Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders C230 Neurologic Complications of Medical and Surgical Therapies C231 ICD-10-CM: How to Optimize for Accurate Diagnosis and Reimbursement C232 Hot Topics in Headaches and Related Disorders I: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances C233 Simposio Español: Actualización Científica Durante el Congreso Anual II 1:00 p.m.–5:00 p.m. C234 Epilepsy Skills Workshop: Focus on Treatment $ (registration required) 1:30 p.m.–2:30 p.m. X Live Intraoperative Monitoring 2:40 p.m.–3:10 p.m. X Recruiting Minorities 3:00 p.m.–4:00 p.m. X Ask Us Anything: Expert Panel on Stroke 3:30 p.m.–5:30 p.m. N7 Neuroscience in the Clinic: REM Sleep Behavior Disorder: Past, Present, Future S52 MS and CNS Inflammatory Disease: Basic Science S53 Epilepsy/Clinical Neurophysiology (EEG) III S54 Ischemic Stroke Prevention C235 Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy C236 Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome and Less Common Disorders of Neuromuscular Transmission C237 Neurologic Complications of Medical Disease C238 Memory Disorders: A Case-based Approach C239 Infections of the Nervous System III: Advanced Topics in Infectious Neurology C240 Neuroimaging for the General Neurologist II: Brain C241 Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders C242 Coding 101: It’s Not Your Father’s Oldsmobile C243 Hot Topics in Headaches and Related Disorders II: Unusual Headaches, Childhood Headaches, and Concussion Management 4:00 p.m.–4:30 p.m. X Historical Perspective on Treating Epilepsy 4:30 p.m.–5:30 p.m. X Ask Us Anything: Expert Panel on Multiple Sclerosis 5:30 p.m.–7:00 p.m. Closing Party Happy Hour
L = Leadership University
$ = Additional Fee Required
AAN 70
th Anniversary Celebration
Join Us in Celebrating 70 Years of the AAN Sunday, April 22 • 7:00 p.m.–11:00 p.m. at
LIMITED QUANTITY OF FREE TICKETS AVAILABLE Hurry—this family friendly event is free only to the first 4,000 registered Annual Meeting attendees* who RSVP for the celebration. Reserve or purchase additional tickets for $115 before March 29.
Ticket includes: • Transportation to/from the event • Delicious food and beverages all evening • Rides and studio tour
*Limit one free ticket per registered Annual Meeting Attendee.
Secure your ticket today at AAN.com/view/70Anniversary
PRESENTAMOS NUESTRO CURRÍCULO EN ESPAÑOL Conozca estos programas impartidos completamente en español, durante la Reunión Anual de 2018 en Los Ángeles: • Actualizaciones científicas de la • Terapia de esclerosis múltiple Reunión Anual • Infecciones del SNC y Medicina Tropical • Examen neurológico • Epilepsia • ¡Y más! • Derrames
Convocatoria a médicos que hablen español para Brain Health Fair 2018 Buscamos expertos de habla hispana para presentar los últimos avances en neurología, en español, durante esta feria gratuita y familiar para pacientes neurológicos, sus familias y responsables de su cuidado en el área de Los Ángeles. El evento se celebra el día 20 de abril. Póngase en contacto con Stephanie Szurek escribiendo a Sszurek@aan.com para ofrecerse como voluntario.
IMPULSANDO A LA NEUROLOGÍA. IMPULSÁNDOLO A USTED.
HOW TO GET THE MOST FROM THIS GUIDE This Annual Meeting guide brings you the most up-to-date schedule of the 2018 AAN Annual Meeting courses, sessions, and events, with a higher level of detail given for the science programs. The various meeting summaries provide you a fast path to what is available for you, whether it’s by neurology topic, time, or program category.
INTRODUCTION AND OVERVIEWS
SESSION SECTIONS
Registration
Experiential Learning Areas
The registration information on pages 6–7 outlines the advantages of registering early and the savings that membership brings. The single-registration fee gives you access to nearly everything the meeting has to offer.
An interactive new way of learning that will engage you intellectually, emotionally, and socially and offer you fresh ideas to help you personally and professionally.
Meeting at a Glance This tear-out guide provides a high-level overview of the daily schedule of courses, sessions, and events so you can map your daily plans. The back has a detailed listing of course and session times to assist with further planning.
Meeting Schedule Colors All Annual Meeting programs all color-coded throughout the book. This will make it easier to find presentations of interest when scanning the schedules.
Program Number Codes Program numbers indicate both program type and their sequential occurrence throughout the week of the meeting. The session type is designated by the first letter of the code:
Invited Science Sessions An AAN platform session featuring authors giving encore presentations of top abstracts previously presented at a subspecialty meeting.
Neuroscience in the Clinic Session A two‐hour session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will introduce and provide background on a case and clinicians will apply the case to a patent. Sessions will feature abstract presentations related to the topic. Sessions end with a panel discussion.
Plenary Sessions
C = Course: An education program using one or more teaching methods, including didactic, interactive, and case-based.
A premiere general session highlighting the latest advances in neuroscience.
N = Neuroscience in the Clinic Session: A two-hour session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application.
“Best of” Scientific Sessions
P = Poster: A poster displayed in one of the scientific poster sessions. Authors will stand by their poster for 90 minutes during a late afternoon reception. S = Scientific Session: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes long with four minutes of question and answer.
Session Icons
X = Experiential Learning L = Leadership University
$ = Additional Fee Required = Abstract of Distinction
A platform session that brings together the top four scoring abstracts in a topic, as rated by the topic reviewers. Interact with the authors in a smaller, more intimate setting at the conclusion of the session. These “Best of” sessions are the perfect lead-in to the plenary sessions that immediately follow.
Scientific Sessions A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more abstracts.
Session Category Symbol
Poster Sessions
G = Research
A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors.
Abstracts of Distinction The first ever Abstracts of Distinction program recognizes the scientific achievements across this year’s Annual Meeting. Look for the Abstracts of Distinction ribbon, which distinguishes the top abstract in each topic as determined by the Science Committee.
AAN.com/view/AM18 13
Reductions in Mean Weekly Rate of Drop Seizures by Dose (N=217, mITT)1,2
Study Design: CONTAIN (ClObazam in PatieNTs with Lennox-GAstaut SyNdrome) was a randomized, double-blind, placebo-controlled study consisting of a 4-week baseline period followed by a 3-week titration period and a 12-week maintenance period (N=238, randomized). Patients aged 2 to 54 years with a current or prior diagnosis of LGS were stratified into 2 weight groups (12.5 kg to ≤30 kg or >30 kg), and then randomized to placebo or 1 of 3 target maintenance doses of ONFI. The dosage groups were placebo (n=59); low-dose (5 mg/10 mg, n=58); medium-dose (10 mg/20 mg, n=62); and high-dose (20 mg/40 mg, n=59). Doses above 5 mg/day were administered in 2 divided doses. The primary endpoint was the percentage reduction in mean weekly rate of drop seizures (atonic, tonic, or myoclonic) from the 4-week baseline period to the 12-week maintenance period.
• In the CONTAIN trial, drop seizures were defined as drop attacks or spells that involved the entire body, trunk, or head, and2: – Led to a fall or injury, slumping in a chair, or hitting the head on a surface – Could have led to a fall or injury, depending on the position of the patient at the time of the attack or spell • Patients in the trial experienced ≥2 drop seizures (atonic, tonic, or myoclonic) per week during 4-week baseline, while receiving stable doses of 1 to 3 AEDs ≥30 days prior to screening2 References: 1. ONFI [package insert]. Deerfield, IL: Lundbeck. 2. Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77(15):1473-1481.
VISIT US AT BOOTH #447
A FORCE FOR REDUCTION Indications and Usage ONFI® (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
Important Safety Information WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS See full Prescribing Information for complete boxed warning. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. • Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. • Limit dosages and durations to the minimum required. • Follow patients for signs and symptoms of respiratory depression and sedation. Contraindication: Hypersensitivity ONFI is contraindicated in patients with a history of hypersensitivity to the drug or its ingredients. Hypersensitivity reactions have included serious dermatological reactions. Risks from Concomitant Use with Opioids (see Boxed Warning) Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drugrelated mortality compared to use of opioids alone. If a decision is made to prescribe ONFI concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use. Advise both patients and caregivers about the risks of respiratory depression and sedation when ONFI is used with opioids. Potentiation of Sedation from Concomitant Use with Central Nervous System (CNS) Depressants ONFI has a CNS depressant effect. Caution patients or their caregivers against simultaneous use with other CNS depressant drugs or alcohol and that the effects of other CNS depressant drugs or alcohol may be potentiated. Somnolence or Sedation ONFI causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related. In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment. Monitor patients for somnolence and sedation, particularly with concomitant use of other CNS depressants. Caution patients against engaging in hazardous activities that require mental alertness, such as operating dangerous machinery or motor vehicles, until the effect of ONFI is known. Withdrawal Symptoms As with all antiepileptic drugs (AEDs), withdraw ONFI gradually to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus. Withdrawal symptoms occurred following abrupt discontinuation of ONFI; the risk of withdrawal symptoms is greater with higher doses.
Serious Dermatological Reactions Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period. Discontinue ONFI at the first sign of rash, unless the rash is clearly not drug-related. Physical and Psychological Dependence Carefully monitor patients with a history of substance abuse when receiving ONFI or other psychotropic agents because of the predisposition of such patients to habituation and dependence. In clinical trials, cases of dependency were reported following abrupt discontinuation of ONFI. The risk of dependence increases with increasing dose and duration of treatment. Suicidal Behavior and Ideation AEDs, including ONFI, increase the risk of suicidal thoughts or behavior in patients. Inform patients, their caregivers, and families of the risk and advise them to monitor and report any emergence or worsening of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts of self-harm. If these symptoms occur, consider whether it may be related to the AED or illness, because epilepsy itself can increase these risks. Pregnancy, Registry and Nursing Mothers • Based on animal data, ONFI may cause fetal harm and should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. º Encourage patients to call the toll-free number 1-888-233-2334 to enroll in the Pregnancy Registry or visit http://www.aedpregnancyregistry.org/. • ONFI is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from ONFI, discontinue nursing or discontinue the drug. Adverse Reactions The most commonly observed adverse reactions reported in an LGS randomized, double-blind, placebo-controlled, parallel group clinical trial of patients who received clobazam as adjunctive therapy (≥10% in any treatment group and at least 5% greater than placebo, respectively) were somnolence or sedation (32% vs. 15%), somnolence (25% vs. 12%), pyrexia (17% vs. 3%), lethargy (15% vs. 5%), aggression (14% vs. 5%), drooling (14% vs. 3%), irritability (11% vs. 5%), ataxia (10% vs. 3%), and constipation (10% vs. 0%).
Please see Brief Summary of Prescribing Information, including Boxed Warning for risks from concomitant use with opioids, on the following pages. For full Prescribing Information, Medication Guide, and Instructions for Use, go to ONFI.com for more information. ©2018 Lundbeck. All rights reserved. ONFI is a registered trademark of Lundbeck CLB-B-100154
ONFI® (clobazam) tablets, for oral use, CIV ONFI® (clobazam) oral suspension, CIV Brief Summary of Prescribing Information (See package insert for full Prescribing Information or visit www.ONFI.com) Rx Only WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS See full Prescribing Information for complete boxed warning. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. • Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. • Limit dosages and durations to the minimum required. • Follow patients for signs and symptoms of respiratory depression and sedation. INDICATIONS AND USAGE – ONFI® (clobazam) CIV is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. CONTRAINDICATIONS – ONFI is contraindicated in patients with a history of hypersensitivity to the drug or its ingredients. Hypersensitivity reactions have included serious dermatological reactions [see Warnings and Precautions in full PI]. WARNINGS AND PRECAUTIONS – Risks from Concomitant Use with Opioids: Concomitant use of benzodiazepines, including ONFI, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids for use in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drugrelated mortality compared to use of opioids alone. If a decision is made to prescribe ONFI concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. Advise both patients and caregivers about the risks of respiratory depression and sedation when ONFI is used with opioids [see Drug Interactions in full PI]. Potentiation of Sedation from Concomitant Use with Central Nervous System Depressants: Since ONFI has a central nervous system (CNS) depressant effect, patients or their caregivers should be cautioned against simultaneous use with other CNS depressant drugs or alcohol, and cautioned that the effects of other CNS depressant drugs or alcohol may be potentiated [see Drug Interactions in full PI]. Somnolence or Sedation: ONFI causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related. In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment. Prescribers should monitor patients for somnolence and sedation, particularly with concomitant use of other central nervous system depressants. Prescribers should caution patients against engaging in hazardous activities requiring mental alertness, such as operating dangerous machinery or motor vehicles, until the effect of ONFI is known. Withdrawal Symptoms: Abrupt discontinuation of ONFI should be avoided. ONFI should be tapered by decreasing the dose every week by 5-10 mg/day until discontinuation. Withdrawal symptoms occurred following abrupt discontinuation of ONFI; the risk of withdrawal symptoms is greater with higher doses. As with all antiepileptic drugs, ONFI should be withdrawn gradually to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus. Withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines. The more severe withdrawal symptoms have usually been limited to patients who received excessive doses over an extended period of time, followed by an abrupt discontinuation. Generally milder withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic doses for several months [see Dosage and Administration and Warnings and Precautions in full PI]. Serious Dermatological Reactions: Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period. Patients should be closely monitored for signs or symptoms of SJS/TEN, especially during the first 8 weeks of treatment initiation or when re-introducing therapy. ONFI should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered [see Contraindications in full PI]. Physical and Psychological Dependence: Patients with a history of substance abuse should be under careful surveillance when receiving ONFI or other psychotropic agents because of the predisposition of such patients to habituation and dependence [see Drug Abuse and Dependence in full PI]. Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including ONFI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing ONFI or any other AED must balance the risk
of suicidal thoughts or behavior with the risk of untreated illness. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers [see Warnings and Precautions in full PI]. ADVERSE REACTIONS – Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. During its development for the adjunctive treatment of seizures associated with LGS, ONFI was administered to 333 healthy volunteers and 300 patients with a current or prior diagnosis of LGS, including 197 patients treated for 12 months or more. The conditions and duration of exposure varied greatly and included single- and multiple-dose clinical pharmacology studies in healthy volunteers and two double-blind studies in patients with LGS (Study 1 and 2) [see Clinical Studies in full PI]. Only Study 1 included a placebo group, allowing comparison of adverse reaction rates on ONFI at several doses to placebo. Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1): The adverse reactions associated with ONFI treatment discontinuation in ≥1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia. Most Common Adverse Reactions in an LGS Placebo Controlled Clinical Trial (Study 1): Table 3 lists the adverse reactions that occurred in ≥5% of ONFI-treated patients (at any dose), and at a rate greater than placebo-treated patients, in the randomized, double-blind, placebocontrolled, parallel group clinical study of adjunctive AED therapy for 15 weeks (Study 1). Table 3. Adverse Reactions Reported for ≥5% of Patients and More Frequently than Placebo in Any Treatment Group ONFI Dose Level Placebo N=59 %
Lowa N=58 %
Mediumb N=62 %
Highc N=59 %
All ONFI N=179 %
Gastrointestinal Disorders Vomiting
5
9
5
7
7
Constipation
0
2
2
10
5
Dysphagia
0
0
0
5
2
General Disorders and Administration Site Conditions Pyrexia
3
17
10
12
13
Irritability
5
3
11
5
7
Fatigue
2
5
5
3
5
10
10
13
14
12
Infections and Infestations Upper respiratory tract infection Pneumonia
2
3
3
7
4
Urinary tract infection
0
2
5
5
4
Bronchitis
0
2
0
5
2
Metabolism and Nutrition Disorders Decreased appetite
3
3
0
7
3
Increased appetite
0
2
3
5
3
15
17
27
32
26
Somnolence
12
16
24
25
22
Sedation
3
2
3
9
5
5
10
5
15
10
Nervous System Disorders Somnolence or Sedation
Lethargy Drooling
3
0
13
14
9
Ataxia
3
3
2
10
5
Psychomotor hyperactivity
3
3
3
5
4
Dysarthria
0
2
2
5
3
Aggression
5
3
8
14
8
Insomnia
2
2
5
7
5
0
3
5
7
5
Psychiatric Disorders
Respiratory Disorders Cough
a Maximum daily dose of 5 mg for ≤30 kg body weight; 10 mg for >30 kg body weight b Maximum daily dose of 10 mg for ≤30 kg body weight; 20 mg for >30 kg body weight c Maximum daily dose of 20 mg for ≤30 kg body weight; 40 mg for >30 kg body weight
Post Marketing Experience: These reactions are reported voluntarily from a population of uncertain size; therefore, it is not possible to estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions are categorized by system organ class. Blood Disorders: Anemia, eosinophilia, leukopenia, thrombocytopenia; Eye Disorders: Diplopia, vision blurred; Gastrointestinal Disorders: Abdominal distention; General Disorders and Administration Site Conditions: Hypothermia; Investigations: Hepatic enzyme increased; Musculoskeletal: Muscle spasms; Psychiatric Disorders: Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination; Renal and Urinary Disorders: Urinary retention; Respiratory Disorders: Aspiration, respiratory depression; Skin and Subcutaneous Tissue Disorders: Rash, urticaria, angioedema, and facial and lip edema. DRUG INTERACTIONS – Opioids: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation [see Warnings and Precautions in full PI]. CNS Depressants and Alcohol: Concomitant use of ONFI with other CNS depressants may increase the risk of sedation and somnolence. Alcohol, as a CNS depressant, will interact with ONFI in a similar way and also increases clobazam’s maximum plasma exposure by approximately 50%. Therefore, caution patients or their caregivers against simultaneous use with other CNS depressant drugs or alcohol, and caution that the effects of other CNS depressant drugs or alcohol may be potentiated [see Warnings and Precautions in full PI]. Effect of ONFI on Other Drugs: Hormonal Contraceptives: ONFI is a weak CYP3A4 inducer. As some hormonal contraceptives are metabolized by CYP3A4, their effectiveness may be diminished when given with ONFI. Additional non-hormonal forms of contraception are recommended when using ONFI [see Clinical Pharmacology and Patient Counseling Information in full PI]. Drugs Metabolized by CYP2D6: ONFI inhibits CYP2D6. Dose adjustment of drugs metabolized by CYP2D6 may be necessary [see Clinical Pharmacology in full PI]. Effect of Other Drugs on ONFI: Strong and moderate inhibitors of CYP2C19: Strong and moderate inhibitors of CYP2C19 may result in increased exposure to N-desmethylclobazam, the active metabolite of clobazam. This may increase the risk of dose-related adverse reactions. Dosage adjustment of ONFI may be necessary when coadministered with strong CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole) [see Clinical Pharmacology in full PI]. USE IN SPECIFIC POPULATIONS – Pregnancy: Pregnancy Category C. Risk Summary: There are no adequate and well-controlled studies of ONFI in pregnant women. In animal studies, administration of clobazam during pregnancy resulted in developmental toxicity, including increased incidences of fetal malformations, at plasma exposures for clobazam and its major active metabolite, N-desmethylclobazam, below those expected at therapeutic doses in patients. ONFI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Available human data on the risk of teratogenicity associated with benzodiazepines are inconclusive. There is insufficient evidence in humans to assess the effect of benzodiazepine exposure during pregnancy on neurodevelopment. Administration of benzodiazepines immediately prior to or during childbirth can result in a syndrome of hypothermia, hypotonia, respiratory depression, and difficulty feeding. In addition, infants born to mothers who have taken benzodiazepines during the later stages of pregnancy can develop dependence, and subsequently withdrawal, during the postnatal period. Data for other benzodiazepines suggest the possibility of adverse developmental effects (including long-term effects on neurobehavioral and immunological function) in animals following prenatal exposure to benzodiazepines at clinically relevant doses. Data: Animal: In a study in which clobazam (150, 450, or 750 mg/kg/day) was orally administered to pregnant rats throughout the period of organogenesis, embryofetal mortality and incidences of fetal skeletal variations were increased at all doses. The low-effect dose for embryofetal developmental toxicity in rats (150 mg/kg/day) was associated with plasma exposures (AUC) for clobazam and its major active metabolite, N-desmethylclobazam, lower than those in humans at the maximum recommended human dose (MRHD) of 40 mg/day. Oral administration of clobazam (10, 30, or 75 mg/kg/day) to pregnant rabbits throughout the period of organogenesis resulted in decreased fetal body weights, and increased incidences of fetal malformations (visceral and skeletal) at the mid and high doses, and an increase in embryofetal mortality at the high dose. Incidences of fetal variations were increased at all doses. The highest dose tested was associated with maternal toxicity (ataxia and decreased activity). The low-effect dose for embryofetal developmental toxicity in rabbits (10 mg/kg/day) was associated with plasma exposures for clobazam and N-desmethylclobazam lower than those in humans at the MRHD. Oral administration of clobazam (50, 350, or 750 mg/kg/day) to rats throughout pregnancy and lactation resulted in increased embryofetal mortality at the high dose, decreased pup survival at the mid and high doses and alterations in offspring behavior (locomotor activity) at all doses. The low-effect dose for adverse effects on pre- and postnatal development in rats (50 mg/kg/day) was associated with plasma exposures for clobazam and N-desmethylclobazam lower than those in humans at the MRHD. Pregnancy Registry: To provide information regarding the effects of in utero exposure to ONFI, physicians are advised to recommend that pregnant patients taking ONFI enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves or their caregiver. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/. Nursing Mothers: ONFI is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from ONFI, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use: Safety and effectiveness in patients less than 2 years of age have not been established. In a study in which clobazam (4, 36, or 120 mg/kg/day) was orally administered to rats during the juvenile period of development (postnatal days 14 to 48), adverse effects on growth (decreased bone density and bone length) and behavior (altered motor activity and auditory startle response; learning deficit) were observed at the high dose. The effect on bone density, but not on behavior, was reversible when drug was discontinued. The no-effect level for juvenile toxicity (36 mg/kg/day) was associated with plasma exposures (AUC) to clobazam and its major active metabolite, N-desmethylclobazam, less than those expected at therapeutic doses in pediatric patients. Geriatric Use: Clinical studies of ONFI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly subjects appear to eliminate clobazam more slowly than younger subjects based on population pharmacokinetic analysis. For these reasons, the initial dose in elderly patients should be 5 mg/day. Patients should be titrated initially to 10-20 mg/day. Patients may be titrated further to a maximum daily dose of 40 mg if tolerated [see Dosage and Administration and Clinical Pharmacology in full PI]. CYP2C19 Poor Metabolizers: Concentrations of clobazam’s active metabolite, N-desmethylclobazam, are higher in CYP2C19 poor metabolizers than in extensive metabolizers. For this reason, dosage modification is recommended [see Dosage and Administration and Clinical Pharmacology in full PI]. Renal Impairment: The pharmacokinetics of ONFI were evaluated in patients with mild and moderate renal impairment. There were no significant differences in systemic exposure (AUC and Cmax) between patients with mild or moderate renal impairment and healthy subjects. No dose adjustment is required for patients with mild and moderate renal impairment. There is essentially no experience with ONFI in patients with severe renal impairment or ESRD. It is not known if clobazam or its active metabolite, N-desmethylclobazam, is dialyzable [see Dosage and Administration and Clinical Pharmacology in full PI]. Hepatic Impairment: ONFI is hepatically metabolized; however, there are limited data to characterize the effect of hepatic impairment on the pharmacokinetics of ONFI. For this reason, dosage adjustment is recommended in patients with mild to moderate hepatic impairment (Child-Pugh score 5-9). There is inadequate information about metabolism of ONFI in patients with severe hepatic impairment [see Dosage and Administration and Clinical Pharmacology in full PI]. DRUG ABUSE AND DEPENDENCE – Controlled Substance: ONFI contains clobazam which is a Schedule IV controlled substance. Abuse: ONFI can be abused in a similar manner as other benzodiazepines, such as diazepam. The pharmacological profile of ONFI is similar to that of other benzodiazepines listed in Schedule IV of the Controlled Substance Act, particularly in its potentiation of GABAergic transmission through its action on GABAA receptors, which leads to sedation and somnolence. The World Health Organization epidemiology database contains reports of drug abuse, misuse, and overdoses associated with clobazam [see Drug Abuse and Dependence in full PI]. Dependence: Dependence: In clinical trials, cases of dependency were reported following abrupt discontinuation of ONFI. The risk of dependence is present even with use of ONFI at the recommended dose range over periods of only a few weeks. The risk of dependence increases with increasing dose and duration of treatment. The risk of dependence is increased in patients with a history of alcohol or drug abuse [see Drug Abuse and Dependence in full PI]. Withdrawal: Abrupt discontinuation of ONFI causes withdrawal symptoms. As with other benzodiazepines, ONFI should be withdrawn gradually. In ONFI clinical pharmacology trials in healthy volunteers, the most common withdrawal symptoms after abrupt discontinuation were headache, tremor, insomnia, anxiety, irritability, drug withdrawal syndrome, palpitations, and diarrhea. Other withdrawal reactions to clobazam reported in the literature include restlessness, panic attacks, profuse sweating, difficulty in concentrating, nausea and dry retching, weight loss, blurred vision, photophobia, and muscle pain and stiffness. In general, benzodiazepine withdrawal may cause seizures, psychosis, and hallucinations [see Dosage and Administration and Warnings and Precautions in full PI]. OVERDOSAGE – Signs and Symptoms of Overdosage: Overdose and intoxication with benzodiazepines, including ONFI, may lead to CNS depression, associated with drowsiness, confusion and lethargy, possibly progressing to ataxia, respiratory depression, hypotension, and, rarely, coma or death. The risk of a fatal outcome is increased in cases of combined poisoning with other CNS depressants, including alcohol. Management of Overdosage: The management of ONFI overdose may include gastric lavage and/or administration of activated charcoal, intravenous fluid replenishment, early control of airway and general supportive measures, in addition to monitoring level of consciousness and vital signs. Hypotension can be treated by replenishment with plasma substitutes and, if necessary, with sympathomimetic agents. The efficacy of supplementary administration of physostigmine (a cholinergic agent) or of flumazenil (a benzodiazepine antagonist) in ONFI overdose has not been assessed. The administration of flumazenil in cases of benzodiazepine overdose can lead to withdrawal and adverse reactions. Its use in patients with epilepsy is typically not recommended. Lundbeck Deerfield, IL 60015, U.S.A. ONFI is a registered trademark of Lundbeck. December 2016 CLB-L-00016c
LUNDBECK LOGO COLOR BREAK: 1-Color Black Usage Starfish Shadow prints 75% screen of black
Lundbeck Name prints
Starfish Shadow prints
ANNUAL MEETING SCHEDULE
SATURDAY, APRIL 21 7:00 a.m.–9:00 a.m. C1 Mild Cognitive Impairment: Implications for Clinicians C2 Functional Neurologic Disorders I: Movement, Seizures, C3 C4
and Multiple Sclerosis Emergency Room Neuro-ophthalmology Hyperkinetic Movement Disorders: Videodiagnosis and Treatment
7:00 a.m.–12:30 p.m. C5 Clerkship and Program Directors Conference:
Demonstrating Your Impact as a Medical Educator
7:00 a.m.–4:00 p.m. C6 Neurology MOC Prep Course $ (registration required) C7 L Women in Leadership $ (registration required) 7:30 a.m.–8:15 a.m.
X
Are You My Mentor? How to Select a Good Mentor for Your Research Career . . . . . . . . . . . . . 77
8:25 a.m.–9:10 a.m.
X
Work Life Balance in Research . . . . . . . . . . . 77
9:15 a.m.–9:45 a.m.
X
How to Network at the Annual Meeting: Strategies for Trainees . . . . . . . . . . . . . . 75
9:15 a.m.–10:00 a.m.
X
Patient Centered Teaching . . . . . . . . . . . . . 75
9:20 a.m.–9:50 a.m.
Saturday
X
How to Successfully Publish Quality Improvement Projects . . . . . . . . . . . . . . . 77
9:30 a.m.–10:00 a.m.
X
What Is the Axon Registry? . . . . . . . . . . . . 73
9:30 a.m.–11:30 a.m. C8 Emergency Neurology: Evaluation of Coma, Meningitis, C9 C10 C11 C12 C13 C14
and Viral Encephalitis in the Emergency Room Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies More than Medicine: How to Access Home Care, Support Caregivers, and Discuss Complex Situations in Advanced Neurologic Disease Treatment of Pediatric Multiple Sclerosis in the Current Era Functional Neurologic Disorders II: Life Experiences and Management of Functional Disorders Neuroimaging Biomarkers Across the Dementia Spectrum Parkinson’s Disease Update
10:00 a.m.–10:30 a.m.
X
Sleep: Why You Should Spend Your Career Helping People Do It Right . . . . . . . . . . . . . . . . 75
10:00 a.m.–10:50 a.m.
X
Investigator Panel: How I Launched My Career with NIH Funding, Private Funding, AAN Research Program Funding and/or Government Funding . . . . . 77
10:15 a.m.–10:45 a.m.
X
Cognitive Biases and Diagnostic Errors at Bedside . . . 75
11:15 a.m.–12:00 p.m.
X
Choosing a Career in Clinical Practice . . . . . . . . 75
11:30 a.m.–12:00 p.m.
X
Office Hours: Research Careers in Industry . . . . . . 77
12:00 p.m.–12:30 p.m.
X X
Navigating the Annual Meeting App and Convention Center Tour . . . . . . . . . . . . . . 69 Office Hours: Writing a Great AAN Research Program Proposal . . . . . . . . . . . . . . . . 77
12:00 p.m.–12:45 p.m.
X
Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? . . 71
12:00 p.m.–4:00 p.m.
Young Investigator Symposium
C15 Resident Basic Science I: Neuropharmacology C16 L Leadership Challenges in Practice C17 Neurophysiologic Intraoperative Monitoring Skills Workshop $ (registration required)
12:15 p.m.–1:00 p.m.
X
What I Learned About Research—An Early Career Perspective . . . . . . . . . . . . . . . . . . . 75
12:20 p.m.–12:50 p.m.
X
How to Find Training: The Best Clinical Research and Methodology Training Options . . . . . . . . . . . 77
12:45 p.m.–1:45 p.m.
X
Ask Us Anything: Expert Panel on Headache and Facial Pain . . . . . . . . . . . . . . . . . . . 69
1:00 p.m.–1:30 p.m.
X
Statistics—Sample Size . . . . . . . . . . . . . . 77
1:00 p.m.–4:00 p.m. C18 L Educators’ Leadership Program
$ (registration required)
1:15 p.m.–2:00 p.m.
X
Interviewing Skills: Medical Students and Residents . . 75
1:30 p.m.–3:30 p.m. C19 Pediatric Neuro-ophthalmology Update C20 The Neurology of Social Behavior C21 Evaluation and Management of Autonomic Disorders II:
Diagnostic Approach and Treatments for Dysautonomia
C22 Stroke in Young Adults and Women C23 Critical Care Consultations for Neurohospitalists C24 Diagnosis and Treatment of Functional Movement Disorders
18 2018 AAN Annual Meeting
X
3:00 p.m.–4:00 p.m.
Clinical Trials Methodology Course—Information Session with William Meurer, MD, MS, CTMC Principal Investigator . . . . . . . . . . . . . . . 77 Paths for Success in the Quality Payment Program . . . 73 Cafe Talk: Narratives in Neurology: Creative Expression to Promote Resilience and Prevent Burnout . 71
X
Rural Neurology . . . . . . . . . . . . . . . . . 69
X
Teleneurology: Is This for Me? Pre-hospital and Nontraditional Uses of Teleneurology . . . . . . . . 75 Ask the Expert: Paths for QPP Success . . . . . . . . 73
3:00 p.m.–3:30 p.m.
X
Clinical Decision Support for Ordering of Diagnostic Imaging . . . . . . . . . . . . . . . . . . . . 73
3:00 p.m.–3:45 p.m.
X
TBI in Domestic Violence Victims: Care for Those Who Need It Most . . . . . . . . . . . . . . . . 73
4:15 p.m.–5:30 p.m.
Hot Topics Plenary Session . . . . . . . . . . . . 60
2:30 p.m.–3:00 p.m.
X
Growing Research in Medical Marijuana . . . . . . . 73
4:00 p.m.–4:30 p.m.
X
2:15 p.m.–3:00 p.m.
Women in Neurology: Crafting Your Leadership Career: Lessons from Leaders . . . . . . . . . . . 69
3:30 p.m.–4:00 p.m.
X
2:00 p.m.–3:00 p.m.
Social Media for Clinicians . . . . . . . . . . . . . 75
3:15 p.m.–4:15 p.m.
X
2:00 p.m.–2:45 p.m.
X
3:15 p.m.–4:00 p.m.
X
2:00 p.m.–2:30 p.m.
X
AAN Business Meeting
6:00 p.m.–8:00 p.m.
Neurobowl . . . . . . . . . . . . . . . . . . . . . . 192 7:00 p.m.–10:00 p.m.
Industry Therapeutic Updates
ANNUAL MEETING SCHEDULE
1:40 p.m.–2:10 p.m.
Acupuncture Demonstration: 4 Gates . . . . . . . . 71
CESC: 18AM NeuroBowl Ad—Half Page Horizontal Placed in 2018 Annual Meeting Education Preview book 8.25 x 5.25 +0.125 bleed, 4C
NEW NIGHT
Saturday Night 6:00 p.m.–8:00 p.m. ■
■
■
Kicking off the Annual Meeting Free event! Food and beverages provided!
Neurobowl: Kick-off Celebration ®
Who Will Win This Year’s Coveted Neurobowl® Trophy?
Come find out during this exciting Annual Meeting event, hosted by AAN former president Thomas R. Swift, MD, FAAN, along with Kapil D. Sethi, MD, FRCP, FAAN, and Bert B. Vargas, MD, FAAN. Enjoy delicious food and beverages as the best and brightest in neurology compete for the coveted Neurobowl trophy in an entertaining game-show format.
ANNUAL MEETING SCHEDULE
SUNDAY, APRIL 22 7:00 a.m.–7:45 a.m.
X
Yoga (All-Levels Vinyasa) . . . . . . . . . . . . . 71
7:00 a.m.–9:00 a.m. C25 Hot Topics and Controversies in Parkinson’s Disease C26 Neuro-ophthalmology I: Visual Loss, Optic Neuropathies, C27 C28 C29 C30 C31 C32 C33 C34
and Papilledema Neurological Intensive Care I: The Essentials Autism Spectrum Disorders What We Know and Where We Are Going Faculty Development: Enhancing Your Role in Student and Resident Training Controversies in Stroke Treatment and Prevention Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies Treatments for Drug-resistant Epilepsy: Surgery, Devices, and Other Updates Clinicopathological Correlation Session in Dementia Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making
7:45 a.m.–8:15 a.m.
X
Research in Residency: How to Choose the Right Project . . 75
8:00 a.m.–9:00 a.m. S1 “Best of” Session: Cerebrovascular Disease and
Interventional Neurology . . . . . . . . . . . . . 92
8:00 a.m.–9:00 a.m.
X X
Meditation for the Practicing Neurologist . . . . . . . 71 How Can the Axon Registry Improve My Practice? . . . 73
8:00 a.m.–9:10 a.m.
X
Sunday
Challenges in Clinicogenetic Correlations: One Gene, Many Phenotypes; One Phenotype, Many Genes . . . . 77
8:15 a.m.–9:00 a.m.
X
K is for Career Development: Tips From Successful Applications for NIH Career Development Awards . . . 75
8:30 a.m.–9:00 a.m.
X
Interviewing Skills: Negotiation . . . . . . . . . . . 75
9:15 a.m.–9:45 a.m.
X
Giving and Receiving Feedback for Medical Students and Residents . . . . . . . . . . . . . . 75
9:15 a.m.–12:00 p.m.
Presidential Plenary Session . . . . . . . . . . . 61 10:00 a.m.–10:30 a.m.
X X
Autoimmune Neurology . . . . . . . . . . . . . . 75 Office Hours: The Researcher Pipeline: The Benefits of Participating in Academic Medicine, Research, and Clinical Trials as a Medical Student or Resident . . . 77
10:45 a.m.–11:15 a.m.
X
So You Want to Be a Residency Program Director? . . . 75
20 2018 AAN Annual Meeting
11:30 a.m.–4:00 p.m.
Exhibit Hall 11:30 a.m.–1:00 p.m. Exhibit Hall Opening Luncheon
11:30 a.m.–5:30 p.m. P1 Poster Session I . . . . . . . . . . . . . . . . 122
Presenters Stand by Posters 4:00 p.m.–5:30 p.m.
12:00 p.m.–12:50 p.m.
Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session . . . . . . . . . . . . 122
12:00 p.m.–12:30 p.m.
X
Office Hours: Finding/Working with Epidemiologists on Your Grant . . . . . . . . . . . . . . . . . . 77
12:00 p.m.–12:45 p.m.
X
How to Promote Healthy Cognitive Aging: What Should We Tell Our Patients and Ourselves? . . . . . . 71
12:00 p.m.–1:00 p.m.
X X
Neurology Pictionary . . . . . . . . . . . . . . . 69 Pursuing a Career in Clinical Informatics . . . . . . . 73
12:15 p.m.–1:00 p.m.
X
Sleep: A Frequently Forgotten Part of Your Patient’s Day . . 75
12:30 p.m.–1:00 p.m.
X
Office Hours: Surviving as a Clinician Researcher . . . . 77
12:30 p.m.–5:30 p.m.
Medical Student Symposium: Careers in Neurology
1:00 p.m.–1:30 p.m.
X
Being a Great Chief Resident . . . . . . . . . . . . 75
1:00 p.m.–1:45 p.m.
X
Solving Burnout . . . . . . . . . . . . . . . . . 71
1:00 p.m.–2:00 p.m.
X
Meet and Greet with the California Neurological Society . 73
1:00 p.m.–3:00 p.m. S2 Clinical Trials and Therapeutic Approaches in S3 S4 S5 S6 C35 C36 C37 C38 C39 C40
Neurodegenerative Diseases . . . . . . . . . . . . 96 Movement Disorders: Parkinson’s Disease: Genetics, Biomarkers, and Diagnosis . . . . . . . . . . . . . 96 Neuroepidemiology: Neurodegeneration, Epilepsy, Cerebrovascular Disease Risks . . . . . . . . . . . 97 General Neurology: Advances in Neurotherapeutics . . 97 MS Neuroimaging . . . . . . . . . . . . . . . . 97 Borderlands of Neurology and Internal Medicine: Chalk Talk Clinical Neurology for Advanced Practice Providers I Nonmotor Manifestations of Parkinson’s Disease I Neurological Intensive Care II: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction Therapy in Neurology I: Headache and Stroke Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS
3:30 p.m.–4:30 p.m. S7 Pain and Palliative Care . . . . . . . . . . . . . . 98
C43 Developing the Treatments of Tomorrow I: Taking
3:30 p.m.–5:30 p.m. N1 Neuroscience in the Clinic: Autism Myth Busters . . . . 80 S8 Progressive MS Therapies and Age-Dependent
in 6 Cases
Molecules from Lab to Man
C44 Neuro-ophthalmology II: Optic Neuritis, Visual Fields,
Factors in MS Therapy . . . . . . . . . . . . . . 98
and Anisocoria
S9 Epilepsy/Clinical Neurophysiology (EEG) I . . . . . . . 98 S10 Intracerebral and Subarachnoid Hemorrhage . . . . . 99 C50 Low and High Pressure Headache: Clinical Presentation
1:00 p.m.–5:00 p.m. C45 L Being a Resilient Leader: How Do You Lead the Change?
C46 L The Most Important Tool in Your Black Bag: Gallup
StrengthsFinders™ Assessment $ (registration required)
1:00 p.m.–5:30 p.m. C47 Resident Basic Science II: Neuropathology C48 Genomic Neurology Skills Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies
C49 Neuromuscular Ultrasound Skills Workshop
C56
$ (registration required)
C57
1:15 p.m.–2:00 p.m.
X
Measuring Success: Quality Improvement 101 . . . . . 75
1:20 p.m.–1:50 p.m.
X
So You Have a Research Idea—How Do You Turn it into a Project? . . . . . . . . . . . . . . . . . . 77
1:30 p.m.–2:30 p.m.
X
Hall of Presidents: Using Past Experience to Solve the Future’s Problems . . . . . . . . . . . . 69
C58 C59
4:00 p.m.–4:30 p.m.
X X
Career Stories: Challenges for the Physician Scientist . . 75
X
2:00 p.m.–2:30 p.m. Breaking Down Silos: Interprofessional Team Education to Enhance Clinical Outcomes in Neurology . . 73
2:15 p.m.–3:00 p.m.
X
Education Administrator Building Blocks: Navigating the Role of the Administrator and Taking Your Role to the Next Level . . . . . . . . . . . . . . . . . 75
2:30 p.m.–3:00 p.m.
X
Ask the Expert: Teaching through Simulation . . . . . 73
3:00 p.m.–3:30 p.m.
X
Tip of the Iceberg: Ultra-High Cost Neurology Drugs . . 73
3:00 p.m.–3:45 p.m.
X
How Your Social Life Might Be Helping (or Harming) Your Brain . . . . . . . . . . . . . . . . . . . . 71
3:00 p.m.–4:00 p.m.
X
Blind Spots: The Impact of Conscious and Unconscious Biases . . . . . . . . . . . . . . . . 69
3:15 p.m.–3:45 p.m.
X
Transitioning from Private Practice to Academics . . . . 75 Why Are Drug Prices So High? And What Can We Do About It? . . . . . . . . . . . . . . . . . . . 73 Cafe Talk: Is that an Emotional or Cognitive Question? Navigating Difficult Conversations with Communication Skills . . . . . . . . . . . . . . . 71
4:15 p.m.–5:00 p.m.
X
Introduction to the Fascinating World of Movement Disorders . . . . . . . . . . . . . . . 75
4:30 p.m.–5:00 p.m.
X X
How to Start a Career in Clinical Trials . . . . . . . . 77 What Does BrainPAC Do for Me? . . . . . . . . . . 73
4:30 p.m.–5:30 p.m.
X
What Is That Twitch? . . . . . . . . . . . . . . . 69
4:45 p.m.–5:15 p.m.
X
Everything You Wanted to Know About the R&F Section of Neurology . . . . . . . . . . . . . . . 75
5:00 p.m.–5:30 p.m.
X
Statistics and Study Design: Pearls and Pitfalls . . . . 77
7:00 p.m.–11:00 p.m.
70th Anniversary Celebration . . . . . . . . . .
192
How to Get into Leadership in Professional Societies . . 75
3:15 p.m.–4:00 p.m.
X
Social Media for the Millennial Neurologist . . . . . . 75
Learning X = Experiential
L = Leadership University
$ = Additional Fee Required
AAN.com/view/AM18 21
Sunday
X
and Approach to Evaluation and Management Clinical Neurology for Advanced Practice Providers II Nonmotor Manifestations of Parkinson’s Disease II Neurological Intensive Care III: Vascular Diseases Therapy in Neurology II: Epilepsy and Movement Disorders Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience Peripheral Neuropathy III: Genetic Testing and Next Generation Sequencing Developing the Treatments of Tomorrow II: Clinical Trials in Neurology Neuro-ophthalmology III: Diplopia, Ocular Motility Disorders, and Nystagmus Actualización Sobre el Tratamiento de la Esclerosis Múltiple
4:00 p.m.–4:45 p.m.
1:45 p.m.–2:15 p.m.
X
C51 C52 C53 C54 C55
ANNUAL MEETING SCHEDULE
C41 Peripheral Neuropathy II: Diabetic and Inherited Neuropathies C42 Acute and Chronic Clinical Epilepsy Update Explained
ANNUAL MEETING SCHEDULE
MONDAY, APRIL 23 7:00 a.m.–7:45 a.m.
X
11:30 a.m.–6:00 p.m.
Yoga (All-Levels Vinyasa) . . . . . . . . . . . . . 71
7:00 a.m.–9:00 a.m. C60 Balance and Gait Disorders C61 Starting a Practice From the Ground Up: A Guide for Early C62 C63 C64 C65 C66 C67 C68
Career Neurologists Neuro-ophthalmology: Overview and Update Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis Child Neurology I: Pediatric Stroke, MS/Autoimmune Clinical Pearls: Learning from Complex Cases Simple Lessons that Apply to Everyday Problems Update on Medical Management of Stroke Video EEG: Name That Spell Cognitive Impairment Due to Alzheimer’s Disease: Using Old Skills and New Tools for Diagnosis and Treatment
7:30 a.m.–8:00 a.m.
X
Defining and Managing Your Message as an Early Career Researcher . . . . . . . . . . . . . . . . 77
7:45 a.m.–8:15 a.m.
X
Using the R&F Section of Neurology for Your Residents and Residency . . . . . . . . . . . . . 75
8:00 a.m.–8:45 a.m.
X
Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? . 71
Exhibit Hall 4:30 p.m.–6:00 p.m. Exhibit Hall Networking Reception
11:30 a.m.–7:00 p.m. P2 Poster Session II . . . . . . . . . . . . . . . . 132
Presenters Stand by Posters 5:30 p.m.–7:00 p.m.
11:45 a.m.–12:35 p.m.
Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session . . . . . . . . . . . . 133
11:45 a.m.–12:30 p.m.
X
Finding Your Niche in Neurology: Perspectives from an Epileptologist and Educator . . . . . . . . . . . 75
12:00 p.m.–12:30 p.m.
X
Office Hours: Working with an Epidemiologist . . . . . 77
12:00 p.m.–1:00 p.m.
X X X
Is There a Neurologist on This Flight? . . . . . . . . 69 Practice Models for Advanced Practice Providers . . . . 73 Using EHR for Better Communication with Patients and Colleagues . . . . . . . . . . . . . . 73
12:25 p.m.–1:45 p.m.
X
Perception Is Reality: Are Neurologists Helping Patients Live Well with Dementia? . . . . . . . . . 71
8:00 a.m.–9:00 a.m. S11 “Best of” Session: Epilepsy/Clinical
12:45 p.m.–1:30 p.m.
8:10 a.m.–9:00 a.m.
1:00 p.m.–1:30 p.m.
Neurophysiology (EEG) . . . . . . . . . . . . . . 92
X
Your CV Is Talking About You Behind Your Back, and Your LORs Are Too! . . . . . . . . . . . . . . . . 77
8:15 a.m.–9:00 a.m.
Monday
X
Choosing An Academic Career in Neurology: Perspectives for Early Career Investigators and Foreign Medical Graduates . . . . . . . . . . . . . 75
8:30 a.m.–9:00 a.m.
X
Tools to Transition from Trainee to Attending . . . . . 75
9:15 a.m.–11:30 a.m.
Contemporary Clinical Issues Plenary Session . . . . . . . . . .
. . . . . . . . . 62
10:00 a.m.–10:30 a.m.
X
How to be “Useful” on Rotations: Tips for Medical Students . . . . . . . . . . . . . . . . . . . . 75
10:45 a.m.–11:15 a.m.
X
Choosing a Neurohospitalist Career . . . . . . . . . 75
11:30 a.m.–12:00 p.m.
X
Child Neurology—Staying on Track . . . . . . . . . 75
X X X
Subspecialty Sessions: IOM and cEEG . . . . . . . . 75 Office Hours: Creating Bridge Funding—How to Use Non-NIH Funding . . . . . . . . . . . . . . . . . 77
1:00 p.m.–2:15 p.m. S12 Autonomic Disorders . . . . . . . . . . . . . . 100 1:00 p.m.–3:00 p.m. S13 Neuromyelitis Optica Spectrum Disorder and other
Autoimmune Disorders . . . . . . . . . . . . . . 100
S14 Education and Patient Outcomes Research . . . . . 101 S15 Cerebrovascular Disease Epidemiology and Outcomes . 101 S16 Neuro-Ophthalmology/Neuro-Otology . . . . . . . 101 C69 L Continuing Your Leadership Journey: Uncharted C70 C71 C72 C73 C74 C75
22 2018 AAN Annual Meeting
Transitioning From a Clinical Research Career to an Educational and Clinical Focused Career . . . . . . . 75
Waters (registration required) Evaluating Tremor in the Office Therapy in Neurology III: Neurological Infectious Diseases and Neuro-ophthalmologic Disorders Sports Neurology: Enhancing Athletic Performance Child Neurology II: Epilepsy and Neuromuscular Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I Safe and Appropriate Opioid Prescribing in Neurology
C77 C78 C79 C80
Muscle Imaging and Genetic Testing Epilepsy Surgery Update Therapeutic Temperature Modulation in the ICU Comprehensive Migraine Education Program I: Diagnosis, Risk Factors, and Neurobiology Present and Future Biomarkers in Dementia: A Casebased Approach
S18 S19 C84 C85 C86 C87
1:00 p.m.–4:00 p.m. C81 Mitigating the Impact of Unconscious Bias Workshop
C88
1:00 p.m.–5:30 p.m. C82 Resident Basic Science III: Neuroanatomy: All the Lesions C83 Neuro-ophthalmology and Neurovestibular Exam Lab
C89
Skills Workshop $ (registration required)
1:30 p.m.–2:00 p.m.
X
Office Hours: Statistics—Sample Size . . . . . . . . 77
1:30 p.m.–2:30 p.m.
X
Eminence-based Medicine vs Evidence-based Medicine . . 69
1:45 p.m.–2:30 p.m.
X
Creating a Career in Global Health with Design Thinking . 75
2:00 p.m.–2:30 p.m.
X
Can Aviation Accidents Teach Neurologists Patient Safety and Error Management? . . . . . . . . . . . 73
2:00 p.m.–2:45 p.m.
X
Physical Exercise and Cognitive Training in Neurology: Application in Aging and Neurodegenerative Disease . . . . . . . . . . . . 71 Office Hours: Defining and Managing Your Message as an Early Career Scientist . . . . . . . . . . . . 77 Mejora Tu Desempeño Como Educador Médico . . . . 75
3:00 p.m.–3:30 p.m.
X
Safety and Quality Awards . . . . . . . . . . . . . 73
3:00 p.m.–3:45 p.m.
X
Introduction to Acupuncture I: Conceptual Framework and Mechanism of Action . . . . . . . . 71
3:00 p.m.–4:00 p.m.
X
Lifting the Curtain: Ask the AAN Publication Editors Anything! . . . . . . . . . . . . . . . . . . . . 69
3:30 p.m.–4:00 p.m.
X
C93 C94 C95
3:45 p.m.–4:30 p.m.
X
What Does the AAN’s Latest Guideline Mean for My Practice? . . . . . . . . . . . . . . . . . . 73
Teaching Communication Skills: From Good to Great . . 75
4:00 p.m.–4:30 p.m. Streamlining Clinic Scheduling and Access . . . . . . 73
4:00 p.m.–4:45 p.m.
X
Striking the Balance—A Neurologist’s Personal Wellness Journey . . . . . . . . . . . . . . . . 71
4:15 p.m.–5:00 p.m.
X
Foundations for Success in the AAN . . . . . . . . . 69
4:30 p.m.–5:00 p.m.
X
Knowing Your Value: How to Negotiate to Get What You’re Worth . . . . . . . . . . . . . . . . . . 73
4:45 p.m.–5:30 p.m.
X
Career Development for Medical Educators . . . . . . 75
5:15 p.m.–6:15 p.m.
X
Practicing Neurology in the 1960s and 1970s . . . . . 69
6:00 p.m.–9:00 p.m.
Faculty and Trainee Reception 7:00 p.m.–10:00 p.m.
Industry Therapeutic Updates
3:30 p.m.–5:30 p.m. N2 Neuroscience in the Clinic: Antisense
Oligonucleotide (ASO) Therapy . . . . . . . . . . . 82
S17 Sleep . . . . . . . . . . . . . . . . . . . . . 102 Learning X = Experiential
L = Leadership University
$ = Additional Fee Required
AAN.com/view/AM18 23
Monday
2:45 p.m.–3:30 p.m.
X
C91 C92
X
2:30 p.m.–3:00 p.m.
X
C90
Movement Disorders: Ataxia and Tremor . . . . . . 102 Epilepsy/Clinical Neurophysiology (EEG) II . . . . . . 102 Evidence Based Neurology Foresights for Busy Clinicians Therapy in Neurology IV: Autoimmune PNS Synaptic Disorders and Neuro-Oncology Child Neurology III: Headache, TBI/Post-concussion Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II Core Concepts in Pain Management: Refractory Neuropathic Pain Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology Comprehensive Migraine Education Program II: Behavioral and Psychological Approaches, and Preventive and Acute Treatment Advances Chronic Traumatic Encephalopathy: Update What Keeps You Up at Night? Addressing Mistakes and Injuries, In-n-Out-Patient Transition, and Building a Team to Support You Advances in Neurogenetics Hot Topics in Stroke Education and Practice . . . . . 103 Actualización Sobre las Infecciones del Sistema Nervioso Central y la Medicina Tropical
ANNUAL MEETING SCHEDULE
C76 Clinical Approach to Muscle Disease I: Role of Antibodies,
ANNUAL MEETING SCHEDULE
TUESDAY, APRIL 24 6:30 a.m.–8:30 a.m.
2018 AAN Run/Walk for Brain Research $ (registration required) 7:00 a.m.–7:45 a.m.
X
Yoga (All-Levels Vinyasa) . . . . . . . . . . . . . 71
7:00 a.m.–9:00 a.m. C96 Status Epilepticus C97 Vascular Cognitive Impairment and Dementia: Current C98 C99 C100 C101 C102 C103 C104
Status and Future Multiple Sclerosis Overview I: Clinical Pearls Good Neurology in Challenging Conditions: Lessons from Military Neurology Basic Principles of Brain Tumors: For Practice and for Certification Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson’s Disease Now You See It, Now You Know It: Pathognomonic Neuro-ophthalmology Examination Findings Sports Concussion Skills Workshop: Event Coverage Foundational Skills and Sport Specific Pearls $ (registration required)
8:00 a.m.–8:30 a.m.
X
Welcome to NINDS Day/Overview of NIH Funding with NINDS Director and NINDS Deputy Director . . . . 77
8:00 a.m.–8:45 a.m.
X
11:30 a.m.–4:00 p.m.
Exhibit Hall 11:30 a.m.–7:00 p.m. P3 Poster Session III . . . . . . . . . . . . . . . . 142
Presenters Stand by Posters 5:30 p.m.–7:00 p.m.
11:45 a.m.–12:35 p.m.
Aging and Dementia Poster Discussion Session . . . . 143
11:45 a.m.–12:30 p.m.
X
Foreign Medical Graduates Adjustment Skills . . . . . 75
12:00 p.m.–12:30 p.m.
X X
Introduction to the 2018-2020 TRANSCENDS Scholars . 77 Office Hours: How to Get a K-Award . . . . . . . . . 77
12:00 p.m.–12:45 p.m.
X
Treatment of Neuropathy Symptoms Without Medication . 71
12:00 p.m.–1:00 p.m.
X X
Neurology Game Show: Localize the Lesion . . . . . . 69 Communicating via EHR . . . . . . . . . . . . . . 73
12:15 p.m.–12:45 p.m.
X
Neurohospitalists 2.0, How to Craft a Satisfying and Sustainable Career . . . . . . . . . . . . . . 75
12:30 p.m.–1:00 p.m.
X
Office Hours: Bridge Funding . . . . . . . . . . . . 77
12:40 p.m.–1:10 p.m.
X
Self-Management in Neurologic Disease . . . . . . . 71
NIH Funding and Professional Development Opportunities for Diverse Researchers . . . . . . . . 77
8:00 a.m.–9:00 a.m. S20 “Best of” Session: Headache . . . . . . . . . . . . 92
12:45 p.m.–1:30 p.m.
8:15 a.m.–9:00 a.m.
1:00 p.m.–1:30 p.m.
X
Career Development for Clinician Educators . . . . . . 75
8:30 a.m.–9:00 a.m.
Tuesday
X
Career Stories: Nuts and Bolts of Academic Leadership—Strategies I Have Learned in My Career . . 75
8:40 a.m.–9:10 a.m.
X
K Awards and Training Programs . . . . . . . . . . 77
9:15 a.m.–11:30 a.m.
Clinical Trials Plenary Session . . . . . . . . . . 63 10:00 a.m.–10:30 a.m.
X
Choosing a Career in Neurocritical Care . . . . . . . 75
10:45 a.m.–11:15 a.m.
X
Staying on an Academic Clinical Track . . . . . . . . 75
11:30 a.m.–12:00 p.m.
X
Reviewer to Editorial Board to Editor . . . . . . . . . 75
24 2018 AAN Annual Meeting
X X X
Choosing Teleneurology as a Career . . . . . . . . . 75 Subspecialty Sessions: IOM and cEEG . . . . . . . . 75 Office Hours: VA Research Funding: Career Development Awards . . . . . . . . . . . . . . . 77
1:00 p.m.–1:45 p.m.
X
Complementary Therapies in Parkinson’s Disease . . . 71
1:00 p.m.–2:00 p.m.
X
Understanding Axon Registry and Using it to Improve Your Value . . . . . . . . . . . . . . . . 73
1:00 p.m.–2:15 p.m.
Special Presentation: Don’t Break the Rules, Change the Game: How Bennet Omalu Single-Handedly Changed American Football, Professional Sports, and How the World Perceives Traumatic Brain Injuries
Bennet Omalu, MBBS, MPH, MBA with Steven DeKosky, MD, FAAN, FANA, FACP
N3 S21 S22 S23 C105 C106 C107 C108
C109 C110 C111 C112 C113 C114 C115 C116 C117 C118
Invited Science: Movement Disorders . . . . . . 88 Neuroscience in the Clinic: Challenges in Genetic Diagnosis in Neurology . . . . . . . . . . . . . . 82 Revascularization in Acute Ischemic Stroke . . . . . 104 Advances in Muscular Dystrophy and Congenital Myopathy . 104 Biologic and Clinical Discoveries in Neuro-oncology . . 105 L Mentoring…Growing the Next Generation of Neurologist $ (registration required) Critical Care EEG Monitoring What Do I Do Now?: Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders Introduction to Primary Headache Disorders I: Migraine and Other Primary Headaches Including Tension-Type, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine Multiple Sclerosis Overview II: Clinical Advances Neurologic Complications in Adults with Down Syndrome Enhancing Your Career and Practice Through Neuropalliative Care Continuum ® Test Your Knowledge: A Multiple-choice Question Review I Sleep for the Practicing Neurologist I: Is it Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence Concussion: Pathogenesis, Fluid and Imaging Biomarkers, Diagnosis, and Treatment of Post-Concussion Headache Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia Cerebrovascular Disease I: Prevention Introduction to Clinical Research and Methods L Leadership in the Era of Burnout: A Practical Approach to Becoming a True Physician Leader
1:20 p.m.–1:50 p.m.
2:30 p.m.–3:00 p.m.
X X X
NIH Grant Review Process . . . . . . . . . . . . . 77 Office Hours: Clinical Research Recommendations for Residents and Fellows . . . . . . . . . . . . . 77
X X
Academic Career Panel: Find out How to Get Your Career Started . . . . . . . . . . . . . . . . 75 The Encompassing Value of the Patient-Physician Relationship . . . . . . . . . . . 75
2:00 p.m.–2:30 p.m.
X X
NINDS Clinical Trials (New NIH Definition) and Networks, NeuroNEXT, StrokeNET, SIREN . . . . . . 77 Caring for Telemedicine Patients . . . . . . . . . . 73
Learning X = Experiential
L = Leadership University
Training in Neurology While on a Visa: Challenges and Possible Solutions for Foreign Medical Graduates . . 75
3:00 p.m.–3:45 p.m.
X
StrengthsFinders Social Hour . . . . . . . . . . . . 71
3:00 p.m.–4:00 p.m.
X
Biological and Chemical Neuroterrorism and Neurowarfare . . . . . . . . . . . . . . . . . . 69
3:15 p.m.–3:45 p.m.
X
Staying on Track: A Career as a Clinical Researcher . . . 75
3:20 p.m.–3:50 p.m.
X
Pain Research Funding Opportunities, Clinical and Basic . . 77
3:30 p.m.–5:30 p.m. S24 MS Outcome Measures and Biomarkers . . . . . . . 106 S25 Advances in Amyotrophic Lateral Sclerosis . . . . . 106 S26 Movement Disorders: Parkinson’s Disease Clinical Trials . 106 C120 Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome
C122 C123 C124
C125
1:45 p.m.–2:30 p.m.
X
Pain Research Funding Opportunities, Clinical and Basic . . 77
2:45 p.m.–3:30 p.m.
Neurological Exam Tips and Tricks . . . . . . . . . . 69
1:45 p.m.–2:15 p.m.
X
What Is the AAN Doing for Small and Solo Practitioners? . 73
2:40 p.m.–3:10 p.m.
1:30 p.m.–2:30 p.m.
X
How to Start a Career in Neurology Education . . . . . 75 Office Hours: Finding Collaborators . . . . . . . . . 77
2:30 p.m.–3:30 p.m.
1:30 p.m.–2:00 p.m.
X
Dancing with Parkinson’s . . . . . . . . . . . . . 71
C121 Introduction to Primary Headache Disorders II: Trigeminal
1:00 p.m.–5:30 p.m. C119 EMG Skills Workshop: Basic $ (registration required)
X
X
C126 C127 C128 C129
Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches Multiple Sclerosis Overview III: The Pathogenesis of Multiple Sclerosis and Mechanism of Action of Treatments for MS Child Neurology: A Case-based Approach The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders Continuum ® Test Your Knowledge: A Multiple-choice Question Review II Sleep for the Practicing Neurologist II: Night Fighting: Sleep Related Hypermotor Epilepsy, Sleepwalking, and Dream Enactment Concussion Management: Chronic Sequelae and Symptom Targeted Treatment in the Acute, Subacute and Chronic Phase After Concussion Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke
$ = Additional Fee Required
AAN.com/view/AM18 25
Tuesday
2:00 p.m.–2:45 p.m.
ANNUAL MEETING SCHEDULE
1:00 p.m.–3:00 p.m.
ANNUAL MEETING SCHEDULE
TUESDAY, APRIL 24 C130 Disorders of Motor Programming: The Apraxias and
Action-Intentional Disorders Chalk Talk C131 Introduction to Integrative Neurology C132 Actualization Científica Durante el Congreso Anual I
3:45 p.m.–4:30 p.m.
X
International Members: What Can the AAN Do for You? . . 75
4:00 p.m.–4:30 p.m.
X
Your Grant Proposal Was Rejected: Now What? Turning a Feedback Into a Successful Project . . . . . 77
4:00 p.m.–4:45 p.m.
X
The Sleep Mythbuster!: Illuminating the Facts and Fiction Towards Achieving the Sleep Healthy Neurologist . . 71
Tuesday 26 2018 AAN Annual Meeting
4:30 p.m.–5:30 p.m.
X
Controversies in Neurology: Is the Zombie Apocalypse Upon Us? Local Outbreaks, Bioterrorism or Bioengineering Run Amok… . . . . . . . . . . . 69
4:45 p.m.–5:30 p.m.
X
Teaching During a Busy Clinic . . . . . . . . . . . . 75
5:00 p.m.–5:30 p.m.
X
Guided Meditation . . . . . . . . . . . . . . . . 71
5:45 p.m.–7:15 p.m.
Emerging Science Session
7:00 p.m.–10:00 p.m.
Industry Therapeutic Updates
7:00 a.m.–7:45 a.m.
X
12:00 p.m.–12:45 p.m.
Yoga (All-Levels Vinyasa) . . . . . . . . . . . . . 71
7:00 a.m.–9:00 a.m. C133 Higher Cortical Visual Disorders: Case-based Review C134 Tuberculosis of the Central Nervous System C135 Neurocognitive Assessment for Neurologists C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I C137 What Do I Do Now?: Emergency and Inpatient
X
C143
X X
Avoid The Common Pitfall of Over-reading Neurologic Case Studies in Pregnancy Paroxysmal Movement Disorders Integrating Sleep Medicine Concepts into Your Child Neurology Practice Mastering EMG Waveform Recognition Skills in Just Two Hours! Evaluation and Treatment of Common Spine Disorders
X X X
Acupuncture Demonstration: Auriculotherapy . . . . . 71
Step Away from the Desktop! Recapturing the Joy in Practice . . . . . . . . . . . . . . . . . . 73 How to Write and Publish Research Papers, Reviews, and Other Scientific Communications . . . . 77 How to Give Effective Feedback . . . . . . . . . . . 75
8:30 a.m.–9:00 a.m. Office Hours: Selecting an AAN Research Program Mentor . . 77
9:15 a.m.–11:30 a.m.
Frontiers in Neuroscience Plenary Session .
64
11:30 a.m.–3:00 p.m.
Presenters Stand by Posters 5:30 p.m.–7:00 p.m.
11:45 a.m.–12:35 p.m. Cerebrovascular Disease and Interventional Neurology Poster Discussion Session . . . . . . . . 153
12:00 p.m.–12:30 p.m.
X X
Office Hours: Recruiting Difficult and Underrepresented Populations in Research . . . . . . 77 Recruiting Minorities . . . . . . . . . . . . . . . 77
Learning X = Experiential
1:00 p.m.–3:00 p.m. S29 Child Neurology and Developmental Neurology I . . . 108 S30 Movement Disorders: Dystonia, Chorea, and
other Disorders . . . . . . . . . . . . . . . . . 109
S31 Therapeutics, Phenotypes, and Biomarkers
S32 Headache: Therapeutics . . . . . . . . . . . . . 109 C144 Neurology Update I: Epilepsy, Behavioral Neurology, C145 C146 C147 C148 C149 C150
L = Leadership University
C152 C153 C154 C155 C156
and Neurologic Infections Severe TBI: From ICU to Rehabilitation Non-Alzheimer’s Dementia I: Frontotemporal Dementias Multiple Sclerosis Therapy: Disease-modifying Treatment II LGBTQI Health in Neurology What Do I Do Now?: Neurologic Consultations in Cancer Patients I Where is the Lesion? A History of Neurological Investigations Part I Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke Nystagmus and Saccadic Intrusions Made Simple Circadian Rhythm Disorders: Implications for Neurology The Global Burden of Neurologic Diseases Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System Clinical EEG II: Focal, Diffuse, and Epileptiform Abnormalities in Adults
1:00 p.m.–5:00 p.m. C157 L Advanced Leadership Training: Preparing for Your Career’s Insurmountable Opportunities
C158 L Leadership Strengths in Neurology: The Data, Tools and Practical Application of Strengths for Leadership, Team Building, and Personal Development $ (registration required)
$ = Additional Fee Required
AAN.com/view/AM18 27
Wednesday
11:30 a.m.–7:00 p.m. P4 Poster Session IV . . . . . . . . . . . . . . . . 152
1:00 p.m.–2:00 p.m. S28 Practice, Policy, and Ethics . . . . . . . . . . . . 108
C151
Exhibit Hall
Community Education in Minority Population . . . . . 77
in Neuromuscular Disorders . . . . . . . . . . . . 109
8:15 a.m.–9:00 a.m.
X
So You Want to Work for a Hospital? . . . . . . . . . 73
1:00 p.m.–1:50 p.m.
8:00 a.m.–9:10 a.m.
X
Clinical Research in the Area of Practice, Quality and Patient Safety . . . . . . . . . . . . . 75
1:00 p.m.–1:30 p.m.
8:00 a.m.–9:00 a.m.
X
Neuroscience of Bias . . . . . . . . . . . . . . . 77
12:45 p.m.–1:30 p.m.
8:00 a.m.–9:00 a.m. S27 “Best of” Session: Movement Disorders . . . . . . . 93
X
Office Hours: Navigating Uncommon Pathways in Academic Neurology: A Journey from Bedside to Bench . . 77
12:40 p.m.–1:10 p.m.
8:00 a.m.–8:45 a.m.
X
Neuro-Jeopardy: Telencephalon Twisters . . . . . . . 69
12:30 p.m.–1:00 p.m.
Management of Migraine and Other Headache Disorders
C142
Neurology and Wellness—Physician, Heal Thyself . . . 71
12:00 p.m.–1:00 p.m.
C138 Clinical EEG I: Normal EEG, Normal Variants, and How to C139 C140 C141
X
ANNUAL MEETING SCHEDULE
WEDNESDAY, APRIL 25
ANNUAL MEETING SCHEDULE
WEDNESDAY, APRIL 25 1:00 p.m.–5:30 p.m. C159 Clinical Uses of Botulinum Toxin for Dystonia Skills Workshop $ (registration required)
1:30 p.m.–2:30 p.m.
X
Parkinson Disease: Raising Your Game . . . . . . . . 69
2:00 p.m.–2:30 p.m.
X X
Office Hours: Mentor-Mentee Relationships . . . . . . 77 Women in Neuroscience . . . . . . . . . . . . . . 77
2:00 p.m.–2:45 p.m.
X
Resiliency for the Neurologist . . . . . . . . . . . . 71
2:40 p.m.–3:10 p.m.
X
Patient-Reported Measures in Neurology . . . . . . . 77
2:45 p.m.–3:30 p.m.
X
Pursing a Career in Health Care Administration . . . . 75
3:00 p.m.–3:30 p.m.
X
Office Hours: Research Careers in Industry . . . . . . 77
3:00 p.m.–3:45 p.m.
X
Introduction to Acupuncture II: Evidence-based Applications for Acupuncture in the Treatment of Neurologic Conditions . . . . . . . . . . . . . . . 71
3:00 p.m.–4:00 p.m.
X
Health Care Disparities Among Underserved Populations . 69
3:30 p.m.–4:15 p.m. S33 Global Health . . . . . . . . . . . . . . . . . . 110 3:30 p.m.–5:30 p.m.
N4 S34 S35 S36 C160
Wednesday
C161
Invited Science: Sleep . . . . . . . . . . . . . 89 Neuroscience in the Clinic: Opioid Use and Abuse: The Overlapping Neurobiology of Pain and Addiction, and the Path Toward Better Treatments . . . 83 Behavioral and Cognitive Neurology . . . . . . . . 110 Child Neurology and Developmental Neurology II . . . 110 MS Therapeutics and Clinical Research . . . . . . . 111 Neurology Update II: Movement Disorders, Spine Disorders, and Sleep Disorders Non-Alzheimer’s Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias
28 2018 AAN Annual Meeting
C162 Multiple Sclerosis Therapy: Symptom Management C163 How to Run a Practice: Business Strategies for Neurology Private Practices, Academic Centers, and the Future
C164 What Do I Do Now?: Neurologic Consultations in Cancer Patients II
C165 Where is the Lesion? A History of Neurological Investigation Part II
C166 Cerebrovascular Disease IV: Telestroke C167 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia
C168 CNS Toxicities C169 Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System
C170 Clinical EEG III: Neonatal and Pediatric C171 Actualización Sobre Opciones Terapéuticas para la Epilepsìa Farmacorresistente
C244 Joint AAN and AHA/ASA Session 3:45 p.m.–4:30 p.m.
X
Navigating Fellowship in Neurology . . . . . . . . . 75
4:00 p.m.–4:45 p.m.
X
Diets and Supplements in MS: What’s the Evidence Thus Far? . . . . . . . . . . . . . . . . . . . . 71
4:15 p.m.–5:00 p.m.
X
The Neurology of VooDoo . . . . . . . . . . . . . 69
4:30 p.m.–5:30 p.m. S37 Neurorehabilitation . . . . . . . . . . . . . . . 111 4:45 p.m.–5:30 p.m.
X
Top Ten Clinical, Educational and Leadership Pearls . . . 75
5:00 p.m.–5:30 p.m.
X
Guided Meditation . . . . . . . . . . . . . . . . 71
5:15 p.m.–6:15 p.m.
X
Neurology Illustrated: The Neurology of Art . . . . . . 69
6:00 p.m.–10:00 p.m.
Commitment to Cures 7:00 p.m.–10:00 p.m.
Industry Therapeutic Updates
7:00 a.m.–7:45 a.m.
X
12:00 p.m.–12:45 p.m.
Yoga (All-Levels Vinyasa) . . . . . . . . . . . . . 71
7:00 a.m.–9:00 a.m. C172 Clinical Epilepsy I: Basics C173 Using Sleep Medicine to Help Solve Difficult C174 C175 C176 C177 C178 C179 C180 C181
X
12:00 p.m.–1:00 p.m.
X X X X X
1:00 p.m.–2:30 p.m.
How to Bridge to Careers in Industry . . . . . . . . . 77 Sleep and Performance in Elite Athletes . . . . . . . 71
8:00 a.m.–9:00 a.m. Enhancing Epilepsy Care in Your Practice: In-Person Digital Learning and Emotional for Self-Management, Education, and Community Supports from the National Epilepsy Education and Awareness Collaborative . . . . . 73
8:40 a.m.–9:10 a.m. The Pathway to Become a Clinical Trialist . . . . . . . 77
9:15 a.m.–11:30 a.m.
Controversies in Neurology Plenary Session .
65
11:30 a.m.–7:00 p.m. P5 Poster Session V . . . . . . . . . . . . . . . . 162 Presenters Stand by Posters 5:30 p.m.–7:00 p.m.
11:45 a.m.–12:35 p.m.
MS and CNS Inflammatory Disease Poster Discussion Session . . . . . . . . . . . . 163
11:45 a.m.–12:30 p.m.
X
Teaching History and Exam with Teleneurology . . . . 75
12:00 p.m.-12:30 p.m.
X
How to Increase Investments in Neuroscience Research . . . . . . . . . . . . . . . . . . . . 73
Learning X = Experiential
L = Leadership University
Invited Science: The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative . . . . . . . . . . . . . . . 89
1:00 p.m.–3:00 p.m. N5 Neuroscience in the Clinic: Treatment of Progressive S40 S41 S42 C182 C183 C184 C185 C186 C187 C188 C189 C190 C191 C192 C193 C194 C195
Multiple Sclerosis . . . . . . . . . . . . . . . . 84 Acute Stroke Care . . . . . . . . . . . . . . . . 112 Neurologic Infections . . . . . . . . . . . . . . 113 Neurocritical Care . . . . . . . . . . . . . . . . 113 Clinical Epilepsy II: Considerations Across the Age Span Pediatrics, Pregnancy, and Elderly Hot Topics in Sleep Neurology Behavioral Neurology I: Network Anatomy of Behavior and Language Neurology Update III: Neuromuscular, Headache, and Stroke Myelopathies I: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes Cerebellar and Afferent Ataxias: Diagnosis and Management Neuroimaging for the General Neurologist I: Spine and Peripheral Nerve Business Strategies for Payer Negotiations and/or How to Go off the Grid Neuro-oncologic Predicaments in the Hospital Setting Neuro-otology I: The Common Peripheral Vestibular Disorders Clinical EMG II: Neuromuscular Junction Testing and Quantitative EMG Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Antibody-Mediated Rapidly Progressive Dementia Actualización Sobre el Manejo del Ictus Cerebrovascular Practical Training in Injection Techniques in the Treatment of Headache Disorders Skills Workshop $ (registration required)
$ = Additional Fee Required
AAN.com/view/AM18 29
Thursday
Medical Marijuana: What do Neurologists Need to Know? . . . . . . . . 71
1:00 p.m.–2:15 p.m. S39 History of Neurology . . . . . . . . . . . . . . . 112
Neuromuscular Disorders . . . . . . . . . . . . . 93
X
Office Hours: Early Career Research Funding and Career Development . . . . . . . . . . . . . . . 77 What Do I Need to Know About Coding in My Practice? . 73
1:00 p.m.–1:45 p.m.
8:00 a.m.–9:00 a.m. S38 “Best of” Session: Clinical Trial Updates in
X
Effective Neurology Residency Program . . . . . . . 75
1:00 p.m.–1:30 p.m.
8:00 a.m.–8:45 a.m.
X
Who Wants to be a Millionaire . . . . . . . . . . . 69
12:45 p.m.–1:30 p.m.
Neurologic Cases Rehabilitation in Neurology Clinical Pearls in Autoimmune Neurology: Real World Cases The Dystonia: Diagnosis, Treatment and Update on Etiologies So You’ve Diagnosed Your Patient with a Neuroinfectious Disease, Now What? Practical Pearls in the Treatment and Management of Neuroinfectious Diseases Neuro-oncology in 2018: Navigating Current Trends Clinical EMG I: Principles and Practice of NCS and Needle EMG Principles of Genomic Medicine: Clinical Exome Sequencing in Neurologic Disease Preventive Neurology: How Neurologists Can Improve Outcomes That Matter to Patients
8:00 a.m.–8:30 a.m.
X
The Purpose Checkup: Find Meaning, Live Longer, Better . 71
ANNUAL MEETING SCHEDULE
THURSDAY, APRIL 26
ANNUAL MEETING SCHEDULE
THURSDAY, APRIL 26 1:00 p.m.–5:30 p.m. C196 Brain Death Skills Workshop: How to Perform a Brain
Death Evaluation, Avoid Pitfalls and Convey the News to the Family $ (registration required)
1:30 p.m.–2:30 p.m.
X
The Value of the Neurologic Exam: Caring for Your Patient for $500 or Less . . . . . . . . . . . . . . 69
1:45 p.m.–2:30 p.m.
X
Interviewing Skills . . . . . . . . . . . . . . . . 75
2:00 p.m.–2:45 p.m.
X
Cafe Talk: Communication in Neurology Practice . . . . 71
2:00 p.m.–3:00 p.m.
X
Using Your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency . . . . . . 73
2:45 p.m.–3:30 p.m.
X
O Funding, Where Art Thou? How to Develop a FullTime Academic Career in Global Neurology . . . . . . 75
3:00 p.m.–3:45 p.m.
X
Magnifying Your Life Through Poetry . . . . . . . . . 71
3:00 p.m.–4:00 p.m.
X
Consejos Prácticos para un Buen Examen Neurológico . 69
3:30 p.m.–5:30 p.m.
Invited Science Session: Neuro Trauma . . . . . 90 N6 Neuroscience in the Clinic: Neurologic Complications of Cancer Immunotherapy: A New Frontier in Neuro-Inflammation . . . . . . . . . . . 84 S43 Migraine . . . . . . . . . . . . . . . . . . . . 114 S44 MS Risk Factors, Susceptibility, Diagnosis, and Cognitive Impairment . . . . . . . . . . . . . . 114 S45 Movement Disorders: Parkinsonian Disorders, Basic Science, and Imaging . . . . . . . . . . . . . . 114 S46 Advances in Spinal Muscular Atrophy . . . . . . . . 115 C197 Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG)
Thursday 30 2018 AAN Annual Meeting
C198 Behavioral Neurology II: Memory and Attention C199 Neurology Update IV: Multiple Sclerosis, Neuro-
ophthalmology, and Autoimmune Encephalopathies
C200 Myelopathies II: Approaches to Rehabilitation and Psychosocial Challenges
C201 Differential Diagnosis of Neurologic Infections C202 Neuroimaging for the General Neurologist II: Spine and Peripheral Nerve
C203 Endovascular Treatment of Acute Stroke and Cerebrovascular Disease
C204 Making Sure You Get Paid Under the New Health Care Laws C205 Neuro-otology II: Diagnosis and Treatment of Nuanced Causes of Dizziness
C206 Clinical EMG III: Nerve Conduction Criteria and
Electrodiagnostic Approaches C207 Mitochondrial Disorders in Neurology C208 Assessment of Rapidly Progressive Dementias II: Neurodegenerative Diseases and Infections Presenting as Rapidly Progressive Dementia C209 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop $ (registration required)
4:30 p.m.–5:00 p.m.
X
Grantwriting 101: Getting Started . . . . . . . . . . 77
4:30 p.m.–5:30 p.m.
X
Neurology History: Weaving Past with Present . . . . 69
6:30 p.m.–9:30 p.m. C210 Case Studies: Unusual Diagnostic and Management of C211 C212 C213 C214 C215
Cases in Neuromuscular Disease Case Studies in the ICU Case Studies: Test Your Knowledge: A Case-based Approach to Neuroimaging Case Studies: Unusual Movement Disorders Case Studies: Challenging Headache Cases Case Studies in Behavioral Neurology: Focus on Frontotemporal Degeneration
C225 Neuromuscular Junction Disorders I: Myasthenia Gravis,
X
Yoga (All-Levels Vinyasa) . . . . . . . . . . . . . 71
7:00 a.m.–9:00 a.m. C216 Neuroendocrine Update: Nuts and Bolts of What You Need to Know
C217 Current Management of Incidental and Asymptomatic
Cerebrovascular Lesions C218 Infections of the Nervous System I: Diagnostic Testing of Neurological Infections C219 The Early-Onset Dementias C220 Drugs and Toxin-induced Neurologic Emergencies C221 REM Sleep Behavior Disorder C222 Therapy of Movement Disorders: A Case-based Approach C223 The Burden of Epilepsy: Managing Comorbidities and Quality of Life
Ocular, and MuSK Myasthenia
C226 Infections of the Nervous System II: Neuro-ID Emergencies C227 Behavioral Neurology: A Case-based Approach (Cancelled) C228 Neuroimaging for the General Neurologist I: Brain C229 Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders
C230 Neurologic Complications of Medical and Surgical Therapies C231 ICD-10-CM: How to Optimize for Accurate Diagnosis and Reimbursement
C232 Hot Topics in Headaches and Related Disorders I: Migraine
Pathophysiology, Brain Imaging, and Therapeutic Advances
C233 Actualización Científica Durante el Congreso Anual II 1:00 p.m.–5:00 p.m. C234 Epilepsy Skills Workshop: Focus on Treatment
$ (registration required)
8:00 a.m.–9:00 a.m. S47 “Best of” Session: MS and CNS Inflammatory
1:30 p.m.–2:30 p.m.
8:00 a.m.–9:10 a.m.
2:40 p.m.–3:10 p.m.
Diseases . . . . . . . . . . . . . . . . . . . . 93
X
Role of Placebo in Neuromuscular Clinical Trials and in Management of NM Disorders . . . . . . . . . . 77
9:15 a.m.–11:30 a.m.
Neurology Year in Review: Emerging Therapies Plenary Session . . . . . . . . . . . . 66 11:30 a.m.–5:30 p.m. P6 Poster Session VI . . . . . . . . . . . . . . . . 172
Presenters Stand by Posters 4:00 p.m.–5:30 p.m.
11:45 a.m.–12:35 p.m.
Movement Disorders Poster Discussion Session . . .
172
12:00 p.m.–12:30 p.m.
X X
How to Bridge to Careers in Industry . . . . . . . . . 77 Incorporating a Semi-Concierge Model into Your Own Neurology Practice . . . . . . . . . . . . 73
12:00 p.m.–12:45 p.m.
X
Outsmart Stress . . . . . . . . . . . . . . . . . 71
12:00 p.m.–1:00 p.m.
X
The Neurology of Creativity and the Keyboard . . . . . 69
12:30 p.m.–1:00 p.m.
X
Office Hours: Making the Transition from Research Fellow to Clinical Research Faculty . . . . . 77
12:40 p.m.–1:10 p.m.
X
How to Put Together an Effective Research Presentation . . 77
1:00 p.m.–3:00 p.m. S48 Novel Biomarkers in Aging and Dementia . . . . . . S49 Neuro Trauma and Sports Neurology . . . . . . . . S50 Updates in General Neurology . . . . . . . . . . . S51 Pediatric MS . . . . . . . . . . . . . . . . . . C224 Neuromyelitis Optica Spectrum Disorders Learning X = Experiential
L = Leadership University
X X
Recruiting Minorities . . . . . . . . . . . . . . . 77
3:00 p.m.–4:00 p.m.
X
Ask Us Anything: Expert Panel on Stroke . . . . . . . 69
3:30 p.m.–5:30 p.m. N7 Neuroscience in the Clinic: REM Sleep Behavior
Disorder: Past, Present, Future . . . . . . . . . . . 85
S52 MS and CNS Inflammatory Disease: Basic Science . . 117 S53 Epilepsy/Clinical Neurophysiology (EEG) III . . . . . . 118 S54 Ischemic Stroke Prevention . . . . . . . . . . . . 118 C235 Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy C236 Neuromuscular Junction Disorders II: Toxins, LambertEaton Syndrome and Less Common Disorders of Neuromuscular Transmission C237 Neurologic Complications of Medical Disease C238 Memory Disorders: A Case-based Approach C239 Infections of the Nervous System III: Advanced Topics in Infectious Neurology C240 Neuroimaging for the General Neurologist II: Brain C241 Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders C242 Coding 101: It’s Not Your Father’s Oldsmobile C243 Hot Topics in Headaches and Related Disorders II: Unusual Headaches, Childhood Headaches, and Concussion Management
4:00 p.m.–4:30 p.m.
X 116 116 117 117
Live Intraoperative Monitoring . . . . . . . . . . . 69
Historical Perspective on Treating Epilepsy . . . . . . 77
4:30 p.m.–5:30 p.m.
X
Ask Us Anything: Expert Panel on Multiple Sclerosis . . 69
5:30 p.m.–7:00 p.m.
Closing Party Happy Hour . . . . . . . . . . . .
$ = Additional Fee Required
192
AAN.com/view/AM18 31
Friday
7:00 a.m.–7:45 a.m.
ANNUAL MEETING SCHEDULE
FRIDAY, APRIL 27
2018 ANNUAL MEETING EXHIBIT HALL
Visit the Exhibit Hall to preview the latest products and services available in the neurology industry from an array of exhibitors including pharmaceutical companies, medical device vendors, and voluntary health organizations—all dedicated to helping people with neurologic disease live better.
HIGHLIGHTS:
• Innovation Hub: Drop by to experience an array of dynamic events, including topic expert presentations and more • Exhibit Hall Buzz Cafes: Grab a cup of joe and mingle with exhibitors throughout the hall • Exhibit Hall Charging Lounges: Stay connected with hubs that keep your devices charged and ready to use • Association Neighborhood: Connect with nonprofit scientific organizations and voluntary health organizations
• Technology Pavilion: Discover emerging technologies and advances in patient care • Publishers Row: Keep up-to-date on what’s new in neurologic research and patient care • Career Fair: Network with organizations recruiting and offering career resources across the field of neurology
EXCITING PRIZES Complete the Exhibit Hall Passport every day for the chance to win exciting prizes!
SUNDAY April 22 11:30 a.m.–4:00 p.m. 11:30 a.m.–1:00 p.m.
Exhibit Hall Opening Luncheon
Sponsored by
MONDAY April 23 11:30 a.m.–6:00 p.m. 4:30 p.m.–6:00 p.m.
Exhibit Hall Networking Reception
Sponsored by
TUESDAY April 24 11:30 a.m.–4:00 p.m.
WEDNESDAY April 25 11:30 a.m.–3:00 p.m.
INNOVATION HUB Located in the center of the Exhibit Hall, this new area will offer dynamic, interactive opportunities to expand your mind into new ways of thinking about your practice, your patients, and the future of neurology. Wine & Paint Sessions will take place daily to allow you to relax, interact, and learn in a novel way
SUNDAY April 22
12:00 p.m.–12:30 p.m.
Welcome to the Exhibit Hall
1:00 p.m.–2:00 p.m.
Korak Sarkar, MD The M3D Lab: 3d Printing, VR and AR in Medicine
2:00 p.m.–2:30 p.m.
Raghav Govindarajan, MD, FAAN Integrating Teleneurology into your Practice-a Hands on Training’
Teleneurology Displays will let you test with colleagues how telemedicine works—and decide if it is a good fit for your practice
1:00 p.m.–1:30 p.m.
Allen Gee, MD, PhD, FAAN Democratizing Technology in Healthcare
2:00 p.m.–2:30 p.m.
Jose Posas, MD Concussion: There’s an App for That
3:00 p.m.–3:30 p.m.
Jaime Hatcher-Martin, MD Telemovement: Using Telemedicine in an Outpatient Neurology Setting
4:30 p.m.–6:00 p.m.
Brainstorm: A Competition for the Innovator in All of Us!
Displays and Presentations from topic experts will showcase new ideas and new ways of thinking about neurology
12:00 p.m.–12:30 p.m.
David Evans, MBA Allison Weathers, MD, FAAN Using Technology to Enhance Patient Engagement
12:30 p.m.–1:00 p.m.
Allen Gee, MD, PhD, FAAN Back to the Future, Innovations Revisiting Neurohealth Space
1:00 p.m.–1:30 p.m.
Brad Klein, MD, MBA, FAAN Get Paid for Your Mental Status Exams... Use App Technology to Innovate What You Do
WEDNESDAY
11:30 a.m.–12:00 p.m.
Do you have an innovative idea that would transform the face of neurology through business, technology, education, or public health? Apply to pitch your idea at this Innovation Hub game show-style event! Finalists will be invited to present their ideas live to a panel of judges. The panel will provide feedback and finalists will get the unique opportunity to refine and improve their ideas for the future.
1:00 p.m.–1:30 p.m.
12:00 p.m.–12:30 p.m.
TUESDAY 11:30 a.m.–12:00 p.m.
1:30 p.m.–2:00 p.m.
3:00 p.m.–4:00 p.m.
Daniel Potts, MD, FAAN Hand in Hand with Art and Advocacy
MONDAY April 23
Jennifer Bickel, MD, FAAN Relaxation Tools: See One, Do One, Teach One Jack W. Tsao, MD, DPhil, FAAN Your Practice a Decade in the Future
12:30 p.m.–1:00 p.m.
Tanuja Chitnis, MD, FAAN Innovations for Multiple Sclerosis Monitoring and Care
April 24
David Evans, MBA Eric Cheng, MD, MS, FAAN Clinical Decision Support for Ordering of Diagnostic Imaging
April 25
11:30 a.m.–12:00 p.m.
Elaine Jones, MD, FAAN Balancing Business and Wellness: NonTraditional Work Settings
12:00 p.m.–12:30 p.m.
Anup Patel, MD, FAAN Utilizing Wearable Technology to Improve Neurological Care Lyell Jones, MD, FAAN Using Axon Registry to Improve Your Practice Jennifer Bickel, MD, FAAN Acupuncture FAQ
ANNUAL MEETING TOPIC LIST
2018 PROGRAMS LISTED BY TOPIC Aging, Dementia, Cognitive, and Behavioral Neurology
11:30 a.m.–7:00 p.m.
P2 Poster Session II
Behavioral and Cognitive Neurology: Genes, Environment, and Interventions
Saturday, April 21
7:00 a.m.–9:00 a.m.
Genetic and Basic Science Studies in Neurodegenerative Diseases
C1 Mild Cognitive Impairment: Implications for Clinicians
9:30 a.m.–11:30 a.m.
C10 More than Medicine: How to
Access Home Care, Support Caregivers, and Discuss Complex Situations in Advanced Neurologic Disease C13 Neuroimaging Biomarkers Across the Dementia Spectrum
4:15 p.m.–5:30 p.m.
Hot Topics Plenary Session: 4:35 p.m.–4:50 p.m. Brain Stimulation for Memory . 60
Sunday, April 22 7:00 a.m.–9:00 a.m.
C33 Clinicopathological Correlation Session in Dementia
11:30 a.m.–5:30 p.m.
Aging/Dementia/Cognitive
P1 Poster Session I
Clinical Issues in Dementia
P1.173–P1.180 . 125
Pathology Studies in Aging and Dementia
P1.181–P1.188 . 125
Vascular Risk Factors in Aging and Dementia
X
C80 Present and Future Biomarkers
X
How to Promote Healthy Cognitive Aging: What Should We Tell Our Patients and Ourselves? . . . . . . . . . 71
1:00 p.m.–3:00 p.m.
S2 Clinical Trials and
Therapeutic Approaches in Neurodegenerative Diseases . 96
Monday, April 23 7:00 a.m.–9:00 a.m.
C68 Cognitive Impairment Due to Alzheimer’s Disease: Using Old Skills and New Tools for Diagnosis and Treatment
34 2018 AAN Annual Meeting
7:00 a.m.–9:00 a.m.
C133 Higher Cortical Visual
Disorders: Case-based Review
C135 Neurocognitive Assessment for Neurologists
9:15 a.m.–11:30 a.m.
P4 Poster Session IV
2:00 p.m.–2:45 p.m.
X
Physical Exercise and Cognitive Training in Neurology: Application in Aging and Neurodegenerative Disease . . . . . . . . . . 71
3:30 p.m.–5:30 p.m.
C91 Chronic Traumatic
Encephalopathy: Update
Tuesday, April 24 7:00 a.m.–9:00 a.m.
11:30 a.m.–7:00 p.m.
P3 Poster Session III
Imaging Studies in Aging and Dementia
P3.173–P3.191 . 146
Language and Language Disorders
P3.192–P3.200 . 146
11:45 a.m.–12:35 p.m.
Aging and Dementia Poster Discussion Session P3.027–P3.036 143
1:00 p.m.–3:00 p.m.
N3 Neuroscience in the Clinic:
Challenges in Genetic Diagnosis in Neurology . . . . 82 C107 What Do I Do Now?: Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders C110 Neurologic Complications in Adults with Down Syndrome 3:30 p.m.–5:30 p.m.
C130 Disorders of Motor
Programming: The Apraxias and Action-Intentional Disorders Chalk Talk
Novel Biomarkers in Aging and Dementia
P4.173–P4.186 . 156
Biomarkers, Biology, Physiology
P4.187–P4.200 . 156
1:00 p.m.–3:00 p.m.
C145 Severe TBI: From ICU to Rehabilitation
C146 Non-Alzheimer’s Dementia I: Frontotemporal Dementias
3:30 p.m.–5:30 p.m.
S34 Behavioral and Cognitive
Neurology . . . . . . . . 110
C161 Non-Alzheimer’s Dementia
II: Lewy Body Dementias and Other Parkinsonian Dementias
C97 Vascular Cognitive Impairment and Dementia: Current Status and Future
Frontiers in Neuroscience Plenary Session: 9:35 a.m.–9:55 a.m. Does Connectomics Make Sense? . 64
11:30 a.m.–7:00 p.m.
in Dementia: A Case-based Approach
Behavioral and Cognitive Neurology: Other
12:00 p.m.–12:45 p.m.
Perception Is Reality: Are Neurologists Helping Patients Live Well with Dementia? . . . 71
1:00 p.m.–3:00 p.m.
P1.189–P1.196 . 125 P1.197–P1.200 . 126
P2.183–P2.200 . 136
12:25 p.m.–1:45 p.m.
1:30 p.m.–3:30 p.m.
C20 The Neurology of Social Behavior
P2.173–P2.182 . 136
Wednesday, April 25
Thursday, April 26 7:00 a.m.–9:00 a.m.
C181 Preventive Neurology: How
Neurologists Can Improve Outcomes That Matter to Patients
9:15 a.m.–11:30 a.m.
Controversies in Neurology Plenary Session: 9:15 a.m.–10:00 a.m. Should We Use Biomarkers Alone For Diagnosis of Alzheimer’s? . . 65
11:30 a.m.–7:00 p.m.
P5 Poster Session V
Cognitive Phenotypes in Aging and Dementia
P5.173–P5.193 . 165
Behavioral and Cognitive Neurology: Other II
P5.194–P5.200 . 166
1:00 p.m.–3:00 p.m.
C184 Behavioral Neurology I:
Network Anatomy of Behavior and Language C193 Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Antibody-Mediated Rapidly Progressive Dementia
C198 Behavioral Neurology II:
Memory and Attention C208 Assessment of Rapidly Progressive Dementias II: Neurodegenerative Diseases and Infections Presenting as Rapidly Progressive Dementia
11:30 a.m.–5:30 p.m.
P1 Poster Session I
Neurology: Focus on Frontotemporal Degeneration
Friday, April 27 9:15 a.m.–11:30 a.m.
Neurology Year in Review: Emerging Therapies Plenary Session: 10:35 a.m.–10:55 a.m. Dementia . . 66
P1.210–P1.218 . 126
P1.219–P1.231 . 126
Intracerebral Hemorrhage
P1.232–P1.258 . 126
P6.173–P6.184 . 175
Healthcare and Caregiver Issues in Dementia
Behavioral and Cognitive Neurology: Other III
C66 Update on Medical
Management of Stroke
9:15 a.m.–11:30 a.m.
S48 Novel Biomarkers in Aging
and Dementia . . . . . . . 116
1:30 p.m.–3:30 p.m.
C22 Stroke in Young Adults and Women
Sunday, April 22 7:00 a.m.–9:00 a.m.
C30 Controversies in Stroke
Treatment and Prevention
8:00 a.m.–9:00 a.m.
S1 “Best of” Session:
Cerebrovascular Disease and Interventional Neurology . . . 92
Stroke Biomarkers and Animal Models
Cerebrovascular Genetics
Pre-Hospital, Telestroke and ED-Based Stroke Care II
1:00 p.m.–3:00 p.m.
Saturday, April 21
Outsmart Stress . . . . . . 71
Cerebrovascular Disease and Interventional Neurology
Stroke Epidemiology, Risk Factors, and Outcomes
P6.197–P6.200 . 176
based Approach
Ischemic Stroke . . . . . . 104
C116 Cerebrovascular Disease I: Prevention 3:30 p.m.–5:30 p.m.
C129 Cerebrovascular Disease II:
Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke
Wednesday, April 25 11:30 a.m.–7:00 p.m.
P4 Poster Session IV
Cerebrovascular Disease and Interventional Neurology I ePoster Session
P2.201–P2.223 . 136
P2.224–P2.240 . 136 P2.241–P2.250 . 137
P2.251–P2.258 . 137
1:00 p.m.–3:00 p.m.
S15 Cerebrovascular Disease
Epidemiology and Outcomes 101
C78 Therapeutic Temperature Modulation in the ICU
3:30 p.m.–5:30 p.m.
C94 Hot Topics in Stroke Education
and Practice . . . . . . . . 103
Tuesday, April 24 9:15 a.m.–11:30 a.m.
Clinical Trials Plenary Session: 9:30 a.m.–9:45 a.m. Expanding the Time Window for Thrombectomy: Results of the DEFUSE 3 Study . 63
11:30 a.m.–7:00 p.m.
P3 Poster Session III
Acute Stroke Imaging
P3.201–P3.214 . 146
P4.201–P4.229 . 156
P4.230–P4.258 . 157
P4.339–P4.344 . 159
Cerebrovascular Disease and Interventional Neurology II ePoster Session
11:45 a.m.–12:35 p.m.
Cerebrovascular Disease and Interventional Neurology Poster Discussion Session P4.027–P4.036 153
1:00 p.m.–3:00 p.m.
C151 Cerebrovascular Disease III:
Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke
3:30 p.m.–5:30 p.m.
C166 Cerebrovascular Disease IV: Telestroke
C244 Joint AAN and AHA/ASA Session
Thursday, April 26 11:30 a.m.–7:00 p.m.
P5 Poster Session V
Inpatient Stroke Care
P5.201–P5.213 . 166
Cerebrovascular Disease and Interventional Neurology: Large Artery Disease: Carotid, Basilar, Vertebral, Intracranial
P5.214–P5.233 . 166
P5.234–P5.248 . 167
X = Experiential Learning
P4.085–P4.090 . 154
Endovascular Treatment
TPA in Acute Ischemic Stroke
P2 Poster Session II
12:00 p.m.–12:45 p.m.
C238 Memory Disorders: A Case-
S21 Revascularization in Acute
Contemporary Clinical Issues Plenary Session: 9:15 a.m.–9:30 a.m. Retinal Microvasculature in Predicting Risk of Stroke Subtypes . . 62
P3.240–P3.258 . 147
1:00 p.m.–3:00 p.m.
11:30 a.m.–7:00 p.m.
P6.185–P6.196 . 175
3:30 p.m.–5:30 p.m.
P3.232–P3.239 . 147
Stroke Case Reports I
Stroke Clinic
Pre-Hospital, Telestroke and ED-Based Stroke Care III
P5.249–P5.258 . 167
AAN.com/view/AM18 35
Cerebrovascular/Interventional
Monday, April 23 7:00 a.m.–9:00 a.m.
P3.215–P3.231 . 146
Stroke Knowledge, Behavior, and Culture
P1.201–P1.209 . 126
3:30 p.m.–5:30 p.m.
Clinical Trials and Therapeutic Approaches in Neurodegenerative Diseases
X
P6 Poster Session VI
Pre-Hospital, Telestroke and ED-Based Stroke Care
Subarachnoid Hemorrhage and Intracranial Aneurysms
11:30 a.m.–5:30 p.m.
Subarachnoid Hemorrhage . . 99
C219 The Early-Onset Dementias
S10 Intracerebral and
7:00 a.m.–9:00 a.m.
Cerebral Venous Sinus Thrombosis (CVST)
C215 Case Studies in Behavioral
Post-Stroke Mood, Cognition, and Recovery
6:30 p.m.–9:30 p.m.
ANNUAL MEETING TOPIC LIST
3:30 p.m.–5:30 p.m.
ANNUAL MEETING TOPIC LIST
2018 PROGRAMS LISTED BY TOPIC 1:00 p.m.–3:00 p.m.
S40 Acute Stroke Care . . . . . . 112 C194 Actualización Sobre el Manejo del Ictus Cerebrovascular
Sunday, April 22 7:00 a.m.–9:00 a.m.
C28 Autism Spectrum Disorders
What We Know and Where We Are Going
3:30 p.m.–5:30 p.m.
C203 Endovascular Treatment
of Acute Stroke and Cerebrovascular Disease
9:15 a.m.–12:00 p.m.
Friday, April 27 7:00 a.m.–9:00 a.m.
C217 Current Management of
Incidental and Asymptomatic Cerebrovascular Lesions
9:15 a.m.–11:30 a.m.
Neurology Year in Review: Emerging Therapies Plenary Session: 10:55 a.m.–11:15 a.m. Finally, Some Closure on PFO Closure . . 66
11:30 a.m.–5:30 p.m.
P6 Poster Session VI
Stroke Case Reports II
Cerebrovascular and Cardiac Disease
P6.201–P6.235 . 176
P6.236–P6.249 . 176
Pre-Hospital, Telestroke and ED-Based Stroke Care IV
P1 Poster Session I
Neurogenetics and Metabolic Disease
Child Neurology
C19 Pediatric Neuro-
ophthalmology Update C22 Stroke in Young Adults and Women
X
Child Neurology - Staying on Track . . . . . . . . . . . 75
P2 Poster Session II
Child Neurology and Developmental Neurology ePoster Session
P2.085–P2.090 . 134
Child Neurology and Developmental Neurology: Epilepsy
P2.295–P2.305 . 138
Child Neurology and Developmental Neurology: Infectious, Inflammatory, and Autoimmune Disorders
P2.306–P2.321 . 138
Child Neurology and Developmental Neurology: Neuromuscular Disease
P2.322–P2.338 . 138
1:00 p.m.–3:00 p.m.
C73 Child Neurology II: Epilepsy and Neuromuscular
P3.302–P3.321 . 148
Child Neurology and Developmental Neurology: Neurodegenerative Disease
P3.322–P3.328 . 148
Clinical and Basic Science Observations
9:15 a.m.–11:30 a.m.
Contemporary Clinical Issues Plenary Session: 10:05 a.m.–10:20 a.m. Pediatric Brainstem Encephalitis Outbreak Investigation with Next-Generation Sequencing . . 62
P3.295–P3.301 . 148
Autism and Developmental Disabilities
Stroke, MS/Autoimmune
36 2018 AAN Annual Meeting
Acquired Brain Injury: Stroke, Traumatic Brain Injury
C64 Child Neurology I: Pediatric
11:30 a.m.–7:00 p.m.
1:30 p.m.–3:30 p.m.
P3 Poster Session III
7:00 a.m.–9:00 a.m.
Clinical Trials Plenary Session: 10:00 a.m.–10:15 a.m. Precision Medicine: Intracerebroventricular Enzyme Replacement Therapy with Cerliponase Alfa in Children with CLN2 Disease: Results from an Ongoing Multicenter Study . 63
11:30 a.m.–7:00 p.m.
Monday, April 23
Child Neurology and Developmental Neurology
Multiple Sclerosis in the Current Era
Autism Myth Busters . . . . 80
S54 Ischemic Stroke Prevention . . 118
C11 Treatment of Pediatric
9:15 a.m.–11:30 a.m.
P1.295–P1.313 . 128
11:30 a.m.–12:00 p.m.
9:30 a.m.–11:30 a.m.
Tuesday, April 24
N1 Neuroscience in the Clinic:
Ask Us Anything: Expert Panel on Stroke . . . . . . . . . 69
Saturday, April 21
TBI/Post-concussion
3:30 p.m.–5:30 p.m.
P6.250–P6.258 . 177
3:30 p.m.–5:30 p.m.
C86 Child Neurology III: Headache,
11:30 a.m.–5:30 p.m.
3:00 p.m.–4:00 p.m.
X
Presidential Plenary Session: 10:45 a.m.–11:15 a.m. Sidney Carter Award in Child Neurology: Spinal Muscular Atrophy Is a Treatable Neurodegenerative Disease . . 61
3:30 p.m.–5:30 p.m.
P3.329–P3.338 . 148
1:00 p.m.–3:00 p.m.
C110 Neurologic Complications in
Adults with Down Syndrome
3:30 p.m.–5:30 p.m.
C123 Child Neurology: A Casebased Approach
Wednesday, April 25 7:00 a.m.–9:00 a.m.
C141 Integrating Sleep Medicine Concepts into Your Child Neurology Practice
9:15 a.m.–11:30 a.m.
Frontiers in Neuroscience Plenary Session: 10:55 a.m.–11:15 a.m. Pediatric MS: A Unique Window into Environmental and Genetic Risk Factors for MS 64
1:00 p.m.–3:00 p.m.
S29 Child Neurology and
Developmental Neurology I . 108
3:30 p.m.–5:30 p.m.
S35 Child Neurology and
Developmental Neurology II . 110
Monday, April 23
9:15 a.m.–11:30 a.m.
7:00 a.m.–9:00 a.m.
Controversies in Neurology Plenary Session: 10:45 a.m.–11:30 a.m. Would You Let Your Child Play Contact Sports? 65
Friday, April 27
C67 Video EEG: Name That Spell
8:00 a.m.–9:00 a.m.
S11 “Best of” Session: Epilepsy/
Clinical Neurophysiology (EEG) . 92
11:30 a.m.–7:00 p.m.
P2 Poster Session II
9:15 a.m.–11:30 a.m.
Saturday, April 21 12:00 p.m.–4:00 p.m.
C17 Neurophysiologic
Intraoperative Monitoring Skills Workshop
Sunday, April 22 7:00 a.m.–9:00 a.m.
C32 Treatments for Drug-resistant Epilepsy: Surgery, Devices, and Other Updates
9:15 a.m.–12:00 p.m.
11:30 a.m.–5:30 p.m.
P1 Poster Session I
Clinical Epilepsy I
P1.259–P1.294 . 127
12:00 p.m.–12:50 p.m.
Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session P1.027–P1.036 122
1:00 p.m.–3:00 p.m.
C42 Acute and Chronic Clinical
Epilepsy Update Explained in 6 Cases
3:30 p.m.–5:30 p.m.
S9 Epilepsy/Clinical
Neurophysiology (EEG) I . . . 98
Epilepsy: Basic Science and Genetics
Terapéuticas para la Epilepsìa Farmacorresistente
Thursday, April 26 7:00 a.m.–9:00 a.m.
C172 Clinical Epilepsy I: Basics
8:00 a.m.–9:00 a.m.
X
P2.259–P2.272 . 137 P2.273–P2.294 . 137
Epilepsy/Clinical Neurophysiology (EEG) ePoster Session
P2.339–P2.344 . 139
1:00 p.m.–1:30 p.m.
X
Subspecialty Sessions: IOM and cEEG . . . . . . . . . 75
11:30 a.m.–7:00 p.m.
P5 Poster Session V
3:30 p.m.–5:30 p.m.
S19 Epilepsy/Clinical
7:00 a.m.–9:00 a.m.
C96 Status Epilepticus
11:30 a.m.–7:00 p.m.
P3 Poster Session III
EEG and Imaging
P3.259–P3.294 . 147
1:00 p.m.–1:30 p.m.
X
Subspecialty Sessions: IOM and cEEG . . . . . . . . . 75
1:00 p.m.–3:00 p.m.
C106 Critical Care EEG Monitoring
C138 Clinical EEG I: Normal EEG,
Normal Variants, and How to Avoid The Common Pitfall of Over-reading
11:30 a.m.–7:00 p.m.
P4 Poster Session IV
Anti-epileptic Drugs and Epilepsy Surgery
Clinical Epilepsy III
Clinical Epilepsy IV
P5.259–P5.283 . 167 P5.284–P5.294 . 168
C182 Clinical Epilepsy II:
Considerations Across the Age Span Pediatrics, Pregnancy, and Elderly
3:30 p.m.–5:30 p.m.
C197 Clinical Epilepsy III: Advanced
(Status, Beyond AED, Video EEG)
Friday, April 27 7:00 a.m.–9:00 a.m.
C223 The Burden of Epilepsy:
Managing Comorbidities and Quality of Life
9:15 a.m.–11:30 a.m.
Wednesday, April 25 7:00 a.m.–9:00 a.m.
Anti-epileptic Drugs
1:00 p.m.–3:00 p.m.
Neurophysiology (EEG) II . . . 102
Tuesday, April 24
1:00 p.m.–3:00 p.m.
C77 Epilepsy Surgery Update
Enhancing Epilepsy Care in Your Practice: In-Person Digital Learning and Emotional for Self-Management, Education, and Community Supports from the National Epilepsy Education and Awareness Collaborative . . . 73
Neurology Year in Review: Emerging Therapies Plenary Session: 10:15 a.m.–10:35 a.m. Pediatric Epilepsy . . 66
11:30 a.m.–5:30 p.m.
P6 Poster Session VI
E pilepsy: Comorbidities, Psychosocial, Health Economics, Quality
P6.259–P6.294 . 177
1:00 p.m.–5:00 p.m.
C234 Epilepsy Skills Workshop: Focus on Treatment
P4.259–P4.279 . 157
1:30 p.m.–2:30 p.m.
P4.280–P4.294 . 158
3:30 p.m.–5:30 p.m.
1:00 p.m.–3:00 p.m.
C156 Clinical EEG II: Focal,
Diffuse, and Epileptiform Abnormalities in Adults
X
Live Intraoperative Monitoring . 69
S53 Epilepsy/Clinical
Neurophysiology (EEG) III . . . 118
3:30 p.m.–5:30 p.m.
C170 Clinical EEG III: Neonatal and Pediatric
X = Experiential Learning
AAN.com/view/AM18 37
Epilepsy (EEG)
Presidential Plenary Session: 10:15 a.m.–10:45 a.m. George C. Cotzias Lecture: How Early-Life Experiences Sculpt Your Brain: From Molecules to Circuits . . 61
Clinical Epilepsy II
Neurology Year in Review: Emerging Therapies Plenary Session: 10:15 a.m.–10:35 a.m. Pediatric Epilepsy . . 66
Epilepsy/Clinical Neurophysiology (EEG)
C171 Actualización Sobre Opciones
ANNUAL MEETING TOPIC LIST
Thursday, April 26
ANNUAL MEETING TOPIC LIST
2018 PROGRAMS LISTED BY TOPIC General Neurology
Sunday, April 22
Saturday, April 21
7:00 a.m.–7:45 a.m.
7:00 a.m.–9:00 a.m.
8:00 a.m.–9:00 a.m.
C2 Functional Neurologic
Disorders I: Movement, Seizures, and Multiple Sclerosis
7:00 a.m.–4:00 p.m.
C6 Neurology MOC Prep Course
X X
How to Network At the Annual Meeting: Strategies for Trainees . . . . . . . . 75
9:15 a.m.–10:00 a.m.
X
X
9:30 a.m.–11:30 a.m.
Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room C12 Functional Neurologic Disorders II: Life Experiences and Management of Functional Disorders
P1 Poster Session I
P1.118–P1.127 . 124
Cognitive Biases and Diagnostic Errors at Bedside . 75
P1.128–P1.132 . 124
Neuroepidemiology: Neuropathy, Neuromuscular Diseases, Demyelinating Diseases, and Other
Navigating the Annual Meeting App and Convention Center Tour . . . . . . . . 69
12:00 p.m.–12:45 p.m.
General Neurology
X
Neuroepidemiology: Cerebrovascular Disease and Epilepsy
Neuroepidemiology: Motor Neuron Disease, Cognitive Impairment, Sleep I
12:00 p.m.–12:30 p.m.
X
Presidential Plenary Session: 9:15 a.m.–10:15 a.m. Presidential Lecture: California Dreaming: BRAIN and Precision Medicine in 2018 . . 61
11:30 a.m.–5:30 p.m.
10:15 a.m.–10:45 a.m.
X
Challenges in Clinicogenetic Correlations: One Gene, Many Phenotypes; One Phenotype, Many Genes . . . . . . . . 77
9:15 a.m.–12:00 p.m.
Patient Centered Teaching . . 75
C8 Emergency Neurology:
Meditation for the Practicing Neurologist . . . . . . . . 71
8:00 a.m.–9:10 a.m.
9:15 a.m.–9:45 a.m.
X
Yoga (All-Levels Vinyasa) . . . 71
Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? . . . 71
P1.133–P1.146 . 125
General Neurology: Autoimmune Neurology
P1.314–P1.338 . 128
1:00 p.m.–1:30 p.m.
12:00 p.m.–1:00 p.m.
1:30 p.m.–3:30 p.m.
1:00 p.m.–1:45 p.m.
X
Statistics - Sample Size . . . 77
C23 Critical Care Consultations for Neurohospitalists
2:00 p.m.–2:45 p.m.
X
Cafe Talk: Narratives in Neurology: Creative Expression to Promote Resilience and Prevent Burnout . . . . . . . 71
X X
C35
2:15 p.m.–3:00 p.m.
C39
X
Rural Neurology . . . . . . .69 Teleneurology: Is this for me? Pre-hospital and Nontraditional Uses of Teleneurology . . . . 75
3:00 p.m.–3:45 p.m.
X
Acupuncture Demonstration: 4 Gates . . . . . . . . . . . 71
Solving Burnout . . . . . . . 71
S4 Neuroepidemiology:
2:00 p.m.–3:00 p.m.
X
Neurology Pictionary . . . . . 69
1:00 p.m.–3:00 p.m.
S5
C40
Neurodegeneration, Epilepsy, Cerebrovascular Disease Risks . 97 General Neurology: Advances in Neurotherapeutics . . . . 97 Borderlands of Neurology and Internal Medicine: Chalk Talk Therapy in Neurology I: Headache and Stroke Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS
1:00 p.m.–5:30 p.m.
C48 Genomic Neurology Skills
Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies
38 2018 AAN Annual Meeting
X
How Your Social Life Might Be Helping (or Harming) Your Brain . 71
3:00 p.m.–4:00 p.m.
X
Blind Spots: The Impact of Conscious and Unconscious Biases . . . . . . . . . . 69
3:15 p.m.–4:00 p.m.
X
Social Media for the Millennial Neurologist . . . . 75
3:30 p.m.–5:30 p.m.
C54 Therapy in Neurology II:
Epilepsy and Movement Disorders
C55 Autoimmune Neurology II
Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience
Monday, April 23 7:00 a.m.–7:45 a.m.
X
Yoga (All-Levels Vinyasa) . . . 71
7:00 a.m.–9:00 a.m.
C65 Clinical Pearls: Learning
from Complex Cases Simple Lessons that Apply to Everyday Problems
8:00 a.m.–8:45 a.m.
X
Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? . . . 71
8:10 a.m.–9:00 a.m.
X
P1.147–P1.172 . 125
General Neurology: Neurogenetics
3:00 p.m.–3:45 p.m.
Your CV is talking about you behind your back, and your LORs are too! . . . . . . . . 77
8:30 a.m.–9:00 a.m.
X
Tools to Transition from Trainee to Attending . . . . . 75
10:45 a.m.–11:15 a.m.
X
Choosing a Neurohospitalist Career . . . . . . . . . . 75
12:00 p.m.–1:00 p.m.
X
Is There a Neurologist on This Flight? . . . . . . . . . . 69
1:00 p.m.–1:30 p.m.
X
Office Hours: Creating Bridge Funding - How to Use NonNIH Funding . . . . . . . . 77
1:00 p.m.–3:00 p.m.
C71 Therapy in Neurology III:
Neurological Infectious Diseases and Neuroophthalmologic Disorders C74 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I C75 Safe and Appropriate Opioid Prescribing in Neurology
X
Office Hours: Statistics Sample Size . . . . . . . . 77
1:30 p.m.–2:30 p.m.
X
Eminence-based Medicine vs Evidence-based Medicine . . . 69
3:00 p.m.–3:45 p.m.
X
Introduction to Acupuncture I: Conceptual Framework and Mechanism of Action . . . . 71
3:00 p.m.–4:00 p.m.
X
Lifting the Curtain: Ask the AAN Publication Editors Anything! . . . . . . . . . 69
3:30 p.m.–5:30 p.m.
C84 Evidence Based Neurology
Foresights for Busy Clinicians
C112 Continuum ® Test Your
Knowledge: A Multiple-choice Question Review I
4:00 p.m.–4:45 p.m.
X
Striking the Balance - A Neurologist’s Personal Wellness Journey . . . . . . 71
Tuesday, April 24 7:00 a.m.–7:45 a.m.
X
Yoga (All-Levels Vinyasa) . . . 71
7:00 a.m.–9:00 a.m.
C99 Good Neurology in
X
X
Self-Management in Neurologic Disease . . . . . 71
11:30 a.m.–7:00 p.m.
P3 Poster Session III
General Neurology ePoster Session
Research Methodology ePoster Session
2:45 p.m.–3:30 p.m.
X
3:00 p.m.–4:00 p.m.
X
4:30 p.m.–5:30 p.m.
X
Controversies in Neurology: Is the Zombie Apocalypse Upon Us? Local Outbreaks, Bioterrorism or Bioengineering Run Amok… . . . . . . . . 69
4:45 p.m.–5:30 p.m.
X
Teaching During a Busy Clinic . 75
5:45 p.m.–7:15 p.m.
Emerging Science Session
7:00 a.m.–7:45 a.m.
Introduction to the 2018-2020 TRANSCENDS Scholars . . . 77 Treatment of Neuropathy Symptoms Without Medication . 71
Neurology Game Show: Localize the Lesion . . . . . 69
1:00 p.m.–3:00 p.m.
N3 Neuroscience in the Clinic:
Challenges in Genetic Diagnosis in Neurology . . . . 82
X = Experiential Learning
X
Yoga (All-Levels Vinyasa) . . . 71
7:00 a.m.–9:00 a.m.
C139 Neurologic Case Studies in Pregnancy
8:00 a.m.–8:45 a.m.
X
Acupuncture Demonstration: Auriculotherapy . . . . . . . 71
9:15 a.m.–11:30 a.m.
P4.006–P4.020 . 152
P4.021–P4.026 . 152
12:00 p.m.–12:30 p.m.
X
Recruiting Minorities . . . . 77
12:00 p.m.–12:45 p.m.
X
Neurology and Wellness Physician, Heal Thyself . . . . 71
12:00 p.m.–1:00 p.m.
X Neuro-Jeopardy:
Telencephalon Twisters . . . 69
12:30 p.m.–1:00 p.m.
X
C122 Multiple Sclerosis Overview III:
The Pathogenesis of Multiple Sclerosis and Mechanism of Action of Treatments for MS C125 Continuum ® Test Your Knowledge: A Multiple-choice Question Review II C131 Introduction to Integrative Neurology C132 Actualization Científica Durante el Congreso Anual I
P4.001–P4.005 . 152
General Neurology: Case Reports I
3:30 p.m.–5:30 p.m.
P3.339–P3.344 . 149
12:00 p.m.–1:00 p.m.
X
Biological and Chemical Neuroterrorism and Neurowarfare . . . . . . . 69
Wednesday, April 25
12:00 p.m.–12:45 p.m.
X
Training in Neurology While on a Visa: Challenges and Possible Solutions for Foreign Medical Graduates . . . . . 75
P3.085–P3.090 . 144
12:00 p.m.–12:30 p.m.
X
Neurological Exam Tips and Tricks . . . . . . . . . . . 69 Office Hours: Finding Collaborators . . . . . . . . 77
General Neurology: Neuroimaging
2:30 p.m.–3:00 p.m.
8:00 a.m.–8:45 a.m.
X
Neurology Practice and Outcomes
Office Hours: Navigating Uncommon Pathways in Academic Neurology: A Journey from Bedside to Bench . . . . 77
12:40 p.m.–1:10 p.m.
X
Neuroscience of Bias . . . . 77
1:00 p.m.–3:00 p.m.
C144 Neurology Update I: Epilepsy, Behavioral Neurology, and Neurologic Infections C148 LGBTQI Health in Neurology
2:00 p.m.–2:30 p.m.
X
X
Office Hours: Mentor-Mentee Relationships . . . . . . . . 77 Women in Neuroscience . . . 77
2:00 p.m.–2:45 p.m.
X
Resiliency for the Neurologist . 71
2:40 p.m.–3:10 p.m.
X
Patient-Reported Measures in Neurology . . . . . . . . . 77
3:00 p.m.–3:45 p.m.
X
Introduction to Acupuncture II: Evidence-based Applications for Acupuncture in the Treatment of Neurologic Conditions . . . . . . . . . 71
3:00 p.m.–4:00 p.m.
X
Health Care Disparities Among Underserved Populations . . . 69
3:30 p.m.–5:30 p.m.
C160 Neurology Update II:
Movement Disorders, Spine Disorders, and Sleep Disorders C168 CNS Toxicities
Frontiers in Neuroscience Plenary Session: 10:35 a.m.–10:55 a.m. BigBrain: A High Resolution 3D Digital Human Brain Atlas 64
AAN.com/view/AM18 39
General Neurology
Challenging Conditions: Lessons from Military Neurology
P4 Poster Session IV
1:30 p.m.–2:30 p.m.
C85 Therapy in Neurology IV:
Autoimmune PNS Synaptic Disorders and Neuro-Oncology C93 Advances in Neurogenetics
11:30 a.m.–7:00 p.m.
ANNUAL MEETING TOPIC LIST
1:30 p.m.–2:00 p.m.
ANNUAL MEETING TOPIC LIST
2018 PROGRAMS LISTED BY TOPIC 3:45 p.m.–4:30 p.m.
2:00 p.m.–2:45 p.m.
C240 Neuroimaging for the General
4:15 p.m.–5:00 p.m.
3:00 p.m.–3:45 p.m.
Global Health
X X
Navigating Fellowship in Neurology . . . . . . . . . . . . . 75
The Neurology of VooDoo . . . 69
5:15 p.m.–6:15 p.m.
X
Neurology Illustrated: The Neurology of Art . . . . . . 69
Thursday, April 26 Yoga (All-Levels Vinyasa) . . . 71
7:00 a.m.–9:00 a.m.
C180 Principles of Genomic
Medicine: Clinical Exome Sequencing in Neurologic Disease
8:00 a.m.–8:30 a.m.
X
How to Bridge to Careers in Industry . . . . . . . . . . 77
8:40 a.m.–9:10 a.m.
X
The Pathway to Become a Clinical Trialist . . . . . . . 77
9:15 a.m.–11:30 a.m.
Controversies in Neurology Plenary Session: 10:00 a.m.–10:45 a.m. Should the Neurologist Be Primarily Responsible For Taking Care of Patients With Functional Disorders? . . 65
11:30 a.m.–7:00 p.m.
P5 Poster Session V
Global Health
Neuroepidemiology: Motor Neuron Disease, Cognitive Impairment, Sleep II
General Neurology
X
X
Multiple Sclerosis, Neuroophthalmology, and Autoimmune Encephalopathies C202 Neuroimaging for the General Neurologist II: Spine and Peripheral Nerve C207 Mitochondrial Disorders in Neurology 6:30 p.m.–9:30 p.m.
C212 Case Studies: Test Your
Knowledge: A Case-based Approach to Neuroimaging
Friday, April 27 X
Teaching History and Exam with Teleneurology . . . . . 75 The Purpose Checkup: Find Meaning, Live Longer, Better . 71
Who Wants to be a Millionaire . 69
1:00 p.m.–2:30 p.m.
Invited Science: The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative . . . . . . 89
1:00 p.m.–3:00 p.m.
C185 Neurology Update III: Neuromuscular,
Headache, and Stroke C188 Neuroimaging for the General Neurologist I: Spine and Peripheral Nerve 1:30 p.m.–2:30 p.m.
X
The Value of the Neurologic Exam: Caring for your Patient for $500 or Less . . . . . . 69
40 2018 AAN Annual Meeting
Neurologist II: Brain
Monday, April 23 1:45 p.m.–2:30 p.m.
X
Tuesday, April 24 11:45 a.m.–12:30 p.m.
X
Yoga (All-Levels Vinyasa) . . . 71
C216 Neuroendocrine Update: Nuts
3:45 p.m.–4:30 p.m.
X
Wednesday, April 25 7:00 a.m.–9:00 a.m.
C134 Tuberculosis of the Central Nervous System
Neurologic Diseases
3:30 p.m.–4:15 p.m.
S33 Global Health . . . . . . . 110
Thursday, April 26
Neurologic Emergencies
11:30 a.m.–7:00 p.m.
11:30 a.m.–5:30 p.m.
P5 Poster Session V
P6 Poster Session VI
General Neurology: Vascular Neurology
P6.001–P6.011 . 172
General Neurology: Case Reports II
P6.012–P6.026 . 172
12:00 p.m.–12:30 p.m.
X
How to Bridge to Careers in Industry . . . . . . . . . . 77 Outsmart Stress . . . . . . 71
12:00 p.m.–1:00 p.m.
The Neurology of Creativity at the Keyboard . . . . . . . . 69
1:00 p.m.–3:00 p.m.
S50 Updates in General Neurology . 117 C228 Neuroimaging for the General Neurologist I: Brain C230 Neurologic Complications of Medical and Surgical Therapies C233 Simposio Español: Actualización Científica Durante el Congreso Anual II
3:30 p.m.–5:30 p.m.
C237 Neurologic Complications of Medical Disease
Infectious Disease and Global Health I ePoster Session
P5.085–P5.090 . 164 Global Health
P5.154–P5.163 . 165
2:45 p.m.–3:30 p.m.
12:00 p.m.–12:45 p.m.
X
International Members: What Can the AAN Do For You? . . . 75
and Bolts of What You Need to Know
C220 Drugs and Toxin-induced
X
Foreign Medical Graduates Adjustment Skills . . . . . . 75
C154 The Global Burden of
7:00 a.m.–9:00 a.m.
X
Creating a Career in Global Health with Design Thinking . 75
1:00 p.m.–3:00 p.m.
7:00 a.m.–7:45 a.m.
P5.317–P5.338 . 168
12:00 p.m.–1:00 p.m.
X
Consejos Prácticos para un Buen Examen Neurológico . . 69
3:30 p.m.–5:30 p.m.
P5.164–P5.172 . 165
12:00 p.m.–12:45 p.m.
X
Magnifying Your Life Through Poetry . . . . . . . . . . 71
3:00 p.m.–4:00 p.m.
11:45 a.m.–12:30 p.m.
X
Cafe Talk: Communication in Neurology Practice . . . . . 71
C199 Neurology Update IV:
7:00 a.m.–7:45 a.m.
X
X
O Funding, Where Art Thou? How to Develop a Full-Time Academic Career in Global Neurology . . . . . . . . . 75
Headache
Saturday, April 21 12:45 p.m.–1:45 p.m.
X
Ask Us Anything: Expert Panel on Headache and Facial Pain . 69
Sunday, April 22 3:30 p.m.–5:30 p.m.
C50 Low and High Pressure
Headache: Clinical Presentation and Approach to Evaluation and Management
9:15 a.m.–11:30 a.m.
Contemporary Clinical Issues Plenary Session: 11:10 a.m.–11:30 a.m. Non-invasive Neuromodulation . . 62
1:00 p.m.–3:00 p.m.
C79 Comprehensive Migraine
Education Program I: Diagnosis, Risk Factors, and Neurobiology
11:30 a.m.–7:00 p.m.
P4 Poster Session IV
Education Program II: Behavioral and Psychological Approaches, and Preventive and Acute Treatment Advances
Tuesday, April 24 8:00 a.m.–9:00 a.m.
S20 “Best of” Session: Headache . 92
11:30 a.m.–7:00 p.m.
Thursday, April 26
7:00 a.m.–9:00 a.m.
1:00 p.m.–3:00 p.m.
C195 Practical Training in Injection Techniques in the Treatment of Headache Disorders Skills Workshop
3:30 p.m.–5:30 p.m.
S43 Migraine . . . . . . . . . 114
6:30 p.m.–9:30 p.m.
C214 Case Studies: Challenging Headache Cases
Friday, April 27 9:15 a.m.–11:30 a.m.
Headache: Imaging, Neurophysiology, and Research Methods
P3.091–P3.100 . 144
The Less Common Headaches
P3.101–P3.122 . 144
P3.123–P3.149 . 145
Headache Diagnosis, Burden and Co-Morbidity
1:00 p.m.–3:00 p.m.
C108 Introduction to Primary
3:30 p.m.–5:30 p.m.
C121 Introduction to Primary
Headache Disorders II: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches
Wednesday, April 25 7:00 a.m.–9:00 a.m.
C137 What Do I Do Now?:
Emergency and Inpatient Management of Migraine and Other Headache Disorders
X = Experiential Learning
Neurology Year in Review: Emerging Therapies Plenary Session: 9:55 a.m.–10:15 a.m. Headache Medicine 2018: Year In Review . . 66
1:00 p.m.–3:00 p.m.
C232 Hot Topics in Headaches and
Related Disorders I: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances
3:30 p.m.–5:30 p.m.
C243 Hot Topics in Headaches and
Related Disorders II: Unusual Headaches, Childhood Headaches, and Concussion Management
Infectious Disease
C134 Tuberculosis of the Central Nervous System
Thursday, April 26 7:00 a.m.–9:00 a.m.
C177 So You’ve Diagnosed Your
Patient with a Neuroinfectious Disease, Now What? Practical Pearls in the Treatment and Management of Neuroinfectious Diseases
11:30 a.m.–7:00 p.m.
P5 Poster Session V
Infectious Disease and Global Health I ePoster Session
Neurologic Infections: Treatments and Outcomes
Neurologic Infections: Unusual Presentations
P5.085–P5.090 . 164 P5.091–P5.107 . 164 P5.108–P5.143 . 164
Neurological Infections: Diagnostics and Animal Models
P5.144–P5.153 . 165
Infectious Disease and Global Health II ePoster Session
P5.339–P5.344 . 169
1:00 p.m.–3:00 p.m.
S41 Neurologic Infections . . . . 113
3:30 p.m.–5:30 p.m.
C201 Differential Diagnosis of Neurologic Infections
Sunday, April 22
Friday, April 27
12:00 p.m.–12:30 p.m.
7:00 a.m.–9:00 a.m.
X
Office Hours: Finding/Working with Epidemiologists on Your Grant . . . . . . . . . . . 77
Monday, April 23 9:15 a.m.–11:30 a.m.
Contemporary Clinical Issues Plenary Session: 10:05 a.m.–10:20 a.m. Pediatric Brainstem Encephalitis Outbreak Investigation with Metagenomic Next-Generation Sequencing . . 62
C218 Infections of the Nervous
System I: Diagnostic Testing of Neurological Infections
1:00 p.m.–3:00 p.m.
C226 Infections of the Nervous
System II: Neuro-ID Emergencies
3:30 p.m.–5:30 p.m.
C239 Infections of the Nervous
System III: Advanced Topics in Infectious Neurology
AAN.com/view/AM18 41
Infectious Disease
Headache Disorders I: Migraine and Other Primary Headaches Including TensionType, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine
Infecciones del Sistema Nervioso Central y la Medicina Tropical
Wednesday, April 25
S32 Headache: Therapeutics . . . 109
P3 Poster Session III
P4.091–P4.153 . 154
C95 Actualización Sobre las
1:00 p.m.–3:00 p.m.
3:30 p.m.–5:30 p.m.
C90 Comprehensive Migraine
Headache Therapeutics
3:30 p.m.–5:30 p.m.
ANNUAL MEETING TOPIC LIST
Monday, April 23
ANNUAL MEETING TOPIC LIST
2018 PROGRAMS LISTED BY TOPIC Leadership
Saturday, April 21 7:00 a.m.–4:00 p.m.
C7 L Women in Leadership
12:00 p.m.–12:45 p.m.
X
Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? . . . 71
12:00 p.m.–4:00 p.m.
C16 L Leadership Challenges in Practice
1:00 p.m.–4:00 p.m.
C18 L Educators’ Leadership Program
1:15 p.m.–2:00 p.m.
X
Interviewing Skills: Medical Students and Residents . . . 75
3:15 p.m.–4:15 p.m.
X
Women in Neurology: Crafting Your Leadership Career: Lessons from Leaders . . . . 69
Sunday, April 22 8:30 a.m.–9:00 a.m.
X
Giving and Receiving Feedback for Medical Students and Residents . . . 75
10:45 a.m.–11:15 a.m.
X
C45 L Being a Resilient Leader:
How Do You Lead the Change? C46 L The Most Important Tool in Your Black Bag: Gallup StrengthsFinders™ Assessment
Leadership
2:00 p.m.–2:30 p.m.
Breaking Down Silos: Using Simulation for Interprofessional Team Education to Enhance Clinical Outcomes in Neurology . . . 73
2:15 p.m.–3:00 p.m.
X
Education Administrator Building Blocks: Navigating the Role of the Administrator and Taking Your Role to the Next Level . . . . . . . . . 75
3:15 p.m.–3:45 p.m.
X
How to Get Into Leadership in Professional Societies . . . . 75
Monday, April 23 8:00 a.m.–8:45 a.m.
X
Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? . . . 71
42 2018 AAN Annual Meeting
How to be “Useful” on Rotations: Tips for Medical Students . . . . . . . . . 75
1:00 p.m.–3:00 p.m.
C69 L Continuing Your Leadership
Movement Disorders
Saturday, April 21 7:00 a.m.–9:00 a.m.
C4 Hyperkinetic Movement
Disorders: Videodiagnosis and Treatment
Journey: Uncharted Waters
1:00 p.m.–4:00 p.m.
C81 L Mitigating the Impact of
Unconscious Bias Workshop
4:15 p.m.–5:00 p.m.
X
Foundations for Success in the AAN . . . . . . . . . . . 69
4:45 p.m.–5:30 p.m.
X
Career Development for Medical Educators . . . . . 75
Tuesday, April 24 8:15 a.m.–9:00 a.m.
X
Career Development for Clinician Educators . . . . . 75
9:30 a.m.–11:30 a.m.
C14 Parkinson’s Disease Update
1:30 p.m.–3:30 p.m.
C24 Diagnosis and Treatment of
Functional Movement Disorders
Sunday, April 22 7:00 a.m.–9:00 a.m.
C25 Hot Topics and Controversies in Parkinson’s Disease
11:30 a.m.–5:30 p.m.
P1 Poster Session I
8:30 a.m.–9:00 a.m.
X
Career Stories: Nuts and Bolts of Academic Leadership Strategies I Have Learned in My Career . . . . . . . . . 75
1:00 p.m.–3:00 p.m.
C105 L Mentoring…Growing the
Next Generation of Neurologist
C118 L Leadership in the Era of
Burnout: A Practical Approach to Becoming a True Physician Leader
So You Want to Be a Residency Program Director? . 75
1:00 p.m.–5:00 p.m.
X
X
Interviewing Skills: Negotiation . 75
9:15 a.m.–9:45 a.m.
X
10:00 a.m.–10:30 a.m.
3:00 p.m.–3:45 p.m.
X
StrengthsFinder Social Hour . . 71
Wednesday, April 25 1:00 p.m.–5:00 p.m.
C157 L Advanced Leadership
Training: Preparing for Your Career’s Insurmountable Opportunities C158 L Leadership Strengths in Neurology: The Data, Tools and Practical Application of Strengths for Leadership, Team Building, and Personal Development 2:45 p.m.–3:30 p.m.
X
Pursing a Career in Healthcare Administration . . . . . . . 75
Thursday, April 26 1:45 p.m.–2:30 p.m.
X
Interviewing Skills . . . . . . 75
Parkinson’s Disease: Non-Motor Manifestations
P1.037–P1.056 . 123
Ataxias I
P1.057–P1.084 . 123
1:00 p.m.–3:00 p.m.
S3 Movement Disorders:
Parkinson’s Disease: Genetics, Biomarkers, and Diagnosis . . 96 C37 Nonmotor Manifestations of Parkinson’s Disease I 1:45 p.m.–2:15 p.m.
X
Career Stories: Challenges for the Physician Scientist . . . . 75
3:30 p.m.–5:30 p.m.
C52 Nonmotor Manifestations of Parkinson’s Disease II
4:30 p.m.–5:30 p.m.
X
What is that Twitch? . . . . . 69
Monday, April 23 7:00 a.m.–9:00 a.m.
C60 Balance and Gait Disorders C67 Video EEG: Name That Spell
11:30 a.m.–7:00 p.m.
P2 Poster Session II
Parkinson’s Disease: Therapeutics
P2.037–P2.048 . 133
P2.049–P2.084 . 133
Parkinson’s Disease: Phenomenology, Epidemiology and Rating Scales
1:00 p.m.–3:00 p.m.
C70 Evaluating Tremor in the Office
3:30 p.m.–5:30 p.m.
S18 Movement Disorders: Ataxia
and Tremor . . . . . . . . 102
7:00 a.m.–9:00 a.m.
11:30 a.m.–7:00 p.m.
C102 Movement Disorders for the
11:30 a.m.–7:00 p.m.
P3 Poster Session III
Parkinson’s Disease: Surgical Management
Movement Disorders: Tardive Dyskinesia
Dystonia, Chorea, and other Disorders . . . . . . . . . 109
C159 Clinical Uses of Botulinum
Thursday, April 26
P3.064–P3.084 . 143
Complementary Therapies in Parkinson’s Disease . . . . . 71
1:00 p.m.–3:00 p.m.
Invited Science: Movement Disorders . . . . . . . . . 88 N3 Neuroscience in the Clinic: Challenges in Genetic Diagnosis in Neurology . . . . 82 C115 Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia
2:00 p.m.–2:45 p.m. 3:30 p.m.–5:30 p.m.
S26 Movement Disorders:
Parkinson’s Disease Clinical Trials . . . . . . . . . . 106 C123 Child Neurology: A Casebased Approach C128 Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics
Wednesday, April 25 7:00 a.m.–9:00 a.m.
C140 Paroxysmal Movement Disorders
8:00 a.m.–9:00 a.m.
S27 “Best of” Session: Movement
Disorders . . . . . . . . . 93
X
Movement Disorders II ePoster Session
P6.068–P6.084 . 173
P6.085–P6.090 . 174 P6.339–P6.344 . 178
Movement Disorders Poster Discussion Session P6.027–P6.036 172
1:00 p.m.–3:00 p.m.
C229 Deep Brain Stimulation
I: Basic Principles and Programming in Movement Disorders
3:30 p.m.–5:30 p.m.
7:00 a.m.–9:00 a.m.
C176 The Dystonia: Diagnosis,
C241 Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders
Treatment and Update on Etiologies
11:30 a.m.–7:00 p.m.
P5 Poster Session V
Dystonia: Phenomenology and Therapeutics
Parkinson’s Disease: Therapeutics II
Ataxias II
Movement Disorders I ePoster Session
Top Ten Clinical, Educational and Leadership Pearls . . . . 75
P6.054–P6.067 . 173
11:45 a.m.–12:35 p.m.
Parkinson Disease: Raising Your Game . . . . . . . . . 69
Atypical Parkinsonism
P5.037–P5.063 . 163
MS and CNS Inflammatory Disease
P5.064–P5.076 . 163
Saturday, April 21
P5.077–P5.084 . 164
9:30 a.m.–11:30 a.m.
1:00 p.m.–3:00 p.m.
C187 Cerebellar and Afferent Ataxias: Diagnosis and Management
3:30 p.m.–5:30 p.m.
S45 Movement Disorders:
Parkinsonian Disorders, Basic Science, and Imaging . . . . 114 C209 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop 6:30 p.m.–9:30 p.m.
C213 Case Studies: Unusual
C11 Treatment of Pediatric
Multiple Sclerosis in the Current Era
4:15 p.m.–5:30 p.m.
Sunday, April 22 7:00 a.m.–9:00 a.m.
C34 Multiple Sclerosis in the
Trenches: Controversy and Consensus in Clinical Decision-Making
Movement Disorders
Friday, April 27 7:00 a.m.–9:00 a.m.
C222 Therapy of Movement
Hot Topics Plenary Session: 5:05 p.m.–5:20 p.m. Monitoring Multiple Sclerosis Using Blood Neurofilament Light Protein . . 60
10:00 a.m.–10:30 a.m.
X
Autoimmune Neurology . . . 75
Disorders: A Case-based Approach
X = Experiential Learning L = Leadership University
AAN.com/view/AM18 43
MS & CNS Disease
Dancing with Parkinson’s . . . 71
X
1:00 p.m.–5:30 p.m.
Toxin for Dystonia Skills Workshop
Movement Disorders: Essential and other Tremor Syndromes
S30 Movement Disorders:
P6.037–P6.053 . 173
1:00 p.m.–3:00 p.m.
Parkinson’s Disease: Imaging
P3.049–P3.063 . 143
P4.074–P4.084 . 154
4:45 p.m.–5:30 p.m.
F unctional Movement Disorders and Other Hyperkinetic Movement Disorders
P4.052–P4.073 . 153
Parkinson’s Disease: Animal Models and Biomarkers
P3.037–P3.048 . 143
P6 Poster Session VI
P4.037–P4.051 . 153
1:30 p.m.–2:30 p.m.
1:00 p.m.–1:45 p.m.
X
Parkinson’s Disease: Wearable Sensors and Remote Monitoring Technology
X
Huntington’s Disease and other Chorea
9:15 a.m.–11:30 a.m.
Clinical Trials Plenary Session: 9:15 a.m.–9:30 a.m. Effects of IONIS-HTTRx in Patients with Early Huntington’s Disease, Results of the First HTT-Lowering Drug Trial . 63
General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson’s Disease
11:30 a.m.–5:30 p.m.
P4 Poster Session IV
ANNUAL MEETING TOPIC LIST
Tuesday, April 24
ANNUAL MEETING TOPIC LIST
2018 PROGRAMS LISTED BY TOPIC 11:30 a.m.–5:30 p.m.
P1 Poster Session I
MS and CNS Inflammatory Disease ePoster Session
P1.085–P1.090 . 124
Neuroinflammatory and Other Autoimmune Disorders I
P1.345–P1.350 . 129
P1.351–P1.382 . 129
Comparative Efficacy of Disease Modifying Therapies Biomarkers and Experimental Studies for Multiple Sclerosis
P1.383–P1.414 . 130
MS and CNS Inflammatory Disease: Quality of Life, Symptoms, and Symptomatic Therapy I
3:30 p.m.–5:30 p.m.
C87 Neuro-rheumatology:
Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II C95 Actualización Sobre las Infecciones del Sistema Nervioso Central y la Medicina Tropical
S8 Progressive MS Therapies and
C98 Multiple Sclerosis Overview I: Clinical Pearls
9:15 a.m.–11:30 a.m.
P3 Poster Session III
P2 Poster Session II
MS Modifiable Risk Factors
MS Diagnosis, Mimickers, and Phenotypes
MS & CNS Disease
P2.345–P2.361 . 139 P2.362–P2.374 . 139
MS Epidemiology and Genetics
P2.375–P2.400 . 139
MS Animal Models
P2.401–P2.414 . 140
MS and CNS Inflammatory Disease: Quality of Life, Symptoms, and Symptomatic Therapy II
P2.415–P2.428 . 140
1:00 p.m.–3:00 p.m.
S13 Neuromyelitis Optica
Spectrum Disorder and other Autoimmune Disorders . . . 100 C74 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I
44 2018 AAN Annual Meeting
P4.345–P4.354 . 159
Pregnancy and Multiple Sclerosis
P4.355–P4.372 . 159
P4.373–P4.408 . 159
P4.409–P4.428 . 160
T ools and Outcome Measures for MS Trials and Clinical Tracking MS and CNS Inflammatory Disease: Quality of Life, Symptoms, and Symptomatic Therapy III
1:00 p.m.–3:00 p.m.
C147 Multiple Sclerosis Therapy:
Disease-modifying Treatment II
3:30 p.m.–5:30 p.m.
S36 MS Therapeutics and Clinical
Research . . . . . . . . . 111
C162 Multiple Sclerosis Therapy: Symptom Management
4:00 p.m.–4:45 p.m.
MS and CNS Inflammatory Disease: Neuroimaging: Novel Techniques
Thursday, April 26
P3.345–P3.376 . 149
P3.377–P3.392 . 149
MS Therapeutics in Development
P3.393–P3.408 . 150
MS Therapeutics I
P3.409–P3.417 . 150
Neuroinflammatory and Other Autoimmune Disorders II
X
C175 Clinical Pearls in Autoimmune Neurology: Real World Cases
11:30 a.m.–7:00 p.m.
P5 Poster Session V
P3.418–P3.428 . 150
Clinical Advances
3:30 p.m.–5:30 p.m.
S24 MS Outcome Measures and
Wednesday, April 25
Disease-modifying Treatment I
9:15 a.m.–11:30 a.m.
Frontiers in Neuroscience Plenary Session: 10:55 a.m.–11:15 a.m. Pediatric MS: A Unique Window into Environmental and Genetic Risk Factors for MS . 64
P5.345–P5.380 . 169
P5.381–P5.406 . 169
Neuroinflammatory and Other Autoimmune Disorders III
P5.407–P5.424 . 170
MS Therapeutics II
P5.425–P5.428 . 170
11:45 a.m.–12:35 p.m.
7:00 a.m.–9:00 a.m.
C136 Multiple Sclerosis Therapy:
MS Therapies: MOA, Safety and Complications
MS and CNS Inflammatory Disease: Encephalities and Encephalopathies
C109 Multiple Sclerosis Overview II:
Biomarkers . . . . . . . . 106 C122 Multiple Sclerosis Overview III: The Pathogenesis of Multiple Sclerosis and Mechanism of Action of Treatments for MS
Diets and Supplements in MS: What’s the Evidence Thus Far? . 71
7:00 a.m.–9:00 a.m.
1:00 p.m.–3:00 p.m.
Pediatric Multiple Sclerosis
MS and CNS Inflammatory Disease: Neuroimaging
9:15 a.m.–11:30 a.m.
11:30 a.m.–7:00 p.m.
Monday, April 23 Contemporary Clinical Issues Plenary Session: 10:50 a.m.–11:10 a.m. Biosimilars and Non-biologic Complex Drugs . . 62
Clinical Trials Plenary Session: 10:30 a.m.–10:45 a.m. A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis . 63
11:30 a.m.–7:00 p.m.
Age-Dependent Factors in MS Therapy . . . . . . . . . . 98 C59 Actualización Sobre el Tratamiento de la Esclerosis Múltiple
7:00 a.m.–9:00 a.m.
1:00 p.m.–3:00 p.m.
3:30 p.m.–5:30 p.m.
P4 Poster Session IV
Tuesday, April 24
P1.415–P1.428 . 130
S6 MS Neuroimaging . . . . . . 97
11:30 a.m.–7:00 p.m.
MS and CNS Inflammatory Disease Poster Discussion Session P5.027–P5.036 . 64
1:00 p.m.–3:00 p.m.
N5 Neuroscience in the Clinic:
Treatment of Progressive Multiple Sclerosis . . . . . . 84
2:00 p.m.–3:00 p.m.
X
Using your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency . . . . . . . 73
S44 MS Risk Factors,
Susceptibility, Diagnosis, and Cognitive Impairment . . . . 114
Friday, April 27 8:00 a.m.–9:00 a.m.
S47 “Best of” Session: MS and
CNS Inflammatory Diseases . . 93
11:30 a.m.–5:30 p.m.
P6 Poster Session VI
MS Therapeutics III
MS Therapeutics: Extension Studies
P6.345–P6.361 . 178
P6.362–P6.396 . 179
MS and CNS Inflammatory Disease: Neuromyelitis Optica and Related Disorders
3:30 p.m.–5:30 p.m.
C53 Neurological Intensive Care III: Vascular Diseases
1:00 p.m.–3:00 p.m.
C72 Sports Neurology: Enhancing Athletic Performance
Tuesday, April 24
9:15 a.m.–11:30 a.m.
S51 Pediatric MS . . . . . . . . 117 C224 Neuromyelitis Optica S52 MS and CNS Inflammatory
Disease: Basic Science . . . . 118
4:30 p.m.–5:30 p.m.
X
Ask Us Anything: Expert Panel on Multiple Sclerosis . . . . 69
Neuro Trauma, Critical Care, and Sports Neurology
Saturday, April 21
X
3:30 p.m.–5:30 p.m.
C127 Concussion Management:
Chronic Sequelae and Symptom Targeted Treatment in the Acute, Subacute and Chronic Phase After Concussion
Wednesday, April 25
C38 Neurological Intensive Care
II: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction
X = Experiential Learning
Neurocritical Care I
P4.295–P4.338 . 158
Cerebrovascular Disease and Interventional Neurology II ePoster Session
P4.339–P4.344 . 159
C211 Case Studies in the ICU
Friday, April 27 11:30 a.m.–5:30 p.m.
P6 Poster Session VI
8:00 a.m.–8:45 a.m.
X
Sleep and Performance in Elite Athletes . . . . . . . . 71
Sports Neurology
Neurocritical Care II
P6.295–P6.321 . 177 P6.322–P6.338 . 178
1:00 p.m.–3:00 p.m.
S49 Neuro Trauma and Sports
Neurology . . . . . . . . 116
Neuromuscular and Clinical Neurophysiology (EMG)
Saturday, April 21 9:30 a.m.–11:30 a.m.
C9 Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies
1:30 p.m.–3:30 p.m.
C21 Evaluation and Management
of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia
Sunday, April 22 7:00 a.m.–9:00 a.m.
C31 Peripheral Neuropathy
I: Anatomical Basis and Acquired Demyelinating Neuropathies
C145 Severe TBI: From ICU to
Thursday, April 26
1:00 p.m.–3:00 p.m.
Rehabilitation
Invited Science: Neuro Trauma . 90
6:30 p.m.–9:30 p.m.
9:15 a.m.–12:00 p.m.
Presidential Plenary Session: 10:45 a.m.–11:15 a.m. Sidney Carter Award in Child Neurology: Spinal Muscular Atrophy Is a Treatable Neurodegenerative Disease . . 61
AAN.com/view/AM18 45
Neuromuscular (EMG)
7:00 a.m.–9:00 a.m.
1:00 p.m.–3:00 p.m.
3:30 p.m.–5:30 p.m.
P4 Poster Session IV
Neurohospitalists
The Essentials
How to Perform a Brain Death Evaluation, Avoid Pitfalls and Convey the News to the Family
11:30 a.m.–7:00 p.m.
C23 Critical Care Consultations for
C27 Neurological Intensive Care I:
Choosing a Career in Neurocritical Care . . . . . . 75
Fluid and Imaging Biomarkers, Diagnosis, and Treatment of Post-Concussion Headache
1:30 p.m.–3:30 p.m.
Sunday, April 22
Clinical Trials Plenary Session: 10:45 a.m.–11:00 a.m. Brain Oxygen Optimization in Severe Traumatic Brain Injury (BOOST) Phase 2 trial: Towards Evidence-Based in the Neurological Intensive Care Unit . 63
C106 Critical Care EEG Monitoring C114 Concussion: Pathogenesis,
ophthalmology
Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room
C196 Brain Death Skills Workshop:
1:00 p.m.–3:00 p.m.
C3 Emergency Room NeuroC8 Emergency Neurology:
1:00 p.m.–5:30 p.m.
10:00 a.m.–10:30 a.m.
7:00 a.m.–9:00 a.m.
9:30 a.m.–11:30 a.m.
S42 Neurocritical Care . . . . . . 113
C104 Sports Concussion Skills
Workshop: Event Coverage Foundational Skills and Sport Specific Pearls
Controversies in Neurology Plenary Session: 10:45 a.m.–11:30 a.m. Would You Let Your Child Play Contact Sports? . . 65
1:00 p.m.–3:00 p.m.
7:00 a.m.–9:00 a.m.
1:00 p.m.–3:00 p.m.
3:30 p.m.–5:30 p.m.
Monday, April 23
P6.397–P6.428 . 180
Spectrum Disorders
9:15 a.m.–11:30 a.m.
ANNUAL MEETING TOPIC LIST
3:30 p.m.–5:30 p.m.
ANNUAL MEETING TOPIC LIST
2018 PROGRAMS LISTED BY TOPIC 11:30 a.m.–5:30 p.m.
9:15 a.m.–11:30 a.m.
P1 Poster Session I
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
P1.339–P1.344 . 129
Neuropathy
P1.429–P1.467 . 131
1:00 p.m.–3:00 p.m.
C41 Peripheral Neuropathy
II: Diabetic and Inherited Neuropathies
11:30 a.m.–7:00 p.m.
C49 Neuromuscular Ultrasound
3:30 p.m.–5:30 p.m.
C63 Therapy of Neuromuscular
Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis
11:30 a.m.–7:00 p.m.
P2 Poster Session II
Autonomic Disorders: Autonomic Neuropathies
Autonomic Disorders: Other
P2.109–P2.116 . 134 P2.117–P2.124 . 135 Neuropathy II
P2.429–P2.453 . 141
Neuromuscular Diagnostics, Genetics, and Biomarkers
P2.454–P2.467 . 141
11:45 a.m.–12:35 p.m.
Neuromuscular (EMG)
Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session P2.027–P2.036 133
1:00 p.m.–2:15 p.m.
S12 Autonomic Disorders . . . . 100
1:00 p.m.–3:00 p.m.
C76 Clinical Approach to Muscle
Disease I: Role of Antibodies, Muscle Imaging and Genetic Testing
3:30 p.m.–5:30 p.m.
N2 Neuroscience in the Clinic:
Antisense Oligonucleotide (ASO) Therapy . . . . . . . 82 C89 Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology
Tuesday, April 24 46 2018 AAN Annual Meeting
Practice of NCS and Needle EMG
8:00 a.m.–9:00 a.m.
S38 “Best of” Session:
Clinical Trial Updates in Neuromuscular Disorders . . . 93
11:30 a.m.–7:00 p.m.
P5 Poster Session V
P3.435–P3.462 . 151
P3.463–P3.465 . 151
ALS I
Treatment of Neuropathy Symptoms Without Medication . 71
1:00 p.m.–3:00 p.m.
N3 Neuroscience in the Clinic:
Challenges in Genetic Diagnosis in Neurology . . . . 82 S22 Advances in Muscular Dystrophy and Congenital Myopathy . . . . . . . . 104
3:30 p.m.–5:30 p.m.
S25 Advances in Amyotrophic
Lateral Sclerosis . . . . . . 106
Neuromuscular Junction Testing and Quantitative EMG
3:30 p.m.–5:30 p.m.
S46 Advances in Spinal Muscular
Atrophy . . . . . . . . . . 115
C206 Clinical EMG III: Nerve
Conduction Criteria and Electrodiagnostic Approaches
6:30 p.m.–9:30 p.m.
C210 Case Studies: Unusual
Diagnostic and Management of Cases in Neuromuscular Disease
Friday, April 27 8:00 a.m.–9:10 a.m.
X
Wednesday, April 25 7:00 a.m.–9:00 a.m.
C142 Mastering EMG Waveform
Recognition Skills in Just Two Hours!
11:30 a.m.–7:00 p.m.
P4 Poster Session IV
ALS II
P4.429–P4.450 . 161
ALS, SMA, and other Neuromuscular Disorders II
P4.451–P4.465 . 161
1:00 p.m.–3:00 p.m.
S31 Therapeutics, Phenotypes,
and Biomarkers in Neuromuscular Disorders . . 109 C155 Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System 3:30 p.m.–5:30 p.m.
C169 Small Fiber Neuropathies:
Sensory, Autonomic, and Both II: Focus on Sensory Nervous System
Thursday, April 26
P5.459–P5.464 . 171
C192 Clinical EMG II:
1:00 p.m.–5:30 p.m.
C119 EMG Skills Workshop: Basic
P5.429–P5.458 . 170
1:00 p.m.–3:00 p.m.
12:00 p.m.–12:45 p.m.
X
Muscular Dystrophy
LS, SMA, and other Neuromuscular A Disorders III
P3.429–P3.434 . 150
C56 Peripheral Neuropathy III:
7:00 a.m.–9:00 a.m.
C179 Clinical EMG I: Principles and
ALS, SMA, and other Neuromuscular Disorders I
Myopathy
Skills Workshop
Monday, April 23
7:00 a.m.–9:00 a.m.
P3 Poster Session III
1:00 p.m.–5:30 p.m.
Genetic Testing and Next Generation Sequencing
Clinical Trials Plenary Session: 9:45 a.m.–10:00 a.m. Patisiran, a RNAi Therapeutic, to Improve Outcomes in Hereditary Transthyretin Mediated (hATTR) Amyloidosis with Polyneuropathy . 63
Role of Placebo in Neuromuscular Clinical Trials and in Management of NM Disorders . . . . . . . . . 77
9:15 a.m.–11:30 a.m.
Neurology Year in Review: Emerging Therapies Plenary Session: 9:15 a.m.–9:35 a.m. A Year in Review of Neuromuscular Diseases: Making Treatments Great Again . . 66
11:30 a.m.–5:30 p.m.
P6 Poster Session VI
Myasthenia Gravis
P6.429–P6.459 . 180 ALS III
P6.460–P6.466 . 181
1:00 p.m.–3:00 p.m.
C225 Neuromuscular Junction
Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia
C236 Neuromuscular Junction
Disorders II: Toxins, LambertEaton Syndrome and Less Common Disorders of Neuromuscular Transmission
Neuro-oncology
Sunday, April 22 9:15 a.m.–12:00 p.m.
Presidential Plenary Session: 11:15 a.m.–11:45 a.m. Robert Wartenberg Lecture: Neuro-Oncology: How Cancer and the Nervous System Interact . . 61
Tuesday, April 24 7:00 a.m.–9:00 a.m.
C100 Basic Principles of Brain
Tumors: For Practice and for Certification
1:00 p.m.–3:00 p.m.
S23 Biologic and Clinical Discoveries
in Neuro-oncology . . . . . . 105
3:30 p.m.–5:30 p.m.
C124 The Palliative Care Guide in
Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders
Wednesday, April 25 11:30 a.m.–7:00 p.m.
P4 Poster Session IV
T herapeutics in Neuro-oncology: From Laser Ablation to Immunotherapy I
P4.154–P4.163 . 155
1:00 p.m.–3:00 p.m.
C149 What Do I Do Now?:
3:30 p.m.–5:30 p.m.
C164 What Do I Do Now?:
Neurologic Consultations in Cancer Patients II
Thursday, April 26 7:00 a.m.–9:00 a.m.
C178 Neuro-oncology in 2018:
Navigating Current Trends
1:00 p.m.–3:00 p.m.
N6 Neuroscience in the Clinic:
Neurologic Complications of Cancer Immunotherapy: A New Frontier in NeuroInflammation . . . . . . . . 84
9:15 a.m.–11:30 a.m.
Neurology Year in Review: Emerging Therapies Plenary Session: 9:35 a.m.–9:55 a.m. Neuro-Oncology Year in Review: Progress, Breakthroughs and Future Directions . . 66
11:30 a.m.–5:30 p.m.
P6 Poster Session VI
Case based Neuro-oncology: the Art and Power of Clinical Observation
P6.091–P6.127 . 174
P6.128–P6.137 . 174
T herapeutics in Neuro-oncology: From Laser Ablation to Immunotherapy II
7:00 a.m.–9:00 a.m.
C62 Neuro-ophthalmology: Overview and Update
9:15 a.m.–11:30 a.m.
Friday, April 27
Monday, April 23
Neuro-oncology: Genes, Biomarkers, Patient Care and Outcomes
P6.138–P6.172 . 174
Neuro-ophthalmology/Neurootology
Saturday, April 21 7:00 a.m.–9:00 a.m.
C3 Emergency Room Neuroophthalmology
1:30 p.m.–3:30 p.m.
C19 Pediatric Neuro-
ophthalmology Update
Sunday, April 22 7:00 a.m.–9:00 a.m.
C26 Neuro-ophthalmology I: Visual Loss, Optic Neuropathies, and Papilledema
1:00 p.m.–3:00 p.m.
C44 Neuro-ophthalmology II: Optic Neuritis, Visual Fields, and Anisocoria
3:30 p.m.–5:30 p.m.
C58 Neuro-ophthalmology III:
Contemporary Clinical Issues Plenary Session: 9:15 a.m.–9:30 a.m. Retinal Microvasculature in Predicting Risk of Stroke Subtypes . . 62
11:30 a.m.–7:00 p.m.
P2 Poster Session II
Neuro-Ophthalmology/ Neuro-Otology
P2.136–P2.172 . 135
1:00 p.m.–3:00 p.m.
S16 Neuro-Ophthalmology/
Neuro-Otology . . . . . . . 101
1:00 p.m.–5:30 p.m.
C83 Neuro-ophthalmology and
Neurovestibular Exam Lab Skills Workshop
Tuesday, April 24 7:00 a.m.–9:00 a.m.
C103 Now You See It, Now You Know It: Pathognomonic Neuro-ophthalmology Examination Findings
Wednesday, April 25 7:00 a.m.–9:00 a.m.
C133 Higher Cortical Visual
Disorders: Case-based Review
1:00 p.m.–3:00 p.m.
C152 Nystagmus and Saccadic Intrusions Made Simple
3:30 p.m.–5:30 p.m.
C167 Eye Movement Disorders: A
Systematic Approach to the Evaluation of Diplopia
Thursday, April 26 1:00 p.m.–3:00 p.m.
C191 Neuro-otology I: The Common
Peripheral Vestibular Disorders
3:30 p.m.–5:30 p.m.
C205 Neuro-otology II: Diagnosis and Treatment of Nuanced Causes of Dizziness
Diplopia, Ocular Motility Disorders, and Nystagmus
C190 Neuro-oncologic Predicaments in the Hospital Setting
X = Experiential Learning
AAN.com/view/AM18 47
Neuro-ophthalmology
Neurologic Consultations in Cancer Patients I
3:30 p.m.–5:30 p.m.
ANNUAL MEETING TOPIC LIST
3:30 p.m.–5:30 p.m.
ANNUAL MEETING TOPIC LIST
2018 PROGRAMS LISTED BY TOPIC Neuro-rehabilitation
Pain and Palliative Care
Tuesday, April 24
Saturday, April 21
3:30 p.m.–5:30 p.m.
9:30 a.m.–11:30 a.m.
C120 Lumbar Radiculopathy, Lumbar
Spinal Stenosis, Low Back Pain, and Failed Back Syndrome
C143 Evaluation and Treatment of
Access Home Care, Support Caregivers, and Discuss Complex Situations in Advanced Neurologic Disease
12:45 p.m.–1:45 p.m.
X
Common Spine Disorders
9:15 a.m.–11:30 a.m.
Frontiers in Neuroscience Plenary Session: 9:15 a.m.–9:35 a.m. The Dynamics of the Unconscious Brain under General Anesthesia . 64
S37 Neurorehabilitation . . . . . 111
Thursday, April 26 C174 Rehabilitation in Neurology P5 Poster Session V
1:00 p.m.–3:00 p.m.
C186 Myelopathies I: Recognizing
and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes
X
Using your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency . . . . . . . 73
3:30 p.m.–5:30 p.m.
C200 Myelopathies II: Approaches
Neuro-rehabilitation
to Rehabilitation and Psychosocial Challenges
Friday, April 27 3:30 p.m.–5:30 p.m.
9:15 a.m.–11:30 a.m.
Contemporary Clinical Issues Plenary Session: 10:30 a.m.–10:50 a.m. Neuropalliative Care . . 62
11:30 a.m.–7:00 p.m.
P2 Poster Session II
Pain and Palliative Care
P2.091–P2.108 . 134
N4 Neuroscience in the Clinic:
Opioid Use and Abuse: The Overlapping Neurobiology of Pain and Addiction, and the Path Toward Better Treatments . 83
Thursday, April 26 1:00 p.m.–1:45 p.m.
X
C195 Practical Training in Injection Techniques in the Treatment of Headache Disorders Skills Workshop
Friday, April 27 3:30 p.m.–5:30 p.m.
C235 Neck Pain, Cervical
Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy
Prescribing in Neurology
3:30 p.m.–5:30 p.m.
C88 Core Concepts in Pain
Management: Refractory Neuropathic Pain Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids
3:45 p.m.–4:30 p.m.
X
Teaching Communication Skills: From Good to Great . . 75
Tuesday, April 24 1:00 p.m.–3:00 p.m.
C111 Enhancing Your Career and Practice Through Neuropalliative Care
3:20 p.m.–3:50 p.m.
X
Pain Research Funding Opportunities, Clinical and Basic . 77
C120 Lumbar Radiculopathy, Lumbar
Spinal Stenosis, Low Back Pain, and Failed Back Syndrome
Medical Marijuana: What do Neurologists Need to Know? . 71
1:00 p.m.–3:00 p.m.
C75 Safe and Appropriate Opioid
3:30 p.m.–5:30 p.m.
48 2018 AAN Annual Meeting
Common Spine Disorders
3:30 p.m.–5:30 p.m.
1:00 p.m.–3:00 p.m.
C235 Neck Pain, Cervical
Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy
Cafe Talk: Is that an Emotional or Cognitive Question? Navigating Difficult Conversations with Communication Skills . . . . . 71
Monday, April 23
2:00 p.m.–3:00 p.m.
X
C143 Evaluation and Treatment of
4:00 p.m.-4:45 p.m.
Neuro-rehabilitation
P5.001–P5.026 . 162
7:00 a.m.–9:00 a.m.
S7 Pain and Palliative Care . . . 98
7:00 a.m.–9:00 a.m.
11:30 a.m.–7:00 p.m.
Wednesday, April 25
3:30 p.m.–4:30 p.m.
C145 Severe TBI: From ICU to
4:30 p.m.–5:30 p.m.
Ask Us Anything: Expert Panel on Headache and Facial Pain . 69
Sunday, April 22
1:00 p.m.–3:00 p.m.
Rehabilitation
Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders
C10 More than Medicine: How to
Wednesday, April 25 7:00 a.m.–9:00 a.m.
C124 The Palliative Care Guide in
Practice, Policy, and Ethics
Saturday, April 21 9:30 a.m.–10:00 a.m.
X
What is the Axon Registry? . . 73
11:15 a.m.–12:00 p.m.
X
Choosing a Career in Clinical Practice . . . . . . . . . . 75
12:00 p.m.–4:00 p.m.
C16 L Leadership Challenges in Practice
2:00 p.m.–2:30 p.m.
X
Paths for Success in the Quality Payment Program . . . 73
2:30 p.m.–3:00 p.m.
X
Ask the Expert: Paths for QPP Success . . . . . . . . . . 73
3:00 p.m.–3:30 p.m.
X
Clinical Decision Support for Ordering of Diagnostic Imaging . 73
X
Social Media for Clinicians . . 75
X
3:30 p.m.–4:00 p.m.
X
Growing Research in Medical Marijuana . . . . . . . . . 73
2:00 p.m.–2:30 p.m.
X
4:00 p.m.–4:30 p.m.
X
TBI in Domestic Violence Victims: Care for Those Who Need it Most . . . . . . . . 73
Sunday, April 22 8:00 a.m.-9:00 a.m.
X
How Can the Axon Registry Improve My Practice? . . . . 73
12:00 p.m.–1:00 p.m.
X
Pursuing a Career in Clinical Informatics . . . . . . . . 73
1:00 p.m.–2:00 p.m.
X
Meet and Greet with the California Neurological Society . 73
1:00 p.m.–3:00 p.m.
C36 Clinical Neurology for
Advanced Practice Providers I
1:15 p.m.–2:00 p.m.
X
Measuring Success: Quality Improvement 101 . . . . . . 75
2:00 p.m.–2:30 p.m.
X
Breaking Down Silos: Using Simulation for Interprofessional Team Education to Enhance Clinical Outcomes in Neurology . . . 73
2:30 p.m.–3:00 p.m.
X
Ask the Expert: Teaching through Simulation . . . . . 73
3:00 p.m.–3:30 p.m.
X
Tip of the Iceberg: Ultra-High Cost Neurology Drugs . . . . 73
3:30 p.m.–5:30 p.m.
C51 Clinical Neurology for
Advanced Practice Providers II
4:00 p.m.–4:30 p.m.
X X
Transitioning from Private Practice to Academics . . . . 75 Why are Drug Prices So High? And What Can We Do About It? . 73
X
What Does BrainPAC Do for Me? . 73
Monday, April 23 7:00 a.m.–9:00 a.m.
C61 Starting a Practice From the
Ground Up: A Guide for Early Career Neurologists
12:00 p.m.–1:00 p.m.
X
Practice Models for Advanced Practice Providers . . . . . . 73
X = Experiential Learning
Can Aviation Accidents Teach Neurologists Patient Safety and Error Management? . . . 73
X
The Encompassing Value of the Patient-Physician Relationship . . . . . . . . 75
2:00 p.m.–2:30 p.m.
X
Caring for Telemedicine Patients . 73
2:30 p.m.–3:30 p.m.
X
3:00 p.m.–3:30 p.m.
X
1:45 p.m.–2:30 p.m.
Safety and Quality Awards . . 73
What is the AAN Doing for Small and Solo Practitioners? . 73
3:30 p.m.–4:00 p.m.
3:45 p.m.–4:30 p.m.
3:30 p.m.–5:30 p.m.
Wednesday, April 25
X
What Does the AAN’s Latest Guideline Mean for My Practice? . 73
C84 Evidence Based Neurology
Foresights for Busy Clinicians
C92 What Keeps You Up at Night?
Addressing Mistakes and Injuries, In-n-Out-Patient Transition, and Building a Team to Support You C94 Hot Topics in Stroke Education and Practice . . . . . . . . 103 4:00 p.m.–4:30 p.m.
X
Streamlining Clinic Scheduling and Access . . . . . . . . 73
4:30 p.m.–5:00 p.m.
X
Knowing Your Value: How to Negotiate to Get What You’re Worth . . . . . . . . . . . 73
Tuesday, April 24 10:45 a.m.–11:15 a.m.
X
Staying on an Academic Clinical Track . . . . . . . . 75
X
8:00 a.m.–9:00 a.m.
X
P4 Poster Session IV
Practice, Policy and Ethics I
P3.150–P3.172 . 145
12:00 p.m.–1:00 p.m.
X
Communicating via EHR . . . 73
12:15 p.m.–12:45 p.m.
X
X
1:00 p.m.–2:00 p.m.
X
Understanding Axon Registry and Using it to Improve Your Value . . . . . . . . . . . 73
1:00 p.m.–3:00 p.m.
1:00 p.m.–3:00 p.m.
C148 LGBTQI Health in Neurology
3:00 p.m.–4:00 p.m.
X
Health Care Disparities Among Underserved Populations . . . 69
3:30 p.m.–5:30 p.m.
C163 How to Run a Practice:
Business Strategies for Neurology Private Practices, Academic Centers, and the Future
Thursday, April 26 8:00 a.m.–9:00 a.m.
X
Enhancing Epilepsy Care in Your Practice: In-Person Digital Learning and Emotional for Self-Management, Education, and Community Supports from the National Epilepsy Education and Awareness Collaborative . . . 73
1:00 p.m.–1:30 p.m.
X
What Do I Need to Know About Coding in My Practice? . 73
1:00 p.m.–3:00 p.m.
C189 Business Strategies for Payer Negotiations and/or How to Go off the Grid
C111 Enhancing Your Career and Practice Through Neuropalliative Care
So You Want to Work for a Hospital? . . . . . . . . . 73
S28 Practice, Policy, and Ethics . . 108
Neurohospitalists 2.0, How to Craft a Satisfying and Sustainable Career . . . . . 75 Choosing Teleneurology as a Career . . . . . . . . . . 75
P4.164–P4.172 . 156
1:00 p.m.–2:00 p.m.
12:45 p.m.–1:30 p.m.
X
Practice, Policy and Ethics II
1:00 p.m.–1:30 p.m.
P3 Poster Session III
Step Away from the Desktop! Recapturing the Joy in Practice . 73
11:30 a.m.–7:00 p.m.
11:30 a.m.–7:00 p.m.
International Members: What Can the AAN Do For You? . . . 75
1:30 p.m.–2:30 p.m.
X
The Value of the Neurologic Exam: Caring for your Patient for $500 or Less . . . . . . 69 AAN.com/view/AM18 49
Practice/Policy/Ethics
4:30 p.m.–5:00 p.m.
Using EHR for Better Communication with Patients and Colleagues . . . . . . . 73
ANNUAL MEETING TOPIC LIST
3:15 p.m.–4:00 p.m.
ANNUAL MEETING TOPIC LIST
2018 PROGRAMS LISTED BY TOPIC 2:00 p.m.–3:00 p.m.
X
Using your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency . . . . . . . 73
3:30 p.m.–5:30 p.m.
12:15 p.m.–1:00 p.m.
X
12:20 p.m.–12:50 p.m.
X
C204 Making Sure You Get Paid
Under the New Health Care Laws
Friday, April 27 Incorporating a SemiConcierge Model into your Own Neurology Practice . . . 73
1:00 p.m.–3:00 p.m.
C231 ICD-10-CM: How to Optimize for Accurate Diagnosis and Reimbursement
3:30 p.m.–5:30 p.m.
C242 Coding 101: It’s Not Your Father’s Oldsmobile
Research Methodology, Education, and History
Saturday, April 21 7:00 a.m.–12:30 p.m.
C5 Clerkship and Program
X
Clinical Trials Methodology Course - Information Session with William Meurer MD, MS, CTMC Principal Investigator . . 77
C29 Faculty Development:
Enhancing Your Role in Student and Resident Training
Research in Residency: How to Choose the Right Project . . 75
X
K is for Career Development: Tips From Successful Applications for NIH Career Development Awards . . . . 75
X
Office Hours: The Researcher Pipeline: The Benefits of Participating in Academic Medicine, Research and Clinical Trials as a Medical Student or Resident . . . . . 77
11:30 a.m.–5:30 p.m.
P1 Poster Session I
Education: Patients
Education: Nursing, APPs, and Others
Education: Needs Analysis and Novel Fields
9:20 a.m.–9:50 a.m.
Work Life Balance in Research . 77 How to Successfully Publish Quality Improvement Projects . 77
10:00 a.m.–10:50 a.m.
X
Investigator Panel: How I Launched My Career with NIH Funding, Private Funding, AAN Research Program Funding and/or Government Funding . . 77
Research/Education/History
11:30 a.m.–12:00 p.m.
X
Office Hours: Research Careers in Industry . . . . . 77
Office Hours: Writing a Great AAN Research Program Proposal . . . . . . . . . . 77
12:00 p.m.–4:00 p.m.
C15 Resident Basic Science I: Neuropharmacology
50 2018 AAN Annual Meeting
P1.008–P1.014 . 122 P1.015–P1.026 . 122
Office Hours: Surviving as a Clinician Researcher . . . . . 77
1:00 p.m.–1:30 p.m.
X
Being a Great Chief Resident . 75
1:00 p.m.–3:00 p.m.
C43 Developing the Treatments of
Tomorrow I: Taking Molecules from Lab to Man
12:00 p.m.–12:30 p.m.
X
C57 Developing the Treatments of Tomorrow II: Clinical Trials in Neurology
X
1:00 p.m.–5:30 p.m.
C47 Resident Basic Science II: Neuropathology
1:20 p.m.–1:50 p.m.
X
So You Have a Research Idea—How Do You Turn it into a Project? . . . . . . . 77
Introduction to the Fascinating World of Movement Disorders . 75
4:30 p.m.–5:00 p.m.
How to Start a Career in Clinical Trials . . . . . . . . 77
4:45 p.m.–5:15 p.m.
Everything You Wanted to Know About the R&F Section of Neurology . . . . . . . . 75
5:00 p.m.–5:30 p.m.
X
Statistics and Study Design: Pearls and Pitfalls . . . . . . 77
Monday, April 23 7:30 a.m.–8:00 a.m.
X
Defining and Managing Your Message as An Early Career Researcher . . . . . . . . 77
7:45 a.m.–8:15 a.m.
X
P1.001–P1.007 . 122
12:30 p.m.–1:00 p.m.
X
Breaking Down Silos: Using Simulation for Interprofessional Team Education to Enhance Clinical Outcomes in Neurology . . . 73
3:30 p.m.–5:30 p.m.
10:00 a.m.–10:30 a.m.
X
X
X
8:15 a.m.–9:00 a.m.
8:25 a.m.–9:10 a.m.
X
2:00 p.m.–2:30 p.m.
X
7:45 a.m.–8:15 a.m.
X
Hall of Presidents: Using Past Experience to Solve the Futures Problems . . . . . . 69
4:15 p.m.–5:00 p.m.
7:00 a.m.–9:00 a.m.
7:30 a.m.–8:15 a.m.
Are You My Mentor? How to Select a Good Mentor for Your Research Career . . . . . . 77
X
Sunday, April 22
Directors Conference: Demonstrating Your Impact as a Medical Educator
X
How to Find Training: The Best Clinical Research and Methodology Training Options . 77
1:30 p.m.–2:30 p.m.
1:40 p.m.–2:10 p.m.
12:00 p.m.–12:30 p.m.
X
What I Learned About Research— An Early Career Perspective . . . 75
Using the R&F Section of Neurology for your Residents and Residency . . . . . . . 75
8:15 a.m.–9:00 a.m.
X
Choosing An Academic Career in Neurology: Perspectives for Early Career Investigators and Foreign Medical Graduates . . 75
11:30 a.m.–7:00 p.m.
P2 Poster Session II
Undergraduate Medical Education: Assessment and Curricular Design I
Undergraduate Medical Education: Novel Formats
Health Services Research and Methodologies
Education: Career Choice and Attitudes
P2.001–P2.005 . 132 P2.006–P2.011 . 132 P2.012–P2.016 . 132
P2.017–P2.026 . 132
X
Finding Your Niche in Neurology: Perspectives from an Epileptologist and Educator . 75
12:00 p.m.–12:30 p.m.
X
Office Hours: Working with an Epidemiologist . . . . . . . 77
12:45 p.m.–1:30 p.m.
X
Transitioning From a Clinical Research Career to an Educational and Clinical Focused Career . . . . . . . 75
1:00 p.m.–3:00 p.m.
S14 Education and Patient
Outcomes Research . . . . 101
1:00 p.m.–5:30 p.m.
C82 Resident Basic Science III:
Neuroanatomy: All the Lesions
12:30 p.m.–1:00 p.m.
X
12:40 p.m.–1:10 p.m.
X
Office Hours: Defining and Managing Your Message As An Early Career Scientist . . . 77
X
Up Your Game as a Medical Educator in Neurology . . . . 75
5:15 p.m.–6:15 p.m.
X
Practicing Neurology in the 1960s and 1970s . . . . . . 69
Tuesday, April 24 8:00 a.m.–8:30 a.m.
X
Welcome to NINDS Day/ Overview of NIH Funding with NINDS Director and NINDS Deputy Director . . . . . . . 77
8:40 a.m.–9:10 a.m.
X
Research and Methods
1:20 p.m.–1:50 p.m.
X
X
Graduate Medical Education: Assessment and Curricular Design II
X
P3.001–P3.007 . 142
P3.008–P3.014 . 142
Graduate Medical Education: Burnout and Professionalism Graduate Medical Education: Novel Formats
P3.015–P3.026 . 142
Research Methodology ePoster Session
P3.339–P3.344 . 149
2:00 p.m.–2:30 p.m.
X
NINDS Clinical Trials (new NIH definition) and networks, NeuroNEXT, StrokeNET, SIREN . 77
2:30 p.m.–3:00 p.m.
X
How to Start a Career in Neurology Education . . . . . 75
2:40 p.m.–3:10 p.m.
X
X
Pain Research Funding Opportunities, Clinical and Basic . 77
Training in Neurology While on a Visa: Challenges and Possible Solutions for Foreign Medical Graduates . . . . . 75
3:15 p.m.–3:45 p.m.
X
Staying on Track: A Career as a Clinical Researcher . . . . . 75
3:20 p.m.–3:50 p.m.
X
Pain Research Funding Opportunities, Clinical and Basic . 77
4:00 p.m.–4:30 p.m.
X
Your Grant Proposal Was Rejected: Now What? Turning a Feedback Into a Successful Project . . . . . . . . . . 77
Wednesday, April 25 8:00 a.m.–9:10 a.m.
X
Office Hours: How to Get a K-Award . . . . . . . . . . 77
How to Write and Publish Research Papers, Reviews and Other Scientific Communications . . . . . . . 77
8:15 a.m.–9:00 a.m.
X
X = Experiential Learning
12:00 p.m.–12:30 p.m.
X
Office Hours: Recruiting Difficult and Underrepresented Populations in Research . . . . . . . . 77
12:45 p.m.–1:30 p.m.
X
Clinical Research in the Area of Practice, Quality and Patient Safety . . . . . . . 75
1:00 p.m.–1:50 p.m.
X
Community Education in Minority Population . . . . . 77
1:00 p.m.–3:00 p.m.
C150 Where is the Lesion? A History of Neurological Investigations Part I
3:00 p.m.–3:30 p.m.
X
Office Hours: Research Careers in Industry . . . . . 77
3:30 p.m.–5:30 p.m.
C165 Where is the Lesion? A History of Neurological Investigation Part II
3:45 p.m.–4:30 p.m.
X
Navigating Fellowship in Neurology . . . . . . . . . 75
Thursday, April 26 11:30 a.m.–7:00 p.m.
P5 Poster Session V
2:45 p.m.–3:30 p.m.
12:00 p.m.–12:30 p.m.
X
Academic Career Panel: Find out How to Get Your Career Started . . . . . . . . . . 75
Office Hours: Selecting an AAN Research Program Mentor . . . 77
History of Neurology
P5.295–P5.316 . 168
12:45 p.m.–1:30 p.m.
X
Effective Neurology Residency Program . . . . . . . . . . 75
1:00 p.m.–1:30 p.m.
X
Office Hours: Early Career Research Funding and Career Development . . . . . . . . 77
1:00 p.m.–2:15 p.m.
S39 History of Neurology . . . . . 112
4:30 p.m.–5:00 p.m.
X
Grantwriting 101: Getting Started . . . . . . . . . . 77
4:30 p.m.–5:30 p.m.
X
Neurology History: Weaving Past with Present . . . . . . 69
Friday, April 27 12:30 p.m.–1:00 p.m.
X
Office Hours: Making the Transition from Research Fellow to Clinical Research Faculty . . . . . . . . . . 77
How to Give Effective Feedback . 75 AAN.com/view/AM18 51
Research/Education/History
Office Hours: Clinical Research Recommendations for Residents and Fellows . . .77
1:45 p.m.–2:15 p.m.
11:30 a.m.–7:00 p.m.
P3 Poster Session III
NIH Grant Review Process . . 77
1:30 p.m.–2:00 p.m.
K Awards and Training Programs . 77
Reviewer to Editorial Board to Editor . . . . . . . . . . 75
Office Hours: VA Research Funding: Career Development Awards . . . . . . . . . . 77
C117 Introduction to Clinical
11:30 a.m.–12:00 p.m.
X
X
1:00 p.m.–3:00 p.m.
2:45 p.m.–3:30 p.m.
X
NIH Funding and Professional Development Opportunities for Diverse Researchers . . . 77
8:30 a.m.–9:00 a.m.
1:00 p.m.–1:30 p.m.
2:30 p.m.–3:00 p.m.
X
Office Hours: Bridge Funding . 77
ANNUAL MEETING TOPIC LIST
11:45 a.m.–12:30 p.m.
ANNUAL MEETING TOPIC LIST
2018 PROGRAMS LISTED BY TOPIC 12:40 p.m.–1:10 p.m.
3:30 p.m.–5:30 p.m.
2:40 p.m.–3:10 p.m.
Tuesday, April 24
X
X
How to Put Together an Effective Research Presentation . . . . . 77 Recruiting Minorities . . . . 77
4:00 p.m.–4:30 p.m.
X
S17 Sleep . . . . . . . . . . 102
C101 Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist
10:00 a.m.–10:30 a.m.
Sleep: Why You Should Spend Your Career Helping People Do It Right . . . . . . . . . . 75
Sunday, April 22 11:30 a.m.–5:30 p.m.
P1 Poster Session I
Sleep: Neurology and Sleep-Disordered Breathing/Sleep Apnea
Sleep: Too Much, Too Little, Abnormal Timing, and Parasomnias
P1.103–P1.117 . 124
9:15 a.m.–11:30 a.m.
C113 Sleep for the Practicing
Neurologist I: Is it Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence
3:30 p.m.–5:30 p.m.
C126 Sleep for the Practicing
Neurologist II: Night Fighting: Sleep Related Hypermotor Epilepsy, Sleepwalking, and Dream Enactment
Sleep: A Frequently Forgotten Part of Your Patient’s Day . . . 75
Monday, April 23 Contemporary Clinical Issues Plenary Session: 9:40 a.m.–9:55 a.m. Predictors of Neurodegeneration in Idiopathic REM Sleep Behavior Disorder: A Multicenter Cohort Study . . 62
Clinical Trials Plenary Session: 10:15 a.m.–10:30 a.m. A Randomized, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Solriamfetol (JZP-110) for the Treatment of Excessive Sleepiness (ES) in Participants with Narcolepsy Types 1 and 2 (NT1/2) . 63
1:00 p.m.–3:00 p.m.
P1.091–P1.102 . 124
12:15 p.m.–1:00 p.m.
X
C141 Integrating Sleep Medicine Concepts into Your Child Neurology Practice
9:15 a.m.–11:30 a.m.
9:15 a.m.–11:30 a.m.
Saturday, April 21 X
7:00 a.m.–9:00 a.m.
7:00 a.m.–9:00 a.m.
Historical Perspective on Treating Epilepsy . . . . . . 77
Sleep
Wednesday, April 25
4:00 p.m.–4:45 p.m.
X
The Sleep Mythbuster!: Illuminating the Facts and Fiction Towards Achieving the Sleep Healthy Neurologist . . 71
Frontiers in Neuroscience Plenary Session: 9:55 a.m.–10:15 a.m. Biology of Bedtime: Understanding Circadian Rhythms and Sleep . 64
1:00 p.m.–3:00 p.m.
C153 Circadian Rhythm Disorders: Implications for Neurology
3:30 p.m.–5:30 p.m.
Invited Science: Sleep . . . . 89
Thursday, April 26 7:00 a.m.–9:00 a.m.
C173 Using Sleep Medicine to Help
Solve Difficult Neurologic Cases
8:00 a.m.–8:45 a.m.
X
Sleep and Performance in Elite Athletes . . . . . . . . 71
1:00 p.m.–3:00 p.m.
C183 Hot Topics in Sleep Neurology
Friday, April 27 7:00 a.m.–9:00 a.m.
C221 REM Sleep Behavior Disorder
3:30 p.m.–5:30 p.m.
N7 Neuroscience in the Clinic:
REM Sleep Behavior Disorder: Past, Present, Future . . . . . 85
2019 ANNUAL MEETING COURSE PROPOSAL SUBMISSIONS Sleep
The AAN is seeking submissions for course proposals for the 2019 Annual Meeting. The submission deadline is May 18, 2018. Please visit aan.com/view/courseproposals for additional information and guidelines.
52 2018 AAN Annual Meeting
Business of Neurology Track We’ve curated audience-focused programming into select tracks to make navigating the meeting easier than ever. This lineup was created specifically for those starting a new practice, as well as anyone who wants to learn the fundamentals of neurology business.
Saturday, April 21 12:00 p.m.–4:00 p.m.
C16 L Leadership Challenges in Practice
2:00 p.m.–2:30 p.m.
X
Paths for Success in the Quality Payment Program . . . 73
2:30 p.m.–3:00 p.m.
X
Ask the Expert: Paths for QPP Success . . . . . . . . . . 73
3:00 p.m.–3:30 p.m.
X
Clinical Decision Support for Ordering of Diagnostic Imaging . 73
Sunday, April 22 3:00 p.m.–3:30 p.m.
X
Tip of the Iceberg: Ultra-High Cost Neurology Drugs . . . . 73
3:30 p.m.–4:00 p.m.
X
How to Increase Investments in Neuroscience Research . . 73
Monday, April 23 3:30 p.m.–4:00 p.m.
X
What Does the AAN’s Latest Guideline Mean for My Practice? . 73
4:00 p.m.–4:30 p.m.
X
Streamlining Clinic Scheduling and Access . . . . . . . . 73
4:30 p.m.–5:00 p.m.
X
Knowing Your Value: How to Negotiate to Get What You’re Worth . . . . . . . . . . . 73
Tuesday, April 24 12:00 p.m.–1:00 p.m.
X
Communicating via EHR . . . 73
1:00 p.m.–2:00 p.m.
X
Understanding Axon Registry and Using it to Improve Your Value . . . . . . . . . . . 73
2:30 p.m.–3:30 p.m.
X
What is the AAN Doing for Small and Solo Practitioners? . 73
X = Experiential Learning
Wednesday, April 25 8:00 a.m.–9:00 a.m.
X
Step Away from the Desktop! Recapturing the Joy in Practice . 73
1:00 p.m.–1:30 p.m.
X
So You Want to Work for a Hospital? . . . . . . . . . 73
3:30 p.m.–5:30 p.m.
C163 How to Run a Practice:
Business Strategies for Neurology Private Practices, Academic Centers, and the Future
Thursday, April 26 1:00 p.m.–3:00 p.m.
C189 Business Strategies for Payer Negotiations and/or How to Go off the Grid
3:30 p.m.–5:30 p.m.
C204 Making Sure You Get Paid
Under the New Health Care Laws
Friday, April 27 1:00 p.m.–3:00 p.m.
C231 ICD-10-CM: How to Optimize for Accurate Diagnosis and Reimbursement
3:30 p.m.–5:30 p.m.
C242 Coding 101: It’s Not Your Father’s Oldsmobile
C23 Critical Care Consultations for Neurohospitalists
Sunday, April 22 7:00 a.m.–9:00 a.m.
C27 Neurological Intensive Care I: The Essentials
1:00 p.m.–3:00 p.m.
C36 Clinical Neurology for
Advanced Practice Providers I
C39 Therapy in Neurology I: Headache and Stroke
C40 Autoimmune Neurology
I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS
1:00 p.m.–5:30 p.m.
C47 Resident Basic Science II: Neuropathology
3:30 p.m.–5:30 p.m.
C50 Low and High Pressure
Headache: Clinical Presentation and Approach to Evaluation and Management C51 Clinical Neurology for Advanced Practice Providers II C54 Therapy in Neurology II: Epilepsy and Movement Disorders
Monday, April 23 7:00 a.m.–9:00 a.m.
Foundations in Clinical Neurology Track For Advanced Practice Providers who are new to neurology, this track will help lay the foundation for success as a new care team member
Saturday, April 21 7:00 a.m.–9:00 a.m.
C1 Mild Cognitive Impairment: Implications for Clinicians
C2 Functional Neurologic
Disorders I: Movement, Seizures, and Multiple Sclerosis
9:30 a.m.–11:30 a.m.
C14 Parkinson’s Disease Update
12:00 p.m.–4:00 p.m.
C15 Resident Basic Science I: Neuropharmacology
1:30 p.m.–3:30 p.m.
C22 Stroke in Young Adults and Women
C66 Update on Medical
Management of Stroke
C68 Cognitive Impairment Due to Alzheimer’s Disease: Using Old Skills and New Tools for Diagnosis and Treatment
1:00 p.m.–3:00 p.m.
C70 Evaluating Tremor in the Office C75 Safe and Appropriate Opioid Prescribing in Neurology
C79 Comprehensive Migraine
Education Program I: Diagnosis, Risk Factors, and Neurobiology
1:00 p.m.–5:30 p.m.
C82 Resident Basic Science III:
Neuroanatomy: All the Lesions
3:30 p.m.–5:30 p.m.
C86 Child Neurology III: Headache, TBI/Post-concussion
C90 Comprehensive Migraine
Education Program II: Behavioral and Psychological Approaches, and Preventive and Acute Treatment Advances
AAN.com/view/AM18 53
PROGRAM TRACKS
2018 PROGRAM TRACKS
PROGRAM TRACKS
2018 PROGRAM TRACKS Tuesday, April 24 7:00 a.m.–9:00 a.m.
C98 Multiple Sclerosis Overview I:
Clinical Pearls C101 Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist C102 Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson’s Disease 1:00 p.m.–3:00 p.m.
C108 Introduction to Primary
Headache Disorders I: Migraine and Other Primary Headaches Including Tension-Type, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine C109 Multiple Sclerosis Overview II: Clinical Advances C116 Cerebrovascular Disease I: Prevention 3:30 p.m.–5:30 p.m.
C121 Introduction to Primary
Headache Disorders II: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches C123 Child Neurology: A Casebased Approach C129 Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke
Wednesday, April 25 7:00 a.m.–9:00 a.m.
C135 Neurocognitive Assessment
for Neurologists C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I C137 What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders 1:00 p.m.–3:00 p.m.
C144 Neurology Update I: Epilepsy, Behavioral Neurology, and Neurologic Infections C146 Non-Alzheimer’s Dementia I: Frontotemporal Dementias
54 2018 AAN Annual Meeting
C147 Multiple Sclerosis Therapy:
Disease-modifying Treatment II
3:30 p.m.–5:30 p.m.
C160 Neurology Update II:
Movement Disorders, Spine Disorders, and Sleep Disorders C161 Non-Alzheimer’s Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias
Thursday, April 26 7:00 a.m.–9:00 a.m.
C172 Clinical Epilepsy I: Basics C175 Clinical Pearls in Autoimmune Neurology: Real World Cases
1:00 p.m.–3:00 p.m.
C182 Clinical Epilepsy II:
Considerations Across the Age Span Pediatrics, Pregnancy, and Elderly C185 Neurology Update III: Neuromuscular, Headache, and Stroke C193 Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Antibody-Mediated Rapidly Progressive Dementia 1:00 p.m.–5:30 p.m.
C196 Brain Death Skills Workshop:
How to Perform a Brain Death Evaluation, Avoid Pitfalls and Convey the News to the Family
3:30 p.m.–5:30 p.m.
C199 Neurology Update IV:
Multiple Sclerosis, Neuroophthalmology, and Autoimmune Encephalopathies C208 Assessment of Rapidly Progressive Dementias II: Neurodegenerative Diseases and Infections Presenting as Rapidly Progressive Dementia 6:30 p.m.–9:30 p.m.
C211 Case Studies in the ICU C214 Case Studies: Challenging
Headache Cases C215 Case Studies in Behavioral Neurology: Focus on Frontotemporal Degeneration
Friday, April 27 7:00 a.m.–9:00 a.m.
C217 Current Management of
Incidental and Asymptomatic Cerebrovascular Lesions C219 The Early-Onset Dementias
C223 The Burden of Epilepsy:
Managing Comorbidities and Quality of Life
1:00 p.m.–3:00 p.m.
C225 Neuromuscular Junction
Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia C226 Infections of the Nervous System II: Neuro-ID Emergencies C228 Neuroimaging for the General Neurologist I: Brain 3:30 p.m.–5:30 p.m.
C240 Neuroimaging for the General Neurologist II: Brain C243 Hot Topics in Headaches and Related Disorders II: Unusual Headaches, Childhood Headaches, and Concussion Management
Neurohospitalist Track Created specifically for neurohospitalists whose primary focus is inpatient care, or for anyone who would like to learn more about the care of hospitalized patients, this lineup of programming will cover the gamut from prevention, telestroke, critical care monitoring and consultations, and issues encountered in the ICU.
Saturday, April 21 7:00 a.m.–9:00 a.m.
C3 Emergency Room Neuroophthalmology
9:30 a.m.–11:30 a.m.
C8 Emergency Neurology:
Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room
1:30 p.m.–3:30 p.m.
C22 Stroke in Young Adults and Women C23 Critical Care Consultations for Neurohospitalists
Sunday, April 22 7:00 a.m.–9:00 a.m.
C27 Neurological Intensive Care I: The Essentials
1:00 p.m.–3:00 p.m.
C38 Neurological Intensive Care
II: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction
I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS
3:30 p.m.–5:30 p.m.
C53 Neurological Intensive Care III: Vascular Diseases C55 Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience
Monday, April 23 7:00 a.m.–9:00 a.m.
C66 Update on Medical
Management of Stroke
1:00 p.m.–3:00 p.m.
C78 Therapeutic Temperature Modulation in the ICU
3:30 p.m.–5:30 p.m.
C95 Actualización Sobre las
Infecciones del Sistema Nervioso Central y la Medicina Tropical
Tuesday, April 24 7:00 a.m.–9:00 a.m.
C96 Status Epilepticus
1:00 p.m.–3:00 p.m.
C106 Critical Care EEG Monitoring C116 Cerebrovascular Disease I: Prevention
3:30 p.m.–5:30 p.m.
C124 The Palliative Care Guide in
Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders C129 Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke
Wednesday, April 25 7:00 a.m.–9:00 a.m.
3:30 p.m.–5:30 p.m.
C166 Cerebrovascular Disease IV: Telestroke
Thursday, April 26 7:00 a.m.–9:00 a.m.
C177 So You’ve Diagnosed Your
Patient with a Neuroinfectious Disease, Now What? Practical Pearls in the Treatment and Management of Neuroinfectious Diseases
1:00 p.m.–3:00 p.m.
C190 Neuro-oncologic Predicaments in the Hospital Setting C194 Actualización Sobre el Manejo del Ictus Cerebrovascular
1:00 p.m.–5:30 p.m.
C196 Brain Death Skills Workshop:
How to Perform a Brain Death Evaluation, Avoid Pitfalls and Convey the News to the Family
3:30 p.m.–5:30 p.m.
C201 Differential Diagnosis of
Neurologic Infections C203 Endovascular Treatment of Acute Stroke and Cerebrovascular Disease 6:30 p.m.–9:30 p.m.
C211 Case Studies in the ICU
Friday, April 27
Spanish Language Track We’re expanding our Spanish-language curriculum! Look for education courses and experiential learning area talks on a variety of topics, including MS, epilepsy, stroke, CNS infection and tropical medicine, and more— taught entirely in Spanish.
Sunday, April 22 3:30 p.m.–5:30 p.m.
C59 Actualización Sobre el
Tratamiento de la Esclerosis Múltiple
Monday, April 23 3:30 p.m.–5:30 p.m.
C95 Actualización Sobre las
Infecciones del Sistema Nervioso Central y la Medicina Tropical
Tuesday, April 24 3:30 p.m.–5:30 p.m.
C132 Actualization Científica
Durante el Congreso Anual I
Wednesday, April 25 3:30 p.m.–5:30 p.m.
C171 Actualización Sobre Opciones
Terapéuticas para la Epilepsìa Farmacorresistente
7:00 a.m.–9:00 a.m.
C218 Infections of the Nervous
System I: Diagnostic Testing of Neurological Infections C220 Drugs and Toxin-induced Neurologic Emergencies 1:00 p.m.–3:00 p.m.
C226 Infections of the Nervous
System II: Neuro-ID Emergencies C230 Neurologic Complications of Medical and Surgical Therapies 3:30 p.m.–5:30 p.m.
C239 Infections of the Nervous
System III: Advanced Topics in Infectious Neurology
Thursday, April 26 1:00 p.m.–3:00 p.m.
C194 Actualización Sobre el Manejo del Ictus Cerebrovascular
3:00 p.m.–4:00 p.m.
X
Consejos Prácticos para un Buen Examen Neurológico . . 69
Friday, April 27 1:00 p.m.–3:00 p.m.
C233 Simposio Español:
Actualización Científica Durante el Congreso Anual II
C137 What Do I Do Now?:
Emergency and Inpatient Management of Migraine and Other Headache Disorders
1:00 p.m.–3:00 p.m.
C145 Severe TBI: From ICU to Rehabilitation
C151 Cerebrovascular Disease III:
Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke
X = Experiential Learning
AAN.com/view/AM18 55
PROGRAM TRACKS
C40 Autoimmune Neurology
Industry Therapeutic Updates
Saturday, April 21 | Monday, April 23 | Tuesday, April 24 Registration is free and open to registered Annual Meeting attendees. Representatives from the following companies invite you to an informational session on therapeutic updates. This program provides you the opportunity to learn about current therapies and projects in the industry pipeline.
Saturday, April 21 Amgen & Novartis Pharmaceuticals Corp. Enhanced Conversation with the Migraine Patient... Assessment, Diagnosis and Management Location: JW Marriott LA Live Diamond Salon 5
GE Healthcare Location: JW Marriott LA Live Platinum Ballroom A-C
Monday, April 23 CSL Behring Location: Hotel Indigo Los Angeles Orpheum Ballroom
Ionis Pharmaceuticals Location: Westin Bonaventure Hotel Beaudry Ballroom B
Genentech, A Member of the Roche Group Industry Therapeutic Update from Genentech Location: JW Marriott LA Live Platinum Ballroom A – D
Mitsubishi Tanabe Pharma America Location: JW Marriott LA Live Gold Ballroom 3 Novartis Pharmaceuticals Corp. Location: Westin Bonaventure Hotel Palos Verdes Ballroom
Sunovion Pharmaceuticals Inc. A Spotlight on Parkinson’s Disease and Innovation Location: JW Marriott LA Live Platinum Ballroom F – J Teva CNS Location: JW Marriott LA Live Gold Ballroom 1
RSVP is recommended for these events. No CME will be given by any accredited organization for the Industry Therapeutic Updates, and the AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
| Wednesday, April 25 | Starting at 7:00 p.m.
Tuesday, April 24 Abbott Location: Hotel Indigo Los Angeles Orpheum Ballroom B Adamas Pharmaceuticals, Inc. Location: Westin Bonaventure Hotel San Jose and San Diego Ballroom
Biogen Navigating an Early Diagnosis of Alzheimer’s Disease: A Call for Action Location: JW Marriott LA Live Diamond Salon 1 - 4 Biogen Location: JW Marriott LA Live Platinum Ballroom C
Alnylam Pharmaceuticals, Inc. Advancing the Care of Patients with hATTR Amyloidosis: Diagnostic Biogen Challenges and Potential New Therapies Location: JW Marriott LA Live Location: Westin Bonaventure Hotel Platinum Ballroom H - J San Francisco Ballroom
Biogen Location: JW Marriott LA Live Gold Ballroom 4 Sarepta Therapeutics Location: Hotel Indigo Los Angeles Metropolitan Ballroom Teva CNS Location: JW Marriott LA Live Gold Ballroom 2
Wednesday, April 25 EMD Serono, Inc. Location: JW Marriott LA Live Platinum Ballroom
Sanofi Genzyme Predicting Patient Trajectory in MS: How Advanced Prognostic Measures Can Support More Informed Treatment Decisions Location: JW Marriott LA Live Gold Ballroom 3 & 4
Please visit AAN.com/view/ITU for more information.
Los Angeles Friday April 20, 2018 10:00 a.m.–4:00 p.m. LA CONVENTION CENTER
See How We’re Giving Back to the Los Angeles Community Designed to connect neurology patients, families, caregivers, and students throughout the Los Angeles area to local and national experts to learn the latest research advances and get their toughest questions answered.
Encourage Your Patients to Attend The Brain Health Fair is a free public event! If you have patients in the area, let them know about this fun-filled, educational event—everyone’s welcome!
Seeking Physician Volunteers While this event is designed for the public, we are looking for volunteers—including Spanish-speaking physicians— to help out during the event in many different ways. Contact wvokaty@aan.com if you’re interested.
Learn more at BrainHealthFair.com
PLENARY SESSIONS
T
hese daily not-to-be-missed premier sessions offer a unique opportunity to hear from some of the most inspiring and innovative thought leaders in the field of neurology.
Hot Topics Plenary Session
Saturday, April 21 4:15 p.m.–5:30 p.m. . . . . .
Presidential Plenary Session
Sunday, April 22 9:15 a.m.–12:00 p.m. . . . . .
60 61
Contemporary Clinical Issues Plenary Session Monday, April 23 9:15 a.m.–11:30 a.m. . . . . .
Clinical Trials Plenary Session
Tuesday, April 24 9:15 a.m.–11:30 a.m. . . . . .
Frontiers in Neuroscience Plenary Session Wednesday, April 25 9:15 a.m.–11:30 a.m. . . .
62
63 64
Controversies in Neurology Plenary Session
Thursday, April 26 9:15 a.m.–11:30 a.m. . . . . . 65
Neurology Year in Review: Emerging Therapies Plenary Session
Friday, April 27 9:15 a.m.–11:30 a.m. . . . . . . 66
AAN.com/view/AM18 59
PLENARY SESSIONS
HOT TOPICS PLENARY SESSION
G
Saturday, April 21 4:15 p.m.–5:30 p.m.
This session features translational research related to clinical issues of importance. Four outstanding physicianscientists provide summaries of their recent research findings and describe the clinical implications of the results. This plenary session will feature audience response technology to create an interactive attendee experience. Please look for more details during this session at the Annual Meeting.
Moderator Eric Klawiter, MD
Member, Science Committee
Coming of Age: Clinical Implementation of Metagenomics for Diagnosis in Meningitis and Encephalitis Michael R. Wilson, MD
Opioid Receptor Modulation of Headache Amynah Pradhan, PhD
University of Illinois at Chicago, Chicago, IL
niversity of California San Francisco, San U Francisco, CA
Saturday
Brain Stimulation for Memory Faculty
Monitoring Multiple Sclerosis Using Blood Neurofilament Light Protein Jens Kuhle, MD
Universitätsspital Basel, Oberwil, Switzerland
60 2018 AAN Annual Meeting
G
Sunday, April 22 9:15 a.m.–12:00 p.m.
This session features the AAN’s premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant findings in neurology in 2018.
Moderator Natalia S. Rost, MD, MPH, FAAN, FAHA
PLENARY SESSIONS
PRESIDENTIAL PLENARY SESSION
Chair, Science Committee
Presidential Lecture California Dreaming: BRAIN and Precision Medicine in 2018 Francis S. Collins, MD, PhD
irector of National Institutes of Health, D Bethesda, MD
Richard S. Finkel, MD
George C. Cotzias Lecture How Early-Life Experiences Sculpt Your Brain: From Molecules to Circuits
Robert Wartenberg Lecture Neuro-oncology: How Cancer and the Nervous System Interact
Tallie Z. Baram, MD, PhD
Lisa M. DeAngelis, MD, FAAN
Nemours Children’s Hospital, Orlando, FL
emorial Sloan-Kettering Cancer Center, M New York, NY
AAN.com/view/AM18 61
Sunday
University of CA-Irvine, Irvine, CA
Sidney Carter Award in Child Neurology Spinal Muscular Atrophy Is a Treatable Neurodegenerative Disease
PLENARY SESSIONS
CONTEMPORARY CLINICAL ISSUES PLENARY SESSION G Monday, April 23
9:15 a.m.–11:30 a.m.
This session highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments. Commentary and discussion follow each presentation.
Moderator Randolph S. Marshall, MD, FAAN Vice Chair, Science Committee Retinal Microvasculature in Predicting Risk of Stroke Subtypes Presenter:
Neuropalliative Care
Michelle P. Lin, MD
Maisha T. Robinson, MD, MS
J ohns Hopkins University School of Medicine, Baltimore, MD
Mayo Clinic, Jacksonville, FL
Discussant:
Valerie Biousse, MD Atlanta, GA
Predictors of Neurodegeneration in Idiopathic REM Sleep Behavior Disorder: A Multicenter Cohort Study Presenter:
Biosimilars and Non-biologic Complex Drugs
Ronald Postuma, MD
Jeffrey Allan Cohen, MD
ontreal General Hospital, M Montreal, QC, Canada
Cleveland Clinic, Cleveland, OH
Discussant:
leksandar Videnovic, A MD, MSc, FAAN
Monday
GH Neurological Clinical Research M Institute, Boston, MA
Pediatric Brainstem Encephalitis Outbreak Investigation with Metagenomic Next-Generation Sequencing Presenter:
Kristoffer Edgar Leon niversity of California San U Francisco, San Francisco, CA
Discussant:
Shibani Mukerji, MD
assachusetts General Hospital, M Boston, MA
62 2018 AAN Annual Meeting
Non-invasive Neuromodulation eborah I. Friedman, MD, D MPH, FAAN
niversity of Texas Southwestern Medical U Center, Dallas, TX
G
Tuesday, April 24 9:15 a.m.–11:30 a.m.
This session covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented. This plenary session will feature audience response technology to create an interactive attendee experience. Please look for more details during this session at the Annual Meeting.
Moderators Deborah Hall, MD, PhD, FAAN Member, Science Committee
Holly E. Hinson, MD, MCR Member, Science Committee
Natalia S. Rost, MD, MPH, FAAN, FAHA
PLENARY SESSIONS
CLINICAL TRIALS PLENARY SESSION
Chair, Science Committee
Effects of IONIS-HTTRx in Patients with Early Huntington’s Disease, Results of the First HTT-Lowering Drug Trial Sarah J. Tabrizi
niversity of College London U London, United Kingdom
A Randomized, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Solriamfetol (JZP-110) for the Treatment of Excessive Sleepiness (ES) in Participants with Narcolepsy Types 1 and 2 (NT1/2) Michael J. Thorpy, MD
Montefiore Medical Center, Bronx, NY
Expanding the Time Window for Thrombectomy: Results of the DEFUSE 3 Study
A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis
Gregory W. Albers, MD
Cleveland Clinic, Cleveland, OH
Robert J. Fox, MD, FAAN
Stanford University, Stanford, CA
Brain Oxygen Optimization in Severe Traumatic Brain Injury (BOOST) Phase 2 Trial: Towards Evidence-Based in the Neurological Intensive Care Unit
David D. Adams
amon R. Diaz-Arrastia, MD, R PhD, FAAN
A PHP, Le Kremlin-Bicetre, France
P enn Presbyterian Medical Center, Philadelphia, PA
Precision Medicine: Intracerebroventricular Enzyme Replacement Therapy with Cerliponase Alfa in Children with CLN2 Disease: Results from an Ongoing Multicenter Study Emily C. De Los Reyes, MD
Nationwide Childrens Hospital, Columbus, OH
= Abstract of Distinction
AAN.com/view/AM18 63
Tuesday
Patisiran, a RNAi Therapeutic, to Improve Outcomes in Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy
PLENARY SESSIONS
FRONTIERS IN NEUROSCIENCE PLENARY SESSION G Wednesday, April 25
9:15 a.m.–11:30 a.m.
This plenary session features basic and translational research related to clinical issues of importance. Six outstanding physician-scientists provide summaries of their recent research findings and describe the clinical implications of the results.
Moderator Paul M. George, MD, PhD, MSE Member, Science Committee
The Dynamics of the Unconscious Brain Under General Anesthesia Emery Brown, MD, PhD
Combining Patient-Derived Cell and Animal Models to Uncover Epilepsy Mechanisms and Precision Therapies
assachusetts Institute of Technology, M Cambridge, MA
Jack M. Parent, MD
Does Connectomics Make Sense?
BigBrain: A High Resolution 3D Digital Human Brain Atlas
Jeff Lichtman, MD, PhD
University of Michigan, Ann Arbor, MI
Wednesday
Harvard University, Cambridge, MA
Alan Evans, PhD
Biology of Bedtime: Understanding Circadian Rhythms and Sleep
Pediatric MS: A Unique Window into Environmental and Genetic Risk Factors for MS
Amita Sehgal, PhD
University of Pennsylvania, Haverford, PA
64 2018 AAN Annual Meeting
McGill University, Montreal, QC, Canada
Emmanuelle Waubant, MD, FAAN UCSF MS Center, San Francisco, CA
9:15 a.m.–11:30 a.m.
This session features experts discussing the most current and controversial issues in neuroscience. It is set up as a debate format in which two speakers argue one side of a single topic, followed by a rebuttal. This plenary session will feature audience response technology to create an interactive attendee experience. Please look for more details during this session at the Annual Meeting.
Moderators Aleksandar Videnovic, MD, MSc, FAAN Member, Science Committee
PLENARY SESSIONS
CONTROVERSIES IN NEUROLOGY PLENARY SESSION G Thursday, April 26
Amy R. Brooks-Kayal, MD, FAAN Member, Science Committee
Should We Use Biomarkers Alone For Diagnosis of Alzheimer’s?
Would You Let Your Child Play Contact Sports?
Yes:
Yes:
Faculty
J ack W. Tsao, MD, DPhil, FAAN
No:
Maria Glymour, ScD, MS niversity of California, San U Francisco, San Francisco, CA
Memphis, TN
No:
Christopher Giza, MD CLA, Dept of Neurosurgery, U Los Angeles, CA
Should the Neurologist Be Primarily Responsible for Taking Care of Patients with Functional Disorders? Yes:
David L. Perez, MD
assachusetts General Hospital, M Boston, MA
No:
Andrea Leigh Haller, MD F ort Wayne Neurological Center, Fort Wayne, IN
Thursday
AAN.com/view/AM18 65
PLENARY SESSIONS
NEUROLOGY YEAR IN REVIEW: EMERGING THERAPIES PLENARY SESSION
G
Friday, April 27 9:15 a.m.–11:30 a.m.
This session will feature six speakers, each focusing on the latest research that has happened in the last year within a specific subspecialty topic.
Moderator Antonio M. P. Omuro, MD Member, Science Committee
A Year in Review of Neuromuscular Diseases: Making Treatments Great Again Ericka P. Simpson, MD, FAAN
Pediatric Epilepsy Kelly G. Knupp, MD
Children’s Hospital Colorado, Aurora, CO
Methodist Hospital, Houston, TX
Neuro-oncology Year in Review: Progress, Breakthroughs, and Future Directions Antonio M. P. Omuro, MD
Dementia Liana Apostolova, MD, FAAN I ndiana University School of Medicine, Indianapolis, IN
niversity of Miami Miller School of Medicine, U Miami, FL
Headache Medicine 2018: Year in Review Matthew S. Robbins, MD, FAAN Montefiore Headache Center, Bronx, NY
Friday 66 2018 AAN Annual Meeting
Finally, Some Closure on PFO Closure teven R. Messé, MD, S FAAN, FAHA
ospital of the University of Pennsylvania, H Philadelphia, PA
EXPAND YOUR HORIZONS WITH EXPERIENTIAL LEARNING AREAS
W
e’re taking learning outside the traditional classroom, every day of the meeting, with dynamic and interactive areas that will offer a variety of real-world experiences to engage you intellectually, emotionally, and socially and offer you fresh ideas to help you personally and professionally.
2. Live Well: Taking Care of Your Patients Starts with Taking Care of You! Start each day with a guided yoga session to refresh your mind and body. Return to the Kentia Foyer throughout the week for thought-provoking sessions revolving around better self-care practices for both you and your patients.
1. HeadTalks Discover transformational experiences in this unconventional platform. Nontraditional neurology topics will be discussed in an energizing format that transports you to another time and place.
3. Maximize Your Value and Advocacy to Action Learn the best business practices for neurology and leave with ready-to-apply strategies. Find out how to make your voice heard for you, your patients, and the future of neurology.
6 West Lobby
2 wn Do
3
5 4
EN TR AN CE
1
South Lobby
5. Research Corner: Moving Neurology Forward 4. Navigating Your Career Receive comprehensive information regarding professional development at every career stage. Panel presentations and small group mentoring options throughout the week provide many opportunities to get your questions answered.
ENTRANCE
6. The Member Experience: Personalize Your Journey Connect and be recognized as a valued AAN member. Learn how to personalize your experience and get the most out of your Academy.
See the importance of research on neurology’s future and its impact on patient care. Find your inspiration in research presentations and award winners.
AAN.com/view/AM18 67
Experiential Learning Areas
So uth Ex hib it
Ha ll
West Exhibit Hall
Those Other Sessions Feed Your Brain.
We’ll Fuel Your Spirit.
Visit the HeadTalks area for transformational experiences In this unconventional platform, non-traditional neurology topics include: • Gamification of Neurology • Zombie Apocalypse • Is There a Neurologist on This Flight? • The Impact of Conscious and Unconscious Biases
Wind down at the end of the day with a glass of wine during the presentations.
See following pages for full program listing
Saturday, April 21
Monday, April 23
Wednesday, April 25
12:00 p.m.–12:30 p.m.
12:00 p.m.–1:00 p.m.
12:00 p.m.–1:00 p.m.
Navigating the Annual Meeting App and Convention Center Tour Speaker: Carlayne E. Jackson, MD, FAAN
12:45 p.m.–1:45 p.m.
Ask Us Anything: Expert Panel on Headache and Facial Pain Speakers: Deborah I. Friedman, MD, MPH, FAAN Peter Goadsby, MD, PhD
2:00 p.m.–3:00 p.m.
Rural Neurology Speakers: Dario Beltran, MD, FAAN Michael Stitzer, MD
3:15 p.m.–4:15 p.m.
Women in Neurology: Crafting Your Leadership Career: Lessons from Leaders Speakers: Allison Brashear, MD, MBA, FAAN Cynthia L. Comella, MD, FAAN Helena C. Chui, MD Merit E. Cudkowicz, MD, MSC Mona Bahouth, MD Barbara G. Vickrey, MD, MPH, FAAN
Sunday, April 22 12:00 p.m.–1:00 p.m.
Neurology Pictionary Speaker: Bert B. Vargas, MD, FAAN
1:30 p.m.–2:30 p.m.
3:00 p.m.–4:00 p.m.
Blind Spots: The Impact of Conscious and Unconscious Biases Speakers: Jeffrey C. McClean, II, MD, FAAN Laraine Kaminsky Charles C. Flippen II, MD, FAAN
4:30 p.m.–5:30 p.m.
What is that Twitch? Speakers: Leonard Verhagen Metman, MD, PhD Susan B. Bressman, MD, FAAN
1:30 p.m.–2:30 p.m.
Eminence-based Medicine vs Evidence-based Medicine Speaker: Martin A. Samuels, MD, MACP, FAAN
3:00 p.m.–4:00 p.m.
Lifting the Curtain: Ask the AAN Publication Editors Anything! Speakers: Joseph E. Safdieh, MD, FAAN Orly Avitzur, MD, MBA, FAAN Robert A. Gross, MD
4:15 p.m.–5:00 p.m.
Foundations for Success in the AAN Speakers: Jeffrey C. McClean, II, MD, FAAN Terrence L. Cascino, MD, FAAN Christine E. Phelps
5:15 p.m.–6:15 p.m.
Practicing Neurology in the 1960s and 1970s Speakers: Martin A. Samuels, MD, MACP, FAAN Thomas R. Swift, MD, FAAN Austin J. Sumner, MD, FAAN Sandra F. Olson, MD, FAAN
Tuesday, April 24 12:00 p.m.–1:00 p.m.
Neurology Game Show: Localize the Lesion Speaker: Luis F. Torres, MD
1:30 p.m.–2:30 p.m.
Neurological Exam Tips and Tricks Speakers: Kapil D. Sethi, MD, FRCP (UK), FAAN Thomas R. Swift, MD, FAAN Christopher H. Hawkes, MD, Bsc, FRCP
3:00 p.m.–4:00 p.m.
Biological and Chemical Neuroterrorism and Neurowarfare Speaker: Thomas P. Bleck, MD, FAAN
4:30 p.m.–5:30 p.m.
Controversies in Neurology: Is the Zombie Apocalypse Upon Us? Local Outbreaks, Bioterrorism or Bioengineering Run Amok… Speakers: Bert B. Vargas, MD, FAAN Joseph I. Sirven, MD, FAAN Constantine Moschonas, MD, FAAN Jennifer Bickel, MD, FAAN
Neuro-Jeopardy: Telencephalon Twisters Speakers: Laurice T. Yang, MD, MHA Veronica E. Santini, MD
1:30 p.m.–2:30 p.m.
Parkinson Disease: Raising Your Game Speakers: Janis Miyasaki, MD, FAAN Cynthia L. Comella, MD, FAAN Oksana Suchowersky, MD, FAAN
3:00 p.m.–4:00 p.m.
Health Care Disparities Among Underserved Populations Speakers: Holly E. Hinson, MD, MCR Charles C. Flippen II, MD, FAAN Lisa M. Shulman, MD, FAAN Temitayo Oyegbile, MD, PhD
4:15 p.m.–5:00 p.m.
The Neurology of VooDoo Speaker: Ann H. Tilton, MD, FAAN
5:15 p.m.–6:15 p.m.
Neurology, Illustrated: The Neurology in Art Speaker: David E. Thaler, MD, PhD
Thursday, April 26 12:00 p.m.–1:00 p.m.
Who Wants to be a Millionaire Speakers: Jose H. Posas, MD
1:30 p.m.–2:30 p.m.
The Value of the Neurologic Exam: Caring for your Patient for $500 or Less Speaker: Donn Dexter, MD, FAAN
3:00 p.m.–4:00 p.m.
Consejos Prácticos para un Buen Examen Neurológico Speakers: Jose Biller, MD, FAAN, FACP, FAHA Vladimir Hachinski, MD, DSc, FAAN
4:30 p.m.–5:30 p.m.
Neurology History: Weaving Past with Present Speaker: Christopher Goetz, MD, FAAN
Friday, April 27 12:00 p.m.–1:00 p.m.
The Neurology of Creativity at the Keyboard Speaker: Phillip L. Pearl, MD, FAAN
1:30 p.m.–2:30 p.m.
Live Intraoperative Monitoring Speaker: Constantine Moschonas, MD, FAAN
3:00 p.m.–4:00 p.m.
Ask Us Anything: Expert Panel on Stroke Speakers: Natalia S. Rost, MD, MPH, FAAN, FAHA Jose Biller, MD, FAAN, FACP, FAHA Italo Linfante, MD
4:30 p.m.–5:30 p.m.
Ask Us Anything: Expert Panel on Multiple Sclerosis Speakers: John W. Rose, MD, FAAN John Corboy, MD, FAAN
AAN.com/view/AM18 69
HeadTalks
Hall of Presidents: Using Past Experience to Solve the Future’s Problems Speakers: Ralph L. Sacco, MD, MS, FAHA, FAAN Terrence L. Cascino, MD, FAAN Robert C. Griggs, MD, FAAN Francis I. Kittredge, Jr., MD,FAAN Roger N. Rosenberg, MD, FAAN Stanley Fahn, MD, FAAN Stephen M. Sergay, MB BCh, FAAN Thomas R. Swift, MD, FAAN Sandra F. Olson, MD, FAAN Timothy A. Pedley, MD, FAAN
Is There a Neurologist on This Flight? Speaker: Joseph I. Sirven, MD, FAAN
EXPERIENTIAL LEARNING AREAS
X HeadTalks
Your Wellness is Not One Dimensional.
Neither is the Live Well Experiential Learning Area.
Taking better care of your patients starts with taking better care of you. Get inspired, motivated, refreshed, and educated about the importance of taking care of the three most important dimensions of your well-being through more than 50 highly interactive opportunities throughout the week.
Physical
Beginner Friendly Yoga - Vinyasa Acupuncture Demonstration 4 Gates and Auriculotherapy The Sleep Mythbuster!: Illuminating the Facts and Fiction Towards Achieving the Sleep Healthy Neurologist
Mental
Meditation for the Practicing Neurologist The Purpose Checkup: Find Meaning, Live Longer,Better Guided Meditation Session
Professional
Perception is Reality: Are Neurologists Helping Patients Live Well with Dementia? Café Talk: Burnout Mitigation—What’s In Your Toolbox? Communication in Neurology Practice
SEE FOLLOWING PAGES FOR FULL PROGRAM LISTING.
Taking Care of Your Patients Starts with Taking Care of You!
Saturday, April 21
Tuesday, April 24
Thursday, April 26
12:00 p.m.–12:45 p.m.
7:00 a.m.–7:45 a.m.
7:00 a.m.–7:45 a.m.
8:00 a.m.–8:45 a.m.
8:00 a.m.–8:45 a.m.
Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? Speakers: Janis Miyasaki, MD, FAAN Kathrin LaFaver, MD, FAAN Elaine C. Jones, MD, FAAN
2:00 p.m.–2:45 p.m.
Cafe Talk: Narratives in Neurology: Creative Expression to Promote Resilience and Prevent Burnout Speaker: Sneha Mantri, MD
3:00 p.m.–3:45 p.m.
Acupuncture Demonstration: 4 Gates Speaker: Jennifer Bickel, MD, FAAN
Sunday, April 22
Yoga (All-Levels Vinyasa) Speaker: Sarah Bird Nelson, JD Self-Management in Neurologic Disease Speakers: Barbara C. Jobst, MD, FAAN Lisa M. Shulman, MD, FAAN
12:00 p.m.–12:45 p.m.
Treatment of Neuropathy Symptoms Without Medication Speaker: Janice F. Wiesman, MD, FAAN
1:00 p.m.–1:45 p.m.
Complementary Therapies in Parkinson’s Disease Speaker: Veronica E. Santini, MD
7:00 a.m.–7:45 a.m.
2:00 p.m.–2:45 p.m.
8:00 a.m.–9:00 a.m.
3:00 p.m.–3:45 p.m.
Yoga (All-Levels Vinyasa) Speaker: Ann Marie Collier, MD Meditation for the Practicing Neurologist Speaker: Sarah Mulukutla, MD, MPH
12:00 p.m.–12:45 p.m.
How to Promote Healthy Cognitive Aging: What Should We Tell Our Patients and Ourselves? Speaker: Kirk R. Daffner, MD, FAAN
1:00 p.m.–1:45 p.m.
Solving Burnout Speaker: Neil A. Busis, MD, FAAN
3:00 p.m.–3:45 p.m.
How Your Social Life Might Be Helping (or Harming) Your Brain Speaker: Joel Armando Salinas, MD
4:00 p.m.–4:45 p.m. Cafe Talk: Is that an Emotional or Cognitive Question? Navigating Difficult Conversations with Communication Skills Speaker: Tara Cook, MD
Monday, April 23 7:00 a.m.–7:45 a.m.
Yoga (All-Levels Vinyasa) Speaker: Jamie L. Heath, MD Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? Speakers: Janis Miyasaki, MD, FAAN Kathrin LaFaver, MD, FAAN Elaine C. Jones, MD, FAAN Amy Hessler, DO Divya Singhal, MD
12:25 p.m.–1:45 p.m.
Perception Is Reality: Are Neurologists Helping Patients Live Well with Dementia? Speakers: Daniel C. Potts, MD, FAAN Neelum T. Aggarwal, MD
2:00 p.m.–2:45 p.m.
Physical Exercise and Cognitive Training in Neurology: Application in Aging and Neurodegenerative Disease Speaker: Ergun Y. Uc, MD
StrengthsFinder Social Hour Speakers: Keri Bischoff Julie Anderson
4:00 p.m.–4:45 p.m.
The Sleep Mythbuster!: Illuminating the Facts and Fiction Towards Achieving the Sleep Healthy Neurologist Speaker: Charlene Gamaldo, MD, FAAN
5:00 p.m.–5:30 p.m.
Guided Meditation Speaker: Divya Singhal, MD
Wednesday, April 25
Sleep and Performance in Elite Athletes Speaker: Scott J. Kutscher, MD
12:00 p.m.–12:45 p.m.
The Purpose Checkup: Find Meaning, Live Longer, Better Speaker: Richard Leider
1:00 p.m.–1:45 p.m.
Medical Marijuana: What Do Neurologists Need to Know? Speaker: Jessica Robinson Papp, MD, FAAN
2:00 p.m.–2:45 p.m.
Cafe Talk: Communication in Neurology Practice Speakers: Jessica Robinson Papp, MD, FAAN Shanna Patterson, MD
3:00 p.m.–3:45 p.m.
Magnifying Your Life Through Poetry Speaker: Michael L. Wynn, DO
Friday, April 27 7:00 a.m.–7:45 a.m.
Yoga (All-Levels Vinyasa) Speaker: Jamie L. Heath, MD
12:00 p.m.–12:45 p.m.
Outsmart Stress Speaker: Marie E. Pasinski, MD
7:00 a.m.–7:45 a.m.
Yoga (All-Levels Vinyasa) Speaker: Ann Marie Collier, MD
8:00 a.m.–8:45 a.m.
Acupuncture Demonstration: Auriculotherapy Speaker: Jennifer Bickel, MD, FAAN
12:00 p.m.–12:45 p.m.
Neurology and Wellness - Physician, Heal Thyself Speakers: Jennifer Rose Molano, MD, FAAN Divya Singhal, MD
2:00 p.m.–2:45 p.m.
Resiliency for the Neurologist Speaker: Justin T. Jordan, MD, MPH
Live Well
8:00 a.m.–8:45 a.m.
Dancing with Parkinson’s Speaker: Diviya Kaul, MD
Yoga (All-Levels Vinyasa) Speaker: Jamie L. Heath, MD
3:00 p.m.–3:45 p.m.
Introduction to Acupuncture II: Evidence-based Applications for Acupuncture in the Treatment of Neurologic Conditions Speaker: Alexandra Dimitrova, MD
4:00 p.m.–4:45 p.m.
Diets and Supplements in MS: What’s the Evidence Thus Far? Speaker: Vijayshree Yadav, MD
5:00 p.m.–5:30 p.m.
Guided Meditation Speaker: Divya Singhal, MD
3:00 p.m.–3:45 p.m.
Introduction to Acupuncture I: Conceptual Framework and Mechanism of Action Speaker: Alexandra Dimitrova, MD
4:00 p.m.–4:45 p.m.
Striking the Balance—A Neurologist’s Personal Wellness Journey Speaker: Neil A. Busis, MD, FAAN
EXPERIENTIAL LEARNING AREAS
X Live Well:
AAN.com/view/AM18 71
EMPOWER YOURSELF, YOUR PRACTICE, YOUR PROFESSION Practice management and advocacy are not mutually exclusive—and neither are this year’s experiential learning areas. These two popular Annual Meeting destinations will share the stage to provide the most powerful and effective tips and tools to arm you for success. A desire to improve our profession’s economic, clinical practice, and regulatory environment can inspire advocacy. And advocacy can lead to the changes necessary to ensure your practice’s success, your patients’ success, and the success of the neurology profession.
Maximize Your Value
When you succeed, your patients succeed.
Advocacy to Action
When neurology succeeds, we all succeed.
Hear from experts about the latest AAN guidelines and quality measurement sets
$
Learn about neurologists’ compensation and increase your own revenue through coding and technology
Learn more and provide input on the AAN’s important legislative priorities
Find out how you can initiate your own advocacy efforts
Visit the Polling Station to tell us what matters most to you—your voice can make a difference! Meet with staff from the AAN’s Axon Registry® and technical vendor FIGMD to learn how this quality improvement tool can work for you
Attend talks on some of the most controversial topics impacting your practice today—like marijuana, telemedicine, and patient portals
Bow Tie Tuesday! Wear your green bow ties and scarves. Learn about Neurology on the Hill
Network with experienced AAN advocates and alumni of the Palatucci Advocacy Leadership Forum Learn about the Quality Payment Program (QPP)
See following pages for full program listing.
Snap a photo at our selfie station and upload it to social media to promote #AANadvocacy
Improve Your Neurology Practice
Empowering Patients and Physicians
Saturday, April 21
Monday, April 23
Wednesday, April 25
9:30 a.m.–10:00 a.m.
12:00 p.m.–1:00 p.m.
8:00 a.m.–9:00 a.m.
What is the Axon Registry? Speaker: Sarah M. Benish, MD, FAAN
2:00 p.m.–2:30 p.m.
Paths for Success in the Quality Payment Program Speaker: Lyell K. Jones, MD, FAAN
2:30 p.m.–3:00 p.m.
Ask the Expert: Paths for QPP Success Speaker: Lyell K. Jones, MD, FAAN
3:00 p.m.–3:30 p.m.
Clinical Decision Support for Ordering of Diagnostic Imaging Speakers: David A. Evans, MBA Eric M. Cheng, MD, MS, FAAN
3:30 p.m.–4:00 p.m.
Growing Research in Medical Marijuana Speaker: Anup D. Patel, MD, FAAN
4:00 p.m.–4:30 p.m.
TBI in Domestic Violence Victims: Care for Those Who Need it Most Speaker: Glynnis Zieman, MD
Sunday, April 22 8:00 a.m.-9:00 a.m.
How Can the Axon Registry Improve My Practice? Speakers: Katie Hentges Tim Parr
12:00 p.m.–1:00 p.m.
Pursuing a Career in Clinical Informatics Speakers: Allison L. Weathers, MD, FAAN Eric M. Cheng, MD, MS, FAAN Allan Ding Wu, MD Melissa Yu, MD
1:00 p.m.–2:00 p.m.
Meet and Greet with the California Neurological Society Speaker: Erik Perkins, MD, FAAN
2:00 p.m.–2:30 p.m.
2:30 p.m.–3:00 p.m.
Ask the Expert: Teaching through Simulation Speakers: Barbara A. Dworetzky, MD, FAAN Tracey A. Milligan, MD, FAAN
3:00 p.m.–3:30 p.m.
Using EHR for Better Communication with Patients and Colleagues Speakers: Allison L. Weathers, MD, FAAN Allan Ding Wu, MD Melissa Yu, MD Radhika Sampat, DO
2:00 p.m.–2:30 p.m.
Can Aviation Accidents Teach Neurologists Patient Safety and Error Management? Speakers: Rohit Das, MD, FAAN Amy E. Sanders, MD, FAAN
3:00 p.m.–3:30 p.m.
Safety and Quality Awards Speakers: Anup D. Patel, MD, FAAN Amy E. Sanders, MD, FAAN
3:30 p.m.–4:00 p.m.
What Does the AAN’s Latest Guideline Mean for My Practice? Speaker: Gregory S. Day, MD, MSc
4:00 p.m.–4:30 p.m.
Streamlining Clinic Scheduling and Access Speakers: Melissa Yu, MD Radhika Sampat, DO
4:30 p.m.–5:00 p.m.
Knowing Your Value: How to Negotiate to Get What You’re Worth Speaker: Eva K. Ritzl, MD, FAAN
Tuesday, April 24 12:00 p.m.–1:00 p.m.
Communicating via EHR Speakers: Allison L. Weathers, MD, FAAN Melissa Yu, MD Radhika Sampat, DO
1:00 p.m.–2:00 p.m.
Understanding Axon Registry and Using it to Improve Your Value Speakers: Lyell K. Jones, MD, FAAN Anup D. Patel, MD, FAAN
Step Away from the Desktop! Recapturing the Joy in Practice Speakers: Allison L. Weathers, MD, FAAN Allan Ding Wu, MD Melissa Yu, MD
1:00 p.m.–1:30 p.m.
So You Want to Work for a Hospital? Speaker: J. Todd Barnes, MBA
1:00 p.m.-2:00 p.m.
Scientific Platform Session S28 Practice, Policy, and Ethics
Thursday, April 26 8:00 a.m.–9:00 a.m.
Enhancing Epilepsy Care in Your Practice: In-Person Digital Learning and Emotional for Self-Management, Education, and Community Supports from the National Epilepsy Education and Awareness Collaborative Speakers: Barbara C. Jobst, MD, FAAN Patricia Shafer, RN
12:00 p.m.-12:30 p.m.
How to Increase Investments in Neuroscience Research Speaker: David Q. Beversdorf, MD, FAAN
1:00 p.m.–1:30 p.m.
What Do I Need to Know About Coding in My Practice? Speaker: Bruce H. Cohen, MD, FAAN
2:00 p.m.–3:00 p.m.
Using Your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency Speakers: Mary R. Rensel, MD, FAAN Nancy B. Isenberg, MD, MPH, FAAN
Friday, April 27 12:00 p.m.–12:30 p.m.
Incorporating a Semi-Concierge Model into your Own Neurology Practice Speaker: Teryn B. Clarke, MD
Maximize Your Value Advocacy to Action
Breaking Down Silos: Using Simulation for Interprofessional Team Education to Enhance Clinical Outcomes in Neurology Speakers: Barbara A. Dworetzky, MD, FAAN Tracey A. Milligan, MD, FAAN Charles Pozner, MD
Practice Models for Advanced Practice Providers Speaker: Calli Leighann Cook, FNP-C
2:00 p.m.–2:30 p.m.
Caring for Telemedicine Patients Speaker: Raghav Govindarajan, MD, FAAN
2:30 p.m.–3:30 p.m.
What is the AAN Doing for Small and Solo Practitioners? Speaker: Elaine C. Jones, MD, FAAN
Tip of the Iceberg: Ultra-High Cost Neurology Drugs Speaker: Nicholas Elwood Johnson, MD, FAAN
4:00 p.m.–4:30 p.m.
Why are Drug Prices So High? And What Can We Do About It? Speaker: Brian Callaghan, MD
4:30 p.m.–5:00 p.m.
What Does BrainPAC Do for Me? Speaker: Mike Amery
EXPERIENTIAL LEARNING AREAS
aximize Your Value: X M Advocacy to Action:
AAN.com/view/AM18 73
Get on Track...
No matter where you are in your professional journey, you’ll want to stop by the Navigating Your Career Experiential Learning Area for essential tips, tools, and resources to get you on the right track to make your professional journey a huge success. Take advantage of one-on-one and small-group mentoring sessions with experts, and congratulate recipients of the 2018 Faculty and Trainee Awards. FOR MEDICAL STUDENTS A Giving and Receiving Feedback for Medical Students and Residents A How to Be “Useful” on Rotations: Tips for Medical Students A Why Choose a Career in Neurology?
FOR RESIDENTS A Being a Great Chief Resident A Research in Residency: How to Choose the Right Project A Navigating Fellowship in Neurology
FOR EDUCATORS A Education Administrator Building Blocks: Navigating the Role of the Administrator and Taking Your Role to the Next Level A Patient Centered Teaching A Up Your Game as a Medical Educator in Neurology
FOR THE JOB SEARCHER A Interviewing Skills A Academic Career Panel: How to Get Your Career Started A Negotiation Skill: You Do Not Get What You Deserve, You Get What You Negotiate
Saturday, April 21 9:15 a.m.–9:45 a.m.
How to Network at the Annual Meeting: Strategies for Trainees Speaker: Safiullah Shareef, MD
9:15 a.m.–10:00 a.m.
Patient Centered Teaching Speaker: Raghav Govindarajan, MD, FAAN
10:00 a.m.–10:30 a.m.
Sleep: Why You Should Spend Your Career Helping People Do It Right Speaker: Logan D. Schneider, MD
10:15 a.m.–10:45 a.m.
Cognitive Biases and Diagnostic Errors at Bedside Speaker: Raghav Govindarajan, MD, FAAN
11:15 a.m.–12:00 p.m.
Choosing a Career in Clinical Practice Speaker: James C. Stevens, MD, FAAN
12:15 p.m.–1:00 p.m.
What I Learned About Research—An Early Career Perspective Speaker: Logan D. Schneider, MD
1:15 p.m.–2:00 p.m.
Interviewing Skills: Medical Students and Residents Speaker: Ezgi Tiryaki, MD, FAAN
2:15 p.m.–3:00 p.m.
Teleneurology: Is this for me? Pre-hospital and Nontraditional Uses of Teleneurology Speaker: Nina J. Solenski, MD
3:15 p.m.–4:00 p.m.
Social Media for Clinicians Speaker: Pearce Korb, MD, FAAN
Sunday, April 22 7:45 a.m.–8:15 a.m.
Research in Residency: How to Choose the Right Project Speaker: Roy E. Strowd, III, MD
8:15 a.m.–9:00 a.m.
K is for Career Development: Tips From Successful Applications for NIH Career Development Awards Speaker: Logan D. Schneider, MD
8:30 a.m.–9:00 a.m.
9:15 a.m.–9:45 a.m.
Giving and Receiving Feedback for Medical Students and Residents Speaker: Ezgi Tiryaki, MD, FAAN
10:00 a.m.–10:30 a.m.
Autoimmune Neurology Speaker: Pooja Santosh Raibagkar, MD
10:45 a.m.–11:15 a.m.
So You Want to Be a Residency Program Director? Speaker: Neil E. Schwartz, MD, PhD
12:15 p.m.–1:00 p.m.
Sleep: A Frequently Forgotten Part of Your Patient’s Day Speaker: Anne M. Morse, DO
1:00 p.m.–1:30 p.m.
Being a Great Chief Resident Speaker: Roy E. Strowd, III, MD
Measuring Success: Quality Improvement 101 Speaker: Justin P. Martello, MD
1:45 p.m.–2:15 p.m.
Career Stories: Challenges for the Physician Scientist Speaker: Mark Hallett, MD, FAAN
2:15 p.m.–3:00 p.m.
Education Administrator Building Blocks: Navigating the Role of the Administrator and Taking Your Role to the Next Level Speakers: Crys Draconi, C-TAGME Shannon H. Darrah
3:15 p.m.–3:45 p.m.
How to Get Into Leadership in Professional Societies Speaker: Mark Hallett, MD, FAAN
3:15 p.m.–4:00 p.m.
Social Media for the Millennial Neurologist Speaker: Safiullah Shareef, MD
4:00 p.m.–4:30 p.m.
Transitioning from Private Practice to Academics Speaker: Neil A. Busis, MD, FAAN
4:15 p.m.–5:00 p.m.
Introduction to the Fascinating World of Movement Disorders Speakers: Shilpa Chitnis, MD, PhD, FAAN, FANA Svjetlana Miocinovic, MD, PhD
4:45 p.m.–5:15 p.m.
Everything You Wanted to Know About the R&F Section of Neurology Speakers: Roy E. Strowd, III, MD John J. Millichap, MD
Monday, April 23 7:45 a.m.–8:15 a.m.
Using the R&F Section of Neurology for your Residents and Residency Speakers: Roy E. Strowd, III, MD John J. Millichap, MD
8:15 a.m.–9:00 a.m.
Choosing An Academic Career in Neurology: Perspectives for Early Career Investigators and Foreign Medical Graduates Speakers: Deepak Kumar Gupta, MBBS Ciro Ramos Estebanez, MD
8:30 a.m.–9:00 a.m.
Tools to Transition from Trainee to Attending Speaker: Safiullah Shareef, MD
10:00 a.m.–10:30 a.m.
How to be “Useful” on Rotations: Tips for Medical Students Speaker: Ezgi Tiryaki, MD, FAAN
10:45 a.m.–11:15 a.m.
Choosing a Neurohospitalist Career Speaker: S. Andrew Josephson, MD, FAAN
11:30 a.m.–12:00 p.m.
Child Neurology—Staying on Track Speaker: Warren D. Lo, MD
11:45 a.m.–12:30 p.m.
Finding Your Niche in Neurology: Perspectives from an Epileptologist and Educator Speaker: Chad Carlson, MD
12:45 p.m.–1:30 p.m.
Transitioning From a Clinical Research Career to an Educational and Clinical Focused Career Speaker: Chad Carlson, MD
1:00 p.m.–1:30 p.m.
Subspecialty Sessions: IOM and cEEG Speaker: Eva K. Ritzl, MD, FAAN
1:45 p.m.–2:30 p.m.
Creating a Career in Global Health with Design Thinking Speaker: Nirali Vora, MD
2:45 p.m.–3:30 p.m.
Mejora Tu Desempeño Como Educador Médico Speaker: Rachel Marie E. Salas, MD, FAAN
3:45 p.m.–4:30 p.m.
Teaching Communication Skills: From Good to Great Speaker: Tara Cook, MD
4:45 p.m.–5:30 p.m.
Career Development for Medical Educators Speaker: Ralph F. Józefowicz, MD, FAAN
Tuesday, April 24 8:15 a.m.–9:00 a.m.
Career Development for Clinician Educators Speaker: Allison Brashear, MD, MBA, FAAN
8:30 a.m.–9:00 a.m.
Career Stories: Nuts and Bolts of Academic Leadership - Strategies I Have Learned in My Career Speakers: Deborah Hall, MD, PhD, FAAN Cynthia L. Comella, MD, FAAN
10:00 a.m.–10:30 a.m.
Choosing a Career in Neurocritical Care Speaker: Matthew B. Maas, MD
10:45 a.m.–11:15 a.m.
Staying on an Academic Clinical Track Speaker: John Probasco, MD
11:30 a.m.–12:00 p.m.
Reviewer to Editorial Board to Editor Speaker: Mark Hallett, MD, FAAN
11:45 a.m.–12:30 p.m.
Foreign Medical Graduates Adjustment Skills Speaker: Ehtesham Khalid, MBBS
12:15 p.m.–12:45 p.m.
Neurohospitalists 2.0, How to Craft a Satisfying and Sustainable Career Speaker: David J. Likosky, MD, SFHM, FAAN, FAHA, FACP
12:45 p.m.–1:30 p.m.
Choosing Teleneurology as a Career Speaker: Eric Anderson, MD, PhD
1:00 p.m.–1:30 p.m.
Subspecialty Sessions: IOM and cEEG Speaker: Eva K. Ritzl, MD, FAAN
1:45 p.m.–2:15 p.m.
Academic Career Panel: Find out How to Get Your Career Started Speakers: Joseph E. Safdieh, MD, FAAN Jennifer Rose Molano, MD, FAAN
2:30 p.m.–3:00 p.m.
How to Start a Career in Neurology Education Speaker: Joseph E. Safdieh, MD, FAAN
2:45 p.m.–3:30 p.m.
Training in Neurology While on a Visa: Challenges and Possible Solutions for Foreign Medical Graduates Speaker: Ahmed Z. Obeidat, MD, PhD
3:15 p.m.–3:45 p.m.
Staying on Track: A Career as a Clinical Researcher Speaker: Rebecca F. Gottesman, MD
3:45 p.m.–4:30 p.m.
International Members: What Can the AAN Do For You? Speakers: Jerome H. Chin, MD, PhD, MPH, FAAN Christi Kokaisel, MBA, CAE
4:45 p.m.–5:30 p.m.
Teaching During a Busy Clinic Speaker: Raghav Govindarajan, MD, FAAN
Wednesday, April 25 8:15 a.m.–9:00 a.m.
How to Give Effective Feedback Speakers: Laurice T. Yang, MD, MHA Veronica E. Santini, MD
12:45 p.m.–1:30 p.m.
Clinical Research in the Area of Practice, Quality and Patient Safety Speakers: Mona Bahouth, MD Justin T. Jordan, MD
2:45 p.m.–3:30 p.m.
Pursing a Career in Healthcare Administration Speaker: Laurice T. Yang, MD, MHA
3:45 p.m.–4:30 p.m.
Navigating Fellowship in Neurology Speaker: Ahmed Z. Obeidat, MD, PhD
4:45 p.m.–5:30 p.m.
Top Ten Clinical, Educational and Leadership Pearls Speaker: Steven Galetta, MD, FAAN
Thursday, April 26 11:45 a.m.–12:30 p.m.
Teaching History and Exam with Teleneurology Speaker: Raghav Govindarajan, MD, FAAN
12:45 p.m.–1:30 p.m.
Effective Neurology Residency Program Speaker: Ralph F. Józefowicz, MD, FAAN
1:45 p.m.–2:30 p.m.
Interviewing Skills Speaker: Ralph F. Józefowicz, MD, FAAN
2:45 p.m.–3:30 p.m.
O Funding, Where Art Thou? How to Develop a Full-Time Academic Career in Global Neurology Speaker: Omar Siddiqi, MD
1:45 p.m.–2:30 p.m.
The Encompassing Value of the PatientPhysician Relationship Speaker: Stephen M. Sergay, MB BCh, FAAN
AAN.com/view/AM18 75
Navigating Your Career
Interviewing Skills: Negotiation Speaker: Allison Brashear, MD, MBA, FAAN
1:15 p.m.–2:00 p.m.
EXPERIENTIAL LEARNING AREAS
X Navigating Your Career
The Research You Do Today Could Be the Cure of Tomorrow. We Can Help. No matter where you’re at in your neurology research career—be it simply considering, early, expert, or late— the Research Corner Experiential Learning Area is your opportunity to get in and discover how you can shape the future. Improve your knowledge and skills through practical tools and resources you won’t find anywhere else at the Annual Meeting. And be the future that you and patients with neurologic disease want to see.
Burning Questions
Get invaluable face-to-face time with expert leaders in any research topic of your choice.
Show Me the Money
Get all the tips and tricks from key decision makers in federal research funding and AAN Research Program grant funding on how to get your proposal funded.
Celebrity Sightings
Get star struck when the biggest names in research take to the stage to present the hottest topics and most recent breakthroughs.
Walk of Fame
Check out the AAN’s 2018 scientific award winners and AAN Research Program grant recipients.
Inspire Others
Inspire your colleagues to get in and join the research movement, too! Snap a selfie for our Faces of Research Wall and tell us what research means to you.
See following pages for full program listing.
Saturday, April 21 7:30 a.m.–8:15 a.m.
Are You My Mentor? How to Select a Good Mentor for Your Research Career Speaker: Deborah Hall, MD, PhD, FAAN
8:25 a.m.–9:10 a.m.
Work Life Balance in Research Speaker: Amanda C. Peltier, MD, MS
9:20 a.m.–9:50 a.m.
How to Successfully Publish Quality Improvement Projects Speakers: Anup D. Patel, MD, FAAN Rohit Das, MD, FAAN
10:00 a.m.–10:50 a.m.
Investigator Panel: How I Launched My Career with NIH Funding, Private Funding, AAN Research Program Funding and/or Government Funding Speakers: An Hong Do, MD Nicoline Schiess, MD Daniel O. Claassen, MD
11:30 a.m.–12:00 p.m.
Office Hours: Research Careers in Industry Speaker: Brandy R. Matthews, MD, FAAN
12:00 p.m.–12:30 p.m.
Office Hours: Writing a Great AAN Research Program Proposal Speaker: Jeffrey Marc Gelfand, MD, MAS, FAAN
12:20 p.m.–12:50 p.m.
How to Find Training: The Best Clinical Research and Methodology Training Options Speaker: Nicole A. Chiota-McCollum, MD
1:00 p.m.–1:30 p.m.
Statistics - Sample Size Speaker: William Joseph Meurer, MD
1:40 p.m.–2:10 p.m.
Clinical Trials Methodology Course— Information Session with William Meurer MD, MS, CTMC Principal Investigator Speaker: William Joseph Meurer, MD
Sunday, April 22 8:00 a.m.–9:10 a.m.
Challenges in Clinicogenetic Correlations: One Gene, Many Phenotypes; One Phenotype, Many Genes Speakers: Kailash P. Bhatia, MD, FAAN Roy Alcalay, MD
10:00 a.m.–10:30 a.m.
12:00 p.m.–12:30 p.m.
Office Hours: Finding/Working with Epidemiologists on Your Grant Speaker: Caroline M. Tanner, MD, PhD, FAAN
12:30 p.m.–1:00 p.m.
Office Hours: Surviving as a Clinician Researcher Speaker: Lisa C. Silbert, MD, FAAN
1:20 p.m.–1:50 p.m.
So You Have a Research Idea—How Do You Turn it into a Project? Speaker: Edward H. Bertram, MD, FAAN
3:30 p.m.-4:30 p.m.
1:00 p.m.-2:15 p.m.
4:30 p.m.–5:00 p.m.
1:00 p.m.–1:30 p.m.
5:00 p.m.–5:30 p.m.
1:20 p.m.–1:50 p.m.
Monday, April 23
1:30 p.m.–2:00 p.m.
Scientific Platform Session S7 Pain and Palliative Care How to Start a Career in Clinical Trials Speaker: Aleksandar Videnovic, MD, MSc, FAAN Statistics and Study Design: Pearls and Pitfalls Speaker: Senan Ebrahim
7:30 a.m.–8:00 a.m.
Defining and Managing Your Message as An Early Career Researcher Speaker: Corey R. Fehnel, MD
8:10 a.m.–9:00 a.m.
Your CV is Talking About You Behind your Back, and your LORs Are Too! Speaker: Na Tosha N. Gatson, MD, PhD
12:00 p.m.–12:30 p.m.
Office Hours: Working with an Epidemiologist Speaker: Kelly Sullivan, PhD
1:00 p.m.–1:30 p.m.
Office Hours: Creating Bridge Funding How to Use Non-NIH Funding Speaker: Lidia Maria Veras Rocha Moura, MD
1:30 p.m.–2:00 p.m.
Office Hours: Statistics—Sample Size Speaker: Jordan J. Elm
2:30 p.m.–3:00 p.m.
Office Hours: Defining and Managing Your Message As An Early Career Scientist Speaker: Christopher D. Anderson, MD, PhD
4:00 p.m.–4:45 p.m.
Cafe Talk: Is that an Emotional or Cognitive Question? Navigating Difficult Conversations with Communication Skills Speaker: Tara Cook, MD
Tuesday, April 24 8:00 a.m.–8:30 a.m.
Welcome to NINDS Day/Overview of NIH Funding With NINDS Director and NINDS Deputy Director Speakers: Walter J. Koroshetz, MD, FAAN Nina F. Schor, MD, PhD, FAAN
8:40 a.m.–9:10 a.m.
K Awards and Training Programs Speakers: Adam L. Hartman, MD Nina F. Schor, MD, PhD, FAAN
12:00 p.m.–12:30 p.m.
Introduction to the 2018–2020 TRANSCENDS Scholars Speaker: Bruce I. Ovbiagele, MD, MSc, FAAN Office Hours: How to Get a K-Award Speaker: Michael Levy, MD, FAAN
12:30 p.m.–1:00 p.m.
Office Hours: Bridge Funding Speaker: Randolph S. Marshall, MD, FAAN
12:40 p.m.–1:10 p.m.
NIH Funding and Professional Development Opportunities for Diverse Researchers Speaker: Michelle Jones-London, PhD
Scientific Platform Session S12 Autonomic Disorders Office Hours: VA Research Funding: Career Development Awards Speaker: Beth Leeman-Markowski, MD, MA NIH Grant Review Process Speakers: Adam L. Hartman, MD Shanta Rajaram, PhD Office Hours: Clinical Research Recommendations for Residents and Fellows Speaker: Benjamin David Tolchin, MD
2:00 p.m.–2:30 p.m.
NINDS Clinical Trials (new NIH definition) and networks, NeuroNEXT, StrokeNET, SIREN Speaker: Clinton B. Wright, MD
2:30 p.m.–3:00 p.m.
Office Hours: Finding Collaborators Speaker: Mia T. Minen, MD
2:40 p.m.–3:10 p.m.
Pain Research Funding Opportunities, Clinical and Basic Speakers: Clinton B. Wright, MD Michael Oshinsky, PhD
3:20 p.m.–3:50 p.m.
Pain Research Funding Opportunities, Clinical and Basic Speaker: Kenneth H. Fischbeck, MD, FAAN
4:00 p.m.–4:30 p.m.
Your Grant Proposal Was Rejected: Now What? Turning a Feedback Into a Successful Project Speaker: Amy R. Brooks-Kayal, MD, FAAN
Wednesday, April 25 8:00 a.m.–9:10 a.m.
How to Write and Publish Research Papers, Reviews and Other Scientific Communications Speakers: Mark Hallett, MD, FAAN Francois Boller, MD, PhD, FAAN Michael J. Aminoff, MD, DSc, FAAN
2:00 p.m.–2:30 p.m.
Office Hours: Mentor-Mentee Relationships Speaker: Nicte I. Mejia, MD Women in Neuroscience Speaker: Amy R. Brooks-Kayal, MD, FAAN
2:40 p.m.–3:10 p.m.
Patient-Reported Measures in Neurology Speaker: Lidia Maria Veras Rocha Moura, MD
3:00 p.m.–3:30 p.m.
Office Hours: Research Careers in Industry Speaker: Brandy R. Matthews, MD, FAAN
3:30 p.m.-4:15 p.m.
Scientific Platform Session S33 Global Health
4:30 p.m.-5:30 p.m.
Scientific Platform Session S37 Neurorehabilitation
Thursday, April 26 8:00 a.m.–8:30 a.m.
How to Bridge to Careers in Industry Speaker: Alfred W. Sandrock, MD, PhD
8:40 a.m.–9:10 a.m.
The Pathway to Become a Clinical Trialist Speaker: James F. Meschia, MD, FAAN
1:00 p.m.–1:30 p.m.
Office Hours: Early Career Research Funding and Career Development Speaker: Ryan R. Walsh, MD, PhD, FAAN
1:00 p.m.-2:15 p.m.
Scientific Platform Session S39 History of Neurology
4:30 p.m.–5:00 p.m.
Grantwriting 101: Getting Started Speaker: Logan D. Schneider, MD
Friday, April 27 8:00 a.m.–9:10 a.m.
Role of Placebo in Neuromuscular Clinical Trials and in Management of NM Disorders Speakers: Aziz I. Shaibani, MD, FAAN Richard J. Barohn, MD, FAAN
8:30 a.m.–9:00 a.m.
12:00 p.m.–12:30 p.m.
12:00 p.m.–12:30 p.m.
12:30 p.m.–1:00 p.m.
Office Hours: Selecting an AAN Research Program Mentor Speaker: Brian Edlow, MD Office Hours: Recruiting Difficult and Underrepresented Populations in Research Speaker: Jessica Robinson Papp, MD, FAAN Recruiting Minorities Speaker: Temitayo Oyegbile, MD, PhD
12:30 p.m.–1:00 p.m.
Office Hours: Navigating Uncommon Pathways in Academic Neurology: A Journey from Bedside to Bench Speaker: Carolina B. Maciel, MD
12:40 p.m.–1:10 p.m.
Neuroscience of Bias Speaker: Jose H. Posas, MD
1:00 p.m.–1:50 p.m.
Community Education in Minority Population Speaker: Olajide Abiodun Williams, MD
How to Bridge to Careers in Industry Speaker: Jose E. Cavazos, MD, PhD, FAAN Office Hours: Making the Transition from Research Fellow to Clinical Research Faculty Speaker: Benzi Kluger, MD, FAAN
12:40 p.m.–1:10 p.m.
How to Put Together an Effective Research Presentation Speaker: Enrique C. Leira, MD, MS, FAAN
2:40 p.m.–3:10 p.m.
Recruiting Minorities Speaker: Bernadette Boden-Albala, MPH
4:00 p.m.–4:30 p.m.
Historical Perspective on Treating Epilepsy Speaker: Gregory K. Bergey, MD, FAAN
AAN.com/view/AM18 77
Research Corner
Office Hours: The Researcher Pipeline: The Benefits of Participating in Academic Medicine, Research and Clinical Trials as a Medical Student or Resident Speaker: Laurie Gutmann, MD, FAAN
Moving Neurology Forward
EXPERIENTIAL LEARNING AREAS
X Research Corner:
MEMBERSHIP
FAAN AAN.COM
SYNAPSE
It’s all about you We our members. And at the Member Experience: Personalize Your Journey Experiential Learning Area, we’re ready to show you all the steps we’ve taken to help you connect, engage, and personalize your member experience to make it all your own.
GET UP TO SPEED
•
Take a look at the new AAN.com and see how it’s personalized just for you
•
Get a new profile picture
•
Join Synapse™ Online Communities
•
Compete with your colleagues to see who can find their way around the new site
GET RECOGNIZED
•
See if you qualify to elevate your membership status to the premier Fellow of the American Academy of Neurology (FAAN)
•
Check out our recognition wall to congratulate your deserving colleagues!
NEUROSCIENCE IN THE CLINIC SESSIONS
A
two-hour session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will introduce and provide background on a case and clinicians will apply the case to a patient. Sessions will feature abstract presentations related to the topic. Sessions end with a panel discussion.
Sunday, April 22 3:30 p.m.–5:30 p.m.
N1 Neuroscience in the Clinic:
Autism Myth Busters . . . . . . . . . . . . . . . 80
Monday, April 23 3:30 p.m.–5:30 p.m.
N2 Neuroscience in the Clinic:
Antisense Oligonucleotide (ASO) Therapy . . . . . . . 82
Tuesday, April 24 1:00 p.m.–3:00 p.m.
N3 Neuroscience in the Clinic:
Challenges in Genetic Diagnosis in Neurology . . . . . 82
Thursday, April 26 1:00 p.m.–3:00 p.m.
N5 Neuroscience in the Clinic:
Treatment of Progressive Multiple Sclerosis . . . . . . 84
3:30 p.m.–5:30 p.m.
N6 Neuroscience in the Clinic:
NeurologicComplications of Cancer Immunotherapy: A New Frontier in Neuro-Inflammation . . . . . . . . 84
Friday, April 27
3:30 p.m.–5:30 p.m.
N7 Neuroscience in the Clinic:
REM Sleep Behavior Disorder: Past, Present, Future . . 85
Wednesday, April 25 3:30 p.m.–5:30 p.m.
N4 Neuroscience in the Clinic:
Opioid Useand Abuse: The Overlapping Neurobiology of Painand Addiction, and the Path Toward Better Treatments . . . . . . . . . . . 83
AAN.com/view/AM18 79
NEUROSCIENCE IN THE CLINIC
NEUROSCIENCE IN THE CLINIC
Sunday, April 22
A two-hour session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will introduce and provide background on a case and clinicians will apply the case to a patient. Sessions will feature abstract presentations related to the topic. Sessions end with a panel discussion.
N1 Neuroscience in the Clinic: Autism Myth Busters Directors: Sarah J. Spence, MD, PhD; and Shafali Jeste, MD
Program Description Rapid advances in our understanding of the underlying neurobiology of autism spectrum disorder (ASD) has prompted more accurate and informed diagnoses, detailed prognostication, and the development of targeted treatment trials. However, these scientific achievements often become overshadowed by community practices that lack evidence or a scientific foundation, leaving patients and caregivers uncertain about best practices. The goal of this symposium is to provide neurologists with clinically relevant scientific updates on autism spectrum disorders (ASD), in order to facilitate more informed dialogues with their patients. We will begin with a representative clinical case, followed by three presentations with paired abstracts on key topics in the autism field, including prediction and diagnostic biomarkers, clinical trials and therapeutics, and advances in genetics. Upon Completion Participants should become familiar with insights on early signs of ASD gained from studies of infants at risk for ASD; the definition of a biomarker and an understanding of the types of biomarkers investigated in ASD; challenges around clinical trial design and implementation in ASD; evidence around pharmacological interventions for ASD and updates from clinical drug trials; and updates on autism genetics, from recommended diagnostic practices to implications for management.
G
3:30 p.m.–5:30 p.m.
3:30 p.m.–3:45 p.m. Clinical Vignette: Autism Spectrum Disorders Sarah J. Spence, MD, PhD, Boston, MA 3:45 p.m.–4:00 p.m. Biomarkers of ASD: From Screening to Clinical Stratification to Quantitative Outcomes Shafali Jeste, MD, Los Angeles, CA 4:00 p.m.–4:10 p.m. N1.001: The Broader Autism Phenotype in Tuberous Sclerosis Complex Jamie K. Capal, MD, Cincinnati, OH 4:10 p.m.–4:25 p.m. Clinical Trials and Treatments in ASD: What Works and Why Trials Fail Evdokia Anagnastou, MD, Toronto, ON, Canada 4:25 p.m.–4:35 p.m. N1.002: Sulforaphane Treatment of Children with Autism Spectrum Disorder (ASD) – A Progress Report Andrew W. Zimmerman, MD, FAAN, Worcester, MA 4:35 p.m.–4:50 p.m. Updates in Autism Genetics: Clinical and Scientific Implications for Precision Medicine Faculty 4:50 p.m.–5:00 p.m. N1.003: Multi-Gene Panels vs. Diagnostic Exome Sequencing: A Comparison of Genetic Testing Options for Neurodevelopmental Disorders Jing Wang, MD, Aliso Viejo, CA 5:00 p.m.–5:30 p.m. Panel Discussion Faculty
2019 ANNUAL MEETING COURSE PROPOSAL SUBMISSIONS The AAN is seeking submissions for course proposals for the 2019 Annual Meeting. The submission deadline is May 18, 2018. Please visit aan.com/view/courseproposals for additional information and guidelines.
80 2018 AAN Annual Meeting
Frontiers in Child Neurology: Cultivating Careers, Networking, and Exploring a Neurologic Disorder Through a Lifespan—Focus on Autism Sunday, April 22
12:30 p.m.–6:00 p.m.
This exciting afternoon starts with a luncheon for medical students, residents, and fellows who are new to the field of child neurology. Afterwards, join leaders in child neurology for a Neuroscience in the Clinic session focused on autism, with presentations covering hot topics in the field to help clinicians have more informed discussions with their patients regarding biomarkers, clinical trials/treatments, and genetics. End the day with a networking reception for child neurologists before heading to the Opening Party.
Highlights
:
Careers in Child Neurology Luncheon— Ask the Experts
Neuroscience in the Clinic: Autism Mythbusters
Co-chairs: Ann H. Tilton, MD, FAAN, and Rujuta Bhatt, MD
Directors: Shafali Jeste, MD, and Sarah Spence, MD, PhD
Medical students and residents who are considering a career as a child neurologist will get a unique opportunity to meet with the experts and have their questions answered regarding a career as a child neurologist. Items discussed will include how different fellowships work, strategies for child neurology research, research funding, careers in child neurology education, and a discussion regarding careers in child neurology inthe community. This event is invite only.
Rapid advances in our understanding of the underlying neurobiology of autism spectrum disorder (ASD) has prompted more accurate and informed diagnoses, detailed prognostication, and the development of targeted treatment trials. However, these scientific achievements often become overshadowed by community practices that lack evidence or a scientific foundation, leaving patients and caregivers uncertain about best practices. The goal of this
session is to provide neurologists with clinically relevant scientific updates on autism spectrum disorders (ASD), in order to facilitate more informed dialogues with their patients. We will begin with a representative clinical case, followed by three presentations with paired abstracts on key topics in the autism field, including prediction and diagnostic biomarkers, clinical trials and therapeutics, and advances in genetics. Networking Reception The program will conclude with a wine and cheese reception allowing attendees an opportunity to network and talk with presenters.
NEUROSCIENCE IN THE CLINIC
NEUROSCIENCE IN THE CLINIC in the Clinic: N2 Neuroscience Antisense Oligonucleotide (ASO) Therapy Directors: John W. Day, MD, PhD; and Richard S. Finkel, MD
Program Description Ongoing clinical research has already identified the genetic cause of hundreds of distinct disorders, most notably in the area of neuromuscular neurology. While knowing the underlying genetic cause provides a clear target for course-modifying treatments, the ability to successfully and safely modify genes in the clinical world has remained difficult until very recently. After decades of development, technologies are now being successfully used to modify pathogenic mutations using antisense technologies. The faculty will discuss the range of antisense technologies now in clinical investigation, and the multiple methods by which they can alter expression of disease-causing mutations, focusing on current successes such as for spinal muscular atrophy, and future targets. Specific cases will be discussed to show how antisense technologies are being used clinically and how they will impact current and future care of neuromuscular disorders. Upon Completion Participants will be able to identify different antisense oligonucleotide chemistries and their relative values. They will understand the biodistribution and pharmacokinetics of some antisense oligonucleotides, and the various ways in which antisense oligonucleotides can impact normal and pathogenic gene expression. They will get an update on recently approved antisense treatments that are now commercially available, as well as those that are currently in development.
in the Clinic: N3 Neuroscience Challenges in Genetic Diagnosis in Neurology Directors: Guy A. Rouleau, MD, PhD; and Massimo Pandolfo, MD, FAAN
82 2018 AAN Annual Meeting
G
3:30 p.m.–5:30 p.m.
3:30 p.m.–3:35 p.m. Introduction John W. Day, MD, PhD, Palo Alto, CA 3:35 p.m.–3:50 p.m. Scientific Content on ASOs Frank Bennett, PhD, Carlsbad, CA 3:50 p.m.–4:05 p.m. Case Presentation Richard S. Finkel, MD, Orlando, FL 4:05 p.m.–4:20 p.m. Case Presentation John W. Day, MD, PhD, Palo Alto, CA 4:20 p.m.–4:30 p.m. Scientific Wrap-up of Case Presentation Treatments Frank Bennett, PhD, Carlsbad, CA 4:30 p.m.–4:45 p.m. N2.001: Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) Morie A. Gertz, MD, Rochester, MN 4:45 p.m.–5:00 p.m. N2.002: Stereopure Antisense Oligonucleotides Preferentially Knockdown G4C2 Repeat-Containing C9ORF72 Transcripts: A Potential Therapeutic Approach for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) Yuanjing Liu, PhD, Cambridge, MA 5:00 p.m.–5:30 p.m. Panel Discussion and Audience Q&A Faculty
NEUROSCIENCE IN THE CLINIC
Program Description Genetic testing is becoming increasingly prevalent and interpretation sometimes difficult. The program will consist of a presentation of a complex case, followed by discussion that will illustrate the science that led to the current state of the art, where it is expected to move, how this impacted practice, what are the unmet needs in the clinic. Upon Completion Participants should become familiar with the issues involved in the interpretation of genetic testing results, including the assessment of the potential pathogenicity of the identified genetic variants and their correlation with phenotype.
Monday, April 23
Tuesday, April 24
G
1:00 p.m.–3:00 p.m.
1:00 p.m.–1:10 p.m. Case Presentation Stefan M. Pulst, MD, FAAN, Salt Lake City, UT 1:10 p.m.–1:35 p.m. Clinical Discussion Stefan M. Pulst, MD, FAAN, Salt Lake City, UT 1:35 p.m.–2:00 p.m. Scientific Discussion Brent L. Fogel, MD, PhD, FAAN, Los Angeles, CA 2:00 p.m.–2:15 p.m. N3.001: Integrated Whole Exome Sequencing and Chromosomal Microarray in Familial Parkinson’s Disease Laurie Robak, MD, PhD, Houston, TX 2:15 p.m.–2:30 p.m. N3.002: Expanding the Genetic Spectrum of Congenital Sensory and Autonomic Neuropathies with Whole Exome Sequencing Jose-Alberto Palma, MD, PhD, New York, NY 2:30 p.m.–3:00 p.m. Panel Discussion Faculty
Wednesday, April 25
in the Clinic: Opioid Use N4 Neuroscience and Abuse: The Overlapping Neurobiology of Pain
and Addiction, and the Path Toward Better Treatments Directors: Jessica Robinson Papp, MD, FAAN; and Walter J. Koroshetz, MD, FAAN
Program Description Chronic pain and substance use disorders frequently co-exist and neurologists often feel ill-equipped to treat patients with these complex disorders. In this session we will travel from bench to bedside and beyond, exploring the neurobiology underlying pain and addiction, and the hope it brings for better treatments; hearing the patient’s perspective; and learning about governmental policy designed to improve the care of chronic pain patients while working to ameliorate the U.S. opioid epidemic. Upon Completion Participants will become familiar with central nervous system mechanisms underlying chronic pain and addiction and how knowledge of these mechanisms can inform drug discovery. Participants will also understand changes in public policy which effect neurologists and their patients with chronic pain, with a focus on the U.S. National Pain Strategy.
G
3:30 p.m.–5:30 p.m.
3:30 p.m.–3:35 p.m. Introduction Jessica Robinson Papp, MD, FAAN, New York, NY 3:35 p.m.–3:50 p.m. Patient Presentation: Use of Opioids in Complex Disease Elyse J. Singer, MD, Los Angeles, CA 3:50 p.m.–4:10 p.m. Neurobiology of Pain and Addiction Catherine Cahill, PhD, Los Angeles, CA 4:10 p.m.–4:30 p.m. N4.001: Association of OPRM1, OPRK1 and COMT Genes with Opioid Response Is Opioid and Pain Modality Specific Kwo Wei David Ho, MD, Gainesville, FL 4:25 p.m.–4:40 p.m. Clinical Follow-up and Discussion of National Pain Strategy Walter J. Koroshetz, MD, FAAN, Bethesda, MD 4:40 p.m.–4:55 p.m. N4.002: Provider Perspectives On Patient-Provider Communication Related to Opioid Use for Chronic Pain Allison P. Navis, MD, New York, NY 4:55 p.m.–5:10 p.m. Scientific Wrap-up and Link to Therapeutics Jessica Robinson Papp, MD, FAAN, New York, NY 5:10 p.m.–5:30 p.m. Panel Discussion, Questions and Answers, and Closing Remarks Faculty
AAN.com/view/AM18 83
NEUROSCIENCE IN THE CLINIC
NEUROSCIENCE IN THE CLINIC
NEUROSCIENCE IN THE CLINIC
NEUROSCIENCE IN THE CLINIC in the Clinic: N5 Neuroscience Treatment of Progressive Multiple Sclerosis Directors: Ellen M. Mowry, MD, FAAN; and Eric Klawiter, MD
Program Description Advances in the understanding of multiple sclerosis have opened up potential therapeutic targets, addressing a great need in progressive MS. Following a case presentation, faculty will discuss disease pathogenesis, biomarker development, and the latest clinical trial results with a focus of relating the recent discoveries in neuroscience in this area back to the bedside. Upon Completion Participants should become familiar with the pathogenesis of progressive multiple sclerosis and how to assess progressive multiple sclerosis. They should be equipped to improve their management of patients with progressive multiple sclerosis.
A New Frontier in Neuro-Inflammation
Directors: Andreas Felix Hottinger, MD; and Antonio M. P. Omuro, MD
84 2018 AAN Annual Meeting
G
1:00 p.m.–3:00 p.m.
1:00 p.m.–1:15 p.m. Progressive MS Case Presentation Faculty 1:15 p.m.–1:35 p.m. From Pathology to Pathogenesis of Progressive MS Gabriele C. De Luca, MD,PhD, Oxford, United Kingdom 1:35 p.m.–1:45 p.m. A Clinician’s Perspective of Progressive MS Jiwon Oh, MD, Toronto, ON, Canada 1:45 p.m.–2:00 p.m. Progress in Progressive MS Faculty 2:00 p.m.–2:15 p.m. N5.001: Continuous Wrist-Worn Accelerometry Captures Change in Average Daily Step Count in People with Multiple Sclerosis Over One Year Valerie A J Block, San Francisco, CA 2:15 p.m.–2:30 p.m. N5.002: Disease-specific Atrophy in Alzheimer’s Disease; An Approach to Identify Grey Matter Regions Linked to Neurodegeneration in MS Daniel Pelletier, MD, Los Angeles, CA 2:30 p.m.–3:00 p.m. Progressive MS Panel Discussion Faculty
in the Clinic: Neurologic N6 Neuroscience Complications of Cancer Immunotherapy: Program Description The use of anti-cancer immunotherapies has become widespread in oncology, and multiple agents spanning a variety of mechanisms of action are currently approved, including immune checkpoint inhibitors (anti-CTLA-4, PD-1 and PD-L1 antibodies), CAR-T cells therapy and dendritic cell vaccines. Many of these agents disrupt mechanisms involved in prevention of auto-immunity and maintenance of selftolerance, or have pro-inflammatory properties. As a result, a wide spectrum of neurologic inflammatory complications have emerged as potential, and at times life-threatening side effects, posing diagnostic and therapeutic challenges that neurologists will be required to address. In this course, the most common immunotherapy complications involving both the CNS and peripheral nervous system will be reviewed, including encephalitis, myelitis, peripheral neuropathies, radiculopathies, neuromuscular junction disorders and myopathy. The mechanisms underlying these side effects, as well as principles governing immune responses within the nervous system will be discussed, integrated with a review on diagnosis and clinical management. Upon Completion Participants should be able to recognize and treat neurologic complications of anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies and CAR-T cell therapies and understand the mechanisms of action of such agents, how they can translate into injury to the nervous system and how they can be reversed.
Thursday, April 26
G
3:30 p.m.–5:30 p.m.
3:30 p.m.–3:35 p.m. Introduction on Cancer Immunotherapy Antonio M. P. Omuro, MD, Miami, FL 3:35 p.m.–3:40 p.m. Case Presentation Bianca Santomasso, MD, New York, NY 3:40 p.m.–4:10 p.m. Neuroscience Background: The Peripheral and CNS Immune System: Physiology and Effects of Anti-Cancer Immunotherapies David A. Hafler, MD, FAAN, New Haven, CT 4:10 p.m.–4:30 p.m. Clinical Implications Bianca Santomasso, MD, New York, NY 4:30 p.m.–4:40 p.m. Future Directions Antonio M. P. Omuro, MD, Miami, FL 4:40 p.m.–4:55 p.m. N6.001: Neurologic Immune Related Adverse Events (irAEs) in Patients with Metastatic Solid Tumors Treated with Immune Checkpoint Inhibitors: A Single Institution Retrospective Analysis Rachna Malani, MD, New York, NY 4:55 p.m.–5:10 p.m. N6.002: Immune-mediated Necrotizing Myositis in Patients Receiving Immune Checkpoint Inhibitors: Clinical and Histopathological Features, Treatment and Outcome Mehdi Touat, Paris, France 5:10 p.m.–5:25 p.m. Abstracts Discussion and Implications for Clinical Practice Andreas Felix Hottinger, MD, Lausanne, Switzerland 5:25 p.m.–5:30 p.m. Panel Discussion/Questions and Answers Faculty
Friday, April 27
in the Clinic: N7 Neuroscience REM Sleep Behavior Disorder: Past, Present, Future Directors: Aleksandar Videnovic, MD, MSc, FAAN; and Phyllis C. Zee, MD, PhD
Program Description REM sleep behavior disorder (RBD) is a parasomnia characterized by dream enactment in the context of loss of physiological atonia during REM sleep. RBD is of particular importance to neurosciences as it is one of the earliest manifestations of α-synuclein related neurodegeneration. Over 80% of patients with idiopathic RBD eventually develop Parkinson’s disease, dementia with Lewy body or multiple system atrophy. This program with highlight clinical aspects of the disorder, its historical perspective, as well as novel findings related to the pathophysiology of the disorder and its relationship with neurodegenerative disorders. Upon Completion Participants should be able to recognize clinical characteristics, diagnosis, differential diagnosis, and treatment of RBD; understand novel advances in the pathophysiology of RBD; and discuss the association between RBD and α-synucleinopathies.
G
3:30 p.m.–5:30 p.m.
3:30 p.m.–3:35 p.m. Introduction Aleksandar Videnovic, MD, MSc, FAAN, Boston, MA 3:35 p.m.–3:45 p.m. Case Presentation Roneil Malkani, MD, Chicago, IL 3:45 p.m.–4:00 p.m. RBD – Historical Perspective Carlos H. Schenck, MD, Minneapolis, MN 4:00 p.m.–4:15 p.m. RBD – Diagnostic and Treatment Challenges Aleksandar Videnovic, MD, MSc, FAAN, Boston, MA 4:15 p.m.–4:30 p.m. RBD – Control of Muscle Tone Across the Sleep-Wake Cycle and in Narcolepsy Jerome Siegel, PhD, Los Angeles, CA 4:30 p.m.–4:45 p.m. N7.001: Diagnostic Yield of REM Sleep Muscle Activity for Presumed Synucleinopathy Neurodegeneration Stuart McCarter, MD, Rochester, MN 4:45 p.m.–5:00 p.m. N7.002: Nocturnal REM Sleep Without Atonia is a Diagnostic Biomarker of Pediatric Narcolepsy Kiran Prasad Maski, MD, Boston, MA 5:00 p.m.–5:30 p.m. Panel Discussion Faculty
AAN.com/view/AM18 85
NEUROSCIENCE IN THE CLINIC
NEUROSCIENCE IN THE CLINIC
NEW AT 2018 ANNUAL MEETING
New for 2018 Medical Student Symposium: Careers in Neurology Sunday, April 22, 2018 12:30 p.m.–5:30 p.m.
Attend this half-day event to explore the exciting opportunities that a career in neurology can offer. This program is specifically designed for medical students to attend and discover their career potential as well as network with other students.
Young Investigators Programming Saturday, April 21–Monday, April 23, 2018
Support your budding career in research with training and mentoring specifically for medical students and residents. Components include training, mentoring, and networking designed to address the specific needs of pre- and early-career researchers.
Visit www.aan.com/view/StudentsRF to learn more about these programs.
INVITED SCIENCE SESSIONS
A
n AAN platform session featuring authors giving encore presentations of top abstracts previously presented at a subspecialty meeting.
Tuesday, April 24 1:00 p.m.–3:00 p.m.
Invited Science: Movement Disorders . . . . . . . . . . . 88
Wednesday, April 25 3:30 p.m.–5:30 p.m.
Invited Science: Sleep . . . . . . . . . . . . . . . . . 89
Thursday, April 26 1:00 p.m.–2:30 p.m.
Invited Science: The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative . . . . . . . . . . . . . . . . . . . 89 3:30 p.m.–5:30 p.m.
Invited Science: Neuro Trauma . . . . . . . . . . . . . . 90
AAN.com/view/AM18 87
INVITED SCIENCE SESSIONS
INVITED SCIENCE SESSIONS Invited Science: Movement Disorders Tuesday, April 24 1:00 p.m.–3:00 p.m.
G
Top abstracts previously presented at the Movement Disorders Society Annual Meeting will be presented by their authors. Select abstracts from their “best of” lineups emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of movement disorders with the overall goal of developing more effective prevention and treatment. This session is being presented in partnership with the International Parkinson and Movement Disorder Society. 1:00 p.m.–1:20 p.m.
2:00 p.m.–2:20 p.m.
Tissue Engineered Nigrostriatal Pathway for Treatment of Parkinson’s Disease John E. Duda, MD
Results From A Phase 1b Multiple Ascending-dose Study of prx002, An Anti–alpha-synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease Joseph Jankovic, MD, FAAN
Veterans Affairs Medical Center, Philadelphia, PA
1:20 p.m.–1:40 p.m.
Baylor College of Medicine, Houston, TX
Which Clinical Features Predict Progressive Supranuclear Palsy Pathology? A Clinicopathological Study on 437 Autopsy Cases and A Literature Review Gesine Respondek, MD
2:20 p.m.–2:40 p.m.
1:40 p.m.–2:00 p.m.
2:40 p.m.–3:00 p.m.
Skin Nerve Phosphorylated a-synuclein Deposits in Idiopathic REM Sleep Behavior Disorder Elena Antelmi, MD
Exercise Alters Response of Reward Anticipation in the Ventral Striatum of Subjects with Parkinson’s Disease Matthew Sacheli
Technische Universität München, Munich, Germany
University of Bologna, Bologna, Italy
88 2018 AAN Annual Meeting
The Effect of Early STN-DBS in PD Patients on Axial Symptoms: a 2-year Randomized Controlled Trial (EARLYSTIM-Gait Analysis) Michael Barbe, MD University Hospital Köln, Köln, Germany
Pacific Parkinson’s Research Centre, Vancouver, BC, Canada
G
Wednesday, April 25 3:30 p.m.–5:30 p.m.
Top abstracts previously presented at the American Academy of Sleep Medicine/Sleep Research Society Annual Meeting will be presented by their authors. Select abstracts from their “best of” lineups emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of sleep disorders with the overall goal of developing more effective prevention and treatment. This session is being presented in partnership with the American Academy of Sleep Medicine and the Sleep Research Society. 3:30 p.m.–3:50 p.m.
4:30 p.m.–4:50 p.m.
Recurrent Circuitry for Balancing Sleep Need Jeffrey Donlea, PhD
Sleep Loading Improves Visual Search Response Time and Reduces Fatigue in Professional Baseball Players Cheri D. Mah, MS
UCLA, David Geffen School of Medicine, Los Angeles, CA
3:50 p.m.–4:10 p.m.
A Circuit For the Circadian Control of Aggression W illiam D. Todd, PhD Beth Israel Deaconess Medical Center, Boston, MA
4:10 p.m.–4:30 p.m.
Direct Electrical Stimulation to the Human Amygdala Enhances Recognition Memory Following Sleep Jon T. Willie, MD, PhD Emory University, Atlanta, GA
niversity of California San Francisco Human Performance Center, San U Francisco, CA
4:50 p.m.–5:10 p.m.
S leep While On-Call Overnight Does Not Restore Performance Among First-Year Resident Physicians Melissa A. St. Hilaire, PhD Brigham and Women’s Hospital, Boston, MA
5:10 p.m.–5:30 p.m.
The Role of Nightly Zopiclone on Obstructive Sleep Apnea Severity and Symptoms in People with Low to Moderate Respiratory Arousal Thresholds: A Randomized, Double-Blind, Placebo-Controlled Trial Sophie Carter NeuRA, Randwick, Australia
Invited Science: The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative Thursday, April 26 1:00 p.m.–2:30 p.m.
G
This program will feature the latest findings from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, a large-scale effort aimed at revolutionizing our understanding of the human brain. Launched in 2013 by President Obama as a “moonshot to explore the frontiers of the mind,” this program seeks development of the technologies and insights to facilitate treatment, cure, and prevention of brain disorders. This session is being presented in partnership with the National Institutes of Health. 1:05 p.m.–1:25 p.m.
1:45 p.m.–2:05 p.m.
Full-scale Neuronal Network Modeling of Spatial Learning and Memory in Hippocampus Ivan Soltesz, PhD
Defining Cell Types, Lineage, and Connectivity in Developing Human Cortex Faculty
Stanford University School of Medicine, Stanford, CA
1:25 p.m.–1:45 p.m.
Non-degenerate multiphoton microscopy for deep brain imaging Anna Devor, PhD University of California, San Diego, San Diego, CA
2:05 p.m.–2:25 p.m.
Using Tissue Clearing and Optogenetics to Dissect the Circuitry Underlying Neurological Disorders Viviana Gradinaru, PhD California Institute of Technology, Pasadena, CA
AAN.com/view/AM18 89
INVITED SCIENCE SESSIONS
Invited Science: Sleep
INVITED SCIENCE SESSIONS
INVITED SCIENCE SESSIONS Invited Science: Neuro Trauma
Thursday, April 26 3:30 p.m.–5:30 p.m.
G
Key talks previously given at the National Neurotrauma Society Annual Meeting will be presented during this session. Speakers will emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of neurotrauma with the overall goal of developing more effective treatments. This session is being presented in partnership with the National Neurotrauma Society. 3:30 p.m.–4:10 p.m.
4:50 p.m.–5:10 p.m.
Operation Brain Trauma Therapy Consortium Patrick M. Kochanek, MD, MCCM
The Invisible Wounds of War: Combat Concussions Christine MacDonald, PhD
4:10 p.m.–4:30 p.m.
5:10 p.m.–5:30 p.m.
The Glymphatic System: Role in Post-TBI Edema? Miranda M. Lim, MD, PhD
Intestinal Dysfunction Following TBI: Lessons from Drosophila David Wassarman, PhD
University of Pittsburgh, Pittsburgh, PA
Washington University School of Medicine, Saint Louis, MO
Oregon Health & Science University, Portland, OR
University of Wisconsin-Madison, Madison, WI
4:30 p.m.–4:50 p.m.
Hormonal Alterations and Sleep Following Brain Injury Faculty
MEM: 17 Membership Continuum Ad—Half Page Horizontal> AN Placed in AANnews, Early 8.25 x 5.25 +0.125 bleed, 4C
Essential Education. Incomparable Support. That’s AAN Membership. Only an AAN membership provides a single source for all the tools and resources you need to thrive throughout your professional lifetime.
See the full listing of exclusive member benefits and apply or renew AAN.com/membership
“BEST OF” SCIENTIFIC PLATFORM SESSIONS
A
platform session that brings together the top four scoring abstracts in a topic, as rated by the topic reviewers. Interact with the authors in a smaller, more intimate setting at the conclusion of the session. These “Best of” sessions are the perfect lead-in to the plenary sessions that immediately follow.
Sunday, April 22 8:00 a.m.–9:00 a.m.
S1 “Best of” Session: Cerebrovascular Disease and
Interventional Neurology . . . . . . . . . . . . . 92
Monday, April 23 8:00 a.m.–9:00 a.m.
S11 “Best of” Session: Epilepsy/Clinical Neurophysiology (EEG)92
Tuesday, April 24 8:00 a.m.–9:00 a.m.
S20 “Best of” Session: Headache . . . . . . . . . . . . 92
Wednesday, April 25 8:00 a.m.–9:00 a.m.
S27 “Best of” Session: Movement Disorders . . . . . . . . 93
Thursday, April 26 8:00 a.m.–9:00 a.m.
S38 “Best of” Session: Clinical Trial Updates
in Neuromuscular Disorders . . . . . . . . . . . . 93
Friday, April 27
8:00 a.m.–9:00 a.m.
S47 “Best of” Session: MS and CNS Inflammatory Diseases . 93
AAN.com/view/AM18 91
“BEST OF” SCIENTIFIC PLATFORM SESSIONS
“BEST OF” SCIENTIFIC PLATFORM SESSIONS Sunday, April 22
Monday, April 23
Tuesday, April 24
8:00 a.m.–9:00 a.m.
8:00 a.m.–9:00 a.m.
8:00 a.m.–9:00 a.m.
S1 “Best of” Session: Cerebrovascular
Disease and Interventional Neurology
8:00 a.m.
G
S1.001
Minocycline Protects against Delayed Cerebral Ischemia after Subarachnoid Hemorrhage via Matrix Metalloproteinase-9 Inhibition —Glenn Harris, Ananth
Vellimana, Meng-Liang Zhou, Itender Singh, Diane Aum, James Nelson, Umeshkumar Athiraman, ByoungJun Han, Gregory Zipfel
8:08 a.m.
S1.002
Genome-Wide Association Study of Hematoma Volume Identifies 17p12 as a Novel Susceptibility Locus for Severity and Outcome in Intracerebral Hemorrhage —Sandro Marini, William J. Devan, Farid Radmanesh,
Laura Miyares, Timothy Poterba, Bjorn Hansen, Bo Norrving, Eva Giralt-Steinhauer, Jordi Jimenez-Conde, Roberto Elosua, Elisa Cuadrado-Godia, Carolina Soriano, Jaume Roquer Gonzalez, Christina Kourkoulis, Alison Ayres, Kristin Schwab, David Tirschwell, Magdy Selim, Devin Brown, Scott Silliman, Bradford Worrall, James Meschia, Chelsea Kidwell, Joan Montaner, Israel Fernandez-Cadenas, Pilar Delgado, Steven Greenberg, Arne Lindgren, Charles Matouk, Kevin Sheth, Daniel Woo, Christopher Anderson, Jonathan Rosand, Guido Falcone
8:16 a.m.
S1.003
Association of prothrombin complex concentrates administration and hematoma enlargement in NOACrelated intracerebral hemorrhage —Stefan Gerner, Stefan Schwab, Hagen Huttner
8:24 a.m.
S1.004
Left Atrial Endothelial Dysfunction, Inflammation and Fibrosis Induced by Selective Insular Cortex Ischemic Stroke in Rats —Brittany Balint, Victoria Thorburn, Victoria Jaremek, Maryse Paquet, Shawn Whitehead, Luciano Sposato
8:32 a.m. Panel Discussion/Meeting the Investigators
92 2018 AAN Annual Meeting
S11 “Best of” Session: Epilepsy/Clinical Neurophysiology (EEG)
8:00 a.m.
G
S11.001
Maintaining Seizure Freedom during Pregnancy and Postpartum: Findings from the MONEAD Study —Page
Pennell, Jacqueline French, Ryan May, Elizabeth Gerard, Laura Kalayjian, Evan Gedzelman, Patricia Penovich, Jennifer Cavitt, Sean Hwang, Alison Pack, Maria Sam, Eugene Moore, Dominic Ippolito, Kimford Meador
8:08 a.m.
S11.002
A Practical Risk Score for EEG Seizures in Hospitalized Patients —Aaron Struck, Berk Ustun, Andres Rodriguez-Ruiz,
Jong Lee, Suzette LaRoche, Lawrence Hirsch, Emily Gilmore, Jan Vlachy, Hiba Haider, Cynthia Rudin, M. Westover
8:16 a.m.
S11.003
Seizure Semiologies and Effects of Anti-epileptic Drugs in Patients with Leucine-rich glioma-inactivated-1 ligand antibody (LGI1-Ab) Autoimmune Epilepsy —Christopher Lamb,
Jeffrey Britton, Sean Pittock, Avi Gadoth, Andrew McKeon, Christopher Klein, Anteneh Feyissa
8:24 a.m.
S11.004
Interictal Spike Rates Are Correlated with Verbal Memory in Patients with Mesial Temporal Lobe Epilepsy —Kimford Meador, David Loring, Tara Crowder Skarpaas, Martha Morrell
8:32 a.m. Panel Discussion/Meet the Investigators
S20 “Best of” Session: Headache
8:00 a.m.
G
S20.001
Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episodic Migraines —Joel Saper, Richard Lipton, David Kudrow, Joe Hirman, David Dodick, Stephen Silberstein, George Chakhava, Jeff Smith
8:08 a.m.
S20.002
Alterations in regional cerebral blood flow during the premonitory stage of nitroglycerin-triggered migraine attacks, assessed with arterial spin-labelled fMRI —Nazia Karsan, Pyari Bose, Fernando Zelaya, Peter Goadsby
8:16 a.m.
S20.003
Untangling the burden of menstrual migraine from headache day frequency: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study —Jelena Pavlovic, Michael Reed, Kristina Fanning, Sagar Munjal, Aftab Alam, Todd Schwedt, David Dodick, Dawn Buse, Richard Lipton
8:24 a.m.
S20.004
Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies —Qi Zhang, Dustin Ruff, Eric Pearlman, Sriram Govindan, Sheena K. Aurora
8:32 a.m. Panel Discussion/Meet the Investigators
Thursday, April 26
Friday, April 27
8:00 a.m.–9:00 a.m.
8:00 a.m.–9:00 a.m.
8:00 a.m.–9:00 a.m.
S27 “Best of” Session: Movement Disorders
8:00 a.m.
G
S27.001
Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations —Charles Adler, Thomas
Beach, Nan Zhang, Holly Shill, Erika Driver-Dunckley, John Caviness, Shyamal Mehta, Marwan Sabbagh, Geidy Serrano, Lucia Sue, Christine Belden, Jessica Powell, Sandra Jacobson, Edward Zamrini, David Shprecher, Kathryn Davis, Brittany Dugger, Joseph Hentz
8:08 a.m.
S27.002
Exenatide Modulates Neuronal Insulin Signalling in Parkinson’s Disease —Dilan Athauda, Seema Gulyani, Hanuma
Karnati, Yazhou Li, David Tweedie, Simon Skene, Kashfia Chowdhury, Nigel Greig, Dimitrios Kapogiannis, Thomas Foltynie
8:16 a.m.
S27.003
Sensitivity and Specificity of Clinical Criteria for 4-Repeat Tauopathies in Autopsy-Confirmed Cases —Jessica
Weinstein, David Irwin, John Trojanowski, Pouya Khankhanian, Murray Grossman, Corey McMillan
8:24 a.m.
S27.004
Multiple Ascending Dose Study of the Tau-Directed Monoclonal Antibody BIIB092 in Patients with Progressive Supranuclear Palsy —Adam Boxer, Irfan Qureshi, Michael Grundman, Giridhar S. Tirucherai, Clifford Bechtold, Michael Ahlijanian, Gerry Kolaitis, Lawrence Golbe, Lawrence Honig, Stuart Isaacson, Murray Grossman, Nikolaus McFarland, Irene Litvan, David Geldmacher, Tao Xie, Yvette Bordelon, Paul Tuite, Padraig O’Suilleabhain, Theresa Zesiewicz
S38 “Best of” Session: Clinical Trial
Updates in Neuromuscular Disorders
8:00 a.m.
G
S38.001
Preliminary Results from a Phase 2 Study to Evaluate ACE-083, a Local Muscle Therapeutic, in Patients with Facioscapulohumeral Muscular Dystrophy —Jeffrey
Statland, Anthony Amato, Elena Bravver, Craig Campbell, Lauren Elman, Nicholas Johnson, Nanette Joyce, Chafic Karam, John Kissel, Lawrence Korngut, Erin O’Ferrall, Georgios Manousakis, Alan Pestronk, Perry Shieh, Alrabi Tawil, Ashley Leneus, Barry Miller, Matthew Sherman, Chad E Glasser, Kenneth Attie
8:08 a.m.
S38.002
NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains —Ralph Kern, Merit Cudkowicz, James Berry, Anthony Windebank, Nathan Staff, Margaret Owegi, Chaim Lebovits, Yael Gothelf, Robert Brown
8:16 a.m.
S38.003
Long-Term Efficacy and Safety of Bimagrumab in Inclusion Body Myositis: 2 Years Results —Anthony Amato, Lixin ZhangAuberson, Michael Hanna, Umesh Badrising, Merrilee Needham, Hector Chinoy, Masashi Aoki, Barbara Koumaras, Laszlo Tanko, Min Wu, Dimritris Papanicolaou, Olivier Benveniste
8:24 a.m.
S38.004
Randomized Phase 2B trial of NP001, a Novel Immune Regulator, in ALS —Robert Miller, Jonathan Katz, Gilbert Block, NP001-10-003 Study Group
8:32 a.m. Panel Discussion/Meet the Investigators
S47 “Best of” Session: MS and
CNS Inflammatory Diseases
8:00 a.m.
G
S47.001
Longitudinal Changes in Quantitative Spinal Cord MRI in Multiple Sclerosis Patients: Results of a 5-year
Study —Jiwon Oh, Kateryna Cybulsky, Min Chen, Suradech
Suthiphosuwan, Estelle Seyman, Aaron Carass, Marie Diener-West, Peter Van Zijl, Jerry Prince, Daniel Reich, Peter Calabresi
8:08 a.m.
S47.002
Effect of Age at Puberty on Risk of Multiple Sclerosis: A Mendelian Randomization Study —Adil Harroud, John
A. Morris, Vincenzo Forgetta, Ruth Mitchell, George Davey Smith, Stephen Sawcer, J. Brent Richards
8:16 a.m.
S47.003
Longitudinal assessment of rates of brain and retinal atrophy in African American versus Caucasian American patients with Multiple Sclerosis —Natalia Gonzalez Caldito,
Shiv Saidha, Elias Sotirchos, Blake Dewey, Norah Cowley, jeffrey Glaister, Kathryn Fitzgerald, James Nguyen, Alissa Rothman, Esther Ogbuokiri, Dorlan Kimbrough, Teresa Frohman, Elliot Frohman, Laura Balcer, Ciprian Crainiceanu, Dzung Pham, Jerry Prince, Peter Calabresi
8:24 a.m.
S47.004
Meta-Analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments —Ann Weideman, Marco Tapia-Maltos, Kory Johnson, Mark Greenwood, Bibiana Bielekova
8:32 a.m. Panel Discussion/Meet the Investigators
8:32 a.m. Panel Discussion/Meet the Investigators
= Abstract of Distinction
AAN.com/view/AM18 93
“BEST OF” SCIENTIFIC PLATFORM SESSIONS
Wednesday, April 25
Annual Meeting Edition
Earn 10 free self-assessment CME credits and receive help planning your 2018 Annual Meeting itinerary Post-test
Pre-test Annual Meeting Take pre-test before
Take post-test before
April 21, 2018
July 27, 2018
Attend Annual Meeting
April 21–27, 2018
Assess your strengths and compare your performance to other neurologists with this ABPN-approved program— available on the Annual Meeting App!
AAN.com/view/NeuroSAEAM
SCIENTIFIC PLATFORM SESSIONS
T
hese popular sessions feature a group of abstracts covering a similar topic presented in an oral format. Format will feature eight-minute presentation followed by four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Sunday, April 22 1:00 p.m.–3:00 p.m.
S2 Clinical Trials and Therapeutic Approaches in S3 S4 S5 S6
Neurodegenerative Diseases . . . . . . . . . . . . 96 Movement Disorders: Parkinson’s Disease: Genetics, Biomarkers, and Diagnosis . . . . . . . . . . . . . 96 Neuroepidemiology: Neurodegeneration, Epilepsy, Cerebrovascular Disease Risks . . . . . . . . . . . 97 General Neurology: Advances in Neurotherapeutics . . 97 MS Neuroimaging . . . . . . . . . . . . . . . . 97
3:30 p.m.–4:30 p.m.
S7 Pain and Palliative Care . . . . . . . . . . . . . . 98 3:30 p.m.–5:30 p.m.
S8 Progressive MS Therapies and Age-Dependent
Factors in MS Therapy . . . . . . . . . . . . . . 98 S9 Epilepsy/Clinical Neurophysiology (EEG) I . . . . . . . 98 S10 Intracerebral and Subarachnoid Hemorrhage . . . . . 99
Monday, April 23 1:00 p.m.–2:15 p.m.
S12 Autonomic Disorders . . . . . . . . . . . . . . . 100 1:00 p.m.–3:00 p.m.
S13 Neuromyelitis Optica Spectrum Disorder and Other
Autoimmune Disorders . . . . . . . . . . . . . . 100
S14 Education and Patient Outcomes Research . . . . . . 101 S15 Cerebrovascular Disease Epidemiology and Outcomes . 101 S16 Neuro-ophthalmology/Neuro-otology . . . . . . . . 101 3:30 p.m.–5:30 p.m.
S17 Sleep . . . . . . . . . . . . . . . . . . . . . 102 S18 Movement Disorders: Ataxia and Tremor . . . . . . 102 S19 Epilepsy/Clinical Neurophysiology (EEG) II . . . . . . 102
Tuesday, April 24 1:00 p.m.–3:00 p.m.
S21 Revascularization in Acute Ischemic Stroke . . . . . 104 S22 Advances in Muscular Dystrophy and Congenital
Myopathy . . . . . . . . . . . . . . . . . . . 104 S23 Biologic and Clinical Discoveries in Neuro-oncology . . 105 3:30 p.m.–5:30 p.m.
S24 MS Outcome Measures and Biomarkers . . . . . . . 106 S25 Advances in Amyotrophic Lateral Sclerosis . . . . . 106 S26 Movement Disorders: Parkinson’s Disease Clinical Trials 106
Wednesday, April 25 1:00 p.m.–2:00 p.m.
S28 Practice, Policy, and Ethics . . . . . . . . . . . . 108 1:00 p.m.–3:00 p.m.
S29 Child Neurology and Developmental Neurology I . . . 108 S30 Movement Disorders: Dystonia, Chorea, and other Disorders . . . . . . . . . . . . . . . . . . . 109
S31 Therapeutics, Phenotypes, and Biomarkers in
Neuromuscular Disorders . . . . . . . . . . . . . 109
S32 Headache: Therapeutics . . . . . . . . . . . . . 109 3:30 p.m.–4:15 p.m.
S33 Global Health . . . . . . . . . . . . . . . . . . 110 3:30 p.m.–5:30 p.m.
S34 Behavioral andCognitive Neurology . . . . . . . . . 110 S35 Child Neurology and Developmental Neurology II . . . 110 S36 MS Therapeutics and Clinical Research . . . . . . . 111 4:30 p.m.–5:30 p.m.
S37 Neurorehabilitation . . . . . . . . . . . . . . . 111
Thursday, April 26 1:00 p.m.–2:15 p.m.
S39 History of Neurology . . . . . . . . . . . . . . . 112 1:00 p.m.–3:00 p.m.
S40 Acute Stroke Care . . . . . . . . . . . . . . . . 112 S41 Neurologic Infections . . . . . . . . . . . . . . 113 S42 Neurocritical Care . . . . . . . . . . . . . . . . 113 3:30 p.m.–5:30 p.m.
S43 Migraine . . . . . . . . . . . . . . . . . . . 114 S44 MS Risk Factors, Susceptibility, Diagnosis, and Cognitive Impairment . . . . . . . . . . . . . . 114 S45 Movement Disorders: Parkinsonian Disorders, Basic Science, and Imaging . . . . . . . . . . . . . . 114 S46 Advances in Spinal Muscular Atrophy . . . . . . . . 115
Friday, April 27
1:00 p.m.–3:00 p.m.
S48 S49 S50 S51
Novel Biomarkers inAging and Dementia . . . . . . 116 Neuro Trauma andSports Neurology . . . . . . . . 116 Updates in General Neurology . . . . . . . . . . . 117 Pediatric MS . . . . . . . . . . . . . . . . . . 117
3:30 p.m.–5:30 p.m.
S52 MS and CNS Inflammatory Disease: Basic Science . . 117 S53 Epilepsy/Clinical Neurophysiology (EEG) III . . . . . . 118 S54 Ischemic Stroke Prevention . . . . . . . . . . . . 118
AAN.com/view/AM18 95
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S1 “Best of” Session: Cerebrovascular
Disease and Interventional Neurology
Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 92 »
1:00 p.m.–3:00 p.m.
G
S2 Clinical Trials and Therapeutic Approaches in Neurodegenerative Diseases
1:00 p.m.–3:00 p.m.
G
1:00 p.m. Potamkin Prize for Research in
Pick’s, Alzheimer’s, and Related Diseases T his award recognizes major contributions to the understanding
of the cause, prevention, treatment of, and ultimately the cure for Pick’s, Alzheimer’s, and related diseases.
Recipient:
David A. Bennett, MD Chicago, IL
1:24 p.m.
S2.003
Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebocontrolled Phase 1b study in patients with prodromal or mild Alzheimer’s disease —Sebastian Von Rosenstiel, Sarah Gheuens, Tianle Chen, John O’Gorman, Ping Chiao, Guanfang Wang, Christian Von Hehn, LeAnne Skordos, Christoph Hock, Roger Nitsch, Samantha Budd Haeberlein, Alfred Sandrock
1:36 p.m.
S2.004
Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease —Samantha Budd Haeberlein, Sarah Gheuens, Tianle Chen, John O’Gorman, Sebastian Von Rosenstiel, Ping Chiao, Guanfang Wang, Christian Von Hehn, LeAnne Skordos, Christoph Hock, Roger Nitsch, Alfred Sandrock
1:48 p.m.
S2.005
Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden - Results for the Marguerite and Scarlet Road Open Label Extension Studies —Gregory Klein,
Paul Delmar, Carsten Hofmann, Mirjana Adjelkovic, Danielle Abi-Saab, Smiljana Milosavljevic-Ristic, Monika Baudler, Paulo Fontoura, Rachelle Doody
2:00 p.m.
S2.006
Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease —Laurence Mignon, Holly Kordasiewcz, Roger
Sunday
Lane, Anne Smith, Timothy Miller, Padma Narayanan, Eric Swayze, Daniel Norris, Bethany Fitzsimmons, Frank Bennett
2:12 p.m.
S2.007
SIAXI: Efficacy and safety of Xeomin (incobotulinumtoxinA) for the treatment of sialorrhea in Parkinson’s disease (PD) and other neurological conditions: Results of a Phase III, placebo-controlled, randomized, double-blind study —
S3 Movement Disorders: Parkinson’s Disease: Genetics, Biomarkers, and Diagnosis
1:00 p.m.
G
S3.001
Validation of the MDS Clinical Diagnostic Criteria for Parkinson’s Disease —Ronald Postuma, Werner Poewe, Irene
Litvan, Simon Lewis, Anthony Lang, Glenda Halliday, Christopher Goetz, Piu Chan, Elizabeth Slow, Klaus Seppi, Eva Schaeffer, Daniela Berg, Silvia Rios Romenets, Taomian Mi, Corina Maetzler, Yuan Li, Beatrice Heim, Ian Bledsoe
1:12 p.m.
S3.002
Application of the Movement Disorder Society Prodromal Criteria in healthy G2019S-LRRK2 carriers —Anat Mirelman, Rachel Saunders-Pullman, Roy Alcalay, Shiran Shustak, Avner Thaler, Deborah Raymond, Helen Mejia Santana, Martha Orbe-Reilly, Laurie Ozelius, Lorraine Clark, Mali Gana-Weiss, Anat Bar-Shira, Avi OrrUrtreger, Susan Bressman, Karen Marder, Nir Giladi
1:24 p.m.
S3.003
Features of GBA-associated Parkinson’s disease at presentation in the United Kingdom Tracking Parkinson’s study —Naveed Malek, Rimona Weil, Catherine Bresner, Lawton
Michael, Katherine Grosset, Manuela Tan, Nin Bajaj, Roger Barker, David Burn, Thomas Foltynie, John Hardy, Nicholas Wood, Yoav BenShlomo, Nigel Williams, Donald Grosset, Huw Morris
1:36 p.m.
S3.004
Genetic risk variants for Parkinson’s disease (PD) and cognitive impairment in four clinical PD subtypes —Angela
Deutschlander, Takuya Konno, Alexandra Soto-Ortolaza, Maryam Ossi, Audrey Strongosky, Michael Heckman, Ryan Uitti, Jay Van Gerpen, Owen Ross, Zbigniew Wszolek
1:48 p.m.
S3.005
Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia —Fernando Pagan, Michaeline Hebron, Yasar TorresYaghi, Abigail Keys, James Starr, Elizabeth Mundel, Nadia Yusuf, Myrna Arellano, Barbara Wilmarth, Charbel Moussa
2:00 p.m.
S3.006
Tear Proteins as Possible Biomarkers for Parkinson’s Disease —Danielle Feigenbaum, Mark Lew, Srikanth Janga, Mihir Kunjeshkumar Shah, Wendy Mack, Curtis Okamoto, Sarah HammAlvarez
2:12 p.m.
S3.007
Automatic Detection of ON/OFF states in Parkinson Disease Patients Using Wearable Sensor Technology —Vibha Anand,
Wolfgang Jost, Andrzej Friedman, Olaf Michel, Birgit Flatau-Baque, Janos Csikós, Andrew Blitzer
Erhan Bilal, Vesper Ramos, Melissa Naylor, Charmaine Demanuele, Hao Zhang, Stephen Amato, Paul Wacnik, Farhan Hameed, Tairmae Kangarloo, Bryan Ho, Michael Erb, Daniel Karlin
2:24 p.m.
2:24 p.m.
S2.008
The Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL) North American Rare Disease Clinical Research Consortium: Progress and Participant Characterization —Adam Boxer, Howard Rosen, Bradley
Boeve, Hilary Heuer, Murray Grossman, Giovanni Coppola, Bradford Dickerson, Brian Appleby, Yvette Bordelon, Danielle Brushaber, Christina Dheel, Kimiko Domoto-Reilly, Kelley Faber, Howard Feldman, Julie Fields, Jamie Fong, Tatiana Foroud, Nupur Ghoshal, Neill GraffRadford, Ging-Yuek Hsiung, Edward Huey, David Irwin, Kejal Kantarci, Daniel Kaufer, Diana Kerwin, Alex Klein, David Knopman, John Kornak, Irene Litvan, Codrin Lungu, Ian R.A. Mackenzie, Mario Mendez, Bruce Miller, Chiadi Onyike, Alexander Pantelyat, Madeline Potter, Rosa Rademakers, Eliana Marisa Ramos, Katya Rascovsky, Erik Roberson, Margaret Sutherland, Carmela Tartaglia, Nadine Tatton, Arthur Toga, Sandra Weintraub, Zbigniew Wszolek
2:35 p.m.
96 2018 AAN Annual Meeting
Sunday, April 22
Discussion
S3.008
Glucose dysregulation in Parkinson’s disease: a controlled cross-sectional study —Ana Marques, Frédéric Dutheil, Elodie Durand, Isabelle Rieu, Aurelien Mulliez, Maria Livia Fantini, Yves Boirie, Franck Durif
2:35 p.m.
Discussion
S4 Neuroepidemiology: Neurodegeneration, Epilepsy, Cerebrovascular Disease Risks
1:00 p.m.–3:00 p.m.
G
1:00 p.m. Bruce S. Schoenberg
International Award in Neuroepidemiology I n tribute to Dr. Schoenberg’s career in training neurologists
internationally in epidemiologic methods, this award salutes a young investigator selected from a developing country or Eastern Europe.
Recipient:
Fred Sarfo, MD, PhD Kumasi , Ghana
1:24 p.m.
S4.003
Pre-diagnostic Plasma Polyunsaturated Fatty Acids and the Risk of Amyotrophic Lateral Sclerosis —Eilis
O’Reilly, Kjetil Bjornevik, Marjorie McCullough, Larry Kolonel, Loic Le Marchand, JoAnn Manson, Alberto Ascherio
1:36 p.m.
S4.004
The influence of genetic mutations on the multistep process in ALS —Adriano Chio, Andrea Calvo, Letizia Mazzini, Sandra D’Alfonso, Maura Brunetti, Marco Barberis, Orla Hardiman, James Rooney, Jan Veldink, Neil Pearce, William Sproviero, Leonard Van den Berg, Ammar Al-Chalabi
1:48 p.m.
S4.005
S5 General Neurology:
Advances in Neurotherapeutics
1:00 p.m.
1:12 p.m.
Michael Kennemer, Thomas Winder, Perry Shieh
1:24 p.m.
2:12 p.m.
S4.007
Association of JNC-8 and SPRINT Systolic Blood Pressure Levels and Regional White Matter Lesion Load: the Northern Manhattan Study (NOMAS) —Michelle Caunca,
Marialaura Simonetto, Chuanhui Dong, Hannah Gardener, Ken Cheung, Noam Alperin, Consuelo McLaughlin, Mitchell Elkind, Tatjana Rundek, Ralph Sacco, Clinton Wright
Gerard Vockley, Amel Karaa
1:36 p.m.
S4.008
Readmission After Epilepsy Discharge in a Nationally Representative Sample —Leah Blank, Dylan Thibault, James Crispo, Kathryn Davis, Allison Wright Willis
2:35 p.m.
Discussion
S5.004
Modulation of Transcriptomic Changes in Alzheimer Disease by Ethnicity —Sathesh Sivasankaran, Anthony J.
Griswold, Olivia Gardner, Farid Rajabli, Brian Kunkle, Kara Hamilton, James Jaworski, William S. Bush, Eden Martin, Gary Beecham, Goldie S. Byrd, Jonathan Haines, Margaret Pericak-Vance
S5.005
Canagliflozin Associated with MELAS Pseudoexacerbation —Ramita Dewan, Christopher Stack, John
2:00 p.m.
S5.006
Inotersen Improves Norfolk Quality of Life-Diabetic Neuropathy Measures in Patients With Hereditary Transthyretin Amyloidosis with Polyneuropathy in the Phase 3 Study NEURO-TTR —Michael Polydefkis, Teresa
Coelho, Marcia Waddington Cruz, Peter Dyck, Morton Scheinberg, Violaine Plante-Bordeneuve, John Berk, Fabio Adrian Barroso, David Adams, Thomas Brannagan, Carol Whelan, Giampaolo Merlini, Brian Drachman, Stephen B. Heitner, Isabel Conceicao, Hartmut Schmidt, Giuseppe Vita, Josep Campistol, Josep Gamez, Edward Gane, Peter Gorevic, Acary Oliveira, Brett Monia, Steven hughes, Jesse Kwoh, Bradley W. McEvoy, Brenda F. Baker, Elizabeth Ackermann, Morie A. Gertz, Merrill Benson, Annabel Wang
2:12 p.m.
S5.007
Variation of Penetrance estimates in a wide spectrum of TTR-FAP families: implication for management of carriers —Farida Gorram, Malin Olsson, Flora Alarcon, Bérénice Hébrard, Benoit Funalot, Gregory Nuel, Ole Suhr, Violaine PlanteBordeneuve
2:24 p.m.
S5.008
Glycemic Control Boosts Glucosylated Nanocarrier Crossing the BBB into the Brain —Hiroya Kuwahara,
Yasutaka Anraku, Kazunori Kataoka, Takanori Yokota
2:35 p.m.
Discussion
S6 MS Neuroimaging
1:00 p.m.
G
S6.001
Association Between Abnormal Functional Connectivity of Thalamic Sub-Regions and Clinical Disability in CIS Patients: A Longitudinal Study —Milagros Hidalgo de la Cruz,
Maria Rocca, Alessandro Meani, Sarlota Mesaros, Jelena Dackovic, Irena Dujmovic Basuroski, Jelena Drulovic, Massimo Filippi
1:12 p.m.
S6.002
Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the OpenLabel Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis —Douglas Arnold, Ludwig Kappos, Stephen Hauser, Xavier Montalban, Anthony Traboulsee, Jerry Wolinsky, Victoria Levesque, Pablo Villoslada, Shibeshih Belachew, Fabian Model, Stanislas Hubeaux, Amit Bar-Or
1:24 p.m.
S6.003
Brain and Spinal Cord Imaging Features in Neuromyelitis Optica Spectrum Disorders —Laura Cacciaguerra, Maria Rocca, Sarlota Mesaros, Marta Radaelli, Jacqueline Palace, Jelena Drulovic, Elisabetta Pagani, Vittorio Martinelli, Lucy Matthews, Irena Dujmovic Basuroski, Giancarlo Comi, Massimo Filippi
1:36 p.m.
S6.004
Corpus callosum axon diameter and axon density from highgradient diffusion MRI are related to cognitive dysfunction and disability in multiple sclerosis —Natalya K. Machado, BS, Susie Y. Huang, MD, PhD, J. Daniel Bireley, BA, Andrew Russo, Sean Tobyne, Qiuyun Fan, Aapo Nummenmaa, PhD, Thomas Whitzel, PhD, Eric Klawiter
1:48 p.m.
S6.005
Baseline cerebellar volume as short-term predictor of clinical disability in Multiple Sclerosis: MRI Findings from the CombiRx trial —Maria Petracca, Sirio Cocozza, Leorah
Freeman, John Kangarlu, Amgad Droby, Stephen Krieger, Gary Cutter, Jerry Wolinsky, Fred Lublin, Matilde Inglese
2:00 p.m.
S6.006
Comparison of Methods for Whole-Brain and Grey Matter Atrophy Assessment in Multiple Sclerosis —Loredana Storelli, Maria Rocca, Elisabetta Pagani, Wim Van Hecke, Mark Horsfield, Nicola De Stefano, Alex Rovira, Jaume Sastre-Garriga, Jacqueline Palace, Diana Sima, Dirk Smeets, Massimo Filippi
2:12 p.m.
S6.007
Dentate nucleus T1 hyperintensity in early relapsingremitting multiple sclerosis patients is associated with cumulative gadopentetate dimeglumine (Gd-DTPA) administration —Robert Zivadinov, Jesper Hagemeier, Niels Bergsland, Deepa Ramasamy, Channa Kolb, Bianca WeinstockGuttman, David Hojnacki
2:24 p.m.
S6.008
Leptomeningeal inflammation is related to cortical thinning in relapsing-remitting multiple sclerosis —Niels Bergsland, Deepa Ramasamy, David Hojnacki, Bianca Weinstock-Guttman, Robert Zivadinov
2:35 p.m.
= Abstract of Distinction
Discussion
AAN.com/view/AM18 97
Sunday
2:24 p.m.
S5.003
Effects of Elamipretide in Adults with Primary Mitochondrial Myopathy: a Phase 2 Double-Blind, Randomized, Placebo-Controlled Crossover Trial (MMPOWER-2) —Bruce Cohen, Richard Haas, Amy Goldstein,
Cole
Bennett, Martha C. Morris
S5.002
Quantitative Determination of SMN2 Copy Number using Next Generation Sequencing and Correlation to Disease Severity —Jody Westbrook, Daniel Kvitek, Erik Gafni, Joshua Paul,
2:00 p.m.
S4.006
S5.001
Maria Rodriguez, John Ravits
1:48 p.m.
Association of Carotenoids, Vitamin E and Vitamin C intake with Parkinsonism and Progression of Parkinsonian signs in Older Adults —Puja Agarwal, Yamin Wang, Aron Buchman, David
G
Characterization of Atxn2 in ALS Patient Samples and Insight into ASO Therapy —Amy Taylor, Sandra Diaz Garcia,
Amyotrophic lateral sclerosis and exposure to diesel exhaust in Denmark —Aisha Dickerson, Johnni Hansen, Ole Gredal, Marc Weisskopf
1:00 p.m.–3:00 p.m.
SCIENTIFIC PLATFORM SESSIONS
1:00 p.m.–3:00 p.m.
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–4:30 p.m. S7 Pain and Palliative Care
3:30 p.m.–5:30 p.m.
G
This session will be presented at the Research Corner Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center 3:30 p.m. Mitchell B. Max Award for
Neuropathic Pain T his award recognizes an individual for outstanding work in the field of neuropathic pain for either a single contribution or for lifetime achievement.
Recipient:
David M. Simpson, MD, FAAN New York, NY
3:42 p.m.
S7.002
Effects of Opioids on Causal Relationships Between Intrinsic Connectivity Brain Networks in Patients with Chronic Low Back Pain - A Resting-State fMRI Study — Behnaz Jarrahi, Sean Mackey
3:54 p.m.
S7.003
Characteristics of Surrogate Decision Makers Selecting Life-sustaining Therapy for Severe Intracerebral Hemorrhage Patients: a Neuropalliative Care Survey of the US Population —David Hwang, Andrea Knies, Douglas White, Robert Holloway, Kevin Sheth, Liana Fraenkel
4:06 p.m.
S7.004
Reversal of allodynia and neurophysiological outcomes by CX-8998, a potent, selective T-type calcium channel modulator, in a model of bortezomib induced peripheral neurotoxicity —Margaret Lee, Yuri Maricich, Guido Cavaletti, Spiridon Papapetropoulos
S8 Progressive MS Therapies and
Age-Dependent Factors in MS Therapy
Sunday, April 22
3:30 p.m.–5:30 p.m.
G
3:30 p.m. John Dystel Prize for
Multiple Sclerosis Research T his prize recognizes outstanding contributions to research in the
S9 Epilepsy/Clinical Neurophysiology (EEG) I
3:30 p.m. Alliance Awards: Founders
This award is designed to encourage clinical and translational
understanding, treatment, or prevention of multiple sclerosis.
research in neuroscience by physicians in clinical neurology training programs.
Recipient:
Recipient:
Frederik Barkhof, MD, PhD Amsterdam, Netherlands
3:54 p.m.
S8.003
ARPEGGIO: a placebo-controlled trial of oral laquinimod in primary progressive multiple sclerosis —Gavin Giovannoni,
Frederik Barkhof, Hans-Peter Hartung, Bruce Cree, Stephen Krieger, Xavier Montalban, Maria Pia Sormani, Antonio Uccelli, Bernard Uitdehaag, Timothy Vollmer, Ayelet Reshef, Thomas Li, Peter Feldman, Aaron Tansy, Joshua Steinerman
4:06 p.m.
S8.004
Long-Term Outcomes in Patients With Progressive Forms of Relapsing MS Treated With Teriflunomide: Real-World Evidence —Flavia Nelson, Christine Lebrun-Freney, Alexey Boyko,
Karthinathan Thangavelu, Matthew Mandel, Steven Cavalier, Philippe Truffinet, Jinjun Liang, Regina Berkovich
4:18 p.m.
S8.005
Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study —Bruce Cree, Robert Fox,
Gavin Giovannoni, Patrick Vermersch, Amit Bar-Or, Ralf Gold, Baldur Magnusson, Nicolas Rouyrre, Daniela Piani Meier, Davorka Tomic, Goeril Karlsson, Frank Dahlke, Ludwig Kappos
4:30 p.m.
S8.006
Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients — Jens Kuhle, Harald Kropshofer, Christian Barro, Rolf Meinert, Dieter Haering, David Leppert, Davorka Tomic, Frank Dahlke, Ludwig Kappos
4:42 p.m.
S8.007
Early versus Later Treatment Start in Multiple Sclerosis - A Register Based Cohort Study —Thor Chalmer, Melinda Magyari,
Sunday
Lisbeth M. Baggesen, Mette Nørgaard, Nils Koch-Henriksen, Per Solberg Sorensen
4:54 p.m.
S8.008
Discontinuation of Disease Modifying Therapies in Stable MS Patients is Associated with Disability Progression Regardless of Age. —Bianca Weinstock-Guttman, Katelyn
Kavak, Caila Vaughn, Andrew Goodman, Patricia Coyle, Lauren Krupp, Malcolm Gottesman, Keith Edwards, Michael Lenihan, Allan Perel, Robert Zivadinov
5:05 p.m.
Discussion
G
Ezequiel Gleichgerrcht, MD Charleston, SC
3:42 p.m.
S9.002
Pediatric to Adult Transition Care Gaps for Youth with Epilepsy with Comorbid Intellectual or Developmental Disability —Christine Baca, Frances Barry, Alice Kuo, Cornelia Drees, Kelly Knupp
3:54 p.m.
S9.003
Normalizing mTOR Activity Has Dose-Dependent Bidirectional Effects on Acute Epileptic Extensor Spasms in the Ts65Dn Mouse Model —O. Snead, Susan dong, krutika joshi, Miguel Cortez
4:06 p.m.
S9.004
Adjunctive Everolimus in Patients with Treatmentrefractory Seizures Associated with Tuberous Sclerosis Complex (TSC): Analysis of Exposure-efficacy and Exposure-safety Relationships in the Randomized, Phase 3, EXIST-3 Trial —Jacqueline French, Paolo Curatolo, John Lawson, Zuhal Yapici, Hiroko Ikeda, Tilman Polster, Rima Nabbout, Petrus de Vries, Dennis Dlugos, Jenna Fan, Neva Coello, Diana Pelov, Maurizio Voi, David Franz
4:18 p.m.
S9.005
Periodic Focal Epileptiform Discharges during Awake Craniotomy —William Tatum, Anteneh Feyissa, Karim ReFaey, Tito Vivas-Buitrago, Alfredo Quinones-Hinojosa
4:30 p.m.
S9.006
Predicting Epilepsy Surgery Outcomes from Presurgical Temporal Lobe Network Architecture —Ezequiel Gleichgerrcht, Sonal Bhatia, Jonathan Edwards, William A. Vandergrift, Ruben Kuzniecky, Leonardo Bonilha
4:42 p.m.
S9.007
Efficacy and Safety of Everolimus Based on Prior and Concomitant Antiepileptic Drugs in Patients with Tuberous Sclerosis Complex (TSC)-Associated Treatment-Refractory Seizures: A Subanalysis of the Phase 3 EXIST-3 Study — David Franz, John Lawson, Zuhal Yapici, Hiroko Ikeda, Tilman Polster, Rima Nabbout, Paolo Curatolo, Petrus de Vries, Dennis Dlugos, Bijoyesh Mookerjee, Jenna Fan, Antonia Ridolfi, Fabian Herbst, Jacqueline French
4:54 p.m.
S9.008
Impact of Mutation Status on Seizure Outcomes in Patients with Tuberous Sclerosis Complex (TSC) Treated in the EXIST-3 Study —Zuhal Yapici, David Franz, John Lawson, Hiroko
Ikeda, Tilman Polster, Rima Nabbout, Paolo Curatolo, Petrus de Vries, Dennis Dlugos, Bijoyesh Mookerjee, Jenna Fan, Antonia Ridolfi, Fabian Herbst, Jacqueline French
5:05 p.m.
98 2018 AAN Annual Meeting
Discussion
S10 Intracerebral and
Subarachnoid Hemorrhage
G
3:30 p.m. Michael S. Pessin
Stroke Leadership Prize T his prize is awarded to emerging neurologists who have a strong interest in, and have demonstrated a passion for, learning and expanding the field of stroke research.
Recipient:
Glen Jickling, MD Edmonton, AB, Canada
3:42 p.m.
S10.002
Intracranial Hemorrhage in Infective Endocarditis: Underlying Arterial and Parenchymal Disease —Jean Khoury, Sung Cho, Cory Rice, Lucy Zhang, Dolora Wisco, Ken Uchino
3:54 p.m.
S10.003
Stress and Risk of Intracerebral Hemorrhage in the Ethnic/ Racial Variation of Intracerebral Hemorrhage (ERICH) Study —Tyler Behymer, Elisheva Coleman, Padmini Sekar, Ashby Turner, Charles Moomaw, Jennifer Osborne, Misty Wethington, Daniel Woo
4:06 p.m.
S10.004
Global Variation and Burden of Hemorrhagic Stroke —Steve O’Donnell, David Tirschwell, Rizwan Kalani, Valery Feigin, Catherine Johnson, Gregory Roth
4:18 p.m.
S10.005
Secular increases in spontaneous subarachnoid hemorrhage during pregnancy —Kaustubh Limaye, Achint Patel,
Sourabh Lahoti, Cynthia Kenmuir, Ashutosh Jadhav, Edgar Samaniego, Santiago Ortega-Gutierrez, James Torner, David Hassan, Colin Derdeyn, Tudor Jovin, Harold Adams, Enrique Leira
4:30 p.m.
S10.006
Spontaneous Intracerebral Hemorrhage in the Elderly Population —Rachel Beekman, Stacy Chu, Samuel Sommaruga,
Join Neurology’s Global Conversation! Connect with neurologists and neuroscience professionals in your area of interest.
SCIENTIFIC PLATFORM SESSIONS
3:30 p.m.–5:30 p.m.
Zachary King, Hooman Kamel, Charles Matouk, David Hwang, Kevin Sheth, Guido Falcone
4:42 p.m.
S10.007
Audrey Leasure, Opeolu Adeoye, Fu-Dong Shi, Steven Kittner, Carl Langefeld, Achala Vagal, Kevin Sheth, Daniel Woo
4:54 p.m.
S10.008
Impact of Pre-existing Dementia on Intracerebral Hemorrhage Outcomes —Eunji Yim, Padmini Sekar, Charles
Moomaw, Jennifer Osborne, Sharyl Martini, Li Xiong, Alessandro Biffi, Jonathan Rosand, Daniel Woo
5:05 p.m.
Discussion
= Abstract of Distinction
Get started at AAN.com/Synapse Sunday
Race/Ethnicity Influences Outcomes in Young Adults with Intracerebral Hemorrhage —Laura Miyares, Guido Falcone,
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S11 “Best of” Session: Epilepsy/Clinical Neurophysiology (EEG)
Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 92 »
1:00 p.m.–2:15 p.m.
G
S12 Autonomic Disorders
1:00 p.m.–3:00 p.m.
G
This session will be presented at the Research Corner Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center 1:00 p.m. Irwin Schatz Award for
Autonomic Disorders T his award recognizes young investigators who have advanced
the field of autonomic disorders, or senior investigators that have made major contributions to the field.
Recipient:
David S. Goldstein, MD, PhD Bethesda, MD
1:12 p.m.
S12.002
Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy Results in Growth Factor Spike —Wolfgang Singer, Ann Schmeichel, Karla Minota, Anita Zeller, James Schmelzer, Tonette Gehrking, David Sletten, Jade Gehrking, Allan Dietz, Phillip Low
1:24 p.m.
S12.003
A double blind-placebo controlled trial of IVIG in the treatment of AAG: Results, Implications and Lessons Learned —Christopher Gibbons, Sharika Rajan, Jenniffer Garcia
Perez, David Robertson, Italo Biaggioni, Horacio Kaufmann, Amanda Peltier, Steven Vernino, Phillip Low, Roy Freeman
1:36 p.m.
S12.004
The Heart of PD is the Heart: Lewy Body Diseases as Neurocardiologic Disorders —David Goldstein, Risa Isonaka, Patti Sullivan, Courtney Holmes, Yehonatan Sharabi
1:48 p.m.
Monday, April 23
S12.005
The Quantitation of Cutaneous Neurovascular Density —
Christopher Gibbons, Eun Hee Sohn, Bum Chun Suh, Ningshan Wang, Roy Freeman
S13 Neuromyelitis Optica Spectrum Disorder and Other Autoimmune Disorders
1:00 p.m.
G
S13.001
Developing Evidence-Based Guidelines for the Diagnosis and Treatment of NMOSD in Alberta, Canada —Jodie Burton, Fiona Costello
1:12 p.m.
S13.002
Clinical Characteristics of MOG and AQP associated Neuromyelitis Optica Spectrum Disorder (NMOSD) in Adults —Marco Alfonso Narduc Capobianco, Arianna Sala, Fabiana Marnetto, Paola Valentino, Simona Malucchi, Maria Malentacchi, Francesca Sperli, Marianna Lo Re, Antonio Bertolotto
1:24 p.m.
S13.003
Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients —Daniel
Whittam, Alvaro Cobo-Calvo, Alfonso Lopez, Santiago Pardo, James Dodd, Alexander Brandt, Klaus Berek, Thomas Berger, Grace Gombolay, Luana Micheli Oliveira, Dagoberto Callegaro, Kimihiko Kaneko, Tatsuro Misu, Bruno Brochet, Bertrand Audoin, Guillaume Mathey, David Laplaud, Eric Thouvenot, Mikael Cohen, Ayman Tourbah, Elisabeth Maillart, Jonathan Ciron, Romain Deschamps, Damien Biotti, Marcelo Matiello, Jacqueline Palace, Ming Lim, Kazuo Fujihara, Ichiro Nakashima, Jeffrey Bennett, Lekha Pandit, Tanuja Chitnis, Brian Weinshenker, Brigitte Wildemann, Douglas Sato, Su-Hyun Kim, Ho Jin Kim, Markus Reindl, Michael Levy, Sven Jarius, Silvia Tenembaum, Friedemann Paul, Sean Pittock, Romain Marignier, Anu Jacob
1:36 p.m.
S13.004
The Mayo Clinic Glial Autoimmunity study: Persistence of MOG-IgG seropositivity predicts relapse after ADEM in both children and adults —Alfonso Lopez, Masoud Majed,
James Fryer, Andrew McKeon, Eoin Flanagan, Jan-Mendelt Tillema, John Chen, Divyanshu Dubey, Naga Kothapalli, Jessica Sagen, Avi Gadoth, Brian Weinshenker, Dean Wingerchuk, Mark Keegan, Claudia Lucchinetti, Vanda Lennon, Sean Pittock
1:48 p.m.
S13.005
Autoimmune GFAP Astrocytopathy: Prospective Evaluation of 90 Patients in 1 year —Divyanshu Dubey, Shannon Hinson, Anastasia Zekeridou, Eoin Flanagan, Sean Pittock, Eati Basal, Daniel Drubach, Daniel Lachance, Vanda Lennon, Andrew McKeon
2:00 p.m.
S13.006
Monday
Glial Fibrillary Acid Protein Immunoglobulin G (GFAP-IgG) Related Myelitis: Characterization and Comparison with Aquaporin-4-IgG Myelitis —Elia Sechi, Padraig Morris, Andrew McKeon, Sean Pittock, Shannon Hinson, Brian Weinshenker, Allen Aksamit, Evan Jolliffe, Anastasia Zekeridou, Dean Wingerchuk, Eoin Flanagan
2:12 p.m.
S13.007
The Mayo Clinic Glial Autoimmunity Study: AQP4/MOG-IgG serostatus and outcomes in 228 patients presenting with recurrent optic neuritis —Jiraporn Jitprapaikulsan, John Chen, James Fryer, Brian Weinshenker, Andrew McKeon, Vanda Lennon, Jacqueline Leavitt, Eoin Flanagan, W. Tobin, Alfonso Lopez, Mark Keegan, Claudia Lucchinetti, Orhun Kantarci, Jessica Sagen, Sean Pittock
2:24 p.m.
S13.008
It’s Not All Transverse Myelitis: The Differential Diagnosis of Spinal Cord Myelopathy —Maureen Mealy, Laura Munoz-
Arcos, Paula Barreras, Maria Garcia, Daniel Becker, Scott Newsome, Philippe Gailloud, Michael Levy, Carlos Pardo-Villamizar
2:35 p.m.
100 2018 AAN Annual Meeting
Discussion
S14 Education and Patient Outcomes Research
1:00 p.m.
1:00 p.m.–3:00 p.m.
G
S14.001
Breaking the curve: moving from normative to criterion-based grading on neurology clerkship —E.
S15 Cerebrovascular Disease
Epidemiology and Outcomes
1:00 p.m.
1:00 p.m.–3:00 p.m.
G
S15.001
Clinical Care and Outcomes of Asian-American Acute Ischemic Stroke Patients —Sarah Song, Li Liang, Gregg
S16 Neuro-ophthalmology/Neuro-otology
1:00 p.m.
S16.001
Optical Coherence Tomography Angiography in pre-clinical Alzheimer’s disease —Gregory Van Stavern,
Alexandra Brown, Nina Garga, Megan Richie, Nilika Singhal, Audrey Foster-Barber, Vanja Douglas
Fonarow, Eric Smith, Deepak Bhatt, Roland Matsouaka, Ying Xian, Lee Schwamm, Jeffrey Saver
Rajendra Apte, Nathan Kung, Bliss O’Bryhim, Dean Coble
1:12 p.m.
1:12 p.m.
Ocular Motor Abnormalities and Reading Difficulties in Different Neuro-Ophthalmic Diseases —Angela Oh,
S14.002
Neurology Clerkship - Predictors of OSCE and Shelf Exam Performance —Ajay Sampat, Gerald Rouleau, Cindy Zadikoff 1:24 p.m.
S14.003
What’s the Right Blend? Identifying the optimal blend of classroom and eLearning to promote immediate and longterm retention in the neurology clerkship —Michael Halstead, Rachel Marie Salas, Mona Bahouth, Deanna Saylor, Bernadette Clark, Charlene Gamaldo, Roy Strowd
1:36 p.m.
S14.004
Utilization of Ultrasound Guided Lumbar Puncture to Improve the Efficacy and Outcome in an Overweight Patient Population: A Resident Driven Quality Improvement Project —Yi Li, Swetha Ade, Kate Daniello 1:48 p.m.
S14.005
A Quality Improvement Curriculum for Neurology Residents —Rebecca Miller-Kuhlmann, Lironn Kraler, Nina Bozinov, Alexander Frolov, Michael Mlynash, Carl Gold, Kathryn Kvam
2:00 p.m.
S14.006
A Resident-driven Intervention To Decrease Door-to-needle Time And Increase Resident Satisfaction In A Resourcelimited Setting —Alexandra J. Lloyd-Smith Sequeira, Michael Fara, John McMenamy, Monica Chan, Koto Ishida, Jose Torres, Cen Zhang, Albert Favate, Anuradha Singh, Ting Zhou, Sara Rostanski
2:12 p.m.
S14.007
Validation of a Uniform, Standardized Testing Model for Emergency Neurological Life Support (ENLS) —Christopher
Robinson, Teddy Youn, Marc-Alain Babi, Carolina Maciel, Jacqueline Baron-Lee, Christa Ochoa, Katharina Busl
2:24 p.m.
S14.008
Stroke Severity and Cognitive Impairment as Predictors of Near-Term Mortality in the Mayo Clinic Florida Familial Cerebrovascular Diseases Registry —Tasneem Hasan, Kevin
2:35 p.m.
Discussion
Temporal Trends in Sex and Age Disparities in Acute Ischemic Stroke Treatment and Outcomes in the United States from 2004 to 2014 —Vasu Saini, Fadar Otite, Priyank Khandelwal, Dileep Yavagal, Seemant Chaturvedi, Amer Malik
1:24 p.m.
Gender disparities in cognitive, motor and mood outcomes: preliminary data from the Bugher Foundation’s Combined Aerobic and Resistance Exercise Training (CARET) program and Cognitive Training Intervention (CTI) Study. —Marialaura Simonetto, Chuanhui Dong, Carolina M. Gutierrez, Clinton Wright, David Loewenstein, Ralph Sacco, Sebastian Koch, Tatjana Rundek
1:36 p.m.
= Abstract of Distinction
S15.004
Effect of Obesity on Inpatient Mortality of Patients with Ischemic Stroke —Sahil Gupta, Mina Lobbous, Frank Benesh, Angela Hays Shapshak
1:48 p.m.
S15.005
Cerebral microbleeds associated with white matter and deep gray matter atrophy in community-dwelling populations —Ning Su, Xin-Yu Liang, Lixin Zhou, Ming Yao, Quan
Wang, Fei Han, Jiang-Tao Zhang, Dong-Hui Ao, Ming-Li Li, Zheng-Yu Jin, Shu-Yang Zhang, Li-Ying Cui, Gao-Lang Gong, Yi-Cheng Zhu, Jun Ni
2:00 p.m.
S15.006
Regulation of HMGB1 inflammation in patients with ischemic stroke by microRNA —Glen Jickling, Bradley Ander, Boryana Stamova, DaZhi Liu, Frank Sharp
2:12 p.m.
S15.007
Frequency of brain death in acute cerebrovascular disease related mortality. —Rakesh Khatri, Alberto Maud, Anantha Vellipuram, Mohammad-Rauf Afzal, Mohtashim Qureshi, Ihtesham Qureshi, Paisith Piriyawat, Darine Kassar, Salvador Cruz-Flores, Gustavo Rodriguez
2:24 p.m.
S15.008
Risk of Transient Ischemic Attack and Stroke in Patients with Herpes Zoster: 2007 - 2014 US Claims Data Analysis —Brandon Patterson, Debora Rausch, Debra Irwin,
S16.002
Mohammad Shariati, Naz Jehangir, Caroline Yu, Tiffany Chen, Rosa Yu, Y. Joyce Liao
1:24 p.m.
S16.003
Mobile Universal Lexicon Evaluation System (MULES) in MS: Evaluation of a New Visual Test of Rapid Picture Naming —Meagan Seay, Omar Akhand, Lucy Cobbs, Lisena
Hasanaj, Prin Amorapanth, John-Ross Rizzo, Rachel Nolan, Liliana Serrano, Barry Jordan, Janet Rucker, Steven Galetta, Laura Balcer
1:36 p.m.
S16.004
Relation of Quantitative Eye Movements with Cognitive Dysfunction in Patients with Concussion —Doria Gold, John
Martone, Yuen Shan Christine Lee, Amanda Childs, Yuka Matsuzawa, Felicia Fraser, Joseph Ricker, Wei-Wei Dai, John-Ross Rizzo, Todd Hudson, Ivan Selesnick, Steven Galetta, Laura Balcer, Janet Rucker
1:48 p.m.
S16.005
2:00 p.m.
S16.006
Long term Reversal of Visual Loss by Mitochondrial Gene Transfer in a Mouse Model of Leber Hereditary Optic Neuropathy —John Guy, Hong Yu Low- and Medium-Dose Gene Therapy in Patients with Prior Unilateral LHON Does Not Prevent Further Visual Loss in the Treated Eye —John Guy, William Feuer, Janet Davis, Vittorio Porciatti, Byron Lam, Huijuan Yuan, Rajeshwari Koilkonda, Phillip Gonzalez
2:12 p.m.
S16.007
Abnormal Visuo-vestibular Interactions in Vestibular Migraine —Marta Casanovas Ortega, Nadja F. Bednarczuk, AnneSophie Fluri, John Chan, Heiko Rust, Fabiano Peixoto, Diego Kaski, Barry M. Seemungal, Adolfo Bronstein, Qadeer Arshad
2:24 p.m.
S16.008
Self-monitoring visual function in Neurology —Nicolas
Dubuisson, Matthew Laws, Adam Paterson, Benjamin Turner, Alison Thomson, Mark Westcott, Gavin Giovannoni
2:35 p.m.
Discussion
Michael Liang, Songkai Yan, Barbara Yawn
2:35 p.m.
S15.003
1:12 p.m.
Discussion
AAN.com/view/AM18 101
Monday
Barrett, Thomas Brott, Elizabeth R. Lesser, David O. Hodge, James Meschia
S15.002
G
SCIENTIFIC PLATFORM SESSIONS
1:00 p.m.–3:00 p.m.
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–5:30 p.m. S17 Sleep
3:30 p.m.–5:30 p.m.
G
3:30 p.m. Alliance Awards: S. Weir Mitchell
This award is designed to encourage basic research in
neuroscience by physicians in clinical neurology training programs.
Recipient:
Eric C. Landsness, MD, PhD St. Louis, MO
3:42 p.m. Wayne A. Hening
Sleep Medicine Investigator Award T his award recognizes scientific contributions in sleep from
promising young investigators. The goal of this award is to reward productive young investigators and to emphasize the essential role of neurology in sleep medicine.
Recipient:
Yo-El Ju, MD, MSCI Saint Louis, MO
3:54 p.m. Sleep Science Award
This award is intended to recognize distinguished academic
contributions by neurologists to the field of sleep medicine or the contributions of non-neurologists to the interface area of sleep neurology.
Recipient:
Bradley F. Boeve, MD Rochester, MN
4:18 p.m.
S17.005
Subcortical Basis of Cognitive Impairment in Idiopathic Rapid Eye Movement Sleep Behavior Disorder —Shady
Rahayel, Ronald Postuma, Jacques Montplaisir, Malo Gaubert, Daphne Genier-Marchand, Frédérique Escudier, Pierre-Alexandre Bourgouin, Julie Carrier, Oury Monchi, Sven Joubert, Jean-Francois Gagnon
4:30 p.m.
S17.006
NREM sleep spindles predict impaired memory consolidation in children with OSA —Kiran Maski, Erin Steinhart, Robert Stickgold
4:42 p.m.
S17.007
A Double-Blind, Placebo-Controlled, RandomizedWithdrawal, Multicenter Study of the Efficacy and Safety of Sodium Oxybate (SXB) in Pediatric Participants with Narcolepsy Type 1 (NT1) —Chad Ruoff, Giuseppe Plazzi, Michel
Monday
Lecendreux, Yves Dauvilliers, Carol Rosen, MD, Jed Black, Rupa Parvataneni, Diane Guinta, Y. Grace Wang, Emmanuel Mignot
4:54 p.m.
S17.008
Adverse Childhood Experiences and Insufficient Sleep: Persistent Association Through Life —Kelly Sullivan, Diane Donley
5:05 p.m.
Discussion
102 2018 AAN Annual Meeting
S18 Movement Disorders: Ataxia and Tremor
3:30 p.m.–5:30 p.m.
G
3:30 p.m. Movement Disorders Research Award
This award recognizes an individual for outstanding work in the
field of Parkinson’s disease or other movement disorders for either a single, outstanding contribution or for lifetime achievement.
Recipient:
Irene Litvan, MD, FAAN La Jolla, CA
3:54 p.m.
S18.003
Unilateral Versus Bilateral Ventral Intermediate Nucleus Deep Brain Stimulation for Axial Essential Tremor Symptoms —Kyle Mitchell, Delea Peichel, Robert Wharen, Michael Okun, Barton Guthrie, Ryan Uitti, Paul Larson, Harrison Walker, Rajesh Pahwa, Khashayar Dashtipour, Joseph Jankovic, Kelly Foote, Jason Schwalb, Blair Ford, Richard Simpson, Fenna Phibbs, Joseph Neimat, R. Malcolm Stewart, Frederick Marshall, Jill Ostrem
4:06 p.m.
S18.004
Deep Cerebellar Stimulation to Treat Degenerative Cerebellar Ataxias —Collin Anderson, Stefan Pulst 4:18 p.m.
S18.005
Spinocerebellar Ataxia Type 2 (SCA2) Spinal Cord Transcriptome Sequencing Informs Understanding on ALS —Daniel Scoles, Warunee Dansithong, Lance Pflieger, Sharan Paul, Karla Figueroa, Matthew Schneider, Frank Rigo, Frank Bennett, Stefan Pulst
4:30 p.m.
Monday, April 23
S18.006
S19 Epilepsy/Clinical Neurophysiology (EEG) II
3:30 p.m. Dreifuss-Penry Epilepsy Award
The intent of this award is to recognize physicians in the
early stages of their careers who have made an independent contribution to epilepsy research.
Recipient:
Kathryn A. Davis, MD, MS, FAES Philadelphia, PA
3:42 p.m.
S19.002
Epilepsy Technotherapy - Results of a 1 Year Pilot Study — Rupert Page, Michelle Knight, Karen Symon
3:54 p.m.
S19.003
Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5) —Ian Miller, Orrin Devinsky, Rima Nabbout, Linda Laux, Marta Zolnowska, Stephen Wright, Claire Roberts
4:06 p.m.
S19.004
: Spectrographic Seizure Detection Using Deep Learning With Convolutional Neural Networks —Peter Yan, Fei Wang,
Zachary Grinspan
4:18 p.m.
S19.005
Efficacy and Tolerability of Adjunctive Cenobamate Therapy in Different Types of Partial-Onset Seizures —Gregory Krauss, Marc Kamin
Characterization of a Murine Model of Spinocerebellar Ataxia 13 —Swati Khare, Jerelyn Nick, Stephanie Niemczyk,
4:30 p.m.
4:42 p.m.
Privitera, Hari Bhathal, Matthew Wong, J. Helen Cross, Kenneth Sommerville
Kristina Sanborn, Jada Lewis, Harry Nick, Michael Waters
S18.007
Longitudinal analysis of low-contrast acuity in Friedreich ataxia —Ali Hamedani, Lauren Hauser, Susan Perlman, Katherine
Mathews, George Wilmot, Theresa Zesiewicz, S Subramony, Tetsuo Ashizawa, Martin Delatycki, Alicia Brocht, David Lynch
4:54 p.m.
S18.008
Longitudinal change of gait and balance in individuals with Friedreich ataxia —Sarah Milne, Seok Kim, Anna Murphy, Theresa
G
S19.006
Cannabidiol (CBD) Treatment Effect and Adverse Events (AEs) by Time in Patients with Lennox-Gastaut Syndrome (LGS): Pooled Results from 2 Trials —Elaine Wirrell, Michael
4:42 p.m.
S19.007
Resting State Functional Connectivity between Thalamic Nuclei and Hippocampal Subfields in Epilepsy Using 7 T MRI —Prantik Kundu, Lara Marcuse, Rebecca Feldman, Madeline Fields, Priti Balchandai
Zesiewicz, Mary Danoudis, Jessica Shaw, Ritchie Malapira, Eppie Yiu, Nellie Georgiou-Karistianis, Martin Delatycki, Louise Corben
4:54 p.m.
5:05 p.m.
Sean Pittock, Maftuna Gafurova, Ember Eldridge, Raymond Dingledine
Discussion
S19.008
Pathogenesis of Seizures in Anti-NMDA Receptor Encephalitis: a Mouse Model —Olha Taraschenko, Howard Fox, 5:05 p.m.
Discussion
C94: Hot Topics in Stroke
Education and Practice
Monday, April 23, 3:30 p.m. – 5:30 p.m.
Director: Pierre Fayad, MD, FAHA, FAAN, Omaha, NE The management of acute ischemic stroke has witnessed a dramatic transformation over the past decades. More recently, the evidence-based introduction of thrombectomy in 2015, as a powerful and effective treatment for patients with intracranial large vessel occlusion (LVO) for up to 6 hours from symptom-onset, with or without intravenous thrombolysis with tPA, accelerated such changes. To translate these findings into clinical settings, acute stroke teams reorganized their screening processes, to evaluate emergently patients with CT or MR angiography and widen the window of screening and treatment from 4.5 hours for IV tPA to 6 hours for IV tPA and thrombectomy. Neurointerventionalists mobilized to perform thrombectomy emergently for eligible patients. Neurointensivists, Vascular Neurologists and Neuro-Hospitalists mobilized to provide the skills, the acute care needed before, during and following the interventions. In 2017, further revolutionary events impacted knowledge and practice. The DAWN study demonstrated that thrombectomy is highly effective at improving outcomes and preventing disability when applied for up to 24 hours from symptom-onset in eligible patients based on neurologic deficits, LVO and presence of “salvageable brain tissue,” based on imaging criteria from cerebral diffusion and perfusion studies based on the RAPID software analysis. In 2018, the DEFUSE-3 study, showed similarly demonstrated dramatic effectiveness of thrombectomy for up to 16 hours from symptom-onset in eligible patients based on variations of the DAWN criteria. These powerful findings were already incorporated in the American Heart Association Guidelines update for the management of acute ischemic stroke, whose values were endorsed by the AAN, with recommendations to treat patients for up to 24 hours with thrombectomy according to the eligibility criteria of both trials. These seismic changes, will have a massive impact on the organization and delivery of acute stroke care services in terms of human, organizational and financial costs in the years to come. Expanding the window of emergent care for up to 24 hours, will require immediate implementation, placing major strains on stroke systems of care, but most importantly on the neurologist and neurology subspecialists, who generally carry the largest burden of screening, evaluating, and treating such patients. This session will explore those changes and potential ways to meet them. Neurological education and training need to incorporate such changes in order to prepare our residents’ readiness for their future practice, once they graduate. Strong knowledge and skills in evaluating and treating stroke will undoubtedly be an essential skill of any neurologic practice, in any setting, in the future. The Roundtable and Q/A Session at the end of the session will discuss the potential impact on neurology training.
Timeline 3:30 p.m.– 3:35 p.m. Welcome and Session Introduction Pierre Fayad, MD, FAHN, FAAN 3:35 p.m.– 3:50 p.m. Major Findings in DAWN and DEFUSE-3 Faculty 3:50 p.m.– 4:05 p.m. Highlights From 2018 ASA/AHA Guidelines for Acute Ischemic Stroke Alejandro Rabinstein, MD, FAAN
4:05 p.m.–4:20 p.m. Role of Advanced Acute Stroke Imaging for the Neurologist Gregory Albers, MD
4:35 p.m.– 4:50 p.m. Potential Strategies to Meet Challenges of The 24-Hours Window For Acute Stroke Lawrence Wechsler, MD, FAAN
4:50 p.m. –5:30 p.m. 4:20 p.m.– 4:35 p.m. Roundtable Discussion with Question & Stroke Training During Neurology Residency Answer Participants and Fellowships: Present and Future Sunil Sheth, MD
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S20 “Best of” Session: Headache
Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 92 »
1:00 p.m.–3:00 p.m.
G
S21 Revascularization in Acute Ischemic Stroke
1:00 p.m.
1:00 p.m.–3:00 p.m.
G
S21.001
Thrombolysis in Ischemic Stroke: Predictors of Thrombolysis Utilization from a National Database —Frank Benesh, Sahil Gupta, Mina Lobbous, Angela Hays Shapshak
1:12 p.m.
S21.002
Region Based Disparities in tPA Utilization in the United States: An Analysis of Nationwide Inpatient Sample Database —Sahil Gupta, Mina Lobbous, Frank Benesh, Margi Patel, Angela Hays Shapshak
1:24 p.m.
S21.003
Frequency, Determinants, and Outcomes of Distal Emboli Related to Mechanical Thrombectomy for Acute Ischemic Stroke —Gregory Wong, Reza Jahan, Viktor Szeder, David
Liebeskind, Latisha Sharma, Gary Duckwiler, Satoshi Tateshima, May Nour, Jin Lee, Sidney Starkman, Jeffrey Saver
1:36 p.m.
S21.004
Decreases in Blood Pressure During Endovascular Stroke Therapy are Common and Associated with Poor Functional Outcome —Anson Wang, David Mampre, Kevin Sheth, Can Tan, Ryan Hebert, Charles Matouk, Nils Petersen
1:48 p.m.
S21.005
Laterality is an independent predictor of endovascular thrombectomy in patients with lower NIHSS Score — Shashvat Desai, Tudor Jovin, Ashutosh Jadhav
2:00 p.m.
S21.006
Systemic Review of Intravenous tPA for Patients with Central Retinal Artery Occlusion. —Mohammed Alkuwaiti,
Connie Bongiorno, Christopher Logue, Shailesh Male, Rwoof Reshi, Benjamin Miller, Kevin Engel, Victor Urrutia, Christopher Streib
2:12 p.m.
S21.007
Safety of Repeated Use of Intravenous Thrombolysis for Recurrent Acute Ischemic Stroke —Yahya Atalay, Alexander Merkler
2:24 p.m.
S21.008
Autoregulation-based Blood Pressure Optimization After Large-vessel Ischemic Stroke using Non-invasive Nearinfrared Spectroscopy Monitoring —Anson Wang, Kevin Sheth, Randolph Marshall, David Mampre, Ryan Hebert, Charles Matouk, Nils Petersen
2:35 p.m.
Discussion
Tuesday, April 24
S22 Advances in Muscular Dystrophy and Congenital Myopathy
1:00 p.m.
G
S22.001
Golodirsen Induces Exon Skipping Leading to Sarcolemmal Dystrophin Expression in Duchenne Muscular Dystrophy Patients With Mutations Amenable to Exon 53 Skipping —
Francesco Muntoni, DE Frank, Valentina Sardone, Jenny Morgan, F Schnell, JS Charleston, Cody Desjardins, Rahul Phadke, Caoline Sewry, Linda Popplewell, Michela Guglieri, Kate Bushby, Pierre Carlier, Chris Clark, George Dickson, Jean-Yves Hogrel, Volker Straub, Eugenio Mercuri, Thomas Voit, Edward Kaye, Laurent Servais
1:12 p.m.
S22.002
Targeted Next Generation Sequencing (NGS) for Analysis of Splicing Biomarkers of Myotonic Dystrophy Type 1 (DM1) — Charles Thornton, Wenli Wang, Ami Mankodi, S Subramony, Tetsuo Ashizawa, John Day, Jeffrey Statland, William Arnold, John Kissel, on behalf of Myotonic Dystrophy Clinical Research Network
1:24 p.m.
S22.003
First-in-human Study of ATB200/AT2221 in Patients with Pompe Disease: Preliminary Results From the ATB200-02 Trial —Tahseen Mozaffar, Drago Bratkovic, Barry Byrne, Paula
Clemens, Tarekegn Geberhiwot, Ozlem Goker-Alpan, Priya Kishnani, Xue Ming, Mark Roberts, Peter Schwenkreis, Kumaraswamy Sivakumar, Ans Van Der Ploeg, Jacquelyn Wright, Franklin Johnson, Sheela Das, Jay Barth, Swati Sathe, Benedikt Schoser
1:36 p.m.
S22.004
Disease progression in Myotonic Dystrophy Type 1 during a non-interventional multicenter study —Ami Mankodi, Jeffrey Statland, Katy Eichinger, Jeanne Dekdebrun, John Day, S Subramony, John Kissel, Tetsuo Ashizawa, Charles Thornton, On behalf of Myotonic Dystrophy Research Network
1:48 p.m.
S22.005
Cardiac atrophy: a Novel Mechanism for Duchenne Muscular Dystrophy (DMD)-Associated Cardiomyopathy — Shaida Khan, Daniel Cheeran, Pradeep Mammen
2:00 p.m.
S22.006
Myo18b-related nemaline myopathy null mutation causes dysfunctional sarcomere contractility —Edoardo Malfatti, Barbara Joureau, Josine de winter, Johann Bohm, Jocelyn Laporte, Norma Romero, Coen AC Ottenheijm
2:12 p.m.
S22.007
Cardiac troponin T as biomarker of cardiac dysfunctions in skeletal muscle from myotonic dystrophy type 1 and type 2 patients —Giovanni Meola, Francesca Bosè, Laura Renna, Barbara Fossati, Elisa Brigonzi, Michele Cavalli, Rosanna Cardani
2:24 p.m.
S22.008
Tuesday
Development of the histone deacetylases inhibitor Givinostat in Duchenne Muscular Dystrophy —Giacomo
Comi, Enrico Bertini, Giuseppe Vita, Eugenio Mercuri, Stefania Petrini, Maurizio Moggio, Paolo Bettica, Alessandra Govoni, Barbara Gatti, Sara Cazzaniga
2:35 p.m.
104 2018 AAN Annual Meeting
Discussion
SCIENTIFIC PLATFORM SESSIONS
1:00 p.m.–3:00 p.m. S23 Biologic and Clinical Discoveries in Neuro-oncology
G
1:00 p.m. Neuro-oncology Investigator Award
This award recognizes young investigators who have advanced the field of neuro-oncology.
Recipient:
Milan Chheda, MD Saint Louis, MO
1:12 p.m.
Neuro-oncology Scientific Award This award recognizes an individual from any discipline and of
any academic rank for a singular scientific achievement that has advanced the field of neuro-oncology.
Recipient:
Scott R. Plotkin, MD, PhD Boston, MA
1:24 p.m.
S23.003
Bone Marrow is a Critical Mediator of Central Nervous System Regeneration after Radiation Injury —Jorg Dietrich,
Ninib Baryawno, Naema Nayyar, Yannis Valtis, Betty Yang, Ina Ly, Antoine Besnard, Nicolas Severe, Karin Gustafsson, Ovidiu Andronesi, Tracy Batchelor, Amar Sahay, David Scadden
1:36 p.m.
S23.004
Multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: an NF Clinical Trials Consortium study — Scott Plotkin, James Tonsgard, Nicole Ullrich, Jeffrey Allen, Jaishri Blakeley, Tena Rosser, David Clapp, Jian Campion, Michael Fisher, Gary Cutter, Bruce Korf, Roger Packer, Coretta Thomas, Matthias Karajannis
1:48 p.m.
S23.005
Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis —Adrienne Boire,
Yilong Zou, Jason Shieh, Danilo Macalinao, Elena Pentsova, Joan Massagué
2:00 p.m.
S23.006
Toca 511 & Toca FC: Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma —Timothy
Cloughsey, Joseph Landolfi, Michael Vogelbaum, Derek Ostertag, Bradley Elder, Bob Carter, Clark Chen, Steven Kalkanis, Santosh Kesari, Albert Lai, Ian Lee, Linda Liau, Phioanh Nghiemphu, David Piccioni, William Accomando, Oscar Diago, Daniel Hogan, Douglas Jolly, Katie Wood, Thian Kheoh, Harry Gruber, Asha Das, Tobias Walbert
2:12 p.m.
S23.007
Tuesday
The Prevalence and Impact of Sleep Disturbance on Patients with Primary Brain Tumors —Neha Garg, Fang-Chi
Hsu, Rachel Marie Salas, Charlene Gamaldo, Peter Dziedzic, Glenn Lesser, Roy Strowd
2:24 p.m.
S23.008
Neurotoxicity Associated with CD19-specific Chimeric Antigen Receptor T cell Therapy for Adult Acute Lymphoblastic Leukemia (B-ALL) —Bianca Santomasso, Jae
Hong Park, Isabelle Riviere, Elena Mead, Daniel Li, Brigitte Senechal, Terrence Purdon, Elizabeth Halton, Claudia Diamonte, Michel Sadelain, Renier Brenjens
2:35 p.m.
Discussion
= Abstract of Distinction
AAN.com/view/AM18 105
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–5:30 p.m. S24 MS Outcome Measures and Biomarkers
3:30 p.m.
3:30 p.m.–5:30 p.m.
G
S24.001
OCTiMS Study: A 3-Year Longitudinal Assessment of RNFL Thickness Measured by Optical Coherence Tomography in Patients with Relapsing-Remitting Multiple Sclerosis — Peter Calabresi, Frederik Barkhof, Ari Green, Randy Kardon, Friedemann Paul, Jaume Sastre-Garriga, Sven Schippling, Patrick Vermersch, Catherine Agoropoulou, Ervin Carolyn Marie, Diego Silva, Axel Petzold
3:42 p.m.
S24.002
Interim Analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Study in Multiple Sclerosis (MS) — Amit Bar-Or, Jeffrey Gelfand, Damian Fiore, Christopher Harp, Ann Herman, Bruno Musch, Hanzhe Zheng, Anne Cross
3:54 p.m.
S24.003
Serum Neurofilament Light (NfL): Towards a Blood Test for Prognosis and Disease/Treatment Monitoring in Multiple Sclerosis Patients —Peter Calabresi, Douglas Arnold, Revere
Kinkel, Carol Singh, Dipen Sangurdekar, Carl DeMoor, Bob Engle, Aaron Deykin, Elizabeth Fisher, Alfred Sandrock, Richard Rudick, Bernd Kieseier, Tatiana Plavina
4:06 p.m.
S24.004
Long-term Prognosis of Disease Evolution and Evidence for Sustained Fingolimod Treatment Effect by Blood Neurofilament Light in RRMS Patients —Jens Kuhle, Jeffrey
S25 Advances in
Amyotrophic Lateral Sclerosis
contributions in research in the search for the cause, treatment, prevention, and cure for amyotrophic lateral sclerosis (ALS).
Recipient:
Timothy M. Miller, MD, PhD Saint Louis, MO S25.003
Extra-Motor Pathology in ALS-FTD: Looking Beyond C9orf72 —Eoin Finegan, Rangariroyashe Chipika, Taha Omer,
S24.006
Link between vascular risk factors and grey matter cortical thickness in early MS and the moderating influence of sex —Ilana Katz Sand, Michelle Fabian, Victoria Leavitt, Patrizia
Frank Rigo, Jeffrey Rothstein
4:18 p.m.
S25.005
Modulation of CSF miRNAs in ALS Phase 2 Study Participants Treated with MSC-NTF Cells (NUROWN®) —
Revital Aricha, Haggai Kaspi, Merit Cudkowicz, James Berry, Anthony Windebank, Nathan Staff, Margaret Owegi, Yossef Levy, Chaim Lebovits, Robert Brown, Yael Gothelf, Ralph Kern
S25.006
Tuesday
S24.008
NeurEx: App-based documentation of neurological exam eliminates noise in current disability scales and provides a new scale with enhanced sensitivity —Peter Kosa, Mary Sandford, Alison Wichman, Bibiana Bielekova
5:05 p.m.
Discussion
106 2018 AAN Annual Meeting
S26.002
Interim Clinical Assessment of a Neural Stem Cell Based Therapy for Parkinson’s Disease —Russell Kern, Ibon
S26.003
Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients —C. Olanow, Fabrizio Stocchi, Werner Poewe, Aaron Ellenbogen, Ruth Djaldetti, Tamar Rachmilewitz, Yael Cohen, Sheila Oren, Karl Kieburtz
4:06 p.m.
S26.004
Inhaled Levodopa Administered With Oral Carbidopa/ Levodopa for Early Morning OFF Symptoms in Patients With Parkinson’s Disease: Exploratory Efficacy Analysis —Stuart Isaacson, Aaron Ellenbogen, Robert Hauser, Beth Safirstein, Daniel Truong, Steven Komjathy, Deena Kegler-Ebo, Ping Zhao
4:42 p.m.
Robert Hauser, Stuart Isaacson, Beth Safirstein, Daniel Truong, Ping Zhao, Steven Komjathy, Charles Oh
S25.007
Sit to Stand (STS) Vs. Stair Climbing (SC) as a Measure of Lower Extremity (LE) Function In Ambulatory Patients with Amyotrophic Sclerosis (ambALS). —Mohammed Sanjak, Cody
Mabe, Scott Holsten, Nigel Rozario, Elena Bravver, William Bockenek, Benjamin Brooks
4:54 p.m.
S25.008
iPSC-derived M2-like ALS macrophages suppress proInflammatory phenotype of M1-like macrophages —Weihua
5:05 p.m.
4:54 p.m.
3:42 p.m.
4:18 p.m.
4:42 p.m.
Maria Pia Sormani, Ludwig Kappos, Dieter Haering, Harald Kropshofer, Christian Barro, David Leppert, Davorka Tomic, Jens Kuhle
Brys, Aaron Ellenbogen, Laura Fanning, Natasha Penner, Minhua Yang, Mackenzie Welch, Erica Koenig, Eric David, Tara Fox, Shavy Makh, Jason Aldred, Ira Goodman, Danielle Graham, Andreas Weihofen, Jesse Cedarbaum
TP73 Is an Amyotrophic Lateral Sclerosis Candidate Risk Gene —Jon Downie, Summer Gibson, Spyridoula Tsetsou, Matthew
Zhao, David Beers, Jason Thonhoff, Loren Ornelas, Clive Svendsen, Stanley Appel
S24.007
S26.001
Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease —Miroslaw
3:54 p.m.
S25.004
Strand-specific antisense oligonucleotides for C9ORF72ALS/FTD —Lindsey Hayes, Alyssa Coyne, Paymaan Jafar-Nejad,
Casaccia, James Sumowski
Including Blood Neurofilament Light Chain in the NEDA Concept in Relapsing-Remitting Multiple Sclerosis Trials —
3:30 p.m.
G
4:06 p.m.
Keefe, Kristi Russell, Karla Figueroa, Mark Bromberg, Charles Murtaugh, Stefan Pulst, Joshua Bonkowsky, Lynn Jorde
4:30 p.m.
Parkinson’s Disease Clinical Trials
Garitaonandia, Rodolfo Gonzalez, Glenn Sherman, Alexander Noskov, Dylan Cardiff, Christiansen-Weber Trudy, Andrey Semechkin, Emma Braine, Azmin Shahrul, Girish Nair, Andrew Evans
4:18 p.m.
Sormani, Mark Freedman, Julie Aldridge, Kurt Marhardt, Nicola De Stefano
S26 Movement Disorders:
Mark A Doherty, Alice Vajda, Russell McLaughlin, Niall Pender, Orla Hardiman, Peter Bede
4:30 p.m.
S24.005
G
Research This award recognizes an individual who has made significant
Cohen, Harald Kropshofer, Rolf Meinert, Christian Barro, Martin Bernhard Merschhemke, Dieter Haering, David Leppert, Davorka Tomic, Ludwig Kappos
Disease Activity as Assessed by the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) Score Predicts Long-Term Clinical Disease Activity (CDA)-Free Status and Disability Progression in Patients Treated with Subcutaneous Interferon beta-1a (scIFN?-1a) —Maria Pia
3:30 p.m.–5:30 p.m.
3:30 p.m. Sheila Essey Award: An Award for ALS
3:54 p.m.
Tuesday, April 24
Discussion
S26.005
Inhaled Levodopa Administered With Oral Carbidopa/ Levodopa for Early Morning OFF Symptoms in Patients With Parkinson’s Disease: Safety Assessment —Aaron Ellenbogen,
4:30 p.m.
S26.006
Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study —Donald Grosset,
Rohit Dhall, Tanya Gurevich, Jan Kassubek, Werner Poewe, Olivier Rascol, Monika Rudzinska-Bar, Jennifer Cormier, Alexander Sedkov, Charles Oh
4:42 p.m.
S26.007
Effect of NP002, a centrally acting cholinergic agent, in reducing dyskinesia, freezing of gait, and falls in patients with Parkinson’s disease —Abraham Lieberman, Thurmon Lockhart, Markey Olson, Victoria Smith, Christopher Frames
4:54 p.m.
S26.008
Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study —Donald Grosset, Rohit Dhall,
Tanya Gurevich, Jan Kassubek, Werner Poewe, Olivier Rascol, Monika Rudzinska-Bar, Jennifer Cormier, Alexander Sedkov, Charles Oh
5:05 p.m.
Discussion
Thank You
2O18 Industry Roundtable Members* The American Academy of Neurology and the Industry Roundtable collaborate on opportunities to support neurology and serve patients with neurologic disease.
$50,000
$40,000
$25,000
Acorda Therapeutics Greenwich Biosciences, Inc. IPSEN Biopharmaceuticals, Inc.
Abbott Adamas Pharmaceuticals, Inc. Allergan Alnylam Pharmaceuticals, Inc. Eisai Inc.
$10,000 GE Healthcare Medtronic Neurocrine Biosciences Sarepta Therapeutics UCB Inc.
CSL Behring Ionis Pharmaceuticals
*commitments as of January 19, 2018
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S27 “Best of” Session: Movement Disorders
Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 93 »
1:00 p.m.–2:00 p.m.
G
S28 Practice, Policy, and Ethics
Wednesday, April 25
1:00 p.m.–3:00 p.m.
G
S29 Child Neurology and
Developmental Neurology I
G
This session will be presented at the Maximize Your Value Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center
1:00 p.m.
1:00 p.m.
Telephonic follow for chronic childhood neurological disorders: A Teach and Treat Initiative —Shefalli Gulati, Shruthi N M, Ramesh Konanki, Manoj Singh, Lokesh Saini, Vishal Sondhi, Prashant Jauhari, Biswaroop Chakrabarty, R M Pandey
Jerry Mendell, Samiah Al-Zaidy, Richard Shell, William Arnold, Louise Rodino-Klapac, Thomas Prior, Linda Lowes, Lindsay Alfano, K Berry, Kathleen Church, John Kissel, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Courtney Wells, Arthur Burghes, Kevin D. Foust, Kathrin Meyer, Shibi Likhite, Brian Kaspar
1:12 p.m.
1:12 p.m.
S28.001
S28.002
Routine and Urgent TeleNeurology consultations improve access to neurological care and decreases length of stay — Robert McCormick, Juan Estrada, Cynthia Whitney, Adam Cohen, Lee Schwamm, Marcelo Matiello
S29.001
AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Continued Event Free Survival and Achievement of Developmental Milestones —
S29.002
AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Patients Treated Early with the Proposed Therapeutic Dose Were Able to Sit Unassisted at a Younger Age —Lindsay Alfano, Linda Lowes, Samiah Al-Zaidy, Richard Shell,
1:24 p.m.
S28.003
Safety of lumbar puncture performed on dual antiplatelet therapy —Ivan Carabenciov, Maximiliano Hawkes, Sara Hocker
William Arnold, Louise Rodino-Klapac, Thomas Prior, Katherine Berry, Kathleen Church, John Kissel, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Courtney Wells, Arthur Burghes, Kevin D. Foust, Kathrin Meyer, Shibi Likhite, Brian Kaspar, Jerry Mendell
1:36 p.m.
S28.004
1:24 p.m.
Variability of Safety Policies Related to Prion Disease Among Top Neurological Institutions —Katherine
Werbaneth, Praveen Tummalapalli, Lironn Kraler, Carl Gold
S29.003
AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Continued Independence from Nutritional and Ventilatory Support in Patients Dosed Early in Disease Progression —Richard Shell, Samiah Al-Zaidy, William Arnold, Louise Rodino-Klapac, Thomas Prior, Linda Lowes, Lindsay Alfano, K Berry, Kavitha Kotha, Kathleen Church, John Kissel, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Courtney Wells, Arthur Burghes, Kevin D. Foust, Kathrin Meyer, Shibi Likhite, Brian Kaspar, Jerry Mendell
1:36 p.m.
S29.004
AVXS-101 Trial Experience: CHOP-INTEND Detects Early Improvements in Infants with SMA Type 1 but is not Sensitive to Continued Advances in Motor Function —Linda Lowes, Lindsay Alfano, Megan Iammarino, Natalie Miller, Melissa Menier, Jessica Cardenas, Douglas M. Sproule, Sukumar Nagendran, Samiah Al-Zaidy, Jerry Mendell
1:48 p.m.
S29.005
A Subset of Axonal and Synaptic Genes with Altered Expression/Splicing in SMA-MNs Harbours a Common Motif that Interacts with SMN/SYNCRIP Complex —
Federica Rizzo, Monica Nizzardo, Shikha Vashisht, Valentina Melzi, Irene Faravelli, Sabrina Salani, Monica Bucchia, Michela Taiana, Andreina Bordoni, Nereo Bresolin, Uberto Pozzoli, Giacomo Comi, Stefania Corti
2:00 p.m.
S29.006
MoveDMD®: Positive Effects of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy in Phase 2 Study with an Open-Label Extension —Richard Finkel, Krista H. Elvire Vandenborne, H. Lee
Wednesday
Sweeney, Erika Finanger, Gihan Tennekoon, Perry Shieh, Rebecca J. Willcocks, Sean C. Forbes, William Triplett, Sabrina Yum, Maria Mancini, Angelika Fretzen, Joanne Donovan
2:12 p.m.
S29.007
Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Pediatric Lower Limb Spasticity: Primary Results —Heakyung Kim, Jill Meilahn, Chengcheng Liu, Henry G. Chambers, Rozalina Dimitrova
2:24 p.m.
S29.008
Gene Therapy in Children with AADC Deficiency with AGIL-AADC Leads to De Novo Dopamine Production and Sustained Improvement in Motor Milestones over 5 Years —Yin-Hsiu Chien, Ni-Chung Lee, Sheng-Hong Tseng, Chun-
Hwei Tai, Anne Marie Conway, Kirsten Gruis, Mark Pykett, Wuh-Liang Hwu
2:35 p.m.
108 2018 AAN Annual Meeting
Discussion
S30 Movement Disorders:
Dystonia, Chorea, and other Disorders
1:00 p.m.–3:00 p.m.
G
1:00 p.m. Jon Stolk Award in Movement Disorders
for Young Investigators T his award recognizes young investigators who have made
significant contributions to movement disorders research. The award is named for Dr. Jon Stolk, a driving force in the drug development field for Parkinson’s disease.
Nandakumar Narayanan, MD, PhD Iowa City, IA S30.002
Establishing Preclinical Proof-of-Concept of Gene Therapy for Huntington Disease —Melvin Evers 1:24 p.m.
S30.003
Perinatal insults and neurodevelopmental disorders may impact age of diagnosis of Huntington’s disease —Filipe B
Rodrigues, Melinda Barkhuizen, David G Anderson, Edward Wild, Boris W Kramer, Danilo Gavilanes
1:36 p.m.
S30.004
Brain Structural Changes in Focal Dystonia—What About Task Specificity? A Multimodal Imaging Study —Elisabetta Sarasso, Federica Agosta, Alexandra Tomic, Nataþa Dragaþevic, Marina Svetel, Elisa Canu, Vladimir Kostic, Massimo Filippi
1:48 p.m.
S30.005
Disease onset in X-linked Dystonia-Parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1 —D. Cristopher Bragg, Nichita Kulkarni, Christine A. Vaine, Rachita Yadav, Mai-Linh Ton, Patrick Acuna, Criscely Go, Trisha Multhaupt-Buell, Ulrich Muller, Xandra Breakefield, Laurie Ozelius
2:00 p.m.
S30.006
Functional Neuroimaging of Functional Movement Disorders (FMD) Before and After a Rehabilitation Program —Kathrin LaFaver, Leonard Faul, Alexandra Jacob, Brendan Depue
2:12 p.m.
S30.007
SIAXI: IncobotulinumtoxinA for sialorrhea in Parkinson’s disease, stroke, and other etiologies-Phase 3 Results —Olaf Michel, Andrew Blitzer, Andrzej Friedman, Birgit Flatau-Baqué, János Csikós, Wolfgang Jost
2:24 p.m.
S30.008
Association analysis of single nucleotide polymorphisms near the DYT3 locus to dystonic symptoms in X-linked dystonia-parkinsonism —Gerard Raimon Saranza, Derick Erl Sumalapao, Aloysius Domingo, Paul Matthew Pasco, Lillian Lee, Roland Dominic Jamora, Ana Westenberger, Christine Klein
1:00 p.m.
Discussion
G
S31.002
Michael Reed, Steve H. Kawahara, Robert Cowan, Firas Dabbous, Karen Campbell, Riya Pulicharam, Hema Viswanathan, Richard Lipton
Clinical Phenotypes of Pure Primary Lateral Sclerosis —
Shivam Mittal, William Hu, Keith Josephs, J. Ahlskog, Eric Sorenson, Anhar Hassan
S31.003
Evaluation of Quality of Life and Disability in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Following Treatment with Patisiran, An Investigational RNAi Therapeutic: Results from the Phase 3 APOLLO Study —David Adams, Alejandra Gonzalez-
Duarte, William O’Riordan, Chih-Chao Yang, Taro Yamashita, Arnt Kristen, Ivaylo Tournev, Hartmut Schmidt, Teresa Coelho, John Berk, Kon-Ping Lin, Peter Dyck, Pritesh Gandhi, Marianne Sweetser, Jihong Chen, Sunita Goyal, Jared Gollob, Ole Suhr
S31.004
More than just fun and games: ACTIVE Workspace volume video game quantifies upper extremity function in individuals with neuromuscular disease —Lindsay Alfano,
Natalie Miller, Megan Iammarino, Margaret Dugan, Melissa MooreClingenpeel, John Kissel, Samiah Al-Zaidy, Kevin Flanigan, Jerry Mendell, Linda Lowes
1:48 p.m.
S31.005
Sporadic Late-Onset Nemaline Myopathy —Elie Naddaf,
Margherita Milone, Ankit Kansagra, Francis Buadi, Taxiarchis Kourelis
2:00 p.m.
S31.006
RA101495, A Subcutaneously Administered Peptide Inhibitor of Complement Component 5 (C5) for the Treatment of Generalized Myasthenia Gravis (gMG): Phase 1 Results and Phase 2 Design —James Howard, Henry Kaminski, Richard Nowak, Gil Wolfe, Michael Benatar, Alonso Ricardo, Michelle D Hoarty, Steven J DeMarco, Ramin Farzaneh-Far, Petra Duda
2:12 p.m.
S31.007
Autologous Hematopoietic Stem Cell Transplantation May Be Highly Effective Treatment for Severe, Treatment Refractory Stiff Person Syndrome —George Georges, Peter McSweeney, James Bowen, Michael Pearlman, Annette Wundes, Gloria Von Geldern, George Kraft, Michael Weiss, Joel Sytsma, Bernadette McLaughlin, Richard Nash
2:24 p.m.
S31.008
Small Fiber Polyneuropathy in Patients with Neurofibromatosis, Type 1 —Vera Bril, Alon Abraham, Raymond
H Kim, Catherine Maurice, Tayir Alon, Paul Kongkham, Gelareh Zadeh, Carolina Barnett Tapia
2:35 p.m.
Discussion
= Abstract of Distinction
S32.001
Migraine Treatment Patterns and Opioid Use Among Chronic and Episodic Migraine Patients Identified by a Clinician-Administered Semi-Structured Diagnostic Interview —Jelena Pavlovic, Justin S. Yu, Stephen Silberstein,
1:12 p.m.
S32.002
Increased Migraine-Free Intervals With Eptinuzumab Were Associated With Improved Health-Related Quality-of-Life Outcomes Through Week 12: Results From the Phase 3 PROMISE-1 Trial —Richard Lipton, David Kudrow, Eric Kassel, Joe Hirman, Roger Cady
1:24 p.m.
S32.003
In Vitro Characterization of Agonist Binding and Functional Activity at a Panel of Serotonin Receptor Subtypes for Lasmiditan, Triptans and Other 5-HT Receptor Ligands and Activity Relationships for Contraction of Human Isolated Coronary Artery —Antoinentte Maassen Van Den Brink, Alejandro
Labastida-Ramirez, Antoon van den Bogaerdt, Ad Bogers, Eric Zanelli, Laurent Meeus, Alexander Danser, Kirk Johnson, Joe Kovalchin, Carlos Villalon, Eloisa Rubio-Beltran
1:36 p.m.
S32.004
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients with Stable Angina —Christophe Depre, Lubomir Antalik, Amaal Starling, Michael Koren, Osa Eisele, Yumi Kubo, Robert Lenz, Daniel Mikol
1:48 p.m.
S32.005
Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine —Stephen Silberstein, Ernesto Aycardi, Marcelo Bigal, Paul Yeung, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, MS, David Dodick, Peter Goadsby
2:00 p.m.
S32.006
Efficacy of Erenumab for the Treatment of Patients With Chronic Migraine With and Without Aura —Messoud Ashina, David Dodick, Peter Goadsby, David Kudrow, Uwe Reuter, Stewart Tepper, Sunfa Cheng, Dean Leonardi, Robert Lenz, Daniel Mikol
2:12 p.m.
S32.007
The Positive Impact of Fremanezumab on Work Productivity and Activity Impairment in Patients with Chronic Migraine —Richard Lipton, Sanjay Gandhi, Timothy Fitzgerald, MA, PhD, Paul Yeung, Josh Cohen, Ronghua Yang, Ernesto Aycardi
2:24 p.m.
S32.008
Lasmiditan Inhibits CGRP Release in the Mouse Trigeminovascular System —Antoinentte Maassen Van Den
Brink, Eloisa Rubio-Beltran, Ingrid Garrelds, Kristian Haanes, Kayi Chan, Joe Kovalchin, Kirk Johnson, Alexander Danser, Carlos Villalon, Alejandro Labastida-Ramirez
2:35 p.m.
G
1:00 p.m.
Mathieu
1:36 p.m.
S31.001
The natural history of impairments and disabilities in Oculopharyngeal Muscular Dystrophy: a large retrospective study —Jean-Denis Brisson, Cynthia Gagnon, Bernard Brais, Jean
1:24 p.m.
S32 Headache: Therapeutics
Discussion
AAN.com/view/AM18 109
Wednesday
2:35 p.m.
Biomarkers in Neuromuscular Disorders
1:12 p.m.
Recipient:
1:12 p.m.
S31 Therapeutics, Phenotypes, and
1:00 p.m.–3:00 p.m.
SCIENTIFIC PLATFORM SESSIONS
1:00 p.m.–3:00 p.m.
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–4:15 p.m. S33 Global Health
3:30 p.m.–5:30 p.m.
G
This session will be presented at the Research Corner Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center 3:30 p.m.
S33.001
LTA4H Genotype is Not Associated with Mortality in Zambian Patients with Tuberculous Meningitis —
Shawn Love, Igor Koralnik, Xin Dang, Kalo Musukuma, Eugene Mubanga, Clayton Buback, Gretchen Birbeck, Masharip Atadzhanov, Omar Siddiqi
3:42 p.m.
S33.002
The Impact of Changes in Health Expenditures Per Capita, Population Growth, and Aging on Ischemic Stroke Deaths by Country, 1995-2014 —Kafi Hemphill, Anthony Kim
S34 Behavioral and
Cognitive Neurology
3:30 p.m.–5:30 p.m.
G
3:30 p.m. Norman Geschwind Prize in Behavioral
Neurology This prize is awarded to an individual for outstanding research
in the field of behavioral neurology. Applicants should have a strong desire to expand the field of behavioral neurology through research.
Zachary Miller, MD San Francisco, CA S34.002
Characterisation of basal ganglia pathology in frontotemporal dementia: a connectivity-based multimodal neuroimaging study —Peter Bede, Eoin Finegan,
Rangariroyashe Chipika, Taha Omer, Niall Pender, Siobhan Hutchinson, Orla Hardiman
3:54 p.m.
S34.003
The Neuroimaging Profile of Primary Progressive Aphasia —Eoin Finegan, Rangariroyashe Chipika, Taha Omer, Siobhan Hutchinson, Mark A Doherty, Alice Vajda, Russell McLaughlin, Orla Hardiman, Peter Bede
4:06 p.m.
S34.004
Network Localization of Disordered Free Will Perception — Richard Darby, Matthew Burke, Michael Fox
4:18 p.m.
S34.005
Gerstmann like Parietal Dysfunction in a Family with Congenital Mirror Movements with a Novel Missense Variant in RAD51 Gene —Adit Friedberg, Merav Kedmi, Shay Ben-Shachar, Avi Orr-Urtreger, Nir Giladi, Iftah Biran
4:30 p.m.
S34.006
A High Prevalence Rate of a Positive Screen for Neurocognitive Dysfunction in Patients with Chronic Hepatitis C infection in an Irish Clinic. —Damien Ferguson, Orla Strahan, Robert Coen, Susan McKiernan, Colm Bergin, Paul Dockree, Colin Doherty, Suzanne Norris
4:42 p.m.
Developmental Neurology II
3:30 p.m.
S34.007
G
S35.001
Natalizumab treatment for highly active children and juveniles multiple sclerosis patients : An Israeli collaborative study —Shay Menascu, Ron Milo, David Magalashvili, Mark Dolev, Anat Achiron
S35.002
A New Rodent Model of Dystonic Cerebral Palsy —Bhooma Aravamuthan, Anne Young, Seward Rutkove
3:54 p.m.
S35.003
Safety of mTOR Inhibitors in Infants with Tuberous Sclerosis Complex (TSC): Multicenter Clinical Experience —Darcy Krueger, Jamie Capal, Paolo Curatolo, Orrin Devinsky, Sergiusz Jozwiak, Petrus de Vries, Michael Wong, Stephanie Bruns, David Franz
4:06 p.m.
S35.004
Seizures at presentation are predictors of relapsing disease in children presenting with acute disseminated encephalomyelitis —Tom Rossor, Sukhvir Wright, Sophie Duignan, Olga Ciccarelli, Krishna Das, Evangeline Wassmer, Ming Lim, Cheryl Hemingway, Yael Hacohen
4:18 p.m.
S35.005
Implications of the International Paediatric Multiple Sclerosis Study Group Consensus Criteria for Paediatric Acute Disseminated Encephalomyelitis: a Nationwide Validation Study —Magnus Spangsberg Boesen, Melinda
Magyari, Nils Koch-Henriksen, Lau Thygesen, Peter Uldall, Morten Bjorn Blinkenberg, Alfred Peter Born
4:30 p.m.
S35.006
Dietary Therapy In Epilepsy Treatment (DIET-Trial): A Randomised Non-Inferiority Trial Comparing KD, MAD & LGIT for Drug Resistant Epilepsy —Vishal Sondhi, Anuja
Agarwala, Biswaroop Chakrabarty, Prashant Jauhari, Rakesh Lodha, R M Pandey, G S Toteja, Vinod K Paul, Shefalli Gulati
4:42 p.m.
S35.007
Understanding Divergent Trajectories in Pediatric Patients with Moderate to Severe Traumatic Brain Injury —Faisal
Resting State Functional Connectivity Correlates of Fatigue Following Mild Traumatic Brain Injury —Jeffrey Lewis, Kristine Knutson, Stephen Gotts, Eric Wassermann
Rashid, Emily Dennis, Monica Ellis-Blied, Talin Babikian, Jeffrey Alger, Julio Villalon-Reina, Yan Jin, Alexander Olsen, Richard Mink, Christopher Babbitt, Jeffrey Johnson, Christopher Giza, Paul Thompson, Robert Asarnow
4:54 p.m.
4:54 p.m.
S34.008
Cerebellar Functional Neuroanatomy: Recent Developments, Outstanding Questions, and Future Directions. —Xavier Guell, John Gabrieli, Jeremy Schmahmann, Satrajit Ghosh
5:05 p.m.
Wednesday 110 2018 AAN Annual Meeting
S35 Child Neurology and
3:42 p.m.
Recipient:
3:42 p.m.
Wednesday, April 25
Discussion
S35.008
DNA methylation in autism brains supports epigeneticmediated effects in GABA signaling. —Jeffery Vance, Juan young, Anthony Griswold, Cheryl Brandenburg, Margaret PericakVance, John Hussman, Gene Blatt
5:05 p.m.
Discussion
S36 MS Therapeutics and Clinical Research
3:30 p.m.
4:30 p.m.–5:30 p.m.
G
S36.001
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis —Stephen Hauser, Ludwig Kappos, Xavier Montalban, Harold Koendgen, Carrie Li, Carole Marcillat, Ashish Pradhan, David Wormser, Jerry Wolinsky
3:42 p.m.
S36.002
Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis —Amit Bar-Or, Daniela Stokmaier, Kevin
Winthrop, Cathy Chognot, Joanna Evershed, Marianna Manfrini, John McNamara
3:54 p.m.
S36.003
Alemtuzumab-Treated Patients Experienced Decreased MRI Disease Activity and Slowing of Brain Volume Loss Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS I (TOPAZ Study) —Alex Rovira, Michael Barnett, Giancarlo Comi, Kunio Nakamura, Daniel Pelletier, Sven Schippling, Anthony Traboulsee, David Margolin, Maria Melanson, Nadia Daizadeh, Douglas Arnold
4:06 p.m.
SCIENTIFIC PLATFORM SESSIONS
3:30 p.m.–5:30 p.m.
S36.004
Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS): interim results of the Multiple Sclerosis International Stem cell Transplant (MIST) Randomized Trial —Richard K Burt, Roumen Balabanov, John Snowden, Basil
S37 Neurorehabilitation
G
This session will be presented at the Research Corner Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center 4:30 p.m.
S37.001
Chronic Nerve Health Following Implantation of Nerve Cuff Electrodes Designed for the Proximal Femoral Nerve —Max Freeberg, Gilles Pinault, Dustin Tyler, Ronald Triolo, Rahila Ansari
4:42 p.m.
S37.002
Structural and Functional MRI Correlates of Hand Motor Performance in Patients with Multiple Sclerosis —Claudio Cordani, Claudio Piazza, Marco Roselli, Federica Esposito, Marta Radaelli, Bruno Colombo, Paolo Preziosa, Giancarlo Comi, Massimo Filippi, Maria Rocca
4:54 p.m.
S37.003
Using Intracortical Microstimulation to Deliver Instructional Information: Towards Neural Rehabilitation Solutions — Kevin Mazurek, Marc Schieber
5:06 p.m.
S37.004
Pre-existing White Matter Disease Burden Impacts Cognitive Outcome after Inpatient Rehabilitation for Ischemic Stroke —Heather Heiser, Laurel Packard, Nathan Bernicchi, Muhib Khan
Sharrack, Maria-Carolina Oliveira, Joachim Burman
4:18 p.m.
S36.005
Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, ActiveControlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) —Ludwig Kappos, Krzysztof Selmaj, Amit Bar-Or, Giancarlo Comi, Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Havrdova, James Sheffield, Kartik Raghupathi, Bruce Cree, Jeffrey Cohen
4:30 p.m.
S36.006
Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) —Bruce Cree, Amit Bar-Or, Giancarlo Comi, Krzysztof Selmaj,
Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Havrdova, James Sheffield, Kartik Raghupathi, Ludwig Kappos, Jeffrey Cohen
4:42 p.m.
S36.007
Wednesday
A Randomized Controlled Pilot Trial of Aspirin to Improve Exercise Performance in Persons with Multiple Sclerosis — Victoria Leavitt, Adam Blanchard, Chu-Yueh Guo, Eva Gelernt, James Sumowski, Claire Riley, Joel Stein
4:54 p.m.
S36.008
Risk of Stroke in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a) —
Meritxell Sabidó Espin, Saritha Venkatesh, Julie Aldridge, Alan Gillett
5:05 p.m.
Discussion
= Abstract of Distinction
AAN.com/view/AM18 111
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S38 “Best of” Session: Clinical Trial Updates in Neuromuscular Disorders
Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 93 »
1:00 p.m.–2:15 p.m.
G
S39 History of Neurology
Thursday, April 26
1:00 p.m.–3:00 p.m.
G
This session will be presented at the Research Corner Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center 1:00 p.m. Lawrence C. McHenry Award: An Award
S40 Acute Stroke Care
1:00 p.m.
G
S40.001
Automated Detection of Facial Weakness Using Machine Learning —Omar Uribe, Mark McDonald, Yan Zhuang, Iris Lin,
Daniel Arteaga, William Dalrymple, Bradford Worrall, Gustav Rohde, Andrew Southerland
for the History of Neurology S elected by the Lawrence C. McHenry Award Workgroup,
1:12 p.m.
Recipient:
Wu, Anne-Katrin Giese, Arne Lauer, Gregoire Boulouis, Brittany Mills, Lisa Cloonan, Kathleen Donahue, William Copen, Pamela Schaefer, Natalia Rost
this award recognizes excellence in research in the history of neurology.
Bart TH Lutters, BSc Utrecht , Netherlands
1:24 p.m.
S39.003
Lymphatics of the Central Nervous System: Forgotten first descriptions. —Daniel Moreno-Zambrano, David
Santana, David Avila, Rocio Santibanez
1:36 p.m.
S39.004
Evolving models of pseudobulbar affect: historical accounts, controversies, localisation —Peter Bede, Eoin Finegan, Rangariroyashe Chipika, Orla Hardiman
1:48 p.m.
S39.005
“These Cases Are So Dramatic That They Could Never Be Overlooked:” A History of Pediatric Neuromyelitis Optica — Alison Christy
S40.002
White Matter Integrity is Associated with Early Neurologic Improvement After Ischemic Stroke —Mark Etherton, Ona
1:24 p.m.
S40.003
Impaired cerebral autoregulation after endovascular stroke therapy is associated with hemorrhagic transformation — Nils Petersen, Anson Wang, Randolph Marshall, David Mampre, Can Ozan Tan, Kevin Sheth
1:36 p.m.
S40.004
Long-term Consequences of Further Post-stroke Disability in Patients with Pre-morbid Disability: Potential for Acute Stroke Therapies —Aravind Ganesh, Sarah T Pendlebury, Rose M Wharton, Ramon Luengo-Fernandez, Peter Rothwell, on behalf of the Oxford Vascular Study
1:48 p.m.
S40.005
CT Brain Calcium Score Predicts Recurrent Transient Ischaemic Attack or Stroke in Patients with First Presentation of Transient Ischaemic Attack —Wan Yee Kong,
Eide Sterling, Nicholas JH Ngiam, Christine CH Yuan, Deborah YC Tan, Han Yang Ong, Sunny Sibi, Benjamin Yong Qiang Tan, Vijay Sharma, Bernard PL Chan, Leonard Yeo
2:00 p.m.
S40.006
Is the Slope of Optic Nerve Sheath Diameter Change in Malignant Middle Cerebral Artery Stroke Associated with Mortality Outcomes? —Grace Kuo, Steven Cen, Ling Zheng, Alejandro Vazquez, John Margetis, Jess Holguin, Kellyn Trummer, Benjamin Emanuel, May Kim-Tenser, Sebina Bulic
2:12 p.m.
S40.007
Sex and Race-Ethnic Disparities in Door-to-CT Time in Acute Ischemic Stroke in the FL-PR CReSD —Enmanuel Perez, Kefeng Wang, Maria Ciliberti-Vargas, Carolina M. Gutierrez, Sofia Oluwole, Chuanhui Dong, Ralph Sacco, Tatjana Rundek
2:24 p.m.
S40.008
Neighborhood differences in stroke knowledge, selfefficacy, and barriers to calling 9-1-1 in Chicago —Sarah
Song, Soyang Kwon, Erin Wymore, Namratha Kandula, Jen Brown, Amy Eisenstein, Christopher Richards, Maryann Mason, Heather Beckstrom, Peggy Jones, Knitasha Washington, Neelum Aggarwal, Shyam Prabhakaran
2:35 p.m.
Thursday 112 2018 AAN Annual Meeting
Discussion
S41 Neurologic Infections
1:00 p.m.
1:00 p.m.–3:00 p.m.
G
S41.001
Clinical performance of the BioFire FilmArray Meningitis/ Encephalitis panel in Korean adult patients with central nervous system infection —Eunjin Kwon, So Yeon Kim, Ji Yun,
Sook Young Roh, Dohyun HAN, Jee Jeong, Kee-Duk Park, Moon-Woo Seong
1:12 p.m.
S41.002
FilmArray Meningitis/Encephalitis Multiplex Polymerase Chain Reaction Performance and Clinical Impact —Sara
Radmard, Prajwal Ciryam, Savina Reid, Nhan Ho, Alexandra Boubour, Jason Zucker, Dean Sayre, Benjamin Miko, Marcus Pereira, Susan Whittier, Daniel Green, Kiran Thakur
1:24 p.m.
S41.003
Rabies Virus Causes Acute Neurological Disease by Inducing Mitochondrial Dysfunction and Oxidative Stress: Critical Role of the Rabies Virus Phosphoprotein —Alan Jackson, Wafa Kammouni, Heidi Wood, Paul Fernyhough
1:36 p.m.
S41.004
Treating Progressive Multifocal Leukoencephalopathy With Expanded Third Party BK Virus Specific Cytoxic T Cells In Acute Myeloid Leukemia Patient Following Cord Blood Transplantation —Sudhakar Tummala, Katy Rezvani 1:48 p.m.
S41.005
A Human derived 3D Brain Microphysiological System as a Model to study Progressive Multifocal Leukoencephalopathy —Paula Barreras, David Pamies, Maria Chiara Monaco, Laura Munoz-Arcos, Xiali Zhong, Eugene Major, Helena Hogberg, Thomas Hartung, Carlos Pardo-Villamizar
2:00 p.m.
S41.006
Long-term Outcomes of West Nile Neuroinvasive Disease. —Maximiliano Hawkes, Ivan Carabenciov, Eelco Wijdicks, Alejandro Rabinstein
2:12 p.m.
S41.007
Aging-Associated Proteins in CSF of Persons Living with HIV —Bryan Smith, Katrina Geannopoulos, Chuen-Yen Lau, Ulisses Santamaria, Robert G. Deiss, Anuradha Ganesan, Brian K. Agan, Avindra Nath
2:24 p.m.
S41.008
The effects of JAK inhibitors in a mouse model of HIV neurocognitive disorders —William Tyor, Woldeab Haile,
Christina Gavegnano, Heather Bimonte-Nelson, Rajeth Koneru, Raymond Schinazi
2:35 p.m.
Discussion
SCIENTIFIC PLATFORM SESSIONS
1:00 p.m.–3:00 p.m.
S42 Neurocritical Care
1:00 p.m.
G
S42.001
Dynamic Changes In EEG Coherence During Cardiac Arrest And Resuscitation In A Rodent Model That Mimics A NeuroIntensive Care Unit —Yama Akbari, Danny Siu, Donald Lee, Lauren Lee, Afsheen Bazrafkan, Juan Alcocer, Niki Maki, Maryam Hosseini, Robert Wilson, Beth Lopour
1:12 p.m.
S42.002
Differential Outcomes in Cardiac Arrest Due to Drug Overdose —Cora Ormseth, Laura Miyares, Sonya Zhou, Mary Barden, Rachel Beekman, Carolina Maciel, David Greer
1:24 p.m.
S42.003
A Multimodal Optical Imaging Platform that Predicts Neurological Recovery after Cardiac Arrest in an “Animal Neuro-Intensive Care Unit” —Robert Wilson, Christian Crouzet, Mohammad Torabzadeh, Afsheen Bazrafkan, Dishant Donga, Shuhab Zaher, Juan Alcocer, Bernard Choi, Bruce Tromberg, Yama Akbari
1:36 p.m.
S42.004
Acute serum GFAP, NF-L, Tau, and UCH-L1 predict CT pathology and 3-month outcome in TBI —Jamie Podell,
Frederick Korley, John Yue, David Wilson, Adam Ferguson, Esther Yuh, Pratik Mukherjee, Kevin Wang, Alex Valadka, Ava Puccio, David Okonkwo, Geoffrey Manley, Ramon Diaz-Arrastia
1:48 p.m.
S42.005
Somatic death and Asystole after brain death diagnosis; duration of circulatory survival in the intensive care unit — Omar Ayoub, Areej Bushnag, Ahmed Abdelaal, Alhassan Ghodeif
2:00 p.m.
S42.006
Data-Driven Comparison Of Acute Imaging Biomarkers For Spinal Cord Injury: A Prospective TRACK-SCI Pilot Study —J. Russell Huie, Jason Talbott, Vineeta Singh, Xuan Duong
Fernandez, Rachel Tsolinas, Lisa Pascual, Jonathan Pan, Nikolaos Kyritsis, Dolores Torres, Michael Beattie, Jacqueline Bresnahan, Adam Ferguson, Sanjay Dhall, William Whetstone
2:12 p.m.
S42.007
Restarting Therapeutic Anticoagulation in Patients with Intracerebral Hemorrhage and Mechanical Heart Valves. —Joji Kuramatsu, Jochen Sembill, Stefan Schwab, Hagen Huttner, Retrace Investigators
2:24 p.m.
S42.008
Racial Variation in Comfort Measures Only Status in Patients with Intracerebral Hemorrhage —Cora Ormseth,
Guido Falcone, Sara Jasak, David Mampre, Audrey Leasure, Laura Miyares, David Hwang, Michael James, Fernando Testai, Kyra Becker, David Tirschwell, Carl Langefeld, Daniel Woo, Kevin Sheth
2:35 p.m.
Discussion
Thursday
= Abstract of Distinction
AAN.com/view/AM18 113
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–5:30 p.m. S43 Migraine
3:30 p.m.–5:30 p.m.
G
3:30 p.m. Harold Wolff-John Graham Award: An
Award for Headache/Facial Pain Research T his award recognizes individuals who have submitted research results in the field of headache and facial pain.
Recipient:
William R. Renthal, MD, PhD Boston, MA
3:42 p.m.
S43.002
Factors Associated with Acute Medication Overuse in Persons with Migraine: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study —Todd
Schwedt, Aftab Alam, Michael Reed, Kristina Fanning, Sagar Munjal, David Dodick, Dawn Buse, Richard Lipton
3:54 p.m.
S43.003
Evaluation of the Identify Chronic Migraine (ID-CM) Screener in a Large Medical Group —Justin S. Yu, Jelena
Pavlovic, Stephen Silberstein, Michael Reed, Steve H. Kawahara, Robert Cowan, Firas Dabbous, Karen Campbell, Riya Pulicharam, Hema Viswanathan, Richard Lipton
4:06 p.m.
S43.004
The King-Devick test (KDT) and visual contrast sensitivity test (VCS) in migraine: the effect of migraine attack on rapid eye movements and visual sensitivity —Chia-Chun Chiang, Amaal Starling, David Dodick, Juliana VanderPluym
4:18 p.m.
S43.005
Randomized Controlled Study of Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Migraine: The PRESTO Trial —Cristina Tassorelli, Licia Grazzi, Marina De Tommaso, Giulia Pierangeli, Paolo Martelletti, Innocenzo Rainero, Pierangelo Geppetti, Anna Ambrosini, Paola Sarchielli, Eric Liebler, Piero Barbanti
4:30 p.m.
S43.006
Cell type-specific expression of migraine associated genes in the CNS and peripheral nociceptors —Angeliki Vgontzas, William Renthal
4:42 p.m.
S43.007
The Relationship Between Sleep Disorders and Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study —Dawn Buse, Jeanetta C. Rains, Kristina Fanning, Michael Reed, Aubrey Manack Adams, Jelena Pavlovic, Richard Lipton
S44 MS Risk Factors, Susceptibility,
Diagnosis, and Cognitive Impairment
3:30 p.m.
3:30 p.m.–5:30 p.m.
G
S44.001
MS in immigrants to Canada in the McDonald era: Increasing prevalence and risk factors —Dalia Rotstein,
Ruth-Ann Marrie, Sima Gandhi, Kinwah Fung, Colleen Maxwell, Jack Tu, Karen Tu
3:42 p.m.
Thursday, April 26
S44.002
Fish, Fatty Acid Biosynthesis Genes, and Multiple Sclerosis Susceptibility —Annette Langer-Gould, Lucinda Black, Jun Wu,
S45 Movement Disorders: Parkinsonian
Disorders, Basic Science, and Imaging
3:30 p.m.
S45.001
3:42 p.m.
S45.002
Defining the pathologic contribution of glia to alphasynucleinopathies —Abby Olsen, Mel Feany Regional Distribution of α-Synuclein and Alzheimer’s Disease pathology in Lewy Body Disorders —David Coughlin,
Jessica Smith, Edlin Gonzales, Lisa Barcellos, Anny Xiang, Robyn Lucas
Mendy Liang, Andrew Williams, Sharon Xie, Daniel Weintraub, Andrew Siderowf, David Wolk, John Duda, Edward Lee, Murray Grossman, John Trojanowski, David Irwin
3:54 p.m.
3:54 p.m.
S44.003
Symptoms of Hypermobility Spectrum Disorder May Mimic Multiple Sclerosis —Kelsey Riggs, Lauren Babcock, Vernon Rowe, John Hunter, Doug Schell, Arlene O’Shea, Dorsey Paul, Gloria OrtizGuerrero, James Barnett
4:06 p.m.
S44.004
Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study —Ralph Benedict, Bruce Cree, Davorka Tomic, Robert Fox, Gavin Giovannoni, Amit Bar-Or, Ralf Gold, Patrick Vermersch, Harold Pohlmann, Goeril Karlsson, Frank Dahlke, Ludwig Kappos
4:18 p.m.
S44.005
G
S45.003
Tau Pathology within Fetal Graft Tissue at Autopsy: A case report —Abbie Ornelas, Charles Adler, Geidy Serrano, Jasmine Curry, Holly Shill, Oleg Kopyov, Thomas Beach
4:06 p.m.
S45.004
In Vitro Seeding of Endogenous α-Synuclein in Primary Oligodendroglial Cells May Potentially Delineate the Cellular Pathogenesis of Multiple System Atrophy —Seiji
Kaji, Takakuni Maki, Hisanori Kinoshita, Norihito Uemura, Takashi Ayaki, Yuichi Ono, Takahiro Furuta, Makoto Urushitani, Xiaobo Mao, Ted Dawson, Ryosuke Takahashi
4:18 p.m.
S45.005
Alpha Galactosidase A Activity in Parkinson Disease —Roy
Time to Cognitive Worsening in Patients With Relapsing Multiple Sclerosis in Ocrelizumab Phase III Trials —Stanley Cohan, Ralph Benedict, Jerome De Seze, Stephen Hauser, Ludwig Kappos, Jerry Wolinsky, Laura Julian, Pablo Villoslada, Jian Han, Ashish Pradhan, Aaron Miller
Alcalay, Oren Levy, Cheryl Waters, Stanley Fahn, Blair Ford, Sheng-Han Kuo, Nora Vanegas-Arroyave, Hiral Shah, Christopher Liong, Sushma Narayan, Michael Pauciulo, William Nichols, Ziv Gan-Or, Guy Rouleau, Wendy Chung, Pavlina Wolf, Petra Oliva, Joan Keutzer, Karen Marder, Xiaokui Zhang
4:30 p.m.
4:30 p.m.
S44.006
Word Finding Deficits in Early Multiple Sclerosis: A Behavioral and Neuroimaging Investigation —Rachel
Brandstadter, Michelle Fabian, Stephen Krieger, Victoria Leavitt, Christina Lewis, Gabrielle Pelle, James Sumowski
4:42 p.m.
S44.007
Benchmarks of Cognitive Performance in a Large, Representative Patient Population —Carl DeMoor, Richard Rudick, James Williams, Lauren Krupp, Carrie Hersh, Stephen Rao
4:54 p.m.
S44.008
Preservation of Functional Connectivity Moderates the Impact of White Matter Tract Disruption on Cognition in Multiple Sclerosis —Tom Fuchs, Ralph Benedict, Sanjeevani
S45.006
Pharmacokinetic/Pharmacodynamic Analysis of Amantadine for Levodopa-Induced Dyskinesia: Correlation of Therapeutic Plasma Concentrations from Multiple Species with Humans —Elizabeth Brigham, Tom Johnston, Carl
Brown, Jonathon Holt, Susan Fox, Patrick Howson, Jonathan Brotchie, Jack Nguyen
4:42 p.m.
S45.007
Bidirectional longitudinal changes in regional cerebral covariance of vesicular acetylcholine transporter binding in Parkinson disease: Evidence for dynamic regional cerebral compensatory mechanisms —Nicolaas Bohnen, Siamak NejadDavarani, Roger Albin, William Dauer, Martijn Muller
Choudhery, Xian Li, Keith Carolus, Matthew Mallory, Alexander Bartnik, Devon Oship, Faizan Yasin, Deepa Ramasamy, Dejan Jakimovski, Bianca Weinstock-Guttman, Robert Zivadinov, Michael Dwyer
4:54 p.m.
5:05 p.m.
Fanning, Sagar Munjal, Aftab Alam, Dawn Buse, Todd Schwedt, Richard Lipton
ROCHA, Ines Debove, Clarissa Yasuda, Rachel Guimaraes, Felipe Bergo, Anelyssa D’Abreu, Kathleen Poston, Roland Wiest, Fernando Cendes, Paul Thompson, Ysbrand van der Werf, for the ENIGMA Parkinson’s Disease Working Gr
5:05 p.m.
5:05 p.m.
4:54 p.m.
S43.008
Predictors of Allodynia in Persons with Migraine: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study —David Dodick, Michael Reed, Kristina
Discussion
Thursday 114 2018 AAN Annual Meeting
Discussion
S45.008
Widespread Cortical Thinning in Parkinson’s Disease: Findings from the ENIGMA-Parkinson’s Disease Working Group —Boris Gutman, Joanna Bright, Christian Rummel, CRISTIANE
Discussion
SCIENTIFIC PLATFORM SESSIONS
3:30 p.m.–5:30 p.m. S46 Advances in Spinal Muscular Atrophy
3:30 p.m.
G
S46.001
Nusinersen Efficacy in Adults with Spinal Muscular Atrophy —John Day, Connie Wolford, Chelsea MacPherson, William Martens, Michael McDermott, Basil Darras, Darryl De Vivo, Zarazuela Zolkipli-Cunningham, Richard Finkel, Jacinda Sampson, Tina Duong
3:42 p.m.
S46.002
A Long-Term, Open-Label Follow-Up Study of Olesoxime in Patients with Type 2 or Non-Ambulatory Type 3 Spinal Muscular Atrophy who Participated in a Placebo-Controlled Phase 2 Trial —Francesco Muntoni, Jeppe Buchbjerg, Enrico Bertini, Eric Dessaud, Eugenio Mercuri, Jan Kirschner, Carol Reid, Anna Lusakowska, Giacomo Comi, Jean-Marie Cuisset, Jean-Louis Abitbol, Bruno Scherrer, Eduardo Paulo Morawski Vianna, Ludo Van Der Pol, Carole Vuillerot, Ksenija Gorni, Paulo Fontoura
3:54 p.m.
S46.003
Preliminary Evidence for Pharmacodynamics Effects of RG7916 in JEWELFISH, a Study in Patients with Spinal Muscular Atrophy who Previously Participated in a Study with Another SMN2-Splicing Targeting Therapy —Claudia Chiriboga, Eugenio Mercuri, Dirk Fischer, Dominik Kraus, Monika Alexander, Gillian Armstrong, Heidemarie Kletzl, Marianne Gerber, Yumi Cleary, Tobias Bergauer, Ksenija Gorni, Omar Khwaja
4:06 p.m.
S46.004
Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Feasibility for Individuals with Severe Spinal Muscular Atrophy II —
Elizabeth Kichula, Tina Duong, Allan Glanzman, Amy Pasternak, Basil Darras, Richard Finkel, Darryl De Vivo, Zarazuela Zolkipli-Cunningham, John Day
4:18 p.m.
S46.005
Evaluation of lean mass through DXA scanning and the correlation to functional outcomes in adults with SMA. —
Arun Nagaraj, William Arnold, Wendy King, John Kissel, Bakri Elsheikh
4:30 p.m.
S46.006
Nusinersen treatment for adults with Spinal Muscular Atrophy; a single center experience —Bakri Elsheikh, William Arnold, Louisa Mezache, John Kissel
4:42 p.m.
S46.007
Relationship Between Central and Peripheral SMN Protein Increase Upon Treatment with RO7034067 (RG7916) — Agnès Poirier, M. Weetall, Hasane Ratni, Katja Heim, Nikolai Naryshkin, S. Paushkin, Lutz Mueller
4:54 p.m.
S46.008
Pervasive Neuromuscular Deficits in Adults with Nephropathic Cystinosis —Reza Sadjadi, Stacey Sullivan, Rachel Duong, Camille Corre, Peter James, Florian Eichler
5:05 p.m.
Discussion
Thursday
= Abstract of Distinction
AAN.com/view/AM18 115
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S47 “Best of” Session: MS and CNS Inflammatory Diseases
Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 93 »
1:00 p.m.–3:00 p.m.
G
S48 Novel Biomarkers in
Aging and Dementia
1:00 p.m.
1:00 p.m.–3:00 p.m.
G
S48.001
Plasma Tau Corresponds to Preclinical Alzheimer’s Disease and is a Strong Predictor of Future Dementia —Matthew Pase, Alexa Beiser, Jayandra Himali, Claudia Satizabal, Hugo Javier Aparicio, Charles DeCarli, Sudha Seshadri
1:12 p.m.
S48.002
CSF non-Beta-Amyloid, non-Tau Biomarkers for Clinical Alzheimer’s Disease Stages —Umesh Gangishetti, J. Christina Howell, Richard Perrin, John Morris, John Trojanowski, Anne Fagan, Steven Arnold, William Hu
1:24 p.m.
S48.003
Cardiovascular Risk Factors and the Risk of Dementia in the Oldest Old —Farah Mozaffar, Maria Corrada, Claudia Kawas 1:36 p.m.
S48.004
Association of Circulating Fibroblast Growth Factor 23 with Incident Dementia: The Framingham Heart Study —Emer McGrath, Jayandra Himali, Daniel Levy, Carmela Abraham, Sarah Connor, Alexa Beiser, Paul Courchesne, Claudia Satizabal, Matthew Pase, Vasan Ramachandran, Sudha Seshadri
1:48 p.m.
S48.005
Biomarkers of Cerebral Small Vessel Endotheliopathy — Fanny Elahi, Marie Altendahl, Adam Staffaroni, Kaitlin Casaletto, Pauline Maillard, John Neuhaus, Jason Hinman, Charles DeCarli, Edward Goetzl, Joel Kramer
2:00 p.m.
S48.006
Immunological Signatures Distinguish FTLD-TDP from FTLD-tau Disorders Across Clinically Defined, Genetic, and Pathologically Proven Cohorts. —Zachary Miller, Wendy Shwe,
S49 Neuro Trauma and Sports Neurology
1:00 p.m.
G
S49.001
Vascular reactivity and microstructural changes association with neurocognitive symptoms in chronic traumatic brain injury —Sarah Woodson, Margalit Haber, Franck
Amyot, Kelley Fleshner, Erika Silverman, Kimbra Kenney, Carol Moore, Yi-Yu Chou, Dzung Pham, Michael Sangobowale, Ramon Diaz-Arrastia
1:12 p.m.
S49.002
Neurofilament Light and Tau in the Aftermath of Human Repetitive Concussive Traumatic Brain Injury —Pashtun Shahim, Yelverton Tegner, Kaj Blennow, Henrik Zetterberg
1:24 p.m.
S49.003
Behavioral and Brain Imaging Changes in Patients Receiving Bright Light Therapy Following a Mild Traumatic Brain Injury (mTBI) —Bradley Shane, Johnny Vanuk, Sahil Bajaj, Melissa Millan, William Killgore
1:36 p.m.
S49.004
Longitudinal Changes in Depression and Cognition in Professional Fighters with Baseline Structural Imaging: The Role of Depression in Cognitive Change and Structural Differences. —Bern Lee, Lauren Bennett, Charles Bernick, Sarah Banks
1:48 p.m.
S49.005
The Association of Reported Cognitive Symptoms and Objective Cognitive Performance in Patients with Prolonged Post-Concussion Symptoms —Douglas Polster, Aliyah Snyder, Alma Martinez, Collin Blout, Christopher Giza, Talin Babikian
2:00 p.m.
S49.006
David Perry, Virginia Sturm, Susanna Kwok, Shoshannah Rubin, Robin Ketelle, Reilly Dever, Hilary Heuer, Nicholas Olney, Anna Karydas, Jennifer Yokoyama, Eliana Marisa Ramos, Giovanni Coppola, Daniel Geschwind, Rosa Rademakers, Dennis Dickson, Neill Graff-Radford, Salvatore Spina, Eric Huang, Lea Grinberg, Katherine Rankin, Howard Rosen, Bradley Boeve, Adam Boxer, Maria Gorno Tempini, William Seeley, Bruce Miller
ENIGMA Military Brain Injury: A Preliminary Meta-Analysis of Diffusion MRI Measures —Emily Dennis, Elisabeth Wilde,
2:12 p.m.
2:12 p.m.
S48.007
Clinical Dementia Rating Score 0.5 Predicts Clinical Decline in Familial Frontotemporal Dementia —Salvatore Spina, Adam Staffaroni, Luke Bonham, Nicholas Olney, Suneth Attygalle, Yann Cobigo, Kevin Chang, Richard Binney, Jennifer Yokoyama, John Kornak, Adam Boxer, Bruce Miller, Suzee Lee, Bradley Boeve, Howie Rosen
2:24 p.m.
S48.008
Genetic Screening of CSF1R in Familial Ischemic Stroke — Takuya Konno, Takeshi Miura, Andrea Harriott, Naomi Mezaki, Emily Edwards, Rosa Rademakers, Owen Ross, James Meschia, Takeshi Ikeuchi, Zbigniew Wszolek
2:35 p.m.
Friday 116 2018 AAN Annual Meeting
Friday, April 27
Discussion
Randall Scheibel, Maya Troyanskaya, Carmen Velez, Benjamin Wade, Ann Marie Drennon, Gerald York, Erin Bigler, Tracy Abildskov, Brian Taylor, Carlos Jaramillo, Blessen Eapen, Heather Belanger, Mary Newsome, Harvey Levin, Sidney Hinds, William Walker, Paul Thompson, David Tate
S49.007
Geriatric Traumatic Brain Injury: Unique Considerations for Presentation and Outcome —Raquel Gardner, Sourabh Sharma, John Yue, Allison Kaup, Geoffrey Manley
2:24 p.m.
S49.008
Large-Scale Frontotemporal Limbic Networks in TBI: Vulnerability and Response to Non-Invasive Brain Stimulation —Kevin Bickart, Keith Main, Anna-Clare Milazzo, Megan Newsom, Chandler Sours, J. Wesson Ashford, Maheen Adamson
2:35 p.m.
Discussion
S50 Updates in General Neurology
1:00 p.m.
1:00 p.m.–3:00 p.m.
G
S50.001
A Neurology Practice Based Research Network for Quality Improvement and Practice Based Research Using the EMR —Kelly Simon, Payal Gupta, Laura Hillman, Christine Boutwell, Ihtsham Haq, Steven Meyers, Matthew Rizzo, James Wymer, Monika Szela, Roberta Frigerio, Demetrius Maraganore
1:12 p.m.
S50.002
Burnout Prevention Measures - Do They Meet the Needs of Women Neurologists? —Lauren Moore, Kathrin LaFaver, Divya Singhal, Craig Ziegler, Amy Hessler
S51 Pediatric MS
1:00 p.m.
3:30 p.m.–5:30 p.m.
G
S51.001
Development of Clinically Isolated Syndrome after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Study, [1985-2017]. —Moamina Fakher Eddin, Janaki Patel, Abdul Rahman Alchaki, Nizar Souayah
1:12 p.m.
S51.002
Oligoclonal Bands in Spinal Fluid Improve the Specificity of Different MRI Criteria for Dissemination in Space to Predict a First Clinical Event in Children with the Radiologically Isolated Syndrome —Naila Makhani, Christine Lebrun-Freney,
Woodward, Jon Reimers
Aksel Siva, Sona Narula, Evangeline Wassmer, James Brenton, David Brassat, Clarisse Carra-Dalliere, Jerome De Seze, Francoise Durand Dubief, Megan Langille, Rinze F Neuteboom, Jean Pelletier, Daniela Pohl, Daniel Reich, Juan Ignacio Rojas, Veronika Shabanova, Eugene Shapiro, Robert Thompson-Stone, Silvia Tenembaum, Mar Tintoré, Ugur Uygunoglu, Wendy Vargas, Sunita Venkateswaran, Orhun Kantarci, Darin Okuda, Daniel Pelletier, Observatoire Francop (OFSEP), Société Francophone (SFSEP), Radiologically Isola (RISC), Pediatric Radiologic Consortium (PARIS)
1:48 p.m.
1:24 p.m.
1:24 p.m.
S50.003
Validation of a Porcine Model for White Matter Developmental Trajectories —Kelsey Cacic, John Sladky, Stephen McGuire
1:36 p.m.
S50.004
Pineal cysts: a long term follow-up —Sarah Wright, Zoe S50.005
LGI1 Limbic Encephalitis after Interleukin-2 Therapy —Bahar Beaver, Sarah Burbank, Emily Tharp, Aimee Szewka
2:00 p.m.
S50.006
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis: Crest-2 —James Meschia,
Brajesh Lal, George Howard, Gary Roubin, Robert Brown, Kevin Barrett, Seemant Chaturvedi, Marc Chimowitz, Bart Demaerschalk, Virginia Howard, John Huston, Ronald Lazar, Wesley Moore, Claudia Moy, Tanya Turan, Jenifer Voeks, Thomas Brott
2:12 p.m.
S50.007
Baseline cognitive function among participants in the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (Crest-2) —Ronald
Lazar, Virginia Wadley, Randolph Marshall, George Howard, Virginia Howard, James Meschia, Jenifer Voeks, Ya Yuan, Brajesh Lal, Donald Heck, Michael Jones, Thomas Brott
2:24 p.m.
S50.008
Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine — Linda Wietecha, Bernice Kuca, Josephine Asafu-Adjei, Sheena K. Aurora
2:35 p.m.
Discussion
S51.003
MRI Contributions to the Diagnosis of Multiple Sclerosis in Children —Giulia Fadda, Robert Brown, Giulia Longoni, Denise
Castro, Julia O’Mahony, Leonard Verhey, Helen Branson, Amit Bar-Or, Ruth-Ann Marrie, E. Ann Yeh, Sridar Narayanan, Douglas Arnold, Brenda Banwell
1:36 p.m.
S51.004
Patterns of Use and Safety of Newer Disease-modifying therapies in Pediatric Multiple Sclerosis in the US —Kristen
Krysko, Jennifer Graves, Mary Rensel, Gregory Aaen, Leslie Benson, Tanuja Chitnis, Mark Gorman, Manu Goyal, Yolanda Harris, Lauren Krupp, Timothy Lotze, Soe Mar, Manikum Moodley, Moses Rodriguez, John Rose, Teri Schreiner, Bianca Weinstock-Guttman, Michael Waltz, Theron Casper, Emmanuelle Waubant
1:48 p.m.
S51.005
Effects of Fingolimod on MRI Outcomes in Patients with Pediatric Onset Multiple Sclerosis: Results from Phase 3 PARADIGMS Study —Douglas Arnold, Brenda Banwell, Amit Bar-
S52 MS and CNS Inflammatory Disease: Basic Science
3:30 p.m.
G
S52.001
Antibodies specific for myelin proteolipid protein can inhibit remyelination in vivo. —Bridget Bagert, Judith Greer, Hannah Savage, Shannon Beasley, Gracy Juba, Michael Pender
3:42 p.m.
S52.002
Immune Cell Profiling during Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of non-T Cell Populations into the CSF - Results from the ToFingo Successor Study —Lisa Lohmann, Claudia Janoschka, Andreas
Schulte-Mecklenbeck, Svenja Klinsing, Timo Wirth, Tilman SchneiderHohendorf, Nicholas Schwab, Catharina Groß, Maria Eveslage, Sven Meuth, Heinz Wiendl, Luisa Klotz
3:54 p.m.
S52.003
Anti-CD20 Antibodies Ofatumumab and Ocrelizumab Have Distinct Effects on Human B-cell Survival —Thalia Pacheco-
Fernandez, Ismahane Touil, Celine Perrot, Gaelle Elain, David Leppert, Anis Mir, Gisbert Weckbecker
4:06 p.m.
S52.004
Immunopathology of Neurosarcoidosis: an Uncommon but Significant Neuroinflammatory Disorder —Lucia Sablich, Laura Munoz-Arcos, Fausto Rodriguez, Carlos Pardo-Villamizar
4:18 p.m.
S52.005
Neuronal Intermediate Filament Autoimmunity —Eati Basal,
Thomas Kryzer, Divyanshu Dubey, Yong Guo, Shannon Hinson, Masoud Majed, Eduardo Benarroch, Claudia Lucchinetti, Sean Pittock, Vanda Lennon, Andrew McKeon
4:30 p.m.
S52.006
NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody —Manish Malviya, Sumanta Barman, Kristin Golombeck, Kim Kristin Falk, Jesús Planagumà, Francesco Mannara, Nathalie Strutz-Seebohm, Guiscard Seebohm, Frank Leypoldt, Sven Meuth, Heinz Wiendl, Hans-Peter Hartung, Josep Dalmau, Nico Melzer, Norbert Goebels
4:42 p.m.
S52.007
Or, Angelo Ghezzi, Benjamin Greenberg, Emmanuelle Waubant, Gavin Giovannoni, Jerry Wolinsky, Jutta Gaertner, Kevin Rostasy, Lauren Krupp, Marc Tardieu, Wolfgang Brueck, Tracy Stites, Yu Chen, Martin Merschhemke, Tanuja Chitnis
Cladribine for the Effective Control of Multiple Sclerosis via Memory B Cell Depletion —Bryan Ceronie, Nicolas Dubuisson,
2:00 p.m.
4:54 p.m.
WITHDRAWN
5:05 p.m.
Discussion
S51.006
Educational Achievement Data is a Patient-Relevant Outcome in Pediatric Multiple Sclerosis —Wendy Vargas,
SCIENTIFIC PLATFORM SESSIONS
1:00 p.m.–3:00 p.m.
Benjamin Jacobs, Zhifeng Mao, Francesca Ammoscato, Helen Lock, Hilary Longhurst, Gavin Giovannoni, David Baker, Klaus Schmierer
Victoria Leavitt, James Sumowski, Hannah Street, Gabriella Tosto, Ji Lee, Brenda Banwell, Philip De Jager
2:12 p.m.
S51.007
The Impact of Occipital Cortical Mantle Thinning on Visual Processing in Pediatric Multiple Sclerosis —Amy Waldman, Jack Sollee, Amy Lavery, Krystle Karoscik, Geraldine Liu, Russell Shinohara, Brenda Banwell, Ritobrato Datta
2:24 p.m.
S51.008
Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) associated disease —Yael Hacohen, Wong Yuyi,
2:35 p.m.
= Abstract of Distinction
Friday
Christian Lechner, Maciej Jurynczyk, Sukhvir Wright, Bahadir Konuskan, Anne lisa Poulat, Helene Maurey, Evangeline Wassmer, Cheryl Hemingway, Eva Maria Hennes, Maria Leite, Olga Ciccarelli, Banu Anlar, Rogier Hintzen, Romain Marignier, Jacqueline Palace, Matthias Baumann, Kevin Rostasy, Rinze F Neuteboom, Kumaran Deiva, Ming Lim
Discussion
AAN.com/view/AM18 117
SCIENTIFIC PLATFORM SESSIONS
SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–5:30 p.m. S53 Epilepsy/Clinical Neurophysiology (EEG) III
3:30 p.m.
3:30 p.m.–5:30 p.m.
G
S53.001
BDNF rs6265 Met and COMT rs4680 Val are Associated with Psychiatric Symptomatology in Pharmacoresistant Epilepsy —Christine Doherty, Olivia Hogue, Jessica Altemus, Imad Najm, Charis Eng, Robyn Busch
3:42 p.m.
S53.002
Alternative Trial Methodology in Pediatric Epilepsy Clinical Trials - Time to “Nth” Seizure Analysis in Children with Partial Onset Seizures Treated With Pregabalin —Jeremias Antinew, Lloyd Knapp, Mary Almas, Jing Liu, Joseph Scavone, B. Parsons
3:54 p.m.
S53.003
Fracture Risk and Bone Health in Veterans Treated for Epilepsy —Anne Van Cott, Robert Adler, Kathy Tortorice, Mary Jo Pugh, Barry Gidal, Diane Dong, Francesca Cunningham
4:06 p.m.
S53.004
Antiseizure properties of cannabidiol (CBD) are attenuated in the absence of transient receptor potential vanilloid 1 (TRPV1) receptors —Benjamin Whalley, Royston A. Gray, Colin Stott, Nicholas Jones
4:18 p.m.
S53.005
Antisense Oligonucleotide Therapy for Lafora Disease —
Saija Ahonen, Tamar Grossman, Julie Turnbull, Holly Kordasiewcz, Melanie Katz, Michael McCaleb, Peixiang Wang, Xiaochu Zhao, Berge Minassian
4:30 p.m.
S53.006
Dynamic Causal Modeling Reveals Altered Effective Connectivity Between Contralateral Hippocampus and Default Mode Network in Temporal Lobe Epilepsy —
Mariana Vallim, Tamires Zanão, Akari Ishikawa, Jose Carlos Moreira, Matheus Zabin, Danielle Garcia, Fernando Cendes, Aluisio Pinheiro, Clarissa Yasuda
S54 Ischemic Stroke Prevention
3:30 p.m.
S54.001
Effect of Extended Thromboprophylaxis with Non-Vitamin K Antagonist Oral Anticoagulant on the Risk of Stroke and Major Bleeding in Acutely Ill Hospitalized Medical Patients: A Meta-Analysis of Randomized Controlled Trials —Jolanta
Marszalek, Adeel Jamil, Umer Jamil, Sunny Kumar, Farima Kahe, Zahra Karimi, Gerald Chi
3:42 p.m.
S54.002
Interarm Systolic and Diastolic Blood Pressure Difference Is Diversely Associated With Cerebral Atherosclerosis in Noncardioembolic Stroke Patients —Yoonkyung Chang, Soo Mee Lim, Yong-Jae Kim, Tae-Jin Song
3:54 p.m.
S54.003
4:06 p.m.
S54.004
Systematic Review and Meta-Analysis of Randomized Control Trials Examining Efficacy of CPAP for Prevention of Stroke in Patients with Moderate to Severe Obstructive Sleep Apnea —Nida Faheem, Suzanne Stevens Are SNPs associated with large artery disease in Caucasians also significant in intracranial atherosclerotic disease? —Thomas Leung, Elvis Dong, Bonaventure Ip, Hing Lung Ip, Yannie Soo, Ronald CW Ma, Ricard KW Choy
4:18 p.m.
S54.005
Influence of on-going Treatment with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker on the Outcome of Patients treated with Intravenous rt-PA for Ischemic Stroke —Sixtine GILLIOT, Igor
Sibon, Jean-Louis Mas, Thierry Moulin, Yannick Bejot, Charlotte Cordonnier, Maurice Giroud, Pascal ODOU, Regis Bordet, Denis Vivien, Didier Leys
4:30 p.m.
S54.006
Electrographic Correlates of Clinical Seizures —Sharanya
Left Atrial Dilatation: A Cohort Analysis With Strong Implications For Future Atrial Fibrillation And Stroke Monitoring. —Muhammad Affan, Sumul Modi, Lonni Schultz,
4:54 p.m.
4:42 p.m.
4:42 p.m.
S53.007
Desai, Thomas Tcheng, Martha Morrell
S53.008
Sleep in Patients with Psychogenic Non-Epileptic Seizures: Time to raise the red flag —Veronique Latreille, Gaston Baslet, Rani Sarkis, Milena Pavlova, Barbara Dworetzky
5:05 p.m.
Discussion
G
Abhimanyu Mahajan, Daniel Miller
S54.007
Device closure of patent foramen ovale reduces the risk of stroke compared to medical therapy in patients with cryptogenic ischaemic stroke and PFO: a meta-analysis — Yao Feng Victor Chong, Bernard Chan
4:54 p.m.
S54.008
Therapeutic Regimen of L-arginine for Patients with MELAS: 9-year, Prospective, Multicentre, Clinical Research Integrating the Data from Two 2-year Clinical Trials with 7-year Follow-up —Yasutoshi Koga, Nataliya Povalko, Eisuke Inoue, Hidefumi Nakamura, Akiko Ishii, Yasuhiro Suzuki, Makoto Yoneda, Fumio Kanda, Masaya Kubota, Hisashi Okada, Katsunori Fujii
5:05 p.m.
Friday 118 2018 AAN Annual Meeting
Discussion
Friday, April 27
Joint AAN/AHA/ASA Session Wednesday, April 25, 3:30 p.m. – 5:30 p.m. Bridging Racial and Ethnic Disparities in the Management of Stroke
Breakthroughs in Engaging Minority and Rural Communities in Stroke Studies
3:30 p.m. – 3:45 p.m.
4:30 p.m. – 4:45 p.m.
State of Racial and Ethnic Disparities in Stroke
3:45 p.m. – 4:00 p.m. hat More Can Be Done to Address Racial and Ethnic Disparities W in Stroke?
4:00 p.m. – 4:15 p.m. Avenues to Engage in Stroke Disparities Research
4:15 p.m. – 4:30 p.m. bstacles and Opportunities in Stroke Care Access Among Racial O and Ethnic Minorities
L earning About Your Community (and Establishing a Community Advisory Board)
4:45 p.m. – 5:00 p.m. Captivating the Community and Sustaining Ties
5:00 p.m. – 5:15 p.m. Building Trust with Your Community Through Communication
5:15 p.m. – 5:30 p.m. Dissemination of Results and Presenting Information
AAN.com/view/AM18 119
POSTER SESSION FLOOR PLAN AND SCHEDULE Poster Session I Sunday, April 22, 11:30 a.m.–5:30 p.m. Presenters Stand by Posters 4:00 p.m.–5:30 p.m. Poster Session II Monday, April 23, 11:30 a.m.–7:00 p.m. Presenters Stand by Posters 5:30 p.m.–7:00 p.m. Poster Session III Tuesday, April 24, 11:30 a.m.–7:00 p.m. Presenters Stand by Posters 5:30 p.m.–7:00 p.m. Poster Session IV Wednesday, April 25, 11:30 a.m.–7:00 p.m. Presenters Stand by Posters 5:30 p.m.–7:00 p.m. Poster Session V Thursday, April 26, 11:30 a.m.–7:00 p.m. Presenters Stand by Posters 5:30 p.m.–7:00 p.m. Poster Session VI Friday, April 27, 11:30 a.m.–5:30 p.m. Presenters Stand by Posters 4:00 p.m.–5:30 p.m.
9 28 0 29 1 29 2 29 3 29 4 29
20 20 20 20 20 20 1 2 3 4 5 6 21 21 21 20 20 20 2 1 0 9 8 7 21 21 21 21 21 21 3 4 5 6 7 8 22 22 22 22 22 21 4 3 2 1 0 9 22 22 22 22 22 23 23 5 6 7 8 9 0 1 23 23 23 23 23 23 23 8 7 6 5 4 3 2 23 24 24 24 24 9 0 1 2 3 24 24 24 24 24 8 7 6 5 4 24 25 25 9 0 1 25 25 25 4 3 2 25 25 5 6 25 25 8 7
8 28 7 28 6 28 5 28 4 28 3 28
17 17 17 16 16 16 2 1 0 9 8 7 16 16 16 16 16 16 1 2 3 4 5 6 16 15 15 15 15 15 0 9 8 7 6 5 14 15 15 15 15 15 9 0 1 2 3 4 14 14 14 14 14 14 8 7 6 5 4 3 13 13 13 14 14 14 7 8 9 0 1 2 13 13 13 13 13 13 6 5 4 3 2 1 12 12 12 12 12 13 5 6 7 8 9 0 12 12 12 12 12 11 4 3 2 1 0 9 11 11 11 11 11 11 3 4 5 6 7 8 11 11 11 10 10 10 2 1 0 9 8 7 10 10 10 10 10 10 6 5 4 3 2 1 10 9 9 9 9 0 9 8 7 6 91 92 93 94 95
7 27 8 27 9 27 0 28 1 28 2 28
8 33 7 33 6 33 5 33 4 33 3 33 2 33 1 33 0 33 9 32 8 32
86
340 339
342
87
7 31 8 31 9 31 0 32 1 32 2 32 3 32 4 32 5 32 6 32 7 32
b1 g1 a1 88
85
343
ePosters
344
32 36 35 34 33 31 27 28 29 30
9 60 4 0 59 5 1 58 5 2 57 5 3 56 5 4 55 5 7 48 3 8 47 3 9 46 3 0 45 4 1 44 4 2 43 4
24 20
21
16 19 15 17 10 14 18 9 11 13 8 12 4 7 3 5 2 6 1
A
22
25 23
26
34 34 34 34 8 7 6 5 34 35 35 35 9 0 1 2 35 35 35 35 35 35 8 7 6 5 4 3 35 36 36 36 36 36 9 0 1 2 3 4 37 37 37 36 36 36 36 36 2 1 0 9 8 7 6 5 37 37 37 37 37 37 37 38 3 4 5 6 7 8 9 0 38 38 38 38 38 38 38 38 8 7 6 5 4 3 2 1 38 39 39 39 39 39 39 39 9 0 1 2 3 4 5 6 40 40 40 40 40 39 39 39 4 3 2 1 0 9 8 7 40 40 40 40 40 41 41 41 5 6 7 8 9 0 1 2 42 41 41 41 41 41 41 41 0 9 8 7 6 5 4 3 42 42 42 42 42 42 42 42 1 2 3 4 5 6 7 8
Poster Discussion
1 72 6 2 71 6 3 70 6 4 69 6 5 68 6 6 67 6
120 2018 AAN Annual Meeting
6 27 5 27 4 27 3 27 2 27 1 27
6 31 5 31 4 31 3 31 2 31 1 31 0 31 9 30 8 30 7 30 6 30
341
89
90
3 84 7 4 83 7 5 82 7 6 81 7 7 80 7 8 79 7
B
F G
5 29 6 29 7 29 8 29 9 29 0 30 1 30 2 30 3 30 4 30 5 30
ePosters
E
5 26 6 26 7 26 8 26 9 26 0 27
D
4 26 3 26 2 26 1 26 0 26 9 25
C
197 188 196 198 187 189 195 199 194 200 178 186 190 177 179 185 191 193 176 180 184 192 175 181 183 174 182 173
434 439 433 440 432 454 457 453 441 431 458 452 442 430 443 429 469 459 451 470 468 460 450 444 471 467 461 449 462 438 477 472 466 445 437 478 476 473 465 446 479 475 474 436 456 463 455 447 435 480 448 464
I
H
POSTER SESSIONS
W
e are once again grouping topic-related posters together into “neighborhoods” to enhance your discussions and make the posters easier to navigate. Please see floor plan on the previous page.
Check out the interactive, touchscreen e-posters at the virtual hall kiosk for another great opportunity to view scientific posters. And if you can’t get enough cutting-edge science, join the quick lunchtime Poster Discussion Session! A group of 10 abstracts will be presented as both a data blitz and a poster with a moderator leading stimulating discussion on the content of the selected posters.
Poster Session I
Sunday, April 22 . . . . . . . . . . . . . . 122
Poster Session II
Monday, April 23 . . . . . . . . . . . . . . 132
Poster Session III
Tuesday, April 24 . . . . . . . . . . . . . . 142
Poster Session IV
Wednesday, April 25 . . . . . . . . . . . .
Poster Session V
Thursday, April 26 . . . . . . . . . . . . .
152 162
Poster Session VI
Friday, April 27 . . . . . . . . . . . . . . . 172
AAN.com/view/AM18 121
POSTER SESSIONS
POSTER SESSION I
G
EDUCATION: PATIENTS
P1.010 Teaching Psychiatrists Neurology
P1.001 Development and Preliminary
Nuri Jacoby, Neel Dixit, Daniel Shalev
A
Results of a Community-Partnered Stroke Preparedness Intervention in Chicago —
Neelum Aggarwal, Sarah Song, Soyang Kwon, Erin Wymore, Namratha Kandula, Jen Brown, Amy Eisenstein, Christopher Richards, Maryann Mason, Peggy Jones, Heather Beckstrom, Knitasha Washington, Shyam Prabhakaran
P1.002 Headache and Arts Program:
Headache and Concussion Education in High School Visual Arts Classes —Alexandra Boubour, Mia Minen
P1.003 Readability assessment of
online Essential Tremor patient educational resources —Keerthana Nalamada, Amar Patel
P1.004 Professional Art Therapy and
Visuospatial Exploration in Parkinson’s Disease: An Experimental Protocol and Preliminary Feasibility Data. —Alberto Cucca, Daniella F Mania, Ikuko Acosta, Marygrace Berberian, Hilary C Bertish, Todd Hudson, Amy Lemen, John-Ross Rizzo, Milton Biagioni, Alessandro Di Rocco
P1.005 Youth Stroke Education Series —
Lucy Fell, Nicte Mejia
through E-Learning: A Model Curriculum —
P1.011 Understanding Resident Workflow and Educational Experience to Implement Advanced Practice Clinicians Into Neurology Residency Training Programs —
D
173–200
C
ePosters
085–090
P1.012 A Pilot Neurology Curriculum To
Train Advanced Practice Clinicians Joining An Inpatient Stroke Service At A Busy Tertiary Care Center —Anna Pace, Laura Stein,
037–084
Stephen Krieger, Mandip Dhamoon
P1.013 Developing a Comprehensive
Pre-Residency Acclimatizing Program for International Medical Graduates —Raghav Govindarajan, Penny McQueen, Pradeep Bollu, Pradeep Sahota
P1.014 Impact on Education and Quality
of Care of a Neurology Free Clinic in Bogota, Colombia —Jaime Toro, Manuel Yepes, Fabián
Cortés, Camilo Diaz-Cruz, Saul Reyes, Maria ReyesMantilla, David Cuellar Giraldo, Lisseth Burbano, Jorge Patiño, Alejandra Duque Ramirez
P1.006 Internet Search Behavior Trends
Saeed Ansari, Rashi Krishnan, Sarah Ganji, Vida Abedi, Katherine Nearing, Andrie Alexandrov, Ramin Zand
P1.015 Integrative Medicine in Child Neurology: What do providers think and what do they need to learn? —Amanda Sandoval Karamian, Ann Ming Yeh, Courtney
P1.007 Clinics as classrooms: Assessing Wusthoff patient knowledge and satisfaction following P1.016 Improving Resident Knowledge of stroke video education —Sarah Tisel, Abigail Rieman, Matthew Hodges, Rishi Desai, M. Ryan Haynes, Kelly Gwathmey
Healthcare Business and Policy through the Development of a High-yield and Dynamic Educational Series —John Legge, Scott Vota
EDUCATION: NURSING, APPS, AND OTHERS
P1.017 Autism Spectrum Disorder (ASD) knowledge variation and gaps in adult neurology residents —Surabhi Kaul, Pauline
Sunday
P1.008 Analysis of Early Post-Training Research Activity: The Effect of the Critical Years on Later Success of PhysicianScientists —Wyatt Bensken, Alexandra Hansen,
091–172
Laura Stein, Anna Pace, Mandip Dhamoon, Stephen Krieger
EDUCATION: NEEDS ANALYSIS AND NOVEL FIELDS
for Public Education in Neurology Field —
Sunday, April 22 11:30 a.m.–5:30 p.m.
Filipek
P1.018 Knowledge of Genetics and
Genetic Testing In an Academic Neurology
Gina Norato, John Heiss, Avindra Nath, Omar Khan Setting —Sami Bajwa, Anthony Geraci, Laura Ragoonanan P1.009 Improving Confidence in
Nurses When Performing a Neurological P1.019 Targeted Needs Assessment Assessment —Scott Le, Leigh Allen, Jeffrey Clark for a Competency-Based “Boot Camp” Curriculum for First-Year Neurology
B
E
201–258
b1 g1 339–344 a1 ePosters
Poster Discussion
027–036
A
001–026
I
F
259–294
295–338
H
G
345–428
429–480
Poster Session 1 A. Research Methodology, Education, and History: 001 – 026
a1. Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session: 027 – 036 B. Movement Disorders: 037 – 084
b1. MS and CNS Inflammatory Disease ePoster Session: 085 – 090 C. D. E. F. G.
Sleep; Neuroepidemiology; General Neurology: 091 – 172 Aging, Dementia, Cognitive, and Behavioral Neurology: 173 – 200 Cerebrovascular Disease and Interventional Neurology: 201 – 258 Epilepsy/Clinical Neurophysiology (EEG): 259 – 294 General Neurology: 295 – 338
g1. Neuromuscular/Clinical Neurophysiology (EMG) ePoster Session: 339 – 344 H. MS and CNS Inflammatory Disease: 345 – 428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429 – 480
Residents —Seraj Makkawi, Michael Yeung, Alexandra Harrison, Lara Cooke
P1.020 A single institutional study
of neurology residents to evaluate the advantages of neuro-oncology didactics during training and understand field-specific attitudes —Aubree Bruhnding, Elizabeth Neil
P1.021 Awakening European
Neurology—Sleep Education in Neurology
(SEN) survey —Martin Rakusa, Mariusz
Sieminski, Fabio Pizza, Sofia Gak, Cristian FalupPecurariu, Ulf Kallweit
P1.022 NA P1.023 NA P1.024 NA P1.025 NA P1.026 NA
Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.
a1
Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 4:00 p.m.-5:30 p.m. Data Blitz: 12:00 p.m.–12:05 p.m.
P1.027 Safety, tolerability, and cognitive
Zachary Stowe, D. Jeffrey Newport, James Ritchie, of Refractory Epilepsy on Health-Related Page Pennell Quality of Life (HRQoL) —Menno Vergeer, Wendela L. de Ranitz-Greven, Maureen Neary, Data Blitz: 12:15 p.m.–12:20 p.m. Raluca Ionescu-Ittu, Bruno Emond, Mei-Sheng P1.030 Response to Pharmaceutical Duh, Bernard Zonnenberg
and behavioral effects of long-term adjunctive lacosamide in children and adolescents with focal seizures —Brian Potter, Formulation of Purified Cannabidiol (CBD) in Data Blitz: 12:30 p.m.–12:35 p.m. Cynthia Beller, Simon Borghs, Ali Bozorg, Nancy Pediatric and Adult Patients with TreatmentYuen, Tony Daniels Refractory Epilepsy —Jerzy Szaflarski, E Bebin, P1.033 Automated and Manual Diffusion Tyler Gaston, Leslie Perry Grayson, Yuliang Liu, Tractography in the Presurgical Evaluation of Data Blitz: 12:05 p.m.–12:10 p.m. Gary Cutter Patients with Temporal Lobe Epilepsy —Iren P1.028 Risk of Spontaneous Abortion Orosz, Vishal Patel, Hajime Yokota, Shennan Data Blitz: 12:20 p.m.–12:25 p.m. in Women with Epilepsy: Where do Newer Weiss, Davis Woodworth, Stephanie Moy, Edgar Antiepileptic Drugs Stand? —Madhukar P1.031 Predictors of Response to A. Rios Piedra, Itzhak Fried, Anatol Bragin, Richard Trivedi, Manna Jose, Helen Simson Babyratnam, Staba, Jerome Engel, Gary Mathern, Noriko Placebo in Phase III Trials of Adjunctive Sankara Sarma, Sanjeev Thomas Eslicarbazepine Acetate (ESL) —JungAh Jung, Salamon David Blum, Todd Grinnell, Hailong Cheng Data Blitz: 12:10 p.m.–12:15 p.m. Data Blitz: 12:35 p.m.–12:40 p.m. Data Blitz: 12:25 p.m.–12:30 p.m. P1.029 Levetiracetam, Oxcarbazepine P1.034 Surgical Success After Epilepsy and Topiramate Clearance Changes During P1.032 Tuberous Sclerosis Complex (TSC) Re-operations —Ruta Yardi, James Bena, Pregnancy —Paula Voinescu, Suna Park, Li Chen, and Epilepsy Manifestations: The Impact
122 2018 AAN Annual Meeting
Imad Najm, Jorge Gonzalez-Martinez, William Bingaman, Shannon Morrison, Lara Jehi
Data Blitz: 12:40 p.m.–12:45 p.m.
P1.035 Towards Improved Diagnosis
in Epilepsy —Robert Yao, Lidia Csernak, Edgar
Salinas, Neel Mehta, Erin Okazaki, Joseph Sirven
Data Blitz: 12:45 p.m.–12:50 p.m.
P1.036 A Common Data Language for
Clinical Research Studies: The National Institute of Neurological Disorders and Stroke Updates to Epilepsy Common Data Element Recommendations —Joy Esterlitz,
Muniza Sheikh, Joan Austin, Jacqueline French, Nicholas Barbaro, Daniel Lowenstein, Sherita Alai, Sarah Tanveer, Vicky Whittemore
PARKINSON’S DISEASE: NONMOTOR MANIFESTATIONS
B
P1.037 Heart Rate Variability (HRV)
from a 10-second Electrocardiogram (ECG) in Parkinson’s Disease (PD) and Control —
Samuel Goldman, Ahro Kim, Chen Meng, Kathleen Comyns, Helen Petrovitch, Caroline Tanner, Robert Abbott, Web Ross
P1.038 Non-motor Symptoms (NMS)
Improvement is Positively Correlated with Baseline NMS Burden and Improved Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-carbidopa Intestinal Gel: A Post-hoc Analysis from the GLORIA Registry —Werner Poewe, Lars Bergmann, Angelo Antonini, Kallol Chaudhuri
P1.049 Bilateral downward finger
displacement in Parkinson disease may be a sign of worsening dementia and a bedside test to distinguish it from Alzheimer’s disease —Aman Deep, Abraham Lieberman, Talal Aboud, Rohit Dhall, Jiong Shi
P1.059 Calcium derangement and
P1.070 Multimodal Neuroimaging
Paul, Warunee Dansithong, Karla Figueroa, Daniel Scoles, Stefan Pulst
Piccinin, Thiago Rezende, Patrick Dion, Guy Rouleau, Marcondes Franca, Orlando Barsottini, Jose Luiz Pedroso
STAU1-dependent ER stress in an in vitro model of SCA2 —Mariana Gandelman, Sharan
P1.060 Evaluation Of Various Movement
Disorders In Patients Of Genetically Proven Spino Cerebellar Ataxia (SCA) : Study From disease patients with and without Visual Hallucinations: A Retrospective Case Control A Tertiary Care Center In Northern India — Divya MR, Vinay Goyal, Achal Srivastava, Garima study —Dharampreet Singh, Guy Schwartz
P1.050 EEG findings in Parkinson
P1.051 No Postural Stability Differences
Shukla, Madhuri Behari
P1.061 Characterization of The between Asymptomatic and Symptomatic Brazilian ARSACS Phenotype: Clinical, Neurological Orthostatic Hypotension in Parkinson’s disease—A Pilot Study —Victoria Ophthalmological, Neuroimaging, and Genetic Features of Fourteen Cases. —Flavio Smith, Christopher Frames, Markey Olson, Thurmon Lockhart, Abraham Lieberman
Rezende Filho, Jose Luiz Pedroso, Juliana Maria Sallum, Fernando Kok, Marcondes Franca, Ingrid De Vasconcellos, Wilson Marques, Charles Lourenco, Paola Giunti, Orlando Barsottini
P1.039 Effects of ADS-5102 on non-
P1.052 Increased Frequency of Suicide
Mehta, Rajesh Pahwa, Caroline Tanner, Robert Hauser, Reed Johnson, Lily Llorens, Rajiv Patni
Anat Mirelman, Roy Alcalay, Sonya Elango, Deborah Raymond, Mark Groves, Nir Giladi, Karen Marder, Susan Bressman, Rachel SaundersPullman
P1.062 A Longitudinal Assessment of
P1.053 A Multivariate Analysis of the
P1.063 TRIO Gene Segregation in a
motor symptoms (NMS) in Parkinson’s disease patients with dyskinesia —Shyamal
P1.040 Clinical Experience with
Pimavanserin for Treatment of Parkinson’s Disease Psychosis —Jessie Sellers, Richard Darby, Daniel Claassen
P1.041 Color vision and contrast
sensitivity in Parkinson Disease —Gupta
Harsh, Nan Zhang, Thomas Beach, Charles Adler
P1.042 A Network Meta-analysis of
Droxidopa and Midodrine for the Treatment of Neurogenic Orthostatic Hypotension —
Jack Chen, Jonathan Tang, Khashayar Dashtipour
P1.043 Cognitive performance and
In First Degree Relatives of LRRK2 G2019S Mutation Parkinson Disease —Robert Ortega,
Effects of Physical Activity and Cognition on Resting-State Brain Networks in Parkinson’s Patients with and without Mild Cognitive Impairment —Behnaz Jarrahi, Andrew Petkus,
Kristen Sundvick, Jiayue Cai, Daryl Wile, Adam Book, Z.J. Wang, Martin McKeown, Silke Cresswell
Huether, Sarah Matcha, Tanya Harlow, Danelle Staebler, Jau-Shin Lou
ATAXIAS I Symptoms of Dysphonia and Dysphagia in P1.057 Prevalence of spinocerebellar Movement Disorder Patients at an Academic ataxia 36 in a US population —Juliana Valera, Medical Center —Mary Finger, Mustafa Tatyana Diaz, Lauren Petty, Beatriz Quintáns,
P1.045 Prevalence of Patient-Reported
Siddiqui, Jessica Tate, Ihtsham Haq, Lyndsay L. Madden
and The Risk of Cerebellar Ataxias: A Systematic Review and Meta-analysis —ChiYing Lin, Min-Jung Wang, Winona Tse, Rachel Pinotti, Sheng-Han Kuo
P1.072 Sleep and Fatigue in Friedreich’s
Ataxia —Addie Patterson, Leonardo Almeida, Erin Hastings, Jen Farmer, S Subramony
P1.073 Lack of Placebo Effect in Fragile X-associated Tremor/Ataxia Syndrome —
Emily Hill, Bichum Ouyang, Randi Hagerman, Jennifer Cogswell, Patrick Adams, Deborah Hall
Family with Cerebellar Ataxia —Rana Hanna AL-Shaikh, Audrey Strongosky, Mavis Matthew, Paldeep Atwal, Ryan Uitti, Zbigniew Wszolek
P1.064 A comparative study of the
P1.065 Quality of life in Spinocerebellar Ataxia type 10 —Nathália Bergamasco,
Napierala
P1.075 Strong correlations observed
among four measures of disease progression in Friedreich’s ataxia —Harry Saal, Frederic Heerinckx, Rezi Zawadzki, Omid Omidvar, Marcus Kilpatrick, Theresa Zesiewicz
P1.076 Spinocerebellar ataxia type 2:
The second most frequent dominant ataxia in Peru —Erick Figueroa-Ildefonso, Karina Milla-
Neyra, Miguel Inca-Martinez, Victoria Marca, Olimpio Ortega-Davila, Elison Sarapura Castro, Maryenela Illanes-Manrique, Maria-Luiza SaraivaPereira, Laura Jardim, Mario Cornejo Olivas
Laudiane Santos, Marise Zonta, Ana Carolina P1.077 Progressive motor and balance Macedo, Francisco Germiniani, Helio Afonso Teive, impairment in Spinocerebellar Ataxia type Tetsuo Ashizawa 10 —Nathalia Bergamasco, Katia Konno, Marise P1.066 Quantitative oculomotor Zonta, Gustavo Ribas, Francisco Germiniani, Tetsuo Ashizawa, Helio Afonso Teive assessment and non-motor biomarkers
in late-onset Tay-Sachs and Sandhoff disease —Christopher Stephen, David Balkwill,
P1.078 Cerebellar Degeneration and
P1.067 Spinocerebellar Ataxias—
Thiago Vale, Jose Luiz Pedroso, Gustavo Ribas, Júlio Kristochik, Maria Cristina Domingues da Silva Fink, Augusto Cesar Penalva de Oliveira, Helio Afonso Teive, Orlando Barsottini
Rodrigues, Fernando Castilho Pelloso, Salmo Raskin, Helio Afonso Ghizoni Teive
P1.079 Nocturnal Hyperkinetic Spells
Peter James, Kenneth Sassower, Jeremy Schmahmann, Richard Lewis, Florian Eichler
Genotypical and Phenotypical Evaluation of 213 Brazilian Families —Vinicius Oliveira Rocha
Progressive Ataxia Associated With HIVVirus Infection —Maria Thereza Drumond Gama,
in Dentatorubral Pallidoluysian Atrophy —
P1.068 Fragile X Low Normal Alleles are Deepmala Nandanwar, Edwin George, Maysaa not associated with Cognitive Dysfunction in Basha
Zuleima Yáñez, Eric Boerwinkle, Donna Muzny, an Elderly Community Population —Deborah Dmitry Akhmedov, Rebecca Berdeaux, Maria Jesus Hall, Aisha Ali, David Bennett, Lili Zhou, Elizabeth Sobrido, Richard Gibbs, James Lupski, Daniel Berry-Kravis P1.046 The Prevalence and Geschwind, Susan Perlman, Piper Below, Brent Characteristics of Probable REM behavior P1.069 Relevance of Superior Vertical disorder in Thai Parkinson Patients. —Patama Fogel Ophthalmoparesis in the Diagnosis of Gomutbutra P1.058 Omaveloxolone Increases Spinocerebellar Ataxia type 3 —Bruno Carniatto Marques Garcia, Fabio Nascimento, P1.047 Is Excessive Daytime Sleepiness Nrf2 Activity, Reduces Inflammation, And Improves Mitochondrial Function In Cultured Francisco Germiniani, Marcia Olandoski, Helio Related to Nocturnal Sleep in Parkinson’s Cell Models Of Friedreich’s Ataxia. —Brandon Afonso Teive Disease? —Aliya Sarwar, Suzanne Moore, Max Probst, Lyndsey McCauley, Deborah Ferguson, Hirshkowitz Christian Wigley
P1.080 Autoimmune Cerebellar Ataxia Associated With Anti-GRAF1 Antibody — Chaitanya Amrutkar, Erik Burton
P1.081 WITHDRAWN P1.082 NA P1.083 NA P1.084 NA
P1.048 WITHDRAWN
AAN.com/view/AM18 123
Sunday
symptoms of anxiety, depression, and apathy Jessika Suescun, Richard Castriotta, Timothy in Parkinson’s patients with and without mild Ellmore cognitive Impairment. —Andrew Petkus, J. P1.055 Somatic items on the Beck Vincent Filoteo, Dawn Schiehser, Megan Gomez, Depression Inventory-II do not affect selfJennifer Hui, Behnaz Jarrahi, Sarah McEwen, reported depression severity in Parkinson’s Giselle Petzinger disease —Veronica Ramirez, Taylor R. Hendershott, Nazlie Faridi, Delphine Zhu, Lu Tian, P1.044 Patterns of responses on Kathleen Poston the Montreal Cognitive Assessment in Parkinson’s Disease Associated Mild P1.056 Defining Clinically Significant Cognitive Impairment —Melissa Mackenzie, Fatigue in Parkinson’s Disease —Asenath
P1.071 Serum Anti-Gliadin Antibodies
P1.074 Upregulation of Mitochondrial Aldehyde Dehydrogenase Activity Inhibits Spinocerebellar Ataxia types 1, 2, 3, 6 and 17 Lipid Peroxidation in Friedreich’s Ataxia in Taiwan. —Yicheng Lin, Yi-Chung Lee, Yi-Chu Cells —Jill Napierala, Yu-Yun Chen, Marek Liao, Bing-Wen Soong
Megan Gomez, J. Vincent Filoteo, Dawn Schiehser, clinical and electrophysiological features Jennifer Hui, Giselle Petzinger, Sarah McEwen between Friedreich ataxia and Ataxia with isolated vitamin E deficiency in Tunisia — P1.054 Preliminary evidence for an altered relationship between uric acid levels Cyrine Jridi, Haifa Kharrat, Jihene Sassi, Fatma Nabli, Samir Blel, Faycal Hentati and resting state functional connectivity in
REM sleep behavior disorder —Mya Schiess,
Analysis in Brazilian Patients with SYNE1 Ataxia —Maria Thereza Drumond Gama, Camila
POSTER SESSIONS
Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.
POSTER SESSIONS
POSTER SESSION I
b1 C
G
Sunday, April 22 11:30 a.m.–5:30 p.m.
MS and CNS Inflammatory Disease ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P1.085 Is the neuroradiological
differentiation between M. Fabry and MS possible? —Paulus Rommer, Oliva Fösleitner,
Compared to Multiple Sclerosis and Healthy Control Subjects —Lisa Eunyoung Lee, Jillian
Adriana Delgado, Jayawant Mandrekar, Kenton Kaufman, Lawrence Berglund
Chan, Anthony Traboulsee, Shannon Kolind, Robert P1.088 Effective treatment of CLIPPERS Jakob Rath, Lukas Haider, Gere Sunder-Plassmann, Carruthers with long-term use of rituximab —Veronica Daniela Prayer, Gregor Kasprian P1.087 McArdle’s sign: A specific sign of Penyak Cipriani, Nancy Arndt, Peter Pytel, Anthony P1.086 Quantitative Myelin multiple sclerosis —Brian Weinshenker, Filippo Reder, Adil Javed Measurement in Brain White Matter Tracts Savoldi, Zahra Nasr, Wei Hu, Nathan Schilaty,
of Rare Progressive Solitary Sclerosis,
SLEEP: NEUROLOGY AND SLEEPDISORDERED BREATHING/SLEEP APNEA
Questionnaire —Hye-Jin Moon, Jong-Ho Byun,
P1.112 Drosophila Myc is Involved in Fly Zheng, Amita Sehgal, Chi Dang
P1.091 The Impact of Co-Morbid Sleep
P1.102 Expediting the Diagnosis of
Obstructive Sleep Apnea by Increasing Awareness of the Sleep Laboratory Scheduling Process —Micaela Nannery, Lisa
Apnea and Stroke on the Cost of Health Care —Majaz Moonis, Baqar Husaini
Young Sun Lee, Yong Won Cho
P1.092 Screening for Sleep Apnea in
Park, Chantale Branson, Marianne Kelly, Yelena Pyatkevich, Sanford Auerbach
Irfan
SLEEP: TOO MUCH, TOO LITTLE, ABNORMAL TIMING, AND PARASOMNIAS
Patients with Ischemic Stroke: A Quality Improvement Project —Abby Metzler, Muna
P1.093 Prevalence of High Risk
Obstructive Sleep Apnea and Insomnia P1.103 Improved primary CNS Ascertained by STOP and Insomnia Severity hypersomnia diagnosis with statistical Index in Neurological Populations —Thapanee machine learning —Lan Jiang, Joe Cheung,
Circadian Behavior —Annie Hsieh, Xiangzhong
P1.095 Treatment of Obstructive Sleep
Apnea with Positive Airway Pressure in Mild Cognitive Impairment —Aarushi Suneja, Virginia Skiba, Marina Novikova, Lonni Schultz, Beth McLellan
Sunday
P1.096 A Motivational and Educational
Assessment of Sodium Oxybate (SXB) on Functioning, Productivity, and HealthRelated Quality of Life in Participants With Narcolepsy —Michael Thorpy, Kathleen F. Villa, Jed Black, Shay Bujanover, Miriam G. Cisternas, David J. Pasta, Maurice Ohayon
P1.106 The Nexus Narcolepsy Registry: Toolkit to Improve CPAP Therapy Adherence: Factors Associated With Use of Different Feasibility of Organizational System Medications and Discontinuation Rates in Implementation —Jamie Slettedahl, Andrew Participants With Narcolepsy —Kathleen F. Yantes, Jean Tsai
P1.097 Text Message Reminders and
Intensive Education Improves Positive Airway Pressure Compliance and Cognition in Veterans with Traumatic Brain Injury and Obstructive Sleep Apnea: ANNIE Pilot Study —Lynn Kataria, Cynthia Sundahl, Lauren Skalina, Medha Shah, Michael Pfeiffer, Marshall Balish, Julie Chapman
P1.098 Serotonin Reuptake Inhibitors in Obstructive Sleep Apnea with Depression: Associations in People With and Without Epilepsy —Jocelyn Cheng
P1.099 Polysomnography is Crucial to
the Diagnosis of Sleep Disordered Breathing Syndromes in Patients with Hypermobility Spectrum Disorder —Lauren Babcock, Kelsey
Villa, David J. Pasta, Jed Black, Shay Bujanover, Miriam G. Cisternas, Maurice Ohayon, Michael Thorpy
call for the elderly at a tertiary care centre in Islamabad, Pakistan —Neha Siddiqui, Rahy
Farooq, Salman Mansoor, Maimoona Siddiqui, Shoab Saadat, Zain Ahmad Javed, Arooj Fatimah Shah
P1.109 The Role of Prescription Drugs
P1.123 Insight into the Burden of Opioids on Stroke Patient Outcomes in the United States —Leila Parand, Asad Ikram, Maryam
Contraception in Women with Epilepsy —
P1.124 Changing Trends for
P1.114 Eveningness Chronotype is
Andrew Herzog, Hannah Mandle, Devon MacEachern
Associated with Sleep Disturbances and Depressive Mood in Korean Working Adults —Hye-Jin Moon, Yeong Seon Lee, Yong Won Cho
P1.115 Defining the Pattern of the
Arousal-Related Motor-Behavioral Episodes (AMBEs) in Agrypnia Excitata (AE)-Limbic Autoinmune Encephalopathy (AE-LAE). — Arturo Garay, Susana Blanco
Suescun, Luca Giancardo, Timothy Ellmore, Laura Ocasio, Arash Kamali, Roy Riascos-Castaneda, Mya Schiess
P1.117 Sleep Duration and Cognitive
P1.125 A Neuroepidemiological Review of Childhood Epilepsy in a Children’s Hospital —Arayamparambil Anilkumar, Jeff Swarz
P1.126 The Incidence of First Seizures, New Diagnosis of Epilepsy and Seizure Mimics in County Cork, Ireland; An Epidemiologic Protocol —Eimer Maloney, Daniel Costello
P1.127 Prevalence of Seizures in Patients with Systemic Lupus Erythematosus in Western Mexico. —Adrian Rodriguez
Hernandez, Valeria Diaz-Rizo, Paloma RiveroMoragrega, Ana Paulina Davalos-delaCruz, Alberto Daniel Rocha-Muñoz
Function: Associations in a Nationally Representative U. S. Sample —Dominique
NEUROEPIDEMIOLOGY: MOTOR NEURON DISEASE, COGNITIVE IMPAIRMENT, SLEEP I
NEUROEPIDEMIOLOGY: CEREBROVASCULAR DISEASE AND EPILEPSY
P1.128 Alcohol consumption and
Low, Mark Wu, Adam Spira
P1.118 Let’s Talk About Stroke: A
Retrospective Descriptive Study —Isabel
Pellicer Espinosa, Juan Antonio Iniesta Valera, Noelia García Lax, José Ángel Motos García, María P1.107 Performance of the Patient Global Palao Rico, Eliot Gómez López, Jose Marin, María Luisa Martínez Navarro, Begoña Palazón Cabanes, Impressions—Severity Scale as a SelfJose Manuel Rodriguez Garcia, M.Purificacion reported Patient Assessment of Insomnia Severity —William Herring, Ellen Snyder, Peining Salmeron Ato, Antonio Díaz Ortuño Tao, Vladimir Svetnik, Christopher Lines P1.119 Identification of Potential
P1.108 Poor Sleep Quality: A wake up
Peter Pytel, Anthony Reder, Adil Javed
Thomas Ferree, Shai Gozani, John Winkelman
P1.116 Longitudinal connectome-base metric (STREAM) aids in discerning central biomarker from Diffusion Tensor Imaging disorders of hypersomnolence —Brynn Dredla, for REM Sleep Behavior Disorder —Jessika Joseph Burns, Ronald Chervin, Cathy Goldstein P1.105 The Nexus Narcolepsy Registry:
antibody encephalomyelitis in an adult man —Veronica Penyak Cipriani, Nancy Arndt,
Zulfiqar, Fares Qeadan, Owen Owens, Atif Zafar
P1.094 Performance Characteristics
Somboon, Jay Alberts, Susan Linder, Lu Wang, James Bena, Nancy Foldvary-Schaefer
P1.090 Treatment-refractory anti-MOG
Classification by Leg-Worn Actigraphy —
Emmanuel Mignot, Logan Schneider
of Sleep Apnea Screening Instruments in Former Professional Athletes —Thapanee
of an Unusual Presentation of NMO with Aquaporin Cross Reactivity to Cryptococcus spp. —Steven Xian, Howard Geyer, Isaac Molinero
P1.113 Pilot Study of Sleep/Wake
Somboon, Harneet Walia, Tyler G. Kinzy, Irene Katzan, Nancy Foldvary-Schaefer
P1.104 Supra-threshold EMG activity
P1.089 Pigeonholed: Misdiagnosis
Triggering Factors for the Occurrence of Stroke: A case-crossover study —Manya
probable REM sleep behavior disorder: A community-based study —Chaoran Ma, Milena Pavlova, Junjuan Li, Ying Liu, Yujie Sun, Zhe Huang, Shouling Wu, Xiang Gao
P1.129 Brain volumes and longitudinal cognitive change: A population-based study —Deepti Vibha, Henning Tiemeier, Saira Mirza, Hieab Adams, Wiro Niessen, Albert Hofman, Kameshwar Prasad, Aad Van Der Lugt, Meike Vernooij, Mohammad Ikram
P1.130 Syphilis screening in Mild
Cognitive Impairment: Is it worth it? —
Prasad
Catarina Assuncao, Cassio Henrique Taqu Martins, Eduardo Hummelgen
P1.120 Identifying predictors of stroke
P1.131 Relationship between central and
preparedness among a high risk churchgoing urban population: Findings from The Tailored Approaches to Stroke Health Education (TASHE) trial —Mark Cort, James
peripheral presbycusis and mild cognitive impairment in a population-based study of Southern Italy: The “Great Age Study” —
Rodolfo Sardone, Petronilla Battista, Rosanna Tortelli, Marco Piccininni, Francesco Coppola, Vito Guerra, Daniela Isabel Abbrescia, Alessandra Riggs, Vernon Rowe, John Hunter, Arlene O’Shea, P1.110 Gr8 Expectations: The Efficacy of Grasso, Maria Barulli, Cristina Didio, Madia Doug Schell, Dorsey Paul, Mark Varona, Shelia BioBoosti 8 Minute Electromagnetic Cycles P1.121 A Striking Preponderance of Lozupone, Davide Seripa, Francesco Panza, Nicola Miller, James Barnett, Snehal Kadia for the Treatment of Insomnia —Nirajan Puri, Hemorrhagic Strokes Among Young Africans: Quaranta, Giancarlo Logroscino P1.100 Polysomnographic Veronique Latreille, Paul Mathew, Milena Pavlova Evidence from the SIREN study. —Fred Characterization of Sleep Disturbance in Sarfo, Bruce Ovbiagele, Mulugeta Gebregziabher, P1.132 Exploring the Potential Risk Factors of Neurodegenerative Disease in Kevin Armstrong, Onoja Akpa, Kolawole Wahab, Angelman Syndrome: A Case Series —Jordan P1.111 Melatonin Promotes Sleep by Inhibiting Orexinergic Neurons in Perifornical Mayowa Owolabi Autopsy Cases —Patricia Henegan, Tanya Butt, Broman-Fulks, Yael Shiloh-Malawsky, Bradley Lateral Hypothalamus —Mahesh Thakkar, Rishi Jessica Crothers, Brenda Waters, Elijah Stommel Vaughn, Zheng Fan P1.122 Association between Sharma, Pradeep Sahota
P1.101 Patients’ Estimates of Their
First Night Effects during in-Laboratory Polysomnography Using a Morning
124 2018 AAN Annual Meeting
in REM Sleep —Elahhe Afkhamnejad, Sandhya Kumar
Noble, Joseph Eimicke, Jeanne Teresi, Olajide Williams
Hospital Teaching Status and Iatrogenic Cerebrovascular Hemorrhage or Infarct — Taylor Johnson, Sheetal Hegde, Ali Seifi
NEUROEPIDEMIOLOGY: NEUROPATHY, NEUROMUSCULAR DISEASES, DEMYELINATING DISEASES, AND OTHER
P1.133 Effectiveness of a
Multidisciplinary Neuropathy Clinic in Diagnosis and Treatment of Peripheral Neuropathy —Martha Cruz, Fang Bai, Lawrence Zeidman
P1.134 The Relationship Between Facial Nerve Palsy and Vaccination —Venkatraman Thulasi, Thomas Savage, Nizar Souayah, Erin Feinstein
P1.135 Title: Does Neurology Have a
Role? Chemotherapy-Induced Peripheral Neuropathy from the Perspective of Breast Cancer Survivors —Barbara Gordon, Gustavo Patino, Ishmael Jaiyesimi
P1.136 Lumbosacral Radiculoplexus
P1.144 Differences in Comorbidity
P1.159 A Tale of Two Thalami: A Case Phenotypes in Afghanistan and Iraq War of Lupus Presenting as Central Neuropathic Veterans with mild and no TBI: A Chronic Pain —Denise Chen, Nikolaos Spilias, Lorenzo Effects of Neurotrauma Consortium Study — Difrancesco Mary Jo Pugh, Alicia Swan, Roxana Delgado, Megan Amuan, David Tate, Chen-Pin Wang
P1.145 Trends of mortality in West
Nile Neuroinvasive Disease (WNND) from 2005-2014 in a US hospital cohort. —Monika Manchanda, Saqib Abbasi, Richard Dubinsky
P1.146 Machine Learning Tools
for Improving the Efficiency of Drug Development Clinical Trials in Neurodegenerative Diseases —David Ennist, Danielle Beaulieu, Samad Jahandideh, Albert Taylor
GENERAL NEUROLOGY: AUTOIMMUNE NEUROLOGY
P1.147 Neurological Complications of
Neuropathy—Incidence and the association Monoclonal Antibodies —Pritikanta Paul, Boyd with Diabetes Mellitus. —Peng Soon Ng, Peter Koffman Dyck, Prabin Thapa, Ruple Laughlin, P. James B. Dyck
P1.137 Ischemic Optic Neuropathies: A
Case Series Study —José Ángel Motos García, María Palao Rico, Isabel Pellicer Espinosa, Eliot Gómez López, Noelia García Lax
P1.138 The Danish National
Epidemiology of Neuromyelitis Optica Spectrum Disorders Based On the 2015 International Panel for NMO Diagnosis (IPND) Criteria —Viktoria Papp, Zsolt Illes,
Melinda Magyari, Nils Koch-Henriksen, Matthias Kant, Monika Góra, Lars Kristian Storr, Claudia Pfleger, Shanu Roemer, Michael Jensen, Lene Rosendahl, Linda Locht, Zsolt Mezei, Tove Christensen, Annett Petersen, Kristina Bacher Svendsen, Helle Hvilsted Nielsen, Jette Lautrup Frederiksen Battisti, Finn Sellebjerg, Egon Stenager, Thor Petersen
P1.139 Interaction of alcohol
Syndrome and Important MalignancyRelated Considerations —Gabriela Gilmour, Alexander Arnold, Marcus Koch
P1.149 A Case of Gait Ataxia and Ophthalmoparesis —Fang Bai, Andrew Christiana, Qin Li Jiang
P1.150 Systemic Lupus Erythematosus Presenting as Rhombencephalitis —Shafaq
Mansoor, Adrian Moritz, Iftekhar Ahmed, Graham Lee
P1.151 Guillain-Barré Syndrome in a
Patient with Shingles Following Multiple Myeloma Treatment —Sean Kennedy, Aldo Mendez Ruiz, Teri Thomsen
P1.152 Anti-Ma-2 Encephalitis causes
Obstructive Hydrocephalus —Stephen English, Mark Keegan, Eoin Flanagan, W. Tobin, Nicholas Zalewski
P1.153 Efficacy and Safety of
Intravenous Immunoglobulin (IVIG) IgPro10 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The PRIMA and P1.140 Epidemiology of multiple sclerosis PATH studies —Orell Mielke, Ivo Van Schaik, Jean-Marc Leger, Vera Bril, Nan van Geloven, in the United States —Kanika Sharma, Frank Domizia Vecchio, Paola Naldi, Sandra D’Alfonso, Massimiliano Copetti, Maurizio Leone
Hans-Peter Hartung, Richard Lewis, Gen Sobue, John-Philip Lawo, Billie Durn, Jan De Bleecker, P1.141 Mitochondrial disease David Cornblath, Claudia Sommer, Wim phenotypes of 999 patients in the North Robberecht, Mika Saarela, Jerzy Kamienowski, American Mitochondrial Disease Consortium Zbigniew Stelmasiak, Bjorn Tackenberg, Ingemar Merkies (NAMDC) —Emanuele Barca, Victoria Cooley, Robert Schoenaker, Valentina Emmanuele, P1.154 Steroid-responsive Salvatore DiMauro, Bruce Cohen, Amel Karaa, Encephalopathy Associated with Georgirene Vladutiu, Richard Haas, Johan Van Autoimmune Thyroiditis: A Case Report — Hove, Fernando Scaglia, Sumit Parikh, Jirair Andres De Leon Benedetti, Daniel Garbin Di Luca, Bedoyan, Suzanne DeBrosse, Ralitza Gavrilova, Sishir Mannava, Mohan Kottapally, Leticia Tornes Russell Saneto, Gregory Enns, Peter Stacpoole, Jaya Ganesh, Austin Larson, Zarazuela ZolkipliP1.155 Acute immune-mediated Cunningham, Marni Falk, Amy Goldstein, Mark polyneuropathies: The Royal North Shore Tarnopolsky, Kathryn Camp, Danuta Krotoski, Kristin Engelstad, Xiomara Rosales, Joshua Kriger, Hospital experience —Stephanie Barnes, Geoffrey Herkes Richard Buchsbaum, John Thompson, Michio Hirano P1.156 A case of Autoimmune Bittner, John Kamholz
P1.142 Psychology: A Truth in Neglect
in Neuromuscular Clinics. A Meta-analysis of Mood Disorders in Myasthenia Gravis Clinics. —Sankar Bandyopadhyay, Alair Altiero
P1.143 Epidemiology of War-related
Spinal Cord Injury among Soldiers: A systematic Review —Julio Furlan, Sivakumar Gulasingam, B. Catharine Craven
Glial Fibrillary Acidic Protein Astrocytopathy(GFAP) Meningo encephalomyelitis —Ambihai Sivalingam
Han Yuan, Barbara Carlson, Johnny O’Keeffe, Lei Ding, Michael Wenger, Linda Hershey
P1.160 Multiple antibody positive
P1.180 Attitudes towards research
Sharmeen Hussaini, Sherif Elwan, Gobind Singh, Laura Simionescu, Robert Beach
Gerson Hernandez, Angélica Zuno Reyes, Mellissa Withers, Yaneth Rodriguez, Esmeralda Matute, Lon Schneider, John Ringman
autoimmune encephalomyelitis; Role of immunosuppression in relapsing disease —
P1.161 Anti-CASPR2 Associated
Encephalitis, A Case Report —Nazaret Peláez, Carlos Sanchez, Raquel Portillo Rivero, Ángela Ortega, Dennis Dunlop
in persons of Mexican origin at-risk for autosomal dominant Alzheimer’s disease —
PATHOLOGY STUDIES IN AGING AND DEMENTIA
P1.181 Abnormal Nighttime Behaviours P1.162 WITHDRAWN along the Spectrum of Alzheimer’s Pathology P1.163 Effect of Coexisting Autoimmune Load —David Munoz, Ka Yi Koo, Tom Schweizer, Disorders on Clinical Outcome in GuillainBarre syndrome: An Analysis from National Inpatient Database —Mohammed Qureshi,
Corinne Fischer
P1.164 WITHDRAWN P1.165 Inflammatory Pseudotumor
Kim, Tom Schweizer, Corinne Fischer
Malik Adil, Daniel Larriviere
P1.182 Structural Basis of Psychosis
in Cognitively Intact Subjects with Severe Alzheimer’s Pathology —David Munoz, Julia
P1.183 Neuropathological and neuropsychological associations in of Skull Base with Intracranial Extension Mimicking Temporal Arteritis —Mausaminben hippocampal sclerosis of ageing; the 90+ Hathidara, Shuchi Chaudhary, David Gordon study —S. Ahmad Sajjadi, Maria Corrada, John P1.166 Primary Angiitis of the Central
Nervous System (PACNS): A 12-year singlecenter review —Tan Guan Zhong, Wai-Yung Yu, Soke Miang Chng, Hwee Yee Lee, Carol Tham, Xuling Lin
P1.167 Case Series of Polineuropathy
and Monoclonal Gammopathy (POEMS) — Nathane Rezende, Yuri Macedo, Camila Pupe, Osvaldo Nascimento
P1.168 Intravenous Immunoglobulin
Use In Treatment Of Central Pontine Myelinolysis: A Case Report —Margi Patel, Manmeet Kaur, Sahil Gupta, Mahvish Ayman, Angela Hays Shapshak
P1.169 Cruciate Paralysis: A Rare
Brainstem-Cord Syndrome —Jeanna WestMiles, Tyler Koehn, Thomas Duginski
P1.170 NA P1.171 NA P1.172 NA CLINICAL ISSUES IN DEMENTIA
D
P1.173 The Left Parietal or “Acalculia”
Robinson, Ron Kim, John Trojanowski, Claudia Kawas
P1.184 Post-Mortem and In Vivo
Assessment of Catecholaminergic Innervation and Alpha-Synuclein Deposition by Multi-Protein Immunofluorescence Microscopy —Risa Isonaka, Patti Sullivan, Courtney Holmes, David Goldstein
P1.185 Divergent Bi-hemispheric
Patterns of FTLD-TDP and FTLD-Tau Neuropathologies in Primary Progressive Aphasia —Lucia Giannini, Mendy Liang, Corey
McMillan, Andrew Williams, Charles Jester, Katya Rascovsky, David Wolk, Sharon Ash, Edward Lee, John Trojanowski, Murray Grossman, David Irwin
P1.186 The Pathology of Rapid Cognitive Decline in Clinically Reported Alzheimer’s Disease —Christin Nance, Aaron Ritter, Justin Miller, Sarah Banks
P1.187 Higher Circulating VEGF is
Associated with Higher Burden of Neuritic Plaques in APOE ε4- Older Adults in the Framingham Study —Mekala Raman, Jayandra Himali, Sarah Conner, Thor Stein, Ann
Variant of Early-Onset Alzheimer’s Disease — McKee, Bertrand Huber, Victor Alvarez, Vasan Negar Moheb, Randy Desarzant, Diana Chavez, Elvira Jimenez, Edmond Teng, Mario Mendez
P1.174 Early-Onset Progressive
Dementia with Persistent Extensive Cortical Diffusion Restriction —Juebin Huang, Mark Cohen, Jiri Safar, Alexander Auchus
P1.175 Peripheral Neuropathy in Patients
Ramachandran, Alexa Beiser, Sudha Seshadri
P1.188 Grey Matter Atrophy as a Marker for Increasing Pathological Burden in TDP-43 Proteinopathies —Pilar M. Ferraro, Christopher
Olm, Katerina Placek, David Irwin, Lauren Elman, Leo McCluskey, Corey McMillan, Edward Lee, John Trojanowski, Murray Grossman
with Prion Disease —Han Wang, Mark Cohen, Jiri Safar, Brian Appleby
VASCULAR RISK FACTORS IN AGING AND DEMENTIA
P1.176 Representation of ethnic
P1.189 Definite Cerebral Amyloid
minorities in dementia trials: A systematic review and meta-analysis —Manav Vyas,
Pranali K. Raval, Jennifer Watt, David Tang-Wai
Angiopathy related granulomatous inflammation in a middle-aged man with Homozygous alleles for ApoE4. —Yan Hou,
P1.177 Posterior Cortical Atrophy with
Aparna Vaddiparti, Xianyuan Song, Lawrence Hudson
P1.157 Rheumatoid Meningitis
Alicia Parker, Leila Saadatpour, Leilani Doty, Kenneth Heilman
P1.190 fMRI Surrogate of Cerebral
McKenna, Simon Cronin
P1.178 Hashimoto’s Encephalitis
presenting as Cough Headache —Mary Clare
P1.158 Steroid-Responsive Hashimoto
Encephalopathy and its association with von-Willebrand disease —Roohi Katyal, Divya Singhal
sleep in aMCI patients & healthy controls —
Quadrantic Spatial Neglect —Usama Tariq,
Presenting as Normal Pressure Hydrocephalus —Ellen Chang, May Kim-Tenser, Benjamin Emanuel, Sebina Bulic, John Ringman, Helena Chui
Vascular Reactivity is Impaired in Cerebral Amyloid Angiopathy but Not Alzheimer’s Disease —Aaron Switzer, Ikreet Cheema, Cheryl
McCreary, Saima Batool, Angela Zwiers, Anna Charlton, Charlotte Zerna, Randall Stafford, Richard Frayne, Bradley Goodyear, Eric Smith
AAN.com/view/AM18 125
Sunday
consumption and smoking on Multiple Sclerosis severity course: A cross-sectional study —Andrei Ivashynka, Simona Arcuti,
P1.148 Four Patients with Numb Chin
P1.179 EEG frequency changes during
POSTER SESSIONS
Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.
POSTER SESSIONS
POSTER SESSION I
G
P1.191 Poststroke Mild Cognitive
Hypertension: A Systematic Review of the Literature —Brandon Bond, Kamila Bond, Chike Impairment and Dementia: A meta-analysis. Prominent role of criterion of cognitive deficit — Ilorah, Jorge Kattah Olivier Godefroy, Momar Diouf, Martine Roussel, P1.204 An Observational Study, On Low Mélanie Barbay, Grecogvasc study group Molecular Weight Heparin (LMWH) Versus P1.192 Endothelial CTACK associated Unfractionated Heparin (UFH) Therapy In with an altered cerebral vasoreactivity in The Treatment Of Cerebral Venous Sinuses Alzheimer Disease. —Juan Gongora Rivera, Thrombosis (CVST) —Sai Sripada Koneru, Vijay Xochitl Ortiz, Eduardo Garza-Villarreal, Antonio Anaya-Escamilla, Meztli Espinoza, Alejandro Gonzalez Aquines, Nancy Garza-Garcia, Carlos Medina, Hector Villarreal, Mario Carmona
P1.193 24-hour ambulatory blood
pressure, cognitive performance, and cerebral microbleeds in the elderly —Annlia
Paganini-Hill, David Floriolli, Natalie Bryant, Dana Greenia, Maria Corrada, Claudia Kawas, Mark Fisher
P1.194 Dementia and vascular risk
Chandran, Sankar Gorthi, Aravind Prabhu
P1.205 Cerebral Venous Thrombosis in
Older Patients —Yvonne Zuurbier, Sini Hiltunen, Erik Lindgren, Suzanne Silvis, Katarina Jood, Sharon Devasagayam, Timothy Kleinig, Frank Silver, Daniel Mandell, Jukka Putaala, Turgut Tatlisumak, Jonathan Coutinho
P1.206 Cerebral Venous Sinus
Thrombosis: Clinical Outcomes in Medical Management and Mechanical Thrombectomy —Quang Vu, Amy Guzik, Bryan
scores in an aging population: An association Neth with cognitive and sensory impairment — Rosanna Tortelli, Marco Piccininni, Petronilla Battista, Luca Di Lena, Daniela Isabel Abbrescia, Maria Rosaria Barulli, Rosa Capozzo, Francesco Coppola, Madia Lozupone, Francesco Panza, Rodolfo Sardone, Nicola Quaranta, Giancarlo Logroscino
P1.195 Elucidating Subtypes and Risk
Factors of Brain Arteriolosclerosis —Eseosa
P1.207 Suspicion of cerebral venous
thrombosis based on the patient’s headache characteristics —Vanessa Rizelio, Paulo Sérgio Faro Santos, Matheus Kahakura Franco Pedro, Pedro Kowacs
P1.208 Cerebral Venous Sinus
Thrombosis: Predictors of Poor Clinical
Outcomes —Bryan Neth, Quang Vu, Amy Guzik Ighodaro, Erin Abner, Sarah Monsell, Walter Kukull, Janna Neltner, Vanessa Smith, David Fardo, P1.209 Trans- Venous Aphasias — Peter Nelson Balasubramanian Samivel, Lakshmi Ranganathan, Harish Jayakumar, Shanmuga Sundaram N, P1.196 Blood pressure and the risk Thamilpavai Natarajan, Venkateswaran Kuttuva of dementia: A systematic review and dose-response meta-analysis of prospective Jeyarman, P Lenin Sankar, Pratheep Kumar S studies —Wei Xu BEHAVIORAL AND COGNITIVE NEUROLOGY: OTHER
P1.197 Features Can Be Bound in
Blindsight Without Consciousness —Chaipat Chunharas, Vilayanur Ramachandran
P1.198 Capgras Syndrome in a 20-Year-
PRE-HOSPITAL, TELESTROKE, AND ED-BASED STROKE CARE
P1.210 Characteristics of Prehospital
Acute Stroke Care in an Urban Setting: Pilot Data from the Pre-hospital Rapid Evaluation via Ambulance Lead Emergency Remote Telemedicine (PRE-ALERT) Study —Mariko Hanson, Michelle Stockner, Elizabeth Aradine,
Sunday, April 22 11:30 a.m.–5:30 p.m. P1.215 Then and Now: Temporal
P1.227 Diabetic Patients with Non-
Sheikhi, Naresh Mullaguri, Andrew Buletko, Jason Mathew, Tapan Thacker, John Nocero, Andrew Reimer, Rasmussen Peter, Andrew Russman, Muhammad Hussain, Ken Uchino
Joshua Santucci, Lance Ford, Kimberly Hollabaugh, Bappaditya Ray
Evolution of a Mobile Stroke Unit —Lila
P1.216 Pre-Hospital Stroke Diagnosis
Aneurysmal Subarachnoid Hemorrhage—A Single Center Perspective —Amna Sohail,
P1.228 The Rise of Non Aneurysmal
Subarachnoid Hemorrhages in the United Accuracy: Cross Sectional comparison States: Analysis of Nationwide Inpatient 2010/11 & 2016 —Michael Schneck, Paula De la Sample from 2006 to 2014 —MohammadPena, Sean Ruland, Camilo Gomez, Mark Cichon, Jose Biller
Rauf Afzal, Omar Saeed, Saqib Chaudhry, Adnan Qureshi
P1.217 Door-to-CT time: A Novel Tool
P1.229 Natural History of Infectious to Assess Effect of Prehospital Notification Intracranial Aneurysms Undergoing of Acute Stroke Patients in a High Volume Antibiotic Treatment —Cory Rice, Sung Cho, Comprehensive Stroke Center. —Arpita Hazra, Lucy Zhang, Jean Khoury, Prateek Thatikunta, Anisha Chaudhry, Erin Hollis, Paul Wright, Elliott Salamon, Rohan Arora
Dolora Wisco, Muhammad Hussain, Ken Uchino
Stroke education: A Model to Increase EMS Prehospital Notification for Acute Ischemic Stroke. —Arpita Hazra, Erin Hollis, Anisha
imaging finding for perioperative neurologic complications? —Lucy Zhang, Cory Rice, Jean
P1.230 Sulcal SAH in patients with P1.218 College Student Led One-on One infective endocarditis : A predictive
Chaudhry, Joe Landers, Tammy Haber, Paul Wright, Rashmeet Gujral, Jeffrey Katz, Rohan Arora
SUBARACHNOID HEMORRHAGE AND INTRACRANIAL ANEURYSMS
P1.219 Anatomical variations
circle Willis, aneurisms correlation, and relationship with subarachnoid haemorrhage —Kledisa Shemsi, Edlira Shemsi, Elton Cekaj, Ferid Domi, Arsen Seferi
P1.220 Convexity Subarachnoid
Hemorrhage: Clinical Features and Etiology of an Argentinian Cohort —Anibal Chertcoff,
Miguel Saucedo, Lucrecia Bandeo, Fatima Pantiu, Luciana Vanesa Leon Cejas, Maria Pacha, Marcela Uribe Roca, Pablo Bonardo, Manuel Fernandez Pardal, Ricardo Reisin
P1.221 Defining clinical and radiological features of nontraumatic convexal subarachnoid hemorrhage in a cohort of 60 Argentinean patients —Federico Eberbach,
Khoury, Sung Cho, Ken Uchino, Dolora Wisco
P1.231 Procedures requiring general
anesthesia in patients with unruptured intracranial aneurysms. —Vijayaleskhmi Nair,
Adekorewale Odulate-Williams, Sameer Sharma, Hesham Masoud
INTRACEREBRAL HEMORRHAGE
P1.232 Microhemorrhages and Cerebral Amyloid Angiopathy: Worth Counting? —
Joseph Carrera, Prachi Mehndiratta, Shareena Rahman, Andrew Southerland, Bradford Worrall
P1.233 Transient Focal Neurological
Episodes with Subsequent Catastrophic Intracerebral Hemorrhage Due To Cortical Superficial Siderosis and Amyloid Angiopathy —Davida Goltz, Derek Cheng, Karen Black, Elliott Salamon, Paul Wright
P1.234 Clinical Characteristics of 100
patients with Angiography-confirmed Lowflow Spinal Arteriovenous Fistulas —Olwen
Sunday
Old Woman with DiGeorge Syndrome and Jamie Ricks, Rashon Britt, Sherita Chapman Diffuse Brain Calcifications —Julien Cavanagh, P1.211 Rapid Arterial Occlusion Ilana Lasner, Hyeyoung Seol, Roderick Alfonso, Evaluation Score Agreement Between Nathan Farkas, Weijun Jin, Arnold Eggers Emergency Medical Services Providers and P1.199 What Day is Today? A Case Stroke Specialized Neurologists —Rahul of a Patient who Developed Significant Rahangdale, Muhammad Adeel Saleemi, Chris Anterograde Amnesia with Abnormal Signal Hackett, Jack Protetch, Sandeep Rana, David Intensity in the Medial Temporal Lobes on Wright, Robert Fishman, Ashis Tayal Brain Magnetic Resonance Imaging (MRI) P1.212 Using the RE-AIM Framework in the Setting of Substance Abuse. —Dena in Formative Evaluation/Planning of a Little, Eric Nagele, Michael Gallagher, Michael Mobile Prehospital Telestroke Intervention Weston in an Urban Setting: Pilot Data for the P1.200 Unusual Amnestic Syndrome Prehospital Rapid Evaluation via Ambulance Associated with Combined Fentanyl and Lead Emergency Remote Telemedicine Cocaine Overdose —Quynh Vo, Uzoma Duru, (PRE-ALERT) Study —Michelle Stockner, Tsion
Veronica Bruno, Hernan Chaves, Sebastian Ameriso
Murphy, Carlos Pardo-Villamizar, Philippe Gailloud
P1.222 Change in outpatient post-
on outcomes after ruptured arteriovenous malformation: A Nationwide Inpatient Sample analysis —Rakesh Khatri, Mohammad-
CEREBRAL VENOUS SINUS THROMBOSIS (CVST)
Norma Castillo, Fernando Testai
Gauri Pawar
E
P1.201 Timing Of Anticoagulation In
Patients With Cerebral Venous Thrombosis Requiring Neurosurgery: Case Series —
Russell Bartt, Kristin Salottolo, Kathryn McCarthy, Rebecca van Vliet, Amy Nieberlein, Judd Jensen, David Bar-Or
P1.202 Cerebral Venous Thrombosis
(CVT) presenting symptoms in Native Americans and Hispanics. —Saif Bushnaq,
Asad Ikram, Saji Bushnaq, Fares Qeadan, Andrew Carlson
P1.203 Endovascular Venous Sinus
Stenting for Refractory Idiopathic Intracranial
126 2018 AAN Annual Meeting
Habtamu, Joshnamaithili Seelam, Shwetha Hara Sridhar, Mirinda Gormley, Alfred Brown, Pamela Brown, Sherita Chapman
P1.213 Predictors for prehospital time
delay in patients with acute stroke in Germany —Katja Kolpatzik, Stelios Grigoriadis,
Hassan Belamkadem, Xenia Stasinaki, Iris Adelt, Zaza Katsarava
P1.214 Air Transport Shortens Arrival Times and May Increase Thrombectomy Rates —Nitish Kumar, Reyanna Massaquoi,
Randall Edgell, Aninda Acharya, Abhay Kumar, Ryan Murphy
discharge clinic follow-up for aneurysmal subarachnoid hemorrhage patients over 5-year period—a single center perspective —Danny Samkutty, Swathy
Chandrashekhar, Joshua Santucci, Lance Ford, Kimberly Hollabaugh, Brad Bohnstedt, Bappaditya Ray
P1.223 Increased Rate of Subarachnoid
P1.235 Aspirin and anticoagulant usage
Rauf Afzal, Mohtashim Qureshi, Ihtesham Qureshi, Anantha Vellipuram, Darine Kassar, Paisith Piriyawat, Alberto Maud, Salvador Cruz-Flores, Gustavo Rodriguez
P1.236 Cerebral Hemangiomas: 53
Times More Likely To Bleed —Dinesh Jillella,
Hemorrhage and Aneurysm Size in Patients with Obstructive Sleep Apnea —Sebastian
Fares Qeadan, Asad Ikram, Christopher Calder, Leila Parand, Maryam Zulfiqar, Piotr Bzdyra, Leslie Morrison, Atif Zafar
P1.224 Early Inflammation as a
P1.237 Intracranial Hemorrhage in
Zaremba, Luca Albus, Erdem Güresir
Predictor of Vasospasm after Subarachnoid Hemorrhage —Muhammad Rizwan Husain,
Familial Cerebral Cavernous Malformation: Clinical presentation vs. incidental MRI findings in the follow-up Imaging —Nazeem
P1.225 Serum lactate and cerebral
Arsalan, Leslie Morrison, Asad Ikram, Atif Zafar, Helen Kim, Jeffrey Nelson, Blaine L Hart
Purón-González
Zafar, Puja Mathur, Asad Ikram, Leslie Morrison
P1.226 Subarachnoid Hemorrhage in
P1.239 Risk factors associated with
vasospasm in subarachnoid hemorrhage. Sequential transcranial doppler in a Hispanic P1.238 Role of Lamotrigine in cohort. A preliminary study —Leticia Alejandra Management of Commonly Encountered Olguín-Ramírez, Hector Martinez, Joan Stephanie Symptoms in Patients with Cerebral Celis Jasso, Norma Lizeth Alvarado-Franco, Emma Cavernous Malformations —Piotr Bzdyra, Atif
the Setting of Electroconvulsive Therapy in a Patient with an Unsecured Cerebral Aneurysm: A Case Report and Review of the Literature —James Gugger, Lauren Dunn
acute symptomatic seizures in patients with intracerebral hemorrhage: A case-control study —Ting Wu, Maria Stefanidou, Jose Romero, Helena Lau
P1.240 Validating the role of Prophylactic P1.254 Evaluation of Prothrombin Antiepileptic Drugs (AEDs) in Cortical Intracranial Hemorrhage in a Large Urban Hospital. —Anusha Boyanpally, Rajanigandhi
Complex Concentrate on Oral Anticoagulation Associated Intracerebral Hemorrhage —Thuy Nguyen, Sophie Samuel,
Hanumanthu, Matthew Sumicad, Francisco Gomez, Sujan Teegala Reddy, Adeola Olowu, Hope Moser, Machteld Hillen Nicole Gonzales
P1.241 Distal Brain Alteration and
P1.255 Modifiable Factors are a Major Delayed Cognitive Impairment Following Cause of Non-traumatic Intracerebral Intracerebral Hemorrhage —Elaine Shi, Kai-Bin Hemorrhage in Young Adults —Matthew Shi, Shenfeng Qiu, Jie Wu, Kevin Sheth, Andrew Ducruet
P1.242 The Impact of Left versus
Broderick, Luca Rosignoli, Abhishek Lunagariya, Supreet Kaur, Teddy Youn, Alexis Simpkins, Anna Khanna, Christina Wilson, Nandakumar Nagaraja
P1.256 A Decade of Intracerebral Right Sided Strokes on Intracerebral Hemorrhage —Russell Bartt, Jan Leonard, Kristin Hemorrhage in the United States: The Salottolo, Amy Nieberlein, David Bar-Or Impact of Teaching Institutions —Sheetal P1.243 Role of Flat Panel Cone Beam
Computed Tomography in Detecting ICH: Single Center Study —Amrinder Singh, Ashish
Kulhari, Siddhart Mehta, Briana DeCarvalho, Anna Barminova, Spozhmy Panezai, Jawad Kirmani
P1.244 Primary Intracerebral
Hemorrhage and Perihematomal Edema Volumes in Diabetics on Sulfonylureas: A Case-Control Study —Hannah Irvine, Shailesh
P1.258 Intracranial Injuries in the Burn
Intensive Care Unit —Brian Stephens, Anthony Frattalone, Kevin Chung, Leopoldo Cancio
CLINICAL EPILEPSY I
P1.245 Multifocal Hemorrhagic Brain
P1.259 Extrapolation of Adjunctive
Parand, Atif Zafar
P1.246 Acute Hyperglycemia is
F
Efficacy and Safety Data from Phase III Partial Epilepsy Trials to Evaluate Perampanel as Monotherapy —Scott Mintzer, Jacqueline French, Betsy Williams, Anna Patten, Antonio Laurenza
P1.260 Clinical Factors Associated Associated with Larger AntithromboticRelated Intracerebral Hemorrhage Volume — with a Major Response (=75% Reduction Himanshu Gupta, Simon Beshara, Tushar Patil, in Seizure Frequency/28 Days) in Phase III Ashkan Shoamanesh Trials of Adjunctive Perampanel in Patients with Partial Seizures: Post Hoc Multivariate P1.247 Characterization of Atrial Analysis —Elinor Ben-Menachem, Gregory Fibrillation in Antithrombotic-Related Krauss, Robert Wechsler, Anna Patten, Betsy Intracerebral Hemorrhage —Simon Beshara, Himanshu Gupta, Tushar Patil, Ashkan Shoamanesh
P1.248 Elevated Serum Troponin Levels Fernando Testai
P1.249 Thromboelastography with
Platelet Mapping (TEG-PM) in Patients with Spontaneous Intracerebral Hemorrhage on Antiplatelet Therapy-Validity and application of Testing —Premkumar Nattanmai Chandrasekaran, Christopher Newey, Keerthivaas Premkumar, Sharmila Suri Mohanram
P1.250 Benign Intracerebral
Hemorrhage: Proposal for a New Definition and Association with Functional Independence —Qi Li, Xiao Wei, Wen-Song
P1.267 Retrospective, Phase IV Study
of Perampanel in Real-World Clinical Care of Patients with Epilepsy: An Interim Analysis —Robert Wechsler, James Wheless, Katherine Moretz, Betsy Williams, Antonio Laurenza, Anna Patten, Manoj Malhotra
P1.268 Assessment of the Long-Term
Efficacy and Safety of Adjunctive Perampanel in Adolescent Patients: Post Hoc Analysis of Open-Label Extension (OLEx) Studies —Jesus
Williams, Antonio Laurenza
P1.261 Effect of Common Concomitant
Antiepileptic Drugs (AEDs) During Adjunctive Treatment with Perampanel: Post Hoc Analysis from the Open-Label Extension (OLEx) of a Phase III Study in Patients with Idiopathic Generalized Epilepsy (IGE) — Terence O’Brien, Francesco Bibbiani, Anna Patten, Antonio Laurenza, Betsy Williams
P1.262 One-year Retention Study
of Adjunctive Perampanel Treatment in Epilepsy Patients —Dayoung Kim, Dong Wook Kim, Jeeyoung Oh
P1.263 Pharmacokinetic Evaluations of ADS-4101 (Lacosamide) Modified Release Capsules versus Lacosamide IR in Two Phase 1 Studies up to 600 mg —Rajiv Patni,
P1.270 Time to Pre-randomization
P1.278 Functional Connectivity of
Idiopathic Generalized Epilepsy Patients vs Frontal Epilepsy Patients using Magnetoencephalography (MEG) —Sira
Carrasco, Laura Burriel, Guiomar Niso, Fernando Maestu, Julia Vaamonde Gamo
P1.279 Altered Frontal Lobe Network
Function in Temporal Lobe Epilepsy Revealed by Graph Theory Analysis —Shankar Iyer, Jedidiah Mathis, Candida Ustine, Veena Nair, Megan Rozman, Taylor McMillan, Peter Kraegel, Dace Almane, Courtney Forseth, Gyujoon Hwang, Andrew Nencka, Rasmus Birn, Douglas Ward, Vivek Prabhakaran, Rama Maganti, Lisa Conant, Bruce Hermann, Colin Humphries, Edgar DeYoe, Manoj Raghavan, Mary Meyerand, Jeffrey Binder
P1.280 ECG reporting in the first seizure
clinic: Are we missing an opportunity? —Xuya Huang, Naveed Malek, Joanne Simpson, Dheeraj Kalladka, Francis Dunn, John Paul Leach
P1.281 Surface EMG from the Brain
Sentinel® Monitoring and Alerting System for classification of seizure events —Jose
Monthly Seizure Count for Perampanel in Cavazos, Damon Cardenas, Kristen Malloy, Luke Patients with Primary Generalized TonicWhitmire Clonic (PGTC) Seizures: A Potential New Clinical Endpoint —Jacqueline French, Christian P1.282 Provider and Patient SUDEP-7 Brandt, Emilia Bagiella, Francesco Bibbiani, Anna Scoring: A Prospective Pilot Study —Allison Patten, Betsy Williams, Antonio Laurenza
P1.271 Exposure-Response Analysis
of Cannabidiol (CBD) Oral Solution for the Treatment of Lennox-Gastaut Syndrome — Gilmour Morrison, Maria Luisa Sardu, Christian Hove Rasmussen, Kenneth Sommerville, Claire Roberts, Graham E Blakey
P1.272 Post Hoc Analysis of Rufinamide Study 303: Seizure-Free Days in Patients with Lennox-Gastaut Syndrome (LGS) —
Stéphane Auvin, Betsy Williams, Rob McMurray, Dinesh Kumar, Carlos Perdomo, Manoj Malhotra
Kiernan, Keerthi Jaliparthy, Anwar Chahal, Anna Myburgh, Tanya Bredesen, Paul Timm, Jeffrey Britton, Gregory Cascino, Gregory Worrell, Elson So, Virend Somers, Erik St. Louis
P1.283 On the Feasibility of Natural
Language Processing for Standardized Data Extraction from Electronic Medical Records of Epilepsy Patients —Pouya Khankhanian,
Nikitha Kosaraju, Jay Pathmanathan, Colin Ellis, Ingo Helbig, Brian Litt, John Pollard, Kathryn Davis
P1.284 Reliability of Patient-Reported
Peri-Ictal Behavior to Identify Psychogenic Nonepileptic Seizures —Wesley Kerr, Andrea
P1.273 Efficacy and Safety of Adjunctive Chau, Emily Janio, Chelsea Braesch, Justine Le, Rufinamide in Lennox-Gastaut Syndrome (LGS): Results from Studies 022, 022E, 303, 304, and 305 —Alexis Arzimanoglou, Gerhard
Jessica Hori, Akash Patel, Norma Gallardo, Janar Bauirjan, Eric Hwang, Emily Davis, Albert Buchard, David Torres-Barba, Shannon D’Ambrosio, Mona Al Kluger, Arnd Müller, Yoko Ohtsuka, Betsy Williams, Banna, Andrew Cho, Jerome Engel, Mark Cohen, John Stern Francesco Bibbiani, Carlos Perdomo, Manoj Malhotra
P1.274 Seizure Outcome After Lesional Epilepsy Surgery: A Report of the First Comprehensive Epilepsy Surgery Program in Iran —Shervin Badihian, Jafar Mehvari
Habibabadi, Houshang Moein, Reza Basiratnia, Bagher Zaki, Navid Manouchehri, Mohammad Zare, Majid Barekatain, Elham Rahimian, Amirali Mehvari Habibabadi, Payam Moein, Yahya AghaKhani, Shahram Amina, Samden Lhatoo
P1.275 Seizure Outcome after Epilepsy
Surgery in a Developing Country using a Non
P1.285 PAP Therapy is Challenging for Epilepsy Patients —Veronique Latreille, Ellen Bubrick, Milena Pavlova
P1.286 Association of
Photoplethysmography (PPG) signals and seizures in patients with epilepsy —Fatemeh Mohammadpour Touserkani, Elelonora Tamilia, Francesca Coughlin, Sarah Hammond, Boram Kim, Jack Connolly, Sheryl Manganaro, Christos Papadelis, Kush Kapur, Tobias Loddenkemper
P1.287 Utilization of Continuous Video
Electroencephalogram and Predictors of Poor Sangita Ghosh, William Wargin, April Ruby, Oriana Invasive Presurgical Evaluation Protocol — Yang, Rui Li, Lan Deng, Peng Xie Outcomes in Non-Convulsive Epilepsy. — Lewallen, Lily Llorens, Jack Nguyen Jayanthi Mani, Sunita Iyer, Pradnya Gadgil, Abhaya Urvish Patel, Ram Mohan Sankaraneni, Anusha P1.251 Comparison of Clinical and Kumar P1.264 Long-term Safety and Efficacy of Lekshminarayanan, Abhishek Lunagariya, Vishal Radiological Characteristics of Warfarin Cannabidiol (CBD) in Patients with LennoxJani, Sanjay Singh P1.276 Magnetoencephalography in versus Novel Oral Anticoagulant Related Gastaut Syndrome (LGS): Results from Epilepsy surgery: Concordance and Yield — P1.288 Reversible Complete Blindness Intracerebral Hemorrhages —Malgorzata Open-label Extension Trial (GWPCARE5) — Arunmozhimaran Elavarasi, P. Sarat Chandra, Ajay Miller, Nils Henninger due to Bilateral Status Epilepticus Jonathan Halford, Eric Marsh, Maria Bronislawa Garg, Vibhin Viswanathan, Kamal Bharti, Chandra Amauroticus Secondary to Hyperglycemia — P1.252 Remote Cerebellar Hemorrhage: Mazurkiewicz-Beldzin, Boudewjin Gunning, Daniel Sekhar Bal, Madhavi Tripathi, Mehar Chand Dennis Chuang, Faisal Alsallom, Pitcha Checketts, Claire Roberts, Elizabeth Thiele Report of Two Cases and Systematic Sharma, Ravindra Pandey, Deepa Dash, Senthil Chompoopong, Trisha Dickey, Fajun Wang, Literature Review —Guilherme Torezani, Kumaran, Pravat Mandal, Arpan Banerjee, Manjari P1.265 Acute Treatment of Prolonged Nataliya Pyatka, Michael Devereaux, Hesham Barbara Diniz, Joao Marcos Ferreira, Pedro Tripathi and Repetitive Seizures in Adults Using Abboud Macedo, Yuri Macedo, Karoline Medeiros, Rodrigo Sublingual Administration of Lorazepam P1.277 Utilization of epilepsy surgery in Sperling Torezani, Gabriel De Freitas Intensol 2 mg/ml Solution —Charlotte Kwok, the United States, 2009–2014 —Ahyuda Oh, P1.289 First Reported Case of Alice in Wonderland Syndrome Due to an P1.253 The Spot Sign in Intraventricular Erie Gonzalez, Gregory Krauss Hyunmi Kim, Joshua Chern Arteriovenous Malformation —Veeresh Kumar Hemorrhage: Prevalence and Relation to Nanjangud Shivamurthy, Prateeka Koul, Jonathan Hematoma Expansion —Mohammad Hamed, P1.266 A randomized, double-blind, placebo-controlled, crossover study to Lim, Jeffrey Kornitzer, David Marks Omar Hussein, Khalid Sawalha, Michel Torbey, evaluate the abuse potential of purified Archana Hinduja
AAN.com/view/AM18 127
Sunday
Predict Worse Outcome After Intracerebral Hemorrhage —Gabriela Trifan, Alex Guman,
Tilden Etges, Naama Levy-Cooperman, Catherine Mills, Edward Sellers, Beatrice Setnik, Isabella Szeto, Kenneth Sommerville
Pina-Garza, Vicente Villanueva, William Rosenfeld, Harumi Yoshinaga, Francesco Bibbiani, Anna Patten, P1.257 Improving appropriate use of DVT Betsy Williams, Antonio Laurenza prophylaxis in spontaneous ICH patients — P1.269 Third-Line Antiepileptic Aparna Prabhu, Sridhara Yaddanapudi, Anusha Treatment Outcomes in Refractory Status Edara, Jalyoung Joe, Dilip Kumar Jayaraman, Steven Yang Epilepticus —Steven Ellis, Lola Morgan Hegde, Taylor Johnson, Ali Seifi
Male, Jetter Robertson, Caitlin Bell, Christopher Streib
Lesions and Leukoencephalopathy Due to Acute Disseminated Intravascular Coagulation —Andrew Lin, Dinesh Jillella, Leila
cannabidiol (CBD) in subjects with a history of recreational polydrug use —Kerri Schoedel,
POSTER SESSIONS
Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.
POSTER SESSIONS
POSTER SESSION I P1.290 The Importance of Early
Immunotherapy in patients with Faciobrachial Dystonic Seizures —Julia
G
Zealanders with neurodevelopmental disorders —Rosamund Hill, Whitney Whitford,
Sunday, April 22 11:30 a.m.–5:30 p.m. P1.316 Neurological Therapeutic goals in P1.326 A Refined Brain Database Fabry Disease: European Expert Consensus
to Study Transcriptomic Changes in
Brendan Swan, Juliet Taylor, Klaus Lehnert, Russell Recommendations —Max Hilz, Ralf Baron, Perry Neurological Disease —Ashkaun Razmara, Snell, Jessie Jacobsen Thompson, Mian Bi, Mateusz Makuch, Andrew Elliott, Dominique Germain, Marco Spada, Miguel Leonardo Collado-Torres Murchison, Christian Bien, Kon Chu, Pue Farooque, Viana-Baptista, Christoph Wanner, Alessandro P1.305 Insights Into a Rare Genetic P1.327 Blood Volatile Organic Jeffrey Gelfand, Michael Geschwind, Ernest Burlina Disease: Unique Behavioral Phenotype Compounds Related to Oxidative Stress Somerville, Bethan Lang, Angela Vincent, Maria P1.317 Fatal Familial Insomnia in a in PURA-related Neurodevelopmental as Potential Biomarkers for Huntington’s Leite, Patrick Waters, Sarosh Irani Canadian family —Nathaniel Bendahan, Sean Disorders —Christina Chrisman, Perry Shieh disease —Hongquan Jiang, Ming Ren, Jing P1.291 NA Taylor, Lysa Boissé Lomax Wang, Changsong Wang, Xiang Yin, Shuyu Wang, P1.306 Recessive mutations in SLC13A5 Tianhang Wang, Xudong Wang, Guangtao Dong, P1.292 NA P1.318 Potential role of gut microbiota result in a loss of citrate transport and Yueqing Yang, Enyou Li, Honglin Feng P1.293 NA
P1.294 NA NEUROGENETICS AND METABOLIC DISEASE
G
P1.295 Thermolabile Carnitine
Palmitoyltransferase II (CPT2) variant susceptibility in influenza-associated encephalopathy—a case report —Wing Cheong Lee
P1.296 WITHDRAWN P1.297 Pitt-Hopkins Syndrome: A
cause refractory epilepsy/status epilepticus, in Amyotrophic Lateral Sclerosis (ALS) pathogenesis —Fabiola De Marchi, Letizia developmental delay and progressive microcephaly —Abdul Aziz Al Ghamdi, Saad Al Mazzini, Luca Mogna, Angela Amoruso, Marco Shahwan, Faisal Alshibani, Brahim Melaiki
P1.307 Clinical phenotypic data is a
key factor necessary to improve molecular interpretation of de novo alterations in neurodevelopmental genetic testing — Rhonda Lassiter
P1.308 Diagnostic Exome Sequencing in Adolescents with Neurological and Neurodevelopmental Disorders —Kirsten
Blanco, Zoe Powis, Kelly D.F. Hagman, Elaine C.
23-Patient Case Series —Kimberly Goodspeed, Weltmer, Sha Tang Cassandra Newsom, Mary Ann Morris, Craig Powell, Patricia Evans, Sailaja Golla
P1.298 GTPBP3 Mutation Leading
Recurrent Lactic Acidosis Associated with Vomiting and Headache —Gozde Erdemir, Neil Friedman, Sumit Parikh
P1.299 Intra-familial variability
P1.309 Quantitative Measures of Motor Function in children with Duplications of 15q11.3-13.1 (Dup15q Syndrome) and Typically Developing (TD) Children —Rujuta Wilson, Abigail Dickinson, Carly Hyde, Sumana Rallipalli, Katie Dahlerbruch, Carolyn Rocha, Shafali Jeste
associated with recessive mutations in P1.310 Expanding the phenotype of MTO1 gene. —Valentina Emmanuele, Christiane ATP1A3 mutations with newly described De Araujo Martins Moreno, Francine Testa, Emily abnormalities on brain MRI —Janet Elgallab,
Pane, Irene Aloisio, Nicole Cionci, Francesca Gaggìa, Ausiliatrice Lucenti, Enrica Bersano, Roberto Cantello, Diana DI Gioia, Giovanni Mogna
P1.328 Human systems analysis
implicates disturbed pathways associated with cognitive dysfunction in Williams Syndrome and shared in Autism —Ursula Bellugi
P1.319 To Study Clinical, Histological
P1.329 VPS35 and Hydrocephalus of the And Radiological Features In Neurological Developing Mouse Brain. —HyunJin Song, Lu Mitochondrial Disorders —Nishita Singh, Achal Zhao, Fulei Tang, Wen-Cheng Xiong Srivastava, Awadh Pandit, Deepti Vibha, Garima Shukla, Kameshwar Prasad
P1.320 ANXA11 mutations prevail
in Chinese amyotrophic lateral sclerosis patients with and without cognitive dementia —Kang Zhang, Qing Liu, Keqiang Liu,
P1.330 Cerebellar Ataxia Renal-failure
Neuropathy with Encephalopathy (mtCARNE): A New Mitochondrial Syndrome Identified by Sequencing Frozen Nerve and Kidney Tissue DNA —Peng Soon Ng, Jadee
Neff, Edward Highsmith, Chenjing Sun, Marcus Dongchao Shen, Hongfei Tai, Shi Shu, Qingyun Pinto, Min Xu, Samantha Roellinger, Linda Hasadri, Ding, Hanhui Fu, Shuangwu Liu, Zhili Wang, Mary Fidler, Ralitza Gavrilova, Christopher Klein Xiaoguang LI, Mingsheng Liu, Xue Zhang, Liying Cui
P1.321 Transcriptional profiling of
P1.331 Burden of Hereditary
Transthyretin Amyloidosis With Primary Progressive Multiple Sclerosis Polyneuropathy in Patients Enrolled in patients identifies Fast and Slow progression the Phase 3 Study NEURO-TTR —John patterns —Michael Gurevich, Carolina Legarda, Berk, Annabel Wang, Teresa Coelho, Marcia Rina Falb, David Magalashvili, Mark Dolev, Anat Achiron
Sunday
Waddington Cruz, Michael Polydefkis, Peter Dyck, Morton Scheinberg, Violaine Plante-Bordeneuve, Fabio Adrian Barroso, David Adams, Thomas Li, Saba Tadesse, Kristin Engelstad, Robert Lesser, P1.322 Niemann Pick Disease (NPD) Kara Anstett, Heather Lau, Lauren Krupp Brannagan, Carol Whelan, Brian Drachman, Michio Hirano presenting as cortical venous sinus Stephen B. Heitner, Isabel Conceicao, Hartmut P1.311 Novel Phenotype of ATP1A3 thrombosis: A rare presentation —Leenu P1.300 Compound Heterozygotes with Schmidt, Giuseppe Vita, Josep Campistol, Josep Mutation Starting in Infancy —Jason Richards, Gupta, Jeyaraj Pandian Three Disparate Orphan Diseases: Pyridoxine Marie McDonald, Allyn McConkie-Rosell, Vandana Gamez, Edward Gane, Peter Gorevic, Acary Dependent Epilepsy, Ataxia Telangiectasia, Shashi, Mohamad Mikati P1.323 Gaboxadol Normalizes Behavioral Oliveira, Brett Monia, Steven hughes, Jesse Kwoh, and Tay Sachs Disease —Richard Young, Peter Abnormalities in a Mouse Model of Fragile X Bradley W. McEvoy, Brenda F. Baker, Elizabeth P1.312 Acroparesthesia may be Davis, Mark Schomer, Joseph Tucker Syndrome —Patricia Cogram, Robert J. Deacon, Ackermann, Spencer Guthrie, Asia Sikora Kessler, of Mitochondrial Origin —Jose-Rafael Melanie J. von Schimmelmann, Matthew During, Morie A. Gertz, Merrill Benson, Giampaolo Merlini P1.301 Defective mitochondrial rRNA Zuzuarregui, H Hutchison Brett Abrahams P1.332 Clinical and Molecular
methyltransferase MRM2 causes MELASlike clinical syndrome —Caterina Garone,
Aaron R D’Souza, Cristina Dallabona, Tiziana Lodi, Pedro Rebelo-Guiomar, Joanna Rorbach, Alice Donati, Elena Procopio, Martino Montomoli, Renzo Guerrini, Massimo Zeviani, Sarah Calvo, Vamsi Mootha, Salvatore DiMauro, Iliana Ferrero, Michal Minczuk
P1.302 The Role of Autophagy
Dysfunction and Mitochondrial Depolarization in Neuronal Death in hiPSCderived Niemann-Pick Type C1 Neurons — Emma Wu, M. Paulina Ordoñez, John Steele, Lawrence Goldstein
P1.303 Yield of Genetic Testing
P1.313 Clinical utility of next generation
sequencing in pediatric neurology —Priyanka Madaan, Biswaroop Chakrabarty, Prashant Jauhari, Ankita Pal, Vishal Sondhi, Shefalli Gulati
GENERAL NEUROLOGY: NEUROGENETICS
P1.314 Argentinian Clinical Genomics
in a Leukodystrophies and Genetic Leukoencephalopathies cohort: Diagnostic yield in our first nine years —Leila Cohen,
Analisa Manin, Nancy Medina, Sergio Rodriguez Quirofa, Dolores Moron, Julieta Rosales, Hernan Amartino, Norma Specola, Marta Cordoba, Marcelo Kauffman, Patricia Vega
P1.324 Open Label Extension of the
Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis —Thomas Brannagan, Annabel
Wang, Teresa Coelho, Marcia Waddington Cruz, Michael Polydefkis, Peter Dyck, Morton Scheinberg, Violaine Plante-Bordeneuve, John Berk, Fabio Adrian Barroso, David Adams, Carol Whelan, Giampaolo Merlini, Brian Drachman, Stephen B. Heitner, Isabel Conceicao, Hartmut Schmidt, Giuseppe Vita, Josep Campistol, Josep Gamez, Peter Gorevic, Brett Monia, Steven hughes, Jesse Kwoh, Bradley W. McEvoy, Brenda F. Baker, Elizabeth Ackermann, Merrill Benson, Morie A. Gertz
Including Targeted Gene Panel in a Clinical Population of Children with Autism Spectrum P1.315 Clinicoradiological Improvement P1.325 In vivo Safety and Efficacy of a Disorder —Louisa Kalsner, Jennifer Twachtman- in MELAS after L-Arginine Therapy —Dominic 3rd generation Antisense Oligonucleotide Bassett, Laurie Derynioski, Stormy Chamberlain Hovsepian, Alexandra Galati, Robert Chong, targetting TGF-ßRII to treat Amyotrophic Mazumder, Catherine Yim, Shrikant Lateral Sclerosis —Sebastian Peters, Eva P1.304 Exome and genome sequencing Rajarshi Mishra, Christopher DeGiorgio Zitzelsperger, Sabrina Kuespert, Rosmarie Heydn, results refine diagnoses and provide Sven Korte, Tim-Henrik Bruun, Ulrich Bogdahn treatment options in a cohort of New
128 2018 AAN Annual Meeting
Characterization of Hereditary Spastic Paraplegias: A Next-Generation Sequencing Panel Approach —Daniela Burguez, Pablo Winckler, Marcia Polese Bonatto, Lais Alves Jacinto Scudeiro, Ingemar Bjorkhem, Ludger Schols, Laura Jardim, Ursula Matted, Maria-Luiza Saraiva-Pereira, Marina Sieber, Jonas Saute
P1.333 MiR-218 as a candidate of
biomarker for early diagnosis of ALS. —
Sandra Diaz Garcia, Giancarlo Costaguta, Amy Taylor, Maria Rodriguez, Samuel Pfaff, Eran Hornstein, John Ravits
P1.334 NA P1.335 NA P1.336 NA P1.337 NA P1.338 NA
g1 H
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P1.339 A Portable Wireless Motion
Polyneuropathy (CIDP): Identifying P1.342 Characterization of Amyotrophic Ultrasonographic Features for Diagnosis and Lateral Sclerosis (ALS) Seen in the Prognosis —Nicholas Crump, Michael Cartwright Medical University of South Carolina ALS Adam Bruetsch, Melissa Currence, Laura Herbelin, Clinic —Jayson Rodriguez, P1.341 Is high-resolution fascicular nerve Multidisciplinary Mary Paulter, Carenina Trujillo, Melissa McIntire, Pramod Chopade, I-Hweii Chen ultrasound an upcoming obligation in the Mazen Dimachkie, Jeffrey Statland, Nicholas P1.343 Prevalence and Incidence Rates neurological diagnostic algorithm? —Anna Johnson Grisold, Elisabeth Lindeck-Pozza, Wolfgang Grisold, of Autonomic Disorders among U.S. Military P1.340 A Retrospective Study of Patients Stefan Meng Healthcare System Beneficiaries Never with Chronic Inflammatory Demyelinating Capture System for Patients with Myotonic Dystrophy —Tekalign Burka, Jessie Huisinga,
NEUROINFLAMMATORY AND OTHER AUTOIMMUNE DISORDERS I
P1.345 The clinical features and
pathophysiology of ataxic form of Hashimoto’s encephalopathy —Makoto
Yoneda, Akiko Matsunaga, Masamichi Ikawa, Yasunari Nakamoto, Hiroshi Mitoma
P1.346 Primary Angiitis of the Central
P1.354 A Panel Survey Analysis of
Nervous System with Unusual Imaging Characteristics —Adam Margolius, Margaret Yu, Niels Bergsland, Jeffrey Chavin, Karthinathan Edward Manno
Thangavelu, Matthew Mandel, Stanley Cohan
P1.347 Neurological spectrum of
P1.356 WITHDRAWN P1.357 Effect of previous therapies
diseases associated with autoimmune thyroid disease: A case series to recognize diagnostically helpful signs. —Ehad Afreen, Mohammad Humayun, Ajaz Sheikh
P1.348 Neurosurgical Awakening of
on treatment retention and satisfaction in patients randomized to fingolimod or injectable disease-modifying therapies in PREFERMS —Florian Thomas, Samuel Hunter,
Cerebral Adrenoleukodystrophy: Phenotypes, Xiangyi Meng, Lesley Schofield, Scott Kolodny, Predictors, and Prevention —Na Tosha Gatson, Nadia Tenenbaum, Bruce Cree Sankeerth Challagundla, Atom Sarkar, Ann Kahler, Syed AJ Kazmi, Ruben Bonilla-Guerrero, Gino Mongelluzzo
P1.349 Neurosarcoidosis Flare with
Multifocal Restricted Diffusion: Stroke, Inflammation, or Both? —Elizabeth Spurgeon,
Justin Abbatemarco, Richard Prayson, Mary Willis
CASPR2 Antibody Syndrome with Optical Coherence Tomography (OCT) —Clarice Zhou, Vy Le, BA, Margaret Kellogg, Jacqueline Bernard
COMPARATIVE EFFICACY OF DISEASE MODIFYING THERAPIES
P1.351 Propensity Score Matched
Comparative Effectiveness Analysis of Dimethyl Fumarate Relative to Interferon, Glatiramer Acetate, or Teriflunomide Treated RRMS Outpatients in the German NeuroTransData Registry —Arnfin Bergmann,
P1.358 Observational, retrospective
study in relapsing-remitting multiple sclerosis to compare the effectiveness of second line treatments Fingolimod and Natalizumab in Spanish clinical practice —
Francisco Javier Ricart, Carmen Duran Herrera, Sergio Martinez-Yelamos, Teresa Ayuso, Miguel Angel Hernandez Perez, Nicolas Herrera, Angel Sempere, Eli Garcia, Jose Meca Lallana
P1.359 WITHDRAWN P1.360 Peginterferon Beta-1a
Demonstrated Better Clinical Outcomes Than Teriflunomide in Newly Diagnosed Relapsing Multiple Sclerosis (RMS) Patients: A Matching-Adjusted Comparison of Phase 3 Trial Data —Scott Newsome, Jang Yun, Carmen Castrillo-Viguera, Maria Naylor
Cohen, Florence Bucciarelli, Jonathan Ciron, beatrice pignolet, David Laplaud, Sandrine Wiertlewski, Laure Michel, Bruno Brochet, Aurelie Ruet, Gilles Defer, Nathalie Derache, Patrick Vermersch, Helene Zephir, Marc Debouverie, Guillaume Mathey, Eric Berger, Pierre Labauge, Jerome De Seze, Lydiane Mondot, Caroline Ranc, David Brassat, Christine Lebrun Frenay
P1.353 Relapse in Patients with Multiple
P1.362 Delayed-release Dimethyl
Fumarate Demonstrated No Difference in Clinical Outcomes Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-World EFFECT Study —Jacob Sloane, J. Theodore Phillips, Jonathan Calkwood, Anneke Van Der Walt, Jinny Min, Fan Wu, Catherine Miller
P1.363 Comparative Effectiveness and
Discontinuation of Dimethyl Fumarate and Sclerosis Newly Initiating scIFN?1a Compared Fingolimod in Two Large Academic Medical with Oral Disease-Modifying Drugs: A RealCenters at 24-Month Follow-Up: Sub-Group World Assessment —James Bowen, Chris K. Analyses —Carrie Hersh, Brandi Vollmer, Anasua Kozma, Megan Grosso, Amy Phillips
P1.365 Comparative effectiveness of
Bandyopadhyay, Samuel Cohn, Kavita Nair, Stefan
P1.344 Whipple’s disease—an unusual
etiology for neurologic disease —Mohammad Kabir, Naveen Addagatla, Sumaiya Khondker, Michael Collins
Rozsa, Cavit Boz, Raymond Hupperts, Vincent Van Pesch, Celia Oreja-Guevara, Vilija Jokubaitis, Tomas Kalincik, Helmut Butzkueven
P1.370 Integrated Transcriptomic
and Physicochemical Characterization of Glatiramer Acetate Products (Copaxone and Glatopa) Available in the United States — Arthur Komlosh, Daphna Laifenfeld, Sarah Kolitz, Kevin Fowler, Tal Hasson, Attila Konya, Shlomo Bakshi, Benjamin Zeskind, Jenny Zhang, Kevin Wells-Knecht, Tatiana Molotsky, Revital Krispin, Galia Papir, Dalia Pinkert, Helena Cooperman, Vera Weinstein, Yousif Sahly, Pippa Loupe, Sigal Melamed-Gal, Iris Grossman, Michael Hayden
dimethyl fumarate and fingolimod using fully P1.371 Confirmed Disability Progression automated algorithms to assess effects on in Different Subgroups of Patients With brain atrophy and T2-lesion volume —Jenny Relapsing Multiple Sclerosis Who Received Ocrelizumab or Interferon Beta-1a in the Feng, Kunio Nakamura, Carrie Hersh, Daniel Phase III OPERA I and OPERA II Studies — Ontaneda
P1.366 Annualized Relapse Rate
and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis —Stephen Hauser, Bruno
Benjamin Turner, Bruce Cree, Johannes Lorscheider, Xavier Montalban, Caroline Papeix, Regine Buffels, Donna Masterman, Jian Han, Victoria Levesque, Jerry Wolinsky
P1.372 Time to treatment failure
following initiation of fingolimod versus teriflunomide for the treatment of multiple sclerosis: A retrospective U.S. claims Brochet, Xavier Montalban, Robert Naismith, Jerry study —Cecilia Vieira da Silva, Devon Conway,
Wolinsky, Marianna Manfrini, Monika Garas, Pablo Gina Cox, James Signorovitch, Miranda Peeples, Arielle Bensimon, Vivian Herrera Villoslada, Fabian Model, Stanislas Hubeaux, Ludwig Kappos P1.373 Propensity Score Matched
P1.367 Efficacy of Delayed-Release
Dimethyl Fumarate in Newly Diagnosed and Other Early Multiple Sclerosis Patients, and Patients Switching from Interferon or Glatiramer Acetate, in Routine Medical Practice: Interim Results from ESTEEM — Kathryn Giles, Jerome Hanna, Fan Wu, Catherine Miller, Konstantin Balashov, Richard Macdonell,
P1.361 Demonstration of Equivalence of Joerg Windsheimer, Nicholas Everage Generic Glatiramer Acetate (GA) Produced by Mylan to Copaxone® —Peter Lipsky, Patrick P1.368 Safety and efficacy of IV
Stefan Braune, Sarah Grimm, Philip van Hövell, Ulrich Vallano, Jeffrey Smith, Viswanath Bandaru, Yunfu Freudensprung, Robert Hyde, NTD Study Group Sun, Ross Wallingford, Joseph Duncan, Joshua P1.352 Comparing Efficacy between Lewis, Jason Southall, Azeem Ansari
Natalizumab and Fingolimod: Radiological Findings from BEST-MS Study —Mikael
Zhang, Isobel Pearson, Michael Tempest, Ulrich Freudensprung, Carlos Acosta, Robert Hyde, Timothy Spelman, Helmut Butzkueven
Christina Shibley, Ernest Williams
Comparative Effectiveness Analysis of Dimethyl Fumarate Relative to FingolimodTreated RRMS Outpatients in the German NeuroTransData Registry —Stefan Braune, Sarah Grimm, Philip van Hövell, Ulrich Freudensprung, Robert Hyde, Arnfin Bergmann, NTD Study Group
P1.374 Comparative Effectiveness of
Dimethyl Fumarate Versus Fingolimod and Teriflunomide on the Risk of Relapse in MS cladribine versus alemtuzumab in aggressive Patients Switching from First-Generation Platform Therapies in the US —Jacqueline multiple sclerosis: A retrospective cohort study —Gauruv Bose, Mark Freedman, Carolina Nicholas, Matthew Carraro, Daniel Ontaneda, Jia Rush, Marjorie Bowman, Harold Atkins
P1.369 A comparative effectiveness
analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: Patients switching within first-line agents or to either natalizumab or fingolimod in active relapsingremitting multiple sclerosis (RRMS) —Timothy Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo Ayuso, Pierre Grammond, Pierre Duquette, Raed Alroughani, Eugenio Pucci, Franco Granella, Jeannette Lechner-Scott, Patrizia Sola, Diana Ferraro, Francois Grand-Maison, Murat Terzi, Csilla
Zhou, Qiang Hou, Jaanai Babb, Katherine Riester, Jason Mendoza, Terrie Livingston, Mehul Jhaveri
P1.375 Injectable disease-modifying
therapies cycling versus switching to fingolimod: A retrospective U.S. claims study of risk of MS related relapses —Cecilia Vieira da Silva, Li Yunfeng, Xiangyi Meng, Huanxue Zhou, Olivia Wenxian Piao, Christen Kutz, Devon Conway
P1.376 Characterization and Comparison
of the Gene Expression Profiles of Copaxone® and Mylan Glatiramer Acetate — Jeffrey Smith, Chun-Nan Hsu, Peter Lipsky
P1.377 Patterns of Regional Gray Matter and White Matter Atrophy in Patients
AAN.com/view/AM18 129
Sunday
P1.350 Quantifying Retinal Layers in
Sillau, Robert Bermel, John Corboy, Robert Fox,
Timothy Vollmer, Jeffrey Cohen, Daniel Ontaneda, Adherence in Patients with Multiple Sclerosis Treated with scIFNβ1a or Dimethyl Enrique Alvarez Fumarate —Amy Perrin Ross, Chris K. Kozma, P1.364 A cost-effectiveness analysis Shaloo Gupta, Amy Phillips using real-world data from the MSBase registry: Comparing natalizumab to P1.355 Comparative Effectiveness of fingolimod in patients with inadequate Teriflunomide and Dimethyl Fumarate in response to disease-modifying therapies Patients With Relapsing Forms of MS in the Real-World Teri-RADAR Study —Robert in relapsing-remitting multiple sclerosis Zivadinov, Chakkarin Burudpakdee, Michael Dwyer, (RRMS) in Scotland —William Herring, Yuanhui
Diagnosed with Diabetes —Glen Cook,
POSTER SESSIONS
Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.
POSTER SESSIONS
POSTER SESSION I
G
Sunday, April 22 11:30 a.m.–5:30 p.m.
Starting Fingolimod or Natalizumab: A 2-Year Aquaporin-4 and Myelin Oligodendrocyte Retroviral Type W Elements (pHERV-W-ENV) MS AND CNS INFLAMMATORY Tensor-Based Morphometry Study —Paolo Glycoprotein Antibody Status —Sara Mariotto, is Specifically Extracted from Demyelinating DISEASE: QUALITY OF LIFE, Preziosa, Maria Rocca, Mariaemma Rodegher, Livia Hofer, Sergio Ferrari, Ruggero Capra, Chiara MS Lesions. —Benjamin Charvet, Rianne Gorter, SYMPTOMS, AND SYMPTOMATIC Lucia Moiola, Andrea Falini, Giancarlo Comi, Mancinelli, Adriana Bonora, Roberto Bombardi, kevin reant, Justine Pierquin, Sandra Amor, Herve THERAPY I Massimo Filippi
Salvatore Monaco, Alberto Gajofatto, Markus Reindl Perron
P1.378 Cytokine changes induced
P1.390 Investigating Immune Phenotype P1.402 Effects of Cladribine Tablets
Zanganeh, Sean Selva, Kavita Nair, Joseph M Machtinger, Timothy Vollmer, Enrique Alvarez
Amit Bar-Or, Bruce Cree, Yang Mao-Draayer, May
by antiCD20 Infusions: A Comparison of Rituximab Versus Ocrelizumab —Nassim
Biomarker Changes in Patients with Relapsing MS Treated with Fingolimod 0.5 mg/day: The FLUENT Study —Jeffrey Cohen,
Barry Singer, Ann Jannu, Scott Kolodny, P1.379 Patients switching to Fingolimod Han, Xiangyi Meng, Ryan Winger from other oral DMTs and different P1.391 Recent Advances in Flow treatment frequencies in daily clinical
routine: Results from PANGAEA 2.0 —Tjalf Ziemssen, Christian Cornelissen
Cytometry Reveal Cellular Immune Dysregulation in MS and NMOSD —Makoto
Matsui, Hiroshi Sugiyama, Nobuaki Uchida, Ukichiro
P1.380 Early versus Delayed Natalizumab Kawai, Miki Oono, Michiyo Nakata, Megumi for Multiple Sclerosis —Devon Conway
Nakanishi, Mitsuru Sanada, Nagayama Shigemi
P1.381 Treatment Experiences of
P1.392 Low Levels of Alpha-Synuclein Patients with MS: Results From the Global in Peripheral Tissues are Related to Clinical vsMS™ Survey —Ann Bass, Bart Van Wijmeersch, Relapse in Relapsing-Remitting Multiple Aaron Boster, Lori Mayer, Matthew Mandel, Kersten Sclerosis —Manuel Mejia Torres, Ildefonso Sharrock, Colin Mitchell, Barry Singer
P1.382 Comparison of Rituximab
vs Fingolimod, Dimethyl Fumarate and Natalizumab in the Treatment of Multiple Sclerosis: Two Year Experience —Brandi
Vollmer, Kavita Nair, Stefan Sillau, John Corboy, Timothy Vollmer, Enrique Alvarez
BIOMARKERS AND EXPERIMENTAL STUDIES FOR MULTIPLE SCLEROSIS
P1.383 Serum neurofilament light chain levels are increased at the onset of PML in natalizumab treated MS patients —Gloria
Rodriguez-Leyva, Fernando Cortés-Enríquez, Erika Chi, Diana Portales-Perez, Miguel Angel MacíasIslas, Maria Jimenez-Capdeville
significance of IgG, IgA, and IgM antibodies against the NMDA receptor —Makoto Hara,
Sunday
Eugenia Martinez-Hernandez, Helena Arino, Thais Armangue, Marianna Spatola, Mar Petit-Pedrol, Albert Saiz, Myrna Rosenfeld, Francesc Graus, Josep Dalmau
Olaf Stuve, Per Soerensen, Yann Hyvert, Doris Damian, Ursula Boschert
Alamri, abdullmgeed Asiri, Reem Alqahtany, Adel Alfaifi
P1.403 Relative Bioavailability of
P1.416 Association of cognitive
Miao Yu, Richard Leigh-Pemberton, Lisa von Moltke
Russell, Geraldine Nolan, Niall Tubridy, Michael Hutchinson, John Garvey, Christopher McGuigan
Monomethyl Fumarate after Administration of ALKS 8700 and Dimethyl Fumarate in Healthy Subjects —Angela Wehr, Marjie Hard,
P1.404 Immune-related microRNAs are
differentially regulated in the cerebrospinal fluid of Multiple Sclerosis patients according to disease activity and their profile mirrors neuroinfectious diseases —Vincent Van Pesch,
Hong Anh Dang, Océane Perdaens, Ludovic D’auria
P1.405 Effects of MS Donor-Derived
Ambrosius, Jeremias Motte, Kalliopi Pitarokoili, Ralf Gold
P1.387 Analysis of lymphocyte counts
and infection rates with fingolimod in patients with primary progressive multiple sclerosis over the INFORMS trial —Edward Fox, Fred Lublin, Jerry Wolinsky, Jeffrey Cohen, Xiangyi Meng, Marina Ziehn, Scott Kolodny, Norman Putzki, Bruce Cree
P1.388 Mesenchymal Stem Cells
from Patients with Secondary Progressive Multiple Sclerosis Show Deficient Immunomodulatory Activity towards Homologous Immune Cells —Cris
P1.396 CCL18 plasma levels are
increased in progressive MS patients and associated with MRI outcomes of tissue injury —Nicole Ziliotto, Giovanna Marchetti,
P1.398 Inhibition of FGFR1/2 decreases oligodendrocyte proliferation through ERK signaling in vitro —Vinothkumar Rajendran, Ranjithkumar Rajendran, Martin Berghoff
Mohammad Fouladvand, Steven Galetta
P1.408 WITHDRAWN P1.409 The Impact of Hard Drug
Abuse as Risk Factor Prognosis in the Clinical Evolution of Patients with Multiple Sclerosis —Maria Curbelo, Judith Steinberg,
Guido Vazquez, Alejandro Thomson, Adriana Carra
Disease Severity in Relapsing Remitting
P1.412 Early disease stage of Multiple Sclerosis in Chilean patients: cognitive impairment is a key domain and does not relate to MRI measures —Carlos Guevara
Oliva, Melissa Martinez, Jose de Grazia, Patricia Orellana, Katya Bulatova, Wendy Soruco, Cristian Methionine Levels are Decreased in Multiple Garrido, Gabriel Abudinen, Carlos Silva, Violeta Diaz Sclerosis Patients —Matthew Mendelsohn, Brian Lyudmer, Fozia Mir, Saud Sadiq
P1.400 Physicochemical and Biological
Characterization of both Copaxone and the European Follow-On Glatiramer Acetate Product —Bracha Timan, Arthur Komlosh, Olga
Constantinescu, Nanci Frakich, Sarah Thevathas, Radu Tanasescu, Bruno Gran, Ian Spendlove, Cherry Chang, Rhodri Jones
P1.389 Comparison of IL6 Levels in
P1.401 An Hexameric Soluble Form the
130 2018 AAN Annual Meeting
scales in assessment of fatigue in patients with multiple sclerosis —Gorana Vukorepa, Tereza Gabelic, Magdalena Krbot Skoric, Biljana Dapic, Mario Habek
P1.418 Depression in Low Income
Wolinsky, Hanzhe Zheng, Shibeshih Belachew, Laura Julian, Pablo Villoslada, Fred Lublin
P1.421 “Real world” experience
of medical marijuana in symptomatic management of multiple sclerosis and transverse myelitis —Tirisham Gyang, Megan Hyland, Lawrence Samkoff, Andrew Goodman
P1.422 The Impact of Cervical Spinal P1.410 Retinal Structure Reflects Clinical Cord Atrophy on Quality of Life in Multiple
P1.399 Cerebrospinal Fluid S-Adenosyl
Beriozkin, Attila Konya, Kevin Wells-Knecht, Vera Weinstein, Yousif Sahly, Adrian Gilbert, Oren BarIlan, Jenny Zhang, Jason Funt, Tal Hasson, Daphna Laifenfeld, Sarah Kolitz, Benjamin Zeskind, Sigal Melamed-Gal, Pippa Loupe, Iris Grossman, Ralph Laufer, Michael Hayden
CNS Inflammatory Conditions according to
P1.417 Evaluation of different fatigue
Population with Multiple Sclerosis —Britany Mesenchymal Stem Cell-Neural Progenitors Klenofsky, Nigar Dargah-Zada, Debra Shabas (MSC-NP) on Microglial Polarization —Gillian Connectome in Patients with Systemic Lupus Carling, Shayna Zanker, Saud Sadiq, Violaine Harris P1.419 Evaluation of a Spasticity Management Program for People with Erythematosus and Multiple Sclerosis: A Multiple Sclerosis: Full-scale Study Graph Theory Study —Paolo Preziosa, Giuseppe P1.406 Immune-regulatory Role of A. Ramirez, Enrica Bozzolo, Patrizia Rovere-Querini, Mucosal-associated Invariant T cells (MAIT) Protocol —Lucinda Hugos, Michelle Cameron in MS: A Follow-up Study. —Jorge Correale, Angelo Manfredi, Massimo Filippi, Maria Rocca P1.420 Impact of Ocrelizumab on Junior Carnero, Mauricio Farez Cognition in Patients at Increased Risk of P1.394 Cerebrospinal Fluid IgA Levels P1.407 The Search for the Missing Progressive Disease —Ralph Benedict, Jerome Correlate with Disease Activity in Patients Antibody —Jessica Lin, Jacob Pellinen, De Seze, Stephen Hauser, Ludwig Kappos, Jerry with Multiple Sclerosis; A Novel Finding —
Dejan Jakimovski, Marcello Baroni, Niels Multiple Sclerosis Patients —Melody Gilroy, Bergsland, Bianca Weinstock-Guttman, Paolo Samuel Lichtman-Mikol, Sara Razmjou, Carla Zamboni, Francesco Bernardi, Murali Ramanathan, Santiago-Martinez, Evanthia Bernitsas, Navid P1.385 Lipoic Acid Stimulates cAMP Robert Zivadinov Seraji-Bozorgzad Production in Healthy Control and Secondary P1.397 Elevated LGI1-IgG CSF index Progressive MS Subjects —Sarah Fiedler, P1.411 FTY720 promotes cellular Vijayshree Yadav, Amelia Kerns, Catherine Tsang, predicts worse neurological outcome — pathways involved in myelination and antiAnastasia Zekeridou, Avi Gadoth, Christopher Sheila Markwardt, Edward Kim, Rebecca Spain, oxidant system in the brain cortex —Mehdi Klein, Colton Thoreson, Masoud Majed, Eoin Dennis Bourdette, Sonemany Salinthone Flanagan, Andrew McKeon, Sarah Jenkins, Vanda Mirzaei, Vivek Gupta, Alexander Klistorner, Stuart Graham P1.386 Capsaicin Increases the AntiLennon, Sean Pittock
inflammatory Potential of Myelinating Schwann Cells —Thomas Grüter, Bjorn
impairment in Multiple Sclerosis with polysomnographic measurement of sleep disorders —Nuala McNicholas, Audrey
P1.393 Impaired Structural Brain
Alexandra Tse, Antara Finney-Stable, Jerry Lin, Dalla Costa, Vittorio Martinelli, Annamaria Finardi, Saud Sadiq Francesca Sangalli, Bruno Colombo, Lucia Moiola, Paola Cinque, Eva-Maria Kolb, Aiden Haghikia, Ralf P1.395 Laboratory Assessment Of Mitochondrial Dysfunction In Patients With Gold, Roberto Furlan, Giancarlo Comi Multiple Sclerosis —Ahmed Mohamed
P1.384 Clinical and pathogenic
P1.415 Insomnia And Disability Severity Among Multiple Sclerosis Patients In Saudi on CD4+ T-cell Subsets in the ORACLEArabia —Adel Ali Alhazzani, Mohammed MS Study: Results from an Analysis of Alqahtani, Mohammed Alahmari, Shahad Lymphocyte Surface Markers —Thomas Leist, Alkhashrami, Leen Sarhan, Mohannad Assiri, Noof
P1.413 Establishment of Optimal
Bioanalytical Parameters for Measuring Neurofilament Light Chain (Nf-L) in Multiple Sclerosis (MS) Subjects from Clinical Trial Cohorts. —Akash Datwani, Christopher Harp,
Bruno Musch, Damian Fiore, Ann Herman, Robert Hendricks
P1.414 Dimethyl Fumarate Treatment
Sclerosis —Jonathan Zurawski, Bonnie Glanz, Brian Healy, Shahamat Tauhid, Fariha Khalid, Tanuja Chitnis, Howard Weiner, Rohit Bakshi
P1.423 Anxiety and Diabetes Adversely
Affect Cognition in Multiple Sclerosis —RuthAnn Marrie, Ronak Patel, James Marriott, Chase Figley, Jennifer Kornelsen, Lesley Graff, James Bolton, Charles Bernstein, John Fisk
P1.424 Let’s raise the awareness of MS specialists concerning the frequency and impact of RLS in MS and consequently the life quality of patients with MS: Striking results of the ‘RELOMS-T’ Study —Serhan
Sevim, Meltem Demirkiran, Murat Terzi, Nur Yüceyar, Bahar Tasdelen, Egemen Idiman, Murat Kurtuncu, Cavit Boz, Deniz Tuncel, Rana Karabudak, Aksel Siva, A. Cemal Ozcan, Münife Neyal, Basak Karakurum Goksel, Mehmet Balal, Sedat Sen, Özgül Ekmekçi, Derya Kara, Turkish Multiple Scl Study Group
P1.425 Prevalence and Characteristics of the Pseudobulbar Affect in a Large Population of People with Multiple Sclerosis —Kathryn Fitzgerald, Amber Salter, Tuula Tyry, Robert Fox, Gary Cutter, Ruth-Ann Marrie
alters T Cell Metabolism in Multiple P1.426 NA Sclerosis —Marie Liebmann, Claudia Janoschka, P1.427 NA Alexander Herrmann, Andreas SchulteMecklenbeck, Nicholas Schwab, Catharina Groß, P1.428 NA
Pathogenic Protein from Human Endogenous Sven Meuth, Heinz Wiendl, Luisa Klotz
NEUROPATHY
I
P1.429 Clinical Meaning and
Responsiveness of Skin Biopsy abnd Corneal Confocal Microscopy to Diabetic Neuropathy Progression —A. Gordon Smith, Brittany Thurgood, Cathy Revere, Peter Hauer, Adrienne Aperghis, J. Singleton
P1.430 Schwann Cells Express
Melanocortin Receptor Subtypes: Activation by ACTH 1-39 and Alpha-MSH Enhances Proliferation —Robert Lisak, Beverly Bealmear, Liljana Nedelkoska, Joyce Benjamins
P1.431 Comparative Study for the
Effects of Several Angiotensin Receptor Blockers on Immune-mediated Experimental Neuritis —Toshiki Fujioka, Hideo Kihara, Wataru Hagiwara, Masashi Inoue, Hisao Kitazono, Shingo Konno, Hideki Sugimoto
P1.432 Multi-parametric MRI of the
Proximal and Distal Nerves of the Leg: Longitudinal Findings in Patients with Inherited Neuropathies —Michael Pridmore, Megan Simmons, Jun Li, Richard Dortch
P1.433 Electrophysiological Testing
in Patients with Chronic Inflammatory Demyelinating Polyneuropathy Treated with Subcutaneous Immunoglobulin: The PATH Study —Vera Bril, Ivo Van Schaik, Nan van
Geloven, Hans-Peter Hartung, Richard Lewis, Gen Sobue, John-Philip Lawo, Orell Mielke, Billie Durn, David Cornblath, Ingemar Merkies
P1.440 Lumbosacral Radiculoplexopathy P1.454 Quantitative Ultrasound to
NEUROSCIENCE RESEARCH Quantify Neurogenic Change in Hand PRIZE RECIPIENTS Muscles in Ulnar and Median Neuropathy — P1.468 Behavioral lateralization and Yuebing Li MD Maria Martucci, Alison Poussaint, Kristin Qi, scototaxis unaltered by near future ocean Seward Rutkove P1.441 The Temporal Profiles of Changes acidification conditions in Poecilia latipinna P1.455 Clinical and Electrodiagnostic in Nerve Excitability Indices in Familial (Sailfin Molly) —Alex Remnitz Findings in Neuropathy with Anti-Fibroblast Amyloid Polyneuropathy —Ming-Jen Lee, P1.469 Utilizing Drug Intervention Hsing Jung Lai, Ya-Wen Chiang, Chih-Chao Yang, Growth Factor Receptor 3 Antibodies — to Inhibit Delayed Neuronal Death by Sung-Tsang Hsieh, Chi-Chao Chao, Chung-Chin Kuo Carmen Boessen, Tammy Mulcahey, Raghav Migrainous Spreading Depolarizations — Govindarajan P1.442 Suprascapular Neuropathy: A Jackie Stochel P1.456 A comparison of different review of 87 cases —Anza Memon, Braydon Dymm, Richard Smith, Bashiruddin Ahmad, Lonni laboratory and clinical findings in Small fiber P1.470 Exacerbated Alzheimer’s Disease Schultz, Arun Chandok neuropathy (SFN) —Reyanna Massaquoi, Jafar Pathology in Female Hippocampus and Kafaie, Atul Kumar, Pin-Win Chen, Ayesha Naeem Frontal Cortex of Tg6799 Mice and Humans P1.443 Neuralgic Amyotrophy in Relative to Males —Sarah Hoffman Children —Fouad Alghamdi, Partha Ghosh P1.457 Elevated Soluble ICAM in Patients with Peripheral Demyelination — CEREBROVASCULAR DISEASE P1.444 WITHDRAWN Adam Andrzey Niezgoda, Slawomir Michalak, as the Initial Presentation of Lymphoma: A Report of Four Cases —Robert Marquardt,
P1.445 Abnormal spontaneous activity
on electromyographic study of intrinsic foot muscles in patients with painful distal small fiber neuropathy. —Prachi Parikh, Steven MacDonald, David Polston, Yuebing Li MD
P1.446 Quality Improvement and
Practice-Based Research in Peripheral Neuropathy Using the Electronic Medical Record —Octavia Kincaid, Alexandru Barboi,
David Randall, Lisette Garduno, Monika Szela, Samuel Tideman, Laura Hillman, Don Macapinlac, Roberta Frigerio, Kelly Claire Simon, Demetrius Maraganore
P1.447 Variability of fasting plasma
Jacek Losy, Wojciech Kozubski
P1.471 Understanding the tPA Gap: The P1.458 Worsening Chronic Inflammatory Role of Socioeconomics in Acute Stroke Demyelinating Polyneuropathy After Pembrolizumab Treatment of Metastatic Melanoma: A Case Report —Shoichi Shimamoto, Anthony Allen, Goran Rakocevic
P1.459 Expanding the Phenotype
of SEPT9 Gene Mutations in Hereditary Neuralgic Amyotrophy: Slowly Progressive and Painless Bilateral Brachial Plexopathies —Rocio Vazquez Do Campo, Eric
DYNC1H1 mutations in Brazilian Patients —
Burnor, Amit Bar-Or, Eric Lancaster
P1.448 Utility of Genetic Testing to
P1.461 Immune-Mediated
Identify Individuals Suspected of Having Hereditary ATTR (hATTR) Amyloidosis —
Neuropathy: Comparison of treatment in real Jordanna Mora, Rebecca Truty, Ruthvik Malladi, life situations (PAIN-CONTRoLS) —Richard Nathan Cheng, Angela Partisano Barohn, Byron Gajewski, Mamatha Pasnoor, Lexie Brown, Laura Herbelin, Kim Kimminau, Omar Jawdat, Tina Liu, Chad Parks, Pam Shlemon, Mazen Dimachkie, PAIN-CONTRoLs Study Team
with anti-myelin associated glycoprotein antibodies responsive to lenalidomide in combination with rituximab —Tiffany Lee, Donika Patel, Jinny Tavee
onset Chronic Inflammatory Demyelinating P1.450 Obinutuzumab (GAZYVA), a Polyneuropathy (A-CIDP) and Acute Inflammatory Demyelinating Polyneuropathy Potent Anti-B Cell Agent, in the Treatment of Rituximab- Unresponsive IgM Anti-Myelin(AIDP) in adult patients. —Lucas Alessandro, Jose Pastor, Miguel Wilken, Luis Querol, Mariano Associated-Glycoprotein (MAG)-MediatedMarrodan, Alberto Rivero, Fabio Adrian Barroso, Neuropathy —Goran Rakocevic, Ubaldo Mauricio Farez
Martínez, Marinos Dalakas
P1.437 Correlation Between Nerve
P1.451 Clinical and Genetic Features in
Krishnan
Parman, Hacer Durmus, Ayse Candayan, Halil Ibrahim Akcay, Gulshan Yunisova, Cagri Ulukan, Piraye Serdaroglu, Feza Deymeer, Esra Battaloglu
Ultrasound and Excitability Parameters in Diabetic Neuropathy —Adeniyi Borire, Arun
P1.438 Peripheral neuropathy in wild
type transthyretin amyloidosis. —Fernanda
X-Linked Charcot-Marie-Tooth Neuropathy (CMT-X) Patients from Turkey —Fatma Yesim
Wajnsztajn, Arreum Kim, Amelia Boehme, Mathew P1.452 Guillain Barre Syndrome Maurer, Thomas Brannagan Following Stem Cell Transplant: A Single
P1.439 Recovery of Sensory Modalities
Institution Five -Year Retrospective Study — Nicholas Metrus, Karin Woodman, Na Tosha
after Peripheral Nerve Lesions at Forearm Gatson, Clement Pillainayagam Level Associated with Mechanoreceptor and Sensory Nerve Fiber Function —Christian P1.453 Quantitative MRI of Nerve Pathology in Mouse Models of CMT1A and Krarup, Birgitta Rosen, Michel Boeckstyns, Allan Ibsen, Göran Lundborg, Mihai Moldovan, Simon HNPP —Isaac Manzanera, Megan Simmons, Archibald
P1.472 Higher Score on Prehospital Los Angeles Motor Scale Predicts Likelihood of Mechanical Thrombectomy After Acute Ischemic Stroke. —Latha Ganti, Paul Banerjee
Eduardo Uchoa Cavalcanti, Savana Camilla Santos, Denise Freitas, Maria Cristina Freitas, Osvaldo Nascimento
Polyradiculopathy in a Patient with Melanoma Responsive to IVIG —Christopher Doughty, Amanda Guidon
P1.462 Diagnostic Challenge of 12 cases of Hereditary Neuropathy with Liability to Pressure Palsy (HNPP) —Lise Phan, Said Beydoun
Sunday
P1.436 Differences between Acute-
P1.449 Demyelinating polyneuropathy
Paul Baneejee
P1.460 Phenotypic Spectrum of
P1.434 Mechanisms of autoantibodies
P1.435 Patient Assisted Intervention for
Care —Latha Ganti, Jessalyn Landeta, Thor Stead,
Goldstein, Devon Rubin
glucose increased risks of painful diabetic peripheral neuropathy in patients with type 2 diabetes —Ming-hong Chang
to neurofascins in acquired demyelinating neuropathies —Kristina Patterson, Elisabeth
POSTER SESSIONS
Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.
P1.463 FGFR3 Antibodies in Neuropathy. What to do with them? —Verena Samara, Jacinda Sampson, Srikanth Muppidi
P1.464 Clinical, Laboratory and
Electrodiagnostic Features of Peripheral Neuropathy in Copper Deficiency and Copper Toxicity —Jennifer Haynes, Jin Luo, Favio Bumanlag
P1.465 Differential Effects of Statins on Motor and Sensory Compared with Cortical Gene Expression Patterns —Beth Hogans, Ethan B. Murinson, Merav Shor
P1.466 Vascular factors to be correlated with diabetic polyneuropathy —Kyong Jin Shin, Byungin Lee, Seong-il Oh
P1.467 EGR2 Mutations in Brazilian
Patients—a Clinical, Electrophysiological and Genetic Profile —Eduardo Uchoa Cavalcanti, Savana Camilla Santos, Maria Cristina Freitas, Denise Freitas, Osvaldo Nascimento
Daniel Moiseev, Bo Hu, Jun Li, Richard Dortch
AAN.com/view/AM18 131
POSTER SESSIONS
POSTER SESSION II UNDERGRADUATE MEDICAL EDUCATION: ASSESSMENT AND CURRICULAR DESIGN I
A
P2.001 Common difficulties medical
G
HEALTH SERVICES RESEARCH AND METHODOLOGIES
Ganesh, Georgirene Vladutiu, Richard Haas, Charles Hoppel, Douglas Kerr, Russell Saneto, P2.004 Published Headache OSCEs Have Bruce Cohen, Johan Van Hove, Fernando Scaglia, Xiomara Rosales, Emanuele Barca, Richard Excellent Inter-rater Reliability —Maryam Shakir, Sheryl Strasser, David Solomon, Samantha Buchsbaum, John Thompson, Salvatore DiMauro, Michio Hirano, North American Mitoc (NAMDC) Syms, Fauzia Nausheen, Diana Barratt Pradeep Sahota
feedback? —Doris Kung
UNDERGRADUATE MEDICAL EDUCATION: NOVEL FORMATS
P2.006 Movement Disorders Video
Curriculum for Neurology Clerkships and Residency Programs —Sagari Bette, Jason
Margolesky, Corneliu Luca, Henry Moore, Carlos Singer, Yolanda Reyes-Iglesias
P2.007 Assessment Of The Difficult
Components Of Neurological Exam Performance In Medical Students —Yi Li, Lan Qin
P2.008 Animated Neurological Exam Videos in PBL Cases —J. Douglas Miles
P2.009 Student Neurology Clerkship Improvement Project (“SNIP”) —Victoria Cannon, Emily Nonnemacher, Amanda Witt
P2.010 Incorporating Formal Nutrition
P2.014 Streamlining Clinical Research
in Sports-Related Concussion: The National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH), and Department of Defense (DOD) Sport-Related Concussion Common Data Elements (CDEs) —Kristen Joseph, Sherita Alai, Joy Esterlitz, Katelyn Gay, Patrick Bellgowan
P2.015 Registration status of clinical
trials published in core neurology journals: A cross-sectional study —Jose Merino, Rebecca Burch, Melissa Rayhill
P2.016 A Common Language for Clinical
Research Studies: The National Institute of Neurological Disorders and Stroke (NINDS) and Centers for Disease Control and Prevention (CDC) Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) Common Data Elements (CDEs) —Robin Feldman, Katelyn Gay, Sherita Alai, Joy Esterlitz, Muniza Sheikh, Sarah Tanveer, Kristen Joseph, Elizabeth Unger, Vicky Whittemore
Monday
Education into a Medical School Curriculum: A Student-Initiated Lecture Series —Vanessa EDUCATION: CAREER CHOICE AND Baute, Amelia Carr, Jacob Blackwell, Estelle ATTITUDES Wilson, Michael Cartwright
P2.011 Expert Patient Tutors: The
Eradication of Neurophobia —Gina Hadley,
Laurice Yang, Veronica Santini, Gabriele De Luca
P2.017 Headache interest in US
academic neurology leadership: A crosssectional study —Matthew Robbins, Noah Rosen
P2.018 Neurology Residency Websites: A Critical Evaluation. —Adeel Memon, Rabia
Jamy, Raima Memon, Bilal Pasha, Manmeet Kaur, Marissa Natelson Love
132 2018 AAN Annual Meeting
D
P2.012 Common Data Elements
(CDEs) for Biomechanical Devices used students have with the neurological physical in Blunt Head Impact and Blast Exposure exam are identified by direct observation. — Dynamics: The National Institute of Juliana Coleman, Chad Hoyle, Jacquelyne Cios, Neurological Disorders and Stroke (NINDS), Adam Quick National Institutes of Health (NIH) and Department of Defense (DOD) Version 1.0 P2.002 Evaluation of a Single Year Competency-Based Clerkship Alternative to Recommendations —Kristen Joseph, Katelyn Gay, Adam Bartsch, David Camarillo, Carol TaylorEffectively Navigate a Fourth-Year to Third Burds, Sherita Alai, Joy Esterlitz, Patrick Bellgowan Year Curricular Transition —Jeff Kraakevik, Meredith Frederick, Nicole Ryan, Patricia Carney P2.013 Development of diagnostic criteria to facilitate research in P2.003 Developing a Student-Centric/ mitochondrial disorders: A proposal from Student Responsive Four Week Neurology the North American Mitochondrial Disease Clerkship —Raghav Govindarajan, Penny McQueen, Susanta Bandyopadhyay, Brandi French, Consortium. —Valentina Emmanuele, Jaya
P2.005 Why aren’t you giving
Monday, April 23 11:30 a.m.–7:00 p.m.
091–172
173–200
C
ePosters
B
b1 g1 339–344 a1 ePosters
085–090
037–084
E
201–258
Poster Discussion
027–036
A
001–026
I
F
259–294
295–338
H
G
345–428
429–480
Poster Session 2 A. Research Methodology, Education, and History: 001 – 026
a1. Neuromuscular/Clinical Neurophysiology (EMG) Poster Discussion Session: 027 – 036 B. Movement Disorders: 037 – 084
b1. Child Neurology and Developmental Neurology ePoster Session: 085 – 090 C. Pain and Palliative Care; Autonomic Disorders; Neuroophthalmology/Neuro-otology: 091 – 172 D. Aging, Dementia, Cognitive, and Behavioral Neurology: 173 – 200 E. Cerebrovascular Disease and Interventional Neurology: 201 – 258 F. Epilepsy/Clinical Neurophysiology (EEG): 259 – 294 G. Child Neurology and Developmental Neurology: 295 – 338
g1. Epilepsy/Clinical Neurophysiology (EEG) ePoster Session: 339 – 344 H. MS and CNS Inflammatory Disease: 345 – 428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429 – 480
P2.019 The Rutgers-NJMS Experience:
P2.022 The Impact of Early Medical
Machteld Hillen
Aghajan, Sean Evans
Why Are Our Medical Students Increasingly Applying to Adult Neurology? —Jessy Walia,
P2.020 Changing the Image of
Neurology —Yolanda Reyes-Iglesias, Michelle Caunca, Ramses Ribot
P2.021 The Importance of Neurology as a Required Third-Year Clerkship: A Medical Student Survey —Enmanuel Perez, Michelle Caunca, Damianie Montero , Yolanda ReyesIglesias
School Exposure to Clinical Neurology on Career Interest in Neurology —Yasmin
P2.023 NA P2.024 NA P2.025 NA P2.026 NA
Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.
a1
Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 5:30p.m.-7:00 p.m. Data Blitz: 11:45 a.m.–11:50 a.m.
P2.027 Machine-learning in
Data Blitz: 12:00 p.m.–12:05 p.m.
Activation in Amyotrophic and Primary
ALS-at-home study —Seward Rutkove, Jeremy
Longitudinal Study —Mohamad J. Alshikho,
Data Blitz: 12:25 p.m.–12:30 p.m.
P2.030 The Long Exercise Test in Primary Lateral Sclerosis: Cross Sectional and
neurodegeneration: Evaluation, optimisation Periodic Paralysis: A Bayesian Analysis — Daniel Simmons, Julie Lanning, James Cleland, and validation of MRI-based diagnostic Araya Puwanant, Paul Twydell, Robert Griggs, methods —Peter Bede, Eoin Finegan, Rangariroyashe Chipika, Orla Hardiman
Alrabi Tawil, Eric Logigian
Data Blitz: 11:50 a.m.–11:55 a.m.
Data Blitz: 12:05 p.m.–12:10 p.m.
Nicole R. Zürcher, Marco Loggia, Paul Cernasov, Beverly Reynolds, Olivia Pijanowski, Daniel Chonde, David Izquierdo Garcia, Caterina Mainero, Ciprian Catana, James Chan, Suma Babu, Sabrina Paganoni, Jacob Hooker, Nazem Atassi
P2.028 Skeletal Muscle Interstitial
P2.031 Congenital Myasthenic
Data Blitz: 12:15 p.m.–12:20 p.m.
Amyloid in Anoctaminopathy-5: Does it Matter? —Charenya Anandan, Margherita Milone, Teerin Liewluck
Data Blitz: 11:55 a.m.–12:00 p.m.
P2.029 Egr2-dependent microRNA-138 is Dispensable for Peripheral Nerve Myelination —Hsin-Pin Lin, Idil Oksuz, John Svaren, Rajeshwar Awatramani
PARKINSON’S DISEASE: THERAPEUTICS
B
P2.037 Effects of Probiotics on
Constipation, Neurological Symptoms, and Quality of Life Associated with Parkinson’s Disease —Duarte Machado, Lucy Honeycutt
P2.038 Exploratory risk analysis
for motor complications and non-motor symptoms: Observations in a registry of a tertiary Parkinson’s disease center in Brasilia, Brazil —Talyta Grippe, Natalia Cunha,
Danilo Pereira, Marcelo Lobo, Flavio Pereira, Pedro Manzke, Pedro Renato Brandao
P2.039 A Phase 2 study of Isradipine as
Syndromes (CMS) Due to Impaired Principal P2.033 Undiagnosed Congenital Coupling Pathway in the ε Subunit of Muscle Myasthenic Syndromes in Adult Acetylcholine Receptor (AChR) —Xin Ming Neuromuscular Practice: A Long Road to Shen, Joan Brengman, Shelley Shen, Hacer Durmus, Preethish Kumar Veeramani, Nur Yuceyar, Diagnosis and Treatment. —Justin Kao, Steven Sine, Andrew Engel
Data Blitz: 12:10 p.m.–12:15 p.m.
Andrew Engel, Teerin Liewluck
Data Blitz: 12:20 p.m.–12:25 p.m.
P2.032 Integrated MRI and [11C]-PBR28
P2.034 ALS progression over short time
PET Imaging to Characterize In vivo Glial
intervals: Early insights from the ongoing
ND0612 infusion given as adjunct treatment to oral levodopa in fluctuating PD —Karl
P2.051 Item Response Theory Analysis
Kieburtz, C. Olanow, Tamar Rachmilewitz, Yael Cohen, Sheila Oren
P2.045 A Phase 3 Study of Tozadenant
(TOZ-PD) as a Maintenance Therapy for Patients With Parkinson’s Disease Experiencing Motor Fluctuations: Characterization of Study Population —Karl
of the Unified Dyskinesia Rating Scale Items —Christopher Goetz, Sheng Luo, Glenn Stebbins
in Primary Periodic Paralysis: Pooled-Data Analysis of Two Phase 3 Clinical Trials —Perry Shieh, Fredric Cohen, Richard Barohn, Robert Griggs
Data Blitz: 12:30 p.m.–12:35 p.m.
P2.036 Decreased EEG Spectral Power
Bahman Nasseroleslami, Michael Broderick, Kieran Mohr, Christina Schuster, Brighid Gavin, Russell McLaughlin, Mark Heverin, Alice Vajda, Parameswaran Iyer, Niall Pender, Peter Bede, Edmund Lalor, Orla Hardiman
cohort study in Olmsted County, MN (19912010) —Pierpaolo Turcano, Michelle Mielke, James Bower, Joseph Parisi, J. Ahlskog, Rodolfo Savica
P2.052 A Clinically Important Difference P2.060 A Real-World Inquiry of the (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson’s Disease (PD) Patients with Dyskinesia —
Rajesh Pahwa, Caroline Tanner, Robert Hauser, Kieburtz, C. Olanow, Jayshree Krishnaswami, Chris Stuart Isaacson, Reed Johnson, Larissa Felt, Rajiv Resburg, Fred Kerwood, Andrew Glass, Christopher Patni, Lily Llorens Kenney
P2.053 Smoking and Coffee
So-Called Parkinsonian Personality -Comparing No-Show Rates of the Neurology Outpatients with and without Parkinson’s disease (PD) —Jeremiah Bell, Yingxing Wu, Ann Sollinger, Ronex Muthukattil, Joseph Ferrara
P2.061 Parkinson’s Diagnostic
Accuracy- What diagnoses cause the most
P2.046 Safety and Efficacy of Levodopa- Consumption Preceding Clinically-diagnosed diagnostic-switches by Movement Disorder Carbidopa Monotherapy in Patients with Synucleinopathies: A Case-control Study in Advanced Parkinson’s Disease —James Boyd, Olmsted County MN (1991-2005). —Jinna Yu, Martin Peter, Michelle Mielke, James Bower, Pierpaolo Turcano, Rodolfo Savica
P2.040 Optimizing Delivery of
Snyder, Erik Barr, Melissa Armstrong, Joseph Savitt, F. Rainer Von Coelln, Stephen Reich, Ann Gruber-Baldini, Lisa Shulman
Intestinal Gel Treatment in Advanced Parkinson’s Disease Patients Receiving ≥ 2000 mg Daily Dose of Levodopa —Cindy
Zadikoff, James Boyd, Stephanie Dubow, Lars Bergmann, Weining Robieson, Horia Ijacu, Janet Benesh
Specialists? —Marzieh Keshtkarjahromi, Danielle Abraham, Ann Gruber-Baldini, Erik Barr, Katrina Schrader, Stephen Reich, Joseph Savitt, F. Rainer Von Coelln, Lisa Shulman
P2.054 Predictors of Disability in
P2.062 Barriers to Vaccination in Parkinson Disease: Motor vs. Cognitive Homebound and Non-Homebound People Impairment Using MMSE vs. MoCA —Allison with Parkinson’s Disease —Jori Fleisher,
P2.055 Communication Regarding Off
Patrick Drummond, Talia Meisel, Naomi Friede, Alessandro Di Rocco, Joshua Chodosh
P2.063 Traumatic brain injury and
P2.041 Objective Evaluation of Levodopa Comparing Levodopa-Carbidopa Intestinal
erectile dysfunction preceding clinically Time with People with Parkinsons and their diagnosed alpha-synucleinopathies: A Caregivers: Qualitative Analysis of Physician case-control study in Olmsted County, MN Interviews —Tara Rastgardani, Connie Marras, (1991-2010). —Shemonti Hasan, James Bower,
Fowler, Summer Gernon, Rajesh Pahwa, Kelly Lyons
Anna Gagliardi, Melissa Armstrong
Michelle Mielke, Rodolfo Savica
P2.056 Foundations for a Patient-
P2.064 Objective Markers of Turning
Michael Gendreau, Jeffrey Meckler
Response on Gait and Balance —Alexandra
P2.042 Effect of PD medication on
disease progression as measured by rate of change in MDS_UPDRS in PPMI study — Zhen Xiao, Jesse Cedarbaum, Minhua Yang
P2.043 Pharmacokinetics of ADS-5102
(amantadine) Extended Release Capsules Administered Once-Daily at Bedtime for the Treatment of Dyskinesia —Robert Hauser,
P2.048 Rationale and Design of an
Open-Label, Randomized, 26-Week Study
Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease - INSIGHTS Study —Kallol Chaudhuri, Daniel Weintraub, Angelo Antonini, Weining Robieson, Mei Li, Krai Chatamra, Janet Benesh, Maurizio Facheris
Reported Natural History of Parkinson Disease: Cross-sectional Analysis of the MJFF Fox Insight (FI) Platform —Lakshmi
PARKINSON’S DISEASE: PHENOMENOLOGY, EPIDEMIOLOGY, AND RATING SCALES
P2.057 Stumbling, Near-falls, Freezing
P2.049 Dry facts are not always
Rajesh Pahwa, William Wargin, Cindy Souza-Prien, inviting: An analysis of Korean videos about Parkinson’s disease on YouTube —Beomseok Natalie McClure, Rajiv Patni Jeon, Ryul Kim, Hye-Young Park, Han Kim, Aryun P2.044 The iNDiGO study: A multicenter, Kim, Mi-Hee Jang
randomized, double-blind, placebo-controlled clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous
in Idiopathic Parkinson’s Disease —Lakshmi Pillai, Kunal Shah, Tuhin Virmani
P2.065 Changes in motor subtypes in
Arbatti, Andrew Nguyen, Lauren McLaughlin, Luba a Mexican Parkinson’s disease cohort — Smolensky, Catherine Kopil, Emily Flagg, Carol Robert Eisinger, Amin Cervantes-Arriaga, Mayela Christopher, Ira Shoulson Rodriguez Violante, Daniel Martinez-Ramirez
or Postural Instability: What Predicts Falling Best in Parkinson Disease? —Zahra Rezvani, Erik Barr, Ann Gruber-Baldini, Joseph Savitt, F. Rainer Von Coelln, Stephen Reich, Lisa Shulman
P2.066 Prevalence and patterns of rest, postural and action tremor in drug-naive Parkinson’s disease —Deepak Gupta, ShengHan Kuo
P2.067 Experiences, impact, and Disorders Subspecialty Consultations at a VA communication of “off” periods in P2.050 Clinical factors associated with Hospital —Brandon Barton Parkinson’s disease: Qualitative experiences clinician certainty in diagnosis of idiopathic of patients and carepartners —Tara Parkinson’s disease —Kishan Ughreja, Sam Wu, P2.059 Levodopa-induced dyskinesias in Rastgardani, Melissa Armstrong, Anna Gagliardi, Parkinson disease: A population basedConnie Marras Fernando Cubillos, Peter Schmidt, Danny Bega P2.058 Diagnostic Impact of Movement
AAN.com/view/AM18 133
Monday
Carbidopa/Levodopa via the Accordion Pill™: Comparative PK and Safety From 2 Randomized Crossover Studies in Healthy Volunteers —Nadav Navon, Zeev Weiss, R.
P2.035 Efficacy of Dichlorphenamide
and Increased Cortico-Cortical Connectivity Correlate with Structural MRI Changes in Seena Vengalil, Atchayaram Nalini, Feza Deymeer, Margherita Milone, Duygu Selcen, Xin Ming Shen, Amyotrophic Lateral Sclerosis —Stefan Dukic,
a disease modifying agent in patients with Cindy Zadikoff, Janet Benesh, Jorge Zamudio, Weining Robieson, Pavnit Kukreja early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update — P2.047 Safety of Levodopa-Carbidopa Tanya Simuni, Robert Holloway, David Oakes, Kevin Biglan, Codrin Lungu
Shefner
POSTER SESSIONS
Presenters Stand by Posters 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION II P2.068 Characteristics of Patients with
Parkinson Disease in Pakistan: Prospective Multicenter Cross-sectional Study —Wagma
Shahzad, Saba Aslam, Kiran Waqar, Muslim Lakhiar, Nabeel Syed, Farheen Niazi, Safia Bano, Waqas Arshad, Manzoor Lakhair, Muhammad Javed, Nadir Syed, Arsalan Ahmad, Zikria Saleem, John Bertoni, Danish Bhatti
P2.069 Predictors of health-related quality of life in Parkinson’s disease —
Gregory Kuhlman, Matthew Barrett, Flanigan Joseph
P2.070 Prenatal Exposure to Chlorpyrifos
G
P2.072 Characterizing Types of Falls in
Shelby DeCardenas, Jonathan Clark, Robert Watson, Charles Maitland
Thurmon Lockhart, Markey Olson, Victoria Smith, Christopher Frames
P2.077 Development of a Parkinson’s
Parkinson’s Disease —Abraham Lieberman,
P2.071 Primary Care Knowledge and
American Patients with Parkinson’s Disease : Cindy Zadikoff A Comprehensive Literature Review and Call P2.078 Sex Disparities in Health and to Action —Shivani Naik, Kathrin LaFaver Health Care Utilization after Parkinson Diagnosis: Rethinking PD Associated P2.074 Deeply Phenotyped Control Cohort for Studies of Parkinson’s Disease — Disability —Michelle Fullard, Dylan Thibault, Rana Hanna AL-Shaikh, Angela Deutschlander, Owen Ross, Zbigniew Wszolek
Margolesky, Sagari Bette, Danielle Shpiner, Tatjana Rundek, Corneliu Luca, Henry Moore, Carlos Singer
Referral Practices Based on Early Symptoms P2.076 Instructed Arm Swing Improves of Parkinson’s Disease —Stephanie Walking Performance and Decreases Fall Bissonnette, Juan Peng, Punit Agrawal Risk in Individuals with Parkinsonism —Evan Fitzgerald, Ranbir Ahluwalia, Brooke Hartenstein,
b1 C
Disease-Specific Admission Order Set —
P2.073 Healthcare Disparities in African- Danielle Larson, Yasaman Kianirad, Mitra Afshari,
P2.075 The Prevalence of Tandem Gait and Parkinson’s risk: A prospective adolescent cohort evaluation —Sarah O’Shea, Abnormality in Parkinson’s Disease —Jason Virginia Rauh, Roy Alcalay
Monday, April 23 11:30 a.m.–7:00 p.m. P2.080 Presentation of Parkinson’s
disease in patients originating of different geographical altitudes —Kelly Meza Capcha, Armando Pezo Pezo, Carlos Cosentino, Luis Eduardo Torres Ramirez
P2.081 Differences in Quality of Life
Between Men and Women with Parkinson’s Disease —Medha Gudavalli, Jiangxia Wang, Catherine Bakker, Nadine Yoritomo, Alexander Pantelyat, Ted Dawson, Liana Rosenthal
Veronica Todaro, Susan Foster, Lori Katz, Robin P2.082 Predictors of Clinically Morgan, Drew Kern, Jason Schwalb, Enrique Meaningful Change in PDQ-39 in Parkinson’s Urrea-Mendoza, Lisa Shulman, Nabila Dahodwala, Disease —Adam Margolius, Fernando Cubillos, Allison Wright Willis Samuel Wu, Peter Schmidt, Tanya Simuni
P2.079 Characterization of variants in
P2.083 Use of a modified STROOP test genes associated with Parkinson’s disease to help with diagnosis in early idiopathic and parkinsonism in the African American Parkinson’s disease —Rebekah Langston, Tuhin population using exome sequencing —Angela Virmani Deutschlander, Alexandra Soto-Ortolaza, Ronald Walton, Joseph Reddy, Audrey Strongosky, Minerva Carrasquillo, Mark LeDoux, Nilufer Taner, Owen Ross, Zbigniew Wszolek
P2.084 NA
Child Neurology and Developmental Neurology ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P2.085 A splice-site mutation in USMG5 Posthemorrhagic Hydrocephalus Treated causes Leigh Syndrome due to lack of ATP synthesis —Emanuele Barca, Marti Juanola-
P2.088 Iron and ferritin levels in patients P2.090 Striatal Changes on MRI in Young
Mary Leppert, Elizabeth Cristofalo, Edward Ahn
with ADHD —Shreya Agarwal, Siddharth Gupta, Children with NMDAR: A Single Center Keith Pecor, Daniel Oh, Jeffrey Kornitzer Experience —Michael Nelson, Monica Marcus,
P2.087 Clinical profile and outcome of
P2.089 Unusual Presentation of
Outcomes in Preterm Infants with
Sondhi, Biswaroop Chakrabarty, Prashant Jauhari, Aparajita Gupta, Shefalli Gulati
Parikh
PAIN AND PALLIATIVE CARE
Chronic Pelvic Pain —Barbara Karp, Hannah
P2.105 The Effectiveness of Spinal Cord P2.112 Dysautonomia in Charcot-Marie-
P2.091 Gluten Neuropathy: Prevalence
Tandon, Ninet Sinaii, Jay Shah, Jackie Aredo, Pamela Stratton
P2.097 WITHDRAWN P2.098 Botulinum Toxin Treatment
P2.106 Efficacy and Safety of Repetitive
Ptolemaios Sarrigiannis, Marios Hadjivassiliou
Ninet Sinaii, Jay Shah, Pamela Stratton
J. do N. Freitas, Jessika Thais da Silva Maia, Marcelo Rodrigues Zacarkim, Juliéli N. Teixeira, Nilson Nogueira Mendes Neto
Falgarona, Valentina Emmanuele, Saba Tadesse, Marcello Ziosi, Orhan Akman, Kurenai Tanji, Wendy Chung, Michio Hirano
P2.086 Long-term Neurodevelopmental
of Pain and the Role of Gluten-Free Diet. —Panagiotis Zis, Dasappaiah Ganesh Rao,
P2.092 The Effectiveness of Injectable
Monday
Extended Release Naltrexone versus daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical trial. — Kristin Solli, Arild Opheim, Zill-E-Huma Latif, Nikolaj Kunoe, Lars Tanum
P2.093 ALS Patient Perspectives on
Physician Assisted Death After Recent Passage of End of Life Options Act —Nicole Heinl, Carol Tran, Elizabeth Lindenberger, Y-Nhy Duong, Catherine Lomen-Hoerth
P2.094 Prognostic Factors and
Effectiveness of Percutaneous Balloon Compression in the Treatment of Trigeminal Neuralgia: An Experience of 222 patients — Sergio Adrian Fernandes Dantas, Juliano Jose da Silva, Daniel Duarte Rolim, Marcelo Rodrigues Zacarkim, Jessika Thais da Silva Maia, Nilson Nogueira Mendes Neto
P2.095 Evaluation of Pain Reproduction
and other Predictive Factors of Selective Lumbar Nerve Block Efficacy for the Diagnosis and Palliative Treatment of Chronic Low Back Pain: A Retrospective Cohort Study —Yi Tong, Nadia Demko, Thierry Gagné, Maia Del Pilar Cortes
P2.096 Widespread Myofascial
Dysfunction and Regional Sensitization in Women with Endometriosis-associated
134 2018 AAN Annual Meeting
with Temporizing Devices —Lydia Bernhardt,
children with Lennox Gastaut Syndrome: Retrospective single centre cohort —Vishal
of Chronic Pelvic Pain in Women with Endometriosis —Barbara Karp, Hannah Tandon,
P2.099 Evaluation of Clinical Symptom
and Signs Related to Histological and Functional Properties of Small Fiber Neuropathy in Diabetic Neuropathic Pain Patients —Isin Unal-Cevik, Diclehan Orhan, Pınar Acar
P2.100 Polarity-specific Modulation
of Central Pain Processing by Transcranial Direct Current Stimulation —Steffen Naegel, Nina Theysohn, Adrian Ringelstein, Christoph Kleinschnitz, H. Diener, Zaza Katsarava, Mark Obermann, Dagny Holle
Stimulation (SCS) In Reduction of Oral Opioid Tooth Disease and Correlations with PatientUse —Derek Yuan, Patricia Tsui Reported Disability —Sindhu Ramchandren, Transcranial Magnetic Stimulation for the Treatment of Fibromyalgia: An open label clinical trial —Levi Higino Jales Junior, Waleska
P2.113 Small Fiber Neuropathy and
Multiple Endocrinopathies with COX6A1 Gene Deletion —Glen Cook, Michael Crimmins, Clesson Turner
P2.114 Characterizing the spectrum
of autonomic impairment in neurologic disorders with calcium channel antibodies —
Falah, Eman Al-Ghawi, Eslam Shosha, Ali Al-Hilly, Moiz Bakhiet
P2.115 Autonomic description in patients
Refractory Trigeminal Neuralgia with Sphenopalatine Ganglion Block —Mohamed
P2.108 Inflamed Brain: A Neuro-
Palliative Approach —Justin Voorhees, Joel
Julie Khoury, Charlene Hoffman-Snyder, Brent Goodman
with very early TTR amyloidosis (Familial Amyloid Polyneuropathy). —Maria Alejandra
Phillips, Brandon Francis
Gonzalez Duarte, Carlo Enrico Bañuelos, Karen García, Omar Fueyo, Carolina Dominguez, Karla Cardenas-Soto
AUTONOMIC DISORDERS: AUTONOMIC NEUROPATHIES
P2.116 The effect of vagal dysfunction
fibromyalgia syndrome combined with small treatment for melanoma —Kyle Kern, Peony fiber pathology. —Walter Maier-Janson Pak, Rajarshi Mazumder, Dylan Alegria, Phioanh Nghiemphu, Lucas Restrepo
Service for Patients with Spinocerebellar Ataxia Type 1. —Patama Gomutbutra, Megan
P2.110 A Case of Paraneoplastic
P2.104 Evaluation of Berberin- a Nrf2
Perero, Gita Harapannahally
Brandeland
Carolyn Tirella
P2.107 Successful Treatment of
P2.101 WITHDRAWN P2.109 Autoimmune polyneuropathy P2.102 Biotin-deficiency in patients with with severe dysautonomia after ipilimumab P2.103 ‘Triggers’ for a Palliative Care
Mered Parnes, Sarah Risen, Eyal Muscal
Wilson Disease in a Pediatric Patient: Case Report —Michael DiSano, Neil Friedman, Sumit
Dysautonomia and Small Fiber Neuropathy —Jacob Didion, Mayra Montalvo
Activator, on Paclitaxel-Induced Neuropathic P2.111 Diagnostic Utility of Sweat Pain Model in Rat —Amitava Chakrabarti, jagjit Gland Nerve Fiber Density in Small Fiber singh, lekha saha, alka bhatia Neuropathy —Peter Novak, Lan Qin
on cytokine networks in HIV —Elizabeth
Pedowitz, Alexandra Nmashie, Emma Benn, Mary Catherine George, Sandeep Sharma, Jacinta Murray, Josef Machac, Sherif Heiba, Saurabh Mehandru, Seunghee Kim-Schulze, Allison Navis, Isabel Elicer, Susan Morgello, Jessica Robinson Papp
AUTONOMIC DISORDERS: OTHER
P2.117 Healthcare Related Costs
of Autonomic Disorders in MHS Beneficiaries —Agata Bogacki, Ernest Willams, Glen Cook
P2.118 Progressive Multiple Sclerosis
Patients Have a Higher Burden of Autonomic
Dysfunction Compared to Relapsing Remitting Phenotype —Ivan Adamec, Luka Crnosija, Magdalena Krbot Skoric, Anamari Junakovic, Mario Habek
Ivan Adamec, Magdalena Krbot Skoric, Anamari Junakovic, Mario Habek
P2.133 Running-Induced Vertigo in
P2.119 Psychosis in Multiple System
an Adolescent: A Treatable Orthostatic Vestibular Migraine Variant —Imad Jarjour
Lucy Norcliffe-Kaufmann, Horacio Kaufmann
P2.134 Elevated Paraneoplastic Markers:
Atrophy —Jose-Alberto Palma, Jose Martinez,
P2.120 Long-term Fingolimod therapy
An Uncommon Finding in Orthostatic Intolerance and Postural Orthostatic Tachycardia —Charlene Hoffman-Snyder, Julie
increases sympathetic cardiovascular modulation —Ruihao Wang, Max Hilz, Sankanika Khoury, Brent Goodman Roy, Mao Liu, Carmen de Rojas Leal, Katharina Hosl, Klemens Winder, De-Hyung Lee, Ralf Linker
P2.121 Cognitive impairment correlates
with autonomic dysfunction in patients with a history of traumatic brain injury —Max Hilz, Carmen de Rojas Leal, Sankanika Roy, Mao Liu, Katharina Hosl, Klemens Winder, Ruihao Wang
P2.122 Seasonal Hypothermia,
Hypersomnolence, Encephalopathy, and Hypoventilation Following Hypothalamus Injury—A Case of Human Hibernation? — Leighton Mohl, Michael Howell
P2.123 Three Shapiro Syndrome cases :
P2.124 Autonomic Dysfunction
in Patients with Down Syndrome and Alzheimer Disease —Eric Huttler, Michal Shauly-Aharonov, Joseph Jeret
AUTONOMIC DISORDERS: ORTHOSTATIC HYPOTENSION AND ORTHOSTATIC INTOLERANCE
The Stanford experience —Safwan Jaradeh, Srikanth Muppidi, Mitchell Miglis, Dong in Sinn, Irina Krugomova, Thomas Prieto
NEURO-OPHTHALMOLOGY/NEUROOTOLOGY in Pregnancy —Noelia García Lax, Ana Esther
Baidez Guerrero, Rocio Hernandez Clares, José Ángel Motos García, Gabriel Valero López, María Palao Rico, Isabel Pellicer Espinosa, Eliot Gómez López
Mingyang Meah Gao, David Chan
Hypotension in Parkinson Disease Patients in a Neurology Resident Continuity Clinic — Elisabeth Golden, Tran Le, Larry Brown, Steven Vernino, Pravin Khemani
Hypotension Burden of Illness Patient and Caregiver Survey: Impact of Symptoms —
of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis —Soren Jonzzon,
Janace Hart, Andrew Yousef, Leena Suleiman, Emmanuelle Waubant, Jennifer Graves
Sclerosis Patients in Jordan: A Case-Control Study. —Mohammad Alkhoujah, Khader AbdulBaqi, Margaret Zuriekat, Oday Halhouli, Omar Qudah, Murad Alkharabsheh, Baeth Alrawashdeh
Ahmed, Fatih Bushara, Basheer Mohamed, Afraa Musa
P2.152 Venous Sinus Stenting
Improves Visual Fields and Cerebrospinal Fluid Opening Pressures in Patients with Idiopathic Intracranial Hypertension —Evan Schloss, Athos Patsalides, Cristiano Oliveira, Jessica Wilcox, Marc Dinkin
Hyperemesis Gravidarum —Pria Anand, Daniel Gold
P2.139 A Case of Severe Wernicke
rTMS —Benjamin Chipper Doudican, Diamond Urbano, Yoon-Hee Cha
P2.154 ‘Sandbagging’ a Vision Test for Encephalopathy with Bilateral Sensorineural Concussion-based Sideline Assessment: Hearing Loss —Michael Hansen, Alireza Bozorgi, An Eye Movement Investigation Objectively Sindhu Richards, Thananan Thammongkolchai, Reveals the ‘Gamers’ Strategies —Janet Michael Devereaux Rucker, Lisena Hasanaj, John-Ross Rizzo, Todd Hudson, Wei-Wei Dai, John Martone, Yash Chaudhry, Oluchi Ihionu, Ivan Selesnick, Laura Balcer, Steven Galetta
P2.141 Hypereosinophilia and
P2.155 Field testing the ICHD 3 beta
Woon Chow, John Bond
Mark Obermann, Daria Lippegaus, Eva Bock, Zaza Katsarava, Dagny Holle
Neuro-ophthalmological manifestations in Lymphoma —Ehtesham Khalid, Alexandra May,
diagnostic criteria of vestibular migraine —
Oculomotor Nerve —Laszlo Mechtler, Sarthak Mittal
P2.143 Horner’s Syndrome as the
Doudican, Yoon-Hee Cha
P2.129 Persistence of Droxidopa
P2.145 Unilateral proptosis, scleral
Experiences With the Diagnosis of Neurogenic Orthostatic Hypotension —
Treatment in Patients With Neurogenic Orthostatic Hypotension —Jan Basile, Steven Kymes, Kenneth Jackson, Michelle Widolff Cyr
P2.130 Management and Treatment of
injection and superior gaze diplopia secondary to spontaneous ophthalmic artery to superior ophthalmic vein fistula—Case report and review of literature —Subin
Neurogenic Orthostatic Hypotension: Results Mathew, Dhara Murray-Frank, Maria Martucci, Pirouz Piran, Nestor Galvez-Jimenez, Michal Obrzut From a Survey of Patients and Caregivers — Lawrence Hewitt, Charles Adler, Daniel Claassen, P2.146 Development of Optic Neuritis Christopher Gibbons, Satish Raj after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) P2.131 Short-Term Outcome in Study, 1990-2017. —Janaki Patel, Abdul Children and Adolescents with Orthostatic Rahman Alchaki, Moamina Fakher Eddin, Nizar Intolerance and Postural Tachycardia Souayah Syndrome —Imad Jarjour, Adriana Hernandez, Laila Jarjour P2.147 Chronic Relapsing Inflammatory P2.132 Joint Hypermobility is Related to Optic Neuropathy —Chaitanya Amrutkar, Erik Pathological Finding on Tilt Table Testing —
Menaka Thounaojam, Amany Tawfik, Diana Gutsaeva, Manuela Bartoli
coherence tomography in non-inflammatory models of retinal neurodegeneration — Michael Dietrich, Andrea Issberner, Christina Hecker, Zippora Kohne, Hans-Peter Hartung, Philipp Albrecht
P2.164 Mkk4 and Mkk7 are Important
for Both Retinal Development and Axonal Injury-Induced Retinal Ganglion Cell Death — Stephanie Syc, Rebecca Rausch, Kimberly Fernandes, Richard Libby
P2.165 Correlation of Visual Field Loss
with MRI Findings in Patients with Pituitary Tumours —Christian Lueck, Emily Kane, Kate Reid, David Ashton
P2.166 Impact of cataract surgery
on cognitive functions in elderly patients presenting to a tertiary care center in Islamabad. —Faleha Zafar, Fiza Shaheen, Javeria Muid, Farooq Afzal
P2.167 Saccadic Intrusions Are Rare
In Multiple Sclerosis —Lisa DePledge, Pavle
Repovic, James Bowen, Peiqing Qian, Bobbie Severson, Steven Hamilton, Bonnie Keung, Eugene May
P2.168 Correlative Enhancement: Evaluation of a new postprocessing Individuals with Mal de Debarquement Syndrome —Diamond Urbano, Benjamin Chipper algorithm for diagnosis of optic neuritis. —
Lawrence Hewitt, Charles Adler, Daniel Claassen, Christopher Gibbons, Satish Raj
P2.128 Patient and Caregiver
Releasing Hormone (GHRH) Protects Retinal Ganglion Cells in a Model of Traumatic Optic Neuropathy —Christian Kim, Ornella Oluwole,
P2.142 Intraorbital Perineural Cyst of the P2.156 Psychological Measures of
Presenting Symptom in Giant Cell Arteritis — P2.157 Vestibular Perceptual Threshold and Motion Sensitivity in Vestibular Stephanie Figueira, Benjamin Farley, Brooke Migraine and Persistent Postural-Perceptual Hartenstein, Charles Maitland Dizziness —Felix Wurthmann, Steffen Naegel, P2.144 Diplopia as the Presenting Miriam Roesner, Christoph Kleinschnitz, H. Diener, Symptom of Systemic T Cell Prolymphocytic Mark Obermann, Dagny Holle Leukemia with Infiltration of the Superior Rectus Muscle. —Humaira Khan, Yu-Ting Chen, P2.158 Erlotinib-Induced Dandy’s Syndrome: Case Report —Kristen Steenerson, Betul Gundogdu
Daniel Claassen, Charles Adler, Christopher Gibbons, Lawrence Hewitt
P2.162 Agonist of Growth Hormone
Burton
Terry Fife
P2.159 Short-Term Memory Loss in
Vestibular Patients can Arise Independently of Psychiatric Impairment, Fatigue and Sleeplessness —S.S. Surenthiran, Laura Smith,
Leanne Stunkel, Amber Salter, Matthew Parsons, Aseem Sharma, Gregory Van Stavern
P2.169 The New MULES: A Sideline-
Friendly Test of Rapid Picture Naming for Concussion —Omar Akhand, Matthew Galetta,
Lisena Hasanaj, Lucy Cobbs, Nikki Webb, Julia Brandt, Prin Amorapanth, John-Ross Rizzo, Liliana Serrano, Rachel Nolan, Janet Rucker, Arlene Silverio, Barry Jordan, Steven Galetta, Laura Balcer
P2.170 NA P2.171 NA P2.172 NA
David Wilkinson, Rowena Bicknell, Mayur Bodani
P2.160 Optimal Inter-Eye Difference
Thresholds in Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis: An International Collaborative Study —Rachel Nolan, Omar Akhand, Peter
Calabresi, Friedemann Paul, Elena MartinezLapiscina, Axel Petzold, Alexander Brandt, Shiv Saidha, Pablo Villoslada, Abdullah Abu Al-Hassan, Raed Behbehani, Elliot Frohman, Teresa Frohman, Joachim Havla, Bernhard Hemmer, Hong Jiang, Benjamin Knier, Thomas Korn, Letizia Leocani,
AAN.com/view/AM18 135
Monday
P2.127 Neurogenic Orthostatic
Knier, Timm Oberwahrenbrock, Janina Behrens, Catherina Pfuhl, Llian Aly, Miriam Kaminski, MunaMiriam Hoshi, Svenja Specovius, Rene Giess, Michael Scheel, Mark Mühlau, Judith BellmannStrobl, Klemens Ruprecht, Bernhard Hemmer, Thomas Korn, Friedemann Paul, Alexander Brandt
P2.149 Clinical Features and Outcomes
P2.153 Long-term Symptom Reduction P2.138 Wernicke’s Encephalopathy After of MdDS Rocking Vertigo with Theta Burst
P2.140 Objective Evidence of HyperNeurogenic Orthostatic Hypotension: Results rapid Olfactory Adaptation in Cranial Nerve I From a Survey of Patients and Caregivers — Dysfunction —Khurram Janjua, Alan Hirsch P2.126 Addressing Orthostatic
Schatz, John Guy
P2.151 Idiopathic Intracranial P2.163 Evaluation of neuroprotective Hypertension (IIH): An Aggressive Disease P2.136 Isolated Sixth Cranial Nerve Palsy in Sudanese Patients —Ammar Ahmed, Hadab properties of dimethylfumarate by optical
P2.125 Understanding the Symptoms of Satish Raj, Daniel Claassen, Charles Adler, Christopher Gibbons, Lawrence Hewitt
Athina Papadopoulou, Marco pisa, Hanna
Zimmermann, Steven Galetta, Laura Balcer treatment in the management of corticosteroid unresponsive optic neuritis: A P2.161 Retinal Ganglion Cell Layer retrospective case series of 15 cases —Yu and Disease Activity in Clinically Isolated Zhao, Angela Herro, William Feuer, Norman Syndrome —Hanna Zimmermann, Benjamin
P2.135 Postural Orthostatic Tachycardia: P2.150 Audiological Profile of Multiple
Diagnostic challenge of clinical spectrum of P2.137 A case of optic neuropathy due the spontaneous paroxysmal hypothermia to cat scratch disease (CSD) and syphilis cosyndrome —Rubens Salomão, Jose Luiz Pedroso, infection with characteristic MRI findings — Orlando Barsottini
P2.148 Intravenous immunoglobulin
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION II
G
Disease —Olivia Gardner, Anthony Griswold, BEHAVIORAL AND COGNITIVE NEUROLOGY: GENES, ENVIRONMENT, Sathesh Sivasankaran, Farid Rajabi, Brian Kunkle, Kara Hamilton, James Jaworski, William AND INTERVENTIONS
D
P2.173 Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype —John
Parker, Tahseen Mozaffar, Ashlynn Messmore, Joshua Deignan, Virginia Kimonis, John Ringman
P2.174 Huntington’s disease across four generations in a Mexican family: Westphal variant with female predominance —Jazmin
Bush, Eden Martin, Gary Beecham, Goldie Byrd, Jonathan Haines, Margaret Pericak-Vance
P2.186 Genetic Basis of Motoric
P2.179 Dietary Approaches to Stop
Hypertension (DASH) Diet Associated with Lower Rates of Depression —Laurel Cherian, Yamin Wang, Thomas Holland, Puja Agarwal, Neelum Aggarwal, Martha Clare Morris
P2.180 An Exploratory Analysis of
Lifetime Surgical History and Cognition — James Bateman, Christopher Filley, Brianne Bettcher
P2.181 Neurostimulation for Functional
Monday
Weakness: A Longitudinal Evaluation of Cortical Neurophysiology —Matthew Burke,
Reina Isayama, Gaayathiri Jegatheeswaran, Carolyn Gunraj, Anthony Feinstein, Anthony Lang, Robert Chen
P2.182 ‘Just Google It’—The Effect of
Media Events on Patterns of Public Interest in the ‘Vaccines Cause Autism’ Fallacy from 2004-2017 —Shehryar Sheikh, Carol Swetlik, Robert Wilson DO
GENETIC AND BASIC SCIENCE STUDIES IN NEURODEGENERATIVE DISEASES
P2.183 Characterization of Regulatory
T Lymphocytes in the progression of Alzheimer’s Disease —Alirexa Faridar, Aaron
Thomas, Neha Pal, Belen Pascual, Weihua Zhao, David Beers, Joseph Masdeu, Stanley Appel
P2.184 Age-Dependent White Matter Inflammation and Cognitive Impairment in the TgAPP21 Rat Model of Alzheimer Disease —Alexander Levit, Brian L. Allman,
Shaykh
Intranuclear Inclusion Disease —Monique
Montenegro, Brian Crum, Joseph Parisi, John Chen, Ralitza Gavrilova, Keith Josephs, Devin Mackay, Timothy Kaufmann, William Mantyh, Eoin Flanagan
Konno, Hiroaki Nozaki, Osamu Onodera, Takeshi Ikeuchi
Daiello, Cyrus Kosar, Richard Jones, Karen Furie
P2.212 Aphasia at Presentation Predicts Poor Functional Outcome After Acute Ischemic Stroke —Kathleen L. Donahue, Anne-
Katrin Giese, Mark Etherton, Ona Wu, Natalia Rost
P2.213 Cancer and Stroke— cognitive decline in a patient with deletion of Presentations and Problems —David Collas, exons 5-17 —Elizabeth Coffee, Hassan Fathallah- Aishah Azam, Manpreet Dhillon P2.199 NA P2.200 NA
P2.214 Stroke in Teens —
STROKE EPIDEMIOLOGY, RISK FACTORS, AND OUTCOMES
Chandramouleeswaran Venkatraman, Pratheep Kumar S, Balasubramanian Samivel, Venkatraman Karthikeayan, Kannan Vellaichamy, Harish Jayakumar, N. Shanmugasundaram, Lakshmi Ranganathan
P2.201 Characterizing Stroke in
P2.215 Development and Validation
E
Transgender Adults—a San Francisco General Hospital Study —Sara LaHue, Dolores Torres, Nicole Rosendale, Vineeta Singh
P2.202 The Role of Acute versus Ever
Use of Cocaine in Ischemic Stroke of Young Adults —Sleiman El Jamal, Mohsen Pirastehfar, Carl-Hans Blanchard, Bauman Kristie, Gabriella Garcia, Victoria Cantoral, Paul Katz
Tamao Tsukie, Toshiyasu Ogata, Toru Baba, Takeshi P2.203 Code 420: A case series Miura, Takanobu Ishiguro, Hiroaki Nozaki, Kensaku of accidental marijuana ingestion Kasuga, Yoshio Tsuboi, Etsuro Mori, Osamu masquerading as acute stroke —Katherine Onodera, Takeshi Ikeuchi Werbaneth, Tarini Goyal, Eric Beriner, Nirali Vora
P2.204 Recreational Use Of Marijuana
and Stroke: A Nationwide Outcome Study —Urvish Patel, Anam Habib, Aparna Saha, Gull Mahvish, Salma Yousuf, Priti Poojary, Liseth Lavado, Abhishek Lunagariya, Tapan Kavi, Vishal Jani
P2.205 Impact of Cocaine Use on Acute
of Graphical Displays for Reporting Acute Stroke Trials that Use a Patient-Centered Disability Outcome Primary Endpoint —Ivie Tokunboh, Jeffrey Saver
P2.216 Classical Crossed Medullary
Syndromes in Patients with Lateral Medullary Infarction —Guillermo Delgado-
Garcia, Fabiola Serrano-Arias, Monica Chavarria, Jose Merino, Antonio Arauz
P2.217 Etiologies, risk factors and
functional outcomes of young stroke in a Taiwanese cohort —Chun-Yu Chen, Ruei-Wun
Syu, Li-Hsin Chang, Jui-Yao Tsai, Hui-Chi Huang, Chun-Jen Lin, Chih-Wei Tang, Yung-Yang Lin, I-Hui Lee
P2.218 Prevalence of HIV Infection
Among Stroke Patients and its Association with Mortality in Southwestern Uganda —
Amir Abdallah, Sam Olum, Cumara O’Carroll, Bart Demaerschalk, Mark Siedner, Samson Okello
BRCA1 lead to reduced neuronal plasticity in Alzheimer’s disease —Tatsuo Mano, Takashi
Ischemic Stroke Patients: Insights from Nationwide Inpatient Sample in the United P2.219 Incidence of Ischemic and States —Zabeend Mahuwala, Chintan Rupareliya, Hemorrhagic Stroke Amongst Asians in the United States —Antonio Moya, Babak Navi, Rupak Desai, Upenkumar Patel, Sandeep Singh,
P2.192 Measuring the Contributions of
and Smoking Predicts Recurrence Rate of Ischemic Stroke in the Young —Muhammad
P2.191 Tau-related dysfunction of
Nonaka, Airi Tarutani, Tadafumi Hashimoto, Shigeo Manan Shah, Rikinkumar Patel, Smit Patel Murayama, Masato Hasegawa, Takeshi Iwatsubo, P2.206 History of Diabetes, Drug Abuse Atsushi Iwata
Hooman Kamel, Santosh Murthy
P2.220 Leukoaraiosis & Metabolic
Syndrome In Middle Age Egyption Ischemic Stroke Patients —Wael Amer, Mahmoud
Heritable and Non-Heritable Risk Factors Ahmed, Haris Kamal, Charlie Zhang, Robert to Alzheimer Disease Age-at-Symptomatic- Sawyer Onset in Adult Children of Affected Parents —Gregory Day, Carlos Cruchaga, Thomas P2.207 Continued Nationwide decline in Stroke related In-Hospital Mortality Wingo, Dean Coble, John Morris in United States —Mohammad-Rauf Afzal, P2.193 Clinical and neuropsychological Mohtashim Qureshi, Ihtesham Qureshi, Darine features of a family with a novel PSEN-1 Kassar, Paisith Piriyawat, Anantha Vellipuram, Alberto Maud, Salvador Cruz-Flores, Gustavo variant (I416T) —Laura Ramírez-Aguilar, Sonia
AbdelSayed, Tarik Menecie, Sayed El zayat, Mohamed Abdel Mouaty, Mohamed AbdAlsalam
P2.194 Genome-wide Association Study P2.208 Clinical Characteristics of Stroke
Mustapha Danesi
Moreno, Sara Henao, Laura Osorio, Mario Parra
Rodriguez, Rakesh Khatri
Patients with Essential Thrombocytosis Based on A/T/N System Identifies New Susceptibility Loci for Alzheimer’s Disease — according to JAK2 mutation —Joung-Ho Rha, Chenchen Tan, Jin-Tai Yu, Lan Tan
P2.195 African Haplotypic Background
Mitigates the Effect of APOE e4 Risk Allele in Alzheimer Disease —Farid Rajabli, Briseida
Hee-Kwon Park, Cindy Yoon, Byung-Nam Yoon, Eun-Kee Bae, Seong Choi, Woochang Chun, Haein Bak, Sang Won Lee, Dan Oh
P2.209 Trauma due to Acute Ischemic
Feliciano-Astacio, Katrina Celis, Kara Hamilton, Patrice Whitehead, Larry D. Adams, Parker L. Bussies, Jacob McCauley, Heriberto Acosta, Angel Chinea, Alejandra Rodriguez Betancourt, Goldie S. Byrd, Eden Martin, Christiane Reitz, Lindsay Farrer, Gerard Schellenberg, Richard Mayeux, Jeffery Vance, Michael L. Cuccaro, Jonathan Haines, Badri Vardarajan, Gary Beecham, Margaret PericakVance
Stroke: A Case Series —Kevin Yeboah, Aakash
P2.196 TREM2 P.Arg47His Is Not
P2.211 Level of Consciousness at
Nagalingam Rajakumar, Vladimir Hachinski, Shawn Associated With Late-Onset Alzheimer’s Whitehead Disease In A Tunisian Population —Mouna P2.185 Case Control Study of RNA Ben Djebara, Zied Landoulsi, Amira Nasri, Saloua Mrabet, Rym Kefi, Sonia Abdelhak, Amina Gargouri Editing in Blood Reveals Decreased Global Ep Berrechid, Riadh Gouider Levels of A-to-I Editing in Alzheimer’s
136 2018 AAN Annual Meeting
Gundimeda, Anat Boehm-Cagan, Jan Johansson, Helena Chui, Michael Harrington, Daniel Michaelson, Hussein Yassine
P2.187 Familial Adult-onset Neuronal
Ayers, Joe Verghese
Leucoencephalopathy with brainstem and spinal cord involvement and lactate elevation P2.190 Identification and Functional Assay of Novel CSF1R Mutations in Patients (LBSL) —Michael Doyle, John Lynch with Adult-onset Leukoencephalopathy with P2.178 Correlation Between Exercise Axonal Spheroids and Pigmented Glia — and Motor Skills with Elderly Patients Takeshi Miura, Naomi Mezaki, Takanobu Ishiguro, Takayoshi Tokutake, Kensaku Kasuga, Takuya Cognition —Cassio Henrique Taqu Martins, Catarina Assuncao
fluid studies implicate decreased ABCA-1 activity with APOE4 —Varun Rawat, Usha
P2.198 Case Report: SPG4-related
Elk-1 SUMOylation Mediate Endogenous P2.175 Fahr’s disease due to a novel Neuroprotection against Amyloid-beta SLC20A2 gene mutation in a Canadian patient: Early Neurocognitive, Structural and Toxicity —Shau-Yu Liu, Yun-Li Ma, Hsiao-Yuan Metabolic changes —Leila Sellami, Louis Verret, Lee Stephane Poulin, Robert Laforce P2.189 Mutational Analysis of AARS2 P2.176 Two Distinct Clinical Phenotypes in Japanese Patients with Adult-Onset Leukoencephalopathy Lacking CSF1R in a Family with ALSP Caused by a Novel Mutation —Naomi Mezaki, Norikazu Hara, CSF-1R Mutation. —Ryan Taylor, Basma
P2.177 A Case of AARS2
P2.197 In vitro, In vivo and cerebrospinal Linda Wendell, Ali Mahta, Nicholas Potter, Lori
Cognitive Risk Syndrome in Health and Retirement Study —Sanish Sathyan, Emmeline
G. Sotelo-Hernandez, Laura DeLeón-Flores, Ingrid Estrada-Bellman, Beatriz E Chavez-Luevanos, Adriana C Cantu-Salinas, Salvador Vazquez, Jessica Merino-Caballero, Nelly M NavaRodriguez, Belen Avila-Montanez, Ricardo Pinales- P2.188 Amyloid-beta Induction of Razo, Christopher Cerda-Contreras PIAS1 Ser-503 Phosphorylation and
Alyamany, Sachin Pandey, Andrew Kertesz, Lee Cyn Ang, Elizabeth Finger
Monday, April 23 11:30 a.m.–7:00 p.m.
Bodhit, Ali Al Balushi, Erik Krause, Abhay Kumar
P2.210 Only hepatic fibrosis,
not steatosis, assessed on transient elastography is an independent predictor of long-term mortality in patients with ischemic stroke. —Minyoul Baik, Hyo Suk Nam, Ji Hoe Heo, Seung Up Kim, Young Dae Kim
Discharge and Associations with Outcome After Ischemic Stroke —Michael Reznik, Shadi Yaghi, Mahesh Jayaraman, Ryan McTaggart, Morgan Hemendinger, Brian Mac Grory, Tina Burton, Shawna Cutting, Bradford Thompson,
P2.221 Impact of Reactive
Hyperglycemia on Stroke Severity and Outcome in Lagos, Nigeria —Osigwe Agabi, Mustapha Danesi
P2.222 Predictors of Stroke
Recurrence at Lagos University Teaching Hospital,Nigeria. —Osemwegie Nosakhare,
P2.223 Clinical characteristics
of borderzone infarction in Egyptian population —Nevine EL Nahas, Hossam Farag,
M Abdulghani, Magd Zakaria, Adel Taha Kamel, Nagia Fahmi, Naglaa Khayat, Aly Shalash, Ahmed El Basiony, Ramez Reda, Sherine Farag, Ihab Abdelbaset, Hany Aref
STROKE BIOMARKERS AND ANIMAL MODELS
P2.224 Neurovascular Protective Effects
of Remote Ischemic Preconditioning in Acute Ischemic Stroke Model —Farris Taha
P2.225 Functional Remapping of the
Mouse Somatosensory Cortex After Ischemic Stroke —William Zeiger, Mate Marosi, Cynthia He, Gengming Liu, Sheyda Mesgarzadeh, Michael Le, Cindy Chen, Carlos Portera-Cailliau
P2.226 Multimodal Imaging of White Matter Inflammation in a Rat Model of
Striatal Ischemic Stroke —Alexander Levit, Matthew S. Fox, Qi Qi, Vladimir Hachinski, Jonathan D. Thiessen, Shawn Whitehead
P2.227 Blockade of Soluble Epoxide Hydrolase Attenuates Post-Ischemic Neuronal Hyperexcitation and Confers Resilience Against Stroke with TrkB Activation —Li-Hsin Chang, Hui-Ching Lin,
Shiang-Suo Huang, I-Chih Chen, Kai-Wen Chu, Chun-Lien Chih, Yao-Wen Liang, Yi-Chung Lee, You-Yin Chen, Yi-Hsuan Lee, I-Hui Lee
P2.228 Characterizing the
Neuroinflammatory Response of Focal Ischemic Stroke in the Rat Insular Cortex —
P2.239 Role of Blood Based Biomarkers for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: Findings from a Multi-Centric Prospective Cohort Study — Kameshwar Prasad, Amit Kumar, Shubham Misra, Ram Sagar, Bhavna Kaul, Surekha Dabla, SP Gorthi, Chandrashekhar Agrawal, Ajay Garg, Kuljeet Anand, Samander Kaushik
P2.240 A Combination of Three
Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Ischemic Stroke —I-Chen Yu, Ping-Chang Kuo,
Jui-Hung Yen, Hallel Paraiso, Benecia Hong-Goka, Robert Sweazey, Fen-Lei Chang
Victoria Thorburn, Brittany Balint, Victoria Jaremek, Maryse Paquet, Luciano Sposato, Shawn CEREBROVASCULAR GENETICS Whitehead P2.241 Molecular Genetic Features Of
PRE-HOSPITAL, TELESTROKE AND ED-BASED STROKE CARE II
P2.265 Impact of Seizures in Temporal
P2.251 Safety and Feasibility of
Hackett, Rahul Rahangdale, Ashis Tayal, Sandeep Rana, Robert Fishman, Jack Protetch, David Wright, Eric Schmidt, Rebekah Pratt
Mathis, Veena Nair, Megan Rozman, Taylor McMillan, Courtney Forseth, Dace Almane, Bruce Hermann, Neelima Tellapragada, Onyekachi Nwoke, Cole Cook, Andrew Nencka, Rasmus Birn, Elizabeth Felton, Aaron Struck, Rama Maganti, Lisa Conant, Colin Humphries, Edgar DeYoe, Manoj Raghavan, Vivek Prabhakaran, Jeffrey Binder, Mary Meyerand
P2.252 Pre-arrival RACE Score-Based
P2.266 Clinical Significance of Bilateral
Sitara Koneru, Samar Sheriff, Jaclyn Mueller, Syed Zaidi
Suchita, David Gonzalez, Lola Morgan, Kameel Karkar, Octavian Lie, Samiya Rashid, Campbell Sullivan, Alexander Papanastassiou, Charles Szabo
Telestroke in the Prehospital Emergency Medical Services Setting—The REACHOUT Project —Muhammad Adeel Saleemi, Chris
Hospital Bypass Protocol Improves Treatment Time Efficiencies —Shazli Khan,
Lobe Epilepsy on Cognitive Functions and Imaging Features —Gyujoon Hwang, Jedidiah
Failures on Wada Memory Testing —Iffat Ara
P2.267 Seizure-induced Behavioral and Autonomic Arousal Localizes to the Anterior and documentation of neurologic deficit by EMS and ED of patients with acute ischemic Cingulate Gyrus: Network Dynamics and Polymorphism Of The Gene Col4a1 Rs605143 P2.229 Association of plasma D-dimer Underlying Mechanism —Harshad Ladha, stroke —Haitham Hussein, Lauren Erickson, G / A In The Development Of Pathological and B-type natriuretic peptide levels with Bhavani Kashyap, Mitchelle Clayton, Mary Fennig, Adeel Memon, Sandipan Pati stroke mechanism, severity, and outcome — Deformations Of Cerebral Vessels In Patients Vesselina Pearsall, Carol Droegemueller, Sandi P2.268 Does A Drug Refractory Epilepsy With Migraine —Gulnora Rahmatullaeva Hyun-Wook Nah Wewerka, Aaron Burnett, Leah Hanson (DRE) diagnosis impact time to seizures in the P2.242 The Cerebral Straight and P2.230 Role Of Blood Biomarkers P2.254 A Prospective Validation of Epilepsy Monitoring Unit (EMU) —Brian Toh, Narrow: A Case Illustration of Moyamoya In Differentiating Ischemic Stroke and Stroke Network Of Wisconsin (SNOW) William Duong, Mary Porter, Leah Loewenstein, Syndrome in the Setting of the ACTA-2 Gene Scale —Kessarin Panichpisal, Maureen Hess, Intracerebral Hemorrhage —Rohit Bhatia, Frank Bertone, Sunita Dergalust Anand Warrier, Prerna Bali, Pranjal Sisodia, Anchal Mutation —Malcolm McDonald, Patrick Reynolds Reji Babygirija, Maharaj Singh, Paul Vilar, Thomas P2.269 The Role Of Immunoreactivity Gupta, Sreenivas Vishnubhatla, S Vivekanadhan, P2.243 Rare Presentation of Malignant Wolfe, Rehan Sajjad, Amin Kassam, Richard Rovin Of Neurotropic Autoantibodies And Padma Hadakasira, Kameshwar Prasad Myxomatous Aneurysms with PRKAR1A P2.255 Safety of intravenous Neuromediators In The Pathogenesis Of P2.231 Circulating inflammatory gene mutation —Usman Shehzad, Alexander Ou, thrombolysis in telestroke and impact of Symptomatic And Idiopathic Epilepsy — biomarkers are related to cerebrovascular Patricia Coyle, Agnes Kowalska an acute stroke training curriculum —Tarun Maruf Salokhiddinov, Rano Azizova disease in a non-demented elderly Girotra, Disha Kohli, Ellen Debenham, Christine P2.270 Epilepsy as a Dynamic population —Nicole Schupf, Jose Gutierrez, Irene P2.244 Molecular - Genetic Features Of The Gene Of Vasculoendothelial Growth Holmstedt, Chirantan Banerjee Disease: Modeling Seizure Burden Based Meier, Vanessa Guzman, Jennifer Manly, Adam Factor (C634G VEGFA) In The Deformations P2.256 NA Brickman, Richard Mayeux On Transitions Between Seizure Risk Of Cerebral Vessels —Gulnora Rahmatullaeva P2.257 NA States —Sharon Chiang, Marina Vannucci, Daniel P2.232 Diapedetic Potential of Goldenholz, Robert Moss, John Stern P2.245 PAI-1 polymorphism and stroke in P2.258 NA Monocytes in Complexes with Platelets pregnancy —Mary Hollist, Yogesh Gujrati, Stacie P2.271 Effect of Anesthesia on Correlates with Clinical Outcome after CLINICAL EPILEPSY II Demel Electrocorticography for localization of Stroke —Maria Lukasik, Radoslaw Kazmierski, Natalia Andrzejewska, Jacek Aniola, Maria P2.246 Ring-enhancing lesions, stroke P2.259 Baroreflex Sensitivity in Patients Epileptic Focus: Literature Review and Future Kamieniarz, Justyna Rosinska, Maciej Directions —Ayse Bayram, Shilpa Rao, Dennis and vascular retinopathy associated with a with Intractable Generalized Tonic Clonic Boruczkowski, Magdalena Frydrychowicz, Robert novel TREX1 mutation —Marcus Cimino, Sylvia Spencer, Mhd Alkawadri Seizures versus Partial Seizures —Behnaz Narozny, Grzegorz Dworacki, Wojciech Kozubski Soo, Mark Morrow Esmaeili, Farhad Kaffashi, Wanchat Theeranaew, P2.272 Can We Predict the prognosis in Aman Dabir, Samden Lhatoo, Kenneth Loparo P2.233 Multiple Biomarkers for the patients with Acute Symptomatic Seizure? P2.247 Systemic Response to Rupture Prediction of Stroke Outcomes: Findings A Prognostic model: A Retrospective study of Intracranial Aneurysms Analyzed with P2.260 Evaluation of Dual Pathology from a Cohort of 792 Patients with Ischemic Whole-transcriptome Sequencing —Joanna Among Drug Resistant Epileptic Patients from a developing nation —Gopal Dash, Stroke in a University Teaching Hospital — Jignesh parajapati, Amitkumar Patanvadiya Pera, Michal Korostynski, Marcin Piechota, Dzesika With Hippocampal Sclerosis —Peyman Zuolu Liu, Kwan Ng
Predicting Outcomes After Acute Stroke —
Hoinkis, Slawomir Golda, Magdalena Zygmunt, Tomasz Dziedzic, Rafal Morga, Marek Moskala, Agnieszka Slowik
Divya MR, Anand Warrier, Rohit Bhatia, Prerna P2.248 Association of Transforming Bali, Pranjal Sisodia, Anchal Gupta, Mohd growth Factor-β1 gene C509T, G800A and Sharique, Padma Srivastava, Kameshwar Prasad, V T869C Polymorphisms with Intracerebral Sreenivas, S Vivekanadhan
P2.235 Marked Leukocytosis on
Presentation with Acute Ischemic Stroke -- What Does it Mean? —Matthew Broderick, Tiffany Sheehan, Katharina Busl, Teddy Youn
Anne-Katrin Giese, Arooshi Kumar, Cathy Zhang, Sarah Nelson, Kelsey Shideler, Lisa Cloonan, Allison Kanakis, Kaitlin Fitzpatrick, Karen Furie, Fanny Herisson, Ona Wu, Natalia Rost
P2.237 Can S100b, IL 6 And BNP
Predict Functional Neurological Outcome In Intracerebral Hemorrhage? —Mohammed
El-Sherif, Abeer Mosbah, Hany Eldawoody, Ashraf Zaher, Mohamed Abdelbary
P2.238 Role of Copeptin as a Biomarker for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: A Prospective Cohort Study —Shubham Misra, Amit Kumar, Pradeep Kumar, Pumanshi Talwar, Dheeraj Mohania, Deepti Vibha, Kameshwar Prasad
P2.261 A New Database Platform
for Clinical and Genetic Investigation Hemorrhage in North Indian Population: A of Epilepsies and the New ILAE Case-Control Study —Shubham Misra, Pradeep Classification —David Discua, Reyna Duron, Kumar, Amit Kumar, Pumanshi Talwar, Kameshwar Prasad
P2.249 Role Of Pharmacogenetics and
Pharmacodynamics On The Antiplatelet count is associated with stroke severity and Effect Of Clopidogrel In North Indian outcome independent of acute infarct size — Ischemic Stroke Patients —Dheeraj Khurana,
P2.236 Admission white blood cell
F
Gookizadeh, Jafar Mehvari Habibabadi, Shervin Badihian, Nasim Tabrizi, Navid Manouchehri, Reza Basiratnia, Majid Barekatain, Houshang Moein, Amirali Mehvari Habibabadi, Payam Moein
Jitender Gairolla, Rupinder Kler, Jasmina Ahluwalia, Madhu Khullar, Manish Modi, Bikash Medhi
P2.250 Association between Tumor
Iris Martinez, Viet-Huong Nguyen, Christopher Patterson, Julia Bailey, Miyabi Tanaka, Adriana Ochoa, Aurelio Jara-Prado, Maria Alonso, Minerva Lopez Ruiz, Marco Medina, Laura Guilhoto, Elza Targas Yacubian, René Silva, Carlos Arias, Antonio Delgado-Escueta
P2.273 Characterization of a Novel
Knock-in Mouse Model of KCNT1 Epileptic Encephalopathy —Lisseth Burbano, Melody
Li, Nikola Jancovski, Kay Richards, Elena Gazina, Snezana Maljevic, Christopher Reid, Steven Petrou
P2.274 NLRP1 Inflammasome is
Activated in Patients with Medial Temporal Lobe Epilepsy and Contributes to Neuronal Pyroptosis in Amygdala Kindling- induced Rat Model —Chenchen Tan, Jin-Tai Yu, Lan Tan
P2.262 Initial Presentations and Surgical P2.275 Autophagy in Juvenile Myoclonic Epilepsy (JME) —Miyabi Tanaka, Iris MartinezOutcomes of Pediatric Patients with Neurovascular Lesions —Janani Kassiri, Thilinie Juarez, Reyna Duron, Viet-Huong Nguyen, Adriana Rajapakse, D Sinclair
P2.263 Comparing the Clinical Profile
necrosis factor-alpha (-308G/A, +488G/A, -857C/T and -1031 T/C) gene polymorphisms and Seizure Control between Focal and Generalized Seizures in Adult Nigerian and risk of ischemic stroke in north Indian population: A case-control study —Pumanshi Patients with Epilepsy. —Chindo Mallum, Talwar, Shubham Misra, Pradeep Kumar, Amit Kumar, Kameshwar Prasad
EPILEPSY: BASIC SCIENCE AND GENETICS
Adedunni Olusanya, Olubunmi Omojowolo, Mustapha Danesi
P2.264 A Fatal Case of Mistaken
Identity: Brugada Syndrome Masquerading as Seizure Disorder —Claribel Wee, Julius Latorre
Ochoa, Aurelio Jara-Prado, Maria Alonso, Minerva Lopez Ruiz, Marco Medina, Laura Guilhoto, Elza Targas Yacubian, Rene Silva, Christopher Patterson, Julia Bailey, Antonio Delgado-Escueta
P2.276 NADPH oxidase inhibitor
attenuated increased seizure susceptibility after systemic inflammation —Wan-Yu Huang, Hung-Ming Wu
P2.277 A role of GPR55 in the
antiepileptic properties of cannabidiol (CBD) —Benjamin Whalley, Michael Bazelot, Evan Rosenberg, Richard Tsien
AAN.com/view/AM18 137
Monday
P2.234 Role Of Blood Biomarkers In
P2.253 Correlation between evaluation
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION II P2.278 Variation in Cortical Impact
Augments Epileptogenesis in Rat Model of Traumatic Brain Injury. —Shammy Chandel, Bikash Medhi
P2.279 Protective effects of
protocatechuic acid against seizure-induced neuronal death in the pilocarpine-induced status epilepticus rat model —Dong Jin Shin, Hongki Song, Sang Won Suh
G
CHILD NEUROLOGY AND DEVELOPMENTAL NEUROLOGY: EPILEPSY
G
P2.295 EEG Patterns in Routine
Polysomnography in Childhood and Risk of Epilepsy —Robert Stowe, Daniel Glaze
P2.296 New Onset Refractory Status
Epilepticus in Pediatric Population: A Single Tertiary Center Experience —Khalil Husari,
P2.280 Association Between Occurrence Katherine Labiner, Rana Said of Hippocampal Spindles and Hippocampal Interictal Spiking. —Kseniia K. Kriukova, Anatol P2.297 Cognitive, Linguistic and Bragin, Evgenia Alexandrova, Lin Li
P2.281 Majority of Epilepsy
Mutations are in Genes with Therapeutic Associations —Elaine Weltmer, Heather Newman, Amal Yussuf, Jing Wang
P2.282 Genotype and Phenotype
Correlation in Patients with Comorbid Epilepsy and Intellectual Disability — Mohamed Taha
P2.283 Screening of PI3K-AKT-mTOR
pathway genes in focal cortical dysplasias in a clinical setting —Andrea Accogli, Judith
Behavioral Characteristics of Children with Comorbid Autism Spectrum Disorder and Epilepsy —Louisa Kalsner, Jennifer TwachtmanBassett, Hudin Jackson, Laurie Derynioski
Monday, April 23 11:30 a.m.–7:00 p.m. P2.307 Cerebrospinal fluid (CSF)
P2.321 Chiari malformations associated Neurofilament and CXCL-13 Levels in with transverse myelitis: Are these Children with Demyelinating Disease —Maria myelopathies truly inflammatory? —Eliza
Galardi, Rachel Butler, Alyssa Lui, Jordan Cole, Gordon-Lipkin, Laura Munoz-Arcos, Paula Barreras, Robert Mikesell, Amber Salter, Laura Piccio, Soe Mar Maria Castaneda, Philippe Gailloud, Carlos PardoVillamizar
P2.308 Pediatric and Adult MS: A
Longitudinal Multimodal MRI Study to Explore the Substrates of the Different Clinical Courses —Ermelinda De Meo,
Alessandro Meani, Lucia Moiola, Bruno Colombo, Mariaemma Rodegher, Angelo Ghezzi, Giancarlo Comi, Andrea Falini, Massimo Filippi, Maria Rocca
P2.309 Chitinase 3-like 1 and
Neurofilament Light Chain Predict Pediatric Demyelination —Magnus Spangsberg Boesen, Poul Erik Hyldgaard Jensen, Melinda Magyari,
Peter Born, Peter Uldall, Morten Bjorn P2.298 Evaluation of new onset seizures Alfred Blinkenberg, Finn Sellebjerg
presenting to the Pediatric Emergency Department(ED). A quality improvement study based on the AAN, CNS and AES practice parameters (2010). —Nitish
Chourasia, Chritie Becu, Liang Zhu, Robert Lapus, Gretchen Von Allmen
P2.299 Cognitive Outcomes In Children With Infantile Spasms: Successful
Eva Chow, rasmus Kiehl, Timo Krings, Anne Bassett, Danielle Andrade
P2.285 STXBP1 is associated with bruxism in awake patients —Arezoo
Rezazadeh, Victor Lira, Alexandra Silberberg, Shelly Weiss, Elizabeth Donner, Maria Zak, Laura Bradbury, Muhammed Uddin, Stephen Scherer, O. Snead, Alfonso Fasano, Danielle Andrade
P2.286 Prevalence and Impact of
Consanguinity in Patients with Mesial Temporal Sclerosis in Saudi Population —
Khalid Alqadi, Saba Rammal, Ashwaq Alshahrani, Mosaab Alam, Saleh Baeesa, Youssef Al Said, Edward Cupler, Husam Kayyali
Prashant Jauhari, Biswaroop Chakrabarty, Vishal Sondhi, Shobha Sharma, Shefalli Gulati
Cases During 2015-2016 Zika Outbreak: A Cohort Study —Tabata De Alcantara, Angelle
Desiree LaBeaud, David Aronoff, Marcelo Rodrigues Zacarkim, Jessika Thais da Silva Maia, Kalyana E. Fernandes, Nilson Nogueira Mendes Neto
P2.302 Rectal Administration of
Vigabatrin Achieves Higher Plasma Concentration than Oral Administration. — Mohammad Hamed, Omar Hussein, Khalid Sawalha, Arun Asha Kalra
P2.303 Utilizing Quality Improvement
Monday
P2.306 The Spectrum of Myelopathies in Children: Beyond Idiopathic Transverse Myelitis —Laura Munoz-Arcos, Eliza Gordon-
Lipkin, Paula Barreras, Maria Jimena CastanedaValderrama, Maureen Mealy, Wendy Piedra, Olwen Murphy, Michael Levy, Daniel Becker, Scott Newsome, Carlos Pardo-Villamizar
P2.313 Autoimmune encephalitis in
Dunaway, Elena Mazzone, Amy Pasternak, Allan Glanzman, Richard Finkel, Basil Darras, Francesco Muntoni, Eugenio Mercuri, Darryl De Vivo, Kathie Bishop, Eugene Schneider, Frank Bennett, Richard Foster, Wildon Farwell
abobotulinumtoxinA (Dysport®) for lower limb spasticity: Pooled analysis of controlled clinical trials —Ann Tilton, Dennis Matthews,
Mark Gormley, Gustavo Suarez-Zambrano, Philippe Picaut, Mauricio Delgado
P2.324 Safety and Efficacy of
Nusinersen in Infants/Children with Spinal Muscular Atrophy (SMA): Part 1 of the Phase 2 EMBRACE Study —Perry Shieh, Gyula Acsadi, Wolfgang Mueller-Felber, Thomas Crawford, Randal Richardson, Nina Natarajan, Diana Castro, Sarah Gheuens, Ishir Bhan, Giulia Gambino, Peng Sun, Wildon Farwell, Sandra Reyna
Peter Riebling, Edward O’Mara, G. Elfring, Xiaohui Luo, Panayiota Trifillis, Joseph McIntosh, Claudio Santos, Julie Parsons, Perry Shieh, Susan Apkon, Craig Campbell, Craig McDonald
children: Clinical profile and outcome from a single tertiary care centre in India —Shefalli
P2.326 Pediatric Myasthenia Gravis
P2.314 Radiological Findings and
Rajanigandhi Hanumanthu, Nirav Sanghani, Shreya Shah, Nizar Souayah
Gulati, Vishal Sondhi, Biswaroop Chakrabarty, Prashant Jauhari, Rachana Dubey
Neurological Disorders in Microcephaly Cases Related to Zika Virus: A Cohort Study —Tabata De Alcantara, Jessika Thais da
Silva Maia, David Aronoff, Daniel Duarte Rolim, Marcelo Rodrigues Zacarkim, Angelle Desiree LaBeaud, Kalyana E. Fernandes, Nilson Nogueira Mendes Neto
After Vaccination in the United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. (1990-2017) —
P2.327 Evaluation of Childhood
Weakness: Utilization of a Web-Based Educational Tool childmuscleweakness. org —Ann Martin, Holly Peay, Jen Ely, Erin O’Rourke, Katherine Mathews
P2.328 Predicting Ambulatory Aid Needs attention and information processing speed with Disease Progression in Charcot-Mariein adolescents with multiple sclerosis —Shay Tooth Disease —Sindhu Ramchandren, Jacob P2.315 Gait variability is related to
Menascu, Alon Kalron, Lior Frid, Anat Achiron
Moore, Joseph Hornyak
P2.316 A Case of Cognitive and
P2.329 Design of a Phase 3 Trial to
Behavioral Decline leading to Onset of Pediatric Onset Multiple Sclerosis —Janet Elgallab, Leigh Charvet, Lauren Krupp
Evaluate the Long-Term Efficacy and Safety of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy —
P2.317 A Case Series of Acute Flaccid
Panayiota Trifillis, Peter Riebling, Edward O’Mara, Xiaohui Luo, Joseph McIntosh
Jayne Ness
P2.330 Assessment of Practice Patterns
Myelitis in Pediatric Patients —Lydia Marcus,
P2.318 Imaging of the Mechanisms
of Thalamic Damage in Pediatric Multiple Sclerosis —Ermelinda De Meo, Lucia Moiola,
Angelo Ghezzi, Pierangelo Veggiotti, Ruggero Capra, Giancarlo Comi, Andrea Falini, Massimo Filippi, Maria Rocca
and Knowledge of Pathophysiology for Spinal Muscular Atrophy Among Neurologists —John Maeglin, Thomas Finnegan
P2.331 Slope Analysis of 6-Minute
Walk Dstance as an Alternative Method to Determine Treatment Effect in Trials in Duchenne Muscular dystrophy —Panayiota
P2.319 Miller Fisher Syndrome in a Case Trifillis, Peter Riebling, Marcio Souza, Gary Elfring, of Identical Twins —Tayyba Anwar, Juma
Mbwana, Katie Kundrat, Anne Vasiliadis, William Suslovic, Elizabeth Wells, Diana Bharucha-Goebel
P2.320 Pediatric Acute Flaccid Myelitis: A Case Series —Alison Christy, Yoon-Jae Cho
138 2018 AAN Annual Meeting
in nusinersen-treated children with spinal muscular atrophy. —Jacqueline Montes, Sally
neurologic syndromes, intellectual disability, P2.325 Meta-Analysis of Deflazacort vs abnormal behavior and sleep related Prednisone/Prednisolone in Patients with problems in HIV infected children —Rajni Farmania, Rakesh Lodha, Biswaroop Chakrabarty, Duchenne Muscular Dystrophy —Basil Darras,
Pediatric Epilepsy: A Review Of Literature. — Pandey, S K Kabra, Shefalli Gulati
Strategies to Increase Continuous EEG Monitoring in Critically Ill Pediatric Patients P2.287 Refractory Status Epilepticus and with Persistent Encephalopathy Following Chronic Kidney Disease in a Large Pedigree Status Epilepticus —Asri Yuliati, Nina Laudato, Katherine Cashen, Amanda Weber Due to a Variant in the Mitochondrial Encoded tRNA Phenylalanine (MT-TF) P2.304 Expanding the clinical spectrum Gene —James Ellis, Katie Mayne, Carina of the rare epilepsy syndrome of Benign Imburgia, Russell Butterfield Infantile Focal Epilepsy with Midline Spikes P2.288 Analysis of 234 Epilepsy Genes (BIMSE) —Reema Butt, Jules Constantinou, Muhammad Salim Khan for Sequence and Copy Number Variants Using Next Generation Sequencing — P2.305 Drug-Resistant Epilepsy Zhenyuan Wang, Marc Meservey, Izabela Karbassi, and Neurodevelopmental Disabilities in Sat Dev Batish, Glen Maston, Michele McCarthy, Randomized Controlled Trials of Therapeutic Joseph Higgins Devices —Lydia Bernhardt, John Powers, Rory Petteys, Rosemary Powers P2.289 Genetic Testing has taken out Guesswork: Cases of Familial and Nonfamilial Benign Infantile Epilepsy Associated CHILD NEUROLOGY AND DEVELOPMENTAL NEUROLOGY: with PRRT2 gene mutations. —Yoshimi INFECTIOUS, INFLAMMATORY, AND Hisamoto, Sonam Verma, Joan Cracco, Radha AUTOIMMUNE DISORDERS Giridharan
P2.290 NA P2.291 NA P2.292 NA P2.293 NA P2.294 NA
P2.312 To determine the prevalence of
P2.301 Long-Term Prognostic Patterns In Prashant Jauhari, Savita Sapra, Atin Kumar, R M Kushal Naik, Susan McCallum, Ton DeGrauw
P2.322 Ambulatory function and fatigue
P2.310 CT Scan Findings in Microcephaly P2.323 Safety profile of
St-Onge, Nassima Addour, Roy Dudley, Jean-Pierre Treatment Response Is Beneficial Regardless P2.311 Use of Induction Immunotherapy Farmer, Jeffrey Atkinson, Chantal Poulin, Francois Of Etiology —Nonita Mittal, Miya Asato, Yoshimi Plus Rituximab for the Treatment of Pediatric Dubeau, Joel Lafond Lapalme, Bernard Rosenblatt, Opsoclonus-Myoclonus Syndrome —Colin Sogawa Steffen Albrecht, Jean-Baptiste Riviere, Myriam Srour Wilbur, Carmen Yea, christoph licht, Meredith P2.300 The clinical and Irwin, E. Ann Yeh P2.284 Characteristics of periventricular
electroencephalographic spectrum of ESES nodules in patients with 22q11. 2 deletion (Encephalopathy with status epilepticus in syndrome —Arezoo Rezazadeh, Eduard Bercovici, sleep) in Indian children —Priyanka Madaan,
CHILD NEUROLOGY AND DEVELOPMENTAL NEUROLOGY: NEUROMUSCULAR DISEASE
Xiaohui Luo, Joseph McIntosh, Stuart Peltz
P2.332 Tolerability of Eteplirsen for
Duchenne Muscular Dystrophy in the Youngest Reported Patient Treated With This Therapy —Sonam Bhalla, Arpita Lakhotia
P2.333 Cervical Puncture to Deliver
P2.334 A unique presentation of rapidly Nusinersen in Patients with Spinal Muscular fluctuating symptoms in a child diagnosed Atrophy and no Lumbar Access —Aravindhan with Congenital Myasthenic Syndrome due Veerapandiyan, Ria Pal, Stephen DAmbrosio, Iris to RAPSN mutation. —Ashutosh Kumar, Sheila Young, Katy Eichinger, Erin Collins, Per-Lennart Westesson, Jennifer Kwon, Emma Ciafaloni
g1 H
Asghar, Robert Kavanagh, Matthew Wicklund
P2.335 Focal Myositis of the Iliopsoas
in a Young Girl with Recurrent Symptoms: A Case Report —Stephanie Manberg, Saunder Bernes
P2.336 Unexpected Neuromuscular
Diagnoses from Chromosomal Microarrays —Rebecca Luke, Sumit Verma
P2.337 NA P2.338 NA
Epilepsy/Clinical Neurophysiology (EEG) ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P2.339 Seizure Risk From Intraoperative Motor Evoked Potential Stimulation —Viet
Nguyen, Breanna Sandoval, Brian Ahuja, Leslie Lee, S. Charles Cho, Scheherazade Le, Jaime Lopez
Albalawi, Khalid Alqadi, Saleh Baeesa, Khalil Kurdi, Disease patient: A Case Report —Alexis Hosam Al-Aradati, Edward Cupler, Youssef Al Said Taylor, Victor Gonzalez-Montoya
P2.344 Analyzing Phenotypes Using
Artificial Intelligence Tools in Subgroups of
P2.341 Long Term Effects of Vagal Nerve P2.343 EEG Cap Placement for Expedited Absence and Myoclonic Epilepsies —Reyna Stimulation on Seizure Control and Quality of
M. Duron, Carlos Arias, Iris Martinez, Christopher
masks undiagnosed epilepsy in a Parkinson’s
Escueta
Identification of Non-Convulsive Status Patterson, Julia Bailey, Miyabi Tanaka, Adriana P2.340 Mesial Temporal Sclerosis (MTS) Life —Justin Abraham, Antoaneta Balabanov Epilepticus —Jake McKay, Caitlin D’Souza, Ugur Ochoa, Aurelio Jara-Prado, Maria Alonso, Marco Undetected by MRI of the Brain —Miad Sener, Christopher Smelick, Anteneh Feyissa, Medina, Viet-Huong Nguyen, Antonio DelgadoP2.342 Unilateral deep brain stimulation William Tatum
MS MODIFIABLE RISK FACTORS
P2.345 Hypertension and heart
disease are independently associated with development of brain atrophy in multiple sclerosis patients. A 5-year longitudinal study —Dejan Jakimovski, Sirin Gandhi, Ivo Paunkoski, Niels Bergsland, Jesper Hagemeier, Deepa Ramasamy, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman, Robert Zivadinov
P2.353 Longer Sleep Duration is Linked
MS DIAGNOSIS, MIMICKERS, AND PHENOTYPES
Victoria Leavitt, Maria Petracca, Matilde Inglese, James Sumowski
P2.362 Sarcoidosis Presenting as
to Preserved Cortical Gray Matter Volume in Early MS —Michelle Fabian, Ilana Katz Sand,
P2.354 Risk Factors Associated with
Multiple Sclerosis in Bogotá, Colombia. —
Intramedullary Spinal Cord Lesions —Prateek Thatikunta, Jude Khatib, Joseph Baar
P2.363 When It’s Not Multiple Sclerosis:
Jaime Toro, Fabián Cortés, Camilo Diaz-Cruz, Saul Reyes, Maria Reyes-Mantilla, Alejandra Duque Ramirez, Jorge Patiño, Camilo Torres, Jorge Ríos, David Cuellar Giraldo
Progressive White Matter Lesions with Inflammation —Julia Bucklan, Mary Willis,
Allen-Philbey, Sebastian Suarez, Özlem Yildiz, Benjamin Turner, Sharmilee Gnanapavan, Klaus Schmierer, Monica Marta, Joela Mathews, Grace Anjorin, Freya Edwards, Cherry Jain, Gavin Giovannoni
Multiple Sclerosis Patients Compared to Controls. —Raffaella Umeton, Evdokia
Increased Mortality —Anja Thormann, Per
P2.347 Vitamin D and physical activity
P2.356 Fecal Microbial Transplantation
P2.346 The Impact of Socioeconomic
Yuebing Li MD
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
P2.372 Retinal Vasculopathy with
Cerebral Leukoencephalopathy (RVCL): A Rare Familial Mimic of Tumefactive Multiple Sclerosis (MS) —Asaff Harel, Jenelle Raynowska, Dhanashri Miskin, Bidyut Pramanik, Saeed Asiry, Todd Anderson, John Boockvar, Souhel Najjar
P2.373 An Extremely Aggressive case of Marburg’s Disease —Jose Avila-Ornelas, Laura Surillo Dahdah, Eduardo Labat, Gishlaine Alfonso,
P2.364 Comorbidity in Multiple Sclerosis Carmen Serrano, Franchesca Fiorito Torres Status on Treatment Choice in Patients with is associated with Diagnostic Delays and P2.355 The Gut Microbiome in Relapsing P2.374 Spectrum of Peripheral Facial Multiple Sclerosis. —Saul Reyes, Kimberley Eleftheriou, Simona Nedelcu, Lauren Hall, Ana Luisa Maldonado-Contreras, Doyle Ward, Beth McCormick, Carolina Ionete
Solberg Sorensen, Nils Koch-Henriksen, Bjarne Laursen, Melinda Magyari
P2.365 Population-Based Prospective
Cohort of RRMS Patients Who Declined or Delayed Disease-Modifying Therapy —
Abdulaziz Al Sultan, Helene Parpal, Dina Lavorato, Jamie Greenfield, Luanne Metz
in multiple sclerosis —Florian Deisenhammer,
in Multiple Sclerosis: Trial design. —Ana
Angelika Bauer, Ivan Lechner
Cristina Dos Santos, Marcelo Kremenchutzky
P2.348 Depression Severity Among
P2.357 Gut microbiota and metagenomic P2.366 Assessment of Relative
Multiple Sclerosis Patients In Saudi ArabiaCross Sectional Study —Adel Ali Alhazzani,
P2.349 Vitamin B12 and its impact on Multiple Sclerosis Type and Severity —
Shymaa Hussain, Omar Salih, Fahad Ali, Reem Bunyan, Talal Harbi, Eman Nassim Ali
P2.350 Cesarean delivery and artificial
lactation are associated with an earlier age of disease onset in multiple sclerosis — Vittorio Martinelli, Gloria Dalla Costa, Marzia Romeo, Francesca Sangalli, Bruno Colombo, Lucia Moiola, Marta Radaelli, Federica Esposito, Giancarlo Comi
P2.351 Distinct Effects of Obesity and Vitamin D on Risk of Multiple Sclerosis: A Mendelian Randomization Study —Adil
Harroud, John A. Morris, Despoina Manousaki, Vincenzo Forgetta, Ruth Mitchell, George Davey Smith, Stephen Sawcer, J. Brent Richards
P2.352 Vitamin D Levels and Clinical
and OCT measures in Progressive Multiple Sclerosis —Justin Abbatemarco, Robert Bermel, Hong Li, Robert Fox, Daniel Ontaneda
Simona Rolla, Ilario Ferrocino, Valentina Bardina, Manfredi Ferraro, Alessandra Cianflone, Roberta Lanzillo, Stefania De Mercanti, Luca Cocolin, Marinella Clerico
P2.358 A Paleolithic Diet-Based
Intervention Decreases Multiple Sclerosis Fatigue via Lipid Profile Changes —Murali
Ramanathan, Kelly Fellows, Terry Wahls, Richard Browne, Babita Bisht, Linda Snetselaar, Bianca Weinstock-Guttman
P2.359 Stress-induced Brain Activity,
Brain Atrophy, and Clinical Disability in Multiple Sclerosis —Lil-Antonia Meyer-Arndt,
Martin Weygandt, Janina Behrens, Katharina Wakonig, Judith Bellmann-Strobl, Kerstin Ritter, Michael Scheel, Alexander Brandt, Stefan Hetzer, Stefan Gold, John Dylan Haynes, Friedemann Paul
P2.360 Case Series of Four High School Football Players with Multiple Sclerosis —
Cynthia Wang, Lana Harder, Benjamin Greenberg
P2.361 Nutrition in the First Year
MS EPIDEMIOLOGY AND GENETICS
P2.375 Impact of age at relapse on
recovery: An EDSS-recovery model for clinical trials —Burcu Zeydan, Brittani Conway, Elizabeth Atkinson, Carmen Castrillo-Viguera,
Importance of Disease Modifying Treatment Orhun Kantarci (DMT) Attributes in Multiple Sclerosis (MS) P2.376 Predictors of Vocational Status Patients —Tobias Sejbaek, Mette Bøgelund, Jens Among Persons with Multiple Sclerosis — Leander, Klaus Madsen
P2.367 Late Onset Fabry Disease: A
Mimicker of CNS Demyelinating Disease — Subhendu Rath, Ninad Desai, Lucas Meira Benchaya, Matthew Imperioli
P2.368 The phenotype of Argentinean Multiple Sclerosis patients is similar to Multiple Sclerosis patients from other regions and has remained stable over the past decade. —Mariano Marrodan, Negrotto Laura, Mauricio Farez, Jorge Correale
Sarah Morrow, Dhwanil Bhatty, Mervin Blair, Swati Mehta, Sascha Gill
P2.377 Relevance of Age and
Cerebrospinal Fluid Measures in Multiple Sclerosis associated with seizures —Shitiz
Sriwastava, Kalyan Yarraguntla, Maysaa Basha, Rohit Marawar, Deepti Zutshi, Evanthia Bernitsas
P2.378 Bone Microarchitecture and Bone Mineral Density in Multiple Sclerosis —Anna Olsson, Annette Bang Oturai, Helle Soendergaard, Finn Sellebjerg, Peter Oturai
P2.369 Impact of Gender on 30-day
P2.379 Impact of multiple comorbidities Readmission After Primary Admissions on EDSS at presentation in patients with for Multiple Sclerosis: A Nationwide multiple sclerosis: A cross-sectional study. — Readmission Database Analysis —Smit Patel, Faisal Alsallom, Sophia Woodson, Farren Briggs, Rupak Desai, Sandeep Singh, Upenkumar Patel, Alessandro Serra, Hesham Abboud Neel Patel, Shubhi Jain, Ninad Desai, Tapan Mehta
P2.370 Residual disability of acute
severe multiple sclerosis relapses —Anat Following the Diagnosis of Multiple Achiron, Shay Menascu, Ida Sarova-Pinhas, David Sclerosis —Yujie Wang, Kevin Alschuler, Annette Magalashvili, Mark Dolev, Michael Gurevich Wundes, Gloria Von Geldern
Jorge Kattah
P2.380 Estimated prevalence of
secondary progressive multiple sclerosis in the USA and Europe: Results from a systematic literature search —Vivek Khurana, Harsh Sharma, Jennie Medin
P2.371 Clinical and Immunologic
P2.381 Erdheim-Chester Disease in Characterization of MRI-Defined Phenotypes the Brainstem Mimicking Tumefactive in Multiple Sclerosis: A Longitudinal Study — Demyelination. —Maria Prieto Eibl, Javier Christopher Hemond, Brian Healy, Shahamat Gonzalez Tauhid, Maria Antonietta Mazzola, Roopali Ghandi, Howard Weiner, Rohit Bakshi
AAN.com/view/AM18 139
Monday
Mohammed Alqahtani, Hassan Ogran, Osamah Abuhawi, Abdulrahman Asiri, Ali Al-hanash, abdullmgeed Asiri, Reem Alqahtany, Adel Alfaifi, Mohannad Assiri
diversity in Clinical Isolated Syndrome —
Involvement in Central Demyelinating Diseases —Elias Samaha, Oscar Mancera Páez,
POSTER SESSIONS
POSTER SESSION II
G
P2.382 Differential Expression of
P2.393 Predictors of Conversion to Alternative Splicing Variants in Individuals Secondary Progressive Multiple Sclerosis in with Relapsing-Remitting Multiple Patients With Relapsing-Remitting Multiple Sclerosis —Michael Hecker, Annelen Rüge, Nina Sclerosis —Davorka Tomic, Ludwig Kappos, Boxberger, Brit Fitzner, Dirk Koczan, Ina Schroder, Hans-Jurgen Thiesen, Uwe Zettl
Daniela Piani Meier, Dieter Haering, Rolf Meinert, Gavin Giovannoni, Tanuja Chitnis
P2.383 Development of Multiple
P2.394 Predicting Physical and Mental
Sclerosis relapse flare after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Study, [1987-2017]. — Moamina Fakhera Eddin, Janaki Patel, Abdul Rahman Alchaki, Nizar Souayah
P2.384 Employment Situation in
Brazilian Patients Diagnosed with Multiple Sclerosis —Denis Bichuetti, Carolina Martines
P2.395 New versus old: Implications of diagnostic criteria for Relapsing Remitting Multiple Sclerosis —Nuala McNicholas,
Estrutti, Gustavo San Martin E Cardoso, Enedina Oliveira
P2.385 Impact of Age on 30-day
P2.396 Familial Multiple Sclerosis:
Rupak Desai, Upenkumar Patel, Sandeep Singh, Neel Patel, Shubhi Jain, Allan Zhang, Ninad Desai
P2.386 The Prevalence and Special
Characteristic of Multiple Sclerosis that Begins in Older Adults —Gabriel Valero López,
Ana Esther Baidez Guerrero, Jose Diaz Perez, Luna Fuentes Rumi, Jose Maria Cabrera Maqueda, Rocio Hernandez Clares, Ester Carreon Guarnizo, Jose Meca Lallana
P2.387 Does Co-morbidity with Familial
An Epidemiological Study in Pontevedra, Spain. —Ana Rodriguez Regal, Luis Anibarro
Garcia, Macarena Soto Dopazo, María del Campo Amigo Jorrín
P2.397 Increased Risk of Ischemic
Stroke Associated with Untreated Multiple Sclerosis: A Nationwide Case-Control Population-Based Study. —Asad Ikram,
Christopher Calder, Fares Qeadan, Dinesh Jillella, Piotr Bzdyra, Maryam Zulfiqar, Joel NunezGonzalez, Tobias Kulik, Corey Ford, Atif Zafar
P2.388 Protective role of Multiple
Sclerosis in Stroke; Analysis of a large national data base —Maryam Zulfiqar, Fares
Qeadan, Christopher Calder, Asad Ikram, Dinesh Jillella, Piotr Bzdyra, Corey Ford, Atif Zafar
MS AND CNS INFLAMMATORY with Demyelination, Brain Atrophy and DISEASE: QUALITY OF LIFE, SYMPTOMS, AND SYMPTOMATIC Motor Impairment in a Model of Multiple Sclerosis —Maria Karamita, Richard Nicholas, Lili THERAPY II Kokoti, Sophia Rizou, Dimos Dimitrios Mitsikostas, Vassilis Gorgoulis, Lesley Probert, Dimitrios Papadopoulos
Zhang, Nazanin Kiapour, Sahil Kapoor, Joseph Merrill, Yongjuan Xia, Woomi Ban, Stephanie Cohen, Bentley Midkiff, Yen-Yu Ian Shih, Silva Markovic Plese
Care and Research in Multiple Sclerosis — Fox, Lori Mayer, Michael Racke
Neutrophils’ Migration to CNS in Passive Transfer RREAE —Nazanin Kiapour, Sahil Kapoor, Xin Zhang, Silva Markovic Plese
P2.408 Teriflunomide (Aubagio®)
decreases microglial density in Theiler’s Murine Encephalomyelitis Virus model of demyelination: Histological approach in combination with neuroimaging —Suyog
Pol, Claire Modica, Ferdinand Schweser, Michele Sveinsson, Michelle Sudyn, Nicola Bertolino, Marilena Preda, Michael Dwyer, Jesper Hagemeier, Danielle Siebert, Robert Zivadinov
activity-regulated oligodendrogenesis — Anna Geraghty, Michelle Monje
P2.410 Effect of Subcutaneous vs
P2.399 Long-term disability outcomes in Intravenous Chronic Treatment with an relapsing-remitting multiple sclerosis: A 10- Anti-CD20 Antibody on B-, T- and Myeloid year follow-up study —Jelena Drulovic, Tatjana Lymphocyte Subsets in Blood, Lymph Nodes and Spleen of C57BL/6 Mice —Anna Schubart, Pekmezovic, Sarlota Mesaros, Irena Dujmovic Basuroski, Vanja Martinovic, Jovana Ivanovic, Kerstin Hellwig
P2.415 Neurocognitive Correlates of
Impaired Perceptual Decision-Making in MS and their Link to Quality of Life —Martin
Weygandt, Janina Behrens, Jelena Brasanac, Eveline Soeder, Katharina Wakonig, Kerstin Ritter, Lil-Antonia Meyer-Arndt, Alexander Brandt, Judith Bellmann-Strobl, Stefan Gold, John Dylan Haynes, Friedemann Paul
P2.416 Treatment satisfaction and illness perception in MS patients —Jarrett Leech, Stefan Sillau, Valdez Brooke, Timothy Vollmer,
P2.407 IL-11-stimulated Encephalitogenic Enrique Alvarez, Luis Medina CD4+ Cells Induce Aggressive RREAE, P2.417 Pain Network and Mediated via Th17, CD8+, CD19+ Cells and
P2.398 The North American Registry for P2.409 BDNF is necessary for neuronal
Mediterranean Fever change the course of Anne Cross, Kottil Rammohan, David Jones, June Multiple Sclerosis? —Aksel Siva, Melih Tutuncu, Halper, Sara Murphy, Lisa Patton Perry, Edward Ugur Uygunoglu, Mustafa Erdogan, Serdal Ugurlu, Bihter Ozcan, Mesude Ozerden, Sabahattin Saip, Ayse Altintas, Emire Seyahi, Huri Ozdogan
P2.405 Cellular Senescence Correlates
Disability in Patients with Multiple Sclerosis: P2.406 IL-11 antagonist suppresses A Longitudinal Analysis of Electronic Health Th17 cells-mediated neuroinflammation and demyelination in a mouse model of Records. —Farren Briggs, Nicholas Thompson, Devon Conway relapsing-remitting multiple sclerosis —Xin
Andrew Lockhart, Siew Mei Yap, Karen O’Connell, Niall Tubridy, Michael Hutchinson, Christopher McGuigan
Readmission After Primary Admission for Multiple Sclerosis: A Nationwide Readmission Databse Analysis —Smit Patel,
Monday, April 23 11:30 a.m.–7:00 p.m.
Gaelle Elain, Cindy Schmid, Julien Perdoux, Catherine Huck, David Leppert, Anis Mir, Gisbert Weckbecker
Neuropsychological Profile in Multiple Sclerosis and Migraine Patients —Claudio
Gobbi, Emanuele Pravatà, Gianna Riccitelli, Chiara Zecca
P2.418 Neuroanatomical Correlates of
Latent Variables Speed and Memory in Early Multiple Sclerosis —Ilena George, Christian Habeck, Christina Lewis, Gabrielle Pelle, Victoria Leavitt, James Sumowski
P2.419 Exploring Cannabis use by
Patients with Multiple Sclerosis in a state where Cannabis is legal —Laura J Weinkle, Ian Shelton, Stefan Sillau, Christopher Domen, Kavita Nair, Enrique Alvarez
P2.420 Screening of cognitive
impairment in patients with multiple sclerosis (MS): The BICAMS short version for patient-centered care in small neurological institutions —Iris Katharina Penner, Melanie Filser, Alina Renner, Sebastian Ullrich, Chrstoph Lassek, Sharon Baetge
P2.421 A new electronic and brief
Monday
neuropsychological scale to detect cognitive impairment (CI) in patients with multiple P2.389 A Whole-Exome Sequencing Discontinuing Disease Modifying Therapies sclerosis (MS): Validation study of the MSSigns and Synergism of the Combination Study In Multiple Sclerosis Multiplex in the NARCOMS Registry —Marisa McGinley, COG-e scale —Jose Meca Lallana, Jose Maria Ponesimod-dimethyl Fumarate in Rat Models Philip Cola, Robert Fox, Deborah Miller Families —Elisabetta Mascia, Andrea Zauli, Prieto Gonzalez, Isabel Jimenez Martín, Judith of Multiple Sclerosis —Laetitia Pouzol, Paul Clara Guaschino, Melissa Sorosina, Silvia Santoro, Jimenez Veiga, Rafael Carles Diez, Francisco Javier Brian, Martine Clozel Donatella Biancolini, Silvia Bonfiglio, Dejan MS ANIMAL MODELS Olascoaga Urtaza, Gabriel Valero López, Rocio Lazarevic, Giovanni Meola, Vittorio Martinelli, Hernandez-Clares, Ester Carreon Guarnizo, Ioana P2.412 Cerebrospinal Fluid Derived Giovanni Tonon, Giancarlo Comi, Federica Esposito, P2.401 Astrocyte Transciptomics in Croitoru, Eva Costa Arpin, Maria cerdan, Andone from Primary Progressive MS Delays EAE Lead to Cholesterol Homeostasis as a Filippo Martinelli Boneschi Sistiaga Berrondo Remyelination after Lysolecithin-induced New Treatment Target —Noriko Itoh, Yuichiro Demyelination —Nathan Kung, Serena P2.390 The Saudi Arabian National P2.422 Effects of Live-Online Education Itoh, Alessia Tassoni, Michael Sofroniew, Rhonda Shimshak, Jamie Wong, Saud Sadiq Multiple Sclerosis Registry (NMSR): Initial on Multiple Sclerosis Disease Management: Voskuhl Results Saudi MS Registry Study Changes in Patient Experience, Clinical P2.413 Dietary Conjugated Linoleic P2.402 Longitudinal Diffusion Group* —Mohammed Al-Jumah, Reem Bunyan, Practice, Provider Knowledge and Acid Supplementation Modulates CNS Tensor Imaging in Theiler’s Murine Hessa Alotaibi, Edward Cupler, S. Ishak, S. Competence —Anne Roc, Wendy Turell, Patricia Autoimmunity —Ann-Katrin Fleck, Stephanie Encephalomyelitis Virus Driven Mouse Shami, Abid Kareem, Mamdouh Kalakatawi, Ghadah Altowaijri, Mousa Almejally, Hussein Al Gahtani, Saad Alrajeh, Ali Al-Mubarak, Sadaga Alawi, Shireen Al-Qureshi, Abdulrahman Almalki, Adel Alhazzani, A.M. Noor, I. Althubaiti, Nasser Alzahrani, Jameela Saeedi
P2.391 Demyelination and
Neurodegeneration along the Visual Pathway are more prominent in Secondary Progressive than Primary Progressive Multiple Sclerosis. —Simone Guerrieri, Marco pisa, Giovanni Di Maggio, Lucia Moiola, Vittorio Martinelli, Giancarlo Comi, Letizia Leocani
P2.392 Regional thalamic volumes
preferentially correlate with extra-thalamic white matter injury and clinical disability in multiple sclerosis subtypes —Kedar Mahajan, Kunio Nakamura, Jeffrey Cohen, Bruce Trapp, Daniel Ontaneda
140 2018 AAN Annual Meeting
P2.400 Patient Perspectives on
P2.411 Complete Resolution of Clinical
Hucke, Marvin Hartwig, Flavio Teipel, Martin Herold, Kerstin Berer, Marie Liebmann, Ivan Kuzmanov, Berit Grützke, Angelos Sagredos, Venkatpavanni Punugu, Michelle Sudyn, Ferdinand Maria Eveslage, Catharina Groß, Gurumoorthy Schweser, Claire Modica, Nicola Bertolino, Krishnamoorthy, Ulrich Dobrindt, Tanja Kuhlmann, Marilena Preda, Michael Dwyer, Robert Zivadinov Heinz Wiendl, Luisa Klotz
Model of MS Reveals White Matter Change —Ely Cuberos Paredes, Suyog Pol,
P2.403 Interaction of Normal and
Antineuronal IgGs with Neurons in Rat Brain Slice Cultures: Comparison of IgG Uptake, Clearance, Intraneuronal Binding to Target Antigens, and Production of Neuronal Death —John Greenlee, Susan Clawson, Kenneth Hill, Blair Wood, Suzanne Liu, Stacey Clardy, Noel Carlson
P2.404 Estrogen Receptor β Ligand
Acts on Two Pathways Within the CNS to Mediate Neuroprotection in the MS Model —Roy Kim, Darian Mangu, Noriko Itoh, Rhonda Voskuhl
P2.414 Passive transfer of human
aquaporin-4 IgG autoantibodies causes complement-independent spinal cord immunopathologies in mice —Koon Ho Chan, Kevin Leung Wah Yick
Coyle, Fred Lublin
P2.423 Cognitive reserve is consistently
related to cognitive performance in Multiple Sclerosis —Alvino Bisecco, Gabriella Santangelo, Luigi Trojano, Rosaria Sacco, Mattia Siciliano, Alessandro d’Ambrosio, Marida Della Corte, Luigi Lavorgna, Simona Bonavita, Gioacchino Tedeschi, Antonio Gallo
P2.424 Impact of Multiple Sclerosis
on Employment and its Association with Anxiety, Depression, Fatigue and Sleep Disorders —Junior Carnero, Pablo Lopez, María Balbuena Aguirre, Veronica Tkachuk
P2.425 NA P2.426 NA P2.427 NA P2.428 NA
NEUROPATHY II
I
P2.429 Skin coldness and painful cold:
P2.444 Novel Mutation in KIF5A
Causing Hereditary Spastic Paraplegia with Axonal Sensorimotor Neuropathy —Mathieu
The common symptom in patients with Cuchanski, Kelly Baldwin clinically suspected small fiber neuropathy in Korea —Eun Bin Cho, Jin Myoung Seok, Ki-Jong P2.445 Eosinophilic Vasculitic Neuropathy As A Presentation Of ChurgPark, Ju-Hong Min, Bum Chun Suh, Byoung-Joon Strauss Syndrome —Sandeep Devarapalli, Kim
P2.457 Smart Somatotopic Quantitative Sensory Testing findings in hATTR with Polyneuropathy —Marcus Vinicius Pinto, Linde
Gove, Brian McCauley, P. James B. Dyck, Elizabeth Ackermann, Marcia Waddington Cruz, Peter Dyck
P2.468 Functional neurological disorders in Parkinson disease —Benjamin Wissel
P2.469 Ghost in the Machine: Historical
P2.430 Is There A Relationship Between B. Dyck Exacerbated Diabetic Peripheral Neuropathy And Metformin? —Mohammed El-Sherif, Manal P2.446 Outcome comparison of
Aspects of Irreversible Brain Injury and Brain hereditary neuropathy —Ernesto Alonso-Labori, Death — Yi Tong Mazen Dimachkie, Omar Jawdat, Jeffrey Statland, P2.470 Discovery of novel recessive Tekalign Burka, Anai Hamasaki, Richard Barohn, Melanie Glenn, Laura Herbelin, Melissa Currence, genes in a consanguineous cohort using genotype-phenotype correlations —Kirsten Bhavana Sharma, Constantine Farmakidis, Duaa
P2.431 Brachial plexopathy after
P2.459 Correlation of supranormal
Hashem, Abdelfattah Nassar, Ahmed Esmael
influenza vaccination in adults in the USA. A report from the CDC/FDA Vaccine Adverse Event Reporting System (1990-2017) — Shreya Shah, Nirav Sanghani, Rajanigandhi Hanumanthu, Nizar Souayah
P2.432 Neuropathy with Dysarthria and Ophthalmoparesis —Tekalign Burka, Mamatha Pasnoor, Omar Jawdat, Melanie Glenn, Duaa Jabari
P2.433 Use of Intravenous
Immunoglobulin in Small Fiber Neuropathy associated with FGFR3 —Ajal Dave, Jonathan Smith
Pariwat Thaisetthawatkul, Rana Zabad, P. James
mechanically ventilated Guillain-Barre Syndrome versus Myasthenia Gravis in US Hospitals —Anantha Vellipuram, Rakesh
P2.458 Genetics in patients with
Jabari, Mamatha Pasnoor, Jasti Swetha
Khatri, Mohtashim Qureshi, Ihtesham Qureshi, Mohammad-Rauf Afzal, Paisith Piriyawat, Darine Kassar, Alberto Maud, Salvador Cruz-Flores, Gustavo Rodriguez
sensory nerve action potential amplitudes (supraSNAPs) with sensory nerve “hyperexcitable” symptoms —Philip Tipton,
P2.447 Guillain-Barre Syndrome as a
P2.460 The Role of Needle
Eduardo De Sousa
Laughlin
Rare Initial Presentation of Systemic Lupus Erythematosus. —Swathy Chandrashekhar,
P2.448 Rapidly Progressive POEMS
Syndrome with Absent M protein in Serum or Urine, Normal Bone Survey, and Normal Non-targeted Bone Marrow Biopsy —Payam Soltanzadeh, Jason Valent
Martin
Devon Rubin
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
Electromyography in the Evaluation of Carpal Tunnel Syndrome —Cory Kogelschatz, Ruple
P2.461 Morphometry of dorsal
rootlets using immunofluorescent confocal microscopy —Adam Loavenbruck, Samuel Roiko, Brian McAdams, Frank Symons
P2.462 Utility of Neuromuscular
P2.434 Isolated external
P2.449 Modifying Hyperglycemic
Porambo, Kaye Sedarsky, Emily Elliott, Brett Theeler, Jonathan Smith
Marca, Hiroshi Takashima, Pilar Mazzetti Soler, Mario Cornejo Olivas
Omer Suhaib, Gozde Demiralp, Eduardo De Sousa
(AMAN) presenting with truncal and appendicular ataxia —Ashmanie Mahatoo,
Bhadola, Kate Daniello
Ultrasound in the Evaluation of Proximal ophthalmoplegia associated with IgG Median Neuropathies: A Case Series —Elina Peripheral Nerve Injury —Mark Stecker anti-GQ1b antibody —Sunhee Kim, Muhammad Zakin, Susan Shin P2.450 Rare Case of Ulnar Neuropathy — Rizwan Husain, Lawrence Zeidman P2.463 Why do we repeat Anai Hamasaki, Mazen Dimachkie, Mamatha P2.435 A case of remission from Pasnoor, Melanie Glenn, Richard Barohn, Omar electrodiagnostic studies? And, does it make multifocal motor neuropathy following Jawdat, Laura Herbelin, Brian Everist, Duaa Jabari a difference? —Shivakrishna Kovi, David Avila rituximab —Natalia Gonzalez, Vern Juel, Sasha P2.451 Ustekinumab related CIDP in a P2.464 Ultrasound Guided Open Muscle Zivkovic patient with psoriatic arthritis —Gamaleldin Biopsy —Shumaila Sultan, Kymberly Gyure, P2.436 Late Onset TTR-related Familial Osman, Kavit Shah, Muhammad Salim Khan, Kara Cheryl Smith Steijlen, Naganand Sripathi Amyloid Polyneuropathy (FAP) in Two P2.465 Clinic and Lab Based Respiratory Patients with Acquired Demyelinating P2.452 Proximal Motor Sensory Testing in Patients with Myasthenia Features —Nazila Rad, Said Beydoun Hereditary Neuropathy (HMSN-P) in a Gravis —Hans Katzberg, Carolina Barnett Tapia, Peruvian Family with Japanese Ancestry — Vera Bril P2.437 A Novel Report of NivolumabElison Sarapura Castro, Darko Quispe, Maryenela Induced Parsonage-Turner Syndrome P2.466 Comparison of Train of Four with Associated with Hourglass-like Constriction Illanes-Manrique, Karina Milla-Neyra, Miguel Repetitive Nerve Stimulation in the ICU — of the Anterior Interosseous Nerve —Michael Inca-Martinez, Erick Figueroa-Ildefonso, Victoria
P2.438 Acute Intermittent Porphyria: Macedo, Raisa Saron Murari, Barbara Diniz, Pedro Macedo, Joao Marcos Ferreira, Guilherme Torezani, Karoline Medeiros, Leonardo Modenezi, Fabio Martins, Leonardo Araujo, Eduardo Davidovich, Camila Pupe, Osvaldo Nascimento
P2.439 Ganglioside Antibodies in
Monday
Sometimes DIfficult to Diagnose —Yuri
P2.467 Should We Refer Patients with P2.453 Acute Motor Axonal Neuropathy Pain for Electromyography? —Shivkumar Karan Topiwala, Amre Nouh, Yan Zhang, Isaac Silverman, Annie Daniel
NEUROMUSCULAR DIAGNOSTICS, GENETICS, AND BIOMARKERS
Acute Inflammatory Demyelinating P2.454 Needle ImpedancePolyradiculoneuropathy (AIDP) and its Electromyography (I-EMG): A New Technique Variants —Mithila Fadia, Ratna Bhavaraju-Sanka for the Electrodiagnostic Laboratory —
P2.440 Cognitive Biases at Bedside
Resulting in Diagnostic Error of GuillainBarré Syndrome —Rohit Gummi, Chakrapani
Pathikonda, Pradeep Bollu, Fang Zhang, Spurthi Surpur, Raghav Govindarajan
P2.441 Heterozygous Mutations of
SH3TC2 as a Cause of HNPP —Devin Prior, Victoria Lawson
P2.442 Reduction in Idiopathic
Peripheral Neuropathy Diagnoses Using a Comprehensive EMR-based Laboratory Order Set —Fang Bai, Martha Cruz, Dilip Pandey, Lawrence Zeidman
P2.443 Brachial Plexopathy Post
Seward Rutkove, Hyeuknam Kwon, Benjamin Sanchez
P2.455 Feasibility and Validation of
Modified Oculobulbar Facial Respiratory Score (mOBFRS) in Amyotrophic Lateral Sclerosis —Marie Wencel, Nadia Araujo, Lishi
Zhang, Eileen Medina, Tahseen Mozaffar, Namita Goyal
P2.456 A New Method to Detect
Potential Causative Genes for Spastic Paraplegia Utilizing Aggregate Data of Whole Exome Sequencing —Masaki Tanaka, Hiroyuki Ishiura, Jun Mitsui, Kishin Koh, Yuta Ichinose, Yoshihisa Takiyama, Shoji Tsuji
Transcatheter Arterial Chemoembolization — Kavneet Kaur, Anila Thomas, Jin Li
AAN.com/view/AM18 141
POSTER SESSIONS
POSTER SESSION III G GRADUATE MEDICAL EDUCATION: ASSESSMENT AND CURRICULAR DESIGN II
A
P3.001 Effectiveness of Blended
Learning for Resident Education in Neurology: Experience from Movement Disorder Course —Danish Bhatti, John Bertoni, Faye Haggar, Linda Love, Ryan Brennan, Peggy Moore, Sachin Kedar, Diego Torres-Russotto
P3.002 Predictors of Strong Performance during Neurology Residency and Beyond — Deborah Bradshaw, Cheryl Roe, Mary Phelan
P3.003 Graduation competencies: What
Tuesday, April 24 11:30 a.m.–7:00 p.m.
P3.010 Developing a Successful
Wellness Program for Child Neurology Residents —Aimee Sato, Sandra Cushner
P3.011 Assessing and Enhancing
Neurology Resident Education on Interpersonal Communication and Professionalism —Arielle Kurzweil, Ariane
091–172
Lewis, Perrin Pleninger, Sara Rostanski, Aaron Nelson, Koto Ishida, Laura Balcer, Steven Galetta
P3.012 Improving Resilience Among Neurology Residents —Adrienne Keener, Brenda Bursch, PhD
Gewirtz, Mercedes Jacobson, Sarah Zubkov, Ivan Cuesta Isabel, Jennifer Haynes
Iqbal, Muhammad Taimur Malik
P3.004 Impact of a Novel Clinic Block
Licensure Actions Involving ABPN Diplomates —Larry Faulkner, Dorthea Juul
Laura Donovan, Barbara Almeida, Christina Ulane
P3.005 Evaluation of Resident Physician Exposure and Patient Access in Outpatient Continuity Clinic —Neeraj Singh, Philip Yeung
P3.006 Implementing a Formal
Faculty-Resident Feedback Protocol for NYU Neurology Residency —Scott Grossman, Alexandra Lloyd-Smith, Cen Zhang, Harold Weinberg, Arielle Kurzweil
P3.007 The development of the National In-training examination for Canadian Pediatric Neurology Residents (NITECaP) —
P3.014 Neurologists in Trouble:
P3.008 Autonomy and Praise from
Co-Residents May Protect Against Burnout in Neurology Residents —Jeffrey Ratliff,
Ted Weissfeld, Christopher Skidmore, Andrew Southerland, Cormac O’Donovan, Joseph Carrera, Vicki Shanker
P3.009 Residents’ Perceptions of
Tuesday
Inappropriate Consults: Expectations of Expertise Among Neurology and Medicine Residents as a Barrier to Interdisciplinary Collaboration —Stephen Krieger, Erik Bortnick
142 2018 AAN Annual Meeting
C
ePosters
037–084
B
b1 g1 339–344 a1 ePosters
Poster Discussion
027–036
A
001–026
B. Movement Disorders: 037 – 084
P3.016 Code Stroke Simulation Training
Benefits Junior Neurology Residents —Linda Wendell, Michael Reznik, David Lindquist, Ali Saad, Jonathan Cahill, Tina Burton, Shawna Cutting, Brian Mac Grory, Ali Mahta, Matthew Siket, Shadi Yaghi, Mahesh Jayaraman, Bradford Thompson, Karen Furie
Neurology Residency In-Service Training Examination (RITE) Scores —Alyssa-Rae
259–294
295–338
H
G
345–428
429–480
A. Research Methodology, Education, and History: 001 – 026
P3.015 Resident Education through Adult Shoirah, Achillefs Ntranos, Rachel Brandstadter, Elisha Medina-Gallagher, Yangbo Liu, Jamie Kwan, Stephen Krieger
I
F
Poster Session 3 a1. Aging and Dementia Poster Discussion Session: 027 – 036
Learning: Two Years of Experience —Hazem
E
201–258
GRADUATE MEDICAL EDUCATION: NOVEL FORMATS
Sunita Venkateswaran, Serena Orr, Timothy Wood, P3.017 Intensive Neuroanatomy Boot Debra Pugh, Susan Humphrey-Murto, David Callen Camp Curriculum Demonstrates Improved
GRADUATE MEDICAL EDUCATION: BURNOUT AND PROFESSIONALISM
173–200
085–090
P3.013 Burnout, resident satisfaction, does a future Neurology resident need and well-being among neurology residents to know at medical school graduation to prepare for Neurology residency? —Alexandra with different service models —Muhammad
Schedule on Resident Satisfaction and Continuity of Care in the adult neurology resident clinic at Columbia University Medical Center —Andrew Taylor, William Roth,
D
Weinstein, James Reese, Amy Kao
b1. General Neurology ePoster Session: 085 – 090 C. D. E. F. G.
Headache; Practice, Policy, and Ethics: 091 – 172 Aging, Dementia, Cognitive, and Behavioral Neurology: 173 – 200 Cerebrovascular Disease and Interventional Neurology: 201 – 258 Epilepsy/Clinical Neurophysiology (EEG): 259 – 294 Neuro Trauma, Critical Care, and Sports Neurology; Child Neurology and Developmental Neurology: 295 – 338
g1. Research Methodology ePoster Session: 339 – 344 H. MS and CNS Inflammatory Disease: 345 – 428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429 – 480
Novroski, Kelly Baldwin, Cynthia Correll, Anthony Noto, David Avila
P3.018 Effectiveness of a Video-Based
P3.020 Flipped Classroom: Applications P3.023 Feasibility of Online Resident Lecture (VBL) EEG Curriculum for Incoming in Teaching EEG —Alyssa-Rae Novroski, Cynthia Education in Pakistan with international Neurology Residents —Rachael Benson, Eliezer Correll collaborations: Implementing Blended Sternberg, Jeremy Moeller, Michelle Bell learning —Danish Bhatti, Nadir Syed, P3.021 Increasing Knowledge and Muhammad Javed, Muhammad Ilyas, John P3.019 Medical Simulation as the Comfortability in the Management of Standard for Acute Stroke Education: Review Pediatric Status Epilepticus —Jeffrey Kornitzer, Bertoni, Arsalan Ahmad of the Literature and Recommendations Jessica Tu P3.024 NA for Future Implementation —Frances Chow, P3.025 NA P3.022 Stroke Code Simulation Has Nerses Sanossian, Gene Sung, Roy Poblete Sustained Benefit on Neurology Resident P3.026 NA Education and Preparedness for Stroke Call —Catherine Legault, Nirali Vora
Aging and Dementia Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.
a1
Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 5:30p.m.-7:00 p.m. Data Blitz: 11:45 a.m.–11:50 a.m.
P3.027 Plasma Biomarkers in Early
Neurodegenerative Disease Stages —Fanny
Elahi, Kaitlin Casaletto, Adam Staffaroni, John Neuhaus, Yann Cobigo, Emily Fox, Samantha Walters, Marie Altendahl, Ryan Fitch, Anna Karydas, Jason Hinman, Charles DeCarli, Adam Boxer, Gil Rabinovici, Howard Rosen, Bruce Miller, Joel Kramer
Data Blitz: 11:50 a.m.–11:55 a.m.
Feingold, Corlier Fabian, Nicki Mostowfi, Paul Thompson, Meredith Braskie
Steven Horton, John Umhau, Helena Chui, Lon Schneider, Michael Harrington, Alfred Fonteh
Mayo Clinic —Vijay Ramanan, David Jones,
Data Blitz: 12:00 p.m.–12:05 p.m.
Data Blitz: 12:15 p.m.–12:20 p.m.
Data Blitz: 12:30 p.m.–12:35 p.m.
P3.030 Multisensory Impairment
P3.033 Changes in Functional and
P3.036 Characteristics and Progress on
Kristine Yaffe
Agosta, Silvia Basaia, Elisa Canu, Francesca imperiale, Giuseppe Magnani, Monica Falautano, Giancarlo Comi, Andrea Falini, Massimo Filippi
is Associated with Increased Risk of Dementia —Willa Brenowitz, Allison Kaup, Data Blitz: 12:05 p.m.–12:10 p.m.
P3.031 Sense-encoded poly-GR
Structural Brain Connectome Along the Alzheimer’s Disease Continuum —Federica
Data Blitz: 12:20 p.m.–12:25 p.m. dipeptide repeat proteins correlate to P3.034 In Vivo [18F]-AV-1451 Tau-PET neurodegeneration and uniquely co-localize levels are associated with risk of Mild Imaging in Sporadic Creutzfeldt-Jakob Cognitive Impairment among individuals with with TDP-43 in dendrites of repeat expanded Disease —Gregory Day, Brian A Gordon, Richard and without low CSF amyloid-beta —Michelle C9orf72 amyotrophic lateral sclerosis —
P3.028 Elevated CSF neurofilament
Mielke, Jeremy Syrjanen, Kaj Blennow, Henrik Zetterberg, Ingmar Skoog, Clinton Hagen, Argonde Van Harten, David Knopman, Clifford Jack, Ronald Petersen, Silke Kern
Data Blitz: 11:55 a.m.–12:00 p.m.
P3.029 VEGF’s Relationship to Brain Aging Biomarkers —Meral Tubi, Franklin
Shahram saberi, Jennifer Stauffer, Jie Jiang, Sandra Garcia, derek schulte, Takuya Ohkubo, Cheyenne Schloffman, Marcus Maldonado, michael baughn, Maria Rodriquez, Donald Pizzo, Don Cleveland, John Ravits
Data Blitz: 12:10 p.m.–12:15 p.m.
P3.032 Role of ABCA-1 Activity in Brain
Perrin, Nigel Cairns, Helen Beaumont, Katherine Schwetye, Cole Ferguson, Namita Sinha, Bob Bucelli, Erik Musiek, Nupur Ghoshal, Maria R Ponisio, Benjamin Vincent, Shruti Mishra, Kelley Jackson, John Morris, Tammie Benzinger, Beau Ances
Data Blitz: 12:25 p.m.–12:30 p.m.
DHA Metabolism in Carriers of APOE4 —
P3.035 Transient Epileptic Amnesia: A
PARKINSON’S DISEASE: WEARABLE SENSORS AND REMOTE MONITORING TECHNOLOGY
P3.043 Developing a Self-Administered
PARKINSON’S DISEASE: ANIMAL MODELS AND BIOMARKERS
P3.037 Using Objective Measurement
Shyamal Patel, Bryan Ho, Paul Wacnik, Hao Zhang, Tairmae Kangarloo, Vesper Ramos, Stephen Amato, Dmitri Volfson, Peter Bergethon, Michael Erb
alpha-synuclein toxicity in a rat model of Parkinsonism —Nikolaus McFarland, Mayur
P3.044 Accelerometry-Based
P3.050 Cytosolic glucocerebrosidase
B
Via Wearable Sensors To Evaluate Realworld Effectiveness Of Carbidopa/Levodopa Enteral Suspension For Managing Motor Fluctuations: PROviDE Study Design And Baseline Characteristics —Rajesh Pahwa, E. Ray Dorsey, Irene Pan, Stephanie van Norman, Thomas Marshall, Dustin Heldman, Yash Jalundhwala
P3.038 Virtual research visits in
Instrumented Motor Exam for Home-based Parkinson’s Disease Assessment Using Wearable Sensors —Charmaine Demanuele,
Quantitative Analysis of Mobility in Parkinson Disease —Jia Zhen Cheng, Rainer
von Coelln, Katrina Schrader, Erik Barr, Ann Gruber-Baldini, Joseph Savitt, Stephen Reich, Lisa Shulman
individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study —Christopher P3.045 Clinical Experience with Personal KinetiGraph Before and After Deep Brain Tarolli, Kelly Andrzejewski, Grace Zimmerman, Michael Bull, Steven Goldenthal, Michael O’Brien, Stimulation for Parkinson’s Disease — Tanya Simuni, Kevin Biglan, E. Ray Dorsey
P3.039 Objective Data in Parkinson’s
Summer Gernon, Alexandra Fowler, Kelly Lyons, Rajesh Pahwa
Horne
P3.040 Using Wireless Wearable
Sensors to Estimate the Severity of Rest Hand Tremor in PD —Md Nafiul Alam, Asenath Huether, Abby Aymond, Tamanna Tabassum Kha Munia, Colin Combs, Reza Fazel-Rezai, Sarah Matcha, Tanya Harlow, Jau-Shin Lou
P3.041 Wearable Motion Quantification
Florian Lipsmeier, Kirsten I. Taylor, Timothy Kilchenmann, Detlef Wolf, Alf Scotland, Jens Schjodt-Eriksen, Wei-Yi Cheng, Igancio Fernandez Garcia, Juliane Siebourg-Polster, Liping Jin, Jay Soto, Lynne Verselis, Meret Martin Facklam, Frank Boess, Martin Koller, Michael Grundman, Andreas Monsch, Ronald Postuma, Anirvan Ghosh, Thomas Kremer, Christian Czech, Christian Gossens, Michael Lindemann
312 Subjects in the Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol —Bradley Boeve,
Howard Rosen, Adam Boxer, Danielle Brushaber, Giovanni Coppola, Christina Dheel, Bradford Dickerson, Kelley Faber, Julie Fields, Jamie Fong, Tatiana Foroud, Ralitza Gavrilova, Nupur Ghoshal, Jill Goldman, Jonathan Graff-Radford, Neill Graff-Radford, Murray Grossman, Hilary Heuer, John Hsiao, Ging-Yuek Hsiung, Edward Huey, David Irwin, David Jones, Kejal Kantarci, Anna Karydas, David Knopman, John Kornak, Joel Kramer, Walter Kukull, Maria Lapid, Ian R.A. Mackenzie, Bruce Miller, Leonard Petrucelli, Madeline Potter, Rosa Rademakers, Katherine Rankin, Margaret Sutherland, Jeremy Syrjanen, Joanne Taylor, Arthur Toga, Sandra Weintraub, Zbigniew Wszolek
Retrospective Analysis of Cases from the
P3.049 Rab8a protects against
Parmar, Hyo-Jin Park, Daniel Ryu, Lyndsee Powell, Rachel Foels, Sofia Anagnostis
P3.057 Support for the Spreading
Hypothesis: Pathologically Proven Alphasynuclein Peripheral Neuropathy 20 years Before Development of Parkinsonism — Olwen Murphy, Jacques Noel, Michael Farrell, Timothy Lynch
P3.058 Role of a-Synuclein in the GFAP. HMOX1 mouse model of PD —Laurianne Garabed, Hyman Schipper
impairs alpha-synuclein degradation P3.059 Alpha-synuclein Protein by blockade of chaperone-mediated autophagy —Sheng-Han Kuo, Inmaculada Tasset, Homeostasis and Oligomerization in Ironoverloaded Cells Expressing Mutant HFE — Ana Maria Cuervo, David Sulzer
P3.051 Evaluation of Glucosylceramide Synthase (GCS) Inhibition for GBAAssociated Parkinson’s Disease —Tanya
Fischer, S. Pablo Sardi, Lamya Shihabuddin, Dan Rudin, Jyoti Bala Sharma, Roberto Araujo, Jian Li, M. Judith Peterschmitt
P3.052 A comparative plasma alpha-
synuclein concentration and metabolic profiling study in Parkinson’s disease and essential tremor —Esther Cubo Delgado,
Olimpio Montero-Domingo, Silvia Albillos, Sara Calvo, Jose Trejo, Berta Solano, Sandra Delgado, Sara Casais
P3.053 Dendritic cells, CD4+ T cells, and
Yunsung Kim, James Connor, Mark Stahl
P3.060 Pilot Assessment of Salivary
Cortisol Levels as a Marker for Depression in Patients with Parkinson Disease —Jared Sweeney, Julia Prusik, Eric Molho
P3.061 Fundamental limit of alpha-
synuclein pathology in gastrointestinal biopsy as a pathologic biomarker of Parkinson’s disease: Comparison with surgical specimens —Beomseok Jeon, Chae
Won Shin, Sung-Hye Park, Ji Yun, Jung Hwan Shin, Guangxun Shen, Yoon Kim, Han-Kwang Yang, Hyuk-Joon Lee, Seong-Ho Kong, Yun-Suhk Suh, Han Kim
α synuclein triangle fuels neuroinflammation P3.062 Neuroprotective Effect of Parkin on Mitochondria in Central Dopaminergic in Parkinson’s disease —Daniel Magnusen, Neurons —Hae-young Hawong, Joseph Tsitsi Nyamajenjere, Jillian Rapien, Mary Mckay, Albert Magnusen, Manoj Pandey
Patterson, Keith Lookingland, John Goudreau
and Electronic Diaries for Long-Term Monitoring of Parkinson’s Disease —Aaron
P3.047 Hypomimia detection with a
P3.054 Patients with Alpha-
P3.063 Modulation of CaMKIIa-NR2B
Carol Zimmerman, Joseph Giuffrida, Zoltan Mari, Michelle Burack, Ilia Itin, Fredy Revilla, Dustin Heldman
Seliverstov, Dmitrii Diagovchenko, Michael Kravchenko, Mikhail Babin, Ekaterina Fedotova, Mikhail Belyaev
Csencsits-Smith, Shivika Chandra, Qianmiao Gao, Hongyu Miao, Mya Schiess
Wen Wang, Si-Yan Chen, Cheng-Long Xie
P3.042 Machine learning algorithms
the Pedunculopontine Tegmental Nucleus as P3.064 Progression of Parkinson’s P3.048 Clinician-Input Study (CIS-PD): a Rat Model of Parkinson’s Disease —Anam Disease: 2-Year Longitudinal Study of How the Fox Wearable Companion Clinical and MRI Changes in Patients at Application can influence treatment and care Syed, Phillip Baker, Michael Ragozzino in Parkinson’s disease —Margaret Daeschler, P3.056 Salivary Alpha-Synuclein a new Different Stages of the Disease —Massimo Jordan Elm, Erin Klintworth, Michal Afek, Shira tool for the diagnosis of Parkinson’s disease? Filippi, Elisabetta Sarasso, Noemi Piramide, Tanya Stojkovic, Vladana Pica, Iva Stankovic, Lazar, Tanya Simuni PARKSYN study —Cecile Aertz, Victoria
smartphone camera as a possible selfHadley, Enrique Urrea-Mendoza, Nicola Mennucci, screening tool for Parkinson disease —Yury
applied to digital biomarker data (iMotor) discriminate Parkinson’s motor status — Ioannis Tsoulos, Athanassios Stavrakoudis, Georgia Mitsi, Spiridon Papapetropoulos
synucleinopathies Display Distinct Chemokine Profiles —Jessika Suescun, Keri
P3.055 The Effect of NMDA Lesions in
interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson’s rats —WenPARKINSON’S DISEASE: IMAGING
Silvia Basaia, Andrea Fontana, Igor Petrovic, Elka Gonzalez, Christophe Hirtz, Sylvain Lehmann, Marie Stefanova, Vladimir Kostic, Federica Agosta Deverdal, Laurent Collombier, Giovanni Castelnovo
AAN.com/view/AM18 143
Tuesday
P3.046 Remote patient testing with Disease: A description of over 10,000 Parkinsons symptom scores across the world smartphones provides reliable, valid and using the Personal KinetiGraph (PKG) —Peter sensitive measures of motor symptom severity in Parkinson’s disease patients — Lynch, Rajesh Pahwa, Filip Bergquist, Malcolm
Jonathan Graff-Radford, Rodolfo Savica
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION III G P3.065 Functional Brain Connectome
Tuesday, April 24 11:30 a.m.–7:00 p.m.
P3.070 Longitudinal Cortical Thickness Architecture in a Large Cohort of Parkinson’s Changes in Early Parkinson’s Disease Disease Patients —Silvia Basaia, Federica Patients with Impulsive Compulsive Agosta, Homa Zahedmanesh, Tanya Stojkovic, Behaviors —Francesca imperiale, Federica
P3.075 Functional Magnetic Resonance
P3.066 Combining Metabolomics and
P3.076 White Matter Tract Alterations
Vladana pica, Iva Stankovic, Igor Petrovic, Elka Stefanova, Vladimir Kostic, Massimo Filippi
Agosta, Vladana pica, Iva Stankovic, Paola Valsasina, Igor Petrovic, Elisabetta Sarasso, Vladimir Kostic, Massimo Filippi
Neuroimaging in mid-stage Parkinson’s P3.071 Zonisamide Co-treatment Slows Disease. A Proof of Concept for CrossReduction of Striatal Dopamine Transporter Fertilization. —Jean-Pierre Trezzi, Andrea Greuel, in Patients with Parkinson’s Disease —Ken Enrico Glaab, Zdenka Hodak, Lars Timmermann, Christian Jaeger, Nico Diederich, Carsten Eggers
P3.067 Longitudinal Cortical Thickness
Changes in GBA-Positive Relative to GBANegative Parkinson’s Disease Patients with Hemiparkinsonism —Francesca imperiale,
Federica Agosta, Vladana pica, Iva Stankovic, Elisabetta Sarasso, Paola Valsasina, Igor Petrovic, Vladimir Kostic, Massimo Filippi
Ikeda, Masaru Yanagihashi, Ken Miura, Yuichi Ishikawa, Takehisa Hirayama, Takanori Takazawa, Osamu Kano, Kiyokazu Kawabe, Sunao Mizumura, Yasuo Iwasaki
P3.072 Cortical Surface Analysis
in Parkinson Disease Patients —Rachel
Guimaraes, Luiza Piovesana, Paula Azevedo, Clarissa Yasuda, Jose Moreira, Daniela Garcia, Anelyssa D’Abreu, Fernando Cendes
P3.068 Domain-specific impact of cerebral P3.073 Microstructural Changes in Balance white matter hyperintensities on Parkinson’s disease cognitive functioning —Patricia
Control Centers, as Measured by Diffusion Tensor Imaging, Correlate with the Ability to Use Somatosensory Information to Maintain Balance in Parkinson’s Disease —Jacob Surkont, Wayne
Imaging-Based Neurofeedback Training in Patients with Parkinson’s Disease —Ayse
P3.080 Pattern Analysis of FDG PET
in Atypical Parkinsonism—an Innovative Approach —Balakrishnan Shankar, Karthikeyan
Tinaz, Keerthana Nalamada, Mine Sezgin, Ana Soundarpandian Vives-Rodriguez, Kiran Para, Dustin Scheinost, Elan P3.081 A CT-Based Diagnostic Index Louis, Michelle Hampson
in Drug-naive Parkinson’s Disease Patients with Impulse Control Disorders —Mahtab Mojtahed Zadeh, Mohammad Hadi Aarabi
P3.077 Analysis of Tc-99m TRODAY
to differentiate between Progressive Supranuclear Palsy and Parkinson’s disease: A potential application for DaT-SPECT/CT. —
Bhumika Balgobin, Rajesh Gupta, Chuan Huang, Vivekanand Tatineni, Robert Matthews, Dinko Franceschi, Karl Spuhler, Tim Duong, Guy Schwartz
study in patients with Parkinsonism —Yu-Wei P3.082 Hyperechogenicity of the Lin, Han-Cheng Wang substantia nigra in non-mutation-carrying family members of LRRK2 PD —Mariel P3.078 Transcranial sonography in real clinical practice: Differential diagnosis between idiopathic Parkinson’s disease, atypical parkinsonism and essential tremor —Talyta Grippe, Nasser Allam, Pedro Renato Brandao, Danilo Pereira, Ana Carolina Aguilar, Natalia Cunha, Iruena Kessler
Pullman, Roberto Ortega, Amanda Glickman, Andres Deik Acosta Madiedo, Deborah Raymond, Karen Marder, Nir Giladi, Susan Bressman, Johann Hagenah, Norbert Bruggemann, Rachel SaundersPullman
P3.083 White Matter Changes in
P3.079 Substantia Nigra
Parkinson’s Disease Mapped with a Novel Tract Mapping Algorithm —Conor Corbin,
Reisin
Çevik, Orhan Sümbül, Semiha Kurt
Hyperechogenicity in Parkinson’s Disease Vikash Gupta, Julio Villalon-Reina, Talia Nir, Faisal and Essential Tremor and Its Association Rashid, Sophia Thomopoulos, Neda Jahanshad, P3.069 Microstructural Changes in the Martin, Marguerite Wieler, Myrlene Gee, Cari-Ann with Premotor Symptoms of Parkinson’s Paul Thompson Thalamus and Putamen, as Measured by Disease. —Marcela Uribe Roca, Anibal Chertcoff, Cooke, Richard Camicioli, Fang Ba P3.084 The Evaluation of the Ganglion Diffusion Tensor Imaging, Correlate with Gait Lucrecia Bandeo, Miguel A. Saucedo, Fatima Abnormalities in Parkinson’s Disease —Jacob P3.074 DAT-SPECT Imaging in Cases of Pantiu, Laura De Francesco, Luciana Vanesa Leon Cell Layer-Inner Plexiform Layer Complex Surkont, Wayne Martin, Marguerite Wieler, Myrlene Drug-Induced Parkinsonism in a Specialty Cejas, Maria Pacha, Galeno Rojas, Gabriel Napoli, Thickness in Early Parkinson’s Disease — Movement Disorders Practice —Jacob Gee, Cari-Ann Cooke, Richard Camicioli, Fang Ba Pablo Bonardo, Manuel Fernandez Pardal, Ricardo Durdane Aksoy, Selim Demir, Hüseyin Ortak, Betül Linortner, Taylor Hendershott, Kathleen Poston
Yomtoob, Kimberly Koloms, Danny Bega
b1 C
General Neurology ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P3.085 Ambulatory Computerized
Tippetts, Blake Zimmerman, Alfred Van Hoek,
Sarang Joshi, Edward Hsu Physician Order Entry Associated with Greater Opioid Prescribing —John Ney, Allison P3.087 Effects of Education on Weathers, Brian Callaghan Symptom Recognition and Management of Pseudobulbar Affect: A Mixed-Methods P3.086 High resolution and high field Evaluation of Knowledge and Behavior diffusion MRI in the visual system of Changes of Clinicians and Patients —Anne primates — Osama Abdullah, Li Dai, Jacob
P3.088 Anterior horn cell (AHC)
involvement in autosomal recessive hereditary spastic paraplegia with thin corpus callosum (ARHSPTCC) patients with SPG 11 mutations. —Nouf Al-Faidi, Qurban Ali, Gulzar Karim, Khalil Kurdi, Haji Khan, Omar Wazzan, Youssef Al Said, Edward Cupler
Roc, Wendy Turell, Erik Pioro
P3.089 “Doctor, I can’t touch my cheek
with my tongue” —Vaibhav Goswami, Michael Tenner, Anila Thomas, Brij Ahluwalia-Singh
P3.090 Posterior Spinal Cord Infarction in a Patient with Moderate Degenerative Cervical Spondylosis —Danielle Stember, Robert Staudinger
Tuesday
HEADACHE: IMAGING, NEUROPHYSIOLOGY, AND RESEARCH METHODS
Study and Review of the Literature —Richard Removing Less CSF May Be Best —Simy
Following Epidural Blood Patch —Alison
P3.091 DEWS (DEep White matter
P3.097 Is cortical dysexcitability is the basis of palinopsia in migraine? —Jayantee
P3.108 Knocked Out: Concussion as
hyperintensity Segmentation framework): Fully automated pipeline for detecting small deep white matter hyperintensities in migraineurs —Mi-Ji Lee, Bo-yong Park, Hyujin Jo, Jihoon Cha, Chin-Sang Chung, Sung Tae Kim, Hyunjin Park
P3.092 WITHDRAWN P3.093 Vascular Wall Imaging in
Lewis, Armando Ruiz, Teshamae Monteith
Kalita, Usha Misra, Robin Bansal
P3.098 Clinical Characterization,
Repetitive Pattern Reversal Visual Evoked Potentials (rVEP), Transcranial Magnetic Stimulation (TMS) and Brain Imaging in Visual Snow —Fatma Gokcem Yildiz, Umur Turkyilmaz, Isin Unal-Cevik
P3.099 N=1 Statistical Approaches to examine Factors that Modify Headache Reversible Cerebral Vasoconstriction Syndrome- a 3-tesla Contrast-Enhanced MRI Severity in Chronic versus Episodic study —Chun-Yu Chen, Shih-Pin Chen, Jong-Ling patients —Ty Ridenour, Marina Vives-Mestres,
Parikh, Franchesca Fiorito Torres, Melissa Rayhill, Matthew McAdams, Michael Perloff
P3.102 Novel anti-neuronal antibodies in idiopathic intracranial hypertension patients —Erdem Tuzun, Güneş Altıokka Uzun,
Ece Erdag, Duygu Gezen-Ak, Erdinç Dursun, Cem Kucukali, Betul Baykan
P3.103 Correlation of Opening Pressure with Unilateral Versus Bilateral Venous Sinus Stenosis in Idiopathic Intracranial Hypertension (IIH) —Roman Kassa, Flavius Raslau, Douglas Lukins, Padmaja Sudhakar
P3.104 Intracranial hypertension and systemic lupus erythematosus —Sawsan
Daoud, nouha Bouzidi, Olfa Hdiji, Hanen Haj Kacem, salma sakka, Mariem Damak, Chokri Mhiri
Thaler, Anna Pace
a trigger for encephalopathic hemiplegic migraine. —Maria Gaughan, Jennifer Clarke, Daniel Healy
P3.109 Stroke-like image findings in sporadic hemiplegic migraine —Cristina
Sánchez-Vizcaíno Buendía, Noelia García Lax, Gabriel Valero López, Ester Carreon Guarnizo, Joaquín Zamarro Parra, Mariano Espinosa de Rueda Ruíz, Guillermo Parilla Reverter
P3.110 Familial Aphasic Migraine —Scott Woolf, Adil Iqbal, Sania Atta, Leah Harburg, Stephen Marks, Brij Ahluwalia-Singh
Fuh, Jiing-Feng Lirng, Yen-Feng Wang, Shuu-Jiun Wang
Gabriel Boucher, Alec Mian, Andrew Hershey
P3.094 Is diffusion restriction of the
Research Studies: The National Institute of Neurological Disorders and Stroke (NINDS) Headache Version 2.0 (V2.0) Common Data Elements (CDEs) —Sarah Tanveer, Sherita Alai,
P3.105 Intra-dural fluid collections in
Vestibular Migraine—Two New Subtypes of the Disorder —Steffen Naegel, Hsin-Chieh Chen,
in First-Visit Primary Headache Patients: A Prospective Multicenter Study —Byung-Su
THE LESS COMMON HEADACHES
Jik Park, Ho-Sung Ryu, Hanim Kwon, Mi Sun Kim, Joon Mo Koo, Kye Won Park, Sun J. Chung
Cheng, Tzu-Hsien Lai, Kuei-Hong Kuo, Siu-Pak Lee, Yen-Jun Lai
P3.096 Reversible Lesions of the Corpus
Cerebrospinal Fluid (CSF) Volume Removal for Idiopathic Intracranial Hypertension (IIH):
P3.107 Rare Cause of Explosive
P3.113 Cerebral Venous Sinus
optic disc head a new marker for Idiopathic Intracranial Hypertension? —Elanagan
Nagarajan, Manjamalai Sivaraman, Pradeep Bollu
P3.095 Neuroimaging Abnormalities Kim, Cho Soo-Jin
Callosum in Migraine with Aura: A Case
144 2018 AAN Annual Meeting
P3.100 Accelerating Headache Clinical
Joy Esterlitz, Michael Oshinsky
P3.101 Updated Results on
P3.111 Chronic and Primary Daily
spontaneous CSF leaks: The dural dissection H. Diener, Mark Obermann, Christoph Kleinschnitz, Dagny Holle theory —Monique Montenegro, Jeremy Cutsforth-Gregory P3.112 Headache in patients with P3.106 Sex-specific clinical features of isolated cortical vein thrombosis: Report of 9 spontaneous intracranial hypotension —Yun cases and review of the literature. —Yu-Chen
Headache: Iatrogenic Pneumocephalus
Thrombosis Presenting With Headache And
Papilledema Without Focal Neurological Deficits —Sai Sripada Koneru, Vijay Chandran,
P3.128 Fibromyalgia and Myositis in
P3.114 New Daily Persistent Headache
Malhi, Liseth Lavado, Salma Yousuf, Priyadarshee Patel, Anam Habib, Gull Mahvish, Ashish Kapoor, Urvish Patel
Sankar Gorthi, Aravind Prabhu
(NDPH) & OnabotulinumtoxinA Therapy — Ashhar Ali, Jennifer Kriegler, Stewart Tepper, Brinder Vij
P3.115 An Unusual Presentation
of Hemicrania Continua —Steven Yang,
Seyedhesamaldin Mostafavitoroghi, Annie Hsieh, Maria Diaz Rojas, Yan Zhang
P3.116 Unusual Presentation Of HaNDL Syndrome —Musab Ali, Boulenouar Mesraoua, Atlantic Dsouza, Hassan Alhussein, Lubna El Sheikh, Noha Mhjob, Gayane Melikyan, Hassan Jassim Al Hail, Dirk Deleu
Migraine: A Nationwide Study of Disability and Discharge outcome —Prutha Soni, Princy
P3.129 Productivity Loss and Indirect
Fanning, Michael Reed, Dawn Buse, Todd Schwedt, Richard Lipton, David Dodick
Headache Disorders in Kuwaiti Children and givers in resource constrained settings — Adolescents. —Samar Ahmed, Jasem Al-Hashel, Shruthi N M, Vishal Sondhi, Biswaroop Raed Alroughani
P3.130 Prevalence And Risk Factors
Dermitzakis, Jobst Rudolf, Michael Vikelis
Associated With Depression In Patients P3.144 Burden of Illness Among Treated With Chronic Headache Cross Sectional Migraine Patients with ≥4 Headache Days Study, In Aseer Region, Saudi Arabia —Hayfa in the Past Month —Lulu Lee, Jvawnna Bell, Timothy Fitzgerald, Joshua Cohen
P3.145 2017 Migraine in America
Symptoms and Treatment (MAST) Study: (HaNDL) presenting with Diffusion Restriction in Gender Differences in Treatment Patterns P3.131 Vitamin D deficiency in migraine — the Splenium of Corpus Callosum: Case report and Unmet Treatment Needs —Aftab Alam, Cho Soo-Jin, Tae-Jin Song, Min-Kyung Chu, and review of literature —Kunal Bhatia, Pradeep Jong-Hee Sohn, Sun Wha Lee, Jee Young Kim Richard Lipton, Sagar Munjal, Dawn Buse, Kristina Bollu, Navpreet Bains
P3.132 Development of a Claims-Based P3.118 Whole Body Cryotherapy Induced Algorithm for Use in Patients with Migraine P3.119 Cognitive and Hearing
to Identify Potentially Undiagnosed Chronic Migraine Patients —Jelena Pavlovic, Justin S.
Complaints in Veterans: Is Central Auditory Processing Disorder an Overlooked Disability? —Eliot Licht, Delia Karahalios, Kimberly Panizzon
Yu, Stephen Silberstein, Michael Reed, Steve H. Kawahara, Robert Cowan, Firas Dabbous, Karen Campbell, Anand R. Shewale, Riya Pulicharam, Jonathan W. Kowalski, Hema Viswanathan, Richard Lipton
P3.120 Cardiac Cephalalgia: A Deadly
P3.133 Medical Comorbidities of
Case Report —Matheus Pedro, Paulo Santos
P3.121 Third Cranial Nerve Palsy
Associated with an Attack of Cluster Headache —Jessica Coleman
Dawn Buse, Peter Goadsby
P3.134 The Cardiovascular Impact of (Never Smoker and No Parental Secondary Intravenous Dihydroergotamine for Pediatric Smoke Exposure as a Child): Results from the Headache Patients —Sara Fridinger, Christina Szperka United States Cluster Headache Survey — HEADACHE DIAGNOSIS, BURDEN AND CO-MORBIDITY
P3.123 Identifying Natural Subgroups of Migraine Based on Profiles of Comorbidities and Concomitant Conditions: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study —Richard Lipton,
P3.124 The Relationship between Pain, Psychiatric, and Endocrine/Neurological Comorbidities of Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study —Aubrey Manack
Headaches in Children with Celiac Disease —Grant Hom, Brian Hom, Barbara Kaplan, A. Rothner
P3.126 Migraine in Postural Orthostatic Tachycardia Syndrome (POTS) —Juliana
VanderPluym, Charlene Hoffman-Snyder, Julie Khoury, Brent Goodman
P3.127 Accuracy and safety of an
artificial intelligent system for nonacute headache diagnosis —Julian Acosta, Francisco Grimaldi, Francisco Dorr, Francisco Varela, Lucas Alessandro, Maria Goicochea, Diego Fernández Slezak, Mauricio Farez
headache: A population study —Jiyoung Kim,
Tae-Jin Song, Soo-Jin Cho, Won-Joo Kim, ChangHo Yoon, Kwang Yang, Min Kyung Chu
P3.147 Online Medical Education
Improves Knowledge of Both Risk Factors for Chronification and Clinical Trial Data in Migraine —Stacey Ullman, Thomas Finnegan,
Murinova, Daniel Krashin, Melissa Schorn
P3.149 Classification of cases with a Kledisa Shemsi, Edlira Shemsi, Ferid Domi
P3.138 Post-Traumatic vs Non-Traumatic Jaclene Dabbour, David Rosenberg Headaches: A Phenotypic Analysis —Andrea P3.153 An Investigation of Tracking
on Quality of Life and Costs Among People with Migraine with ≥4 Headache Days in the Past Month —Jvawnna Bell, Lulu Lee, Timothy Fitzgerald, Joshua Cohen
P3.140 Sleepy Brain in Pain; Prevalence of Sleep Problems in a University-Based Headache Clinic —Natalia Murinova, Daniel Krashin, Melissa Schorn, Sau Mui Chan-Goh, Flavia Consens
P3.141 Symptom Bothersomeness in
Migraine: Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study —Sagar Munjal, Aftab Alam, Kristina
Neurology —Paul Fu, Babar Khokhar
P3.159 Using Data Analytics to Increase
Neurology Access With Existing Providers — Neil Holland, Kristina Barron, Megan Brosious, Trudi Dempsey, Teena Kubasti, Greg Strevig
P3.160 Barriers to Appropriate
Inpatient Stroke Code Activation: A Quality Improvement Survey —Chandler Gill, Stasia Rouse, Kalea Colletta, Saima Chaudhry, Stephen Yeung, Adriana Perilla, Michael Schneck, Sean Ruland, Matthew McCoyd
Modifying Therapies for Multiple Sclerosis in Medicare Part D —Daniel Hartung, Kirbee Johnston, Dennis Bourdette
P3.162 Factors Associated with
Outpatient Follow-up in Stroke Clinic after Discharge from a Comprehensive Stroke Center —Reema Butt, Mohammed Ismail, Daniel Miller, Shaneela Malik, Lonni Schultz
P3.163 Stroke Stat: Notification System for In-Hospital Acute Strokes —Jillian
Alderson, Neishay Ayub, Ka-wai Ho, Kathie Lin, Sandeep Kumar, Magdy Selim, Pushpa Narayanaswami
diagnosis of acute headache, to emergency P3.164 Characteristics of General division in Regional Hospital Durres, Albania. — Neurology Readmissions —Nina Kim, Sanjeev
Migraine and Medication-Overuse Headache PRACTICE, POLICY, AND ETHICS I in University-Based Headache Clinic —Pooja P3.150 Multimodal Communication Puvvadi, Melissa Schorn, Daniel Krashin, Natalia Enhances Family Centered Care in the Murinova Neurocritical Care Unit (NCCU) —Matthew P3.136 Improving Patient-Centeredness Jaffa, Tachira Tavarez, Taghi Ryder, Brigid Blaber, of Headache Questionnaires —Edlin Gonzales, Abbey Friets, Mary Ann Bautista, Melissa Motta Jessica Smith, Kenneth Nudelman, Sonja Potrebic, P3.151 Utilizing a Patient Contact Index Annette Langer-Gould to Determine Staffing of an Academic P3.137 Evaluation of Post-traumatic (PT) Neurology Department —Benjamin Greenberg, Emmitt Rathore, Debra Clamp, Jaya Trivedi Chronic Migraine (CM) in Veterans of OEF/ OIF Campaigns Using Serum Mass Profiling P3.152 Improving Warfarin Management to Distinguish CM from other PT Headaches Through Pharmacy Lead Dose Capping for by Identification of Peptide Changes in Patients ≥85 Years Old —Jonathan Falsetta, Serum —James Couch, Jay Hanas Elissa Dipasquale, Zachary Klein, Alan Mensch,
P3.139 The Impact of Headache Free Days
P3.158 Burnout and Vitality for Yale
P3.146 Insufficient sleep in tension-type P3.161 Trends in Coverage for Disease
P3.135 Diagnostic Delay of Chronic
Adams, Richard Lipton, Vincent Martin, Michael Reed, Kristina Fanning, Dawn Buse, Peter Goadsby Metti, Karen Schwab, Lisa Brenner, Wesley Cole, Ann Scher
P3.125 Frequency of Recurrent
Chakrabarty, Prashant Jauhari, Harsh Patel, Lokesh Saini, Jaya Shankar Kaushik, Rachana Dubey, Shefalli Gulati
Kothare, Harold Weinberg
P3.165 Optimization of Ambulatory
Neurology Clinics at an Academic Medical Center —Babar Khokhar
P3.166 Improving cost and laboratory utilization in Paraneoplastic Antibody Testing —Dana Vanino, Kelly Baldwin
P3.167 A Quality Improvement Project to Improve Trainee Compliance with Direct-toPharmacy Electronic Prescriptions —Shivika
Chandra, Kim Yen Thi Vu, Louise McCullough, Anjail Sharrief
P3.168 Progress Note Quality
Improvement Study: Results From a Resident and Faculty Survey —Carolyn Zyloney, Robert Thompson-Stone
P3.169 Implementation of Advanced Technology in the Setting of an Established Practice Provider (AAP) Practice Models in Neurology —Calli Cook Exercise Program for Individuals with Parkinson’s Disease —Sarah Ingersoll, Kenneth P3.170 Transitioning Neurology Hayashida, Jason Chen, Rushabh Modi, Kris Outpatients from a Tertiary Care Center Mendenhall, Daniel Togasaki to Primary Health Care Centers (PHCC). — P3.154 Trainee Responses to Hurricane Edward Cupler, Alanood Abdulfattah, Khadeejah Al-Hasani, Khalid Alqadi, Moira Abrahams, Bandar Harvey: Correlating Volunteerism with Rashwan, Manal Badawi, Ahmad Hassan, Sameer Burnout —Crystal Yeo, Gustavo Roman, Dottie Al-Kathiri, Rainavel Romano, Omar Wazzan, Mersinger, David Kusnerik, Shaylor Thomas, Trevor Youssef Al Said Burt, Timothy Boone, Suzanne Powell
P3.155 Improving access to sleep
medicine clinic services through the implementation of an econsult program —
P3.171 NA P3.172 NA
Asha Singh, Jon Billinger, Darren Malinoski
AAN.com/view/AM18 145
Tuesday
Kristina Fanning, Dawn Buse, Vincent Martin, Michael Reed, Aubrey Manack Adams, Peter Goadsby
Fanning, Michael Reed, Todd Schwedt, David Dodick
Migraine: Results from the Chronic Migraine David Dodick Epidemiology and Outcomes (CaMEO) P3.148 What do Headache Patients Study —Aubrey Manack Adams, Richard Lipton, Want? Patient Goals in Headache Medicine Vincent Martin, Michael Reed, Kristina Fanning, in a Tertiary Headache Center. —Natalia
P3.122 A Cluster Headache Phenotype
Todd Rozen
Neurodevelopmental Care: Initiatives to
P3.142 Prevalence and Burden of Primary empower health care professionals and care
P3.143 A Population Based Survey for Costs of Chronic Migraine and Episodic Headaches in Greece to Estimate Prevalence P3.157 Improving Patient Satisfaction Migraine in a Commercially-Insured and Treatment Preferences —Dimos Dimitrios By Implementing Existing Tools in EHR Using Population —Justin S. Yu, Emily Durden, William Mitsikostas, Chryssa Arvaniti, Theodoros Young, Oth Tran, Hema Viswanathan Lean Methodology —Anil Neelakantan Constantinidis, Nikolaos Fakas, Emmanouil
A Dhafer, Adel Ali Alhazzani, Abrar A BinAbbas, Ahmed Abouelyazid, Hanan A Albishi, Abdullah S P3.117 Syndrome of transient headache Alomari, Badr A Alfard, Ashwaq Z Abdulrahman, with neurological deficits and CSF lymphocytosis Walaa A Aldarwish
Reversible Cerebral Vasoconstriction Syndrome —David Atkins, Ryan Smith
P3.156 Comprehensive
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION III G IMAGING STUDIES IN AGING AND DEMENTIA
D
P3.173 Bilingualism and Age of
P3.184 Neurodegeneration: Prion-like
Behavior of Misfolded Proteins in the Syntactic Network —Belen Pascual, Quentin
Funk, Paolo Zanotti Fregonara, Elijah Rockers, Acquisition in Alzheimer Disease: A 18F-FDG Neha Pal, Meixiang Yu, Christof Karmonik, Bryan PET Study —Jean-Benoit Epiney, Mitsouko Spann, Gustavo Roman, Paul Schulz, Joseph van Assche, Giulia Frasca Polara, Perani Daniela, Masdeu Frederic Assal, Valentina Garibotto
P3.174 Amyloid and Hypertension Are Independently Associated with White Matter Injury Assessed by FLAIR and DTI MRI —Omar Al-Janabi, Christopher Brown, Ahmed Bahrani, Richard Murphy, Brian Gold, Donna Wilcock, Peter Nelson, Larry Goldstein, Charles Smith, Gregory Jicha
P3.175 Occipital and Cingulate
Hypometabolism is Significantly Under-reported and Probably Missed on 18-Fluorodeoxyglucose Positron Emission Tomography Scans of Patients with Lewy Body Dementia —Moath Hamed, Frank Schraml, Jeffrey Wilson, Marwan Sabbagh
P3.176 Quantitative dopaminergic
imaging identifies normal pressure hydrocephalus from its mimics —Gilles
Allali, Valentina Garibotto, Ismini Mainta, Nicolas Nicastro, Frederic Assal
P3.177 Multimodal MRI Staging
Improves Clinico-Imaging Correlations in sJCD. —Simone Sacco, Eduardo Caverzasi,
Matteo Paoletti, Adam Staffaroni, Isabel Allen, Gabriel Marx, Joel Kramer, Stefano Bastianello, Roland Henry, Howard Rosen, Michael Geschwind
P3.178 White matter microstructural
damage and cerebral atrophy in middle age. The longitudinal CARDIA MRI sub-study. — Justine Moonen, Nick Bryan, Guray Erus, Ilya Nasrallah, Pam Schreiner, Christos Davatzikos, Lenore Launer
P3.179 Automatic classification of
P3.185 Volume and Functional
Connectivity of the Ventral Tegmental Area as Early Markers of Alzheimer’s Disease — Matteo De Marco, Annalena Venneri
P3.186 The impact of localized gray
matter damage on connectivity: Posterior Cortical Atrophy study —Haya Glick-Shames, Yael Backner, Noa Raz, Netta Levin
P3.180 Distinct Spatial Distribution of
White Matter Hyperintensities Associated with Alzheimer’s Disease Pathology and Hypertension. —Omar Al-Janabi, Christopher
Tuesday
Brown, Ahmed Bahrani, Richard Murphy, Brian Gold, Peter Nelson, Donna Wilcock, Larry Goldstein, Charles Smith, Gregory Jicha
P3.181 MRI-derived markers of disease progression in early versus late PSP and CBS —Kimiko Domoto-Reilly, Daniel Peterson,
Shubir Dutt, Hilary Heuer, Phi Luong, Carmela Tartaglia, Irene Litvan, Scott McGinnis, Bradford Dickerson, John Kornak, Norbert Schuff, Gil Rabinovici, Bruce Miller, Anne Fagan, Kejal Kantarci, Alexander Pantelyat, Tatiana Foroud, Bradley Boeve, Howard Rosen, Adam Boxer
P3.182 Added Value of Multimodal
Structural MRI to the Clinical Diagnosis of Primary Progressive Aphasia Variants —
Federica Agosta, Elisa Canu, Francesca imperiale, Francesca Caso, Andrea Fontana, Giuseppe Magnani, Andrea Falini, Giancarlo Comi, Massimo Filippi
Kesayan, Kenneth Heilman
P3.199 Pure apraxia of speech
associated with infarction in premotor cortex —Riddhi Patira
P3.200 NA ACUTE STROKE IMAGING
E
P3.201 Average Time from CT to CTP
Completion is Long: What are we getting in return? —Umar Shariff, Ameer Hassan, Christina Sanchez, Ahmed Malik, Adnan Qureshi
P3.202 Role of Thin-sliced Reformatted
Patients: A Perfusion Study using Deep Learning —Yannan Yu, Danfeng Guo, Min Lou, David Liebeskind, Fabien Scalzo
P3.213 Magnetic Resonance
Angiography with Black Blood as Routine for Evaluate Cerebrovascular Disease —Hennan Teixeira, Christiane Monteiro Siqueira Campos, André Luiz Guimarães de Queiroz, Karlla Danielle Ferreira Lima, Victor Hugo Marussi, Alex Baeta
P3.214 Is Contrast Staining on Post-
thrombectomy CT Predictive of Final Stroke Volume? —Kristie Wang, Lawrence Chu, Benjamin Emanuel, May Kim-Tenser, Matthew Tenser, William Mack, Arun Amar, Sebina Bulic
CT Imaging for acute Ischemic Stroke Patients, do we need CT angiography before POST-STROKE MOOD, COGNITION, AND RECOVERY Metabolic Network Activity Associated with deciding for acute neurointervention? — Siddhart Mehta, Ashish Kulhari, Amrinder Singh, the Progression of Alzheimer’s Disease — P3.215 Diffuse Abnormal Cerebral Rafia Jawed, Sara Strauss, Spozhmy Panezai, Chris Tang, Michael Small, Paul Mattis, Amir Activation may Underlie Post-Stroke Jawad Kirmani Nazem, Phoebe Spetsieris, David Eidelberg Cognitive Dysfunction, or the “Minor Stroke P3.188 Longitudinal Cortical Thickness P3.203 Impact of Acute Interventions for Syndrome” —Elisabeth Marsh, Rafael Llinas, Ischemic Strokes on Infarcted Tissue Volume: Rodolfo Llinas Analysis in Alzheimer Disease. ADNI-Arg Cohort —Ismael Calandri, Ignacio Demey, Patricio Comparison of MRI Profiles —Michael P3.216 MIND Diet Slows Cognitive Gezalian, Jeremy Moretz, Walshe Izumigawa, Chrem Mendez, Maria Julieta Russo, Gabriela Shauna Cheung, Brian Cristiano, Laura Nist, Bryan Decline in Stroke Survivors —Laurel Cherian, Cohen, Ezequiel Surace, Horacio Martinetto, Federico Nahas, Maria Eugenia Martin, Paula Harris, Varela Yanina, Jorge Campos, Gustavo Sevlever, Silvia Vazquez, Ricardo Allegri
P3.189 Diffusion MRI Measures from
the Updated ADNI3 Protocol are Associated with Cognitive Impairment in the Elderly — Talia Nir, Sophia Thomopoulos, Neda Jahanshad, Paul Thompson
P3.190 White matter connectivity
differences between typical amnestic and variant non-amnestic individuals with earlyonset Alzheimer’s disease (EOAD) —Paul
Tsao, Paul Jacobson, Vincent Truong
P3.204 Comparing Safety and Efficacy
Yamin Wang, Keiko Fukuda, Sue Leurgans, Neelum Aggarwal, Martha Clare Morris
of Biplane versus Monoplane Angiography in P3.217 Motor Impairment and Lack of Hyperacute Neuroendovascular Therapy — Functional Independence as Predictors of Depression in Post-Stroke Patients —Sen Gregory Kurgansky, Igor Teslya, Ryan Bo, Jeffrey Farkas, Karthikeyan Arcot, Ambooj Tiwari, David Turkel-Parrella
P3.205 Choice of Pretreatment
Neuroimaging Impacts Clinical Outcomes Following Mechanical Thrombectomy —
Sitara Koneru, Shazli Khan, Jaclyn Mueller, Samar Sheriff, Syed Zaidi
Ninan, Nadege Gilles, Jeremy Weedon, Clotilde Balucani, Jonathan Singer, Susan Law, Steven Levine
P3.218 Prevalence and Factors
Associated with Depression in Young Argentinian Patients with Ischemic Stroke —
Anibal Chertcoff, Julieta Quiroga, Miguel Saucedo, Lucrecia Bandeo, Fatima Pantiu, Luciana Vanesa Thompson, Mario Mendez, Madelaine Daianu, P3.206 Pitfalls of CT Perfusion Imaging in Leon Cejas, Maria Pacha, Marcela Uribe Roca, Randy Desarzant, Rebecca Melrose, Elvira Jimenez Acute Ischemic Stroke: A Case Series —Rae Pablo Bonardo, Manuel Fernandez Pardal, Ricardo Reisin Bacharach, Muhammad Niazi, David Ermak
Brown, Nathan Johnson, Brian Gold
LANGUAGE AND LANGUAGE DISORDERS
P3.192 Longitudinal decline in the
concreteness of speech in semantic variant primary progressive aphasia (svPPA) —
Katheryn Cousins, Sharon Ash, Murray Grossman
P3.193 WITHDRAWN P3.194 Dysprosody markers in PPA — Naomi Nevler, Sharon Ash, David Irwin, Mark Liberman, Murray Grossman
P3.195 Cerebrospinal Fluid Biomarkers
of Likely Pathology in Primary Progressive Aphasia —Catherine Norise, Amy Halpin, David Irwin, Murray Grossman
P3.196 Investigating the use of high
frequency repetitive transcranial magnetic stimulation for primary progressive apraxia of speech —Danielle Shpiner, Dannaly Reyes-
Baerga, Katalina McInerney, Corneliu Luca, Alyssa Bautista, Joyce Gomes-Osman
P3.197 Clinicopathological Correlates
of Verbal Fluency in Parkinson’s Disease: A
P3.183 Assessing Test-Retest Reliability Pilot Study —Rasheda El-Nazer, Jonathan Artz,
of Phase Contrast MRI for Measuring Wencong Chen, Christine Belden, Charles Adler, Cerebrospinal Fluid Flow Dynamics in Thomas Beach, Jared Benge Alzheimer’s Disease —Ashwin Sakhare, Lisette P3.198 Unilateral Apraxic Agraphia Isenberg, Judy Pa without Ideomotor Apraxia in a patient with
146 2018 AAN Annual Meeting
callosal and frontal lobe lesions —Tigran
P3.187 Longitudinal Changes in
patients with Alzheimer’s disease (AD) and P3.191 Differential Susceptibility of Large-Scale Brain Networks to White mild cognitive impairment (MCI) who will convert to AD using deep neural networks — Matter Alterations in Aging —Christopher Silvia Basaia, Federica Agosta, Luca Wagner, Giuseppe Magnani, Massimo Filippi
Tuesday, April 24 11:30 a.m.–7:00 p.m.
P3.207 Inter-User Scoring Discrepancies P3.219 The Influence of Sleep Amongst Residents using The Alberta Stroke Program Early CT Score (ASPECTS) Shows Limited Use of this Scoring Tool without Formal Training. —Saman Zafar, Ylec Cardenas Castillo, Simon Castro, Lakshmi Leishangthem, Brooke Devenney-Cakir, Rakesh Ahuja, Aparna Prabhu
Derangement, Low Energy and Fatigue on Depression after Stroke —Pratik Bhattacharya, Phillip Kucab, Advait Mahulikar, Ramesh Madhavan
P3.220 Anxiety and Depression in
Patients Who Undergo a Cerebrovascular Procedure —Lauren Lombardo, Richard Shaw,
P3.208 Impact of Ultra-Rapid-Sequential Dorothea Altschul IV/Contrast on Renal Function and incidence P3.221 Beta Blockers do not Increase of CIN in a Comprehensive Stroke Center —
the Risk of Post-stroke Depression in a
Phillip Ye, Jennifer Frontera, Ryan Bo, Karthikeyan Arcot, Jeffrey Farkas, David Turkel-Parrella, Ambooj Predominantly Afro-Caribbean Population — Elizabeth McCuaig, Jeremy Weedon, Nadege Tiwari Gilles, Cindy Tsui, Lucy Tan, Jonathan Singer, P3.209 Flat- Panel Cone Beam Computed Susan Law, Steven Levine
Tomography is a NOT a Reliable Predictor for P3.222 Post-Traumatic Stress Disorder in Early Changes in Ischemic Stroke Patients functionally independent patients following with Large Vessel Occlusions (LVO) — a first-ever Ischemic Stroke/TIA —Marcos Amrinder Singh, Ashish Kulhari, Siddhart Mehta, Lange, Beltrami Larissa, Paula Marques, Francisco Briana DeCarvalho, Hemal Patel, Spozhmy Panezai, Germiniani, Francisco Jaime Barbosa, Rafael Jawad Kirmani Massuda, Viviane Zetola
P3.210 CTP Mismatch Imaging
Underestimates Tissue Viability in UltraEarly Large Artery Occlusion —James Frey, Carol Darbonne
P3.211 Diffusion And Perfusion
Mismatch Is Associated with Early Neurologic Deterioration in Single Small Subcortical Infarction —Si Baek Lee, Yoo Dong Won
P3.212 The Prediction of The
Hemorrhagic Transformation Locations After Reperfusion Therapy in Acute Stroke
P3.223 A Depression Screening Protocol for Patients With Acute Stroke: A Quality Improvement Project —Celia McIntosh
P3.224 Do Selected Stroke Risk Factors Predict Post-Stroke Fatigue in an AfroCarribean Population? —Cindy Tsui, Clotilde Balucani, Jeremy Weedon, Elizabeth McCuaig, Lucy Tan, Susan Law, Nadege Gilles, Jonathan Singer, Steven Levine
P3.225 Thalamic Atrophy Mediates the
Effects of Cerebral Small Vessel Disease on Gait Impairment —Ning Su, Xin-Yu Liang, Fei-Fei
Zhai, Lixin Zhou, Jun Ni, Ming Yao, Feng Tian, ShuYang Zhang, Zheng-Yu Jin, Li-Ying Cui, Gao-Lang Gong, Yi-Cheng Zhu
P3.239 Evaluation Times and Outcomes
P3.226 Consciousness disorders in
Alejandro Vargas, Laurel Cherian, James Conners, Sarah Song, Rima Dafer, Joshua Bock, Nicholas Osteraas
thalamic vascular lesions —Blas Couto, Guido
Vazquez, Carla Florencia Bolaño Diaz, Alejandro Thomson, Carlos Santiago Claverie, Francisco Klein
P3.227 Early tablet-assisted cognitive
rehabilitation for aneurysmal subarachnoid hemorrhage: Feasibility of a single-center randomized controlled trial —Bing Yu Chen,
P3.254 Unilateral Vocal Cord Paralysis in English versus Non-English Speaking associated with Ipsilateral Acute Cortical Patients Undergoing Telestroke Evaluation — Stroke: A Rare Case Presentation —Khalid
Associated with Aiming Neglect After Right Brain Stroke —Jonathan Thomas, Meghan Caulfield, A. Barrett
P3.229 Late Functional Recovery
After Lacunar Stroke: Implications For Rehabilitation Studies —Aravind Ganesh, Rose M Wharton, Sergei A Gutnikov, Peter Rothwell, on behalf of the Oxford Vascular Study
P3.230 Aphasia Rapid Test—
Quantification and assessment of Aphasia in Stroke —Harish Jayakumar, Balasubramanian Samivel, Manickvasagam Janarthanam, Shanmuga Sundaram N, Lakshmi Ranganathan, Krishnamoorthy Kuppusamy, Kaushik Gowthaman
P3.231 Prevalence of Cognitive
Impairment and Effects on Survival in the Mayo Clinic Florida Familial Cerebrovascular Diseases Registry —Kevin Barrett, Tasneem
Hasan, Thomas Brott, Elizabeth R. Lesser, David O. Hodge, James Meschia
STROKE KNOWLEDGE, BEHAVIOR, AND CULTURE
P3.232 Help-seeking delay in stroke increases mortality and hospital stay: Results from a developing country. —
Alejandro Gonzalez Aquines, Adolfo Cordero, Nicolás Escobedo-Zúñiga, Luis Ramirez, Alan Treviño-Herrera, Helda E Sanchez-Teran, Juan Gongora Rivera
Sawalha, Omar Hussein, Ahmed Abd-Elazim, Diana Gugger, Brin Freund, Peter Kaplan Greene-Chandos, Michel Torbey
P3.255 An Unexpected Imitator: HLH
P3.240 A 31-year old Postpartum
Tijil Agarwal, Rebecca Romero
Britton, Sara Hocker, Amy Crepeau
P3.256 Reversal of Fortune: Congenital
P3.274 EEG Predictors of Post-Stroke
Woman with Thunderclap Headache: A Case PCA Laterality is Detrimental to Infarct of Segmental Cerebral Vasoconstriction Volume —Kalea Colletta, Geeta Verma, Camilo Secondary to Pheochromocytoma —Stephen Gomez
Vasoconstriction Syndrome with Bilateral Intraocular Hemorrhage —Hae Young Baang,
P3.235 Health Literacy and Length of
Stay in Stroke —Wendy Tian, Lakshmi Warrior, Lisa Diep, Michael Kelly
P3.236 Hmong Stroke Knowledge
P3.275 Mapping the dynamics of heart
EEG AND IMAGING
Manmeet Kaur, Rabia Jamy, Margi Patel, Angela Hays Shapshak, Sandipan Pati
F
P3.259 Resident Competency and
Sachin Kedar, T. Scott Diesing
Interrater Agreements Using the ACNS Critical Care EEG Terminology —Joy Ding,
and Cognitive Impairments from ThalamicHypothalamic Stroke —Jessica Ng, Kasun
P3.265 Time to Detection of Seizures
P3.238 Primary Language Predicts
Outcomes in Acute Ischemic Stroke —Afra
rate variability and complexity changes with progressive focal status epilepticus. —
P3.276 Bilateral independent
periodic discharges are associated with
Josee Carpentier, Kristin McBain, Nicolas Gaspard, electrographic seizures and poor outcome: A case-control study —Gamaleldin Osman, Rahul P3.243 Stroke-like Symptoms following M. Westover, Tadeu Fantaneanu Rahangdale, Jeffrey Britton, Emily Gilmore, Hiba a Lumbar Epidural Block: A Rare Case Report P3.260 Improving Diagnostic Accuracy Haider, Stephen Hantus, Aline Herlopian, Sara of Pneumocephalus —Nicholas Lannen, in Epilepsy: Effect of Online Medical Hocker, Jong Lee, Benjamin Legros, Vineet Punia, Brandon Francis, Muhammad Farooq Nishi Rampal, Jerzy Szaflarski, Adam Wallace, M. Education on EEG Interpretation Among Westover, Lawrence Hirsch, Nicolas Gaspard P3.244 Painless Labor: A Case of Neurologists —Stacey Hughes, Thomas Progressive Myelopathy during Pregnancy — Finnegan, Selim Benbadis P3.277 Comparison of Ambulatory and Andrea Wasilewski, Tirisham Gyang, Lawrence Inpatient 24 hour EEG: A Value Analysis — P3.261 Utility of Inpatient EEG and Samkoff Sotiris Mitropanopoulos, Jeffrey Britton Role of Neurologic Input in Tertiary Care P3.245 Ruptured Anterior Spinal Artery Hospital —Bakhtier Nurmukhamedov, Vishal P3.278 A Case of Focal REM-Sleep of the Craniocervical Junction: Case Report Shah, Robert Beach Epilepsy Originating from the Occipital and Review —Lakshmi Leishangthem, Sudhakar P3.262 Testing and Turnaround Time for Lobe —Umar Shuaib, Mohammad Humayun, R. Satti Sharjeel Panjwani, Ajaz Sheikh Stat EEGs: How do we get faster? —Brian P3.246 Spinal Cord Infarction: Clinical Hanrahan, Eric Jackowiak, James Lee, Stephanie P3.279 Functional Connectivity Analysis and Imaging Insights from the Periprocedural Paolini, Anto Bagic, Alexandra Popescu on Scalp EEG for Identification of Deep Setting —Nicholas Zalewski, Alejandro P3.263 Analysis of EEG Use Utilizing Parenchymal Lesions —Jalyoung Joe, George Rabinstein, Karl Krecke, Robert Brown, Eelco Newman the National Inpatient Sample —Rebecca Wijdicks, Brian Weinshenker, Derrick Doolittle, Bernheimer, Seth O’Neal, Marissa Kellogg Eoin Flanagan P3.280 Mapping Cortical Connectivity P3.264 Survey of Neurologists Regarding Using Cortico-Cortical Evoked Potentials — P3.247 Pathological Crying Prior to the Onset of Pontine Ischemic Stroke —Eric Lee, the Use of Continuous EEG (cEEG) Monitoring Lawrence Crowther, Peter Brunner, Anthony in Children Presenting With Encephalopathy Ritaccio, Gerwin Schalk Bradley Jacobs, Thomas Pitts, Suraj Rajan Following Status Epilepticus (SE) —Asri P3.281 Spectral analysis of dynamic P3.248 First-order Horner’s Syndrome Yuliati, Amanda Weber Navarathna, Malveeka Sharma, Jose Romero
P3.249 Atypical ipsilateral Dejerine
Roussy syndrome following a left thalamic
Almallouhi, Marian Dale
with Continuous EEG (cEEG) Monitoring: The Correlation with Seizure Etiologies, Neurologic Status and EEG Findings —Ifrah Zawar, Stephen Hantus
P3.267 Efficacy of Simultaneous Scalp
P3.251 Frontal eye field ischemic stroke
and Intracranial EEG in Detecting Seizure Onset Zone —Ying Sun, Arun Antony, Jullie Pan,
Shaker, Abdallah Hamdallah, Blake Senay, Vivek Rai
P3.268 Electroencephalogram
functional connectivity between restingstate networks reveals information beyond static connectivity —Sharon Chiang, Emilian Vankov, Hsiang Yeh, Michele Guindani, Marina Vannucci, Zulfi Haneef, John Stern
P3.282 Involvement of Different
Networks in Mesial Temporal Lobe Epilepsy Subtypes Identified by Interictal EEG Source Analysis and Structural Neuroimaging —Luiz
Betting, Elaine Fujisao, Karen Alves, Thais Rezende
P3.283 Reduced Resting State
Functional Connectivity of the Hippocampi as a Biomarker of Temporal Lobe Epilepsy —
presenting with internuclear opthalmoplegia: Alexandra Urban, Joanna Fong, Naoir Zaher, Tanya Thomas Henry, Scott Burwell, Eric Waldron, Bryon Mueller, Jazmin Camchong, Kelvin Lim, Abhrajeet Case report and review of anatomy —Hussam Rath, Mark Richardson, Anto Bagic
P3.252 Rapid Revascularization of
Simultaneous Bilateral ICA Occlusions causing Coma —C. Frances Fan, David
Survey —Carol Droegemueller, Zong Xiong, Pakou Liebeskind, Jason Hinman, Charles Windon Xiong, Jodi Mueller-Hussein, Nour Eldin Hussein, P3.253 Typical Stroke Symptoms with Sidney VanDyke, Haitham Hussein Atypical Imaging: A case series of cortical ribboning on MRI representing acute ischemic P3.237 Language Barrier Does Not stroke —Muhammad Niazi, Harmanpreet Tiwana, Affect Acute Stroke Management and Cheran Elangovan, David Ermak Treatment —Noriko Anderson, Afra Janarious, Wengui Yu, Dana Stradling
Christine Smith, Leonardo Almeida, Anna Khanna, Maria Hella, Stephan Eisenschenk
Characteristics in Critical Ill Patients before Cardiac Arrest: A Small Case Series —Jian Xu, Wazim Mohamed, Aaron Desai, Maysaa Basha, Deepti Zutshi
P3.269 WITHDRAWN P3.270 Concordance of Focal
Electrographic Slowing with Structural Lesions on MRI —Syed Shabbir, Alexis Boro
P3.271 Heart Rate Variability as a Prognostic Marker Following Cardiac Arrest —Rahul Guha, Andrew Schomer
Roy
P3.284 The Role of Generalized Tonic-
Clonic Seizures and Partial Onset Seizures and the Effects of Antiepileptic Drugs on Retinal Architecture. —Samuel Lichtman-Mikol, Kalyan Yarraguntla, Melody Gilroy, Varun Chauhan, Elise Wiersma, Navid Seraji-Bozorgzad, Maysaa Basha, Deepti Zutshi, Aashit Shah
P3.285 Using Surface Electromyography to Differentiate between Generalized Tonic-Clonic Seizures and Psychogenic NonEpileptic Spells —Damon Cardenas, Jonathan Halford, Kristen Malloy, Luke Whitmire, Jose Cavazos
Janarious, Noriko Anderson, Wengui Yu
AAN.com/view/AM18 147
Tuesday
Gazi, Terri Hunter, Edward Miech, Linda Williams, Michael Lyerly
Seizure —Lesley Kaye, Zachary Newcomer,
P3.257 NA P3.258 NA
P3.266 Quantitative EEG Spectrograms: Symptom Onset and Emergency Department Venkataraman, Eric Mariuma Diagnostic efficacy in Intensive care and Arrival in Stroke Patients —Scott Le, Laurel P3.250 Acute Bilateral Apraxia of Eyelid Epilepsy Monitoring units and the common Copeland, John Zeber, I-Chia Liao, Leigh Allen, Closure (AEC) Following Bilateral Subcortical seizure mimickers. —Ajay Goenka, Alexis Boro Jared Benge, Jennifer Rasmussen Frontal Infarctions-Case Report —Eyad among Veterans with Acute Ischemic Stroke —Carolina Temple, Miles Cobia, Melissa
P3.273 Electroencephalography in West
Nile virus Neuroinvasive Disease —Angela Presenting as CNS Infarction —Hanna Blaney, Parsons, Marie Grill, Anteneh Feyissa, Jeffrey
P3.233 Factors Affecting Time Between ischemic stroke —Faddi Saleh Velez, Sandheep
P3.234 Reasons for Delayed Arrival
Etiology and Prognostic Value of Bilateral Independent Periodic Discharges —James
STROKE CASE REPORTS I
Hisham Aldhukair, Jonathan Cote, Julie Flinois, Tuan Hoang, Hao Cheng Shen, Chloe Xu, Morgane English, Deena Nasr Laverdure, Yi Tong, Emily Nolan, Ke Xuan Li, Leila P3.241 A Case of Fulminant Unilateral Cattelan, Christine Audi, Noemie La HayePerioperative RCVS —Lin Zhang, Sanjeev Caty, Vanessa Danielova Gueorguieva, Eugene Brailovski, Kourosh Lalavi, Lo Benjamin, Etienne De Taneja Villers-Sidani P3.242 Catastrophic Reversible Cerebral
P3.228 Anterior Striatal Lesions are
P3.272 Retrospective Analysis of the
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION III G P3.286 Anxiety and Depression
children with hemiplegic migraine. —Rachit Symptoms Disrupts Resting State Networks Patil, Rahul Nikam, Badal Jain, Vinay Kandula in Patients with Generalized Epilepsies — AUTISM AND DEVELOPMENTAL Danielle dos Santos Garcia, Mateus Nogueira, DISABILITIES Marina Alvim, Marina Polydoro, Akari Ishikawa, Tamires Zanão, Brunno de Campos, Lucas Lodi Montanher, Marcia Morita, Fernando Cendes, Clarissa Yasuda
P3.302 STARS: A Phase 2 Adult
Angelman Syndrome Clinical Trial: Randomized, Double-blind, Safety and
P3.287 Frontal Lobe Functions in Children Efficacy Study of Gaboxadol —Cesar Ochoawith Newly Diagnosed Temporal Lobe Epilepsy: Functional Magnetic Resonance Imaging —Temitayo Oyegbile, J VanMeter, William Gaillard, Bruce Hermann
P3.288 Status epilepticus: What do
peri-ictal changes in brain images mean? —
Alejandro Thomson, Guido Vazquez, Carla Bolaño, Blas Couto, Carlos Santiago Claverie, Diego Minarro, Guillermo Di Lorenzo, Alfredo Thomson
P3.289 Yield of Emergent Computed
Tomography in Epilepsy Patients Presenting with a Seizure —Kathryn Kvam, Vanja Douglas, William Whetstone, S. Josephson, John Betjemann
P3.290 Arterial spin labeling (ASL) MRI in a patient with non-convulsive status epilepticus (NCSE) —Jae Eun Lee, Pritikanta Paul, Mark Buehler, Xin Wang, Imran Ali
P3.291 NA P3.292 NA P3.293 NA P3.294 NA ACQUIRED BRAIN INJURY: STROKE, TRAUMATIC BRAIN INJURY
G
P3.295 The Influence of Presenting
Lubinoff, Logan Wink, Joseph Grieco, Jeannie Visootsak, Rebecca Burdine, Alexander Kolevzon, Ronald Thibert, Lynn Bird
P3.303 Comparison of Functional
Connectivity Abnormalities in Autism and Williams Syndrome —Julie Korenberg
Tuesday
Bridget MacDonald, Doris Trauner
P3.300 Reversible Cerebral
a novel mutation —Sireesha Chinthaparthi,
P3.315 Micronutrient Levels in Patients
Treatment of an Infantile Neuroaxonal Dystrophy Patient with a Novel Stabilized Polyunsaturated Fatty Acid Drug —Darius
Sacco, Don Bailey, Jeannie Visootsak, Raquel Cabo
With ADHD —Siddharth Gupta, Keith Pecor, Shreya Agarwal, Daniel Oh, Jeffrey Kornitzer
P3.316 Anatomic and Functional
Kimberly McDonald, Lamar Davis
P3.327 Case Report: Expanded Access
Adams, Janannaz Dastgir, Robert Molinari, Frederic Heerinckx
P3.328 Expanded Phenotypes of
Vanishing White Matter disease —Hitha CLINICAL AND BASIC SCIENCE OBSERVATIONS
Selena Chea, Patricia Lasutschinkow, Carole Samango-Sprouse
P3.306 MicroRNAs and Gene-
Predictors of Adult Outcomes —David
Heidrich, Stephany Nguyen, Keith Crenshaw, Drake Duane
P3.318 Cannabidiol Based Medical
Cannabis in Children with Autism- a Retrospective Feasibility Study —Adi Aran,
Environment Interactions in Autism: Prenatal Hanoch Cassuto, Asael Lubotzky Maternal Stress and the SERT Gene —David P3.319 A Literature Review of the Beversdorf, Ayten Shah, Janelle Noel-MacDonnell, Economic Burden of Fragile X Syndrome — Patrick Hecht, Bradley Ferguson, Zohreh Talebizadeh
Patricia Sacco, Melissa Raspa, Leslie Leahy, Raquel Cabo
P3.307 Healthcare and Medical Service
P3.320 EEG Endophenotypes in Autism
Utilization Among Patients With Angelman Syndrome By Molecular Subtype: Results From The AS-NHS Study —Raquel Cabo, Nasreen Khan, Wen-Hann Tan, Regina Tayang,
Spectrum Disorder —Jamie Capal, Paul Horn, Christopher Carosella, Elora Corbin, Patricia Manning-Courtney
P3.321 Prospective validation of
molecular subtype diagnostics for autism spectrum and neurodevelopmental disorders —Elizabeth Donley, Robert Burrier,
Joseph King, Alan Smith, Paul West, Lindsay Feuling, Michael Ludwig, DelRay Sugden, Brandon Smart, David Amaral
CHILD NEUROLOGY AND neonates: Size at birth and postnatal growth DEVELOPMENTAL NEUROLOGY: NEURODEGENERATIVE DISEASE predict neurodevelopmental outcomes — Thiviya Selvanathan, Vann Chau, Rollin Brant, Anne P3.322 LeukoSeq Whole Genome Synnes, Ruth Grunau, Steven Miller Sequencing Clinical Trial: An Interim P3.310 Profile of Children with Cerebral Analysis —Guy Helman, Omar Sherbini, Zachary Cross, Sarah Woidill, Asako Takanohashi, Holly Palsy and Congenital Malformations in Dubbs, Joseph Flores, Maren Bennett, Julia Canada —Marcel Severe, Pamela Ng, Maryam
P3.312 Social Functioning Mediates
ADHD Symptomatology and Mental Health Functioning in Neurotypical Children versus Children with Autism Spectrum Disorder or Williams Syndrome —Rowena Ng, Ursula
Vasoconstriction Syndrome: A novel mechanism for neurologic complications in Bellugi, Doris Trauner Schimke Immuno-osseus Dysplasia. —Darrah Haffner, Nancy Rollins, Michael Dowling P3.313 Effect of a Combination of Carnitine, Coenzyme Q10 and Alpha-Lipoic P3.301 Role of Arterial Spin Labelling Acid (MitoCocktail) on Mitochondrial Perfusion weighted MRI in evaluation of
148 2018 AAN Annual Meeting
in Fragile X Syndrome: Results of a Targeted Literature Review —Melissa Raspa, Patricia
P3.317 Tourette Syndrome: Childhood
disorder: The Relationship with Autism Spectrum Disorders (ASD), Developmental delay, and Testosterone —Andrea Gropman,
Michael Karras, Larry Goldstein, Ricki F Goldstein, Marc Wolfe, Muralimohan Palla, Robert Baumann, P3.311 Chandigarh Autism Spectrum Michael Dobbs Disorder Study: Prevalence in India —Priti Arun, Bir Singh Chavan
Outcomes with Neonatal EEG Activity —
P3.314 Clinical Unmet Needs and Burden with peripheral neuropathy associated with
P3.305 49,XXXXY, a rare genetic
Neonatal Stroke —Ana Albuja, Valeria Naranjo, Oskoui
P3.299 Predicting Perinatal Stroke
P3.325 WITHDRAWN P3.326 A case of Alexander disease
Amin, Nilesh Desai, Lisa Emrick
P3.309 Head circumference in preterm
P3.298 Inaccuracies In Coding In
Barash, Aric Orbach, Iris Grossman, Ralph Laufer, Michael Hayden
Estevez, Gerry Leisman, Philip Defina
Cristancho, Drew Streicher, Arastoo Vossough, James Treat, Daniel Licht, Jenna Streicher
Woodward, Helen Carlson, Adam Kirton
BDNF Expression in a Rett Syndrome Mouse Model —Michal Geva, Jennifer Dreymann, Steve
Hanoch Cassuto
Xun Zhang, Nicole Pigeon, Louise Koclas, Céline Lamarre, Francine Malouin, Carol L. Richards, Michael Shevell, Maryam Oskoui
Functional Connectivity in Hemiparetic Children With Perinatal Stroke —Kristine
Brigid Garvin, Shirish Damle, Kelleen Corrigan, James Connell, Diana Thao, Ignacio Valencia, Joseph Melvin, Divya Khurana, Mitzie Grant, Craig Newschaffer
Connectivity Relationship in Autistic Children —Yanin Machado, Mauricio Chinchilla, to stimulants effect in Autism Spectrum Disorder —Itai Berger, Julia Peled, Dorit Shmueli, Yazmina Machado, Calixto Machado, Mario
P3.296 Characterization of Features of
P3.297 Sensory-Motor Network
Function and Neurobehavioral Performance in Children with Autism Spectrum Disorder —Agustin Legido, Michael Goldenthal,
P3.304 Processing Speed as a marker
Characteristics on Outcomes in Moderate Lynn Bird to Severe Pediatric Traumatic Brain Injury: Penetrating versus Blunt Mechanisms —Ryan P3.308 A Portrait of Cerebral Palsy in Chae, Cynthia Austin, Nathan Evanson, Katrina Quebec Over a Decade : Birth years 1999Peariso 2010 —Aristides Hadjinicolaou, Pamela Ng, PHACE Syndrome on Fetal MRI and Natural History of Postnatal Management —Ana
Tuesday, April 24 11:30 a.m.–7:00 p.m.
P3.329 A Novel RMND1 knock-in Mouse Recapitulates Clinical and Biochemical Abnormalities Observed in Patients —Maria
J Sanchez-Quintero, Carlos Lopez Gomez, Catarina Quinzii Hirano
P3.330 Retinal Nerve Fiber Layer
(RNFL) and Ganglion Cell Inner Plexiform Layer (GCIPL) in Persistently Myelin Oligodendrocyte Glycoprotein Antibody Positive Youth —Stephanie Grover, Carmen
Yea, Tara Berenbaum, Danusha Nandamalavan, Renisha Iruthayanathan, Colin Wilbur, Fahad Albassam, Giulia Longoni, Arun Y. Reginald, Michael Wan, Fiona Costello, Julia O’Mahony, Douglas Arnold, Brenda Banwell, Amit Bar-Or, Ruth-Ann Marrie, Donald Mabbott, E. Ann Yeh
P3.331 Nervus Intermedius Neuralgia Caused By Craniofacial Fibrous Dysplasia In A Pediatric Patient: A Case Report And Literature Review —Philip Eye, Adam Lewis, David Dennison, Sarah Cantrell, Latanya Agurs
P3.332 Chemotherapy Exposure Disrupts the Gliogenic Microenvironment —Erin Gibson, Michelle Monje
P3.333 Isolated ophthalmoplegia as
presenting sign of pediatric Wernicke encephalopathy —Danielle Takacs, Ariel LyonsWarren
P3.334 Neonatal Dexamethasone
McEachern, Denise Perry, Nicole Ulrick, Johanna Schmidt, Amy Pizzino, Genevieve Bernard, Ryan Taft, Adeline Vanderver
Treatment Attenuates Hippocampal and Amygdaloid GPR30 Gene Expression in Adult Female Rats —Keiko Lo, Kowk-Tung Lu
P3.323 Pilot study of the use of
P3.335 A Patient with 4H Syndrome Who
Janus Kinase Inhibitor, Baricitinib, in the treatment of heritable interferonopathy Aicardi Goutières Syndrome —Adeline
Vanderver, Ulrick Nicole, Francesco Gavazzi, Asako Takanohashi, Thais Armangue, Jullie Rhee, Jamie Koh, Sarah Woidill, Justine Shults, Deborah Foerster, Raphaela Goldbach-Mansky, Laura Adang, Amy Waldman
P3.324 Pridopidine Treatment Recovers Gait Abnormalities and Rescues Impaired
Presents in Adulthood —Ozge Uygun, Tuncay Gunduz, Murat Kurtuncu, Mefkure Eraksoy
P3.336 PURA Syndrome and Myotonia: A Case Report and Review of the Literature — Steven Trau, Carolyn Pizoli
P3.337 Neurological manifestations of
X-linked ichthyosis: Case report and review of the literature —William Baek, Umut Aypar
P3.338 NA
Research Methodology ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P3.339 Autoimmune Cerebellitis as
as Neurology Residents —Saman Zafar, Ylec
P3.342 Massive Right-sided Ovarian
Darshan Pandya, Michael Goldberg, Linda Lewis
Cardenas Castillo, Lakshmi Leishangthem, Aparna Tumor as a Probable Cause of Left-sided Prabhu, Sridhara Yaddanapudi, David Roby, George Meralgia Paresthetica —Nikesh Bajaj Newman
P3.340 Amateur Fundus Photography
P3.341 Developing a First-of-its-Kind
with Various New Devices- Our Experience
Telemedicine Rotation for Neurology Residents —Mitra Afshari, Nicholas Galifianakis
MS AND CNS INFLAMMATORY DISEASE: NEUROIMAGING
Stephen Jones, Izlem Izbudak, Yvonne Lui, Lauren Krupp, Ellen Mowry, Carl DeMoor, Richard Rudick, James Williams, Elizabeth Fisher
a paraneoplastic syndrome in Ovarian Teratoma —Ashley Roque, MaryKay Pavol,
P3.345 Magnetic Resonance Imaging in Multiple Sclerosis associated Seizures —
Kalyan Yarraguntla, Shitiz Sriwastava, Rohit Marawar, Maysaa Basha, Deepti Zutshi, Evanthia Bernitsas
P3.346 Atrophied lesion volume: A
P3.355 MRI predictors of improvement
P3.348 Regional brain atrophy and its
Ivo Paunkoski, Deepa Ramasamy, Diego Silva, Ellen Carl, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman, Robert Zivadinov
P3.349 Great reduction of correlation
in multiple sclerosis patients may be sexspecific —Dejan Jakimovski, Robert Zivadinov,
clinical correlations in single MS patients at first visit —Alaleh Raji, Gerhard Winkler between global and regional brain volume and spinal cord volume in multiple sclerosis patients with severe disability —Manuela
interprofessional competency in opioidsparing acute pain management —Joseph
P3.357 Accelerated central atrophy
P3.351 Brain lesion segmentation and
Johannes Gregori, Luc Bracoud, Christian Cornelissen
P3.365 Cognitive impairment in Multiple
P3.352 Gray Matter Atrophy and
P3.359 Multiple sclerosis patients who
improve in their disability over time develop less brain atrophy compared to those who remain stable or progress —Emanuele
Ghione, Niels Bergsland, Michael Dwyer, Jesper Hagemeier, Dejan Jakimovski, Ivo Paunkoski, Deepa Ramasamy, Ellen Carl, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman, Robert Zivadinov
Valentina Poretto, Silvia Franciotta, Alice Riccardi, Monica Margoni, Davide Poggiali, Francesco Causin, Paolo Gallo
Microstructural White Matter Abnormalities Underlying Cognitive Impairment in Benign P3.361 Thalamic Atrophy and MS —Maria Rocca, Gianna Carla Riccitelli, Disability in Progressive Multiple Sclerosis Elisabetta Pagani, Marta Radaelli, Paolo Preziosa, Subgroups —Sean Tobyne, Andrew Russo, Giancarlo Comi, Andrea Falini, Massimo Filippi
P3.353 Disappearing Brainstem MRI Lesions in Multiple Sclerosis —Svetlana
Eckert, Bianca Weinstock-Guttman, Channa Kolb, David Hojnacki
P3.354 Comparison of Techniques for
Measurement of Brain Volume in Multiple Sclerosis Patients —Adrian Tsang, Carrie
Wager, Ricardo Corredor-Jerez, Mario J. Fartaria, Benedicte Marechal, Tobias Kober, Robert Bermel,
P3.374 INSPIRATION: Towards individual determination of NEDA 4—Qualitative visual determination of short term stable brain volumes from standardized MRI acquisition in daily clinical routine of MS patients —Achim Gass, Luc Bracoud, Johannes Gregori, Stefan Hoffmann, Christian Cornelissen
P3.375 Relationship between clinical Sclerosis: The contribution of cognitive reserve and regional gray matter volumes — manifestation of MS relapse and Gadolinium Alvino Bisecco, Gabriella Santangelo, Luigi Trojano, enhancing lesions in brain MRI —Lorena Renato Docimo, Rocco Capuano, Mattia Siciliano, Alessandro d’Ambrosio, Marida Della Corte, Simona Bonavita, Gioacchino Tedeschi, Antonio Gallo
Martín-Aguilar, Silvia Presas, José Vicente HervásGarcía, Anna Massuet-Vilamajo, Laia Grau-Lopez, Cristina Ramo
P3.366 Prospective multi-modal MRI
Tissue Damage in Chronic Active Lesions as Measured by Change in T1 HypoIntensity of Slowly Evolving Lesions in Patients With Primary Progressive Multiple Sclerosis —Colm Elliott, Jerry Wolinsky, Stephen
study to examine the effect of Fingolimod on tissue injury and repair in the brain in patients with relapsing remitting multiple sclerosis —Sara Razmjou, Fen Bao, Samuel
P3.376 Ocrelizumab May Reduce
Jesper Hagemeier, Niels Bergsland, Bianca Weinstock-Guttman, Channa Kolb, David Hojnacki, Lichtman-Mikol, Melody Gilroy, Kalyan Yarraguntla, Hauser, Ludwig Kappos, Frederik Barkhof, Fabian Model, Wei Wei, Corrado Bernasconi, Shibeshih Ralph Benedict, Michael Dwyer Rishi Sood, Carla Santiago-Martinez, Evanthia Belachew, Douglas Arnold Bernitsas, Navid Seraji-Bozorgzad
atrophy measurement in MS patients: Comparison between manual and automated methods —Hernán Chaves, Matías Varela, P3.360 Cerebellar cortical lesions Mercedes Serra, Emilia Osa Sanz, Nadia Stefanoff, selectively contribute to cognitive Iván Itzcovich, Jorge Correale, Diego Fernández dysfunction in early Multiple Sclerosis — Slezak, Mauricio Farez
Mendiratta, Sweta Patel, Michelle Bell
inhibitors and MRI outcomes in multiple sclerosis —Nicole Ziliotto, Francesco Bernardi, Dejan Jakimovski, Marcello Baroni, Giovanna Marchetti, Niels Bergsland, Bianca WeinstockGuttman, Paolo Zamboni, Murali Ramanathan, Robert Zivadinov
P3.369 The functional brain network
remains stable in natalizumab-treated multiple sclerosis patients: A one year study —Kim A Meijer, Oliver Wiebenga, Anand
JC Eijlers, Martijn D Steenwijk, Jeroen JG Geurts, Menno M Schoonheim
MS AND CNS INFLAMMATORY DISEASE: NEUROIMAGING: NOVEL TECHNIQUES
P3.377 Longitudinal change of myelin
water fraction (MWF) within chronic multiple sclerosis (MS) lesions —Sneha Pandya, Ulrike Kaunzner, Eric Morse, Thanh Nguyen, Nancy Nealon, Jai Perumal, Timothy Vartanian, Yi Wang, Susan Gauthier
P3.378 Double Inversion Recovery
Imaging MRI: A Good Tool to Identify Optic Neuritis Lesions in Multiple Sclerosis and Neuromyelitis Optica —Izumi Kawachi, Etsuji
Saji, Mariko Hokari, Akiko Yokoseki, Takahiro Wakasugi, Fumihiro Yanagimura, Osamu Onodera
P3.370 Evolution of New Lesions and its P3.379 Reduced Dynamism of Functional Temporal Patterns in Patients with Clinically Isolated Syndrome (CIS) Treated with Subcutaneous Interferon beta-1a (scIFNβ1a) —Hugo Vrenken, Marlieke de Vos, Marco
Connectivity Is Associated with Cognitive Impairment in Multiple Sclerosis Patients: A Dynamic Functional Connectivity Study in a Multi-Center Setting —Alessandro D’Ambrosio,
Maria Rocca, Paola Valsasina, Antonio Gallo, Battaglini, Gijs J. Nagtegaal, Bernardo De Almeida Nicola De Stefano, Debora Pareto, Frederik Teixeira, Kurt Marhardt, Nicola De Stefano, Barkhof, Olga Ciccarelli, Christian Enzinger, Robert Fox, Eric Klawiter Frederik Barkhof Gioacchino Tedeschi, Maria Laura Stromillo, Maria-Jesus Arevalo, Hanneke Hulst, Nils Muhlert, P3.362 Brain Volume Increase in Multiple P3.371 Brain Volume Loss in RRMS is Sclerosis Patients —Michaela Andelova, Jan Associated to Clinical Scores Irrespective of Marisa Koini, Massimo Filippi Krasensky, Niels Bergsland, Zdenek Seidl, Barbora Quantification Method —Jozef Magdic, Žiga P3.380 One Size Does Not Fit All: Benova, Eva Havrdova, Manuela Vaneckova, Dana Špiclin, Tanja Hojs Fabjan Large-scale neuronal network Functional Horakova, Tomas Uher ®
P3.363 Brain Activity Induced by
Psychological Stress Predicts Future Gray Matter Atrophy Accumulated in a Two-Year
P3.372 Use of LesionQuant to Measure Connectivity differs across Cognitive
Cerebral White Matter Lesion Distribution in Phenotype groups in Multiple Sclerosis — Neuromyelitis Optica and Relapsing Multiple Korhan Buyukturkoglu, David Parker, Qolamreza Razlighi, Christian Habeck, Claire Riley, Victoria Leavitt
AAN.com/view/AM18 149
Tuesday
Fuchs, Niels Bergsland, Deepa Ramasamy, Tomas Uher, Dana Horakova, Manuela Vaneckova, Eva Havrdova, Ralph Benedict, Robert Zivadinov, Michael Dwyer
(EEG) Tutorial Atlas as a Learning Tool for Neurology Residents —Rachael Benson, Anil
Sclerosis —Cameron L. Schubert, Enrique Antonia Meyer-Arndt, Janina Behrens, Katharina Alvarez, Justin Honce, Christopher Filley Wakonig, Michael Scheel, Alexander Brandt, Judith Bellmann-Strobl, John Dylan Haynes, Stefan P3.373 Brain atrophy staging of single MS patients with MRI at first visit —Alaleh Gold, Friedemann Paul Raji, Gerhard Winkler
Vaneckova, Michaela Andelova, Jan Krasensky, P3.358 Micro and Macrostructural Lukas Sobisek, Zdenek Seidl, Eliska Kusova, Tomas Limbic System Correlates of Comprehensive P3.367 Optic Neuritis Neuroimaging Uher, Eva Havrdova, Barbora Benova, Benedicte Characteristics Are Affected By Etiology — Cognitive Symptomatology in Multiple Marechal, Tobias Kober, Dana Horakova Sclerosis using Quantitative MRI and DTI — Casey Farin, Christopher Eckstein P3.350 Accelerated subcortical atrophy Zafer Keser, Khader Hasan, Benson Mwangi, Arash P3.368 Plasma levels of hemostasis Kamali, Kyan Younes, John Lincoln, Flavia Nelson following new lesion accrual in directly
connected tracts is significant and appears limited to the first year —Keith Carolus, Tom
P3.344 A Mobile Electroencephalogram
Period in MS Patients —Martin Weygandt, Lil-
during specific rehabilitation of information P3.364 INSPIRATION: An approach processing speed and attention in MS: A randomized trial against non-specific training to brain volume and quantitative lesion load assessments from standardized MRI with semi-ecological evaluation. —Ismail Koubiyr, Delphine Lamargue-Hamel, Mathilde acquisition in daily clinical routine of MS Deloire, Aurore Saubusse, Julie Charre-Morin, patients —Achim Gass, Stefan Hoffmann,
novel and robust imaging biomarker in multiple sclerosis for predicting disability Aurelie Ruet, Bruno Brochet progression —Robert Zivadinov, Niels Bergsland, P3.356 Whole Brain and Lateral Jesper Hagemeier, Deepa Ramasamy, Tomas Ventricular Volume Changes are associated Uher, Manuela Vaneckova, Eva Havrdova, Dana with Development of Disability Progression Horakova, Michael Dwyer in Multiple Sclerosis: Results from a LargeP3.347 Disability-Specific Atlases of Scale Clinical Routine 5-Year Observational Gray Matter Loss in Relapsing-Remitting Study —Emanuele Ghione, Michael Dwyer, Niels Multiple Sclerosis —Allan MacKenzie-Graham, Bergsland, Jesper Hagemeier, Dejan Jakimovski, Florian Kurth, Yuichiro Itoh, HeJing Wang, Michael Montag, Robert Elashoff, Rhonda Voskuhl
P3.343 Online education for
Nugent, Luis Buenaver, Marlis Gonzalez-Fernandez, Sharon Kozachik, Suzanne Nesbit, Beth Hogans
POSTER SESSIONS
g1 H
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION III G P3.381 Quantitative Magnetization
MS THERAPEUTICS Transfer Imaging in Multiple Sclerosis: A 3.0 IN DEVELOPMENT Tesla Clinical Study —Francesca Bagnato, Giulia P3.393 Phase 1 Trial of Intrathecal Franco, Nikita Thomas, Seth Smith, Junzhong Xu, Rituximab in Progressive MS Patients Richard Dortch with Evidence of Leptomeningeal Contrast P3.382 Column-specific demyelination Enhancement —Pavan Bhargava, Cassie Wicken, in Spinal Cord Normal Appearing White Matthew Smith, Irene Cortese, Daniel Reich, Peter Matter occurring in Multiple Sclerosis: A Calabresi, Ellen Mowry preliminary study using inhomogeneous P3.394 WITHDRAWN Magnetization Transfer and DTI —Henitsoa Rasoanandrianina, Bertrand Audoin, Manuel Taso, P3.395 Ozanimod (RPC1063) Reduces Olivier Girard, Guillaume Duhamel, Lauriane Pini, Plasma Levels of Neurofilament Light Chain Sarah Demortiere, Maxime Guye, Jean Philippe (NfL) in Patients With Relapsing Multiple Ranjeva, Jean Pelletier, Virginie Callot Sclerosis (RMS): Results From RADIANCE Part A, a Randomized, Placebo-Controlled, P3.383 Multi-compartment Spherical Phase 2 Study —Kristen Taylor Meadows, Brett Microscopic Diffusion Imaging Using Spherical Mean Techniques to Probe Axonal Skolnick, Paul Frohna, Richard Aranda, Harry Southworth, Gregory Opiteck Injury in Multiple Sclerosis —Francesca Bagnato, Giulia Franco, Nikita Thomas, Seth Smith, P3.396 Ozanimod Demonstrates Efficacy Richard Dortch, Junzhong Xu and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, ActiveP3.384 Modulation of CorticoSubcortical Functional Connectivity Occurs Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM) —Giancarlo After Symptomatic Treatment of Fatigue Comi, Douglas Arnold, Bruce Cree, Ludwig Kappos, in Patients with Multiple Sclerosis —Maria Rocca, Paola Valsasina, Bruno Colombo, Paolo Preziosa, Vittorio Martinelli, Andrea Falini, Giancarlo Comi, Massimo Filippi
P3.385 Dynamic Functional Network
Connectivity in CIS Patients: A Longitudinal Study —Milagros Hidalgo de la Cruz, Paola
Tuesday, April 24 11:30 a.m.–7:00 p.m. P3.405 Rapid Improvement of Symptoms P3.416 Bayesian analysis of glatiramer after Fibrinolysis in a Patient with Multiple Sclerosis Exacerbation —Konstantin Balashov, Suhayl Dhib-Jalbut, Igor Rybinnik
P3.406 Comparison of Biodistribution
Following Subcutaneous and Intravenous Administration of a Novel Zirconium-89 Labeled Anti-CD20 Antibody Using Imaging —Mary-anne Migotto, Rajiv Bhalla, Karine Mardon, Jacqueline Orian, Gisbert Weckbecker, Rainer Kneuer, David Reutens
P3.407 Integrated Safety Analysis of
Infections during Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5mg/kg —Stuart Cook, Thomas Leist,
Giancarlo Comi, Xavier Montalban, Elke Sylvester, Christine Hicking, Fernando Dangond
P3.408 Predictors of an Opicinumab
Treatment Effect and Identification of an Efficacy Subpopulation: A Post hoc Analysis of the SYNERGY Study —Sarah Sheikh, Peter
P3.397 Efficacy and Safety of Tabalumab From A Phase 2 Multicenter Study Of
Filippi, Maria Rocca
Eric Nantz
P3.386 [F-18]PBR06 PET to assess
P3.398 Efficacy and Safety of 2 Doses
Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), In Patients With Relapsing Forms Of Multiple Sclerosis (RMS), Demonstrates Complete Elimination Of Gd-Enhancing Lesions —
Matilde Inglese, Maria Petracca, Sergio Cocozza,
Sibyl Wray, Michael Racke, Richard Shubin, Cary TSPO binding and its association with brain of Ponesimod (10 and 20 mg o.d.): Interim Twyman, Wendy Su, James Eubanks, Koby Mok, atrophy and disability in multiple sclerosis — Analysis of a Phase II Extension Trial in Tarun Singhal, Kelsey O’Connor, Shipra Dubey, Relapsing-remitting Multiple Sclerosis —Eva Michael Weiss, Edward Fox Anthony Belanger, Shelley Hurwitz, Renxin Chu, Havrdová, Anat Achiron, Patricia Coyle, Daniele P3.410 Clinical and Magnetic Resonance Shahamat Tauhid, Marie Kijewski, Marcelo DiCarli, D’Ambrosio, Juha-Pekka Eralinna, Brian Hennessy, Imaging Results From RADIANCE Part Howard Weiner, Rohit Bakshi Ewa Lindenstroem, Jan Lycke, Guillermo Izquierdo B, a Multicenter, Randomized, DoubleAyuso, Carlo Pozzilli, Mark Freedman P3.387 WITHDRAWN Blind, Phase 3 Trial of Ozanimod Versus P3.399 Safety, Tolerability and Intramuscular Interferon β-1a in Relapsing P3.388 Diagnostic Utility of FDG-PET Pharmacodynamics of Intravenous Multiple Sclerosis (RMS) —Jeffrey Cohen, in Neuro-sarcoidosis: A Case Report and Siponimod in Healthy Subjects —Kasra Giancarlo Comi, Krzysztof Selmaj, Amit Bar-Or, Review of the Literature —Yujie Wang, James Shakeri-Nejad, Anne Gardin, Cathy Gray, Srikanth Douglas Arnold, Lawrence Steinman, Hans-Peter Andrews, Annette Wundes
P3.389 Ultra-Small Superparamagnetic
Neelakantham, Swati Dumitras, Eric Legangneux
Hartung, Xavier Montalban, Eva Havrdova, Bruce Cree, James Sheffield, Kartik Raghupathi, Ludwig
P3.400 Personalised dosing of cladribine Kappos Iron Oxide (USPIO) Nanoparticle Enhanced for people with multiple sclerosis —Zhifeng High-Field Imaging of Neuro-inflammation — Mao, Cesar Alvarez-Gonzalez, Ozlem Yildiz, P3.411 Clinical Features and 7T
Tuesday
Michelle Sudyn, Ferdinand Schweser, Marilena Kimberley Allen-Philbey, Benjamin Turner, Preda, Venkatpavanni Punugu, Michelle Sveinsson, Sharmilee Gnananpavan, Monica Marta, Joela Robert Zivadinov, Suyog Pol Mathews, Gavin Giovannoni, David Baker, Klaus Schmierer P3.390 Natalizumab Treatment of
Multiple Sclerosis Leads to Diminished Microglial Activation in the Normal Appearing White Matter —Laura Airas,
Marcus Sucksdorff, Jouni Tuisku, Eero Rissanen
P3.391 Effect of teriflunomide on gray
Bergsland, Robert Zivadinov, Jesper Hagemeier, Ellen Carl, Channa Kolb, David Hojnacki, Bianca Weinstock-Guttman
P3.403 Treatment Optimization Using
a Multidimensional Decision Model (TIME Study): A Proof-of concept Study to P3.392 The role of Right Anterior Assess a Multidimensional Standardized White Matter area in Multiple SclerosisDocumentation Model to Optimize related fatigue: A Magnetic Resonance Management of Patients with Multiple Spectroscopy (MRS) Study —Shitiz Sriwastava, Sclerosis in Germany —Martin Stangel, Boris Kalyan Yarraguntla, Samuel Lichtman-Mikol, Sara Razmjou, Fen Bao, Rishi Sood, Navid SerajiBozorgzad, Evanthia Bernitsas
Kallmann, Ruth Schruefer, Iris Katharina Penner
P3.417 Longitudinal Assessment of
Retinal Structure of Patients with RelapsingRemitting Multiple Sclerosis on Glatiramer Acetate 40mg —Samuel Lichtman-Mikol, Melody Gilroy, Sara Razmjou, Carla SantiagoMartinez, Evanthia Bernitsas, Navid SerajiBozorgzad
NEUROINFLAMMATORY AND OTHER AUTOIMMUNE DISORDERS II
P3.418 Checkpoint Inhibitor-Induced
Central Nervous System Autoimmunity: A Case Series —Suma Shah, Anastasie Dunn-Pirio,
Matthew Luedke, Joel Morgenlander, Mark Skeen, Christopher Eckstein
P3.419 A Distinct Case of CLIPPERS with
Relapsing-Remitting Multiple Sclerosis Treated with Dimethyl Fumarate —Maria
Di Cristinzi, Lucia Moiola, Marco pisa, Francesca Sangalli, Gloria Dalla Costa, Marta Radaelli, Paolo Preziosa, Marzia Romeo, Filippo Martinelli Boneschi, Bruno Colombo, Federica Esposito, Vittorio Martinelli, Giancarlo Comi
P3.414 Efficacy and Safety of
Mitoxantrone Use in Aggressive Multiple Sclerosis —Marzena Pedrini, William Carroll, Allan Kermode
P3.420 Evaluating the Positive Predictive Value of Onconeural Antibody Testing in Patients with Suspected Paraneoplastic Neurologic Syndromes —Adrian Budhram, Liju Yang
P3.421 Polyneuritis Cranialis Associated With Franciscella Tularemia Infection —
Benzion Blech, Marie Grill, Kara Asbury, Mark Ross, Michael Christiansen, Robert Orenstein
P3.422 Amyloid Beta-Related Angiitis: A
Rare Cause of CNS Vasculitis —Zachery Rohm
P3.423 Multiple Autoantibody-Related Paraneoplastic Limbic Encephalitis with Complete Neurologic Recovery —Thomas Shoemaker, Scott Newsome
P3.424 NA P3.425 NA P3.426 NA P3.427 NA P3.428 NA ALS, SMA, AND OTHER NEUROMUSCULAR DISORDERS I
I
P3.429 Utility of Intrathecal Baclofen
Pump in Primary Lateral Sclerosis —Adeel Zubair, Matthew Raymond, Huned Patwa
P3.430 Successful Percutaneous
Gastrostomy Tube Placement with Fluoroscopy in ALS Patient Requiring 24/7 Ventilation —Senda Ajroud-Driss, Cosette Burian, John-Michael Li, Lisa Wolfe
P3.431 A Systematic Review of the
Blood-central Nervous System Barrier Pathology in ALS —Ario Mirian, Agessandro Abrahao, Serena Soleimani, Lorne Zinman
P3.432 Unreported Gene Mutation of
Episodic Ataxia —Abdallah Hamdallah, Hussam Shaker, Pascal Atanga, Paul Twydell
P3.433 Patient with MT-ATP 6 gene
mutation and NARP like disease —Yasushi Kisanuki, Yasmeen Rauf
P3.415 Defining Glatiramer Acetate:
P3.434 Spastic Dysarthria as a P3.404 Siponimod is a Functional Agonist The USA Definition of Sameness and the EU presenting sign of Stiff Person Syndrome — for the S1P5 Receptor —Marc Bigaud, Barbara Definition of Similarity —Sigal Melamed-Gal, Nuesslein-Hildesheim, Thi-Thanh-Thao Tran, Danilo Guerini
150 2018 AAN Annual Meeting
MRI Findings of Progressive Multifocal Leukoencephalopathy in the Setting of Extended Natalizumab Dosing: A Case Report —Laura Baldassari, Stephen Jones,
P3.401 Biotin—the forgotten Vitamin in Robert Fox MS ? —Gerhard D. Roth, Walter Maier-Janson, P3.412 WITHDRAWN Erich Scholz, Matthias Schmid P3.413 Prospective Observational P3.402 Absolute Bioavailability of Study in a Cohort of Patients Affected by
Single, Oral Dose of Siponimod in Healthy and white matter brain pathology in multiple Subjects —Anne Gardin, Kasra Shakerisclerosis using volumetric and diffusionNejad, Cathy Gray, Srikanth Neelakantham, Eric tensor imaging MRI measures —Niels Legangneux, Swati Dumitras
Robert Noble, Joshua Steinerman, Jessica Alexander, David Ladkani
Calabresi, Gavin Giovannoni, Raju Kapoor, Douglas predominant Spinal Cord Involvement — Maha Khan, Shitiz Sriwastava, Praveen Vemuri, Arnold, Yi Chai, Bing Zhu, Carmen CastrilloNavid Seraji-Bozorgzad Viguera, Aaron Deykin, Ih Chang
Krzysztof Selmaj, Amit Bar-Or, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva MS THERAPEUTICS I Havrdova, James Sheffield, Kartik Raghupathi, Jeffrey Cohen P3.409 Final MRI Results At 6 Months
in Patients with Relapsing-Remitting Valsasina, Sarlota Mesaros, Jelena Dackovic, Irena Multiple Sclerosis: A Randomized, DoubleBlind, Placebo-Controlled Study —Maria Silk, Dujmovic Basuroski, Jelena Drulovic, Massimo
acetate 40 mg/mL TIW treatment effect in reducing relapse rate —Ofra Barnett-Griness,
Samuel Giles, Amanda Persaud, Michael Pulley, Pippa Loupe, Iris Grossman, Benjamin Zeskind, Natalya Shneyder Vera Weinstein, Bracha Timan, Sarah Kolitz, Arthur Komlosh, Tal Hasson, Yousif Sahly
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m. MYOPATHY
P3.435 Efficacy and safety of
dichlorphenamide in adolescent patients with primary periodic paralysis —Emma Ciafaloni, Fredric Cohen, Robert Griggs
P3.448 Diagnostic Spectrum and
Treatment Outcomes of Granulomatous Myopathy —Reem Alhammad, Teerin Liewluck
P3.449 RNA-sequencing analysis of
muscle biopsy samples from patients with inclusion body myositis and those with
ALS I
P3.463 Neuromuscular Ultrasound to
Identify Deep Muscle Fasciculations in a Suspected Case of Amyotrophic Lateral Sclerosis (ALS) —Arjumond Khan, Arben Brahaj,
P3.436 Open Label Trial of Ranolazine for polymyositis —Chiseko Ikenaga, Akatsuki
Huned Patwa
Samantha LoRusso, David Kline, Amy Bartlett, Julie Agriesti, Miriam Freimer, Mark Rich, John Kissel, William Arnold
Lateral Sclerosis in Cinema and Television —
the Treatment of Paramyotonia Congenita — Kubota, Hiroyuki Ishiura, Hidetoshi Date, Shoji
P3.437 Circulatory Kv1.3+ cells in
patients with sIBM —Karissa J. Munoz, Ali H Mannaa, Jenna Kastenschmidt, Marie Wencel, Namita Goyal, S. Armando Villalta, Tahseen Mozaffar
P3.438 MRI prognostic outcome
Tsuji, Jun Goto, Jun Shimizu
P3.450 Variable penetrance of Andersen-
P3.440 A series of aggregated
randomized-controlled N-of-1 trials with mexiletine in non-dystrophic myotonia: Clinical trial results and validation of rare disease design —Bas Stunnenberg, Joost
Raaphorst, Hans Groenewoud, Jeffrey Statland, Robert Griggs, Willem Woertman, Dick Stegeman, Janneke Timmermans, Jaya Trivedi, Emma Matthews, Christiaan Saris, Bas Schouwenberg, Gea Drost, Baziel van Engelen, GertJan van der Wilt
P3.441 Sensitivity of IBM Criteria in
a Large Multicenter Cross-Sectional IBM Cohort —Sumiko Weir, Tahseen Mozaffar,
Matthew Wicklund, Jeffrey Statland, Mamatha Pasnoor, Omar Jawdat, Melanie Glenn, Bachir Estephan, Jonathan McKinnon, Sarita Said-Said, Richard Barohn, Mazen Dimachkie
P3.442 Muscle Biopsy and
Electromyography Correlation —Elie Naddaf,
Margherita Milone, William Litchy, Michelle Mauermann, Jayawant Mandrekar, Andrew Engel
P3.443 Willingness to Participate in
Natural History Studies amongst Sporadic Inclusion Body Myositis Patients —Veena Mathew, Marie Wencel, Namita Goyal, Robert Goldberg, Tahseen Mozaffar
David Avila
Tawil Syndrome in a Caucasian family with a P3.465 Hypersensitivity and rare missense KCJN2 mutation —Reem Deeb, Edaravone—Summary of Case Reports — Aravindhan Veerapandiyan, Alrabi Tawil, Simona Treidler
P3.451 Follow-up of clinical and MRI
changes in juvenile adult onset DM1 —Sigrid Baldanzi, Corrado Angelini, Francesca Bevilacqua,
in asymptomatic/paucisymptomatic Gabriele Siciliano HyperCKemia —Piar Marti, Nuria Muelas, Jorge P3.452 Response to Liver Transplant and Alberto Diaz-Manera, Juan Vilchez Padilla Riboflavin in MADD Myopathy —Elisabeth P3.439 Myopathies Presenting with Golden, Rahul Abhyankar, Kyle Womack, Jaya “dropped-head syndrome” —Reem Alhammad, Trivedi Elie Naddaf
P3.464 The Portrayal of Amyotrophic
P3.453 Necrotizing Inflammatory
Myopathy Following Immune Checkpoint Inhibitor Therapy Presenting With Progressive Upper Extremity Weakness — Pariwat Thaisetthawatkul, Rodney McComb
Laura Bower, Benjamin Shander, Alexander Kalin
TRANSCENDS SCHOLARS
P3.466 Saving the survivors of cardiac
arrest: Exploring novel mechanisms of secondary brain injury and improving accuracy of neuroprognostication —Carolina Barbosa Maciel
P3.467 Healthcare expenditure patterns among elderly with seizure in the United States: Medical Expenditure Panel Survey, 2003-2014 —Alain Lekoubou
P3.468 Should we do cardiac monitoring
in young adults with ischemic stroke? Analysis of the IMS Health database —Karen
P3.454 Subacute paresis in a 28-year-old Orjuela, Michelle Leppert, Sharon Poisson man with HIV —Yohei Harada, Neil Masangkay, P3.469 Taking Steps Backward to Move Murat Gokden, Reza Sadjadi
Forward: A Preliminary Feasibility Study in
P3.455 Individual N-of-1 Trial Salbutamol Stroke —Oluwole O. Awosika Versus Placebo as Attack Treatment in P3.470 Combining Neuroimaging and a Patient with Hyperkalemic Periodic Paralysis —Robyn Weijma, Esther Merkus, Bas van Vlijmen, Hans Groenewoud, Gert Jan van der Wilt, Baziel van Engelen, Joost Raaphorst, Christiaan Saris, Bas Stunnenberg
P3.456 Severe Necrotizing Myopathy Associated with Pembrolizumab for Urothelial Carcinoma —Chandler Gill, Ewa
Blood Biomarkers in Cerebrovascular Disease —Alexis N. Simpkins
P3.471 Understanding the Role of
Alzheimer Disease Pathology in Parkinson Disease: Focus on Language —Federico Rodriguez-Porcel
Borys, Ryan Jacobson
P3.457 Diminished Distal Finger Creases in Patients with Inclusion Body Myositis — Benjamin Koo, Leo Wang
P3.458 Role of microRNAs in lipid
storage myopathies. —Valentina Pegoraro, Corrado Angelini
P3.459 Correlation of MRI with
Sener, Jennifer Martinez-Thompson, Elliot Dimberg, Ruple Laughlin, Devon Rubin
P3.446 Feasibility and Validation of
Modified Oculobulbar Facial Respiratory Score (mOBFRS) in Sporadic Inclusion Body Myositis —Marie Wencel, Nadia Araujo, Lishi
Zhang, Eileen Medina, Tahseen Mozaffar, Namita Goyal
P3.447 Diagnoses in HyperCKemia:
Study from classical aproach to the use of new technologies (NGS). —Piar Marti, Nuria
Tuesday
Muscle Biopsy Findings in Critical Illness Myopathy —Edward Labin, Georgios Manousakis (Ilaris), an IL-1β Receptor antagonist, in the treatment of patients with sporadic Inclusion P3.460 Pulmonary-Sparing Anti-MDA5Body Myositis (sIBM) —Michail Kosmidis, Positive Dermatomyositis with Scleroderma Dimitrios Pikazis, Panayiotis Vlachoyiannopoulos, Overlap, Glomerulonephritis and Athanasios Tzioufas, Marinos Dalakas Cardiomyopathy —Cina Sasannejad, Marcus P3.445 Correlation of Electromyography Cimino, Luis Chui, Margaret Adler Findings to Muscle Biopsy Findings in P3.461 Anti-dopaminergic medication Patients with Suspected Myopathy —Ugur related myopathy causing respiratory muscle
P3.444 A pilot trial of Canakinumab
weakness without neuroleptic malignant syndrome —Yohei Harada, Murat Gokden, Tuhin Virmani, Vikki Stefans
P3.462 Acute necrotizing myopathy
associated with bronchiolitis obliterans with organizing pneumonia (BOOP) responding to treatment with rituximab and steroids. — Guru Ramaiah, Boyd Koffman, Kevin Litzenberg, Preeti Rao
Muelas, Immaculada Azorin, Teresa Jaijo, Jose Maria Millan, Juan Vilchez Padilla
AAN.com/view/AM18 151
POSTER SESSIONS
POSTER SESSION IV G NEUROLOGY PRACTICE AND OUTCOMES
A
P4.001 Autoencoder— a new method
Wednesday, April 25 11:30 a.m.–7:00 p.m.
case report and review of the literature. —
Amanda Persaud, Fatoumata Sakho, Sukhwinder Sandhu, Suparna Krishnaiengar MD
P4.011 Comparing brain structural and for keeping data privacy when analyzing videos of patients with motor dysfunction — perfusion MRI changes across ALS-FTD Marcus D`Souza, Matthew Johnson, Jonas Dorn, continuum —Dongchao Shen, Bo Hou, Bo Cui, C.E.P. Van Munster, Manuela Diederich, Christian Kamm, Saskia Steinheimer, Kristina Kravalis, Jacques Boisvert, Ian Ormesher, Lorcan Walsh, Abigail Sellen, Frank Dahlke, Bernard Uitdehaag, Ludwig Kappos
Hongfei Tai, Liying Cui, Mingsheng Liu, Jing Gao, Feng Feng
P4.002 Teleneurology Clinics for
Sanei Moghaddam, Guru Ramaiah, Mouhammad Jumaa, Syed Zaidi
Polyneuropathy: A Pilot Study —Andrew
Wilson, Nasheed Jamal, Moira Inkelas, Michael Ong
P4.003 Improving Outcomes in Inpatient Send-Out Studies —Michael Robers, Harlori
Disorders: A Systematic Review —Bas
Stunnenberg, Joost Berends, Robert Griggs, Jeffrey Statland, Gert Jan van der Wilt, Joost Raaphorst, Baziel van Engelen
P4.005 Hybrid Charting Improves
Documentation Compliance in a Comprehensive Stroke Center —Paul Wright, Danielle Gonsalves, Christina Paiva, Suzanne Pine, Shantel Coleman, Neeroopa Surendranath, Saeyoan Thirunavukkarasu
Encephalopathy Syndrome PRES Clinical Presentation and Epidemiology in Different south Asian Population —Faisal Ibrahim,
functional magnetic resonance imaging between Neurological and Liver-only affected Wilson’s Disease patients —
Keerthana Nalamada, Ayse Tinaz, Jagriti Arora, Ana Vives-Rodriguez, Todd Constable, Michael Schilsky, Daphne Robakis
P4.015 Semiquantitative Analyses
of Dopamine Transporter Imaging in the Patients with Idiopathic Normal Pressure Hydrocephalus (iNPH) —Nobutoshi Morimoto, Motonori Takamiya, Mizuki Morimoto
GENERAL NEUROLOGY: NEUROIMAGING
P4.016 An Atypical Presentation of
P4.006 DTI-Correlated Parkinsonism
Deirdre Donaldson
after Chronic Carbon Monoxide Poisoning —
Posterior Reversible Encephalopathy Syndrome —Melissa Martinez, Dinesh Jillella,
Eric Hirsch, Erica Glants, Tahir Sheikh, Daryl Duran, P4.017 Use of Proton Magnetic Resonance Spectroscopy (MRS) to Detect Ranga Krishna
P4.007 Bilateral Superior Ophthalmic Vein Dilatation as an Early Indicator of Increased Cranial Pressure —Erin Flynn,
Himanshi Suri, Jessica Stevens, Lynn Kataria
P4.008 Magnetic resonance
characteristic of Parkinson’s disease based on the presence of cognitive impairment — Farangis Doniyorova
P4.009 Hypobaric Exposure in Aircrew
Personnel: Possible Basis for Group Differences on Arterial Spin Labeling (ASL) —Michael Hossack, Timothy Fullam, John Sladky, Stephen McGuire
P4.010 Reversible splenial lesion
Wednesday
syndrome (RESLES) associated with Idiopathic Intracranial Hypertension: A rare
152 2018 AAN Annual Meeting
037–084
P4.013 Posterior Reversible
P4.014 A comparison of resting-state
Regional Differences in Absolute Neurometabolite Concentrations in Aircrew Personnel with Hypobaric Exposure —Timothy Fullam, John Sladky, Stephen McGuire
P4.018 Posterior Reversible
173–200
C
ePosters
085–090
Encephalopathy Syndrome (PRES) Secondary to Use of Axitinib in Renal Cell Cancer —Amin
Bains, Bill Jacobsen, Sana Aslam, Robert Jackson, Yasir Mohamed, Dirk Deleu, Gayane Melikyan, Boulenouar Mesraoua, Najib Murr Edward Chen, Jennifer Heim, Ganesh Murthy, Aaron Zigelbaum, Kerry Knievel
P4.004 N-of-1 Trials in Neurological
091–172
P4.012 Posterior Reversible
D
B
b1 g1 339–344 a1 ePosters
Poster Discussion
027–036
A
001–026
P4.020 Osmotic Demyelination
Syndrome in Liver Failure Patient Without Hyponatremia —Izabela Biesiada
I
F
259–294
295–338
H
G
345–428
429–480
Poster Session 4 A. General Neurology: 001 – 026
a1. Cerebrovascular Disease and Interventional Neurology Poster Discussion Session: 027 – 036 B. Movement Disorders: 037 – 084
b1. Cerebrovascular Disease and Interventional Neurology I ePoster Session: 085 – 090 C. D. E. F. G.
Headache; Neuro-oncology; Practice, Policy, and Ethics: 091 – 172 Aging, Dementia, Cognitive, and Behavioral Neurology: 173 – 200 Cerebrovascular Disease and Interventional Neurology: 201 – 258 Epilepsy/Clinical Neurophysiology (EEG): 259 – 294 Neuro Trauma, Critical Care, and Sports Neurology: 295 – 338
g1. Cerebrovascular Disease and Interventional Neurology II ePoster Session: 339 – 344 H. MS and CNS Inflammatory Disease: 345 – 428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429 – 480
GENERAL NEUROLOGY: CASE REPORTS I
Encephalopathy Syndrome during Treatment with Lenvatinib —Jean Khoury, Pauline Funchain P4.021 Vitamin B6 Toxicity Revisited: A Case of Reversible Pyridoxine-associated P4.019 Examining the Spectrum of Neuropathy and Disequilibrium. —Rohitha Reversibles: Cerebral ischemia in PRES and Moudgal, Shahla Hosseini, Patricia Colapietro, RCVS —Ashley Pena, Cumara O’Carroll, Kristen Oluwole Awosika Steenerson, Amaal Starling
E
201–258
P4.022 Systemic Botulinum Toxicity in an Emery-Dreifuss Muscular Dystrophy Patient Secondary to a Botox Injection —Diviya Kaul, Hena Waseem, George Thomas, Elijah Stommel, Mary Feldman, Stephen Lee, Jeffrey Cohen
P4.023 An interesting case of
transient recurrent plegic events: Sprengel Deformity —Barbara Santos, Larissa Carvalho,
Vanessa Dinis, Kamilla Daveiro, Stephanie Queiroz
P4.024 Metastasis to the Conus
Medullaris and Cauda Equina Presenting with Primarily Motor Symptoms —Christeena Kurian, Rafia Shafqat, Jin Li
P4.025 “Right Insula: Maintaining
language and speech qualities”. A review of literature and a case report on Foreign Accent Syndrome. —Varun Chauhan, Richa
Tripathi, Hamidreza Saber, Navid Seraji-Bozorgzad
P4.026 NA
Cerebrovascular Disease and Interventional Neurology Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.
a1
Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 5:30p.m.-7:00 p.m. Data Blitz: 11:45 a.m.–11:50 a.m.
Data Blitz: 12:00 p.m.–12:05 p.m.
Data Blitz: 12:10 p.m.–12:15 p.m.
P4.027 What are the Molecular
P4.030 Prevalence and Risk Factor of
P4.032 Prevalence of Carotid Webs in
Mechanisms of WldS-Mediated Axon Protection in Stroke? —Jack Wang, Jason Hinman
Data Blitz: 11:50 a.m.–11:55 a.m.
P4.028 In vivo Electrical Stimulation
of Neural Stem Cells via Conductive Polymer Scaffold Improves Endogenous Repair Mechanisms of Stroke Recovery —
Large Perivascular Spaces in a PopulationBased MRI Study —Jiang-Tao Zhang, Si-Yu
Chen, Ming-Li Li, Jun Ni, Lixin Zhou, Ming Yao, Ding-Ding Zhang, Shu-Yang Zhang, Zheng-Yu Jin, Li-Ying Cui, Yi-Cheng Zhu
Data Blitz: 12:05 p.m.–12:10 p.m.
P4.031 Early Elevated Troponin
Levels after Ischemic Stroke Suggests a Cardioembolic Source —Andrew Chang,
Cryptogenic Stroke —Joel Nunez Gonzalez,
Payam Sajedi, Prashant Raghavan, Steven Kittner, Carolyn Cronin
Data Blitz: 12:25 p.m.–12:30 p.m.
P4.035 Seizures and the impact on
clinical outcomes at discharge in acute stroke patients from a large multicenter P4.033 Safety Outcomes of Thrombolysis FL-PR registry —Fanglin Zhang, Kefeng Wang, Chuanhui Dong, Kathy Fenelon, Carolina M. for Acute Ischemic Stroke in Patients with Gutierrez, Ralph Sacco, Tatjana Rundek, FL-PR History of Intracranial Hemorrhage —Stacy CReSD Investig and Collaborators Data Blitz: 12:15 p.m.–12:20 p.m.
Chu, Samuel Sommaruga, David Hwang, Jennifer Dearborn, Lauren Sansing, Branden Cord, Gargi Brittany Ricci, Grace B Russo, Mahesh Jayaraman, Samarth, Nils Petersen, Emily Gilmore, Joseph Schindler, Charles Matouk, Kevin Sheth, Guido Ryan A McTaggart, Morgan Hemendinger, Priya Data Blitz: 11:55 a.m.–12:00 p.m. Narwal, Katarina Dakay, Brian Mac Grory, Shawna Falcone P4.029 Bypassing Interhospital Transfers Cutting, Tina Burton, Christopher Song, Emile Data Blitz: 12:20 p.m.–12:25 p.m. Mehanna, Matthew Siket, Tracy E Madsen, for Large Vessel Occlusions in the Era of P4.034 Utilization, Outcomes and Safety Michael Reznik, Alexander Merkler, Michael Mobile Stroke Units —Lila Sheikhi, Payal Patel, of IV tPA for Acute Ischemic Stroke during Naresh Mullaguri, Pravin George, Andrew Reimer, Lerario, Hooman Kamel, Mitchell Elkind, Karen Furie, Shadi Yaghi pregnancy —Abhishek Lunagariya, Branko HuisaGabor Toth, Muhammad Hussain, Ken Uchino, Andrew Russman Byeongtaek Oh, Shang Song, Vivek Lam, Alexa Levinson, Paul George
Garate, Achint Patel, Zabeend Mahuwala, Vishal Jani, Thomas Hemmen
Data Blitz: 12:30 p.m.–12:35 p.m.
P4.036 Care and Outcome of Stroke
Patients with Language Barrier in a Busy Stroke Centre —Fatemeh Rezania, Angelos
Sharobeam, Elizabeth Mackey, Michael Seman, Christopher Neil, Tissa Wijeratne
HUNTINGTON’S DISEASE AND OTHER CHOREA
Sanjay Gandhi, Victor Abler, Brian Davis, Debra Irwin, Victor Sung
PARKINSON’S DISEASE: SURGICAL MANAGEMENT
P4.059 Long-term Outcomes with
P4.037 Frequency of Single Nucleotide
P4.045 Nitric Oxide as an Exercise
Polymorphisms (SNPs) rs362307 or rs362331 in Patients with Huntington’s Disease (HD): Results from a Prospective Observational Research Study —Daniel Claassen, Mary
Induced Mitochondrial Function Modulator in the CAG140 KI Huntington’s Mouse Model —Charles Caldwell, Enrique Cadenas,
P4.052 Five Year Outcomes of a
Zeilman, Edward Ofori, David Vaillancourt, Kelly
P4.038 Clinical manifestations of
Rojas, Gustavo Da Prat de Magahlaes, Javier Ziliani
Michael Barbe, Steven Gill, Alan Whone, Mauro Porta, Domenico Servello, Francois Alesch
Guillermo Moguel-Cobos
P4.047 Laughing and Dancing: A case
P4.053 Efficacy of Subthalamic Neural
the Effects of GPi DBS on Features of Dopamine Dysregulation Syndrome —Lenora
Mary-Ann Fares, Samuel Giles, Emil Gaitour, Natalya Shneyder
Bronte-Stewart, Muhammad Furqan Afzal, Anca Velisar, Chioma Anidi
B
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
Rescue Target Deep Brain Stimulation in Patients with Dystonia —Abigail Hatcher, Pam
Prospective, Multi-Center Trial Evaluating Foote, Michael Okun, Aparna Wagle-Shukla Deep Brain Stimulation with a New Multiple P4.060 Subcortical Atrophy Predicts Source, Constant-Current Rechargeable Michael Jakowec, Giselle Petzinger Motor Response in Idiopathic Parkinson’s System in Parkinson’s Disease —Lars Disease Patients with Pallidal (GPi) but not Edmondson, Ralf Reilmann, Nenad Svrzikapa, P4.046 Late onset Huntington’s disease Timmermann, Roshini Jain, Nic Van Dyck, Lilly Subthalamic (STN) Deep Brain Stimulation Kenneth Longo, Jaya Goyal, Serena Hung, Michael in an Argentinian cohort —Emilia Gatto, Martin Chen, Thomas Brucke, Fernando Seijo, Esther (DBS) —Moath Hamed, Francisco Ponce, Suarez San Martin, Veerle Visser-Vandewalle, Panzara Cesarini, Jose Luis Etcheverry, Natalia Gonzalez homozigote allele carriers in Huntington’s disease —Esther Cubo Delgado, Saul
Martinez-Horta, Maria Antonia Ramos-Arroyo, Cecilia Gil-Polo, Frederic Sampedro, Asuncion Martinez-Descalls, Sara Calvo, Katia LLano, Ignacio Muñoz-Siscart
report of Pseudobulbar Affect in Late Onset Huntington’s Disease —Amanda Persaud,
P4.039 Huntington Disease: The ‘typical’ P4.048 Loss of the Sigma-1 receptor phenotype for the commonest CAG repeat expansion in the ENROLL-HD study across varying functional levels —Florence Ching-Fen
disrupts pridopidine-induced gene expression —Jennifer Dreymann, Michal Geva,
Closed-loop Deep Brain Stimulation for Bradykinesia in Parkinson’s Disease —Helen
P4.054 Electrophysiologic Mapping of
Cortical Networks Activated by Dorsal vs. Ventral Subthalamic Nucleus Deep Brain Stimulation —Aarathi Minisandram, Kristen
Gandhi, Victor Abler, Kristen Bibeau, Daniel Claassen, Samuel Frank
eicosapentaenoic acid as a treatment for Huntington’s disease: A systematic review and meta-analysis of randomized clinical trials —Mohamed Fahmy Doheim, Sara Morsy,
Chang, Elizabeth McCusker, Clement Loy
Compliance, Satisfaction, and Patient Perception of Change in Huntington Disease Symptoms —Victor Sung, Ravi Iyer, Sanjay
P4.049 Efficacy and safety of ethyl-
P4.056 Real-World Outcomes Using
Florence Ching-Fen Chang, Elizabeth McCusker, Clement Loy
Deuschl, Roshini Jain, Heleen Scholtes, Alex Wang, Michael Barbe, Monica Pötter-Nerger, Andrea Kuehn, Jens Volkmann, Steffen Paschen, Jan Vesper
phenotype for the commonest CAG repeat expansion in the ENROLL- HD study —
P4.042 The Impact of Family History
on the Clinical Features of Huntington’s Disease —Danny Bega, Gabriel Kringlen, Lisa
P4.050 Experience of Individuals With Huntington Disease and Chorea —Eileen
Kinsley, Sharon Aufox, Gerald Rouleau
Mack Thorley, Ravi Iyer, Noelle Carlozzi, Paul Wicks, Chris Curran, Sanjay Gandhi, Victor Abler, Karen E. Anderson
P4.043 Niemann Pick Type C
P4.051 Evaluation of ataxia in patients
as Presentation of Huntington-Like Syndrome —Lucia Zavala, Nelida Garretto,
with Huntington’s Disease —Gustavo Franklin, Helio Afonso Teive, Francisco Branco Germiniani, Tomoko Arakaki, Sergio Rodriguez Quirofa, Dolores sibele milano, Giovanna Pavanelli, Nayra Lima, Moron, Patricia Vega, Nancy Medina, Marcelo Salmo Raskin, Gustavo Ribas Kauffman
P4.044 Healthcare Utilization and Costs for Huntington Disease Patients Prescribed Tetrabenazine —Karen E. Anderson, Ravi Iyer,
P4.062 The Effect of Short Pulse Width
Settings on the Therapeutic Window in Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s disease —Viswas Dayal, Patricia Limousin, Thomas Foltynie
P4.063 Finding ways to decrease gait
and speech impairment in patients with chronic STN DBS for Parkinson’s disease —
in patients with Parkinson’s disease and Jessica Karl, Leonard Verhagen Metman substantial Action/Postural Tremor —Kamilia P4.064 RAD-PD: Registry for the Nozile-Firth, Vyas Viswanathan, Adolfo Ramirez Zamora, Kelly Foote, Michael Okun, Aparna Wagle- Advancement of DBS in Parkinson’s Disease —Joohi Jimenez-Shahed, Susan Shukla
P4.041 Huntington Disease: The ‘typical’ Samar Morsy Khalil, Mohamed Gomaa Kamel,
Doaa Saeed Mahmoud El-Basiony, Hossam Idrees Ahmed Hassan, Ahmed Abdelaziz Eisa, Cao Thi Anh Ngoc, Nguyen Phu Dang, Kenji Hirayama, Nguyen Tien Huy
Higginbotham, Stewart Factor
a Novel Directional Lead from a Registry of DBS for Parkinson’s Disease —Guenther
P4.057 STN vs. GPi deep brain
stimulation for tremor suppression in Parkinson’s disease: A systematic review and meta-analysis —Joshua Wong, James
Bressman, Michelle Burack, Elana Farace, James McInerney, James Kirk, Rachel Saunders-Pullman, Jason Schwalb, Ludy Shih, Meredith Spindler, Elena Moro, Michele York
P4.065 The mutual relationship of
bilateral subthalamic stimulation impact on the non-motor and motor symptoms in Parkinson’s disease: Open, prospective pilot study —Petr Kanovsky, Sandra Kurcova,
Jan Bardon, Marketa Vecerkova, Miroslav Vastik, Martin Nevrly, Katerina Mensikova, Tereza Bartonikova, Pavel Otruba, David Krahulik, Egon Cauraugh, Kwo Wei David Ho, Matthew Broderick, Kurca Adolfo Ramirez Zamora, Leonardo Almeida, Aparna Wagle-Shukla, Christina Wilson, Robertus De Bie, P4.066 Effect of Subthalamic NucleusDeep Brain Stimulation Surgery on Frances Weaver, Michael Okun Impulsivity in Parkinson’s Disease Patients — P4.058 Speech Side Effects from DBS: Abhinav Raina, Roopa Rajan, Gangadhara Sarma, Differential Effects of Target, Handedness, Syam Krishnan, K Krishnakumar, Asha Kishore and Hemisphere. —Adeel Memon, Manmeet Kaur, Jesse Faulk, Barton Guthrie, Harrison Walker
AAN.com/view/AM18 153
Wednesday
P4.040 Initial Deutetrabenazine
Jermaine Ross, Yoonjeong Cha, Rebecca Kusko, Kanoff, Emad Eskandar, Todd Herrington Renan Escalante-Chong, Benjamin Zeskind, Daphna Laifenfeld, Iris Grossman, Michael Hayden P4.055 Comparison of STN and GPi DBS
P4.061 A Case Series Analysis of
POSTER SESSIONS
POSTER SESSION IV G P4.067 Predicting Depression and
Anxiety Following DBS Implantation —Mary Flaherty, Carol Schramke, Timothy Leichliter
P4.068 DIRECT DBS: A Prospective,
Multi-center Clinical Study with Blinding for a Directional Deep Brain Stimulation (DBS) Lead —Frank Steigerwald, Jens Volkmann,
P4.072 Outcomes of a Prospective,
Multicenter International Registry of Deep Brain Stimulation —Guenther Deuschl, Roshini
Tam, Radha Bhavsar, Courtney Timms, Leonard Verhagen Metman, Deborah Hall, Karen Marder
MOVEMENT DISORDERS: TARDIVE DYSKINESIA
P4.070 Impact of Deep Brain Stimulation P4.074 Estimation of an MCID for AIMS on hospital and related outcomes in patients with comorbid Parkinson’s disease and Major Depressive Disorder: A Nationwide Inpatient Sample study —Rikinkumar Patel, Amit Chopra
P4.071 Sixty hertz subthalamic deep
brain stimulation improves freezing of gait with less attenuation of beta band power than 140Hz stimulation —Chioma Anidi,
Johanna O’Day, Muhammad Furqan Afzal, Judy Syrkin-Nikolau, Anca Velisar, Helen Bronte-Stewart
b1 C
P4.076 Long-Term Treatment With
Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study —Robert Hauser, Hubert
Jain, Heleen Scholtes, Alex Wang, Steffen Paschen, Michael Barbe, Andrea Kuehn, Monica Pötter-Nerger, Jens Volkmann, Yen Tai, Jan Vesper Fernandez, David Stamler, Mat Davis, Stewart Factor, Joohi Jimenez-Shahed, William Ondo, L. P4.073 Health disparities and shortFredrik Jarskog, Scott W. Woods, Mark LeDoux, term outcomes analysis of a multiethnic David Shprecher, Karen E. Anderson
Cordula Matthies, Dalal Kirsch, Stephan Chabardes, Robertus De Bie, P.R. Schuurman, sample receiving deep brain stimulation for Elena Moro, Valérie Fraix, Sara Meoni, David Blum, Parkinson’s Disease at a tertiary referral Leon Juarez Paz, Kenny Wynants, Nic Van Dyck center —Daniel Garbin Di Luca, Juan Sebastian Diaz, Henry Moore, Carlos Singer, Bonnie Levin, P4.069 Interest in Genetic Testing in Iahn Cajigas, Jonathan Jagid, Corneliu Luca
Parkinson’s disease patients with Deep Brain Stimulation —Avram Fraint, Gian Pal, Eric
Wednesday, April 25 11:30 a.m.–7:00 p.m.
Total Score Change in Tardive Dyskinesia — Roger Kurlan, Mark Stacy, Khodayar Farahmand, Joshua Burke, Scott Siegert, Grace Liang
P4.077 Effect of Tardive Dyskinesia on
Quality of Life: Patient-reported Symptom Severity is Associated with Deficits in Physical, Mental, and Social Functioning —
Joseph McEvoy, Benjamin Carroll, Sanjay Gandhi, Avery Rizio, Stephen Maher, Mark Kosinski, Jakob Bjorner
Khodayar Farahmand, Sean Hinton, Grace Liang, Scott Siegert
P4.080 Cardiovascular Safety
Assessment of Deutetrabenazine in Healthy Volunteers and Implications for Patients With Huntington Disease or Tardive Dyskinesia —Donna Cox, Micha Levi, Laura Rabinovich-Guilatt, David Truong, David Stamler
P4.081 Tardive Dyskinesia Among
Patients Using Antipsychotic Medications in Customary Clinical Care in the United States —Anita Loughlin, Nancy Lin, Victor Abler, Benjamin Carroll
P4.082 A Case of Tardive Dyskinesia and Parkinsonism Following Use of Phentermine
P4.078 Effects of Long-Term Valbenazine for Weight Loss —Ryan Barmore, Christopher on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study —Stewart Factor, John Kane, Stephen
Marder, Robert Hauser, Khodayar Farahmand, Roland Jimenez, Joshua Burke, Scott Siegert, Deutetrabenazine for Tardive Dyskinesia in a Grace Liang 2-Year Open-Label Extension Study —Hubert P4.079 Short- and Long-term Effects Fernandez, David Stamler, Mat Davis, Stewart of Once-Daily Valbenazine on Tardive Factor, Robert Hauser, Joohi Jimenez-Shahed, William Ondo, L. Fredrik Jarskog, Scott W. Woods, Dyskinesia by Body Region —Cynthia Comella, Mark LeDoux, David Shprecher, Karen E. Anderson Carlos Singer, Stephanie Lessig, Joshua Burke,
P4.075 Confirmed Safety of
Hess, Nikolaus McFarland, Michael Okun
P4.083 RE-KINECT: A Prospective
Real-World Dyskinesia Screening Study and Registry in Patients Taking Antipsychotic Agents: Patient Demographics —Caroline
Tanner, Andrew Cutler, Stanley Caroff, William Lenderking, Karen Yeomans, Huda Shalhoub, Linda Ross, Charles Yonan
P4.084 NA
Cerebrovascular Disease and Interventional Neurology I ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P4.085 The FAST VAN Tool for
Priyank Khandelwal, Joshua Lukas, Kunakorn Atchaneeyasakul, Robert Starke, Eric Peterson, Dileep Yavagal
Michael Kelly, Kimberly Davy, Gary Hunter
P4.087 Support of New Triage Protocol
Identifying Large Vessel Occlusion in Acute Stroke —Sanchea Wasyliw, K. Ruth Whelan,
P4.086 Intra-arterial tPA administration
Among Acute Stroke Care Providers —David
during Mechanical Thrombectomy is associated with increased risk of Subarachnoid Hemorrhage. —Vasu Saini,
Anderson, Haitham Hussein
HEADACHE THERAPEUTICS
P4.095 The Impact of Fremanezumab
P4.091 Eptinezumab Reduced Migraine
Frequency, Duration, and Pain Intensity Through Week 24: Results From the Phase 3 PROMISE-1 Trial —Stephen Silberstein, Peter McAllister, Gary Berman, Roger Cady, Jeff Smith, David Biondi, Joe Hirman
P4.092 Eptinezumab Achieved
Wednesday
Meaningful Reductions in Migraine Activity Within 24 Hours That Were Sustained Through Week 12: Results From PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Phase 3 Trial —Timothy Smith, David Biondi, Gary Berman, Marshall Freeman, Joe Hirman, Eric Kassel
P4.093 Efficacy and Safety of 2 Dose
Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine —David Dodick, Ernesto Aycardi,
Marcelo Bigal, Paul Yeung, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, Stephen Silberstein, Peter Goadsby
P4.094 Efficacy of Erenumab For the
P4.088 Design and Implementation of a
P4.090 SPAN-100 Designation as an
P4.089 Cervical Epidural Hematoma
Priyank Khandelwal, Kunakorn Atchaneeyasakul, Omar Alkhatib, Eric Peterson, Dileep Yavagal
Stephen Silberstein, Paul Yeung, Tricia Blankenbiller, Xiaoping Ning, Ronghua Yang, Yuju Ma, Ernesto Aycardi, Marcelo Bigal
P4.104 Efficacy of Fremanezumab
Catherine Legault, Shefali Dujari, Sam H Shen, Alexie M. Wagner, Gregory Albers, Eric Bernier, Patrice Callagy, Nirali Vora
mimicking Acute Ischemic Stroke: A better look at the imaging —Ary De Sousa
Early Predictor of 24-36 hour NIHSS in Patients with LVO Status-post Mechanical Thrombectomy. —Joshua Lukas, Vasu Saini,
Novel Acute Stroke Code for the Extended
on Headache-Related Disability in Patients with Episodic Migraine using the Migraine Disability Assessment —Paul Winner, Timothy Fitzgerald, Sanjay Gandhi, Paul Yeung, Joshua Cohen, Yuju Ma, Ernesto Aycardi
P4.096 Efficacy of Erenumab in Women
With and Without a History of MenstruallyRelated Migraine —Jelena Pavlovic, Koen
P4.100 Erenumab Safety Among
Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors —Paul
Winner, Uwe Reuter, David Dodick, David Kudrow, Jacek Rozniecki, Fei Xue, Feng Zhang, Sunfa Cheng, Hernan Picard, Daniel Mikol
Paemeleire, Hartmut Gobel, Jo Bonner, Alan P4.101 Impact of Fremanezumab Rapoport, Feng Zhang, Hernan Picard, Daniel Mikol on the Number of Days with Use of
P4.097 Efficacy of Fremanezumab
Acute Headache Medications in Chronic Migraine —Ernesto Aycardi, Paul Yeung, Tricia
in Patients With Chronic Migraine and Blankenbiller, Melissa Grozinski-Wolff, Ronghua Comorbid Moderate to Moderately Severe Depression —Joshua Cohen, Paul Yeung, Ernesto Yang, Yuju Ma, Egilius Spierings, Marcelo Bigal Aycardi, Marcelo Bigal, Ronghua Yang, Kristen P4.102 Early Onset of Action with Bibeau, Maja Galic, Michael Seminerio, Richard Fremanezumab Versus Placebo for the Lipton, Dawn Buse Preventive Treatment of Chronic Migraine — Paul Yeung, Ernesto Aycardi, Marcelo Bigal, Tricia P4.098 Erenumab Immunogenicity: A Blankenbiller, Melissa Grozinski-Wolff, Ronghua Pooled Analysis of Phase 2 and Phase 3 Yang, Yuju Ma, Jan Brandes Migraine Prevention Clinical Trials —Bert Vargas, Amaal Starling, Stephen Silberstein, P4.103 Analysis of Blood Pressure Yanchen Zhou, Marie-Louise Trotman, Fei Xue, Following Short-Term and Long-Term Farhad Sahebkar-Moghaddam, Hernan Picard, Treatment with Erenumab —Stewart Tepper, Daniel Mikol
Treatment of Patients with Episodic Migraine P4.099 Efficacy Of Fremanezumab in with Aura —Peter McAllister, Julio Pascual, Lora Patients With Chronic Migraine With or McGill, Lawrence Newman, Cristina Tassorelli, Without Concomitant Use of Preventive Feng Zhang, Hernan Picard, Daniel Mikol Medication —Peter Goadsby, David Dodick,
154 2018 AAN Annual Meeting
Window of Endovascular Treatment —
Julio Pascual, Uwe Reuter, Hernan Picard, Frank Hong, Marie-Louise Trotman, Fei Xue, Daniel Mikol, Jan Klatt
in Patients With Chronic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA —Paul Yeung, Egilius
Spierings, Tricia Blankenbiller, Xiaoping Ning, Ronghua Yang, Yuju Ma, Marcelo Bigal, Ernesto Aycardi
P4.105 Efficacy of Erenumab for the
Treatment of Patients with Episodic Migraine with Depression and/or Anxiety —Stewart Tepper, Gregor Broessner, Dawn Buse, Todd Schwedt, Erik Strauss, Feng Zhang, Hernan Picard, Daniel Mikol
P4.106 Impact of Fremanezumab
on the Number of Days With Use of Acute Headache Medications in Episodic Migraine —Jan Brandes, Fumihiko Sakai, Paul
Yeung, Tricia Blankenbiller, Melissa GrozinskiWolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi, Marcelo Bigal
P4.107 Early Onset of Action with
Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine — Jan Brandes, Paul Yeung, Ernesto Aycardi, Marcelo Bigal, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, MS
Young, John Rothrock, J. Lopez, Aubrey Manack Adams, Andrew Blumenfeld Azarci, Rachel Sobolev, Amanda Shallcross, Audrey Halpern, Thomas Berk, Naomi Simon, Scott P4.134 A Multicenter, Prospective, Powers, Richard Lipton, Elizabeth Seng
Migraine: A Pilot Study using Turk Prime —
P4.121 WITHDRAWN P4.122 Deep Brain Stimulation of the
Placebo-Controlled, Study Evaluating the Efficacy of DFN-02 (Nasal Spray of Sumatriptan 10 mg + Permeation Enhancer) in Migraine With or Without Aura —Sagar
P4.108 Repeat Infusions of Eptinezumab Observational Study —Mia Minen, Sarah Associated With Greater Migraine Reductions and Longer Migraine-Free Intervals: Results From the Phase 3 PROMISE-1 Trial —Egilius Spierings, Timothy Smith, Roger Cady, Eric Kassel, Joe Hirman
P4.109 The Impact of Fremanezumab
on Headache-Related Disability in Patients with Chronic Migraine Using the Headache Impact Test (HIT-6) —Paul Winner, Timothy Fitzgerald, Sanjay Gandhi, Paul P. Yeung, Joshua Cohen, Ronghua Yang, Yuju Ma, Ernesto Aycardi
P4.110 Efficacy of Fremanezumab in
Posterior Hypothalamus for the Treatment Chronic Cluster Headache: A Systematic Review —Nilson Nogueira Mendes Neto, Erich
Talamoni Fonoff, Sergio Adrian Fernandes Dantas, Marcelo Rodrigues Zacarkim, Levi Higino Jales Junior, Tatyana Vidal Mendes, Sebastiana Jayne Alves Vidal, Daniel Duarte Rolim, Jessika Thais da Silva Maia
Randomized, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine: The FORWARD Study —John
P4.135 Effectiveness of Intravenous
Dihydroergotamine for Pediatric Headache: Does Headache Diagnosis Matter? —Sara Fridinger, Christina Szperka
Rashmi Halker, Jessica Ailani
Egilius Spierings, Donald Kellerman, Pete Schmidt
P4.113 Achievement of Response with
P4.126 Effects of OnabotulinumtoxinA
Richard Lipton, Scott Powers, Mia Minen
Aycardi, Paul Yeung, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma
Pain within the First Week of Beginning Treatment in the Phase 2 Episodic Migraine Study —Marcelo Bigal, Ernesto Aycardi, Mirna
Silberstein
P4.115 The Impact of Fremanezumab on
R. Shewale, Rachel Halpern, Sally W. Wade, Eleena Koep, Hema Viswanathan
McDonald, Robert Noble, Pippa Loupe
Migraine-Specific Health-Related Quality of Life in Episodic Migraine —Richard Lipton, Sanjay Gandhi, Timothy Fitzgerald, Paul Yeung, Joshua Cohen, Yuju Ma, Ernesto Aycardi
P4.116 Analysis of Injection Site
Reactions across Four Placebo Controlled Trials of Erenumab for Migraine Prevention —Julio Pascual, David Doleüil,
Brendan Davies, Hernan Picard, Frank Hong, Feng Zhang, Fei Xue, Daniel Mikol, Jan Klatt
P4.117 The Impact of Fremanezumab on
Timothy Fitzgerald, Paul Yeung, Joshua Cohen, Ronghua Yang, Yuju Ma, Ernesto Aycardi
associated Extracranial Arterial Vasoconstriction and Stroke —Malveeka Sharma, Brian McGeeney, Carlos Kase, Hugo Javier Aparicio
P4.120 Factors Related to Migraine
Patients’ Decisions to Follow a Headache Specialist’s Recommendation for Migraine Behavioral Treatment: A Prospective
P4.137 The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-Migraine Headaches —Cassie Jia, Fang Zhang, Scott Lucchese, Kristen Scheitler, Raghav Govindarajan
P4.138 The Feasibility of RELAXaHEAD
(A Smartphone Based Progressive Muscle Relaxation (PMR) Therapy and Electronic Diary Application) For Use in a Headache Center —Sarah Jinich, Thomas Berk, Sait Ashina,
Babcock, Vernon Rowe, John Hunter, Arlene O’Shea, Doug Schell, Dorsey Paul, James Barnett
P4.140 Hybrid High Cervical and Diagnosed Chronic Migraine Patients in a Occipital Nerve Stimulation for Chronic Large US Health Insurer’s Population —Anand Intractable Migraine —Chad Domangue, Lilly P4.128 The Efficacy of Transcranial Direct
P4.130 Evaluation of
IncobotulinumtoxinA as Prophylactic Treatment of Chronic Headache in Veterans —Amanda Vu, Keith Yuge, Leah
Loewenstein, Hyo-Jin Chae, Mary Wen, Frank Bertone, Sunita Dergalust
Lawrence Robbins, Aubrey Manack Adams, Stephen Silberstein
P4.132 Transcranial Magnetic
Stimulation (TMS) for Migraine Prevention in Adolescents: A Pilot Open-Label Study —
Samantha Irwin, William Qubty, Isabel Allen, Irene Patniyot, Peter Goadsby, Amy Gelfand
P4.133 Effects of OnabotulinumtoxinA
OnabotulinumtoxinA for the Symptomatic Treatment of Chronic Migraine: The REPOSE Study —Fayyaz Ahmed, Charly Gaul, Paolo Martelletti, Juan Garcia Monco Carra, Aubrey Manack Adams
P4.151 Menigeal Extravasation, Efficacy of Botulinum Toxin or Triptans are not specific for Pathophysiology of Migraine only —Zdravko Lackovic, Ivica Matak, Boris
Filipovic, Visnja Drinovac-Vlah, Lidija Bach-Rojecky
P4.152 American Headache Society
Survey about Urgent and Emergency Management of Headache Patients —Mia Minen, Emma Ortega, Richard Lipton, Robert Cowan
P4.153 The effect of regional anesthetic sphenopalatine ganglion block on selfreported pain in patients with intractable migraines —Dev Mehta, Megan Leary, Hussam
Yacoub, Mohammed El-hunjul, Hope Kincaid, John Castaldo
THERAPEUTICS IN NEUROONCOLOGY: FROM LASER ABLATION TO IMMUNOTHERAPY I
P4.154 Single-agent Dabrafenib
for Intracranial BRAFV600E-mutated Histiocytosis —Ankush Bhatia, Gary Ulaner,
Raajit Rampal, David M Hyman, Omar AbdelWahab, Benjamin Durham, Julio Hajdenberg, Chezi Ganzel, Eli Diamond
P4.155 Laser interstitial thermotherapy (LITT) for newly diagnosed and recurrent P4.141 Migraines relieved by apixaban, a glioblastoma: Safety, effectiveness and Chen, Kristen Lechleiter, Roshini Jain
case report —Michael Yang, Deborah Reed Current Stimulation in Patients with Medication P4.142 Erythromelalgia Secondary to Overuse Headaches Secondary to Chronic Verapamil —Ashhar Ali, A. Rothner Migraines —Naji Riachi, Anthony Mansour, Maher Salem, Christelle Khoury, Tony Sabbouh, P4.143 User Design and Experience Tarek Jabri, Georges Khazen, Rechdi Ahdab Preferences in a Novel Smartphone Application for Migraine Management: A P4.129 Visual Snow Syndrome Successfully Treated with Lamotrigine: Case Think Aloud Study of the RELAXaHEAD Application —Emma Ortega, Adama Jalloh, Mia Report. —Robert Fekete
P4.131 The Effects of Migraine Medications in Patients with OnabotulinumtoxinA Treatment on the Episodic Migraine in the STRIVE Phase 3 Chronic Migraine Comorbidities of Sleep and Trial of Erenumab for Migraine Prevention — Fatigue —Andrew Blumenfeld, Stewart Tepper,
P4.119 Case of Dihydroergotamine
William Young, Aubrey Manack Adams, John Rothrock
P4.127 Treatment Patterns for Newly
P4.118 Use of Acute Headache and
Uwe Reuter, Julio Pascual, Gregor Broessner, Yngve Hallstrom, Hernan Picard, Sunfa Cheng, Feng Zhang, Daniel Mikol, Jan Klatt
Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Headache Every Day: A COMPEL Subanalysis —J. Lopez, Andrew Blumenfeld,
P4.150 Real-Life Use of
Minen
P4.144 Sphenopalatine Ganglion
Block for the Treatment of Acute Migraine Headache —Mohamed Falah, Eman Al-Ghawi, Eslam Shosha, Ali Al-Hilly, Moiz Bakhiet
P4.145 Treatment Plans for Various
Neurologic Conditions Include the Use of Smartphone Applications: An observational study of the privacy issues related to commercial smartphone applications using headache applications as an example —Rose Sciortino, Eric Stieglitz, John Torous, Mia Minen
P4.146 A Case of Lamotrigine
association between time to initiation of chemotherapy post-procedure and outcome —Stefania Maraka, Dhiego Chaves De Alm Bastos, Barbara O’Brien, Diane D. Liu, Olga Starostina, Kristin Alfaro-Munoz, Rao Ganesh, John De Groot, Sujit Prabhu
P4.156 Combining Traditional Herbal
Medicines for the Treatment of Malignant Gliomas —Prateeksunder Pinchi, Amishi Taneja, Uday Kode, Prahlad Parajuli
P4.157 Correlating Radiographical and
Pathological Response to Immunotherapy in Primary Brain Tumors —Jessica Schulte, Peter Canoll, Angela Lignelli, Fabio Iwamoto
P4.158 Safety of Alteplase for Acute
Ischemic Stroke in Patients with Intracranial Neoplasms: An Institutional Experience — Sasmit Sarangi, Shadi Yaghi, Heinrich Elinzano
P4.159 Neurological Complications
of Immune Checkpoint Inhibitors: A case series —Sarah Mancone, Thomas Lycan, Tamjeed
Responsive Post-Stroke SUNA —Asad Rauf, Sofia Loucao, Melissa Cortez, Seniha Ozudogru
Ahmed, Andrew Dothard, Umit Topaloglu, William Petty, Roy Strowd
P4.147 Dead Ends in the History of
P4.160 CD38 Targeted Therapy in
Duarte
Sonikpreet, Paula Schiapparelli, Alak Manna, Aneel Paulus, Steven Rosenfeld, Asher ChananKhan, Alfredo Quinones-Hinojosa
Treatment of Headache —Noah Rosen, Robert
Treatment on Disability and Quality of Life in P4.148 Message Framing to Determine Patients with Chronic Migraine with Baseline Best Methods for Discussing Migraine Allodynia: A COMPEL Subanalysis —William Behavioral Treatments with Persons with
Glioblastoma : A Step Forward. —Dr
AAN.com/view/AM18 155
Wednesday
Migraine-Specific Health-Related Quality of Life and Overall Health Status in Chronic Migraine —Sanjay Gandhi, Richard Lipton,
P4.136 Effects of OnabotulinumtoxinA
Treatment on Chronic Migraine Comorbidities P4.139 Onabotulinum Toxin Serves as of Depression and Anxiety: Psychiatric an Effective Treatment for Chronic Daily Comorbidities Responder Analysis —Andrew Headache in Patients with Hypermobility Blumenfeld, Stewart Tepper, Lawrence Robbins, Spectrum Disorder —Kelsey Riggs, Lauren
P4.114 Fremanezumab Reduces Headache Aubrey Manack Adams, Dawn Buse, Stephen
P4.149 A Randomized, Double-Blind,
Rothrock, Aubrey Manack Adams, Esther Jo, Xiang Munjal, Elimor Brand-Schieber Zhao, Andrew Blumenfeld
Patients With Episodic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA — P4.123 Long-Term Safety and Tolerability David Kudrow, Fumihiko Sakai, Paul Yeung, Tricia of OnabotulinumtoxinA Treatment in Chronic Blankenbiller, Xiaoping Ning, Ronghua Yang, Yuju Migraine Patients: COMPEL Analysis by Ma, Ernesto Aycardi, Marcelo Bigal Treatment Cycle —Mitchell Brin, Paul Winner, Andrew Blumenfeld, Eric Eross, Amelia Orejudos, P4.111 Fremanezumab Decreases Aubrey Manack Adams Migraine Symptoms such as Nausea, Vomiting, Photophobia and Phonophobia and P4.124 Subjects with Episodic Migraine Reduces the Need for Acute Medications Treated with DFN-02 (Sumatriptan 10 mg in the First Week of Treatment in the HFEM + the permeation enhancer DDM) Report Study —Marcelo Bigal, Mirna McDonald, Ernesto Higher Treatment Satisfaction and Reduced Aycardi, Pippa Loupe, Robert Noble Functional Disability Compared with Placebo —Elimor Brand-Schieber, Sagar Munjal P4.112 Reversion of Patients With Chronic Migraine to an Episodic Migraine P4.125 Effectiveness and Safety of Classification With Fremanezumab a New Zolmitriptan Rapid Absorption Treatment —Joshua Cohen, Kristen Bibeau, Maja Microneedle Array (M207) for the Acute Galic, Michael Seminerio, Verena Ramirez Campos, Treatment of Migraine (The ZOTRIP Study) — Fremanezumab in the Treatment of Chronic Migraine —Paul Winner, Marcelo Bigal, Ernesto
Adama Jalloh, Olivia Begasse De Dhaem, Elizabeth Seng, Mia Minen
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION IV G P4.161 Neurologic Immune-related
Wednesday, April 25 11:30 a.m.–7:00 p.m.
NOVEL BIOMARKERS IN AGING AND Adverse Events Associated with Check-point DEMENTIA Inhibitors: A Case Study and Systematic P4.173 Choroid Plexus Volume Is Review of the Literature —Kelsey JusterAssociated with CSF Protein Levels in Switlyk, Nicholas Johnson Healthy and Diseased Individuals —Ehsan P4.162 Neurologic complications of Tadayon, Alvaro Pascual-Leone, Emiliano immune checkpoint inhibitors in cancer Santarnecchi patients —Michael Youssef, Karin Woodman P4.174 Cerebrospinal fluid α-synuclein P4.163 Durable response to bevacizumab as a potential biomarker for Alzheimer’s in adults with recurrent pilocytic disease —JieQiong Li, Jintai Yu, Lan Tan astrocytoma —Andrea Wasilewski, Nimish P4.175 CSF Cytokine Profiles Uniquely Mohile Identify Different Neurodegenerative Disorders —Umesh Gangishetti, J. Christina PRACTICE, POLICY, AND ETHICS II
P4.186 Peripheral Blood Markers of Cell
P4.164 Glioneuronal Growth of Spinal
P4.176 CSF neurofilament-light chain
Leilani Doty, Sudha Seshadri, Kenneth Heilman
Bruce Miller, Adam Boxer
Talisha Davis, Babak Baban, Anilkumar Pillai
Cord Following Intrathecal Stem Cell Transplant —Rahul Rahangdale, Mohammad
Ali, Susan Baser, Mary Flaherty, Cunfeng Pu, M.D., Ph.D., Sandeep Rana, Andrea Synowiec, Ruchi Wanchoo
D
Howard, Alexander Kollhoff, William Hu
Cycle Dysregulation are Associated with Alzheimer’s Disease Biomarkers —Jocelyn Argueta, Judy Pa
BIOMARKERS, BIOLOGY, PHYSIOLOGY
in Schizophrenia —Steven Vernino, Mindy Kim, Elena Ivleva, Elliott Gershon, Sarah Keedy, Carol Tamminga
P4.188 Autoimmune Encephalitis
Secondary to Neuronal Ganglionic Acetylcholine Receptor Antibodies —Alicia
and phosphorylated-tau predict disease P4.189 C3aR-dependent infiltrating progression in PSP —Julio Rojas -Martinez, Jee monocytes promote stress-induced Bang, Iryna Lobach, Richard Tsai, Gil Rabinovici, depressive behavior in mice —Tami Feng,
P4.177 Circulating Angiogenic Cell
Himali, Daniel Levy, Sarah Connor, Alexa Beiser, Paul Courchesne, Claudia Satizabal, Matthew
P4.170 Economic Impact of Older Age on Pase, Vasan Ramachandran, Sudha Seshadri the Initial Care of Patients with Acute Spine P4.181 Event Related Potentials as a Trauma —Julio Furlan, Michael Fehlings, B. Catharine Craven
P4.171 Assess the Implementation
of Stroke Performance Measures in the Acute-Care Setting at West LA VA Medical Center —Amy Huang, Melisa Kamali-Grigorian,
Wednesday
Shelly de Peralta, Mary Wen, Hyo-Jin Chae, Frank Bertone, Roi Wallis, Sunita Dergalust
P4.172 Sleep clinic follow up, co-
morbidities, mortality rates in patients screened high positive with STOP BANG Questionnaire —Sanath Kasi Reddy, Kalyan
Sajja, Kamalika Banerjee, Erin Smith, Sachin Kedar
Prognostic Measure: Predictive Value for Rate of Cognitive Decline in Patients with Mild Alzheimer’s Disease. —Marco Cecchi, Carl Sadowsky, Diana Michalczuk, Elizabeth Vassey
Hassan, Umar Shariff, Christina Sanchez, Ahmed Malik, Adnan Qureshi
ischemic stroke: Trends and predictors of utilization of thrombectomy using a national database —Michael Hamer, Sahil Gupta, Mina Lobbous, Frank Benesh, Angela Hays Shapshak
P4.203 Mechanical Thrombectomy with Roman Herzig, Dagmar Krajickova, Antonin Krajina, Eva Vitkova, Simona Haluskova, Oldrich Vysata, Pavla Cabelkova, Martin Valis
P4.204 Get with The Guideline on
Reducing Door-to-Reperfusion Time and Good Clinical Outcomes for Endovascular Reperfusion Therapy —Shuichi Suzuki, Jason
Meng, Ravi Patel, Li-Mei Lin, Kiarash Golshani, Hermelinda Abcede, Mohammad Shafie, Wengui Yu, Steven Cramer, Mark Fisher, Frank Hsu
P4.205 Readmission After Mechanical Thrombectomy for Acute Ischemic Stroke: A Nationwide Readmission Database Analysis —Preethi Ramchand, Dylan Thibault, James Crispo, Joshua Levine, Robert Hurst, Michael Mullen, Scott Kasner, Allison Wright Willis
P4.206 Emergent Carotid Stenting in
Acute Anterior Circulation Ischemic Stroke Due to Tandem Lesions Has Very Low Risk of Hemorrhage —Arpan Shrivastava, Richard W Crowley, Laurel Cherian, James Conners, Reneta Costa, Kathryn Ess, Nicholas Osteraas, Sarah Song, Alejandro Vargas, Rima Dafer
P4.207 Safety of endovascular
thrombectomy for M2 compared to M1 middle cerebral artery occlusion. —Asma
Arash Kamali, Zafer Keser, Larry Kramer, Paul Schulz
Moussaoui, Michael Chen, Renata Costa, Bichum Ouyang, Laurel Cherian, James Conners, Nicholas Osteraas, Sarah Song, Alejandro Vargas, Rima Dafer
P4.193 Neural correlates of self-
P4.208 Downstream Clot Fragment
Nair, Jane Allendorfer, Rodolphe Nenert, Amber Martin, Daniel Mirman, Jennifer Vannest, Jerzy Szaflarski
James Frey
generation and verbal memory performance during paired-associate learning —Sangeeta
P4.194 Application of Quantitative
P4.182 Diagnostic accuracy of biomarker MR Imaging Volumetrics to a Combined combinations in the A/T/N classification for Alzheimer’s disease —Patricio Chrem Mendez,
Number of Passes with a Stentreiver and Hemorrhagic Transformation? —Ameer
Stent-retrievers is Safe in Anticoagulated Parker, Sarah Rehl, Leila Saadatpour, Usama Tariq, Patients with Anterior Circulation Stroke —
Neurology —Jaya Trivedi, Pravin Khemani,
Todorov
E
P4.201 Is There a Correlation with
P4.187 Presence of NMDA-R Antibodies P4.202 Mechanical thrombectomy in
P4.190 Behavioral correlates of Attenuation and Senescence Correlates with cerebrospinal fluid concentrations of Worse Memory and Greater White Matter aminoacids and monoamine metabolites Debra Clamp, Kimberly Kelley, David Pool, Paula Lesion Burden in Older Adults —Daniel Nation, according to APOE-ε4 carrier status in Hardeman, Emmitt Rathore, Matthew Stowe, Alick Tan, Elissa McIntosh, Shubir Dutt, Jean Kim Siniscalchi, Padraig O’Suilleabhain, Steven dementia with Lewy bodies compared with Ho, Jung Jang, Belinda Yew, Kathleen Rodgers, Vernino, Benjamin Greenberg, Mark Goldberg Alzheimer’s dementia and cognitively healthy Katherine Chang, Aimee Gaubert, Anna Blanken people —Fabricio De Oliveira, Marjorie Miraldo, P4.166 Implementation of Protocols Eduardo Castro, Fernando Machado, Sandro P4.178 Peripheral Innate Immune to Mitigate Violence Within a Health Care Activation Correlates with Disease Severity Almeida, Sandro Matas, Paulo Bertolucci, Maria Setting for Patient and Healthcare Worker Naffah-Mazzacoratti in GRN Mutation Carriers —Peter Ljubenkov, Safety —Michael Goldberg, Paul Wright, Paige Mumford, Michael McGrath, Isabel Allen, Saeyoan Thirunavukkarasu, Richard Schwarz P4.191 Negative BOLD Response and Zachary Miller, Laura Mitic, Anna Karydas, Hilary Functional Connectivity in the Default P4.167 The State of Ethics Education in Heuer, Julio Rojas -Martinez, Ping Wang, Jane Mode Network are Representative Neurology Residencies —Douglas McAdams, Zhang, Adam Staffaroni, Yann Cobigo, Rodney Pearlman, Bruce Miller, Howie Rosen, Adam Boxer of Two Overlapping but Separate James Giordano Neurophysiological Processes —David Parker, P4.179 The association of plasma P4.168 High patient participation rate Qolamreza Razlighi neurofilament light chain and cognitive in Post-Stroke Depression screening at function in patients with Alzheimer disease P4.192 Quantitative Diffusion Tensor an Acute Stroke Center —Amanda Persaud, and Parkinson disease —Jong-Ling Fuh, Wei-Ju Tractography of the Superior Thalamic Loretta Schnepel, Fatoumata Sakho, Wayne Radiation and the Corticospinal tract in Lee, Shuu-Jiun Wang Hodges, Vicki Coppen, Michelle Prosje, Scott relation to Ventricular and Sulcal CSF Silliman P4.180 Circulating BNP and GDF15 and Volumes in Patients with Ventriculomegaly P4.169 Quality measure in teleneurology Risk of Incident Dementia: The Framingham Diagnosed with Normal Pressure consultations —Alexandre Todorov, Daniele Offspring Cohort —Emer McGrath, Jayandra Hydrocephalus —Kyan Younes, Khader Hasan, P4.165 Southwestern Access to
ENDOVASCULAR TREATMENT
Cognitive Neurology and Geropsychiatry Clinic Case Series —Somayeh Meysami, Cyrus
Migration During Endovascular Thrombectomy Adversely Affects Clinical Outcome —Carol Darbonne, Kristina Chapple,
P4.209 Isolated M2 Segment Occlusions: Should These Patients Receive Endovascular Therapy? —Anusha Boyanpally, Matthew Nardi, Vikas G. Patel, Molly Jacob
Ismael Calandri, Ignacio Demey, Lucia Pertierra, Raji, Verna Porter, Jamila Ahdidan, David Merrill Maria Russo, Ezequiel Surace, Horacio Martinetto, P4.195 Magnetic Resonance Jorge Campos, Silvia Vazquez, Gustavo Sevlever, Spectroscopy (MRS) predict cognitive Ricardo Allegri
P4.210 Assessing the Affect
P4.183 The Potential Role of Optical
Kurgansky, Phillip Ye, Ryan Bo, Jeffrey Farkas, Karthikeyan Arcot, David Turkel-Parrella, Ambooj Tiwari
outcomes in children after cardiac transplantation —Pilar Pichon, Barbara Coherence Tomography as a Marker of Holshouser, Vidhya Krishnamurthy, Stephen Disease Severity in Alzheimer’s Dementia — Ashwal, Richard Chinnock, Kiti Freier Roberto Santangelo, Giancarlo Comi, Giuseppe Magnani, Letizia Leocani
P4.196 Multitasking in Early Multiple
Cognitive Decline in MCI Patients —Xiaoyan
Roy Martin, Jerzy Szaflarski
of Clot Firmness on the Speed and Grade of Recanalization in Hyperacute Neuroendovascular Therapy —Gregory
P4.211 Safety and Effectiveness of Ticagrelor in Patients with Clopidogrel
Sclerosis —Christina Lewis, Gabrielle Pelle, P4.184 Aetiology of cognitive impairment Stephen Krieger, Victoria Leavitt, James Sumowski Resistance Undergoing Angioplasty, Stent or Flow Diverter Placement —Umar Shariff, in patients with inconclusive cerebrospinal Ameer Hassan, Adnan Qureshi fluid results for Alzheimer’s disease —Martin P4.197 Stress Perception Modulates Neural Response to Psychosocial Stress in Rakusa, Sofia Gak, Evgenija Modric P4.212 Incidence of Hemorrhage of Psychogenic Nonepileptic Seizures —Jane P4.185 CSF Neurogranin Levels Predict Allendorfer, Rodolphe Nenert, Kathleen Hernando, Combination IV tPA and Eptifibatide Therapy Sun, Alison Headley, Andres De Leon Benedetti, Chuanhui Dong, Steven Lang, Bonnie Levin, Tatjana Rundek, Christian Camargo, Clinton Wright, Henrik Zetterberg, Kaj Blennow, David Loewenstein
156 2018 AAN Annual Meeting
P4.198 NA P4.199 NA P4.200 NA
in Stroke Endovascular Thrombectomy — Ashik Shrestha, Phillip Ye, Ting Zhou, Ambooj Tiwari, David Turkel-Parrella, Jeffrey Farkas, Karthikeyan Arcot, Danielle Crotty
P4.213 Mechanical Thrombectomy
P4.227 DamAGE cONTrol: A novel tool in Acute Ischemic Stroke: A Regional for predicting outcomes after successful Comprehensive Stroke Center Experience — endovascular thrombectomy —David Ermak, Agnieszka Slowik, Dorota Wloch-Kopec, Joanna Chrzanowska-Wasko, Aleksandra Golenia, Antoni Ferens, Bartlomiej Lasocha, Wojciech Serednicki, Pawel Brzegowy, Tadeusz Popiela
P4.214 Direct aspiration (ADAPT) and
primary stent retriever thrombectomy for acute ischemic stroke: A systematic review of radiographic and clinical outcomes in 5441 patients —Christopher Primiani, Aquilla Turk, III, Italo Linfante, Elad Levy, Adnan Siddiqui, Maxim Mokin
Muhammad Niazi, Raymond Reichwein, Kevin Cockroft
Anterior Circulation Large Vessel Occlusion and Mild Symptoms. —Mohammad Anadani,
Sami Alkasab, Madison Hyer, Alejandro Spiotta, Raymond Turner, Jonathan Lena, Joseph Jamison, Mohammed Imran Chaudry
P4.229 Impact of Ictal Definition on
Reperfusion Outcomes in eLVO Cases —
Ryan Bo, Phillip Ye, Jeremy Liff, Jeffrey Farkas, Karthikeyan Arcot, David Turkel-Parrella, Ambooj Tiwari
Sohyun Boo, Amelia Adcock
TPA IN ACUTE ISCHEMIC STROKE
P4.216 Unrelenting Posterior Circulation
P4.230 Thrombolysis in Posterior TIAs Improved by Left Vertebral Angioplasty Circulation Stroke Patients is associated and Stenting —Ramita Dewan, Christopher with Prolonged Door to needle Time —Faisal Stack, John Cole
P4.217 Safety of Acute Intracranial
Stenting for treating Posterior Circulation Strokes in the Stentriever Era. —Siddhart Mehta, Ashish Kulhari, Amrinder Singh, Rafia Jawed, Spozhmy Panezai, Jawad Kirmani
P4.218 Dose and Time Dependence
of Eptifibitide Complications in Patients undergoing Neuroendovascular Therapy with and Without Hyperacute Stenting —
Ryan Bo, Ashik Shrestha, Ting Zhou, David TurkelParrella, Karthikeyan Arcot, Jeffrey Farkas, Ambooj Tiwari, Danielle Crotty
P4.219 Reasons and Outcomes of
Patients Who Do Not Receive Mechanical Thrombectomy for Acute Ischemic Stroke —
Ibrahim, Naveed Akhtar, Najib Murr, Saadat Kamran, Dirk Deleu, Ashfaq Shuaib
Alkuwaiti, Connie Bongiorno, Christopher Logue, Shailesh Male, Benjamin Miller, Rwoof Reshi, Kevin Engel, Victor Urrutia, Christopher Streib
P4.232 WITHDRAWN P4.233 Initial Presenting Stroke
Symptoms Impact Treatment Timeline Among Ischemic Stroke Patients —Elizabeth Baraban, Lindsay Lucas, Archit Bhatt
P4.234 Should Fibrinogen levels be
P4.220 Outcome of Distal Clot Migration Repeat Head Computed Tomography (CT) Ryan Bo, Jeremy Liff, Jeffrey Farkas, Karthikeyan Arcot, David Turkel-Parrella, Ambooj Tiwari
in Acute Ischemic Stroke Patients Treated with Intravenous (IV) Tissue Plasminogen Activator (tPA)? —Justine Milligan, Harleen Kaur, Christopher Newey
P4.221 Predictive Value of Procedure
P4.236 Ultra-early IV tPA for emergent
Reichwein, Kevin Cockroft, David Ermak
Donohue, Ken Uchino, Dolora Wisco
Duration in Outcomes After Endovascular Thrombectomy —Muhammad Niazi, Raymond
large vessel occlusion strokes improves clinical outcomes —Rodica Di Lorenzo, Megan
P4.222 Outcomes in Patients with Acute P4.237 Response of Intravenous Tissue Plasminogen Activator in Large Artery Atherosclerosis Stroke Etiology —Nidhi
Rybinnik, Kiwon Lee, Deviyani Mehta
Kasatwar, Lee Birnbaum
P4.223 Outcomes Of Mechanical
P4.238 A Comparative Study Of
Hussain Shallwani, Felix Chin, Adnan Siddiqui, Robert Sawyer, Kunal Vakharia, Hakeem Shakir, Elad Levy
Population Characteristics in Stroke Mimic vs Acute Stroke Receiving tPA —Muhammad Aman, Nidhi Kasatwar, Lee Birnbaum
Shazli Khan, Sitara Koneru, Syed Zaidi
P4.225 Does Intra-Arterial Therapy Help Patients with Mild Acute Ischemic Stroke: A 6-Year Look at Large Vessel Occlusions — Alessandro Orlando, Johnathan Davis, Judd Jensen, David Bar-Or
P4.226 Outcomes of Mechanical
Thrombectomy in Tandem ICA Occlusion — Omar Hussein, Khalid Sawalha, Dilip Singh, Randheer Yadav, Deepak Gulati
P4.243 Effect of Statins and Dose
Relation on Intracerebral Hemorrhage and Outcome after IV Thrombolysis for Acute Ischemic Stroke —Harshit Shah, Navdeep Lail,
Thrombolysis in Unusual Stroke Mimics —
Felipe Franco da Graca, Thiago Prado, Leo Gordiano Azevedo
P4.240 Anticoagulant Use Is Not
Associated With Higher Post tPA Hemorrhagic Conversion —Achint Patel,
Abhishek Lunagariya, Urvish Patel, Vishal Jani, Nandakumar Nagaraja, Branko Huisa-Garate, Thomas Hemmen
P4.241 Time Intervals of Symptomatic Intracereberal Hemorrhage (sICH) after Tissue Plasminogen Activator (rt-PA) Treatment —Patrick Chen, Brett Meyer, Karen Rapp, Thomas Hemmen, Royya Modir, Kunal
F
P4.259 Electroclinical and Historical
Features Related to Response to AEDs in Juvenile Myoclonic Epilepsy. —Iffat Ara
Suchita, Samiya Rashid, Charles Szabo, Lola Morgan, Kameel Karkar, Octavian Lie, Linda Leary, Caila Vaughn, Annemarie Crumlish, Robert Sawyer, Ishan Adhikari Ashkan Mowla
P4.244 WITHDRAWN P4.245 Mixed but Unused Doses of
Thrombolytic Therapy in Acute Ischemic Stroke: What is an Acceptable Rate for Wasted Drug? —Reid Taylor, Erika Prezas, Ameran Tooley, Alexander Schneider
P4.246 Imaging Characteristics of
Sumera Ali, Manoj Kumar
P4.247 Impact of Mock Code Stroke on
Door to Needle times —Tijil Agarwal, Andrew Slusher, Michael Palm, Lee Birnbaum
P4.260 Relationship between
Levetiracetam exposure and Psychogenic Non-Epileptic Seizures —Andrew Brown, Kalyan Yarraguntla, Rohit Marawar
P4.261 A Proof-of-Principle Quantitative EEG Study of an Oral, Potent and Selective T-Type Calcium Modulator in Healthy Volunteers —Spiridon Papapetropoulos, Stacey Boyer, Margaret Lee
P4.262 Tendencies in Antiepileptic Drugs use and polytherapy in a mexican General Hospital —Fernando Cortés-Enríquez, Ildefonso Rodriguez-Leyva, Adriana Patricia MartínezMayorga, Sandor Quintero-Aparicio, Fernando Alcides Lozano-Sánchez, Alejandro FloresSobrecueva
P4.263 Posterior Reversible Encephalopathy Syndrome in a Patient stroke thrombolysis delay from 70 to 31 Treated with Cisplatin/Pemetrexed —Chelsea minutes in Christchurch, demonstrating Zhu, Guru Ramaiah, Vicki Ramsey-Williams transferability with ‘real-world’ resources. — Erin Coleman, Sarah Wright, Deborah Mason, Jon P4.264 Combination AED Treatment Reimers, Roderick Duncan, Mary Griffiths, Michael With Clobazam in Patients With LennoxHurrell, David Dixon, Atte Meretoja, John Fink, Gastaut Syndrome: Post Hoc Analyses of the Teddy Wu CONTAIN Study —Steve Chung, Barry Gidal, Ole Michael Lemming, Meghana Karnik-Henry, P4.249 Impact on IV TPA Treatment Times Following RACE Score-Based Hospital Elizabeth Hackler, David Tworek, Salma Sayeed Protocol Implementation: Northwest Ohio P4.265 Pharmacometrics of Clobazam Experience —Jaclyn Mueller, Samar Sheriff, in Pediatrics: Population PK Modeling to Sitara Koneru, Shazli Khan, Syed Zaidi Predict Effective Clobazam Doses for Dravet Syndrome —Dwain Tolbert, Hui-May Chu, Ene Ette P4.250 Quality Improvement Initiative Reduces Door-to-Needle Time for P4.266 The PK/PD Basis for Clobazam Intravenous Thrombolysis —Demi Tran, Dana Use in Refractory Seizures: Is There a Stradling, Hermelinda Abcede, Mohammad Shafie, Need for Clobazam Dosage Reduction in Wengui Yu the Presence of Other Antiepileptic Drugs (AEDs)? —Dwain Tolbert, Pavel Klein, Barry P4.251 “Time Out Before Bolus” for Gidal, Hui-May Chu, Ene Ette Safe and Efficient Administration of IV tPA for Acute Ischemic Stroke —Sandhya Mehla, P4.267 Efficacy of Clobazam as Maria Zambrano, Muhammad Ahmed, Harshit Add-on AED in Partial Onset Seizures Shah, Ashkan Mowla Management —Aashit Shah, Kalyan Yarraguntla, P4.252 The Effectiveness of Combination Deepti Zutshi, Maysaa Basha, James Bathe Therapeutic Craniocerebral Hypothermia P4.268 Effect of Perampanel and and Trombolysis in Hyperacute Stroke Amantadine on Rat Model of Pilocarpinemanegment. —Irina Sharinova, Igor Stulin, Irina Induced Status Epilepticus: Evidence on P4.248 Helsinki Stroke model reduced
Kalenova, Oleg Shevelev, Sofya Ustinskaya, Nikita
P4.239 Under Pressure: A Case Series of Litvinov, Andrey Butrov, Vyacheslav Ardashev,
P4.224 Outcomes Following Mechanical Matias, Larissa Vilany, Wagner Avelar, Paula Thrombectomy in Nursing Home Residents —Samar Sheriff, Jaclyn Mueller,
ANTI-EPILEPTIC DRUGS AND EPILEPSY SURGERY
Sang-Hoon Kim, Kang-Ho Choi, Man Seok Park
Marina Petrova
P4.253 Intravenous Thrombolysis
Before Endovascular Treatment Leads to Higher Hospital Charges without Improving Outcomes —Ameer Hassan, Umar Shariff, Christina Sanchez, Ahmed Malik, Adnan Qureshi
P4.254 Intravenous Thrombolysis and
Endovascular Treatment in Chronically Anticoagulated Patients with Ischemic Stroke in the United States: Analysis of Nationwide Inpatient Sample from 2006 to 2014. —Ameer Hassan, Mohammad-Rauf Afzal, Omar Saeed, Saqib Chaudhry, Adnan Qureshi
Seizure Termination, Behavioral Alterations, Epileptogenesis and Neuronal Damage — Hanan Mohammad, Changiz Taghibiglou, Farzad Moien Afshari
P4.269 Topiramate induced reversible
hyperammonemic encephalopathy. —Jaime Shoup, Vishwanath Sagi
P4.270 Lack of pharmacokinetic
interaction of lacosamide on carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate and valproic acid in children and adolescents with epilepsy: Post-hoc analysis of a randomized, double-blind, placebocontrolled trial —Barbara Steinborn, Armel Stockis, Ying Zhang, Svetlana Dimova, Paul Martin
AAN.com/view/AM18 157
Wednesday
M2 Occlusions Undergoing Endovascular Reperfusion Therapy —James Lee, Igor
Thrombectomy in acute ischemic stroke patients with Large Vessel Occlusions and Low NIHSS —Haris Kamal, Muhammad Ahmed,
Thrombolysis —Joontae Kim, Bang-Hoon Cho,
P4.242 Clinical Implications of
Ischemic Stroke Patient Not Thrombolysed P4.231 Guideline-Based Intravenous tPA Due to Mild or Resolving Symptoms (“Too for Central Retinal Artery Occlusion: A Case Good To Treat”) and Findings associated with Series and Systematic Review —Mohammed Poor Outcomes —Lindsay Malatesta, Syed Ali,
monitored with IV-tPA? —Rafia Shafqat, Vaibhav Goswami, Christeena Kurian, Ervis Han Wang, Macym Rizvi, Trisha Dickey, Ciro Xhihani, Ramandeep Sahni Ramos Estebanez, Wei Xiong, Michael De Georgia, Cathy Sila, Anthony Furlan, Sophia Sundararajan P4.235 What is the Utility of a 24 Hour in the Setting of IV r-tPA and Stroke Endovascular Thrombectomy —Phillip Ye,
Serial Glucose Measurements in Acute
P4.255 NA P4.256 NA P4.257 NA P4.258 NA
P4.228 Long Term Functional Outcome of Ischemic Stroke Treated with Intravenous
P4.215 Rare Phenomenon of Limb-
Shaking TIA, Resolved with Intracranial Wingspan Stenting —Tamra Ranasinghe,
Agrawal, Branko Huisa-Garate, Lovella Hailey, Kevin Attenhofer, Abhishek Lunagariya, Pradeep Selvan, Dawn Meyer
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION IV G P4.271 Effect of Pharmaceutical
Formulation of Purified Cannabidiol (CBD) on Seizure Frequency and Severity is Independent of Drug-Drug Interactions with other Anti-Epileptic Drugs (AEDs) —Tyler Gaston, Gary Cutter, Yuliang Liu, Leslie Perry Grayson, E Bebin, Jerzy Szaflarski
P4.272 Safety and Pharmacokinetics
of Diazepam Buccal Soluble Film —Allen H
Heller, Stephen Wargacki, Cassie Jung, David J Wyatt, Mark Schobel
P4.273 Comparative Pharmacokinetics of
titer —Kushak Suchdev, Kalyan Yarraguntla, Mohammad Ibrahim, Aashit Shah
P4.287 Relevance of Serial Anti-GAD titers in relation to Seizure Frequency in Autoimmune Epilepsy (AIE): An Observational Study —Kalyan Yarraguntla,
Kushak Suchdev, Mohammad Ibrahim, Aashit Shah
P4.304 WITHDRAWN P4.305 Rapidly Resolving and
presenting at a tertiary care hospital, in Islamabad Pakistan —Faleha Zafar, Raja Shoaib,
Tara Becker, Tasneem Hasan, Lauren K. Ng Tucker, James Meschia, William Freeman
P4.320 A rare case of cyclophosphamide
Astrocytopathy underlies Autoimmune Epilepsy case-control study —Naillid Felipe, Sok Lee, Helena Lau, Ayshe Beesen, Melissa Mercado, in the setting of Multi-Organ Failure —Dina Dababneh, Derek Notch, Jafar Kafaie
Stephanie Zhang, Will Ross
wasim Tariq, Ehsanul Haq, Danish Hassan, Ibrahim
Contralateral Recurrent Subdural Hematoma Shamael in Disseminated Intravascular Coagulation —
P4.306 Predictors of acute respiratory P4.288 Glial Fibrillary Acidic Protein (GFAP) failure in acute ischemic stroke patients: A
P4.289 EpxEpilepsy: A SMS-Based Diazepam Buccal Soluble Film and Diazepam Intervention for Patients with Epilepsy — Rectal Gel —Allen H Heller, Stephen Wargacki, Rajat Duggirala, Sirui Ma, Robert Peters, Tracy Stalvey, David J Wyatt, Mark Schobel
Wednesday, April 25 11:30 a.m.–7:00 p.m.
Courtney Takahashi, Julie Shulman, Hugo Javier Aparicio, Thanh Nguyen, Jose Romero, Viken Babikian, David Greer, Anna Marisa CervantesArslanian
induced Posterior reversible encephalopathy syndrome (PRES). —Taha Nisar, Abdul Rahman Alchaki, Erin Feinstein
P4.321 Bilateral Dentate nuclei injury
after global cerebral hypoperfusion: A case report —Shashank Shekhar, Shreyas Gangadhara, Fouad Abuzeid, Christa O’hana Nobleza, Rebecca Sugg, Hartmut Uschmann
P4.322 Long-term functional outcome in P4.307 Potentially modifiable risk factors patients with acquired infections after acute
for long-term cognitive impairment after spinal cord injury. —Jan Schwab, Peter Martus, critical illness—a systematic review —Tarun Ralf Watzlawick, YuYing Chen, Michael DeVivo, of Nonconvulsive Status Epilepticus in Pediatric Epilepsy (DRE) in the Veteran Population — Singh, John O’Horo, Amra Sakusic, Rahul Kashyap, Marcel Kopp Patients with Angelman Syndrome —Lila Hyo-Jin Chae, Alexander Crossley, Leah Loewenstein, Ronald Petersen, Alejandro Rabinstein Worden, Olivia Grocott, Amanda Tourjee, Fonda Mary Porter, Frank Bertone, Sunita Dergalust P4.323 Early Mobilization in the ICU: Chan, Ronald Thibert P4.308 WITHDRAWN Assessing a Standardized Early Mobility P4.291 NA Protocol on Neurological Patients —Sandeep P4.275 Man’s Best Friend: A Survey of P4.309 In-Hospital Complications Walia, Simrit Sodhi, Doris Chen, Hugh Black Academic Neurologists and Subsequent Review P4.292 NA following acute neurological injuries — P4.293 NA of the Literature Exploring Seizure Dogs — Anantha Vellipuram, Rakesh Khatri, Mohtashim P4.324 Consent Rate For Organ Donation Christopher Stack, Ramita Dewan, Ana Sanchez Qureshi, Mohammad-Rauf Afzal, Ihtesham P4.294 NA After Brain Death: A Single Center’s Qureshi, Alberto Maud, Darine Kassar, Paisith Experience over 11.5 years —Mohammed P4.276 Medical Marijuana-receptivity NEUROCRITICAL CARE I Piriyawat, Salvador Cruz-Flores, Gustavo Rodriguez Kananeh, Paul Brady, Lisa Louchart, Lonni Schultz, and knowledge in a cohort of Hispanic Chandan Mehta, Mohammed Rehman, Stephan patients with Epilepsy —Laura Surillo Dahdah, P4.295 Impaired Dynamic Cerebral P4.310 GCS Predicts Survival and Ignacio Pita Garcia Discharge Disposition in Patients with Acute Mayer, Panayiotis Varelas Autoregulation is a Predictor of Worsening Cerebral Injury —Ross Hamilton, Hia Ghosh, Hepatic Encephalopathy Severity —Eric P4.325 Multidisciplinary Management P4.277 High Times? Prevalence and Jean Nickels, Franchesca Konig-Toro, Matthew Liotta, Leena Thomas, Katie LaHaye, Shyam Approach to Fulminant Hepatic Perceptions of Marijuana Use Among Kruppenbacher, Debra Roberts, Peter Kaplan, Prabhakaran, Farzaneh Sorond Encephalopathy in the Neurocritical Patients with Epilepsy —Ginette Moores, Gretchen Birbeck, Olga Selioutski Care Unit: A single-center experience — Andrew Lockey, Ahmed Attar P4.296 Plasma IL-6 Levels are P4.311 Improving Cytotoxic Edema With Mohammed Rehman, Chandan Mehta, Riad Independently Associated with Functional P4.278 Evaluation of Quality of life in Ramadan, Bradley Howell, Hussam Elkambergy, Outcome and Markers of Secondary Injury in Cerebral Fat Embolism Syndrome, From A patients treated with VNS —Victoria Grassi Nightmare To A Shiny Morning: Two Cases Stephan Mayer Spontaneous Intracerebral Hemorrhage — Bonamigo, Bruno Takeshita, Talita Perboni, Pedro Presentation —Furkan Yilmaz, Alok Patel, Tapan P4.326 Single or Dual Brain Death Audrey Leasure, Arthur Steinschneider, Guido Kowacs, Murilo Meneses, Samanta Rocha Kavi Falcone, Emily Gilmore, Lauren Sansing, Kevin Exams: Tertiary Hospital Experience Over P4.279 Knowledge of and Attitude Sheth 11.5 Years —Paul Brady, Mohammed Kananeh, P4.312 Race, Insurance and SocioToward Epilepsy Surgery Among Lisa Louchart, Chandan Mehta, Mohammed P4.297 Brain Tissue Oxygenation as an Economic Status Among Donors Versus Neurologists in Saudi Arabia — Bandar Nasser Rehman, Ariane Lewis, David Greer, Stephan Adjunctive Monitor for Determining Optimal Recipients In United States from years A Aljafen, Majed Alomar, Nawaf Abohamra, Mayer, Panayiotis Varelas Cerebral Perfusion Pressure in Subarachnoid 2011-14 —Ihtesham Qureshi, Mohtashim Mohammed Alanazy, Taim Muaygil Qureshi, Mohammad-Rauf Afzal, Rakesh Khatri, P4.327 Live Simulation for Emergency Hemorrhage Patients —Jenna Ford, Soojin Park, Alberto Maud, Darine Kassar, Paisith Piriyawat, Amelia Boehme, Murad Megjhani, Kalijah Terilli Neurology Life Support —Peggy White, CLINICAL EPILEPSY III
P4.274 Diazepam for Outpatient Treatment P4.290 Managing Drug Resistant
G
P4.280 Adoption of Responsive
Neurostimulation (RNS) at a typical level 4 Epilepsy Center —Angelica Rivera Cruz, Himali Jayakody, Selim Benbadis
P4.281 Saccadic Eye Movement
Abnormalities in Genetic Epilepsy —Saloua
Mrabet, Mouna Ben Djebara, Fatma Laatar, Amira Nasri, Imen Kacem, Amina Gargouri Ep Berrechid, Riadh Gouider
Wednesday
P4.282 Clinical Vignette: Limbic Encephalitis Presenting as Bilateral Epilepsia Partialis Continua —Vishal Mandge, James Castellano, Daryl McHugh, Mark Milstein, Alexis Boro
P4.283 Hospitalization Rate For
P4.298 IL-17F and IFN-beta May Predict Acute Clinical Course after Traumatic Brain Injury —Annie Chiu, Holly Hinson
P4.299 Intracranial Pressure (ICP)
Trajectories: A Novel Tool that may Inform Outcome and Mortality in Severe Traumatic Brain Injury —Ruchira Jha, Jonathan Elmer, Benjamin Zusman, Ava Puccio, David Okonkwo, Seo Young Park, Lori Shutter, Jessica Wallisch, Yvette Conley, Patrick Kochanek
P4.300 Risk Factors and Outcomes of
P4.285 Neuroimmune Mechanisms
Of Epilepsy As A Key To Pathogenetic Treatment Of The Disease —Rano Azizova, Maruf Salokhiddinov
P4.286 Role of other autoantibodies
in patients with autoimmune epilepsy in presence of elevated anti-GAD antibody
158 2018 AAN Annual Meeting
P4.313 Atypical Presentation of
Intracranial Hypotension Secondary to Hypothalamic Compromise —Ahmed
Abd Elazim, Omar Hussein, Khalid Sawalha, Mohammad Hamed, Michel Torbey
Amra Sakusic, Ognjen Gajic, Rahul Kashyap, Alejandro Rabinstein
Desaturation Is Associated with Ipsilateral Epileptiform Activity on Continuous EEG in Comatose Patients —Leah Dickstein, Batya
Christopher Robinson, Carolina Maciel, Marc-Alain Babi, Jennifer Munoz, Lars Beattie, Nicholas Maldonado, Teddy Youn, Chris Giordano, Katharina Busl
P4.328 Burnout and Resiliency Amongst Neurological Critical Care Unit Clinical Staff —Taylor Purvis, Brittany Powell, Gail Biba,
P4.314 Rituximab for treatment of
Deena Conti, Thomas Crowe, Heather Thomas, Juan Carhuapoma, John Probasco, Paula Teague, Deanna Saylor
John Liang, Syed Omar Shah
P4.329 A Single-Center Intervention
refractory fulminant acute disseminated encephalomyelitis (ADEM) —Jane Khalife,
Critically Ill Patients with Acute Brain Failure: P4.315 Delayed post-hypoxic A novel end point —Tarun Singh, John O’Horo, encephalopathy: A prognostic dilemma —
Epilepsy And Convulsion In Lagos, P4.301 Institutional Variability in Status Nigeria. —Oguntunde Olapeju, Mustapha Danesi, Epilepticus Management: Intubation Use and Oluwadamilola Ojo, Njide Okubadejo Implications for In-Hospital Mortality —Elan P4.284 Glucose and Seizure Guterman, James Burke, S. Josephson, John Betjemann Relationships in an Ambulatory Patient Where Both are Continuously Monitored — P4.302 Regional Cerebral Oxygen Kathryn Kinnear, Nicole Warner, Alan Haltiner, Alyssa Brandt, Michael Doherty
Anantha Vellipuram, Gustavo Rodriguez, Salvador Cruz-Flores
Bharathi Sundar, Meenakshi Sundaram Salvadeeswaran, Somalinga Nagendran Karthik, Pandi Suresh, Jude Vinoth, Sanjeevirajah Madhanrajah
P4.316 Metabotropic Glutamate
to Discontinue Postoperative Antibiotics after Spinal Fusion —Ariane Lewis, Jessica Lin, Herbert James, Anne Krok, Nicole Zeoli, Janine Healy, Tyler Lewis, Donato Pacione
P4.330 Neurologic Implications of
Increased ICP-Induced Thinning of the Ocular Sheath —Meagan Newell, Lauren East, Parth
Agrawal, Brittany Earnest, Ian M. Heger, Robert W.
Receptor Subtype 5 and Encephalitis —Caitlin Gibson, Matt Lyon Hof, Larry Burris
P4.317 A Cautionary Tale of Synthetic Marijuana Use —Lucy Zhang, Payal Patel, Dhimant Dani
P4.318 Aneurysmal Subarachnoid
Radzik, Eva Ritzl, Rohan Mathur, Wendy Ziai, Hemorrhage Complicated by Central Charles Hogue, Romergryko Geocadin, Ryan Healy, Neuronal Hyperventilation —Ahmed Abd Caitlin Palmisano, Vishank Shah, Lucia Rivera Lara Elazim, Omar Hussein, Mohammad Hamed, Khalid Sawalha, Michel Torbey, Diana Greene-Chandos P4.303 Neurologic Recovery after
Anoxic Brain Injury with Marked Diffusion P4.319 Clinical re-audit of intravenous Restriction —Paul Elsbernd, Tyler Koehn, Thomas recombinant tissue plasminogen activator Duginski (r-tPA) recipients in ischemic stroke patients
P4.331 Control of vascular risk factors
at baseline in Crest-2 —James Meschia, Kevin
Barrett, Gary Roubin, Donald Heck, Michael Jones, Lawrence Wechsler, Joseph Rapp, Tanya Turan, Bart Demaerschalk, Brajesh Lal, Jenifer Voeks, George Howard, Virginia Howard, Thomas Brott
P4.332 Serial Pupillometer Readings
Predicting Intracranial Pressure Crisis —Antje Giede-Jeppe, Julia Koehn, Stefan Gerner, Joji Kuramatsu, Hagen Huttner, Stefan Schwab
P4.333 Attitudes Towards Hospital
P4.334 The Significance of Contrast
Powell, Gail Biba, Deena Conti, Thomas Crowe, Heather Thomas, Juan Carhuapoma, John Probasco, Paula Teague, Deanna Saylor
Mohammad Hamed, Shraddha Mainali
Chaplains Among Neurological Critical Care Unit Clinical Staff —Taylor Purvis, Brittany
g1 H
Density of the Computed TomographyAngiographic Spot Sign: The Spot Sign Ratio —Omar Hussein, Khalid Sawalha,
to the Hospital EMR: Effects on Nursing Satisfaction and Patient Outcomes After Two Years. —Patrick Chen, Diem Kieu Tran, Jefferson Chen
P4.336 To study if levetiracetam (Lev) is
P4.335 The Development of a System for effective in reducing the incidence of early Direct Download of Pupillometer Information post traumatic seizures in 0-17 year old
children with closed head trauma —Brittany Taylor, Sarah Cobb, Kapil Arya
P4.337 Factors associated with code
status in acute neurologic illness —Kaitlyn Lillemoe, Aaron Lord, Jose Torres, Koto Ishida, Barry Czeisler, Ariane Lewis
P4.338 NA
Cerebrovascular Disease and Interventional Neurology II ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P4.339 Safety and Clinical outcomes
after Transverse Venous Sinus Stenting for Treatment of Idiopathic Intracranial Hypertension: Single Center Experience —
Ashish Kulhari, Siddhart Mehta, Rebekah Amarini, Spozhmy Panezai, Jawad Kirmani
in the setting of a left atrial myxoma with concomitant RCVS —Shane Stone, Eduardo Cortez-Garcia, Patrick Reynolds
P4.341 Case report: Artery of Percheron
P4.340 All Myxed Up- A Case Report:
infarction detected by CT perfusion imaging, prompting thrombolytic treatment with excellent outcome —Kiddy Ume, Matthew
PEDIATRIC MULTIPLE SCLEROSIS
P4.354 Evaluation of Teriflunomide in
Cardioembolic multivessel ischemic infarcts
P4.346 Anakinra(IL-1 blockade) Use in
Children with Suspected FIRES: A Single Institution Experience —Nikita Shukla, Sarah Risen, Jennifer Lee, Yi-Chen Lai, James Riviello, Eyal Muscal
P4.347 Effects of Childhood
SCLEROSIS
Comparison —Fatima Ismail, Eliza Gordon-Lipkin, P4.357 Cumulative Data from the Katherine Huether, Iain Blair, Miklós Szólics, Faisal European Interferon Beta Pregnancy Aziz, Taoufik Alsaadi, Jehan Suleiman, Nicoline Registry —Kerstin Hellwig, Yvonne Geissbuhler, Findings in Pediatric anti-MOG Ab Positive Patients —Cynthia Wang, Darrel Conger, Benjamin Greenberg
Treatment in Children with RRMS —Canan
P4.358 Disease activity and disability after Natalizumab (NTZ) withdrawal due to planning a pregnancy in women with multiple sclerosis —Nina Esters, Charlotte
P4.362 Pregnancy outcomes in patients with multiple sclerosis and exposure to branded glatiramer acetate during all three trimesters —Kerstin Hellwig, Orit Neudorfer,
Sigal Melamed-Gal, Peleg Baruch, Shahd Qassem
P4.363 Pregnancy Outcomes in
P4.364 Vitamin D and Postpartum
Amethyst Leimpeter, Kathleen Albers, Eric Kerezsi, Keeli McClearnen, Stephen Van Den Eeden, Annette Langer-Gould
P4.365 Parenthood and Multiple
Sclerosis: An explorative web-based study. —Luigi Lavorgna, Sabrina Esposito,
Roberta Lanzillo, Eleonora Cocco, Marinella Clerico, Giuseppe Fenu, Giovanna Borriello, Stefania De Mercanti, Jessica Frau, Rocco Capuano, Laura Rosa, Alice Laroni, Vincenzo Brescia Morra, Gioacchino Tedeschi, Simona Bonavita
Leigh Charvet
P4.367 Design of the Ocrelizumab
P4.352 Variation in Treatment
and Outcomes of Children With Acute Disseminated Encephalomyelitis —Craig
Press, Matthew Kirschen, Kerri LaRovere, Sarah Risen, Kristin Guilliams, Melissa Chung, Jennifer Griffith, Jennifer Lee, Katrina Peariso, Laurence Ducharme-Crevier, Samir Shah, Matthew Hall, Mark Wainwright
P4.353 Two Cases of Pediatric Multiple Sclerosis after Human Papillomavirus Vaccination —Ye Hu, Leticia Tornes, Robert Lopez-Alberola
Spicher, Sandra Thiel, Ralf Gold, Kerstin Hellwig
Vincent Damotte, Jeffrey Gelfand, Carolyn Bevan, Bruce Cree, Lynn Do, Ari Green, Stephen Hauser
P4.360 Interferon-β /glatiramer acetate
Maria Didden, Joanna Evershed, Monika Garas, Qing Wang, Kerstin Hellwig
P4.361 Pregnancy Outcomes in Patients With MS Treated With Teriflunomide: Clinical Study and Postmarketing Data —
P4.370 Effect of Pregnancy Loss on MS Disease Activity —Tamara Kaplan, Riley Bove,
Kristin Galetta, Brian Healy, Tanuja Chitnis, Maria Houtchens
P4.371 Teriflunomide (Aubagio®)
International Pregnancy Registry: Enrollment Update —Christine Lebrun-Freney, David Rog, Myriam Benamor, Stephanie Jurgensen, Philippe Truffinet, Angelo Ghezzi
P4.372 Design of a Multi-Source Post-
Marketing Study to Evaluate Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Who Were Exposed to Ocrelizumab During, or Within 6 Months Before, Pregnancy —Andrea Margulis, Elizabeth
Andrews, Sonia Hernández-Diaz, Melinda Magyari, Elena Rivero-Ferrer, Silvia Bader-Weder, Joanna Evershed, Monika Garas, Qing Wang, David Wormser
TOOLS AND OUTCOME MEASURES FOR MS TRIALS AND CLINICAL TRACKING
P4.373 An investigation into the
Justin Underwood, Karl Wissemann, Lori Fafard, Jared Srinivasan, Barbara Bumstead, Marijean Buhse, Myassar Zarif, Karen Blitz-Shabbir, Donald Morisky
P4.374 Factors Influencing Best Practices in Treating Multiple Sclerosis: Results from a Predictive Modeling Analysis —Jamie Reiter, Jan Perez, Sharon Tordoff, Whitney Faler
P4.375 Impact of Multiple Sclerosis P4.368 Risk of relapses during pregnancy Relapse Severity on Health Care Costs —
and post-partum period among multiple treatment during lactation in women with Multiple Sclerosis —Andrea Ciplea, Anna Stahl, sclerosis patients —Raed Alroughani, Saeed Sandra Thiel, Ralf Gold, Kerstin Hellwig
an Acute Top of the Basilar Artery Stroke —
Relationship between the Multiple Sclerosis Impact Scale (MSIS-29) and Predicted Technologies and Multiple Sclerosis Medication Adherence as Measured Relapses: A New Case Series, and Pooled Analyses of Existing Studies. —Kelsey Rankin, by the Morisky Medication Adherence Chao Zhao, Jorge Correale, Kerstin Hellwig, Laure Scale (MMAS-8) in People with Multiple Michel, David Laplaud, Tanuja Chitnis, Riley Bove Sclerosis —Zohra Hamid, Mark Gudesblatt,
P4.366 Assisted Reproductive
Pregnancy Registry to Assess Maternal, Fetal and Infant Outcomes in Women With Multiple Sclerosis Who Were Exposed to P4.351 Computerized Measurement of P4.359 Rituximab treatment before Processing Speed Predicts Cognitive Decline conception in women with multiple sclerosis Ocrelizumab During, or Within 6 Months Before, Pregnancy —David Wormser, Pierre and neuromyelitis optica: Case series and in Pediatric Onset Multiple Sclerosis — Engel, Kristen Hahn, Silvia Bader-Weder, Evasystematic review. —Riley Bove, Gitanjali , Michael Shaw, Ashley Clayton, Lauren Krupp, duman ilki, Mefkure Eraksoy
P4.344 Pourfour du Petit Syndrome in
Akhtar, Maya Zeineddine, Maryam Alowayesh, Yehya EL Kouzi, Samar Ahmed, Raed Behbehani, Samia Khoury, Jasem Al-Hashel, Bassem Yamout
P4.369 Pregnancy Outcome, Changes in
Lymphocyte Subsets in Peripheral Blood, and Sandra Vukusic, Patricia Coyle, Stephanie Plasma Osteopontin in Japanese Patients Jurgensen, Philippe Truffinet, Myriam Benamor, Elizabeth Poole, Jeffrey Chavin, Christina Chambers with Multiple Sclerosis after Assisted Reproductive Technology —Yuko Shimizu, Ryotaro Ikeguchi, Kazuo Kitagawa
Jacqueline Nicholas, Li Yunfeng, Maria Cecilia Vieira Da Silva, Huanxue Zhou, Ching-An Wang, Vivian Herrera
P4.376 Improved Clinical Detection of
Cerebellar Lesions in Multiple Sclerosis Patients —Oluwasheyi Ayeni, Stephen Krieger,
Rachel Brandstadter, Asaff Harel, Maria Petracca, Christina Lewis, Fred Lublin, Aaron Miller, Gabrielle Pelle, Alessio Pepe, Matilde Inglese, James Sumowski
AAN.com/view/AM18 159
Wednesday
P4.350 The Results of Fingolimod
Meritxell Sabidó Espin, David Appiah-Badu, Evra Köfüncü, Joachim Klinger, Peter Huppke, Asher Ornoy
EEG in Comatose Survivors of Cardiac Arrest —S Cooley, Gary Hunter
Bakhtier Nurmukhamedov, Aiga Rakhesh, Vishal Shah, Antonio Culebras
P4.355 The interplay of multiple sclerosis Multiple Sclerosis Relapses —Jessica Smith,
Badihian, Navid Manouchehri, Vahid Shaygan Anusha Yeshokumar, Michelle Fabian, Victoria Leavitt, Christina Lewis, Gabrielle Pelle, Mohamed- Nejad Mounir El Mendili, Amgad Droby, Matilde Inglese, P4.356 Low relapse risk under disease James Sumowski modifying treatment during ART in women with relapsing remitting multiple sclerosis — P4.348 Pediatric Multiple Sclerosis in Barbara Zurawski, Sandra Thiel, Ralf Gold, Kerstin the United Arab Emirates: Characteristics Hellwig From a Multi-Center Study and Global
P4.349 Optical Coherence Tomography
Mehmood Rashid
Skripchenko, Banu Anlar, Miqun Robinson, Rita Deng, Margaux Dupin, Philippe Truffinet, Stephanie the Ozanimod Nonclinical and Clinical Development Program —Denise Campagnolo, Jurgensen, Jeffrey Chavin, Ludwig Kappos Catherine Montero-Embalsado, Susan MeierDavis, Neil Minton PREGNANCY AND MULTIPLE
Socioeconomic Status on Neuroimaging and and menstrual cycle: Which one affects Functional Outcomes in Patients with MS — the other one? —Omid Mimosayyeb, Shervin
Schiess
distortions associated with the recovery from posterior reversible encephalopathy syndrome (PRES) —Payam Sadry, Irfan Sheikh,
Hileman, Vismay Thakkar, Sajjad Mueed
Children and Adolescents With Relapsing P4.345 Sub-acute Hemiplegia in a MS: TERIKIDS Phase 3 Study Design, Toddler: A Case Study in Anti-MOG Antibody Enrollment Update, and Baseline Data — Positive Tumefactive Demyelinating Tanuja Chitnis, Marc Tardieu, Brenda Banwell, Encephalitis —Jason Gill, Danielle Takacs, Kivilcim Gücüyener, Kumaran Deiva, Natalia Timothy Lotze
P4.342 Metamorphopsia and other visual P4.343 Continuous Bedside Subhairline
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION IV G P4.377 No Significant Genetic or
survey —Giovanna Borriello, Luigi Lavorgna, Sabrina Esposito, Rocco Capuano, Laura De Giglio, Transcriptomic Predictors of Severe and Prolonged Lymphopenia in MS Cases Treated Alessandra Logoteta, Gioacchino Tedeschi, Simona Bonavita with Dimethyl Fumarate —Paola Bronson, Dipen Sangurdekar, Michelle Penny P4.388 Comparing Benefit-Risk Profiles P4.378 Telemedicine Reduces Barriers to of Oral DMTs for Relapsing MS: A Likelihood Care for Patients with Multiple Sclerosis and of Help vs. Harm (LHH) Analysis. —Dimos Neuroinflammation —Riley Bove, Priya Garcha, Dimitrios Mitsikostas, Dimitrios Papadopoulos Carolyn Bevan, Elizabeth Crabtree-Hartman, Ari P4.389 Usefulness of the unification Green, Jeffrey Gelfand of the criterion for the evaluation of the P4.379 Driving Continuous Improvement functional system cerebral functions of the Expanded Disability Status Scale (EDSS) — of MS Care Quality—Initial Launch Experience from the First Continuous Quality Ricardo Alonso, Barbara Eizaguirre, SIlva Berenice, Cecilia Pita, Sandra Vanotti, Fernando Caceres, Improvement Research Learning Health Domingo Garcea System in Multiple Sclerosis —Brant Oliver, Terrie Livingston, Michelle Patel, Amy Hall, Randy P4.390 Patient Reported Disease Messier, Carolyn Schwarz Modifying Therapy Adherence in the Clinic: A P4.380 Overall Response Score: A Novel Reliable Metric? —Devon Conway, Maria Cecilia Vieira Da Silva, Nicholas Thompson, Kaila Parker, Disability Endpoint That Allows for the Integrated Assessment of Improvement and Xiangyi Meng, Robert Fox Worsening over Time in Patients with MS — P4.391 Predicting Falls in Multiple Ih Chang, Ludwig Kappos, Gavin Giovannoni, Peter Sclerosis: Are Electrophysiological Measures Calabresi, Alfred Sandrock, Yi Chai, Bing Zhu, more accurate than Clinical Measures? —
Wednesday, April 25 11:30 a.m.–7:00 p.m. P4.400 Multiple Sclerosis, Gait and
Digital Devices: A Comparison of Two FDA approved validated devices that provide multidimensional quantifiable gait parameters in People with Multiple Sclerosis (PwMS) —Mark Gudesblatt, Stacy Trebing, Christina Burke, Karl Wissemann, Myassar Zarif, Barbara Bumstead, Lori Fafard, Marijean Buhse, Karen Blitz-Shabbir
Lakshmi Ranganathan, Shunmugasundaram Kanthimathinathan, Sarala Govindarajan, Uma Maheswari E, Jawahar Marimuthu, R M Bhoopathy
P4.402 Delivering Education to
Patients with MS—a Survey of Canadian Neurologists —Olga Lekontseva, Penelope Smyth, Carol Hodgson
P4.403 Cognitive-Motor interaction in patients with multiple sclerosis —Barbara
P4.381 The Multiple Sclerosis Partners
P4.392 Multiple Sclerosis Treatment
Ellen Mowry, Lauren Krupp, Stephen Jones, Robert Naismith, Aaron Boster, Megan Hyland, Izlem Izbudak, Yvonne Lui, Carrie Hersh, Bjorn Tackenberg, Mar Tintoré, Alex Rovira, Xavier Montalban, Hagen Kitzler, Tjalf Ziemssen, Eunice Jung, Tatiana Plavina, Carl DeMoor, Elizabeth Fisher, Bernd Kieseier, Himanshu Pandya, James Williams, Richard Rudick
P4.382 FLOODLIGHT: Remote
Self-Monitoring Is Accepted by Patients and Provides Meaningful, Continuous Sensor-Based Outcomes Consistent With and Augmenting Conventional In-Clinic Measures —Xavier Montalban, Patricia Mulero,
Luciana Soledad Midaglia Fernandez, Jennifer Graves, Stephen Hauser, Laura Julian, Mike Baker, Jan Schadrack, Christian Gossens, Alf Scotland, Florian Lipsmeier, Gregoire Pointeau, Corrado Bernasconi, Shibeshih Belachew, Michael Lindemann
P4.383 Tool for Semi-Automated and
Reproducible Histological Analysis of Brain Tissue —Suyog Pol, Tommy Tsang, Michelle Sveinsson, Michelle Sudyn, Robert Zivadinov
P4.384 Long-term predictors of clinical
Wednesday
outcomes in patients with multiple sclerosis randomized to fingolimod 0.5 mg in the phase 3 FREEDOMS, FREEDOMS II and TRANSFORMS studies —Till Sprenger, Aaron Boster, Xiangyi Meng, Shannon Ritter, Daniela Piani Meier, Davorka Tomic, Diego Silva, Frederik Barkhof, Pavle Repovic
P4.385 Dynamic Visual Tests as a
Measure of Demyelination in the Visual System of Progressive MS Patients —Yael
Gudesblatt, Karl Wissemann, Myassar Zarif, Barbara Bumstead, Lori Fafard, Jared Srinivasan, Ilir Topalli, Jeffrey Wilken, Karen Blitz-Shabbir, Marijean Buhse, Glen Doniger
P4.393 Real-World Use of Wearable
Devices in a Large Multiple Sclerosis Cohort —Luca Foschini, Jennie Medin, Vladimir
Bezlyak, David Stuck, Diego Silva, Wei-Nchih Lee
P4.394 Overcoming Therapeutic
Inertia in Multiple Sclerosis care: A pilot Randomized Trial evaluating an Educational Intervention —Gustavo Saposnik, Jorge
Alejandro Maurino, Angel Sempere, Muhammad Mamdani, Maria Terzaghi, Christian Ruff, Philippe Tobler, Xavier Montalban
P4.395 Is Routine Renal US Indicated for
Daily Self-Report Fall Calendars Accurate? A Comparison with a Real-Time Body-Worn Self-Report Device in Multiple Sclerosis —
Nahian Chowdhury, Andrea Hildebrand, Jonathon Folsom, Peter Jacobs, Michelle Cameron
P4.405 A Preliminary Investigation into
the Relationship between the Multiple Sclerosis Walking Scale (MSWS-12) and an Objective Multi-dimensional Digital Gait Analysis —Mark Gudesblatt, Stacy Trebing, Christina Burke, Karl Wissemann, Myassar Zarif, Barbara Bumstead, Lori Fafard, Marijean Buhse, Karen Blitz-Shabbir
Fernanda Mendes, Samira Apóstolos-Pereira, Dagoberto Callegaro
P4.409 Psychological Resilience is
Katherine Heller
Gabrielle Pelle, Christina Lewis, James Sumowski
Linked to Lower Disability in Early Multiple Sclerosis —Sylvia Klineova, Michelle Fabian,
P4.398 Quantifying Cognitive Fatigue
P4.410 Response time for identifying shapes and textures with Interactive Sensory Digital Platform in patients with multiple sclerosis —Michal Greenberg-
Abrahami, David Magalashvili, Shay Menascu, Mark Dolev
P4.399 Performance on a digital resonance spectroscopy in differentiating neuropsychological test battery in individuals P4.411 Relation between Fatigue tumefactive demyelinating lesions from Severity Scale and Pupillary Indices in gliomas —Ryotaro Ikeguchi, Yuko Shimizu, Kayoko with relapsing remitting multiple sclerosis Patients with Multiple Sclerosis —Ye Hu, and healthy controls. Normative values. — Abe, Koichiro Abe, Takakazu Kawamata, Kazuo Kitagawa
P4.387 How an early diagnosis has
impacted on clinical practice in the last years in Italy: A web-based patient-centered
160 2018 AAN Annual Meeting
Daniel Sanchez, Maria Goldfeder, Pagani Cassara Fatima, Vladimiro Sinay, Teresa Torralva, Maria Roca, Diana Bruno
P4.415 Impaired Sexual Quality of Life in
Women with Neuromyelitis Optica Spectrum Disorder —Maureen Mealy, Michael Levy
P4.416 At-Home Transcranial Direct
Current Stimulation Benefits Depression and Cognition in Multiple Sclerosis: Two Case Reports —Ashley Clayton, Robert Charlson, Bryan Dobbs, Jonathan Howard, Lauren Krupp, Michael Shaw, Leigh Charvet
Quality of Life in Multiple Sclerosis —
Heidemarie Lex, Sara Weisenbach, Jacob Sloane, Sana Syed, Eva Rasky, Wolfgang Freidl
P4.418 Cognitive stimulation in patients with relapsing-remitting multiple sclerosis: Effects on cognition, quality of life and MR functional connectivity. —Riccardo Manca,
Micaela Mitolo, Basil Sharrack, Annalena Venneri
P4.419 The relationship between
memory and executive functions in relapsing remitting multiple sclerosis patients. —Maria Goldfeder, Diana Bruno, Pagani Cassara Fatima, Vladimiro Sinay, Maria Roca
P4.420 Analysis of Cognitive Impact on Evaluation of Brazilian Portuguese version Physical Disability in People with Multiple of Fatigue Severity Scale and Modified Sclerosis (PwMS) —Karl Wissemann, Mark Fatigue Impact Scale —Fernanda Dantas, Maria Gudesblatt, Zohra Hamid, Lori Fafard, Jared
Feasibility of Incorporating PhotoVoice into MS Mosaic —Fletcher Hartsell, Casey Farin,
P4.386 Usefulness of proton magnetic
Maria Luisa Martinez Ginés, Jose Manuel Garcia Dominguez, Lucía Forero, Daniel Prefasi, Jorge Maurino
P4.406 Fatigue in Multiple Sclerosis:
P4.397 MS PhotoMosaic: Evaluating
in Multiple Sclerosis using P300 Evoked
Samadzadeh, Roya Abolfazli, Siamak Najafinia, Christian Morcinek, Peter Rieckmann
P4.404 Are “Gold Standard” Prospective P4.417 Social-Emotional Aspects of
MS Patients? —Victoria Titoff, Igor Titoff, Thomas P4.407 Overview of the North American Registry for Care and Research in MS Scott (NARCRMS) —David Jones, June Halper, Lisa P4.396 TITRE: Dedicated Mobile Patton, Sarah Murphy, Kottil Rammohan Application for Drug Adverse Reactions P4.408 WITHDRAWN Reporting by Patients with Relapsing Remitting Multiple Sclerosis: A Multicenter Cluster-Randomized Controlled Trial —Gilles MS AND CNS INFLAMMATORY Defer, Florian Le Caignec, Sophie Fedrizzi, François DISEASE: QUALITY OF LIFE, SYMPTOMS, AND Montastruc, Damien Chevanne, Jean-Jacques SYMPTOMATIC THERAPY III Parienti, Laure Peyro Saint Paul
Backner, Panayiota Petrou, Noa Raz, Haya Shames, Potentials —Somasundaram Chinnadurai, Avathvadi Srinivasan, Lakshmi Ranganathan, Dimitrios Karussis, Netta Levin Bhanu Kesavamurthy
as a valuable tool to assess visual pathway function in Multiple Sclerosis: First results on potential association with fatigue —Sara
P4.414 Stigma in Multiple Sclerosis: Sclerosis: Correlation Between Objective and Revisiting the psychometric properties of Subjective Measures —Guhan Ramamurthy, the SSCI-8 questionnaire —Javier Ballesteros,
Eizaguirre, Angeles Merino, Cecilia Yastremiz, SIlva Berenice, Ricardo Alonso, Sandra Vanotti, Somasundaram Chinnadurai, Avathvadi Srinivasan, Domingo Garcea Bhanu Kesavamurthy, Lakshmi Ranganathan
Decisions: EDSS Independent Disease Impact/Reserve and the Use of Additional Milestones that Matter —Daniel Golan, Mark
P4.413 Quantitative manual pupillometry
P4.401 Cognitive Fatigue In Multiple
Carmen Castrillo-Viguera, Aaron Deykin, Sarah Sheikh
Advancing Technology and Health Solutions (MS PATHS) patient cohort —Robert Bermel,
Fabian, Victoria Leavitt, Christina Lewis, Gabrielle Pelle, Mounir El Mendili, Amgad Droby, Matilde Inglese, James Sumowski
Hong Jiang, Jianhua Wang, Byron Lam, Kottil Rammohan
Srinivasan, Barbara Bumstead, Marijean Buhse, Myassar Zarif, Karen Blitz-Shabbir, Cynthia Sullivan, Jeffrey Wilken
P4.421 The reduced version of the
Reading the mind in the eyes test. It’s utility in evaluating complex emotion recognition in relapsing remitting multiple sclerosis. — Milagros García, Daniel Sanchez, Katia Rosenbaum, Pagani Cassara Fatima, Vladimiro Sinay, Teresa Torralva, Maria Roca, Diana Bruno
P4.422 Higher Openness is related to
Higher Social Network Density in Persons with Multiple Sclerosis —Rebecca Straus
Farber, Amar Dhand, Seth Levin, Gabriella Tosto, Eva Gelernt, Victoria Leavitt
P4.423 Effect of Fampridine on the
Manual Functions of Patients with Multiple Sclerosis: Difference Between Cerebellar and Pyramidal Dysfunction —Serkan Ozakbas, Bilge Piri Cinar, Turhan Kahraman
P4.424 Predictors of Fatigue Severity in Multiple Sclerosis Patients —Zainab Alalawi, Kalyan Yarraguntla, Rishi Sood, Navid SerajiBozorgzad, Evanthia Bernitsas
P4.425 Observations of a Multiple
Sclerosis Patient-Centered Specialty Practice: Analysis of Depression Patterns — Eric Meninno, Terrie Livingston, Susan Stuart,
P4.412 Fatigue in early multiple sclerosis Sonya Powell, Alexis Carlson, Nasima Afsari, and the role of the caudate nucleus. —
Achillefs Ntranos, Stephen Krieger, Michelle
Michelle Patel, Tom Valuck, Pat Farmer, Carlo Tornatore
P4.426 Prevalence of Stigma in
Caribbean Hispanic patients with Multiple Sclerosis —Angelica Rivera Cruz, Janice Vargas, Valerie Wojna, Gishlaine Alfonso
P4.427 Quality Of Life Assessment
Among Multiple Sclerosis Patients , Saudi Arabia—Cross Sectional Study —Adel Ali
Alhazzani, Mohammed Alqahtani, Mohammed Alahmari, Mohannad Assiri, Noof Alamri, Leen Sarhan, Shahad Alkhashrami, abdullmgeed Asiri
P4.428 The relationship between
the ALS Japanese Severity Scale and Use over Time —Laura Bower, Benjamin Shander, Alexander Kalin
James Carroll, Darius Seidler, John Dessaint, Louis Patients —Brooke Lubinski, Monserrat DiazVaickus, Patricia Henegan, Tanya Butt, Angeline Abad, Justin Kwan Andrew, Elijah Stommel
P4.439 A New Grading Scale for
P4.450 Study Design and Preliminary
Phenotypic Diversity in Amyotrophic Lateral Results of Safety and Efficacy of Ranolazine Sclerosis/Frontotemporal Dementia —Yin Liu, for the Treatment of Amyotrophic Lateral Sclerosis —Anai Hamasaki, Mazen Dimachkie, Jeffrey Rosenfeld
P4.440 Graph Theory Network Analysis Distinguishes Regional Brain Changes in UMN-predominant ALS Patients With and Without Corticospinal Tract Hyperintensity —Erik Pioro, Venkateswaran
incidental learning and executive functions in relapsing remitting multiple sclerosis Rajagopalan patients. —Agostina Galiani, Diana Bruno, Pagani P4.441 Contribution of Rare Homozygous Cassara Fatima, Vladimiro Sinay, Maria Roca Variants in ALS in a Homogenous Population —Vivian Drory, Orly Goldstein, Merav ALS II
I
P4.429 Measuring Disease Progression in Amyotrophic Lateral Sclerosis: Correlations between Slow Vital Capacity and ALSFRS-R Measures of Respiratory Function —Carlayne Jackson, Mamede de
Kedmi, Mali Gana-Weiss, Beatrice Nefussy, Shir Twito, Yaara Feinmesser, Omri Nayshool, Avi OrrUrtreger
P4.442 Coactivation of TRPA1/TRPV1
Mamatha Pasnoor, Melanie Glenn, Omar Jawdat, Laura Herbelin, Duaa Jabari, Richard Barohn, Jeffrey Statland
ALS, SMA, AND OTHER NEUROMUSCULAR DISORDERS II
Kurt, Sevim Erdem-Ozdamar, Ersin Tan
P4.431 Low expression of mutant
subscore of ALSFRS-R? —Nimish Thakore,
Ubiquilin-2 exacerbates ALS/FTD features in a TDP-43 mouse model —Vincent Picher-
P4.444 How good is the respiratory Brittany Lapin, Erik Pioro
Ian Cheong, Gulin Oz, Malgorzata Marjanska, David Walk
P4.452 Reliability of Spinal Muscular
Atrophy Functional Rating Scale (SMAFRS) in Ambulatory Adults with Spinal Muscular Atrophy. —Bakri Elsheikh, Wendy King, William
Primary Lateral Sclerosis with Minor Electromyographic Abnormalities —Shivam
Mittal, William Hu, Keith Josephs, J. Ahlskog, Eric Sorenson, Anhar Hassan
P4.463 PLS in a Connecticut ALSA Datta, Kevin Felice
P4.464 Use of Ommaya Reservoir with a Thoracic Spinal Catheter for Intrathecal Delivery of Nusinersen in a Patient with Spinal Muscular Atrophy Type 2 —Arpita Lakhotia, Sonam Bhalla, Elizabeth Doll, Willam Gump
P4.465 Diseases that simulate
Amyotrophic lateral sclerosis: Clinical differences —Maria Constanza Segamarchi, Raul Rey, Gabriel Rodriguez
P4.454 Characterization of Later
Childhood/Adult Spinal Muscle Atrophy Patients and Their Transitions of Care within U.S. Hospitals —Jaanai Babb, Megan Teynor,
P4.432 The natural history of dysphagia
the survival of SOD1 G93A mice when administered after the onset of disease —
Andrea Calvo, Cristina Moglia, Stefania Cammarosano, Antonio Ilardi, Antonio Canosa, Enrica Bersano, Letizia Mazzini, Adriano Chio
Jill Dreyfus, Teresa Davis, Sandra Reyna, Michelle Hongquan Jiang, Ming Ren, Xiang Yin, Jing Wang, Patel, Terrie Livingston, Mehul Jhaveri Yan Qi, Honglin Feng P4.455 Phase Sensitive Inversion
P4.446 Overestimation of Renal Function Recovery (PSIR) spinal cord imaging as
Alterations in Amyotrophic Lateral Sclerosis Are Modulated by the Topology of the Anatomical Brain Connectome —Massimo
P4.462 Clinical Phenotypes of
Gerber, Christian Czech, Yumi Cleary, Margaret Chan, Stephan Nave, Ksenija Gorni, Omar Khwaja
P4.445 Guanabenz does not affect
P4.433 Structural Connectivity
Shah
Center: Retrospective study of progression Spectroscopy in ALS: Clinical Correlations — rate and clinical course in 46 patients —Neil
Martel, Jean-Pierre Julien
in ALS patients with bulbar and spinal onset —Umberto Manera, Fabrizio D’Ovidio,
(MUNIX) in Spinal Muscular Atrophy (SMA) —Jasmine Forte, Sumit Verma, Durga
P4.451 Longitudinal 7 Tesla MR
and its Potential Impact on Cramps, Spasms, Arnold, John Kissel Spasticity and Pain in Amyotrophic Lateral Carvalho, Angela Genge, Terry Heiman-Patterson, Sclerosis —Glenn Short, Brooke Hegarty, P4.453 Updated pharmacodynamic and Jeremy Shefner, Amy Wohltman, Andrew Wolff safety data from SUNFISH Part 1, a study Jennifer Szegda, David Golod, William McVicar, Thomas Wessel evaluating the oral SMN2 splicing modifier P4.430 Exploiting Integrated miRNAs RG7916 in patients with Type 2 or 3 spinal Analysis of Patient-derived iPSCs-Motor P4.443 The expression of epidermal muscular atrophy —Eugenio Mercuri, Giovanni Neurons to Develop a Molecular Therapy growth factor (EGF) and keratinocyte growth Baranello, Jan Kirschner, Laurent Servais, Nathalie for ALS —Mafalda Rizzuti, Monica Nizzardo, factor (KGF) in skin biopsy of amyotrophic Valentina Melzi, Giuseppe Filosa, Laura Dioni, Luca lateral sclerosis patients —Erdal Kurt, Can Ebru Goemans, Maria Carmela Pera, Anne Marquet, Gillian Armstrong, Heidemarie Kletzl, Marianne Calandriello, Martina Locatelli, Nereo Bresolin, Silvia Barabino, Giacomo Comi, Stefania Corti
P4.461 Motor Unit Number Index
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
by Creatinine-derived Estimated Glomerular Filtration Rate Correlates with the Loss of Appendicular Skeletal Muscle Index in Amyotrophic Lateral Sclerosis Patients —Yuji
a potential biomarker for Motor Neuron Disease —Nicholas Olney, Antje Bischof,
P4.447 C-Reactive Protein ( CRP ) is
P4.457 Long-term Outcome of Filgrastim
Howard Rosen, Eduardo Caverzasi, William Stern, Catherine Lomen-Hoerth, Bruce Miller, Roland Henry, Nico Papinutto
Saitoh, Masaki Kakizawa, Yuka Hama, Yohei Aoshima, Daiki Takewaki, Taiji Mukai, Tomoya P4.456 Results from the Cure SMA Filippi, Silvia Basaia, Nilo Riva, Edoardo Spinelli, Kawazoe, Asami Tasaki, Yuko Morimoto, Masayuki Newly Diagnosed Survey —Lisa Belter, Yuri Falzone, Adriano Chio, Andrea Falini, Giancarlo Miyazaki, Takashi Odo, Madoka Mori-Yoshimura, Rosangel Cruz, Jill Jarecki, Cynthia Jones, Sandra Comi, Federica Agosta Miho Murata, Yuji Takahashi Reyna, Kenneth Hobby
P4.434 Characterization of ALS patients
based on MIP & FVC at first visit —Keerthana
Kassar, Mohtashim Qureshi, Mohammad-Rauf Afzal, Anantha Vellipuram, Paisith Piriyawat, Ihtesham Qureshi, Mohammad Ghatali, Gustavo Rodriguez, Rakesh Khatri, Alberto Maud, Salvador Cruz-Flores
P4.436 Alterations in Hippo pathway
signaling as a mechanism of neuronal death in Amyotrophic Lateral Sclerosis —Ghazaleh Sadri-Vakili, Kaly Mueller, Eric Granucci, Amanda Dios, James Berry, Khashayar Vakili
P4.437 Successful Postmortem
Collection of Neurological Tissues: The National ALS Biorepository Experience —
Wendy Kaye, Laurie Wagner, Thor Stein, Thomas Bell, Ben Buehrer, Maureen Orr
P4.438 A Comparative Safety Analysis of the Edaravone Safety Profile Based on
Mohammed Sanjak, Elena Bravver, William Bockenek, Tiffany Williamson, Scott C Lindblom, William Dawson, Melissa Johnson, Nicole Lucas, Cynthia Lary, Lisa Ranzinger, Allison NewellSturdivant, Nicol Brandon, Scott Holsten, Amber Ward, Rachel Hillberry, Kathryn Wright, Nigel Rozario, Benjamin Brooks
P4.448 Frequency and Clinical
Characteristics of Mexican Patients with Vulpian-Bernhardt Syndrome —Juan Lopez, Guillermo Delgado-Garcia, Karina Carrillo-Loza, Edwin Vargas
P4.449 Identifying Aerosolized
(G-CSF) in ALS Patients —Siw Johannesen,
Tim-Henrik Bruun, Bettina Budeus, Sebastian Peters, Anne-Louise Meyer, Ines Kobor, Ohnmar Hsam, Anna Maria Wirth, Wilhelm SchulteMattler, Sabine Klatt, Ulrich Bogdahn
Wednesday
Significantly Higher in Amyotrophic Lateral Sclerosis (ALS) Patients on Non-Invasive Ventilation (NIV) and TracheostomyP4.435 Impact Of In-Hospital Mechanical Invasive Ventilation (TIV) Compared with ALS Patients at Intake Clinic Evaluation Ventilation On In-Hospital Outcomes Of Amyotropic Lateral Sclerosis (ALS) In United and Decreases Following Riluzole States: Analysis From Nationwide Inpatient Administration—Is CRP Potentially a Sample (NIS) Database (2011-2014) —Darine Biomarker for Treatment Responsiveness? — Akkineni, Ericka Simpson, Vanessa Holland, Leif Peterson
P4.458 ALS Dashboard—Cognitive,
Affect, Bulbar, Respiratory, Arm, Leg Staging Algorithm—Single Center Longitudinal Assessment —Benjamin Brooks, Elena Bravver, Urvi Desai, Mohammed Sanjak, William Bockenek, William Dawson, Scott C Lindblom, Benjamin Bringardner, Robert Taylor, Velma Langford, Melissa Johnson, Amy Lindville, Tiffany Williamson, Nicole Lucas, Cynthia Lary, Lisa Ranzinger, Allison Newell-Sturdivant, Rachel Hillberry, Kathryn Wright, Scott Holsten, Amber Ward, Nigel Rozario, Nicol Brandon
P4.459 Big Data Analytics for
Early Diagnosis of Amyotrophic Lateral Sclerosis —Tara Grabowsky, Oodaye Shukla, Manjula Kasoji, Chris Miller, Charlotte Merrill,
Wendy Agnese, Nazem Atassi Cyanobacteria as an Environmental Risk Factor for ALS using Human Bronchoalveolar P4.460 Application of Amyotrophic Lavage and Nasal Swab Specimens — Lateral Sclerosis Staging Systems in ALS Dominic Facciponte, Matthew Bough, Jacob Rauh,
AAN.com/view/AM18 161
POSTER SESSIONS
POSTER SESSION V NEURO-REHABILITATION
A
G
Thursday, April 26 11:30 a.m.–7:00 p.m.
P5.011 Physician’s Global Assessment of
Response to Repeated AbobotulinumtoxinA Injections in Adults with Lower Limb Transcranial Direct Current Stimulation Spasticity Post-Stroke or Traumatic Brain (RS-tDCS) Improves Parkinson’s Disease (PD) Injury —Alberto Esquenazi, Wuwei Feng, Symptomatology —Bryan Dobbs, Shashank Khashayar Dashtipour, Anthony Rodrigues, Claire
P5.001 Remotely-Supervised
Agarwal, Charles Feinberg, Natalie Pawlak, Michael Shaw, Milton Biagioni, Leigh Charvet
Vilain, Gustavo Suarez-Zambrano, Jean-Michel Gracies
091–172
P5.002 At-Home Tele-Monitored
P5.012 Safety of IncobotulinumtoxinA transcranial Direct Current Stimulation in Adult Spasticity: Results from a Pooled (tele-tDCS) Therapy for Fatigue in Parkinson’s Analysis of Randomized, Prospective, Clinical Disease —Kush Sharma, Daniella Mania, Studies —David Simpson, Michael Hast, Angelika
a randomized double-blind remotely supervised tDCS trial for symptomatic management in multiple sclerosis —Michael Shaw, Bryan Dobbs, Natalie Pawlak, Maria Palmeri, Lauren Krupp, Kathleen Sherman, Leigh Charvet
Robert Jech, François Constant Boyer, Pascal P5.004 Effects of Repetitive Transcranial Maisonobe, Jovita Balcaitiene
Magnetic Stimulation in Aphasic Stroke: A Randomized Double-blind Controlled Clinical Trial. —Federico Silva, Marlen Y Pachon Poveda, Alexander Pabon Moreno, Jose A Mendoza Sanchez, Luis A Lopez Romero, Ligia C Rueda Guzman, Juan S Parra Mendez, Yizel K Leon Vargas, Ramiro F Trillos Leal, Yuletzy Castellanos, Ronald G García Gomez
P5.005 Remotely-Supervised
Transcranial Direct Current Stimulation (RS-tDCS) is Feasible for 40 Treatment Sessions —Bryan Dobbs, Natalie Pawlak,
P5.014 Intrathecal Baclofen Therapy
Decreases Pain and Improves Quality of Life Compared to Conventional Medical Management in Severe Post-Stroke Spasticity: The SISTERS Study —Michael
Yochelson, Michael Creamer, Geoffrey Cloud, Peter Kossmehl, Gerard Francisco, Anthony Ward, Jorg Wissel, Mauro Zampolini, Meghann Loven, Abdallah Abouihia, Alessandra Calabrese, Leopold Saltuari
P5.015 Challenges and Strategies for
Implementing Interventions in a Statewide
Michael Shaw, Ashley Clayton, Kathleen Sherman, System-Based Pragmatic Trial —Barbara Lutz, Leigh Charvet Sylvia Coleman, Cheryl Bushnell, Pamela Duncan, Sabina Gesell P5.006 Spinal cord epidural
stimulation: Classifying movement using accelerometers —Nicholas Peterson, Bryan
P5.016 Modified Approach to Stroke
P5.007 Neofect Glove: Virtual Reality
MaryKay Pavol, Clare Bassile, Jacqueline Callender, Nancy Ferreira, Emma Harmon, Jennifer Lehman, Brittany Shinn, Nancy St. James, Joel Stein
Ladd, David Darrow
Device for Home Therapy in Stroke Survivors —Alay Parikh, Catherine Legault, Kara Flavin, Maarten Lansberg
Rehabilitation (MAStR)-Feasibility Study —
P5.017 Validation of the Spanish version
of the CAL scale in stroke patients —Maria Electromyographic Automated Rehabilitation Julieta Russo, Solange Louzao, Valeria Prodan, Technology (HEART) Project —Mingjian Zhang, Maria Marta Saavedra, Josefina Courtis, Lucas
P5.008 The Holographic
Shuyang Liu, M. Ehsan Hoque, Ania Busza
P5.009 Cortical Somatosensory
Responses after Botulinum Toxin Therapy of Post-Stroke Spasticity —Petr Hlustik, Tomas Veverka, Pavel Hok, Pavel Otruba, Jana Zapletalova, Alois Krobot, Petr Kanovsky
P5.010 Pooled Safety Analysis of
Randomized, Prospective Studies on IncobotulinumtoxinA for the Treatment of Cervical Dystonia, Blepharospasm, and Upper Limb Spasticity —David Simpson,
Thursday
Michael Hast, Angelika Hanschmann
037–084
P5.013 Effect on Voluntary Movements
of Simultaneous Upper and Lower Limb AbobotulinumtoxinA Injections in Conjunction with Guided Self-Rehabilitation Contracts in Adults with Spastic Hemiparesis: Methodology of the ENGAGE Study —Jean-Michel Gracies, Gerard Francisco,
Bonamico, Lisandro Olmos, Liliana Sabe, Ricardo Allegri
P5.018 Analysis of discharge functional outcomes & disposition locations following inpatient rehabilitation in Guillain-Barre Syndrome patients —David Kushner, Maite Maguregui, Stacy A. Thomashaw
C
ePosters
B
b1 g1 339–344 a1 ePosters
Poster Discussion
027–036
M Abdulghani, Mohamed Khaled, Tamer Roushdy, Dalia Maher
I
A
F
259–294
295–338
H
G
345–428
429–480
Poster Session 5 A. Neuro-rehabilitation: 001 – 026
a1. MS and CNS Inflammatory Disease Poster Discussion Session: 027 – 036 B. Movement Disorders: 037 – 084
b1. Infectious Disease and Global Health I ePoster Session: 085 – 090 C. D. E. F. G.
Infectious Disease; Global Health; Neuroepidemiology: 091 – 172 Aging, Dementia, Cognitive, and Behavioral Neurology: 173 – 200 Cerebrovascular Disease and Interventional Neurology: 201 – 258 Epilepsy/Clinical Neurophysiology (EEG): 259 – 294 History of Neurology; General Neurology: 295 – 338
g1. Infectious Disease and Global Health II ePoster Session: 339 – 344 H. MS and CNS Inflammatory Disease: 345 – 428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429 – 480
P5.020 The efficacy of
acetylcholinesterase inhibitor on poststroke aphasia: A systemic review and metaanalayis of experimental studies —Ian Shih
P5.021 Anti-fibrotic approach and
P5.024 Amantadine Use in Post-
Concussive Headaches: An Exploratory Retrospective Review —Conor Ryan, Ivan
Carabenciov, Britta Bureau, F. Cutrer, Rodolfo Savica
P5.025 Compare serum Creatinine reactivation of neurogenesis by targeting the TGF-ß System —Sabrina Kuespert, Michael versus Renal 99mTc-DTPA scan determined Glomerular Filtration Rates in Veterans with Poellmann, Rosmarie Heydn, Eva Zitzelsperger, Sebastian Peters, Anne-Louise Meyer, Tim-Henrik Traumatic Spinal Cord Injury and Neurogenic Bruun, Ludwig Aigner, Ulrich Bogdahn bladder —Meheroz Rabadi P5.022 Taking Steps Backward to Move Forward: A Preliminary Feasibility Study in Stroke —Oluwole Awosika, Katie Krier, Emily
P5.019 A Predictive model for functional Wasik, Boyne Pierce, Kari Dunning, Daniel Woo, recovery of upper extremity after acute ischemic stroke —Nevine El Nahas, Hany Aref,
E
201–258
001–026
Brett Kissela
P5.023 Amelioration of left hand apraxia in a patient with callosal disconnection by use of mirror visual feedback therapy — Riddhi Patira
162 2018 AAN Annual Meeting
173–200
085–090
Shashank Agarwal, Leigh Charvet, Michael Shaw, Hanschmann Alberto Cucca, Hamzeh A Migdadi, Milton Biagioni
P5.003 Long term outcome from
D
P5.026 NA
MS and CNS Inflammatory Disease Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.
a1
Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 5:30p.m.-7:00 p.m. Data Blitz: 11:45 a.m.–11:50 a.m.
P5.027 Ozanimod (RPC1063) Preserves
Central Nervous System (CNS) Tissue in Rodents by Reducing Neuronal Breaks in Vivo and Modulating Astrocyte Activity in Vitro —Kristen Taylor Meadows, Mohd Waseem Akhtar, Morgan Brand, Christiane Villescaz, Bryan Clemons, Carlos Lopez, Samantha SawaBallweber, Kevin Dines, Gregory Opiteck, Fiona Scott, Julie Selkirk
Data Blitz: 11:50 a.m.–11:55 a.m.
P5.028 Multitasking is the Cognitive
Hagemeier, Dejan Jakimovski, Ivo Paunkoski, Deepa Ramasamy, Ellen Carl, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman, Robert Zivadinov
Data Blitz: 12:00 p.m.–12:05 p.m.
P5.030 Impacting The Natural History
of Multiple Sclerosis: A Report on the First Generation of Treated Patients —Thomas
Scott, Troy Desai, Chris Hackett, Edward Gettings, Teresa Hentosz, Wisam Elmalik, Carol Schramke
Data Blitz: 12:05 p.m.–12:10 p.m.
P5.031 Alemtuzumab Reduced MRI Ability Most Linked to Depression in Multiple Lesions and the Rate of Brain Volume Loss Sclerosis —Daniel Kurz, Michelle Fabian, in CARE-MS II Patients Switching From SC Gabrielle Pelle, Christina Lewis, Fred Lublin, Aaron IFNB-1a: 5-Year Follow-up (TOPAZ Study) — Miller, James Sumowski
Data Blitz: 11:55 a.m.–12:00 p.m.
P5.029 Aging is accelerating brain
atrophy in MS patients —Emanuele Ghione, Michael Dwyer, Niels Bergsland, Jesper
DYSTONIA: PHENOMENOLOGY AND THERAPEUTICS
B
P5.037 Outcomes of Week-24
Completers and Subjects Who Had FollowUp Beyond Week 24 After a Single Treatment of DaxibotulinumtoxinA for Injection (RT002): Results of a Phase 2, Open-Label (Level II), Dose Escalating Study in Isolated Cervical Dystonia —Joseph Jankovic, Daniel Truong, Atul Patel, Allison Brashear, Marian Evatt, Roman Rubio, Chad Oh, Daniel Snyder, Cynthia Comella
P5.038 Golfer’s Cramp: Quantitative
Method for Separating Golfers with a TaskSpecific Dystonia —Charles Adler, M’hamed Temkit, Debbie Crews, Troy McDaniel, Jennifer Tucker, Joseph Hentz, Christian Marquardt, Dale Abraham, John Caviness
P5.039 The Phenotype of ATP1A3+
Data Blitz: 12:10 p.m.–12:15 p.m.
after Fingolimod withdrawal due to planning Junctional Adhesion Molecule-A (JAM-A) a pregnancy in women with multiple controls cytokine and protease secretion, sclerosis —Spalmai Hemat, Maria Houtchens, T cell infiltration of the CNS and clinical Angela Vidal-Jordana, Michael Guger, Doriana disability during autoimmune attack —Sam Landi, Miguel D’Haeseleer, Pietro Annovazzi, Mar Tintoré, Sandra Thiel, Ralf Gold, Kerstin Hellwig
Data Blitz: 12:15 p.m.–12:20 p.m.
P5.033 WITHDRAWN Data Blitz: 12:20 p.m.–12:25 p.m.
P5.034 Progressive Motor Impairment
from a Critically Located Lesion in Highly Restricted CNS Demyelinating Sven Schippling, Daniel Pelletier, Michael Barnett, Disease —Mark Keegan, Timothy Kaufmann,
Data Blitz: 12:30 p.m.–12:35 p.m.
P5.036 Serum and CSF Neuroflament
Light Chain levels normalise following Bone Marrow Transplant in MS Patients —Simon
Thebault, Daniel Tessier, Iva Stonebridge, Vincent Tabard-Cossa, Mark Freedman
A single-centre case-controled study —Maja P5.052 Cervical Dystonia Patients Relja, Vladimir Miletic Treated with OnabotulinumtoxinA Report Improvements in Health-Related Quality P5.044 Validation of a Questionnaire of Life in a Multicentre, Prospective, for Distinguishing X-linked Dystonia Parkinsonism from XDP mimics —Jose Danilo Observational Study: POSTURe —Marc Diestro, Mark Willy Mondia, Mark Ang, Paul Matthew Pasco
P5.045 Comparison of
OnabotulinumtoxinA Utilization and Effectiveness Across Various Etiologies of Spasticity from the Adult Spasticity International Registry Study: ASPIRE —
Gerard Francisco, Daniel Bandari, Ganesh Bavikatte, Wolfgang Jost, Aleksej Zuzek, Joan Largent, Alberto Esquenazi
P5.046 Evolution of cervical dystonia
patterns in subjects new to botulinum toxin treatment —Richard Trosch, Vivay Peter Misra, Pascal Maisonobe, Savary Om
Petitclerc, Martin Cloutier, Meetu Bhogal, Goran Davidovic
P5.053 A case of levodopa responsive
rapid onset dystonia-parkinsonism. —Yeva Fernandez, Steven Frucht
P5.054 Mingo Supplemental Trial:
An Open-Label Prospective Randomized Controlled Trial in X-linked Dystonia Parkinsonism Patients in the Province of Capiz, Philippines —Patrick Acuna, Greta
Solinap, Jan Kristoper De Guzman, Mark Ang, Criscely L. Go
P5.055 Deep brain stimulation of the
P5.060 Body Region Response to
Pallidal Deep Brain Stimulation in Isolated Dystonia —Jennifer Choi, Laura Scorr
P5.061 Cervical dystonia and substance abuse —Abhimanyu Mahajan, Joseph Jankovic,
Laura Marsh, Achint Patel, H. Jinnah, Cynthia Comella, Richard Barbano, Joel Perlmutter, Neepa Patel
P5.062 Focal Task-Specific Dystonia
Affecting the Proximal Arm—An UnderRecognized Disorder? —Christine Stahl, Steven Frucht
P5.063 Acute and Reversible Sadness
Following Deep Brain Stimulation Targeting the Globus Pallidus Internus in Dystonia — Rohit Kesarwani, Tejas Sankar, Fang Ba
PARKINSON’S DISEASE: THERAPEUTICS II
P5.064 Extended-release (ER) formulations of aminoadamantanes as NMDA-receptor antagonists: Pharmacokinetic (PK) determinants of improved tolerability —Jack Nguyen, Timothy
Fultz, Charles Davis, Rajiv Patni, Elizabeth Brigham, Jonathon Holt, Greg Went
P5.065 Pimavanserin use in a movement
disorders clinic: A single center experience — Abhimanyu Mahajan, Bisena Bulica, Ayesha Ahmad, Patricia Kaminski, Peter LeWitt, Danette Taylor, Shana Krstevska, Neepa Patel
P5.066 A Long-term Study on
Effectiveness of Levodopa-carbidopa Intestinal Gel Treatment in Advanced Parkinson’s Disease Patients —Kallol
Chaudhuri, Angelo Antonini, Werner Poewe, David Standaert, Per Odin, Jorge Zamudio, Lars Bergmann
P5.067 ITI-214, A Novel
Phosphodiesterase Type I Inhibitor, For The Treatment Of Motor And Non-motor Symptoms Of Parkinson’s Disease —Robert Davis, Kimberly Vanover, Sharon Mates
AAN.com/view/AM18 163
Thursday
Horng, Candice Chapouly, Daivd Dai, Gareth John
Aaron Boster, Giancarlo Comi, Hans-Peter Hartung, Brian Weinshenker, Orhun Kantarci, William Schmalstieg, M. Paz Soldan, Eoin Flanagan Alex Rovira, Barry Singer, Anthony Traboulsee, David Margolin, Luke Chung, Nadia Daizadeh, Kunio Nakamura, Douglas Arnold
globus pallidus interna with microelectrode recording for Myoclonus-Dystonia (DYT-11): P5.047 Therapeutic benefits persist at Haq, Beverly Snively, Cynthia Suerken, Jared the end of one botulinum toxin injection cycle One year Outcome in Two Patients —Murat Gultekin, Halil Ulutabanca, Ahmet Selcuklu, Meral Cook, Charlotte Miller, Kathleen Sweadner, Laurie in cervical dystonia—results from a metaMirza, Yasin Temel, Ersoy Kocabicak Ozelius, Allison Brashear analysis of 1091 subjects —Vivay Peter Misra, Richard Trosch, Savary Om, Pascal Maisonobe P5.056 Which factors predict patient P5.040 In Vivo RNA Transcriptional / Translational Landscape in X-linked Dystonia P5.048 The Adult Spasticity International satisfaction with botulinum toxin treatment for cervical dystonia in routine practice? — - Parkinsonism (XDP/DYT3) Patient-Specific Registry (ASPIRE) Study: Real-World Tae Mo Chung, Carlo Colosimo, Vivay Peter Misra, Neuronal Cells —Anna Szekely, Ellen Penney, Treatment Utilization and Effectiveness of P. Charles, Pascal Maisonobe, Savary Om Jennifer Yang, Cristopher Bragg, Nutan Sharma, OnabotulinumtoxinA in Post-Stroke Patients Sherman Weissman P5.057 Deep brain stimulation: A Treated for Spasticity —Ganesh Bavikatte, Gerard Francisco, Daniel Bandari, Wolfgang Jost, Treatment Modality for Generalized Dystonia P5.041 Safety and Efficacy of Aleksej Zuzek, Joan Largent, Alberto Esquenazi Secondary to Anoxic Brain Injury in Adults — IncobotulinumtoxinA for the Treatment of Padmaja Vittal, Joshua M Rosenow, Mark Nolt, Blepharospasm in Botulinum Toxin-Naive P5.049 The Prevalence of Dystonic Jennifer Pallone, Martha T McGraw, Alison Subjects —Fernando Pagan, Andrzej Dekundy, Tremor and Tremor Associated with Dystonia Monette, Laura Guzman, Archana Shrivastava, Kati Sternberg, Dimos Dimitrios Mitsikostas in Patients with Cervical Dystonia —Lenka Michael Rezak Hvizdosova, Martin Nevrly, Pavel Otruba, Petr P5.042 Drivers of change in Toronto P5.058 Evaluation of DTI-Tractography Western Spasmodic Rating Scale (TWSTRS) Kanovsky Findings in Botulinum Neurotoxin Injected scores following botulinum toxin treatment: P5.050 Psychiatric Manifestations of Hemifacial Spasm Patients —Hakan Cavus, Impact of geographical region —Carlo Autosomal Dominant Dopa Responsive Pervin Iseri Colosimo, Vivay Peter Misra, P. Charles, Tae Mo Dystonia —Lindsey Neimand, Robert Ortega, Chung, Pascal Maisonobe, Savary Om Deborah Raymond, Gary Heiman, Susan Bressman, P5.059 Early onset tremulous dystonia-a Rachel Saunders-Pullman familial case and novel mutation —Mariam Al P5.043 Assessment of non-motor symptoms and cognitive functions in patients P5.051 Family structures in adult-onset Hussona, Eavan McGovern, David Webb, Michael Hutchinson, Sean O’Riordan with isolated adult-onset cervical dystonia focal Dystonia —Maryamnaz Zaribaf, H. Jinnah previously not treated with botulinum toxin: Rapid-Onset Dystonia-Parkinsonism (RDP) is Broader than Previously Defined. —Ihtsham
Data Blitz: 12:25 p.m.–12:30 p.m.
P5.032 Disease activity during pregnancy P5.035 Astrocyte-T cell signaling via
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION V
G
P5.068 A Phase 2a study of nilotinib in
Disease Clinical Trials. —Pinky Agarwal, patients with advanced and early Parkinson’s Sudeshna Ray, Daniel Burdick, Alida Griffith disease. Study design —Tanya Simuni, Brian P5.072 Improvement in Attention/ Fiske, Kalpana Merchant, Christopher Coffey, Helen Memory Domains in Advanced Parkinson’s Matthews, Richard Wyse, Patrik Brundin, Gary Disease Patients Treated with LevodopaRafaloff, David Simon, Michael Schwarzschild, carbidopa Intestinal Gel is Associated with David Weiner, Charles Venuto, Laura Trusso Better Quality of Life —David Standaert, Ramon P5.069 Movement Disorder Specialists’ Rodriguez, John Slevin, Coleen Hall, Maurizio Determination of Eligibility for Device Aided Facheris, Janet Benesh, Stephanie Dubow Treatment in Advanced Parkinson’s Disease: P5.073 Barriers to Adherence to Results from the OBSERVE-PD Study — Physical Therapy, Occupational therapy, and Alfonso Fasano, Klaus Seppi, Victor Fung, Juan Speech/Swallowing Therapy in Parkinson’s Carlos Parra, Lars Bergmann, Kavita Sail, Yash Disease —Gregory Vurture, Catherine Kulick, Jalundhwala, Koray Onuk
P5.070 Genomic analysis identifies new loci associated with motor complications in Parkinson’s disease —Sun J. Chung, Juyeon Kim, Kiju Kim, Mi-Jung Kim, Young Jin Kim, HoSung Ryu
Kathryn Montgomery, Melissa Nirenberg
P5.076 Modulating BDNF Activity
in Parkinson’s Disease: The Impact of Aerobic Exercise and Transcranial Magnetic Stimulation —Hamzeh A Migdadi, Hoau-Yan Wang, Shashank Agarwal, Kush Sharma, Alberto Cucca, Angelo Quartarone, Maria Ghilardi, Alessandro Di Rocco, Milton Biagioni
ATAXIAS II
on Activities of Daily Living and Motor Trials And Tribulations of The Limited English Symptoms of Parkinson’s Disease —Danielle Proficiency Patient Volunteer in Parkinson`s Larson, Danny Bega, Eric Johnson, Laura Slowey
genes in spinocerebellar ataxia type 3 —Shi-
Rui Gan, Ning Wang, Sheng-Han Kuo, Zhi-Ying Wu
P5.080 Beyond Whole-Exome
Sequencing: A Propos of Two Neurodegenerative Diseases. —Fabio
Nascimento, Salmo Raskin, Brunhilde Wirth, Helio Afonso Teive
P5.081 Ataxia with Oculomotor Apraxia 2 : Clinical and Genetic study of 17 of Spinocerebellar Ataxia Type 10 —Bernardo patients —Haifa Kharrat, Cyrine Jridi, Jihene Machado Dias Domingues, Adriana Moro, Salmo Raskin, Tetsuo Ashizawa, Helio Afonso Teive
P5.078 Feasibility of Arterial Spin
Labeling MR Imaging for Detecting Movement Therapy in Parkinson’s Disease — Cerebellar Hypoperfusion in Patients with Spinocerebellar Degeneration —Masamichi Kristi Michels, Erica Hornthal, Danny Bega
P5.075 Effects of Rock Steady Boxing
P5.079 Interplay of repeat expansion
P5.077 Clinical and Genetic Evaluation
P5.074 A Pilot Study on Dance/
P5.071 Clinical Research Participation:
b1 C
Thursday, April 26 11:30 a.m.–7:00 p.m.
Ikawa, Hirohiko Kimura, Yuki Kitazaki, Akiko Matsunaga, Koji Hayashi, Osamu Yamamura, Tadanori Hamano, Makoto Yoneda, Hidehiko Okazawa, Yasunari Nakamoto
Sassi, Fatma Nabli, Samir Blel, Faycal Hentati
P5.082 Quality of Life in Fragile
X-associated Tremor/Ataxia Syndrome (FXTAS) — Danielle Thorarson, Erin RobertsonDick, Bicham Ouyang, Bryan Bernard, Joan O’Keefe, Deborah Hall
P5.083 NA P5.084 NA
Infectious Disease and Global Health I ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P5.085 Neurons on Wheels (NOW)—
Severe Acidosis —Akanksha Sharma, Jenny Siv, P5.088 Epilepsy-related Injuries: A Neuroschistosomiasis —Paul Elsbernd, Kathryn Liz Schackmann, Arielle Davis Lago, Tatjana Calvano, John Sladky Bringing Neurologists Into Shelters for Case-control Study —Mamta Singh, Coral Stredny, Saloni Kapoor, Arunmozhimaran Elavarasi, Better Patient Care —Joy Ding, Wendy Muckle, P5.087 Polyarteritis Nodosa from P5.090 Gas-containing Cervical and V Sreenivas, Victor Patterson Christopher Skinner, Jeffery Turnbull Hepatitis B Infection Presenting with Thoracic Spinal Epidural abscess secondary P5.089 Complete Neurologic Recovery to Klebsiella Pneumonia infection —Annie P5.086 Invasive Mucormycosis in an Bilateral Basal Ganglia Strokes and Immunocompetent Non-Diabetic with Sensorimotor Neuropathy —Vincent Arnone, after Acute Cauda Equina Syndrome due to Hsieh, Maria Rojas, Steven Yang, Saman Zafar, Indira De Jesus-Alvelo
Shumaila Sultan
P5.097 Treatment practices and
P5.103 Neurosyphilis, Neither Gone
P5.110 MS and HIV: A case of MS-IRIS
Sankaranarayanan, Kameshwar Prasad, Garima Shukla, Parthiban Balasundaram
Héctor Sánchez-Rodríguez, Pedro A HernándezRodríguez, Beatriz Chávez-Luevanos, Ingrid Estrada-Bellman, Alejandro Marfil-Rivera
P5.111 Subacute ZIKA Virus encephalitis
Kumar, Jayantee Kalita
P5.098 Epidemiology, Outcomes and
P5.104 Clinical Features Of Seizures
Coccidioidomycosis: A descriptive 19-year experience at an endemic tertiary care center —Erin Okazaki, Chia-Chun Chiang, Akta
neurological intensive care unit —Johann
NEUROLOGIC INFECTIONS: TREATMENTS AND OUTCOMES
P5.091 Safety and efficacy of
fludrocortisone in treatment of cerebral salt wasting in tuberculous meningitis: a preliminary study —Usha Misra, Mritunjai
Persistent disease activity after 9 months of treatment in CNS tuberculosis- an ambispective cohort study —Muthukani
Nor Forgotten: A Retrospective Study From Northeast México. —Sergio Castillo-Torres,
associated with antiretroviral therapy initiation —Pria Anand, Deanna Saylor
in Rio de Janeiro. —Joao Marcos Ferreira,
Thursday
Pamela Passos dos Santos, Luiz Felipe Dantas Pagliarini, Pedro Macedo, Ivan Da Silva, Celso In Hiv Patients With Toxoplasma Hygino, Ana Carolina Andorinho, Caroline Amaral, Prognosis of Central Nervous System P5.092 Central Nervous System Infections in Singapore—preliminary results Encephalitis. —Annick Melanie Magnerou, Victor Pedro Moreira Filho, Camila Pupe, Osvaldo Manifestations of Mycoplasma Pneumoniae, from the Singapore Neurologic Infections Nascimento Sini, Halima Fidelie Schol Ngoungoure, Denahin Systematic Review of the Literature with Hinnoutondji Toffa, Mouhamadou Mansour Ndiaye Programme (SNIP) —Kevin Tan, Yvonne Chan, P5.112 Enteroviral T-Cell Encephalitis Regard to Pathogenosis and Treatment in Derek Soon, Humaira Shafi, Monica Chan, Say-Tat P5.105 Daclizumab, a Potential Exit Related to Immnuosupresive Therapy Adult Subjects, with First Case Report of Ooi, Jenny Low, October Sessions, Eng-Eong Ooi, Strategy in MS Patients at High Risk for Including Rituximab —Nicolas Garzo Caldas, Successful Treatment with Intravenous Lin-fa Wang, Angela Vincent, Limin Wijaya Sara Vila Bedmar, Sara Llamas, Juan Ruiz Morales, Natalizumab-Associated PML? —Tobias Immunoglobulin in an Adult —Pirouz Piran, Aurelio Hernandez Lain, Dolores Folgueira Lopez, Moser, Bsteh Christian, Mihael Varosanec, Peter P5.099 Development of Transverse Subin Mathew, Alex Linn, Mei Lu, Efrain Salgado Wipfler, Ferdinand Otto, Annemarie Pokorny, Julia Elena Ruiz-Beato, Claudia Rodríguez López, Luisa Myelitis after Vaccination, A CDC/FDA Panadés Oliveira, David Uriarte Perez de Urabayen, Feige, Zslot Nagy, Johann Sellner P5.093 Neurocysticercosis: A Spanish Vaccine Adverse Event Reporting System Alberto Villarejo Galende center experience —Luna Fuentes Rumi, Jose (VAERS) Study, 1985-2017. —Shreya Shah, P5.106 A case of Listeria Maria Cabrera Maqueda, Ester Carreon Guarnizo, Janaki Patel, Abdul Rahman Alchaki, Moamina P5.113 Central Nervous System Tuberculosis Rhombencephalitis: Emphasizing good Ana Esther Baidez Guerrero, Gabriel Valero López, Fakher Eddin, Nizar Souayah presenting as Acute Meningioencephalitis: A outcome with awareness and prompt Jose Diaz Perez, Estefania Garcia Molina, Jose Case series describing an under recognized treatment. —Vivek Yadala, Yu-Ting Chen, P5.100 Agitation in autoimmune and Meca Lallana, Rocio Hernandez-Clares infectious encephalitis: A comparative study Humaira Khan, Sen Sheng, Mai Vuong, Shirley Ong entity. —Irfan Shah, Ravouf Asimi, Mushtaq Wani, Bashir Sanaie, Mudasir Mushtaq P5.094 Central Nervous System of clinical course and management at the Sellner, Gayane Harutyunyan, Martin Dünser, Fabio Rossini, Markus Leitinger, Helmut Novak, Patel, Holenarasipur Vikram, Janis Blair, Marie Grill Wolfgang Aichhorn, Eugen Trinka, Larissa Hauer
P5.095 Acute Flaccid Myelitis: Treatment P5.101 Defining PML Spectrum
Outcomes From a Tertiary Referral Center — Disease —Lauren Reoma, Bryan Smith, Matthew Benjamin Greenberg, Patricia Plumb, Cynthia Wang Schindler, Daniel Reich, Avindra Nath, Irene Cortese
P5.096 Is Infection at Stroke Onset
Associated with Prognosis Following Acute Ischemic Stroke? —Hamidreza Saber, Mahsa Sadeghi, Azara Singh, Morad Nasseri, Kushak Suchdev, Mohammad Ibrahim, Wazim Mohamed
164 2018 AAN Annual Meeting
P5.102 Clinical characteristics of HIV
patients with acute stroke —Hemil Gonzalez,
Lakshmi Warrior, Fabian Sierra Morales, Danielle Rice, Lisa Diep, Michael Kelly
P5.107 Elevated CSF 14- 3- 3 and Tau and Negative RT Quic after ECT —Miriam
P5.114 Clinical Characteristics of
NEUROLOGIC INFECTIONS: UNUSUAL PRESENTATIONS
Ueda, Hideaki Shibata, Megumi Yamada, Yuichi Hayashi, Akio Kimura, Kenichi Ando, Takayoshi Shimohata
Freimer, Yasmeen Rauf
P5.108 Candida meningitis and
ventriculitis after IV brown heroin use: A case series. —Carolina Vivar, Kelly Baldwin
Persistent/ Intractable Hiccups Caused by VZV Infection —Nobuaki Yoshikura, Natsuko
P5.115 Lyme Disease Presenting with
Meningoradiculitis: A Case of Variant Bannwarth Syndrome —Monica Diaz, Sarah
P5.109 Concurrent Faciobrachial Diplegia Wesley and Diaphragmatic Weakness Caused by P5.116 Palatal Tremor and Hypertrophic Lyme Neuroborreliosis —Seyedali Hejazi, Taqi Zafar, Armin Maghsoudlou, Golshan Fahimi, Laura Simionescu
Olivary Degeneration after Listerial Rhombencephalitis —Seong-il Oh, Kyong Jin Shin
P5.117 IL6 and IL17 as inflammatory response in a case of Neurobrucellosis presenting as Leucoencephalopathy —
Mariem Kchaou, Mariem Belguith, khadija Bahrini, Mohamed jalleli, slim echebbi, Hela Jamoussi, Nadia Ben Ali, Mohamed Fredj, Ridha Barbouche
P5.118 Bilateral Spontaneous Subdural
Lima, Hennan Teixeira, Carmen Lucia Penteado Lancellotti, Leonardo Furtado Freitas, Alex Baeta
P5.149 Image studies in Zika Virus
P5.134 An interesting case of Nocardial
Luiz Felipe Dantas Pagliarini, Joao Marcos Ferreira, Pamela Passos dos Santos, Ana Carolina Andorinho, Eduardo Davidovich, Ivan Da Silva, Celso Hygino, Camila Pupe, Osvaldo Nascimento
brain abscess mimicking brain tumor in an immunocompetent patient. —Aiga Rakhesh,
Gobind Singh, Bakhtier Nurmukhamedov, Eufrosina Young
Hematomas in an HIV Patient with A Normal P5.135 Acute Streptococcal pneumoniae Platelet Count —Hisham Elkhider, Lindsay Meningoencephalitis Associated with a Malatesta, Shirley Ong, Mallory Smith, Atul Kothari Multitude of Vascular Complications —Sara Dawit, Marie Grill P5.119 HIV Related OpsoclonusMioclonus-Ataxia Syndrome As The Initial P5.136 A New Tick Palsy: Case of Neurological Presentation: A Case Report. — Guillian-Barre Syndrome Associated with Marlene Arbeu Reyes, Alicia Garmendia Rebolledo Lyme Disease —Mena Samaan, Anna Van P5.120 A Rare Case of Neuroborreliosis Venrooy, Claire Botros, Raghuveer Puttagunta Presenting with Intracranial Hypertension — P5.137 Myoclonic jerks as a unique Anvi Patel, Subhendu Rath, Sarah Meira Benchaya, clinical manifestation in a patient with Amre Nouh Murine Typhus —Ahmad Yusuf Solaiman, Hunaid Hasan, Neel Patel, Xiang Fang P5.121 Lemierre’s Syndrome Complicated by Epidural Abscess —Shoichi P5.138 A severe case of Shimamoto, John Liang, Shah Syed
P5.122 Tuberculous myopathy —Marco Julio Flores, Maria Alejandra Gonzalez Duarte
P5.123 Isolated abducens palsy from
neurological complications —Pedro Macedo,
brachial neuritis following Salmonella paratyphi bacteraemia —Aravindhan Baheerathan, Sabrina Kalam
P5.152 Viral encephalitis: What are the most common viruses in patient admitted to an University Hospital in the Tropics? —
Karylsa Torres Gomez, Valerie Wojna, Mariela Cuebas
P5.127 Starry Sky Image: Miliary
Neurotuberculomas without apparent Pulmonary Injury —Barbara Diniz, Yuri
metagenomic sequencing after 18 months of meningitis and spinal cord compromise —
GLOBAL HEALTH
Macedo, Joao Marcos Ferreira, Pedro Macedo, Karoline Medeiros, Guilherme Torezani, Leonardo Modenezi, Fabio Martins, Nathane Rezende, Camila Pupe, Osvaldo Nascimento
P5.128 Paroxysmal Singultus as the result of Brainstem Histoplasmosis —
Nicholas Metrus, Carlos Kamiya Matsuoka, Jennifer Johnson
P5.129 The Danger of Flying with
Acute Otitis Media, Which May Result in Gradenigo’s Syndrome —Lauren Spiegel, Lily Pham, Pitchaiah Mandava
P5.130 Vision impairment and
Woc-Colburn, Rod Foroozan, Jacob Mandel
P5.142 Neurosyphilis Mimicking
Disorders at an Outpatient Clinic in Addis Ababa, Ethiopia —Mehila Wuhib, Guta Zenebe,
P5.143 Cerebral Histoplasmosis: Relate of Case. —Nayme Monfredini, Andre Franzoi, Felipe Ibiapina dos Reis, Laura Parolin
P5.156 The Spectrum of Neurological James Johnston
P5.157 Head CT Findings at a Public
Hospital in Rural Haiti: Retrospective Analysis of 3614 CT Scans —Ioannis Valtis, Maggie Cochran, Louine Martineau, Bregenet Lamour, Jeffrey Mendel, Aaron Berkowitz
NEUROLOGICAL INFECTIONS: DIAGNOSTICS AND ANIMAL MODELS P5.158 Etiology and clinical profiles of pediatric encephalitis in Myanmar: A prospective study —Alyssa Smith, Robert P5.144 Brain Heme Oxygenase Antioxidant and Type I Interferon Responses Rudock, Cameron Crockett, Cho Thair, Ayemu Saan, Chaw Su Hlaing, Aye Mya Min Aye, Kyaw in Simian Immunodeficiency Virus (SIV)Linn, Soe Mar Infected Rhesus Macaques: A Model for Human Brain Responses to HIV —Maria Diaz P5.159 Perception of Functioning Ortiz, Rolando Garza, Fiorella Rossi, Ferzin Sethna, as a Potential Screening Modality for Michael R. Betts, Guido Silvestri, Dennis Kolson HIV-Associated Neurocognitive Disorder in Nigeria —Deidre Ammah, Jibreel Jumare, Walter P5.145 MRI Brain Abnormalities in Royal Acute Flaccid Myelitis: Characteristics and Differentiation from Acute Disseminated P5.160 Perinatal Case Fatality Rate Encephalomyelitis —Sarah Hopkins, Eliza in Cases of Congenital Zika Syndrome: A Gordon-Lipkin, Keith Van Haren, Jonathan Santoro, Cross-Sectional Study —Jessika Thais da Silva
P5.132 Longitudinally Extensive Spinal
P5.133 Atypical presentation of
Cytomegalovirus meningoencephalitis in a immunocompetent patient —André Luiz Guimarães Queiroz, Karlla Danielle Ferreira
P5.166 Pre-diagnostic branched
chain amino acids and the risk of ALS —
Kjetil Bjornevik, Eilis O’Reilly, Clary B. Clish, Larry Kolonel, Loic Le Marchand, Marjorie L. McCullough, Sabrina Paganoni, Michael Schwarzschild, Zhongli Zhang, JoAnn E. Manson, Alberto Ascherio
P5.167 Are ALS Motor Phenotypes
stochastic? —Adriano Chio, Fabrizio D’Ovidio,
Letizia Mazzini, Cristina Moglia, Umberto Manera, Enrica Bersano, Antonio Canosa, Gabriele Mora, Andrea Calvo
P5.168 Evaluating the completeness of
the National ALS Registry, United States — Wendy Kaye, Laurie Wagner, Ruoming Wu, Paul Mehta
P5.169 NA P5.170 NA P5.171 NA P5.172 NA COGNITIVE PHENOTYPES IN AGING AND DEMENTIA
D
P5.173 Machine-driven Classification of
Cognitive Profiles —Jordan Weiss, Eli Puterman, Aric Prather, David Rehkopf
P5.174 The Correlation Between
Reported Changes in Cognitive Functioning and Objective Performance on Cognitive Screening in English- and Spanish-speaking Patients —Reena Gottesman, Erica Weiss,
Ronda Facchini, Karen Valdesuso, Carlos Marquez, Jessica Zwerling
P5.175 Sleep Patterns In Patients At Risk For Alzheimer’s Disease May Be Related To Cognitive Performance and Amyloid Burden —Peter Yan, Ryan Thorpe, Olivia Scheyer, Aneela Rahman, Richard Isaacson
P5.148 HIV and Alzheimer’s Disease: Tat, P5.162 Telemedicine as a pivotal
Thinning Associated with Poorer Cognitive Performance Regardless of Amyloid Burden in Normal Elderly —Catherine Veilleux, Pénélope
Arachnoid Cyst Secondary to Chronic P5.147 Florence Foster Jenkins and Coccidioides immitis Meningitis —Tyler Koehn, Neurosyphilis in the 1940s —David Avila Jeffrey McClean, Anthony Frattalone
Rotem, Monique Breteler, Linda Valeri, David Sparrow, Marc Weisskopf
Maia, Sebastiana Jayne Alves Vidal, Tatyana Vidal Mendes, Maria Goretti Lins, Marcelo Rodrigues Zacarkim, Daniel Duarte Rolim, David M. Aronoff, Virus Leads to Neuroinvasive-Like Syndrome Angelle Desiree LaBeaud, Nilson Nogueira in Mice —Parminder Vig, Amber Paul, Dobrivoje Mendes Neto Stokic, A Leis, Fengwei Bai, Michael Garrett, P5.161 Developing a Child Neurology Mariper Lopez, Qingmei Shao Training Program in Cambodia: A Pilot
Laura Munoz-Arcos, Susan Matesanz, Carlos
P5.131 Atypical Presentation of Probable Pardo-Villamizar, Brenda Banwell Creutzfeldt-Jakob Disease Associated with P5.146 Chronic Exposure to West Nile Anti-Zic4 Antibody: Literature Review of Neuronal Antibodies in Creutzfeldt-Jakob Disease —Richard Salazar
Interaction with Uric Acid —Vy Nguyen, Ran
Beta-Amyloid, and Neprilysin —Tugba Ozturk, Jessica Howell, William Hu
P5.176 In-vivo mapping of
monoaminergic network disruption in Alzheimer’s disease: Implications for neuropsychiatric symptoms —Marco Bozzali,
Laura Serra, Marcello D’Amelio, Carlotta Di Domenico, Camillo Marra, Nicola Mercuri, Carlo Study —Brian Wong, Heng Nhoung, Pei Liu, Soma Caltagirone, Mara Cercignani Sahai-Srivastava P5.177 Alzheimer Signature of Cortical
part of rural neurology and migraine management. —Nawaz Hack, Claudio Osorio, Regine Reimers
Sévigny-Dupont, Marie-Maxime Lavallée, Maude Joanette, Jim Nikelski, Howard Chertkow, Sven Joubert, Kevin Whittingstall, Christian Bocti
AAN.com/view/AM18 165
Thursday
papilledema as the initial manifestation of neurosyphilis in a young immunocompetent patient —Doyle Yuan, Fabio Nascimento, Laila
Meya, Joseph DeRisi, Michael Wilson
Kuybu, Charoskhon Turabova, Catherine S. Chaudoir, Erik Burton
Horton, Shannon Graham, Reshma Punjani, Grete Wilt, Wendy Kaye, Kimberly Maginnis, Lauren Webb, Judy Richman, Richard Bedlack, Edward Tessaro, Paul Mehta
P5.165 Association of Lead Exposure P5.153 Candida dubliniensis identified by on Cognitive Decline due to Mediation and
Cardenas Castillo, Lakshmi Leishangthem, Saman Zafar, Sridhara Yaddanapudi, Aparna Prabhu
Sarcoidosis with CNS Involvement. —Okkes
Soma Sahai-Srivastava
NEUROEPIDEMIOLOGY: MOTOR profile and Validation of Thwaites Diagnostic NEURON DISEASE, COGNITIVE Criteria. —Sankar Gorthi, Reshma Susan, Aravind IMPAIRMENT, SLEEP II Prabhu, Vijay Chandran P5.164 A Spatial Analysis of P5.151 Evaluation of Adenosine Deaminase Amyotrophic Lateral Sclerosis (ALS) Cases in the United States and their Proximity to activity in CSF for diagnosis of Tuberculous Multidisciplinary ALS Clinics, 2013 —D. Kevin Meningitis —Abul Shoab, Mostafa Hosen
sinusitis related septic dural venous thrombosis P5.139 Optic Neuritis and Hemiparesis in P5.154 The International HIV Dementia invading Dorello’s canal. —Aparna Vaddiparti, Ninad Desai, Neil Datta, Stephen Conway a Previously Healthy Young Woman —Dulanji Scale as a screening tool for HAND in Uganda —Maria Molinaro, Deanna Saylor, Kuruppu, G Giuliari, Devin Mackay P5.124 Mysterious Meningitis: Recurrent Gertrude Nakigozi, Noeline Nakasujja, Kevin P5.140 A Rare Case of Creutzfeldtchemical meningitis due to ruptured Robertson, Ronald Gray, Maria Wawer, Ned Sacktor epidermoid cyst —Bhavesh Trikamji, Mark Morrow Jakob Disease with Elevated Anti-Thyroid Antibodies —Subhendu Rath, Yan Hou, Ilavarasy P5.155 Etiologies and Outcomes among P5.125 Streptococcus Pneumoniae Maran, Lawrence Bluth Non-Traumatic Spinal Cord Injuries in Uganda — Meningitis Presenting as Pseudo-subarachnoid Hemorrhage —Jared Yee, Laura Nist, Bryan Tsao, P5.141 An Intriguing Case of Unresolved Kisekka Musubire, David Boulware, Ana-Claire Meyer, Akshaya Ramesh, Debarko Banerji, David Post-Operative Pneumocephalus —Ylec Vincent Truong
P5.126 A rare case of parainfectious
Neurology Education and Engagement During Short-Term Global Health Initiatives —Brian Wong, Heng Nhoung, Pei Liu,
P5.150 Tubercular Meningitis—Clinical
Cytomegalovirus (CMV) meningoencephalitis Akshaya Ramesh, Debarko Banerji, Lilian Khan, Jonathan Blum, Gary Green, Joseph DeRisi, in an otherwise healthy immunocompetent Michael Wilson 2 month old male. —Whitney Gervelis, Jade Davis, Saurabh Singhal, John Christenson, Susan Conrad
P5.163 Using Social Media to Enhance
POSTER SESSIONS
Stand-by time for this session is 5:30 p.m. to 7:00 p.m.
POSTER SESSIONS
POSTER SESSION V P5.178 The relationship between
Mini-Mental State Examination (MMSE) & Alzheimer’s Disease Assessment Scalecognitive subscale (ADAS-cog) using real world data in US & Europe —Rezaul Khandker, Christopher Black, James Pike, Joseph Husbands, Baishali Ambegaonkar, Eddie Jones
P5.179 Picture Memory Impairment
Screen: Montefiore-Einstein Center for the Aging Bra